



सत्यमेव जयते

INDIA NON JUDICIAL

Government of Karnataka

Rs. 100



e-Stamp

Certificate No.
 Certificate Issued Date
 Account Reference
 Unique Doc. Reference
 Purchased by
 Description of Document
 Description
 Consideration Price (Rs.)
 First Party
 Second Party
 Stamp Duty Paid By
 Stamp Duty Amount (Rs.)

IN-KA67876552421185R
 03-Aug-2019 06:00 PM
 NONACC (FI)/ kacrsf08/ BELGAUM3/ KA-BL
 SUBIN-KAKACRSFL0860538889411497R
 PRINCIPAL KAHER JNMC BELAGAVI
 Article 12/Bond
 AGREEMENT
 0
 (Zero)
 DISTRICT HEALTH AND F W OFFICER BELAGAVI
 PRINCIPAL KAHER JNMC BELAGAVI
 PRINCIPAL KAHER JNMC BELAGAVI
 100
 (One Hundred only)

Shri Siddhivirayak Banjara M...
 C/o. K. T. Path Building Chaval Gally BGM

Authorised Signature



Please write or type below this line

- 3 -

4. The first party hereby covenants to reimburse the amounts to the second Party in consideration of the provision the Services stated above once a quarter as provided in the Scheme notified by the Government of Karnataka.

ATTESTED

[Handwritten Signature]

Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education and Research, BELAGAVI

Statutory Alert:

1. The authenticity of this Stamp Certificate should be verified at www.e-stamp.gov.in. Any discrepancy in the details on this Certificate and as available on the website renders it invalid.
2. The onus of checking the legitimacy is on the user of the Certificate.
3. In case of any discrepancy please inform the Competent Authority.

01

5. The period of maintenance being from 02/07/2019 to 30/06/2024
6. Both the parties can terminate the contract by giving 90 days notice in writing. Termination of Contract by the agency without notice will entail penalties equal to the amounts due for such duration.
7. All other terms and conditions laid down in the guidelines will be adhered to. (As per Govt. order No: Aakuk/10/sijis/2015 dated 07/11/2016)

IN WITNESS: where of the parties here to have caused this Agreement to be executed in accordance with their respective laws the day and year first above written.


Signed, sealed and Delivered by the

ಜಿಲ್ಲಾ ಆರೋಗ್ಯ ಮತ್ತು ಕುಟುಂಬ ಕಲ್ಯಾಣ
ಅಧಿಕಾರಿಗಳು ಬೆಳಗಾವಿ.
Said
(for the First Party)

Signed, sealed and delivered by the

W.H.
said
(for the Second Party)
PRINCIPAL
Jawahar Lal Nehru Medical College

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI.

WHEREAS the First Party has formulated a scheme for involvement of the Private Medical Colleges and Non- Government Organizations in management of Primary Health Centers and Urban Health Centers in the State. The Second Party who is Principal, KAHER, Jawaharlal Nehru Medical College, Belagavi is desirous of participating in the scheme and offered its services in terms formulated by the Government.

NOW THIS AGREEMENT WITNESSETH AS FOLLOWS:

1. Words and expression used in the agreement shall have the same meanings as are respectively assigned to them in the Scheme notified by the Government Organizations in Management of Primary Health Centers and Urban Health Centres.
2. The Scheme notified by the Government of Karnataka for involvement of Private Medical Colleges and Non-Government Organizations in Management of Primary Health Centers and Urban Health Centres shall be deemed to form and be read and constructed as part of this agreement.
3. In consideration of the payments to be made by the First Party to the Second party as hereinafter mentioned, the Second party hereby covenants with the First Party to manage the Primary Health Centers and Urban Health Centres at Kinaye, Vantamuri and Ashok Nagar, Rukmini Nagar, Tal/Dist: Belagavi and the sub-centre coming under its jurisdiction and provide the services in conformity with all conditions laid down under the said schemes of the Government of Karnataka.

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI





सत्यमेव जयते

INDIA NON JUDICIAL Government of Karnataka

e-Stamp

Certificate No.	: IN-KA60473314329165P
Certificate Issued Date	: 29-Jun-2017 03:32 PM
Account Reference	: NONACC (FI)/ kaksfcl08/ BELGAUM27/ KA-BL
Unique Doc. Reference	: SUBIN-KAKAKSFCL0869663245246168P
Purchased by	: PRINCIPAL KLE UNIVERSITY J N M C BELAGAVI
Description of Document	: Article 12 Bond
Description	: AGREEMENT
Consideration Price (Rs.)	: 0 (Zero)
First Party	: DIST HEALTH AND F W OFFICER BELAGAVI
Second Party	: PRINCIPAL KLE UNIVERSITY J N M C BELAGAVI
Stamp Duty Paid By	: PRINCIPAL KLE UNIVERSITY J N M C BELAGAVI
Stamp Duty Amount(Rs.)	: 100 (One Hundred only)



(Signature)
 Authorized Signatures
 Aadhar Multi-Purpose Souhard Sahasani
 Hvt. Shivabasaev Nagar, BELGAUM.

-----Please write or type below this line-----

- 3 -

4. The first party hereby covenants to reimburse the amounts to the second Party in consideration of the provision the Services stated above once a quarter as provided in the Scheme notified by the Government of Karnataka.

- 4 -

ATTESTED

Statutory Alert:

1. The authenticity of this Stamp Certificate should be verified at "www.shciestamp.com". Any discrepancy in the details on this Certificate and as available on the website renders it invalid.
2. The onus of checking the legitimacy is on the users of the certificate.
3. In case of any discrepancy please inform the Competent Authority.

(Signature)
 Prof. Dr. V.A.KOTHIWALE
 Registrar

KLE Academy of Higher Education
 and Research, BELAGAVI


05


5. The period of maintenance being from 01-07-2017 to 30-06-2019
6. Both the parties can terminate the contact by giving 90 days notice in writing. Termination of Contract by the agency without notice will entail penalties equal to the amounts due for such duration.
7. All other terms and conditions laid down in the guidelines will be adhered to. (As per Govt. order No: Aakuk/10/sijis/2015 dated 07/11/2016)


IN-WITNESS: where of the parties here to have caused this Agreement to be executed in accordance with their respective laws the day and year first above written.

Signed, sealed and Delivered by the

Signed, sealed and delivered by the

Said 
(for the First Party) 11/7/2017
District Health & F.W. Officer
BELGAUM.

said 
(for the ~~Principal~~ Party)
JANAKI LAL MEHRU MEDICAL COLLEGE
BELAGAVI-590018



Executed to before me



S. I. TIGADI

BA., LL.B. (Spl.)

Advocate & Notary, Belagavi.

ATTESTED

06 JUL 2017



Prof. Dr. V.A. KOTHIWALE

Registrar

**KLE Academy of Higher Education
and Research, BELAGAVI**



ಜನಾರ್ಜನ ಸರ್ಕಾರ

ಸಂ:ಅಭಿವೃದ್ಧಿ:ವಿವ-೬೧ :2019-20

ಜಿಲ್ಲಾ ಆರೋಗ್ಯ ಮತ್ತು ಕು.ಕ.ಕಚೇರಿ
ಬೆಳಗಾವಿ, ದಿನಾಂಕ: ೨೩.೦೮.೨೦೧೯

ರಿಗೆ,

ಪ್ರಾಂಶುಪಾಲರು,
ಜಿ.ಎನ್.ಎಂ.ಸಿ,
ಬೆಳಗಾವಿ.

ಮಾನ್ಯರೇ

ವಿಷಯ:-ಪರಿಷ್ಕೃತ ಸರ್ಕಾರದ ಆದೇಶದ ಪ್ರಕಾರ ಆರೋಗ್ಯ ಬಂಧು ಯೋಜನೆಯಡಿ ಪ್ರಾ.ಆ.ಕೇಂದ್ರಗಳನ್ನು ದತ್ತು ನಿರ್ವಹಣೆಯನ್ನು ಮುಂದುವರಿಸುವ - ಕುರಿತು.

ಉಲ್ಲೇಖ:- 1)ಸರ್ಕಾರದ ಆದೇಶ ಸಂ.ಆಕುಕ/10/ಸಿಜಿಎಸ್/2015
ದಿನಾಂಕ:07.11.2016

2)ಮಾನ್ಯ ಪ್ರಧಾನ ಕಾರ್ಯದರ್ಶಿಗಳು, ಆರೋಗ್ಯ ಮತ್ತು ಕು.ಕ.ಇಲಾಖೆ,ಬೆಂಗಳೂರು ಇವರ ಅ.ಸ.ಪ.ಸಂ.ಆಕುಕ-10/ ಸಿಜಿಎಸ್ 2016 ದಿ:07.02.2017.

3) ಮಾನ್ಯ ಆಯುಕ್ತರು, ಆರೋಗ್ಯ ಮತ್ತು ಕು.ಕ.ಸೇವೆಗಳು, ಬೆಂಗಳೂರು ಇವರ ಪ.ಸಂ. ಹೆಚ್‌ಎಸ್‌ಪಿ(3)/08/2017-18, ದಿ:06.05.2017.

4) ಜಿಲ್ಲಾ ಆರೋಗ್ಯ ಸಂಘದ ಸಭೆಯ ನಡವಳಿಗಳು ದಿ:02.07.2019

5) ಮುಖ್ಯ ಕಾರ್ಯನಿರ್ವಾಹಕ ಅಧಿಕಾರಿಗಳು, ಜಿ.ಪಂ.ಬೆಳಗಾವಿ ಇವರ ಕಡತ ಅನುಮೋದನೆ ದಿನಾಂಕ: 31.07.2019

ಮೇಲ್ಕಂಡ ವಿಷಯಕ್ಕೆ ಸಂಬಂಧಿಸಿದಂತೆ, ಪರಿಷ್ಕೃತ ಸರ್ಕಾರದ ಆದೇಶದ ಪ್ರಕಾರ ಆರೋಗ್ಯ ಬಂಧು ಯೋಜನೆಯಡಿ ಬೆಳಗಾವಿ ಜಿಲ್ಲೆ ಮತ್ತು ತಾಲೂಕಿನ ಪ್ರಾಥಮಿಕ ಆರೋಗ್ಯ ಕೇಂದ್ರಗಳಾದ, ವಂಟಮುರಿ, ಕಿಣಯೇ, ಹಾಗೂ ನಗರ ಆರೋಗ್ಯ ಕೇಂದ್ರಗಳಾದ ರುಕ್ಕಿಣಿನಗರ, ಅಶೋಕನಗರ ಇವುಗಳ ಕಾರ್ಯಭಾರವನ್ನು "ಆರೋಗ್ಯ ಬಂಧು" ಯೋಜನೆಯಲ್ಲಿಯೆ ಎಲ್ಲ ನಿಬಂಧನೆಗಳು ಹಾಗೂ ಷರತ್ತುಗಳಿಗೊಳಪಟ್ಟು ದಿ ; 01.07.2019 ರಿಂದ 30.06.2024 ರವರೆಗೆ ಮುಂದುವರಿಸಲಾಗಿದೆ.

ತಮ್ಮ ವಿಶ್ವಾಸಿ

ಜಿಲ್ಲಾ ಆರೋಗ್ಯ ಮತ್ತು ಕು.ಕ.ಅಧಿಕಾರಿಗಳು,
ಬೆಳಗಾವಿ.

ಪ್ರತಿ: ತಾಲೂಕಾ ಆರೋಗ್ಯಾಧಿಕಾರಿಗಳು, ಬೆಳಗಾವಿ ಇವರಿಗೆ ಮಾಹಿತಿಗಾಗಿ.

ಪ್ರತಿ: ವೈದ್ಯಾಧಿಕಾರಿಗಳು ಪ್ರಾಥಮಿಕ ಆರೋಗ್ಯ ಕೇಂದ್ರ, ವಂಟಮುರಿ, ಕಿಣಯೇ, ಹಾಗೂ ನಗರ ಆರೋಗ್ಯ ಕೇಂದ್ರ, ರುಕ್ಕಿಣಿನಗರ, ಅಶೋಕನಗರ ಇವರಿಗೆ ಮಾಹಿತಿಗಾಗಿ

ಪ್ರತಿಯನ್ನು ಮಾಹಿತಿಗಾಗಿ ಗೌರವಗಳೊಂದಿಗೆ ಸಲ್ಲಿಸಿದೆ.

1. ನಿರ್ದೇಶಕರು, ಆರೋಗ್ಯ ಮತ್ತು ಕು.ಕ.ಸೇವೆಗಳು, ಬೆಂಗಳೂರು-9.
2. ಸಹ ನಿರ್ದೇಶಕರು (ಆರೋಗ್ಯ ಮತ್ತು ಯೋಜನೆ), ಆ ಮತ್ತು ಕು.ಕ.ಸೇವೆಗಳು, ಬೆಂಗಳೂರು.
3. ಜಿಲ್ಲಾಧಿಕಾರಿಗಳು, ಬೆಳಗಾವಿ
4. ಮುಖ್ಯ ಕಾರ್ಯನಿರ್ವಾಹಕ ಅಧಿಕಾರಿಗಳು, ಜಿ.ಪಂ.ಬೆಳಗಾವಿ

ATTESTED

Prof. D. V. KOTHIWALE
Principal

KLE Academy of Higher Education
and Research, BELAGAVI

07





सत्यमेव जयते

INDIA NON JUDICIAL Government of Karnataka

e-Stamp

Certificate No.	: IN-KA60471638692753P
Certificate Issued Date	: 29-Jun-2017 03:31 PM
Account Reference	: NONACC (FI)/ kaksfcl08/ BELGAUM27/ KA-BL
Unique Doc. Reference	: SUBIN-KAKAKSFCLO869665230825633P
Purchased by	: PRINCIPAL KLE UNIVERSITY J N M C BELAGAVI
Description of Document	: Article 12 Bond
Description	: AGREEMENT
Consideration Price (Rs.)	: 0 (Zero)
First Party	: DIST HEALTH AND F W OFFICER BELAGAVI
Second Party	: PRINCIPAL KLE UNIVERSITY J N M C BELAGAVI
Stamp Duty Paid By	: PRINCIPAL KLE UNIVERSITY J N M C BELAGAVI
Stamp Duty Amount(Rs.)	: 100 (One Hundred only)



Authorized Signatures
Aadhar Multi-Purpose Souhard Sahasraj
Nyt. Shivabesev Nagar, BELGAUM.

Please write or type below this line

CONTRACT FORM

THIS AGREEMENT, 1st July 2017 made between the Government of Karnataka represented by the District Health and Family Welfare Officer, Belagavi, Government of Karnataka, of one part and Principal, KLE University's Jawaharlal Nehru Medical College, Belagavi of the other part.

ATTESTED

- 2 -

Statutory Alert:


1. The authenticity of this Stamp Certificate should be verified at "www.shcilestamp.com". Any discrepancy in the details on this Certificate and as available on the website renders it invalid.
2. The onus of checking the legitimacy is on the users of the certificate.
3. In case of any discrepancy please inform the Competent Authority.

V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

WHEREAS the First Party has formulated a scheme for involvement of the Private Medical Colleges and Non- Government Organizations in management of Primary Health Centers and Urban Health Centres in the State. The Second Party who is Principal, KLE University's Jawaharlal Nehru Medical College, Belagavi is desirous of participating in the scheme and offered its services in terms formulated by the Government.

NOW THIS AGREEMENT WITNESSETH AS FOLLOWS:

1. Words and expression used in the agreement shall have the same meanings as are respectively assigned to them in the Scheme notified by the Government Organizations in Management of Primary Health Centers and Urban Health Centres.
2. The Scheme notified by the Government of Karnataka for involvement of Private Medical Colleges and Non-Government Organizations in Management of Primary Health Centers and Urban Health Centres shall be deemed to form and be read and constructed as part of this agreement.
3. In consideration of the payments to be made by the First Party to the Second party as hereinafter mentioned, the Second party hereby covenants with the First Party to manage the Primary Health Centers and Urban Health Centres at Kinaye, Vantamuri and Ashok Nagar, Rukmini Nagar, Tal/Dist: Belagavi and the sub-centre coming under its jurisdiction and provide the services in conformity with all conditions laid down under the said schemes of the Government of Karnataka.



ATTESTED

Prof. Dr. V.A. KOTHIWALE
Registrar,
KLE Academy of Higher Education
and Research, BELAGAVI




INDIA NON JUDICIAL
Government of Karnataka

e-Stamp

Certificate No	: IN-KA47955791346129M
Certificate Issued On	: 01-Apr-2014 05:31 PM
Account Reference	: SHCIL (FI) KARNATAK SHCIL BELGAUM KA-BL
Under Doc Reference	: SUS N-KAKA-SHCIL51926378474338M
Purchaser's	: PRINCIPAL J N M C BELGAUM
Description of Document	: Article 12 Bond
Description	: AGREEMENT
Consideration Price (Rs.)	: 0
	: (Zero)
First Party	: DIRECTOR OF HEALTH AND F W SER GOVT OF KARNATAKA
Second Party	: PRINCIPAL J N M C BELGAUM
Stamp Duty Paid (Rs.)	: PRINCIPAL J N M C BELGAUM
Stamp Duty Amount (Rs.)	: 100
	: (One Hundred only)

Authorized Signatory
for Stock Holding Corporation of India Ltd.
No. 1, Basavakrupa, Opp. Civil Hospital,
Near Hanstraju Super Market,
Club Road, BELGAUM- 590003



Please write or type below this line

In consideration of the payments to be made by the First Party to the Government party as hereinafter mentioned, the Second Party hereby covenants with the First Party to provide the Primary Health Centres at (1) Mahalingpur (2) Hanstraju (3) Kalye of Taluka Belgaum, Dist Belgaum, and the subcentres coming under its jurisdiction and provide the services in conformity with the conditions laid down under the said schemes of the Government of Karnataka.

ATTESTED

K. K. B.

Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI.

The first party hereby covenants to reimburse the amounts to the Second Party in consideration of the provision of the Services stated above on a quarterly basis as provided in the Scheme notified by the Government of Karnataka.

5. The agreement period is for 5 year from 13-02-2014 to 12-02-2019. Evaluation from an Independent Agency will be conducted, based on the report the Health Department may continue or cancel the agreement in accordance with respect to adaption of the Primary Health Center.

IN WITNESS: Where of the parties here to have caused this Agreement to be executed in accordance with their respective laws the day and year first above written.

Signed, sealed and delivered by _____
Said _____ (for the First Party)


Signed, sealed and delivered by the
Said _____ PRINCIPAL (for the Second Party)
Jawaharal Nehru Medical College
BELGAUM


ATTESTED

TKK
Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

Scanned with CamScanner

ಸರ್ಕಾರದ ಆದೇಶ ಸಂಖ್ಯೆ : ಆ.ಕು.ಕ 33/ ಸಿ.ಜಿ.ಎಂ:/2011 ದಿನಾಂಕ: 30.09.2011 ರ ಪ್ರಕಾರ
ಬೆಳಗಾವಿ ಮಹಾನಗರ ಪ್ಯಾಪ್ಪಿಯಲ್ಲಿ ಬರುವ ನಗರ ಆರೋಗ್ಯ ಕೇಂದ್ರ - ರುಕ್ಮಿಣಿನಗರ, ರಾಮನಗರ,
ಹಾಗೂ ಅಶೋಕನಗರ ಇವುಗಳನ್ನು ಪ್ರಾಂಶುಪಾಲರು ಜವಾಹರಲಾಲ್ ನೆಹರು ವೈದ್ಯಕೀಯ
ಮಹಾವಿದ್ಯಾಲಯ ಬೆಳಗಾವಿ ಇವರಿಗೆ ದತ್ತು ನಿರ್ವಹಣೆಗಾಗಿ ಪೂರ್ಣ ಕಾರ್ಯಭಾರವನ್ನು ದಿನಾಂಕ:
01.12.2011 ರಿಂದಾ ಹಸ್ತಾಂತರಿಸಲಾಗಿದೆ.


ಪ್ರಾಂಶುಪಾಲರು
ಜವಾಹರಲಾಲ್ ನೆಹರು
ವೈದ್ಯಕೀಯ ಮಹಾವಿದ್ಯಾಲಯ ಬೆಳಗಾವಿ
28/11/2011



ಡಾ|| ಎ.ಎಂ. ಮುರಗೋಡ
ಜಿಲ್ಲಾ ಆರೋಗ್ಯ ಮತ್ತು ಕು.ಕೆ ಅಧಿಕಾರಿಗಳು
ಬೆಳಗಾವಿ

ATTESTED



Prof. Dr. V. A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELGAUM

Scanned with CamScanner





सत्यमेव जयते

INDIA NON JUDICIAL Government of Karnataka

e-Stamp

Certificate No	IN-KA47955667573409M
Certificate Issued Date	01-Apr-2014 05:30 PM
Account Reference	SHCIL (FI)/ ka-shcil/ SHCIL BELGAUM/ KA-BL
Unique Doc. Reference	SUBIN-KAKA-SHCIL51925755352160M
Purchased by	PRINCIPAL J N M C BELGAUM
Description of Document	Article 12 Bond
Description	AGREEMENT
Consideration Price (Rs.)	0 (Zero)
First Party	DIRECTOR OF HEALTH AND F W SER GOVT OF KARNATAKA
Second Party	PRINCIPAL J N M C BELGAUM
Stamp Duty Paid By	PRINCIPAL J N M C BELGAUM
Stamp Duty Amount (Rs.)	100 (One Hundred only)


 Authorised Signatory
 For Stock Holding Corporation of India Ltd.
 No.1, Basavakrupa, Opp. Civil Hospital
 Near Hansraj Super Market,
 Club Road, BELGAUM-590001



Please write or type below anything.....

APPENDIX V

CONTRACT FORM

THIS AGREEMENT made the 7th day of MAY 2014 between Governor of Karnataka, represented by the Director of Health and Family Welfare Services, Government of Karnataka, (hereinafter referred to as the "first party") of one part and Principal, K.L.E Society's Jawaharal Nehru Medical College, Belgaum - 590010, Karnataka, (hereinafter referred to as the "second party") of the other part.

ATTESTED


 Prof. Dr. V.A.KOTHIWALE
 Registrar

KLE Academy of Higher Education
 and Research, BELAGAVI

Scanned with CamScanner

[Handwritten Signature]

ATTESTED

NOW THIS AGREEMENT WITNESSETH AS FOLLOWS:

WHEREAS the Government of Karnataka has formulated a scheme - Arogya Bandhu Scheme for involvement of the Private Medical Colleges and Non-Government Organizations in management of Primary Health Centres in the State; and whereas the Government of Karnataka is desirous of participating in the scheme and offered its services; and whereas the Government of Karnataka has formulated the terms; formulated by the Government

Words and expressions used in this agreement shall have the same meanings as are respectively assigned to them in the Scheme and Government Organizations in Management of Primary Health Centres notified by the Government of Karnataka for involvement of Private Medical Colleges and Non-Government Organizations in Management of Primary Health Centres shall be deemed to form part of and construed as part of this agreement.




सत्यमेव जयते

INDIA NON JUDICIAL Government of Karnataka

e-Stamp

Certificate No. : IN-KA29548044460739J
 Certificate Issued Date : 08-Nov-2011 02:41 PM
 Account Reference : SHCIL (FI)/ ka-shcil/ SHCIL BELGAUM/ KA-BL
 Unique Doc. Reference : SUBIN-KAKA-SHCIL38737286415854J
 Purchased by : PRINCIPAL KLE UNIV J N MEDICAL COLLEGE BGM
 Description of Document : Article 12 Bond
 Description : AGREEMENT
 Consideration Price (Rs.) : 0
 (Zero)
 First Party : DIRECTOR OF HEALTH AND FW SER GOVT OF KARNATAKA
 Second Party : PRINCIPAL KLE UNIV J N MEDICAL COLLEGE BGM
 Stamp Duty Paid By : PRINCIPAL KLE UNIV J N MEDICAL COLLEGE BGM
 Stamp Duty Amount (Rs.) : 100
 (One Hundred only)

Authorised Signatory
 for Stock Holding Corporation of India Ltd.
 No. 1, ... Hospital,
 ...
 ... 530001



Please write or type below this line

- : 3 : -

3. In consideration of the payments to be made by the First Party to the Second party as hereinafter mentioned, the Second Party hereby covenants with the First Party to manage the Urban Health Centres at (1) Rukmini Nagar (2) Ram Nagar and (3) Ashok Nagar of Belgaum, Dist: Belgaum, and provide the services in conformity with all conditions laid down under the said scheme of the Government of Karnataka.

Contd....4.

ATTESTED

Prof. Dr. V.A.KOTHIWALE
 Registrar
 KLE Academy of Higher Education
 and Research, BELAGAVI

Scanned with CamScanner

4. The first party hereby covenants to reimburse the amounts to the Second Party in consideration of the provision the Services stated above once a quarter as provided in the Scheme notified by the Government of Karnataka.

IN WITNESS: Where of the parties here to have caused this Agreement to be executed in accordance with their respective laws the day and year first above written.

Signed, sealed and delivered by the

Said.....Director
(for the First Party) Services
Health
BANGALORE

Signed, sealed and delivered by the

Said.....
(for the Second Party)
Jawaharlal Nehru Medical College
BELGAUM-590 010

IN THE PRESENCE OF WITNESS:

1. M. K. Kulkarni

2. M. N. Kumbhar

WITNESSED

Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

ಆರೋಗ್ಯ ಮತ್ತು ಕುಟುಂಬ ಸೇವೆಗಳ ನಿರ್ದೇಶನ
ಅನಂದರಾವ್ ವೃತ್ತ, ಬೆಂಗಳೂರು.
ದಿನಾಂಕ: -12-2014.

Office of the
DEAN
MEDICAL COLLEGE
BELAGAVI
2721
07 JAN 2015
Dr. Katti
Inward
Sign

ಅಧಿಕೃತ ಜ್ಞಾಪನಾ ಪತ್ರ 31/12/2015

ವಿಷಯ:- ಶ್ರೀ ಜವಹಾರಲಾಲ್ ನೆಹರು ಮೆಡಿಕಲ್ ಕಾಲೇಜು, ಬೆಳಗಾವಿ ಇವರಿಂದ ಆರೋಗ್ಯ ಬಂಧು ಯೋಜನೆಯಡಿ ಕಾರ್ಯ ನಿರ್ವಹಿಸಲಾಗುತ್ತಿರುವ ರುಕ್ಮಿಣಿ ನಗರ, ರಾಮನಗರ ಹಾಗೂ ಆರೋಕ ನಗರ ಪ್ರಾಥಮಿಕ ಆರೋಗ್ಯ ಕೇಂದ್ರಗಳ ನಿರ್ವಹಣೆಯನ್ನು ನೋಡಿಸುವ ಬಗ್ಗೆ.

- ಉಲ್ಲೇಖ:- 1. ಜಿ.ಎನ್.ಎಂ.ಸಿ.ಬೆಳಗಾವಿ ಇವರ ಪತ್ರ ಸಂಖ್ಯೆ: ಎಂಡಿಸಿ/ಎಚ್‌ಎಸ್/1307. ದಿ:28-06-2014.
- 2. ಆರೋಗ್ಯ ಬಂಧು ಯೋಜನೆಯಡಿಯ ರಾಜ್ಯ ಮಟ್ಟದ ಸಮನ್ವಯ ಸಭೆಯ ನಡವಳಿ ದಿನಾಂಕ:14-11-2014.

ಮೇಲ್ಕಂಡ ವಿಷಯಕ್ಕೆ ಸಂಬಂಧಿಸಿದಂತೆ, ಉಲ್ಲೇಖಿತ ಪತ್ರದನ್ವಯ ಜವಹಾರ್‌ಲಾಲ್ ನೆಹರು ಮೆಡಿಕಲ್ ಕಾಲೇಜು, ಬೆಳಗಾವಿ ಇವರಿಂದ ಆರೋಗ್ಯ ಬಂಧು ಯೋಜನೆಯಡಿಯಲ್ಲಿ ಕಾರ್ಯನಿರ್ವಹಿಸುತ್ತಿರುವ ಬೆಳಗಾವಿ ನಗರ ಜಿಲ್ಲೆಯ ರುಕ್ಮಿಣಿ ನಗರ, ರಾಮನಗರ ಹಾಗೂ ಆರೋಕ ನಗರ ಪ್ರಾಥಮಿಕ ಆರೋಗ್ಯ ಕೇಂದ್ರಗಳ ನಿರ್ವಹಣೆಯನ್ನು ಎರಡು ವರ್ಷದ ಕಾಲಾವಧಿಗೆ ಆಂದರೆ ದಿನಾಂಕ:16-11-2013 ರಿಂದ ದಿನಾಂಕ:15-11-2015ರವರೆಗೆ ಮುಂದುವರಿಸಲಾಗಿದೆ.


ಈ ಪ್ರಾಥಮಿಕ ಆರೋಗ್ಯ ಕೇಂದ್ರ ಆರೋಗ್ಯ ಬಂಧು ಯೋಜನೆಯ ಷರತ್ತು ಹಾಗೂ ಮಾರ್ಗ ಸೂಚಿಗಳು ಅನ್ವಯಿಸುತ್ತವೆ ಹಾಗೂ ಈ ಯೋಜನೆಯಡಿ ಕಾಲಕಾಲಕ್ಕೆ ಹೊರಡಿಸಲಾದ ಆದೇಶಗಳು ಅನ್ವಯವಾಗುತ್ತವೆ. ಪ್ರಾಥಮಿಕ ಆರೋಗ್ಯ ಕೇಂದ್ರದ ನಿರ್ವಹಣೆಯನ್ನು ಅಂಗೀಕೃತ ಸಂಸ್ಥೆಯಿಂದ ಬಾಹ್ಯ ಮೌಲ್ಯ ಮಾಪನ ಮಾಡಿಸಿ ಅವರ ವರದಿಯ ಆಧಾರದ ಮೇಲೆ ನವೀಕರಣವನ್ನು ಮುಂದುವರಿಸಲು/ರದ್ದುಪಡಿಸುವ ಬಗ್ಗೆ ತೀರ್ಮಾನವನ್ನು ಇಲಾಖೆಯು ತೆಗೆದುಕೊಳ್ಳಲಾಗುವುದು.

ಈ ಪತ್ರ ತಲುಪಿದ 15 ದಿನದೊಳಗಾಗಿ ರೂ.200/- ಗಳ ಭಾಜ ಕಾಗದದಲ್ಲಿ ಆರೋಗ್ಯ ಬಂಧು ಯೋಜನೆಯ ಕೃತಿಯಲ್ಲಿರುವ ಅನುಬಂಧ-5ರಂತೆ ಕರಾರು ಒಪ್ಪಂದವನ್ನು ನಿರ್ದೇಶನಾಲಯದಲ್ಲಿ ಮಾಡಿಕೊಳ್ಳುವುದು.

[Signature]
ಆಯುಕ್ತರು,
ಆರೋಗ್ಯ ಮತ್ತು ಕುಟುಂಬ ಸೇವೆಗಳು,
ಬೆಂಗಳೂರು.

ಇವರಿಗೆ:-
ಪ್ರಾಂಶುಪಾಲರು,
ಜವಹಾರ್‌ಲಾಲ್ ನೆಹರು ಮೆಡಿಕಲ್ ಕಾಲೇಜು,
ನೆಹರು ನಗರ, ಬೆಳಗಾವಿ - 590 010.

ಪ್ರತಿಯನ್ನು:- ಜಿಲ್ಲಾ ಆರೋಗ್ಯ ಮತ್ತು ಕುಟುಂಬ ಸೇವೆಗಳು, ಬೆಳಗಾವಿ - 590 001. ಇವರ ಮಾಹಿತಿಗಾಗಿ ಹಾಗೂ ಮುಂದಿನ ಕ್ರಮಕ್ಕಾಗಿ




सत्यमेव जयते

INDIA NON JUDICIAL Government of Karnataka

e-Stamp

Certificate No. : IN-KA29547021078857J
 Certificate Issued Date : 08-Nov-2011 02:40 PM
 Account Reference : SHCIL (FI)/ ka-shcil/ SHCIL BELGAUM/ KA-BL
 Unique Doc. Reference : SUBIN-KAKA-SHCIL38735204093398J
 Purchased by : PRINCIPAL KLE UNIV J N MEDICAL COLLEGE BGM
 Description of Document : Article 12 Bond
 Description : AGREEMENT
 Consideration Price (Rs.) : 0
 (Zero)
 First Party : DIRECTOR OF HEALTH AND F W SER. GOVT OF KARNATAKA
 Second Party : PRINCIPAL KLE UNIV J N MEDICAL COLLEGE BGM
 Stamp Duty Paid By : PRINCIPAL KLE UNIV J N MEDICAL COLLEGE BGM
 Stamp Duty Amount(Rs.) : 100
 (One Hundred only)



Signature
 No. 1, ...
 Club Road, BELGAUM - 590001

-----Please write or type below this line-----

APPENDIX V CONTRACT FORM

THIS AGREEMENT made the 16 day of November 2011 between Governor of Karnataka, represented by the Director of Health and Family Welfare Services, Government of Karnataka, (hereinafter referred to as the "first party") of one part and Principal, KLE University's Jawaharlal Nehru Medical College, Belgaum - 590010, Karnataka (name of the Agency) (hereinafter referred to as the "second party") of the other part.

ATTESTED

Contd....2...

Secretary Alert

Prof. Dr. V.A.KOTHIWALE
 Registrar
 KLE Academy of Higher Education
 and Research, BELAGAVI

Scanned with CamScanner

: 2: -

WHEREAS the First Party has formulated a scheme - Arogya Bandhu Scheme for involvement of the Private Medical Colleges and Non-Government Organizations in management of Urban Health Centres in the State. The Second Party who is Principal, KLE University's Jawaharlal Nehru Medical College, Belgaum is desirous of participating in the scheme and offer its services in terms formulated by the Government.

NOW THIS AGREEMENT WITNESSETH AS FOLLOWS:

1. Words and expressions used in the agreement shall have the same meanings as are respectively assigned to them in the Scheme notified by the Government Organizations in Management of Urban Health Centres.
2. The Scheme notified by the Government of Karnataka for involvement of Private Medical Colleges and Non-Government Organizations in Management of Urban Health Centres shall be deemed to form and be read and constructed as part of this agreement.

Contd....3.

ATTESTED



Principal, Jawaharlal Nehru Medical College

KLE A. J. S. University of Higher Education
and Research, BELGAUM

Scanned with CamScanner


90. No. Comm. Medicine
(Imp)

ಕರ್ನಾಟಕ ಸರ್ಕಾರ

ಸಂ.ಪಚ್.ಎಸ್.ಪಿ/(1)65/2000-01

ಆರೋಗ್ಯ ಮತ್ತು ಕುಟುಂಬ ಕಲ್ಯಾಣ
ಸೇವೆಗಳ ನಿರ್ದೇಶನಾಲಯ,
ಬೆಂಗಳೂರು. ಡಿ. 30 7-2009

ಇವರಿಗೆ
ಜಿಲ್ಲಾ ಆರೋಗ್ಯ ಮತ್ತು ಕುಟುಂಬ ಕಲ್ಯಾಣ ಅಧಿಕಾರಿಗಳು
ಬೆಳಗಾವಿ.



ವಿಷಯ: ಜಿ.ಎನ್.ಎಂ.ಸಿ. ಮಹಾವಿದ್ಯಾಲಯ, ಬೆಳಗಾವಿ ಇವರು ನಿರ್ವಹಿಸುತ್ತಿರುವ ಪ್ರಾಥಮಿಕ
ಆರೋಗ್ಯ ಕೇಂದ್ರಗಳಾದ ಕಿಣಿಯೇ, ಹಂದಿಗನೂರು ಮತ್ತು ಪಂಟಮುರಿ ಪುರಾತನಕಾಲದ
ಬಗ್ಗೆ.

- ಉಲ್ಲೇಖ : 1. ದಿನಾಂಕ 15-6-2009 ರಂದು ಆಯ್ಕೆ ಸಮಿತಿ ನಡವಳಿಗಳು
2. ಜಿ.ಎನ್.ಎಂ.ಸಿ. ಪ್ರಸ್ತಾವನೆ

ಮೇಲ್ಕಾಣಿಸಿದ ವಿಷಯ ಹಾಗೂ ಉಲ್ಲೇಖದನ್ವಯ ಜಿ.ಎನ್.ಎಂ.ಸಿ. ಮಹಾವಿದ್ಯಾಲಯ,
ಬೆಳಗಾವಿ ಇವರು ದತ್ತು ತೆಗೆದುಕೊಂಡು ನಿರ್ವಹಿಸುತ್ತಿರುವ ಕಿಣಿಯೇ, ಹಂದಿಗನೂರು ಮತ್ತು
ಪಂಟಮುರಿ ಪ್ರಾಥಮಿಕ ಆರೋಗ್ಯ ಕೇಂದ್ರಗಳ ದತ್ತು ನಿರ್ವಹಣೆಯನ್ನು ಮುಂದುವರಿಸಲು ಕೋರಿವುದು.
ಮೇಲಿನ ಉಲ್ಲೇಖಗಳನ್ವಯ ದತ್ತು ನಿರ್ವಹಣೆಯನ್ನು ಮುಂದಿನ 5 (ಐದು) ವರ್ಷಗಳ ವರೆಗೆ
ವಿಸ್ತರಿಸಲಾಗಿದೆ. ಅನುಮತಿಯು ಆರೋಗ್ಯ ಬಂಧು ಯೋಜನೆಯ ಎಲ್ಲ ನಿಬಂಧನೆಗಳನ್ನು ಪಾಲಿಸುವ
ಷರತ್ತುಗಳಿಗೆ ಒಳಪಟ್ಟಿದೆ.

2009-10 ನೇ ಸಾಲಿಗೆ ವೇತನವನ್ನು ಲೆಕ್ಕಶೀರ್ಷಿಕೆ 2210-03-103-0-72 ಯೋಜನೆ ಅಥವಾ
ಕರುಣಾ ಟ್ರಸ್ಟ್ - ಸಹಾಯಾನುದಾನ ಲೆ.ಶಿ.2211-00-101-0-04 (ಯೋಜನೆ) ಅಡಿಯಲ್ಲಿ
ನಿಗದಿಪಡಿಸಿಕೊಂಡು ಭರಿಸಬಹುದಾಗಿದೆ.

(Signature)

ನಿರ್ದೇಶಕರು

ಆರೋಗ್ಯ ಮತ್ತು ಕುಟುಂಬ ಕಲ್ಯಾಣ ಸೇವೆಗಳು
ಬೆಂಗಳೂರು

ಪ್ರತಿಯನ್ನು ಜಿ.ಎನ್.ಎಂ.ಸಿ. ಮಹಾವಿದ್ಯಾಲಯ, ಬೆಳಗಾವಿ ಇವರಿಗೆ ಮಾಹಿತಿಗಾಗಿ ಹಾಗೂ ವೇತನ
ಸಂಬಂಧವಾಗಿ ಜಿಲ್ಲಾ ಆಹುಕ ಅಧಿಕಾರಿಯವರನ್ನು ಸಂಪರ್ಕಿಸಬಹುದಾಗಿದೆ. 5

ATTESTED

(Signature)

Professor V.A. (1) - MALE

College of Health Sciences, Bangalore

Scanned with CamScanner

Office of the Registrar
KLE Academy of Higher Education
and Research, Belagavi
Date: 11-05-2014
610

ಅಧಿಕೃತ ಪ್ರಕಟಣೆ ಬಗ್ಗೆ

ಮಾನ್ಯ ಅಧ್ಯಾಪಕರುಗಳಿಗೆ ಸೇರಿದಂತೆ ಪ್ರಾಚಾರ್ಯರುಗಳಿಗೆ ಮತ್ತು ಅಧ್ಯಾಪಕರುಗಳಿಗೆ ವಿವಿಧ ಯೋಜನೆಗಳಡಿ ಕೆಲವು ಅಧಿಕೃತ ಪ್ರಕಟಣೆಗಳನ್ನು ಪ್ರಕಟಿಸಲು ಮತ್ತು ಪ್ರತಿಪಾಲಕರುಗಳಿಗೆ ಸೇರಿದಂತೆ ಅಧಿಕೃತ ಪ್ರಕಟಣೆಯನ್ನು ಮುಂದುವರಿಸುವ ಬಗ್ಗೆ.

1. ಅಧಿಕೃತ ಪ್ರಕಟಣೆಗಳಿಗೆ ಸೇರಿದಂತೆ ಅಧಿಕೃತ ಪ್ರಕಟಣೆಗಳನ್ನು ಪ್ರಕಟಿಸಲು ದಿನಾಂಕ: 08-01-2014
2. ಅಧಿಕೃತ ಪ್ರಕಟಣೆ ಯೋಜನೆಗಳಿಗೆ ಸೇರಿದಂತೆ ಅಧಿಕೃತ ಪ್ರಕಟಣೆಗಳನ್ನು ಪ್ರಕಟಿಸಲು ದಿನಾಂಕ: 26-02-2014
3. ಅಧಿಕೃತ ಪ್ರಕಟಣೆಗಳಿಗೆ ಸೇರಿದಂತೆ ಅಧಿಕೃತ ಪ್ರಕಟಣೆಗಳನ್ನು ಪ್ರಕಟಿಸಲು ದಿನಾಂಕ: 28-03-2014

ಮೇಲ್ಕಂಡ ವಿಷಯಕ್ಕೆ ಸಂಬಂಧಿಸಿದಂತೆ, ಸುಸ್ಥಿರವಾಗಿ ಕಾರ್ಯನಿರ್ವಹಿಸುತ್ತಿರುವ ಮತ್ತು ಕಾರ್ಯನಿರ್ವಹಿಸುತ್ತಿರುವ ಬೆಳಗಾವಿ ಇವುಗಳ ಅಧಿಕೃತ ಪ್ರಕಟಣೆಗಳನ್ನು ಪ್ರಕಟಿಸಲು ಅಧಿಕೃತ ಪ್ರಕಟಣೆಗಳನ್ನು ದಿನಾಂಕ: 26-02-2014 ರಂದು ಪ್ರಕಟಿಸಲು ಮತ್ತು ಪ್ರಕಟಣೆಗಳನ್ನು ಪ್ರಕಟಿಸಲು ದಿನಾಂಕ: 13-01-2014 ರಂದು ಪ್ರಕಟಿಸಲು ದಿನಾಂಕ: 12-02-2014 ರವರೆಗೆ ಮುಂದುವರಿಸಲಾಗಿದೆ.

ಈ ಪ್ರಾಥಮಿಕ ಅಧಿಕೃತ ಪ್ರಕಟಣೆಗಳನ್ನು ಅಧಿಕೃತ ಪ್ರಕಟಣೆಗಳನ್ನು ಪ್ರಕಟಿಸಲು ದಿನಾಂಕ: 26-02-2014 ರಂದು ಪ್ರಕಟಿಸಲು ದಿನಾಂಕ: 13-01-2014 ರಂದು ಪ್ರಕಟಿಸಲು ದಿನಾಂಕ: 12-02-2014 ರವರೆಗೆ ಮುಂದುವರಿಸಲಾಗಿದೆ.

ಸಹಿ
ಅಧಿಕೃತ ಪ್ರಕಟಣೆ
Registrar

ATTESTED

Kelle
Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

Certified that a sum of Rs. 100/- (Rupees one hundred only) has been paid towards Karnataka Stamp duty

by Sri/Smt. Principal J.N. Medical College

s/d/w of _____

Mr. Name: _____
Date: 13 FEB 2004 Belgaum Branch
Proper Officer / SS Number _____

N. KULKARNI
SS No. 2050


121

4) The First Party hereby covenants to reimburse the amounts to the second party in consideration of the provision of the services stated above, once a quarter as provided in the scheme notified by the Government of Karnataka.

IN WITNESS: Whereof the parties hereto have caused this agreement to be executed in accordance with their respective laws the day and year first above written.

Signed, sealed and Delivered by
The said.....
(For the first party)

DIRECTOR
Health & F.W. Services
Bangalore-2.



Signed, sealed and delivered by the
said K.L.E. Society's Principal
Jawaharlal Nehru Medical College,
Belgaum
(For the second party)

In the presence of (Witness - I)

(Dr. S.S. Malhedgar)
A.D. (CMD)
DH (HWS, Belgaum)

In the presence of (Witness - II)

(Dr. H.B. Rajasekhari)
Director
KLE, Belgaum.

ATTESTED

[Signature]
Prof. Dr. V.A KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

ISSUED BY STATE BANK OF MYSORE ON BEHALF OF GOVERNMENT OF KARNATAKA

CP/I 478107

100

Certified that a sum of Rs. 100/- (Rupees one hundred only) has been paid towards Karnataka Stamp duty

by Sri/Smt. Principal J.N. Medical College

of

Its Name:

Date 3 FEB 2004

[Signature]
Proprietor/Officer's Number

R. H. KULKARNI

SS No. 2050

100


**APPENDIX IV
CONTRACT FORM**

THIS AGREEMENT made the 16th Day of February 2004 Between Governor of Karnataka, represented by the Director of Health and Family Welfare Services, Government of Karnataka, (hereinafter referred to as the First Party) of one part and Principal, K.L.E.Society's, Jawaharlal Nehru Medical College, Belgaum-5900010 (name of the Agency) hereinafter referred to as the second Party) of the other parts -

WHEREAS the first party has formulated a scheme for involvement of the Private Medical Colleges and Non-Governmental Organisations in management of Primary Health Centres in the State. The Second Party who is Principal of K.L.E.Society's, J.N.Medical College, Belgaum (Nature of the agency) is desirous of participating in the scheme and offered its services in Terms of the scheme formulated by the Government.

NOW THIS AGREEMENT WITNESSETH AS FOLLOWS -

- 1) Words and expressions used in this agreement shall have the same meanings as are respectively assigned to them in the scheme notified by the Government of Karnataka for involvement of Private Medical Colleges and Non-governmental Organisations in Management of Primary Health Centres.
- 2) The Scheme notified by the Government of Karnataka for involvement of Private Medical Colleges and Non-governmental organization in Management of Primary Health Centres shall be deemed to form and be read and constructed as part of this agreement.
- 3) In consideration of the payments to be made by the First Party to the second party as hereinafter mentioned, the second party hereby covenants with the First Party to manage the Primary Health Centres at Vantamuri, Handiganur and Kinaye, Taluka and District Belgaum and the Sub-Centres coming under their jurisdiction and provide the services in conforming or conformity with all conditions laid down under the said scheme of the Government of Karnataka.



Contd...2...

[Signature]
PRINCIPAL
Jawaharlal Nehru Medical College
BELGAUM

ATTESTED

[Signature]
Prof. Dr. V.A.KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

Scanned with CamScanner

ಸರ್ಕಾರದ ಆದೇಶ ಸಂಖ್ಯೆ: ಆಕೆ/ಃ: ೨೭೦ ಆಯೋಜನೆ: ೨೦೦೦ ದಿನಾಂಕ ೦೮/೦೨/೨೦೦೨

ಮತ್ತು ನಿರ್ದೇಶಕರು ಆರೋಗ್ಯ ಕುಟುಂಬ ಕಲ್ಯಾಣ ಸಚಿವರುಗಳ ಪಂಗಡದ ಇವರ ಆದೇಶ

ಸಂಖ್ಯೆ: ಹೆಚ್‌ಎಸ್‌ಪಿ (೧): ೭೫: ೨೦೦೦-೦೧ ದಿನಾಂಕ ೨೦/೦೨/೨೦೦೨ರ ಪ್ರಕಾರ ಹಾಗೂ

ದಿನಾಂಕ ೨೭/೦೨/೨೦೦೨ ದಿನಾಂಕದ ಜಿ.ಎನ್.ಎಂ.ಸಿ ಬೆಳಗಾವಿಯಲ್ಲಿ ಆದ ಸಭೆಯ

ಒಪ್ಪಂದದ ಪ್ರಕಾರ ಪ್ರಾಥಮಿಕ ಆರೋಗ್ಯ ಕೇಂದ್ರ ವಂಟಪುಲಂ, ಹಂಪಿಗನೂರು, ಕಣಿವೆಯ

ಇವುಗಳನ್ನು ಕೆ.ಎಲ್.ಇ. ಸಂಸ್ಥೆಯ ಜವಾಬ್ದಾರಿಯ ನಡವಳಿಯ ಮಹಾಯುಜ್ಜಿಯ ಮಹಾಯುಜ್ಜಿಯ

ಬೆಳಗಾವಿ ಇವರಿಗೆ ನಿರ್ದೇಶಿಸಿರುವ ಪ್ರಾಧಿಕಾರವನ್ನು ದಿನಾಂಕ ೦೭/೦೨/೨೦೦೨

ರಂದು ಹಸ್ತಾಂತರಿಸಲಾಗಿದೆ.

ಇ: ಡಿ. ಕೆ. ಶರಣ್
ಪ್ರಾಂಶುಪಾಲರು
ಜಿ.ನ್.ಪೈದೇಕೆಯ ಮಹಾಯುಜ್ಜಿಯ
ಬೆಳಗಾವಿ.

ಇ: ಎಸ್. ಸಿ. ಶರಣ್
ಜಿ.ಎಂ.ಸಿ ಬೆಳಗಾವಿ
ಕುಟುಂಬ ಕಲ್ಯಾಣ ಅಧಿಕಾರಿಗಳು
ಬೆಳಗಾವಿ.

ATTESTED

W.L.


INDIA NON JUDICIAL

Government of National Capital Territory of Delhi



सत्यमेव जयते

Certificate No. : IN-DL43293428071778S
Certificate Issued Date : 21-May-2020 01:11 PM
Account Reference : IMPACC (IV)/ dl870703/ DELHI/ DL-DLH
Unique Doc. Reference : SUBIN-DL43293428071778S
Purchased by : SMILE TRAIN INDIA
Description of Document : Article 5 General Agreement
Property Description : Not Applicable
Consideration Price (Rs.) : 0
(Zero)
First Party : SMILE TRAIN INDIA
Second Party : Not Applicable
Stamp Duty Paid By : SMILE TRAIN INDIA
Stamp Duty Amount (Rs.) : 150
(One Hundred And Fifty only)



Please write or type below this line

Grant Agreement

This grant agreement ("**Agreement**") is made between Smile Train India, a not-for-profit company incorporated under the laws of India, having its registered office at Plot No.3, LSC Sector-C, Pocket 6/7, Vasant - Kunj New Delhi - 110070 (hereinafter referred to as "**Smile Train**", which expression shall unless repugnant to the context or meaning thereof mean and include its successors and permitted assigns); and Karnataka Lingayat Education Society ("**Organization**") which owns and operates a hospital in the name and style of KLES Prabhakar Kore Hospital & Medical Research Centre located at Nehru Nagar, Belagavi 590010, Karnataka (collectively hereinafter referred to as "**the Hospital**", which expression shall unless repugnant to the context or meaning thereof mean and include its successors and permitted assigns).

Smile Train and the Hospital are hereinafter individually referred to as "**Party**" and collectively referred to as "**Parties**".

[Signature]
Secretary
Medical Director & Chief Executive
KLES Dr Prabhakar Kore Hospital &
Medical Research Centre, BELAGAVI, KARNATAKA

[Signature]
Project Director
KLES Smile Train Project
KLES Dr Prabhakar Kore Hospital &
Medical Research Centre, BELAGAVI, KARNATAKA

1. The authenticity of this Stamp Certificate should be verified at www.stampcert.gov.in. Any discrepancy in the details on this certificate and as available on the website renders it invalid.
2. The onus of checking the legitimacy is on the users of the certificate.

Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

Grant Agreement

This grant agreement ("Agreement") is made between Smile Train India, a not-for-profit company incorporated under the laws of India, having its registered office at Plot No.3, LSC Sector-C, Pocket 6/7, Vasant - Kunj New Delhi - 110070 (hereinafter referred to as "Smile Train", which expression shall unless repugnant to the context or meaning thereof mean and include its successors and permitted assigns); and Kamataka Lingayat Education Society ("Organization") which owns and operates a hospital in the name and style of KLES Prabhakar Kore Hospital & Medical Research Centre located at Nehru Nagar, Belagavi 590010, Kamataka (collectively hereinafter referred to as "the Hospital", which expression shall unless repugnant to the context or meaning thereof mean and include its successors and permitted assigns).

Smile Train and the Hospital are hereinafter individually referred to as "Party" and collectively referred to as "Parties".

Handwritten signature

Handwritten initials

SECRETARY
Board of Management
K.L.E. Society, BELAGAVI

Handwritten signature
ATTESTED
KLES Smile Train Project
KLES Dr. Prabhakar Kore Hospital & Medical Research Centre
Belagavi

Handwritten signature
Medical Director & Chief Executive
KLES Dr. Prabhakar Kore Hospital & Medical Research Centre BELAGAVI

Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

RECITALS

- A Smile Train is a charity whose mission is to provide assistance and support for treatments required by underprivileged children born with cleft lips and palates.
- B The Hospital has the requisite equipment, infrastructure and suitably qualified and trained medical staff capable of providing medical treatment for cleft lips and palates.
- C The Parties now desire to enter into a cooperative, joint effort initiative through which the Hospital will undertake cleft reconstructive surgeries, extend other comprehensive care to the patients referred by Smile Train, assist Smile Train in spreading awareness/ education on cleft lips and palates and educating and training medical professionals that are part of the initiative ("Program").

1. DEFINITIONS

- 1.1 Capitalized terms used herein (including in the introductory paragraph and recitals) shall have the meaning assigned to them under this Agreement.
- 1.2 Clause headings and other headings in this Agreement are for reference purposes only and shall not affect the meaning or interpretation of this Agreement.
- 1.3 Words denoting the singular shall include the plural and vice-versa.
- 1.4 When the word "including" is used in this Agreement, it shall mean "including without limitation".

2. TERM AND EFFECTIVE DATE

- 2.1 This Agreement shall begin on 1st April 2020 (the "Effective Date") and continue until 31st October 2021, unless expressly terminated as provided in Section 9 (Termination) of this Agreement.
- 2.2 Upon expiration of such period, this Agreement shall stand terminated unless Smile Train in its sole discretion renews this Agreement.

3. GRANT CONDITIONS

- 3.1 Smile Train will provide grants to the Hospital towards the performance of Hospital's obligations under the Program and this Agreement. The Hospital must ensure that the Program is carried out in accordance with this Agreement, and the grants given by Smile Train to the Hospital for carrying out the Program, are utilized only for the Program.
- 3.2 The grants provided by Smile Train in furtherance to this Agreement will be subject to the issuance of letters by Smile Train which capture the details of the grants and the manner in which such grants would need to be utilized by the Hospital ("Cover Letter"). The Hospital hereby agrees to comply with any additional condition mentioned under the Cover Letter, in addition to the conditions mentioned under this Agreement. It is hereby clarified that until the issuance of the Cover Letter, Smile Train does not undertake any representation in respect of any grants to be provided in furtherance of this Agreement, towards the Program.
- 3.3 The Hospital will not, offer, give or agree to offer or give (either alone or in agreement with others) any payment, gift or other advantage with respect to any matters which are the subject of this Agreement or which would violate any anti-corruption or bribery laws or regulations.
- 3.4 Grants must never be used for any political activity or any activity to carry out religious conversions.
- 3.5 The Hospital will inform Smile Train if there has been or may be a material change:
 - (a) in the Hospital's ability to carry out the Program, or any adverse effect or significant delay in carrying out the Program;
 - (b) the compliance with this Agreement (including suspicion of or actual fraud, corruption, financial impropriety, conflict of interest or other misuse of grants); or
 - (c) financial and other information concerning you and your operations which may influence Smile Train's decision to provide or continue disbursing grants to the Hospital for the Program.

B. J. ...
SECRETARY

Board of Management
KLE Society, BELAGAVI

Dr. Rajesh S. Power
Project Director

KLES Smile Train Project
Dr. Prabhakar K. ...
B.A.C. ...

ATTESTED

...
Medical Director & Co-ordinator
KLES Smile Train Project
B.A.C. ...

support under this Program and records pertaining to those paying patients shall not be submitted to STX.

- (g) The Hospital shall not solicit or accept any payment or donation from or on behalf of any patient treated as part of the Program.
- (h) The Hospital shall not claim nor accept any support, partial or complete, from any source other than Smile Train for surgeries sponsored and paid for by Smile Train under this Agreement.
- (i) The Hospital shall maintain a separate account of all grants received from Smile Train under this Agreement and all uses of such grants. Smile Train shall have the right to periodically audit the Hospital's book of accounts by independent external auditors chosen by Smile Train for which the Hospital agrees to extend all cooperation for such audits.
- (j) The Smile Train policy on Smile Train Funded Multiple Interventions during one surgery is attached to this Agreement as set out under Annexure D, and the Hospital shall abide by this policy.
- (k) The Hospital shall submit an online Grant Verification Form in the format provided from time to time by Smile Train prior to the remittance of any financial support by Smile Train.
- (l) The Hospital shall also comply with Smile Train's Child Protection Policy ("Policy"), by submitting the duly signed Child Protection Policy Declaration ("Declaration") at the time of execution of this Agreement. Both the Policy and Declaration are attached to this Agreement as set out under Annexure E.
- (m) The Hospital will not assign any part or all of this Agreement without Smile Train's prior written consent. Any attempt to assign in violation of this Section is void in each instance. Smile Train reserves the right to assign this Agreement or any of its rights or obligations under this Agreement without the Hospital's consent.
- (n) The Hospital understands and acknowledges that Smile Train in performing its obligations under this Agreement will partner with, employ or engage third parties or any entity from Smile Train's affiliates.
- (o) The Hospital shall significantly expand its continuing educational programs (including spreading awareness) in the field of reconstructive surgery for medical specialists through financial, technical and other support from Smile Train.
- (p) The Hospital has adequate Personnel (defined hereinafter), and resources with the necessary skills and qualifications to perform the obligations under the Program. The Hospital has sufficiently ascertained that the Personnel's credentials (including checking criminal track records, background investigation or references), are suitable to perform the Hospital's obligations under the Program.
- (q) The Hospital shall be solely responsible for all other compensation to its Personnel including any statutory contributions that are required and maintain all other compliance requirements as mandated under Applicable Laws in respect of its Personnel.
- (r) In the event Smile Train is required to make any payments in respect of any Personnel, Smile Train shall have the right amongst others, to adjust the same against any sum payable to the Hospital under this Agreement. In addition to the above, Smile Train shall have the right to recover any grant which has not been utilized by the Hospital towards the performance of its obligations under the Program.
- (s) The Parties agree that except as otherwise provided under this Agreement, all administrative costs and general overheads involved under the Program will be borne by the Hospital and shall not be paid by Smile Train.
- (t) The Hospital will be required to submit periodic data reports on a quarterly basis, which will be in a format as approved by Smile Train. The data report will include, information relating to the grants that have been received and utilized by the Hospital and will be submitted to Smile Train within the timelines prescribed by Smile Train.

The Hospital will keep all invoices, receipts, accounts and other relevant documents relating to the grants received from Smile Train in each financial year during the term of this Agreement and for a period of eight years thereafter and provide these to Smile Train promptly if required.

[Handwritten signature]

[Handwritten signature]

[Handwritten signature]
Dr. [Name]
Project Director
KIDS & Smiles Trust
3RD Fl. Prabhakar Kher House
2ND St. Bangalore

ATTESTED

[Handwritten signature]

SECRETARY
Board of Management
KIDS & Smiles Trust

- (v) The Hospital will maintain insurance policy that are sufficient to protect Hospital's business against all applicable risks and will provide Smile Train with evidence of such insurance on request.

4.2. SMILE TRAIN

- (a) Smile Train will contribute a mutually agreed amount as a grant (to be separately communicated for each primary cleft lip repair, primary cleft palate repair and a few specified secondary surgical interventions) carried out by the Hospital. For the purpose of receiving this grant, the surgeries will be limited to:
 - (i). patients over the age of 3 months for cleft lips and 6 months for cleft palates; and
 - (ii). those within ASA Classes 1 and 2 only. (for clarifications please refer Annexure A, the Protocol).
- (b) Smile Train reserves the right to amend the above criteria at any time at its sole discretion, without any notice and without assigning any reasons.
- (c) Smile Train will remit the agreed grant on a monthly basis as set forth in the Program Summary – Attachment-A attached hereto, based on the number of Patient Medical Records uploaded to the STX server in the prior month, subject to such Patient Medical Records being verified and accepted by Smile Train.
- (d) The grants by Smile Train under this Agreement shall be used solely for the purposes specified. Diversion of these grants for any other purpose without the prior written approval of Smile Train is expressly forbidden and shall be grounds for immediate termination of this Agreement. The Hospital shall indemnify Smile Train, its directors and officers with respect to any misuse of grants. Smile Train shall also have the right to stop the grant forthwith if directed by a lawfully established authority.

5. REPRESENTATIONS OF THE PARTIES

5.1. THE HOSPITAL

- (a) The Hospital is a running, well established medical facility, validly existing and in good standing under the laws of India and in the state where it operates and has the requisite rights and authority to carry on its activities as now being conducted and to execute, deliver and perform its obligations under this Agreement, and will ensure that the hospitals where surgeries take place under this Agreement have the licenses and meet the qualifications required by law in India for providing the medical services described herein and have licensed medical professionals with the skill, experience and appropriate medical facilities to provide safe and quality care. Hospital shall report any change to this status immediately to Smile Train.
- (b) The execution, delivery and performance by the Hospital of this Agreement has been duly authorized by all required corporate action on the part of the Hospital. The obligations of the Hospital under this Agreement are valid, legal and binding obligations of the Hospital, enforceable against it in accordance with its terms.
- (c) Neither the execution and delivery by the Hospital of this Agreement, nor the performance of any other obligation of the Hospital under this Agreement will violate, conflict with, result in the breach of, constitute a default under the governing documents of the Hospital, any material contract by which the Hospital is bound, or any statute, ordinance, judgment, order, decree, regulation or rule of any court, governmental or medical body affecting or relating to the Hospital.
- (d) Except as otherwise provided in or contemplated by this Agreement, no consent of, waiver from, application or notice to any party is required in order for the Hospital to execute, deliver and perform this Agreement or to consummate the transactions contemplated hereby.
- (e) Notwithstanding the generality of the foregoing, the Hospital represents that it is authorized to receive foreign contribution in accordance with applicable Indian laws (including the Foreign Contribution Regulation Act, 2010 and the rules framed thereunder, as may be amended from time to time), and will ensure that the contribution is utilized only for the purposes as provided under this Agreement and in accordance with applicable Indian laws.

[Signature]
 Dr. Pratiksha Kothiwale
 Project Director
 KLES Academy of Higher Education
 and Research, Belagavi
 KLES Dr. Pratiksha Kothiwale Hospital
 Belagavi
 WRO- Belagavi

[Signature]
 SECRETARY
 Hospital Management
 ATTESTED

[Signature]
 Medical Director & Chief Executive
 KLES Dr. Pratiksha Kothiwale Hospital
 Belagavi
 KLES Dr. Pratiksha Kothiwale Hospital
 Belagavi

[Signature]
 Prof. Dr. V. A. KOTHIWALE
 Registrar
 KLE Academy of Higher Education
 and Research, BELAGAVI

- (f) The Hospital and its consultants, employees, representatives, agents, contractors, subcontractors, doctors ("Personnel") are in compliance and will comply, at the Hospital's sole cost, with all applicable ordinances, codes, standards, laws, rules, regulations and orders of any governmental authority having jurisdiction over the Hospital's performance of its obligations hereunder ("Applicable Laws"), and will hold and fully comply with all required licenses, permits and approvals as may be required under Applicable Laws.
- (g) The Personnel have not been convicted of a felony in the previous seven years, or, if they have, the Hospital has (to the extent in accordance with the Applicable Laws) provided information to Smile Train regarding the nature, severity, and date of each such conviction.
- (h) The Personnel are its own employees and shall not be construed as employees of Smile Train at any time under this Agreement.
- (i) The Hospital has exclusive control over its Personnel, and over its labor and employee relations and its policies relating to wages, hours, working conditions and other employment conditions. The Hospital has the exclusive right to hire, transfer, suspend, lay off, recall, promote, discipline, discharge and adjust grievances with its Personnel. The Hospital is solely responsible for all salaries and other compensation of its Personnel, and for making all deductions and withholdings from its employees' salaries and other compensation and paying all contributions, taxes and assessments, in accordance with the Applicable Laws. The Hospital's Personnel are not eligible to participate in any employment benefit plans or other benefits available to Smile Train's employees. For the sake of clarity, the Hospital hereby represents that it has no authority to bind Smile Train to any agreement or obligation relating to The Hospital's Personnel, its labor and employee relations and its policies mentioned in this Section. The Hospital will be responsible for all acts, omissions, negligence and misconduct of its Personnel. The Hospital will be solely responsible for all misconduct related to its Personnel.
- (j) The Hospital will perform its obligation under Program and this Agreement with all due care, skill and ability, in compliance with prevailing high standards of accepted business/ medical practice and ethics.
- (k) The Hospital will comply with Smile Train's lawful directions, policies and procedures insofar as they relate to the performance of the Hospital's obligations under the Program and this Agreement.
- (l) The Hospital will promptly give to Smile Train all such information and reports as it may reasonably require in connection with matters relating to Hospital's performance of its obligations under the Program and this Agreement.
- (m) The Hospital will comply with all reasonable standards of safety at the Hospital's premises and report to Smile Train any unsafe working conditions or practices.
- (n) The Hospital warrants that the grants will be used in compliance with all applicable Indian laws and United States anti-terrorist financing and sanction laws and regulations. In this regard, the Hospital agrees to take all reasonable steps to ensure that no person or entity expected to receive grants in connection with this Agreement (including the Hospital) is subject to sanctions or otherwise designated on any list of prohibited or restricted parties or owned or controlled by such a party, including but not limited to the lists maintained by the United Nations Security Council, the US Government (e.g., the US Department of Treasury's Specially Designated Nationals list and Foreign Sanctions Evaders list and the US Department of Commerce's Entity List), the European Union or its member states, or other applicable government authority or list of banned terrorist organisations under Section 35 of Unlawful Activities (Prevention) Act, 1967, maintained by the Ministry of Home Affairs, Government of India or any such equivalent list.

5.2. SMILE TRAIN

- (a) The execution, delivery and performance by Smile Train of this Agreement has been duly authorized by all required corporate action on the part of Smile Train. The obligations of Smile Train under this Agreement are valid, legal and binding obligations of Smile Train, enforceable against it in accordance with its terms, except as such enforceability may be subject to or limited by bankruptcy, insolvency, reorganization, moratorium, receivership and similar laws affecting creditors' rights generally and general principles of equity.
- (b) Neither the execution and delivery by Smile Train of this Agreement, nor the

Entera
SECRETARY
 Board of Management
 K.L.E. Society, BELAGAVI

Dr. Rajesh S. Kewar
 Director
 KLES Smile Train Project
ATTESTED
Dr. Prabhakar Kore
 MRC - Belagavi

Jahnu
 Medical Director & Chief Executive
 KLES Dr. Prabhakar Kore Hospital &
 Medical Research Centre, BELAGAVI

KAD
 Prof. Dr. V.A.KOTHIWALE
 Registrar
 KLE Academy of Higher Education
 and Research, BELAGAVI

performance of any other obligation of Smile Train under this Agreement will violate, conflict with, result in the breach of, constitute a default under the governing documents of Smile Train, any material contract by which Smile Train is bound, or any statute, ordinance, judgment, order, decree, regulation or rule of any court or governmental body affecting or relating to Smile Train.

- (c) Except as otherwise provided in or contemplated by this Agreement, no consent of, waiver from, application or notice to any party is required in order for Smile Train to execute, deliver and perform this Agreement or to consummate the transactions contemplated hereby.

6. REPORTING, RENEWAL AND SUSPENSION

- 6.1. At least 30 days prior to the end of the grant period (which would be the period between January 1 to December 31 each year) ("Grant Period") the Hospital will submit a Final Grant Report or as may be updated from time to time and shared with the Hospital) highlighting the achievements of the goals of this Program as set out under Attachment - A (Program Summary), and representatives from the Hospital and Smile Train will meet to assess the progress of grant efforts.
- 6.2. Subsequent to which, Smile Train will determine whether grant will be renewed/extended. The decision to renew grant will be at the sole discretion of Smile Train, and Smile Train will not be obliged to give any reasons should it decide not to renew the same. If Smile Train does not renew, grant will cease at the conclusion of the Grant Period.
- 6.3. Smile Train reserves the right to suspend this Agreement, wholly or in part, for any reason at any time during the subsistence of this Agreement, by providing written notice to the Hospital.

7. PUBLIC RELATIONS

- 7.1. Smile Train reserves the right to publicize the cooperative efforts between the parties hereto through the use of literature, photographs, video film production and other media. The Hospital permits and allows Smile Train to use any and all of its materials including its trademarks and any literature in relation to the matters that it works on with Smile Train under this Agreement. Smile Train will also issue press releases and have the option to hold press conferences to announce the Program and its progress over the duration of the Grant Period. The Hospital agrees to be receptive in assisting Smile Train's efforts for publicity and/or additional fundraising.
- 7.2. The Hospital acknowledges that the words "Smile Train", "Changing the World One Smile at a Time" and the logo of the smiling train are the exclusive intellectual property of Smile Train's affiliates ("Smile Train IP") as set out under License Agreement. The Hospital shall immediately cease use of the Smile Train IP if instructed by Smile Train or its affiliates. In any and all publications and other public relations vehicles describing the Program, the Hospital agrees to receive prior approval from Smile Train before using the Smile Train IP.

8. INDEMNIFICATION; LIABILITY

The Hospital shall be solely responsible for any losses arising out of Hospital's performance of this Agreement. The Hospital agrees to indemnify and hold harmless Smile Train, its affiliates, members, officers, directors, employees, agents and representatives from and against any and all losses, claims, damages and liabilities, whether joint or several, related to, or arising out of, or in connection with, Hospital's actions in performance of this Agreement, including but not limited to the performance of Hospital's obligations under the Program, or any other information, services or products that the Hospital or any director, officer, member, manager, employee, affiliate or associate of the Hospital provides to any patient.

9. TERMINATION

- 9.1. This Agreement may be terminated by either party without assigning any reasons, by giving 30 days' notice of its intention to do so, in writing to the other.
- 9.2. Notwithstanding the above, Smile Train reserves the right to terminate this Agreement immediately at any time, at its sole discretion, in the event of fraud, violation of medical standards, misuse of grant of any kind, or misrepresentation, without any further liability under this Agreement.

[Handwritten signatures and stamps]

SECRETARY Medical Director
ATTESTED
Prof. Dr. V. K. ...
KLE Academy of Education
M. ROSARIO FLAGAY

- 9.3. This Agreement shall stand terminated immediately if, directed by any statutory body or government department acting within the framework of the law.
- 9.4. On the termination or expiry of the term of this Agreement, the Hospital shall return all records, publicity material, brochures, etc. pertaining to the Program, and furnish to Smile Train a full accounting of the disbursement of grants and expenditures incurred under the Program up to the effective date of termination within 30 days. As of the effective date of termination of this Agreement, for any reason whatsoever, Smile Train will not be required to provide any money to the Hospital except for grants required to be provided prior to the date of termination, in accordance with the terms of this Agreement and the process prescribed herein.
- 9.5. On termination of this Agreement, the Hospital shall promptly repay to Smile Train any unused sums of the grants.

10. AMENDMENT

This Agreement may not be amended or modified except by an instrument in writing signed by, or on behalf of, each of the parties hereto.

11. NONDISCLOSURE

The specific terms of this Agreement are privileged and confidential, and the parties hereto undertake not to divulge the same to any third party without the prior, express written permission of the other. The only exceptions to this will be their duly appointed legal attorneys and advisors, or duly empowered statutory bodies and government agencies acting within the requirements of the law. The parties hereto also undertake to institute all reasonable steps to ensure that the confidentiality is maintained within their respective organizations.

12. PRIOR AGREEMENT

This Agreement supersedes and replaces any and all previous agreements between the parties.

13. CONFIDENTIALITY

All information provided by Smile Train will remain Smile Train's exclusive property, and the Hospital will have no rights to use such information except as expressly provided herein. The Hospital will not and will prevent the Personnel from using any trade name, trademark, service mark, logo or commercial symbol, or any other proprietary rights of Smile Train or any of its affiliates in any manner without prior written authorization of such use by an authorised signatory of Smile Train. Smile Train will not and shall ensure that its Personnel shall not disclose, issue press releases or publicity relating to Smile Train or the existence or contents of this Agreement or reference Smile Train or its affiliates to any third party or in any brochures, advertisements, client lists or other promotional materials.

14. OTHERS

- 14.1. Notices under this Agreement are sufficient if given by nationally recognized overnight courier service, speed post with acknowledgment receipt, facsimile with electronic confirmation or personal delivery to the other Party at the address below the Party's signature line below. If no address is listed for the Hospital, notice to the Hospital will be effective if given to the last known address. Notice is effective: (a) when delivered personally, (b) three business days after sending by speed post, (c) on the business day after sending by a nationally recognized courier service, or (d) on the business day after sending by facsimile with electronic confirmation to the sender. A Party may change its notice address by giving notice in writing in accordance with this section.

- 14.2. The Hospital and Smile Train are independent contractors. Nothing in this Agreement will be construed as creating any relationship such as joint venture, partnership, association of persons, employer-employee, principal-agent or franchisor-franchisee. This Agreement is on a 'principal-to-principal' basis and it does not confer any right to either party to represent the other, act on its behalf as its agent or authorized representative, issue public statements, make commitments of any kind or claim any relationship beyond the one provided in this Agreement. The duties and responsibilities of the Hospital shall be rendered solely by the Hospital and not

Handwritten signature
SECRETARY
 Board of Management
 KLE Academy, BELAGAVI

Handwritten signature
DR. RAJESH S. DAVAR
 Director
 KLE Academy, Belagavi
 KLEAS Smile Train Project
 KLEAS Dr. Prabhakar Kore Laboratory
 Belagavi

Handwritten signature
ATTESTED
Handwritten signature

INDIA NON JUDICIAL

Government of National Capital Territory of Delhi



सत्यमेव जयते

Certificate No.	: IN-DL43293055411921S
Certificate Issued Date	: 21-May-2020 01:10 PM
Account Reference	: IMPACC:(IV)/dl870703/DELHI/ DL-DLH
Unique Doc. Reference	: SUBIN-DL DL87070395301682085678S
Purchased by	: SMILE TRAIN INDIA
Description of Document	: Article 5 General Agreement
Property Description	: Not Applicable
Consideration Price (Rs.)	: 0 (Zero)
First Party	: SMILE TRAIN INDIA
Second Party	: Not Applicable
Stamp Duty Paid By	: SMILE TRAIN INDIA
Stamp Duty Amount(Rs.)	: 150 (One Hundred And Fifty only)



Please write or type below this line

LICENCE AGREEMENT

This Licence Agreement (the "Agreement") is executed at New Delhi and is entered into as of the 1st day of April, 2020

BETWEEN

SMILE TRAIN INC., having its registered office at 633, Third Ave, 9th Floor, New York 10017, USA (hereinafter referred to as "Licensor") which expression shall, unless repugnant to the context or meaning thereof, include its successors and permitted assigns of the First Part;

SECRETARY

Statutory Agent

284090

The onus of checking the legitimacy is on the users of the certificate

Medical Director & Chief Executive

KLES Dr. Prabhakar Kore Hospital

Medical Research Center, BELAGAVI

for Dr. DEV ANKOTHIVALE

Dr. Rajesh B. Power

Project Director

KLES Smile Train Project

KLES Dr. Prabhakar Kore Hospital

Medical Research Center, BELAGAVI

Registrar
KLE Academy of Higher Education
Kland Research, BELAGAVI
and Research, BELAGAVI

LICENCE AGREEMENT

This Licence Agreement (the "Agreement") is executed at New Delhi and is entered into as of the 1st day of April, 2020

BETWEEN

SMILE TRAIN INC., having its registered office at 633, Third Ave, 9th Floor, New York 10017, USA (hereinafter referred to as "Licensor") which expression shall, unless repugnant to the context or meaning thereof, include its successors and permitted assigns of the First Part;

Bacrai
In-284698
SECRETARY
Board of Management
KLE Society, BELAGAVI

AND
[Signature]
Dr. Rajesh S. Pawar
Project Director
KLES Smile Train Project
KLES Dr. Prabhakar Kore Hospital
KLE Society, BELAGAVI

[Signature]
Medical Director & Chief Executive
KLES Dr. Prabhakar Kore Hospital
Medical Research Centre, BELAGAVI

[Signature]
Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

Karnataka Lingayat Education Society, having its registered office at Nehru Nagar, Belagavi 590010, Karnataka which owns and operates a Hospital in the name and style of KLES Prabhakar Kore Hospital & Medical Research Centre located at Nehru Nagar, Belagavi 590010, Karnataka (hereinafter referred to as "Licensee") of the Second Part;

AND

Smile Train India, a company incorporated under the laws of India having its registered office at Plot No.3, LSC Sector-C, Pocket 6/7, Vasant - Kunj New Delhi - 110070 (hereinafter referred to as "Smile Train India") which expression shall, unless repugnant to the context or meaning thereof, include its successors and permitted assigns of the Third Part.

RECITALS:

WHEREAS, Smile Train India, an affiliate of the Licensor, incorporated under Section 25 of the Companies Act, 1956, having its registered office at - Plot No.3, LSC Sector-C, Pocket 6/7, Vasant - Kunj New Delhi - 110070, has entered into an Agreement dated 1st January 2018 with the Licensee, whereby the Licensee is to extend *totally free* cleft reconstructive surgeries to poor patients who would not otherwise have been able to afford them, and significantly expand its continuing educational programs in the field of reconstructive surgery for medical specialists through financial, technical and other support from Smile Train India ("Program Agreement");

WHEREAS, pursuant to the Program Agreement, the Licensee desires to obtain the license for use of the Materials (as defined below), to effectively participate and comply with its obligations under the Program Agreement ("Licensee Works");

WHEREAS, Licensor is the owner of, *inter alia*, all right, title and interest in and to those certain materials, a copy of which is attached hereto as "Exhibit A" and made part hereof, (the "Materials"); and

WHEREAS, Licensor is willing to grant to the Licensee a non-exclusive limited license to use the Materials for the purpose(s) described herein.


NOW, THEREFORE, in consideration of the foregoing and of the covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto do hereby agree as follows:


1. LICENSE OF RIGHTS


- (a) Licensor hereby non-exclusively licenses to Licensee the right to include the Materials in the Licensee Works and all related promotional materials for non-profit and non-commercial purposes only, worldwide during the Term;
- (b) Licensee may use the Materials only in strict adherence with this Agreement and may not use the Materials in connection with any commercial purposes whatsoever.

2. APPROVALS

Prior approval of the Licensor shall be required for any and all uses of the Materials who shall have the right to approve, in its own discretion, any and all uses of the Materials. Wherever in this Agreement Licensor's approval or consent is required, Licensee will request Licensor for such approval or consent in writing (which may be given by email) and provide Licensor with the information in respect of which such approval or consent is sought. Approval or disapproval of the Licensor shall be communicated within five (5) business days of receipt of such request from Licensee. Failure to respond within the stipulated period provided herein shall be deemed as denial by the Licensor of the approval or consent request.


In-284698
SECRETARY
Board of Management
KLE Academics BELAGAVI


ATTESTED
REGISTRAR
KLE Academics BELAGAVI


KLES Prabhakar Kore Hospital & Medical Research Centre

- (b) This Agreement may be terminated by either party without assigning any reasons, by giving 30 days' notice of its intention to do so, in writing to the other.
- (c) Notwithstanding the above, Licensor reserves the right to terminate this Agreement immediately at any time, at its sole discretion, in the event the Licensee commits fraud, misrepresentation, or a substantial breach of any of the provisions contained herein or with respect to its obligations to be performed without prejudice to any and all rights at law which Licensor may have.
- (d) This Agreement shall terminate immediately upon termination of the Program Agreement, in terms thereof.

7. ASSIGNMENT

Licensee may not assign this Agreement, by operation of law or otherwise, without the prior written consent of Licensor, which consent may be withheld at Licensor's sole discretion.

8. RELATIONSHIP OF PARTIES

The relationship between the parties hereto is that of licensor and licensee. Neither party hereto is an agent, partner or employee of the other and neither party has any right or any other authority to enter into any contract or undertaking in the name of or for the account of the other or to either assume or create any obligation of any kind, express or implied, on behalf of the other, nor will the acts or omissions of either create any liability for the other. This Agreement shall in no way constitute or give rise to a partnership or joint venture between the parties.

9. NOTICES

All notices or other communications required or permitted to be delivered hereunder shall be in writing and (i) delivered personally, (ii) sent by registered or certified mail (return receipt requested), postage prepaid, (iii) sent by recognized national or international air courier, or (iv) via facsimile with confirmation of receipt, addressed to the parties at the addresses first written hereinabove. Any such notice or other communication shall be deemed to have been given or made as of the date received.

10. MISCELLANEOUS

- (a) This Agreement sets forth the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all prior discussions, representations, understandings and agreements, whether written or oral, between the parties with respect to the subject matter hereof. This Agreement may be altered, modified or amended only by a written document signed by the parties hereto.
- (b) The rights and remedies provided herein shall be cumulative and not exclusive of any other rights or remedies provided at law or in equity. Failure or delay on the part of either party to exercise any right, remedy, power or privilege provided for herein or by statute, by law, in equity or otherwise shall not operate as a waiver thereof, nor shall any single or partial exercise of any such right, remedy, power or privilege preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.
- (c) This Agreement shall be binding upon and shall ensure to the benefit of Licensor, its successors and assigns, and Licensee, its successors and permitted assigns.
- (d) Notwithstanding anything to the contrary contained herein, in the event that any clause, term or provision of this Agreement which is not material is determined by any court or administrative agency of competent jurisdiction to be illegal, unenforceable or in conflict with any applicable law, this Agreement shall continue in full force and effect as if the offending clause, term and provision hereof were no longer incorporated herein.

Signature

ln-284608
Signature

SECRETARY

Board of Management
 N.E. Soc. of B. & M.

Signature

U.S. ROBERT S. POWELL
 ATTESTED

Signature

Signature

- (e) The parties agree that the failure or delay of any party at any time to require performance of any provision under this Agreement shall not affect the right of such party to require the full performance thereof and that a waiver by any party, which shall be in writing and signed by the party against whom such waiver is sought to be enforced, of a breach of any provision of this Agreement shall not be held to be a waiver of any further or similar breach or as nullifying the effectiveness of such provision.
- (f) This Agreement will be governed by the laws of India and the courts at New Delhi will have exclusive jurisdiction in connection with any matters arising out of this Agreement.
- (g) This Agreement may be executed in several counterparts and via facsimile, each of which shall be deemed an original and all of which shall constitute one and the same instrument.

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the date and year first written above.


For and on behalf of Smile Train Inc.

By: B. G. Desai
Date: 26.03.2020


SECRETARY
Board of Management
K.L.E. Society, BELAGAVI


For and on behalf of Karnataka Lingayat Education Society

By: DR. M. V. JALI
Date: 26.03.2020


Medical Director & Chief Executive
KLES Dr. Prabhakar Kore Hospital &
Medical Research Centre BELAGAVI

For and on behalf of KLES Prabhakar Kore Hospital & Medical Research Centre


By: DR. RAJESH PONDIC
Date: 26.03.2020


Dr. Rajesh S. Pongar
Project Director
KLES Smile Train Project

For and on behalf of Prabhakar Kore Hospital & Medical Research Centre -- Project Director

By: _____
Date: _____

For and on behalf of Smile Train India

By: 
Mamta Carroll
Date: March 2020

In-284698

5

ATTESTED




KLES AC 101

EXHIBIT A


The Materials




Dr. Rajesh S. Poojar
Project Director
KLES Smile Train Project
KLES Dr. Prabhakar Kore Hos.
MRC - Belagavi



Medical Director & Director
KLES Dr. Prabhakar Kore Hos.
Medical Research Centre, BELAGAVI




SECRETARY
Board of Management
K.L.E. Society, BELAGAVI

In-284698

6

ATTESTED



Registrar
KLE Academy of Higher Education
and Research, BELAGAVI



सत्यमेव जयते


INDIA NON JUDICIAL

Government of National Capital Territory of Delhi

e-Stamp

Certificate No. : IN-DL73527689604590Q
 Certificate Issued Date : 08-Jan-2018 07:45 PM
 Account Reference : IMPACC (IV)/ d1959203/ DELHI/ DL-DLH
 Unique Doc. Reference : SUBIN-DL73527689604590Q
 Purchased by : SMILE TRAIN INDIA
 Description of Document : Article 5 General Agreement
 Property Description : Not Applicable
 Consideration Price (Rs.) : 0
 (Zero)
 First Party : SMILE TRAIN INDIA
 Second Party : Not Applicable
 Stamp Duty Paid By : SMILE TRAIN INDIA
 Stamp Duty Amount(Rs.) : 150
 (One Hundred And Fifty only)

Dr. Rajesh S. P...
 Project Director
 KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, BELAGAVI



B. N. N. N.
 SECRETARY
 Board of Management
 K.L.E. Society, BELAGAVI

Dr. Prabhakar Kore
 28/1/18
 Medical Director & Chief Executive
 KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, BELAGAVI.

.....Please write or type below this line.....

LICENCE AGREEMENT

This Licence Agreement (the "Agreement") is executed at New Delhi and is entered into as of the 1st day of January, 2018

BETWEEN

SMILE TRAIN INC., having its registered office at 41 Madison Avenue, 28th Floor, New York, New York 10010, USA (hereinafter referred to as "Licensor") which expression shall, unless repugnant to the context or meaning thereof, include its successors and permitted assigns of the First Part;

AND

Dr. Prabhakar Kore AND *B. N. N. N.*
 Medical Director & Chief Executive ATTESTED SECRETARY
 Board of Management
 KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, BELAGAVI

SMILE TRAIN INC., having its registered office at 41 Madison Avenue, 28th Floor, New York, New York 10010, USA (hereinafter referred to as "Licensor") which expression shall, unless repugnant to the context or meaning thereof, include its successors and permitted assigns of the First Part;



Karnataka Lingayat Education Society, having its registered office at Nehru Nagar, Belagavi 590010, Karnataka which owns and operates a Hospital in the name and style of KLES Prabhakar Kore Hospital & Medical Research Centre located at Nehru Nagar, Belagavi 590010, Karnataka (hereinafter referred to as "Licensee") of the Second Part;

AND

Smile Train India, a company incorporated under the laws of India having its registered office at Plot No.3, LSC Sector-C, Pocket 6/7, Vasant - Kunj New Delhi - 110070 (hereinafter referred to as "Smile Train India") which expression shall, unless repugnant to the context or meaning thereof, include its successors and permitted assigns of the Third Part.

RECITALS:

WHEREAS, Smile Train India, an affiliate of the Licensor, incorporated under Section 25 of the Companies Act, 1956, having its registered office at - Plot No.3, LSC Sector-C, Pocket 6/7, Vasant - Kunj New Delhi - 110070, has entered into an Agreement dated 1st January 2018 with the Licensee, whereby the Licensee is to extend *totally free* cleft reconstructive surgeries to poor patients who would not otherwise have been able to afford them, *and* significantly expand its continuing educational programs in the field of reconstructive surgery for medical specialists through financial, technical and other support from Smile Train India ("Program Agreement");

WHEREAS, pursuant to the Program Agreement, the Licensee desires to obtain the license for use of the Materials (as defined below), to effectively participate and comply with its obligations under the Program Agreement ("Licensee Works");

WHEREAS, Licensor is the owner of, *inter alia*, all right, title and interest in and to those certain materials, a copy of which is attached hereto as "Exhibit A" and made part hereof, (the "Materials"); and

WHEREAS, Licensor is willing to grant to the Licensee a non-exclusive limited licence to use the Materials for the purpose(s) described herein.

NOW, THEREFORE, in consideration of the foregoing and of the covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto do hereby agree as follows:

1. LICENSE OF RIGHTS

(a) Licensor hereby non-exclusively licenses to Licensee the right to include the Materials in the Licensee Works and all related promotional materials for non-profit and non-commercial purposes only, worldwide during the Term;

Licensee may use the Materials only in strict adherence with this Agreement and may not use the Materials in connection with any commercial purposes whatsoever.

2. APPROVALS

Prior approval of the Licensor shall be required for any and all uses of the Materials who shall have the right to approve, in its own discretion, any and all uses of the Materials. Wherever in this Agreement Licensor's approval or consent is required, Licensee will request Licensor for such approval or consent in writing (which may be given by email) and provide Licensor with the information in respect of which such approval or consent is sought. Approval or disapproval of the Licensor shall be communicated within five (5) business days of receipt of such request from Licensee. Failure to respond within the stipulated period provided herein shall be deemed as denial by the Licensor of the approval or consent request.

REPRESENTATIONS AND WARRANTIES BY LICENSOR

Licensor represents and warrants that:

Medical Director & Chief Executive
KLES Dr. Prabhakar Kore Hospital &
Medical Research Centre, BELAGAVI

ATTESTED

2
Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

SECRETARY
Board of Management
K.L.E. Society, BELAGAVI

42

Dr. Rajesh S. P
KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, BELAGAVI

Medical Director & Chief Executive
KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, BELAGAVI

SECRETARY
Board of Management
K.L.E. Society, BELAGAVI

Dr. Rajesh S. P
KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, BELAGAVI

88

Manchi

- (a) Licensors has the full right, power, legal capacity and authority to enter into this Agreement and to carry out the terms hereof and to grant to Licensee the rights and privileges granted hereunder;
- (b) There are no liens, claims, encumbrances, legal proceedings, restrictions, agreements or understandings which will or which may conflict or interfere with, limit, or are inconsistent with or otherwise affect any of the provisions of this Agreement or the enjoyment by Licensee of any right granted to it hereunder; and
- (c) Licensors owns or controls without any limitations, restrictions or encumbrances, all rights granted to Licensee hereunder and Licensors has obtained all necessary licenses and permissions required for the manufacturing, distribution, exhibition, advertising, exploitation and otherwise of the assets worldwide, as may be required for the full and unlimited exercise and enjoyment by Licensee of all of the rights herein granted to it.

4. REPRESENTATIONS AND WARRANTIES BY LICENSEE

Licensee represents and warrants to the Licensors as follows:

- (a) Licensee, and each of Licensee's shareholders, officers, employees, representatives and other persons acting on its behalf, has and will continue to have all necessary licenses, registrations and qualifications necessary or appropriate to enable Licensee to perform its services as described herein and Licensee shall perform its services in full compliance with all applicable laws, rules and regulations;
- (b) Licensee has the full right, power, legal capacity and authority to enter into this Agreement and to carry out the terms hereof and to exercise and fulfill the rights granted by Licensors to Licensee hereunder;

all information given or to be given to the Licensors by Licensee is and shall be accurate and complete in all respects and shall not contain any misstatement of material information nor any intentional or negligent omission of any material fact; and

the use of the Materials by Licensee in the Licensee Works shall not infringe upon or violate the rights of any third party.

The foregoing shall survive the termination of this Agreement for any reason.

INDEMNITY

The Licensee shall be solely responsible for any losses arising out of Licensee's performance of this Agreement. The Licensee agrees to indemnify and hold harmless Licensors, its affiliates, members, officers, directors, employees, agents and representatives against all losses and damages, including reasonable attorney's fees, but excluding any lost profits, arising out of any action or proceeding by third parties resulting from any breach by the Licensee of any of the provisions hereof, or the breach of any of the warranties and representations set forth herein. Prompt written notice will be given to Licensors of any action or proceeding to which the foregoing indemnity relates.

SECRETARY TERM AND TERMINATION

- (a) This Agreement shall become effective on the date of execution of this Agreement unless terminated in accordance with Sections 6 (b), (c) or (d) below (the "Term").
- (b) This Agreement may be terminated by either party without assigning any reasons, by giving 30 days' notice of its intention to do so, in writing to the other.

Notwithstanding the above, Licensors reserves the right to terminate this Agreement immediately at any time, at its sole discretion, in the event the Licensee commits fraud, misrepresentation, or a substantial breach of any of the provisions contained herein or

[Signature]
 Dr. Rajesh S. Poojar
 Project Director
 KLES Smile Train Project
 KLES Dr. Prabhakar Kore Hospital
 MRC - Belgavi

[Signature]
 Medical Director & Chief Executive
 KLES Dr. Prabhakar Kore Hospital
 Medical Research Centre, BELGAVI

[Signature]
 SECRETARY
 Board of Management
 K.L.E. Society, BELAGAVI

[Signature]
 Dr. Rajesh S. Poojar
 Project Director
 KLES Smile Train
 KLES Dr. Prabhakar Kore
 MRC - Belgavi

In-284698
 Medical Director & Chief Executive
 KLES Dr. Prabhakar Kore Hospital

[Signature]
 REGISTRAR
 K. A. KOTHIVALE

[Signature]
 SECRETARY
 Board of Management
 K.L.E. Society, BELAGAVI

[Signature]
 Manki

with respect to its obligations to be performed without prejudice to any and all rights at law which Licensor may have.

(d) This Agreement shall terminate immediately upon termination of the Program Agreement, in terms thereof.

7. ASSIGNMENT

Licensee may not assign this Agreement, by operation of law or otherwise, without the prior written consent of Licensor, which consent may be withheld at Licensor's sole discretion.

8. RELATIONSHIP OF PARTIES

The relationship between the parties hereto is that of licensor and licensee. Neither party hereto is an agent, partner or employee of the other and neither party has any right or any other authority to enter into any contract or undertaking in the name of or for the account of the other or to either assume or create any obligation of any kind, express or implied, on behalf of the other, nor will the acts or omissions of either create any liability for the other. This Agreement shall in no way constitute or give rise to a partnership or joint venture between the parties.

9. NOTICES

All notices or other communications required or permitted to be delivered hereunder shall be in writing and (i) delivered personally, (ii) sent by registered or certified mail (return receipt requested), postage prepaid, (iii) sent by recognized national or international air courier, or (iv) via facsimile with confirmation of receipt, addressed to the parties at the addresses first written hereinabove. Any such notice or other communication shall be deemed to have been given or made as of the date received.

MISCELLANEOUS

(a) This Agreement sets forth the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all prior discussions, representations, understandings and agreements, whether written or oral, between the parties with respect to the subject matter hereof. This Agreement may be altered, modified or amended only by a written document signed by the parties hereto.

The rights and remedies provided herein shall be cumulative and not exclusive of any other rights or remedies provided at law or in equity. Failure or delay on the part of either party to exercise any right, remedy, power or privilege provided for herein or by statute, by law, in equity or otherwise shall not operate as a waiver thereof, nor shall any single or partial exercise of any such right, remedy, power or privilege preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.

This Agreement shall be binding upon and shall ensure to the benefit of Licensor, its successors and assigns, and Licensee, its successors and permitted assigns.

Notwithstanding anything to the contrary contained herein, in the event that any clause, term or provision of this Agreement which is not material is determined by any court or administrative agency of competent jurisdiction to be illegal, unenforceable or in conflict with any applicable law, this Agreement shall continue in full force and effect as if the offending clause, term and provision hereof were no longer incorporated herein.

The parties agree that the failure or delay of any party at any time to require performance of any provision under this Agreement shall not affect the right of such party to require the full performance thereof and that a waiver by any party, which shall be in writing and signed by the party against whom such waiver is sought to be enforced, of a breach of any provision of this Agreement shall not be held to be a waiver of any further or similar breach or as nullifying the effectiveness of such provision.

[Signature]
Dr. Rajesh S. Powar
Project Director
KLES Smile Train Project
KLES Dr. Prabhakar Kore Hospital
MRC - BELAGAVI

[Signature]
Medical Director & Chief Executive
KLES Dr. Prabhakar Kore Hospital
Medical Research Centre, BELAGAVI

[Signature]
SECRETARY
Board of Management
K.L.E. Society, BELAGAVI

[Signature]
Dr. Rajesh S. Powar
Project Director
KLES Smile Train Project
KLES Dr. Prabhakar Kore Hospital
MRC - BELAGAVI


Medical Director & Chief Executive
KLES Dr. Prabhakar Kore Hospital
Medical Research Centre, BELAGAVI
Dr. V.A. NOTHIVDLO
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

[Signature]
SECRETARY
Board of Management


- (f) This Agreement will be governed by the laws of India and the courts at New Delhi will have exclusive jurisdiction in connection with any matters arising out of this Agreement.
- (g) This Agreement may be executed in several counterparts and via facsimile, each of which shall be deemed an original and all of which shall constitute one and the same instrument.

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the date and year first written above.

For and on behalf of Smile Train Inc.


By: 
 Date: 5/31/2018


For and on behalf of Karnataka Lingayat Education Society

By: 
 Date: SECRETARY
 Board of Management
 K.L.E. Society, BELAGAVI



SECRETARY
 Board of Management
 K.L.E. Society, BELAGAVI

For and on behalf of KLES Prabhakar Kore Hospital & Medical Research Centre


By: 
 Medical Director & Chief Executive
 KLES Dr. Prabhakar Kore Hospital &
 Medical Research Centre, BELAGAVI.
 Date: _____



 Medical Director & Chief Executive
 KLES Dr. Prabhakar Kore Hospital &
 Medical Research Centre, BELAGAVI.

For and on behalf of Prabhakar Kore Hospital & Medical Research Centre – Project Director

By: 
 Project Director
 KLES Smile Train Project
 KLES Dr. Prabhakar Kore Hospital &
 MRC, Belagavi.
 Date: _____


For and on behalf of Smile Train India

By: 
 Date: _____


Dr. Rajesh S. Powar
 Project Director
 KLES Smile Train Project
 KLES Dr. Prabhakar Kore Hospital &
 MRC, Belagavi.

ATTESTED


 Prof. Dr. V.S. K. P. RAJALE
 Registrar




सत्यमेव जयते

INDIA NON JUDICIAL

Government of National Capital Territory of Delhi

e-Stamp

Certificate No.	: IN-DL65958169921487P
Certificate Issued Date	: 19-Dec-2017 08:27 PM
Account Reference	: IMPACC (IV)/ dl959203/ DELHI/ DL-DLH
Unique Doc. Reference	: SUBIN-DL DL95920334797332387022P
Purchased by	: SMILE TRIN INDIA
Description of Document	: Article 5 General Agreement
Property Description	: Not Applicable
Consideration Price (Rs.)	: 0 (Zero)
First Party	: SMILE TRIN INDIA
Second Party	: Not Applicable
Stamp Duty Paid By	: SMILE TRIN INDIA
Stamp Duty Amount(Rs.)	: 150 (One Hundred And Fifty only)



Please write or type below this line

Agreement

This agreement ("Agreement") is made between Smile Train India, a *not-for-profit* company incorporated under Section 25 of the Companies Act, 1956, registered under Section 11(1) of the Foreign Contribution (Regulation) Act, 2010 having its registered office at - Plot No.3, LSC Sector-C, Pocket 6/7, Vasant - Kunj New Delhi - 110070, hereinafter referred to as "Smile Train"

and

Karnataka Lingayat Education Society, which owns and operates a Hospital in the name and style of KLES Prabhakar Kore Hospital & Medical Research Centre, Nehru Nagar, Belagavi 590010, Karnataka, hereinafter referred to as "the Hospital"

Medical Director & Chief Executive
 KLES Dr. Prabhakar Kore Hospital &
 Medical Research Centre, BELAGAVI

ATTESTED SECRETARY
 Board of Management
 K.L.E. Society, BELAGAVI

Mamthi
 Page 1 of 7

RECITALS

- A Smile Train is promoted by a global charity whose mission is to provide assistance and support for required treatments for poor children born with cleft lip and palate around the world.
- B The Hospital has the requisite equipment, infrastructure and suitably qualified and trained medical staff capable and willing to provide, *inter alia*, free or subsidized medical treatment to poor and needy patients.
- C While the Hospital is desirous of extending totally free cleft lip and palate surgeries to patients and offer other related rehabilitative services free of cost, it does not have the financial resources to do so.
- D The parties now desire to enter into a cooperative, joint effort (the "Program") through which the Hospital will extend *totally free* cleft reconstructive surgeries to poor patients who would not otherwise have been able to afford those and significantly expand its continuing educational programs in the field of reconstructive surgery for medical specialists through financial, technical and other support from Smile Train.

I. TERM AND EFFECTIVE DATE

- A Funding of the partnership shall begin on January 1, 2018 (the "Effective Date") and continue until December 31, 2019, unless expressly terminated as provided in the Termination Clause VII of this Agreement.
- B Upon expiration of such period, this Agreement shall stand terminated unless Smile Train in its sole discretion renews this Agreement.

II. OBLIGATIONS OF THE PARTIES

A. THE HOSPITAL

- 1. The Hospital shall ensure that only qualified medical personnel perform or assist in Program surgeries, all of whom shall be duly certified and in good standing with appropriate medical oversight authorities. Program surgeries and treatments shall be performed only in hospitals that have been explicitly approved by Smile Train, and that are permitted to operate in accordance with and in full compliance with the governing laws, rules and standards in India, and the terms of this Agreement.

Dr. Prabhakar Kore
 Project Director
 KLES Smile Train
 KLES Dr. Prabhakar Kore
 Medical Research Centre, Belagavi

In addition to meeting the requirements of Section II.A.1., prior to commencement of this Agreement, the Hospital will carry out a thorough internal medical audit of participating Hospital(s) to ensure compliance with Smile Train's Safety and Quality Protocol, as described at Attachment B (the "Protocol") and shall comply with the Protocol throughout the term of the Program. The Hospital acknowledges that (i) Smile Train has developed the Protocol for the express purpose of ensuring and maintaining high safety standards, quality improvement and quality control and (ii) the adoption and continued implementation of the Protocol by the Hospital is a condition to Smile Train's obligations hereunder. In the event of any conflict between the Protocol and applicable laws or medical standards in the Hospital's territory, the Hospital shall inform Smile Train and Smile Train shall have the right, in its sole discretion, to terminate this Agreement and withdraw funding or to waive such conditions of the Protocol as may be necessary to permit compliance with such applicable laws and/or medical standards in the territory.

Dr. Prabhakar Kore
 Medical Director & Chief
 KLES Dr. Prabhakar Kore
 Medical Research Centre, Belagavi

- 3. In the event of serious complications leading to irreversible, grievous harm or patient death (a "Sentinel Event" as defined in the Protocol), the Hospital will (i) immediately notify Smile Train of such Sentinel Event, and (ii) implement the review process set forth by Smile Train for Sentinel Event protocol. As part of the Protocol, the Hospital specifically undertakes to report all Sentinel Events within 24 hours of the event's occurrence, using Smile Train's "Sentinel Event Report Form" (Attachment C to this Agreement). The Hospital will report any Sentinel Event to Smile Train, in the manner provided under the Protocol.

Dr. Prabhakar Kore
 SECRETARY
 Board of Management
 K.L.E. Society, BELAGAVI

ATTESSED
Prof. Dr. V.A. KOTHIWALE
 Registrar
 KLE Academy of Higher Education
 and Research, BELAGAVI

Manish

4. The Hospital shall participate in Smile Train Express ("STX"), a free, global, cleft care database, by submitting the completed patient record information (Attachment D "Patient Medical Record"), and gathering patient consent forms, subject to restrictions imposed by and compliance with all applicable laws in the Hospital's territory regarding the treatment of medical information, including but not limited to, the Information Technology Act, 2000 Information Technology (Reasonable Security Practices and Procedures and Sensitive Personal Data or Information) Rules, 2011. Further, the Hospital hereby grants consent to Smile Train to use, disclose and transfer any information (including the Patient Medical Records and Sentinel Event Report Forms) submitted by the Hospital, to third parties, Smile Train affiliates, in accordance with the Agreement and the Protocol.
5. The Hospital shall upload only such Smile Train sponsored surgeries to STX as have been performed at its own hospital(s) or those that have been explicitly approved by Smile Train in writing as affiliates to the Hospital's hospital(s). The Hospital shall list the affiliated hospital(s) on the initial Smile Train application for approval. Any subsequent affiliated hospital(s) must be approved by Smile Train in writing before the surgery takes place. In the event that the affiliated Hospital is a separate legal entity, a separate agreement will be executed between such affiliated Hospital and Smile Train.
6. The Hospital shall extend totally free cleft lip and palate surgeries to all poor patients covered under this Program *with no hidden costs*. The Hospital also accepts that patients paying for cleft lip and palate surgeries will not be eligible for Smile Train support under this Program and records pertaining to those paying patients shall not be submitted to STX.
7. The Hospital shall not solicit or accept any payment or donation from or on behalf of any patient treated as part of the Program.
8. The Hospital shall not claim nor accept any support, partial or complete, from any source other than Smile Train for surgeries sponsored and paid for by Smile Train under this Agreement.
9. The Hospital shall maintain a separate account of all funds received from Smile Train under this Agreement and all uses of such funds.
10. Smile Train shall have the right to have the separate account and all of Hospital's accounts periodically audited by independent external auditors chosen by Smile Train and the Hospital agrees to extend all cooperation for such audits.
11. The Smile Train policy on Smile Train Funded Multiple Interventions during one surgery is attached to this Agreement as Attachment E, and the Hospital shall abide by this policy.
12. The Hospital shall submit an online Payment Verification Form in the format provided from to time by Smile Train prior to the remittance of any financial support by Smile Train.
13. The Hospital shall also comply with Smile Train's Child Protection Policy ("Policy"), by submitting the duly signed Child Protection Policy Declaration ("Declaration") at the time of execution of this Agreement. Both the Policy and Declaration are attached to this Agreement as Attachment F.
14. The Hospital will not assign any part or all of this Agreement without Smile Train's prior written consent. Any attempt to assign in violation of this Section is void in each instance. Smile Train reserves the right to assign this Agreement or any of its rights or obligations under this Agreement without the Hospital's consent.
15. The Hospital understands and acknowledges that Smile Train in performing its obligations under this Agreement will partner with, employ or engage third parties or any entity from Smile Train's affiliates.

Dr. Rakesh S. [Signature]
 Project Director
 KLES Smile Train
 KLES Dr. Prabhakar Kore Hospital &
 Medical Research Centre, BELAGAVI.

[Signature]
 Medical Director & Chief Executive
 KLES Dr. Prabhakar Kore Hospital &
 Medical Research Centre, BELAGAVI.

SECRETARY
 Board of Management
 K.L.E. Society, BELAGAVI

ATTESTED

[Signature]

Prof. Dr. V.A.KOTHIWALE
 Registrar

KLE Academy of Higher Education
 and Research, BELAGAVI


B. SMILE TRAIN


- Smile Train will contribute a mutually agreed amount as contribution (to be separately communicated) for each primary cleft lip repair, primary cleft palate repair and a few specified secondary surgical interventions ("**Contribution**") carried out by the Hospital. For the purpose of receiving this Contribution, the surgeries will be limited to:
 - patients over the age of 3 months for cleft lips and 6 months for cleft palates; and
 - those within ASA Classes 1 and 2 only.(for clarifications please refer Attachment B, the Protocol)
- Smile Train reserves the right to amend the above criteria at any time at its sole discretion, without any notice and without assigning any reasons.
- The Contribution per surgery envisaged above is neither a reimbursement nor a service fee. It is a donation intended to *partially* defray the costs of treatment, with the remainder borne by the Hospital. The amounts paid by Smile Train will be all-inclusive, and there shall be no additional reimbursement of any expenses unless agreed by Smile Train in advance, in writing.
- Smile Train will remit the agreed funding on a monthly basis as set forth in the Program Summary attached hereto as Attachment A, based on the number of Patient Medical Records uploaded to the SIX server in the prior month, subject to such Patient Medical Records being verified and found correct by Smile Train.
- The Contribution by Smile Train under this Agreement shall be used solely for the purposes specified. Diversion of these funds for any other purpose without the prior written approval of Smile Train is expressly forbidden and shall be grounds for immediate termination of this Agreement. The Hospital shall indemnify Smile Train, its directors and officers with respect to any misuse of funds. Smile Train shall also have the right to stop the funding forthwith if directed by a lawfully established authority.

III. REPRESENTATIONS OF THE PARTIES


A. THE Hospital


- The Hospital is a running, well established medical facility, validly existing and in good standing under the laws of India and in the state where it operates and has the requisite rights and authority to carry on its activities as now being conducted and to execute, deliver and perform its obligations under this Agreement, and will ensure that the hospital(s) where surgeries take place under this Agreement have the licenses and meet the qualifications required by law in India for providing the medical services described herein and have licensed medical professionals with the skill, experience and appropriate medical facilities to provide safe and quality care. Hospital shall report any change to this status immediately to Smile Train.
- The execution, delivery and performance by the Hospital of this Agreement has been duly authorized by all required corporate action on the part of the Hospital. The obligations of the Hospital under this Agreement are valid, legal and binding obligations of the Hospital, enforceable against it in accordance with its terms.
- Neither the execution and delivery by the Hospital of this Agreement, nor the performance of any contractual obligation of the Hospital under this Agreement will violate, conflict with, result in the Hospital being in breach of, constitute a default under the governing documents of the Hospital, any material contract by which the Hospital is bound, or any statute, ordinance, judgment, order, decree, regulation or rule of any court, governmental or medical body affecting or relating to the Hospital.
- Except as otherwise provided in or contemplated by this Agreement, no consent of, waiver from, application or notice to any party is required in order for the Hospital to execute, deliver and perform this Agreement or to consummate the transactions contemplated hereby.


Medical Director & Chief Executive Officer
KLES Dr Prabhakar Kote
Medical Research Centre, BELAGAVI


SECRETARY
Board of Management
K.L.E. Society, BELAGAVI

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI


Page 4 of -

- Notwithstanding the generality of the foregoing, the Hospital represents that it is authorized to receive foreign contribution in accordance with applicable Indian laws and will ensure that the Contribution is utilized only for the purposes as provided under this Agreement and in accordance with applicable Indian laws.

B. SMILE TRAIN

- Smile Train is a not-for-profit company incorporated under Section 25 of the Companies Act, 1956, registered under Section 11(1) of the Foreign Contribution (Regulation) Act, 2010 vide Registration Number 231661597 having its registered office at Plot No.3, LSC Sector-C, Pocket 6/7, Vasant - Kunj New Delhi - 110070.
- Smile Train Inc., is a promoter and amongst the highest contributors of Smile Train, located at 41 Madison Avenue, 28th floor, New York, NY 10010, USA and is set up and registered as a Section 501(c)(3) public charity as defined by Section 501(c)(3) of the Internal Revenue Code under Federal tax law of the United States of America.
- All signatories to this Agreement confirm they have the necessary and valid authorities delegated to them to sign this Agreement.
- The execution, delivery and performance by Smile Train of this Agreement has been duly authorized by all required corporate action on the part of Smile Train. The obligations of Smile Train under this Agreement are valid, legal and binding obligations of Smile Train, enforceable against it in accordance with its terms, except as such enforceability may be subject to or limited by bankruptcy, insolvency, reorganization, moratorium, receivership and similar laws affecting creditors' rights generally and general principles of equity.
- Neither the execution and delivery by Smile Train of this Agreement, nor the performance of any other obligation of Smile Train under this Agreement will violate, conflict with, result in the breach of, constitute a default under the governing documents of Smile Train, any material contract by which Smile Train is bound, or any statute, ordinance, judgment, order, decree, regulation or rule of any court or governmental body affecting or relating to Smile Train.
- Except as otherwise provided in or contemplated by this Agreement, no consent of, waiver from, application or notice to any party is required in order for Smile Train to execute, deliver and perform this Agreement or to consummate the transactions contemplated hereby.

IV. REPORTING, RENEWAL AND SUSPENSION

A At least 30 days prior to the end of the funding period (which would be the period between January 1 to December 31 each year) ("Funding Period") the Hospital will submit a Final Grant Report (annexed hereto as Attachment G or as may be updated from time to time and shared with the Hospital) highlighting the achievements of the goals of this Program as set forth in Attachment A (Program Summary), and representatives from the Hospital and Smile Train will meet to assess the progress of funding efforts.

B At that time, Smile Train will determine whether funding will be renewed/extended. The decision to renew funding will be at the sole discretion of Smile Train, and Smile Train will not be obliged to give any reasons should it decide not to renew the same. If Smile Train does not renew, funding will cease at the conclusion of the Funding Period.

Smile Train reserves the right to suspend this Agreement, wholly or in part, for any reason at any time during the subsistence of this Agreement, by providing written notice to the Hospital.

V. PUBLIC RELATIONS

Smile Train reserves the right to publicize the cooperative efforts between the parties hereto through the use of literature, photographs, video film production and other media. The Hospital permits and allows Smile Train to use any and all of its materials including its trademarks and any literature in relation to the matters that it works on with Smile Train under this Agreement. Smile Train will also issue press releases

SECRETARY

Board of Management
K.L.E. Society, BELAGAVI

ATTESTED

Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

Page 5 of 7

and have the option to hold press conferences to announce the Program and its progress over the duration of the Funding Period. The Hospital agrees to be receptive in assisting Smile Train's efforts for publicity and/or additional fundraising. The Hospital acknowledges that the words "Smile Train", "Changing the World One Smile at a Time" and the logo of the smiling train are the exclusive intellectual property of Smile Train's affiliates. The Hospital shall immediately cease use if so instructed by Smile Train or its affiliates. In any and all publications and other public relations vehicles describing the Program, the parties hereto agree to receive prior approval from the other before using the other's name or intellectual property.

VI. INDEMNIFICATION; LIABILITY

The Hospital shall be solely responsible for any losses arising out of the Hospital's performance of this Agreement. The Hospital agrees to indemnify and hold harmless Smile Train, its affiliates, members, officers, directors, employees, agents and representatives (each such person, an "Indemnified Party") from and against any and all losses, claims, damages and liabilities, whether joint or several (the "Indemnifiable Losses"), related to, or arising out of, or in connection with, Hospital's actions in performing this Agreement, including but not limited to the performance of Program surgeries and related services and any advice, course of treatment, diagnosis or any other information, services or products that the Hospital or any director, officer, member, manager, employee, affiliate or associate of the Hospital provides to any patient.

VII. TERMINATION

- A. This Agreement may be terminated by either party without assigning any reasons, by giving 30 days' notice of its intention to do so, in writing to the other.
- B. Notwithstanding the above, Smile Train reserves the right to terminate this Agreement immediately at any time, at its sole discretion, in the event of fraud, violation of medical standards, misuse of funding of any kind, or misrepresentation, without any further liability under this Agreement.
- C. The Agreement shall stand terminated immediately if so directed by any statutory body or government department acting within the framework of the law.
- D. On the termination or expiry of the term of this Agreement, the Hospital shall return all records, publicity material, brochures, etc. pertaining to the Program, and furnish to Smile Train a full accounting of the disbursement of funds and expenditures incurred under the Program up to the effective date of termination within 30 days. As of the effective date of termination of the Agreement, for any reason whatsoever, Smile Train will not be required to provide any contribution to the Hospital, except for payments required to be made prior to the date of termination, in accordance with the terms of this Agreement and the payment process prescribed

[Signature]
Dr. Rajesh S. ...
Project Director
Smile Train
KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, BELAGAVI

VIII. AMENDMENT

This Agreement may not be amended or modified except by an instrument in writing signed by, or on behalf of, each of the parties hereto.

IX. NONDISCLOSURE

[Signature]

The specific terms of this Agreement are privileged and confidential, and the parties hereto undertake not to divulge the same to any third party without the prior, express written permission of the other. The only exceptions to this will be their duly appointed legal attorneys and advisors, or duly empowered statutory bodies and government agencies acting within the requirements of the law. The parties hereto also undertake to institute all reasonable steps to ensure that the confidentiality is maintained within their respective organizations.

Dr. Prabhakar Kore, Chief Executive
KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, BELAGAVI

X. PRIOR AGREEMENT

This Agreement supersedes and replaces any and all previous agreements between the parties.

[Signature]
ATTESTED

[Signature]
SECRETARY
Board of Management
K.L.E. Society, BELAGAVI

Prof. Dr. V.A. ROTHIAWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

XI. OTHERS

- A. This Agreement is on a 'principal-to-principal' basis and it does not confer any right to either party to represent the other, act on its behalf as its agent or authorized representative, issue public statements, make commitments of any kind or claim any relationship beyond the one provided in the Agreement. The duties and responsibilities of the Hospital shall be rendered solely by the Hospital and not as an agent, representative, or employee of Smile Train. The Hospital shall have full control of all its acts, doings, and proceedings relating to or requisite in connection with the discharge of its duties and responsibilities under this Agreement.
- B. The Hospital warrants that funds will be used in compliance with all applicable Indian laws and United States anti-terrorist financing and sanction laws and regulations. In this regard, the Hospital agrees to take all reasonable steps to ensure that no person or entity expected to receive funds in connection with this agreement is named on the either List of Specially Designated Nationals and Blocked persons and entities maintained by the Office of Foreign Assets Control of the U.S. Department of the Treasury or list of banned terrorist organisations under Section 35 of Unlawful Activities (Prevention) Act, 1967, maintained by the Ministry of Home Affairs, Government of India or any such equivalent list.
- C. The Hospital shall ensure that it is at all times in compliance with all relevant laws of the land affecting the implementation of the terms of this Agreement.
- D. In the event of any litigation arising out of this Agreement, both parties accept and acknowledge that the laws of India shall apply, and the courts in New Delhi shall have exclusive jurisdiction.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their duly authorized representatives as of the dates written below:

<p>For and on behalf of Karnataka Lingayat Education Society</p> <p>..... Signature <i>B. Prasad</i> Place Name of Officer SECRETARY Date Title of Officer Board of Management K.L.E. Society, BELAGAVI</p>	<p>For and on behalf of Smile Train</p> <p>New Delhi <i>Mamta Carroll</i> Mamta Carroll Director</p> <p>..... Date</p>
<p>For and on behalf of KLES Prabhakar Kore Hospital & Medical Research Centre</p> <p>..... Signature <i>[Signature]</i> Place Name of Officer Medical Director & Chief Executive KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, BELAGAVI.</p> <p>..... Date Title of Officer Medical Director/Superintendent</p>	
<p>For and on behalf of KLES Prabhakar Kore Hospital & Medical Research Centre – Project Director</p> <p>..... Signature <i>[Signature]</i> Place Name of Officer Project Director KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, BELAGAVI.</p> <p>..... Date Title of Officer</p>	

ATTESTED

Korke
Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI



The Smile Train

PRESIDENT

Dean J. Moloney
Executive Director
The Smile Train

BOARD OF DIRECTORS

Charles B. Wang
Executive Director
The Smile Train

Mark L. Johnson
Executive Director
The Smile Train

Robert E. Bell
Executive Director
The Smile Train

Joseph McCarthy, M.D.
Executive Director
The Smile Train

Donald B. Murphy
Executive Director
The Smile Train

Susan M. Schaefer
Executive Director
The Smile Train

Robert K. Smith, Esq.
Executive Director
The Smile Train

Thomas Van Zilt
Executive Director
The Smile Train

ADVISORY COMMITTEE

Pauline Bergen
Executive Director
The Smile Train

George Bush
Executive Director
The Smile Train

Walter Cronkite
Executive Director
The Smile Train

Justice Walter Haddock
Executive Director
The Smile Train

John McCain
Executive Director
The Smile Train

Frank Miller
Executive Director
The Smile Train

Earl Simon
Executive Director
The Smile Train

Dr Rajesh Powar
Dept of Plastic Surgery
K.L.E.S Hospital & Medical Research Centre
Nehru Nagar,
Belgaum 590 010
Karnataka

March 10, 2004

Dear Dr Powar

I refer to the Agreement No IN-S-5-1 signed between our two organizations for the extension of free cleft lip and palate surgeries to poor children.

As provided in Clause IV of the said Agreement, I am pleased to extend the validity of the same up to 31st December 2005 on the same terms.

Please sign the duplicate copy of this letter confirming your acceptance and return the same to me for our records.

I'd like to take this opportunity of placing on record our sincere appreciation of the good work done by you, your team and the management of KLES Hospital providing cleft reconstructive surgeries to poor children since the start of our "partnership". We regard it a privilege to be associated with a team like yours and look forward to working together with all of you - putting smiles on desperate faces and giving those unfortunate children a second chance at life.

Best regards

Yours sincerely,

Anaha
Satish Kalra
Regional Director - South Asia

[Signature]
Dr. RAJESH S. POWAR
M.S., M.Ch., D.N.B.,
PROJECT DIRECTOR
KLES SMILE TRAIN PROJECT
K.L.E.S. HOSPITAL & MRC, BELGAUM

The Smile Train Headquarters
215 Park Avenue, Suite 2204
New York, NY 10016
Tel: 212 679 9199
Fax: 212 479 9299
www.smiletrain.org

Smile Train China
Building 15, Room 302
51 Shuangcheng Nan Road
Shanghai 201103 P.R.
Tel: 86 21 62190750
Fax: 86 21 62190752

Smile Train India
S 240 Panchsheel Park
New Delhi 110 017
INDIA
Tel: 91 11 2644 36 43
Fax: 91 11 2644 36 49

ATTESTED

[Signature]
Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI



Smile Train

PRESIDENT

Dr. Rajesh Powar
Project Director - Smile Train Cleft Project
Dept of Plastic Surgery
K.L.E.S Hospital & Medical Research Centre
Nehru Nagar
Belgaum 590 010
Karnataka

BOARD OF DIRECTORS

Dr. Satish Kaira
Regional Director - South Asia

December 5, 2005

Dear Dr Powar

I refer to the subsisting Agreement and the subsequent amendments thereto between our two organizations for the provision of free cleft lip and palate surgeries to poor children at your hospital.

As provided in Clause IV of the original Agreement, we are pleased to extend the validity of the same up to 31st December 2007 on the terms as presently applicable.

This letter is being sent in triplicate; please sign all three copies confirming your acceptance and return two copies to me for our records.


I'd like to take this opportunity of placing on record our sincere appreciation of the good work done by you, your team and the management of K.L.E.S Hospital providing cleft reconstructive surgeries to poor children since the start of our 'partnership'.


We deem it a privilege to be associated with a team like yours and look forward to working together with all of you - putting smiles on desperate faces and giving those kids a second chance at life.

With all good wishes to you, your colleagues and your loved ones for the coming holiday season.

Best regards

Yours sincerely,


Satish Kaira
Regional Director - South Asia


Dr. RAJESH S. POWAR
M.S., M.Ch., D.N.B.,
PROJECT DIRECTOR
KLES SMILE TRAIN PROJECT
K.L.E.S. HOSPITAL & MRC, BELGAUM


cc: Hana Fuchs

The Smile Train - Headquarters
245 Fifth Avenue, Suite 2201
New York, NY 10016
Tel: 212.689.9199
Fax: 212.689.9299
www.SmileTrain.org

Smile Train China
Building 2, Room 2C
889 Wuzhong Road
Shanghai 201103 PRC
Tel: 86.21.6401.8985
Fax: 86.21.6401.8984

Smile Train India
S 240 Panchsheel Park
New Delhi 110 017
INDIA
Tel: 91.11.2601.36.48
Fax: 91.11.2601.36.49

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI



March 28, 2007

PRESIDENT

Brian F. Mullaney
Co-Founder, President
& Board Member

BOARD OF DIRECTORS

Charles B. Wang
Co-Founder & Chairman
The Smile Train

Mark E. Atkinson
Executive Director
Ohio Studies

Robert T. Bell
Executive Director
Charles B. Wang Foundation

Donald B. Murphy
Partner
Brown Brothers Harriman & Company

Susannah Schaefer
New York Lawyers

Robert K. Smith, Esq.
Schenectady

Tamara Ann Ziff
Honorary Board Member
The Smile Train

SUPPORTERS

Candice Bergen
Actress

Tom Brokaw
Former Anchor & Managing Editor
NBC Nightly News

Warren Buffett
CEO of Berkshire Hathaway

George Bush
13th President of the United States

Walter Cronkite
Former Managing Editor & Anchor
CBS Evening News

Dr. h.c. Walter Haefner
Chairman
Central Holding AG

Jane Kaczmarek
Actress

Bette Midler
Singer, Actress

Colin Powell
Former U.S. Secretary of State

Carly Simon
Singer, Actress

Lily Tomlin
Actress, Comedian

Alex Trebek
Host of Jeopardy!

Donald Trump
Entrepreneur

Bradley Whitford
Actor

Dr. Rajesh Powar
Project Director
K.L.E.S. Hospital & Medical Research Centre
Dept. of Plastic Surgery
Nehru Nagar
Belgaum 590 010
Karnataka
India

Dear Dr. Powar,

We refer to the existing Agreement and the subsequent amendments thereto between our two organizations for the provision of free cleft lip and palate surgeries to poor children at your hospital.

We wish to make the following additions to Clause II that spells out the 'Obligations of the Parties':

1. All cleft lip and palate surgeries and other related treatments provided to patients covered under this program shall be totally free, with no hidden costs.
2. Paying patients treated for cleft lip and palate surgeries and other related treatments will not be eligible for Smile Train support and records pertaining to those shall not be submitted.
3. No donation shall be solicited or accepted from or behalf of any patient treated under this program.

These additions shall form an integral part of the Agreement.

This letter is being sent in triplicate; please sign all three copies confirming your acceptance and return two copies to Satish Kalra, Regional Director-South Asia, for our records.

We greatly value our 'partnership', deem it a privilege to be associated with a team like yours, and look forward to working together with all of you – putting smiles on desperate children's faces and giving them a second chance at life.

Kind regards.

Yours sincerely,

DeLois H. Greenwood
Vice President

Satish Kalra
Regional Director – South Asia

Dr. Rajesh Powar
Project Director
K.L.E.S. Hospital & Medical
Research Centre

The Smile Train Headquarters
245 Fifth Avenue, Suite 2201
New York, NY 10016
Tel: 212.689.9199
Fax: 212.689.9299
www.smiletrain.org

The Smile Train China
Building 2, Room 2C
819 Wuxiang Road
Shanghai 201103 PRC
Tel: 06.21.6401.8985
Fax: 86.21.6401.8984

The Smile Train India
S 240 Paradiseeek Park
New Delhi 110017
INDIA
Tel: 91.11.2601.3648
Fax: 91.11.2601.3649

The Smile Train Africa
P.O. Box 2168
Marogoli Avenue Central
Nairobi
KENYA
Tel: 254.726.260405

The Smile Train Brazil
Rua Dr. Luis Caprigliano 200
Itaeranga 22644-050
Rio de Janeiro, RJ, BRAZIL
Tel: 55.21.2492.3509
Fax: 55.21.24948472

The Smile Train Mexico
Privada San Diego No. 8
Acapulco, Guerrero
Morelos 62440
MEXICO
Tel: 52.777.3141000

Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI



Smile Train

Creating Smiles Around the World

PRESIDENT

DIRECTORS

Dr Rajesh Powar
Dept of Plastic Surgery
K.L.E.S Hospital & Medical Research Centre
Nehru Nagar
Belgaum 590 010
Karnataka, INDIA

December 27, 2008

Dear Dr. Powar,

I refer to the subsisting Agreement and the subsequent amendments thereto between our two organizations for the provision of free cleft lip and palate surgeries to poor children at your hospital.

As provided in Clause IV of the original Agreement, we are pleased to extend the validity of the same up to 31st December 2010 on the terms as presently applicable.

This letter is being sent in triplicate; please sign all three copies confirming your acceptance and return *two* copies to me for our records.

I'd like to take this opportunity of placing on record our sincere appreciation of the good work done by you, your team and the management of K.L.E.S Hospital & Medical Research Centre for providing cleft reconstructive surgeries to poor children since the start of our 'partnership'.

We deem it a privilege to be associated with a team like yours and look forward to working together with all of you – putting smiles on desperate faces and giving those kids a second chance at life.

With all good wishes to you, your colleagues and your loved ones for the coming New Year.

Best regards

Yours sincerely,



Satish Kalra

Regional Director – South Asia

cc: Hana Fuchs

SUPPORTERS

The Smile Train World Headquarters, 41 Madison Avenue, 20th Floor, New York, NY 10010 Tel: 1.212.689.9199 Fax: 1.212.689.9299 www.smiletrain.org
The Smile Train UK, PO Box 583, Northampton, NN3 6UH Tel: 0870 127 6269 www.smiletrain.org.uk Registered Charity No. 1114748
Smile Train offices are also located in Brazil, China, India, Indonesia, Kenya, Mexico, Nigeria, Philippines, Thailand and Vietnam.


ATTESTED



Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI



Smile Train

Changing The World One Smile At A Time.

PRESIDENT

Brian F. Mullaney
Co-Founder, President
& Board Member

DIRECTORS

Charles B. Wang
Co-Founder & Chairman
The Smile Train

Mark E. Atkinson
Creative Director
Oto Studios

Robert T. Bell
Executive Director
Charles B. Wang Foundation

Donald B. Murphy
Partner
Brown Brothers Hardman
& Company

Richard Price
Managing Director
ING Clavin Partners

Susanah Schaefer
New York Islanders

Robert K. Smith, Esq.
Salon

Tamsen Ann Ziff
Honorary Board Member
The Smile Train

SUPPORTERS

Candice Bergen
Actor

Tom Brokaw
Former Anchor & Managing Editor,
NBC Nightly News

Warren Buffett
CEO Berkshire Hathaway

Walter Cronkite
Former Managing Editor & Anchor
CBS Evening News

Dr. h.c. Walter Haefner
Chairman
Cureal Holding AG

Jane Kazmarek
Actor

Bette Midler
Singer, Actor

Colin Powell
Former U.S. Secretary of State

Carly Simon
Singer, Author

Lily Tomlin
Actor, Comedian

Alex Trebek
Host of Jeopardy!

Donald Trump
Entrepreneur

Bradley Whitford
Actor

Dr. Rajesh Powar
KLES Dr. Prabhakar Kore Hospital & MRC
Dept. of Plastic Surgery
Nehru Nagar
Belgaum 590010
Karnataka

December 17, 2012

Dear Dr Powar

I refer to the subsisting Agreement and the subsequent amendments thereto between our two organizations for the provision of free cleft lip and palate surgeries to poor children at your hospital.

As provided in Clause IV of the original Agreement, we are pleased to extend the validity of the same up to 31st December 2014 on the terms as presently applicable.

This letter is being sent in triplicate; please sign all three copies confirming your acceptance and return two copies to your region Program Director for records.


I'd like to take this opportunity of placing on record our sincere appreciation of the good work done by you, your team and the management of KLES Dr. Prabhakar Kore Hospital & MRC for providing cleft reconstructive surgeries to poor children since the start of our 'partnership'.

We deem it a privilege to be associated with a team like yours and look forward to working together with all of you – putting smiles on desperate faces and giving those kids a second chance at life.


With all good wishes to you, your colleagues and your loved ones for the coming New Year.

Best regards


Yours sincerely,


Satish Kalra
Regional Director – South Asia

cc: Robert Toth


11.01.2013
Dr. Rajesh S. Powar
Project Director
KLES Smile Train Project
KLES Dr. Prabhakar Kore Hospital & MRC - Belgaum.

The Smile Train World Headquarters, 41 Madison Avenue, 28th Floor, New York, NY 10017 Tel: 1.212.689.9199 Fax: 1.212.689.9299 www.smiletrain.org
The Smile Train UK, PO Box 583, Northampton, NN3 6UH Tel: 0870 127 6269 www.smiletrain.org.uk Registered Charity No. 1114748
Smile Train offices are also located in Brazil, China, India, Indonesia, Kenya, Mexico, Nigeria, Philippines, Thailand, and Vietnam.

ATTESTED

Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

Representative Office
Smile Train Inc.
S 240 Panchsheel Park
New Delhi 110 017, India



".... one of the most productive
charities –
dollar for deed —
in the world."
— *The New York Times*

Dr. Rajesh Powar
KLES Dr. Prabhakar Kore Hospital & MRC
Dept. of Plastic Surgery
Nehru Nagar
Belgaum 590010
Karnataka

December 15, 2014

Dear Dr Powar

I refer to the subsisting Agreement and the subsequent amendments thereto between our two organizations for the provision of free cleft lip and palate surgeries to poor children at your hospital.

As provided in Clause IV of the original Agreement, we are pleased to extend the validity of the same up to 31st December 2016 on the terms as presently applicable.

This letter is being sent in triplicate; please sign all three copies confirming your acceptance and return two copies to your region Program Director for records.

I'd like to take this opportunity of placing on record our sincere appreciation of the good work done by you, your team and the management of KLES Dr. Prabhakar Kore Hospital & MRC for providing cleft reconstructive surgeries to poor children since the start of our 'partnership'.

We deem it a privilege to be associated with a team like yours and look forward to working together with all of you – putting smiles on desperate faces and giving those kids a second chance at life.

With all good wishes to you, your colleagues and your loved ones for the coming New Year.

Best regards

Yours sincerely,

Mamta Carrol
Regional Director – South Asia

cc: Leela Imam
cc: Mackinnon Engen

ATTESTED

Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

PARTNERSHIP AGREEMENT

This agreement is by and between Smile Train, Inc., a New York based not-for-profit corporation represented by its India office located at S-240 Panchsheel Park, New Delhi 110 017 ("Smile Train") and the KLES Hospital & Medical Research Centre, Nehru Nagar, Belgaum 590 010 in the state of Karnataka ("KLESH").

RECITALS

- A. Smile Train is a non-profit charitable organization whose mission is to provide assistance to children born with cleft lip and palate around the world.
- B. KLESH is a multi specialty hospital run by the Karnatak Lingayat Education Society, where some cleft reconstructive surgeries are already being carried out within the Department of Plastic Surgery.
- C. The parties, therefore, desire to enter into a cooperative, joint effort (the "Partnership") through which KLESH will, in a phased manner, augment its resources to substantially increase the number of cleft reconstruction surgeries, through financial, technical and other support from Smile Train.
- D. The purpose and details of the Partnership are described in Attachment A.

I. TERM AND EFFECTIVE DATE

Funding of the Partnership shall begin on April 1, 2001 (the "Effective Date") and shall continue for three years until March 31, 2004 (the "Funding Period"), unless extended or terminated as provided in the Renewal or Termination sections below.


II. OBLIGATIONS OF THE PARTIES

A. KLESH

1. KLESH shall make a full and thorough review of available resources in its existing Department of Plastic Surgery, identify those that need to be added to meet the requirements of this Agreement, and draw up an appropriate action plan for putting them in place in accordance with KLESH's personnel practices, procedures and standards.
2. KLESH shall provide Smile Train with complete patient information for each surgical case (Attachment E) conducted through funding of the Partnership. KLESH shall preferably provide these completed records to Smile Train on a continuous basis but at no time later than 10 days after the end of each calendar month. Smile Train reserves the right to hold payment until receipt of this information.
3. Immediately following the Effective Date, KLESH will implement credentialing and monitoring procedures in accordance with Smile Train's Safety and Quality Improvement Protocol (the "Protocol"), as described in Attachment E. KLESH acknowledges that (i) Smile Train has developed the Protocol for the express purpose of ensuring and maintaining high safety standards, quality improvement and quality control and (ii) the adoption and continued implementation of the Protocol by KLESH is a condition to Smile Train's obligations hereunder. In the event that any patient is harmed in any manner that is not in the ordinary course of cleft operations (Sentinel Event), KLESH will (i) immediately notify Smile Train of such event, and (ii) implement the review process set forth by Smile Train for Sentinel Event protocol. As part of the Protocol, KLESH specifically undertakes to report all sentinel events within 24 hours of the event's occurrence, using Smile Train's Reporting Form (Attachment E). KLESH will report these events to Smile Train's main office in New York and its India office in New Delhi.
4. To reach the mutually agreed goals for this Partnership, KLESH undertakes, *inter alia* to
 - a) Set up a separate Speech Therapy Department and recruit a full-time, appropriately qualified and trained Speech Therapist within 6 months of the commencement of this Agreement.

ATTESTED

Page 1 of 22


Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

- b) Add at least one more fully qualified and trained Plastic Surgeon by December 31, 2001.
- c) Provide the KLES Smile Train Cleft Centre a suitably furnished, independent office of at least 400 sq. ft, one full time clerk / secretary, a dedicated PC, a digital camera & a separate internet connection.

5. On a semi-annual basis, KLESH will meet with representatives of Smile Train to evaluate the progress of the Partnership. At the time of each meeting, KLESH will provide Smile Train with a narrative report, documenting the progress of the Partnership. Included in this report should be a monthly breakdown of the number of surgeries performed split up by the categories agreed. Please see Attachment F for report guidelines. The parties will agree upon the date and time of each of the meetings.

6. KLESH agrees to participate in Smile Train Express (A free, global, cleft care database) by submitting the completed patient record information, which includes the patient consent form (Attachment E).

7. At the conclusion of each year (March 31, 2002, March 31, 2003 and March 31, 2004), KLESH will submit a final written report that includes progress of the Partnership to date and outlining the specific programs planned for the coming year.

8. At the end of every year, a duly authorized representative of KLESH shall submit to Smile Train an affidavit (as per Attachment C) confirming the use of the Funded Amount.

B. SMILE TRAIN

1. Smile Train will contribute a *maximum* Financial Support of Rs. 12,400,000 or US\$ 270,000 (Indian Rupees Twelve Million Four Hundred Thousand or US\$ Two Hundred and Seventy Thousand), whichever is *lower*, hereinafter referred to as the "Funded Amount", during the entire Funding Period, with monthly disbursements based on the actual number and categories of cleft reconstruction surgeries performed, calculated on the basis of the formula laid down in Attachment D (the "Funded Amount").

2. The Funded Amount will be all-inclusive, and there shall be no additional reimbursement of any expenses, unless explicitly agreed by Smile Train in advance, in writing.

3. To enable KLESH to obtain some equipment needed for the effective management and control of the program envisaged under this Agreement, Smile Train will advance a sum of Rs 300,000 within 15 days of the signing of this Agreement. This advance will be free of interest and shall be adjusted in ten equal installments of Rs 30,000 each from the monthly payments due to KLESH starting with the payment for the month of September 2001. In the event of this Agreement being prematurely terminated for any reason, KLESH shall return the outstanding balance to Smile Train at the time of such termination.

III. REPRESENTATIONS OF THE PARTIES

A. KLESH

KLESH is part of the Karnatak Lingayat Education Society, Belgaum, a Registered Trust set up and registered under Act XXI of 1860 & the Bombay Public Trust Act of 1950, validly existing and in good standing under the laws of India and has the requisite authority to carry on its activities as now being conducted. Any change to this status shall be reported immediately to Smile Train.

B. SMILE TRAIN

Smile Train is a not-for-profit corporation, as defined by Subparagraph (a)(5) of Section 102 of the New York Not-for-Profit Corporation Law, duly organized, validly existing and in good standing under the laws of New York and has the requisite corporate authority to carry on its business as now being conducted.

IV. RENEWAL

A. At the review at the end of the first funding year (April 1, 2001 – March 31, 2002) representatives from KLESH and Smile Train will meet to assess the progress of funding efforts. At this time, Smile Train will determine whether funding will be renewed/extended for the next two-year period (April 1, 2002 – March 31, 2004). The decision to renew funding will be at the sole discretion of Smile Train, and it will not be

Page 2 of 22 ^{ATTESTED}



Prof. Dr. V.A. KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI



60

obliged to give any reasons should it decide not to renew the same. If Smile Train does not renew, funding will cease at the conclusion of the initial one-year period, ending on March 31, 2002.

V. PUBLIC RELATIONS

Smile Train reserves the right to publicize the cooperative efforts between the two parties through the use of literature, photographs, video film production and other media. Smile Train will also issue press releases and have the option to hold press conferences to announce the Partnership and its progress over the duration of the funding period. Both parties agree to be receptive to assisting in each other's efforts for publicity and/or additional fundraising. KLESH acknowledges that the words "The Smile Train," "Changing the World One Smile at a Time," and the logo of the smiling train are the exclusive intellectual property of Smile Train. KLESH shall forthwith cease to use them in any manner, if so instructed by Smile Train. In any and all publications and other public relations vehicles describing the Partnership, both parties agree to receive prior approval from the other before using the name of that party or logo.

VI. INDEMNIFICATION

A. KLESH agrees to indemnify and hold harmless Smile Train, its affiliates, members, officers, directors, employees, agents and representatives (each such person, an "Indemnified Party") from and against any and all losses, claims, damages and liabilities, whether joint or several (the "Indemnifiable Losses"), related to, arising out of, or in connection with, the actions contemplated by this Agreement or the performance by Smile Train of its obligations contemplated by, this Agreement.

VII. TERMINATION

A. This agreement may be terminated by either party without assigning any reasons, by giving 90 days notice of its intention to do so, in writing to the other.

B. Notwithstanding the above, Smile Train reserves the right to terminate this agreement forthwith, at its sole discretion, in the event of fraud, gross violation of medical standards or willful and malafide misrepresentation of facts.

C. The agreement shall also stand terminated forthwith if so directed by any statutory body or government department acting within the framework of the law.

D. On the termination of this agreement, KLESH shall return all records, publicity material, brochures, etc. pertaining to the Project, and furnish to Smile Train a full accounting of the disbursement of funds and expenditures incurred under the grant up to the effective date of termination.

VIII. AMENDMENT

This Agreement may not be amended or modified except by an instrument in writing signed by, for and on behalf of, KLESH and Smile Train.

IX. NONDISCLOSURE

The contents of this agreement are privileged and confidential, and both parties undertake not to divulge the same to any third party without the prior, express written permission of the other. The only exceptions to this will be their duly appointed legal attorneys and advisors, or duly empowered statutory bodies and government agencies acting within the requirements of the law. Both parties also undertake to institute all reasonable steps to ensure that the confidentiality is maintained within their respective organizations.


X. OTHERS

A. This agreement is on a 'principal-to-principal' basis and it does not confer any right to either party to represent the other, act on its behalf as its agent or authorized representative, issue public statements, make commitments of any kind or claim any relationship beyond the one provided in the agreement. It is explicitly acknowledged by both parties that the term 'partnership' in the context of this Agreement does not constitute a partnership firm.

B. In the event of any litigation arising out of this agreement, both parties accept and acknowledge that the laws of India shall apply, and the courts in New Delhi shall have the exclusive jurisdiction.









ATTESTED

Page 3 of 22


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

61

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives as of the dates written below:

For and on behalf of Smile Train			For and on behalf of KLESH		
Date	Signature	Designation	Date	Signature	Designation
	 J. Baxter Urist	President	14 March, 2001	 Prabhakar Kore,	Chairman, KLE Society
	 DeLois H. Greenwood	Vice President for Strategic Projects	14 March, 2001	 Col. A.K. Singh	Medical Director & CEO
	 Satish Kalra	Managing Director - India	14 March, 2001	 V.S. Sadhunar	Director, KLE Society
14 March, 2001			14 March, 2001	 Rajesh Powar	Consultant & H.O.D. of Plastic Surgery,
			14 March, 2001	 Pradip R. Shetye	Associate Prof. of Orthodontics KLES Dental College

Attachments:

- Project Summary (A)
- Payment Schedule (B)
- Affidavit (C)
- Schedule of Funding Support by Category of Surgery (D)
- Smile Train Express Package (E)
 - Safety and Quality Improvement Protocol
 - Patient Record
 - Patient Consent Form
 - Reporting Form
- Semi-Annual Report Guidelines (F)



ATTACHMENT A: PROJECT SUMMARY

Title of Project: Smile Train Cleft Program at KLESH

Project Director: Dr Rajesh Powar


Project Description/Objectives:

It is estimated that approximately 35,000 children are born with this birth effect in India each year. A large majority of these (estimated at 80%) grow into adulthood without receiving any reconstructive surgery for want of money. The current rate of surgeries performed at KLESH is about 100 per year. The goal of the Smile Train Cleft Program at KLESH is to significantly step up the number of cleft reconstructive surgeries and provide a full and comprehensive rehabilitation package of services to as many affected children as possible.

Funding support to achieve this objective will be provided by Smile train as part of its global commitment to helping children born with cleft lips and cleft palates. Surgeries will be conducted through the Cleft Palate Center within KLESH.

It is estimated that as a result of this funding, at least 300 surgeries will be performed in Year 1, at least 500 in Year 2 and at least 750 surgeries in Year 3. Therefore, in total, at least 1,550 children will receive cleft lip and palate surgeries over the next three years. The financial support for surgeries is further outlined in Attachment D. If it is anticipated that the actual number of cases is likely to exceed these projections, a prior written request for additional funding based on the same formula and on the same terms will be favorably considered, but approval shall be at the sole discretion of Smile Train.


Initialize for Smile Train:


.....
J. Baxter Urist

Date :



.....
DeLois H. Greenwood

Date:



.....
Satish Kalra

Date: 14 March, 2001


Initialize for KLESH:


.....
Prabhakar Kore

Date: 14 March, 2001


.....
Col. A.K. Singh


Date: 14 March, 2001


.....
V.S. Sadhunavar

Date: 14 March, 2001


.....
Rajesh Powar

Date: 14 March, 2001


.....
Pradip R. Shetye

Date: 14 March, 2001

ATTESTED









Page 5 of 22

Prof. Dr. V.A. KOTHIWALE

Registrar


KLE Academy of Higher Education
and Research, BELAGAVI

ATTACHMENT B: PAYMENT SCHEDULE

Financial Officer:	Contract No: IN/S/5-1
Funding Period	
Start Date: April 1, 2001	End Date: March 31, 2004
Cheques to be made payable to: KLESH & MRC a/c Smile Train Project	
<i>If applicable, please provide the following for wire transfers:</i>	
Name of Bank: CANARA BANK	Account Name: KLESH & MRC a/c Smile Train Project
Address: KLESH EXTN., COUNTER, NEHRU NAGAR, BELGAUM-16	Account No.: 1621
ABA Routing Number/Swift Code:	
Payment Schedule:	
Within 10 working days of the receipt of fully complete Quarterly Reports from KLESH, due on the last days of October, January, April and July of every year during the funding period.	
Initialize for Smile Train:	Initialize for KLESH:
 J. Baxter Urist Date :	 Prabhakar Kore Date: 14 March, 2001
 DeLois H. Greenwood Date:	 Col. A.K. Singh Date: 14 March, 2001
 Satish Kalra Date: 14 March, 2001	 V.S. Sadhunavar Date: 14 March, 2001
	 Rajesh Powar Date: 14 March, 2001
	 Pradip R. Shetye Date: 14 March, 2001

ATTESTED

Page 6 of 22


P. D. V. A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

64

ATTACHMENT C: AFFIDAVIT

Affidavit of Foreign Entity to Qualify as Organization Described in Section 509(a)(1), (2) or (3) or Section 4942(j)(3) of Internal Revenue Code

The undersigned,.....[Name], being an authorized principal officer of the Karnatak Lingayat Education Society Hospital & Medical Research Centre ("KLESH"), an organization formed under the laws of India ("Grantee"), does hereby certify that:

I am the _____ [Title] of Grantee. The Grantee was created and is operated exclusively for charitable purposes. The laws and customs applicable to Grantee do not permit any of its income or assets to be distributed to, or applied for the benefit of, a private person or non-charitable organization other than pursuant to the conduct of Grantee's charitable activities, or as payment of reasonable compensation for services rendered or as payment representing the fair market value of property which Grantee has purchased.

Grantee has no shareholders or members who have a proprietary interest in the income or assets of KLESH. In the event that Grantee were to be liquidated or dissolved, under the laws and customs applicable, or under the governing instruments, all of its assets would be distributed to another not-for-profit organization for charitable, religious, scientific, literary, or educational purposes, or to a government instrumentality.

The laws and customs applicable to Grantee do not permit KLESH, other than as an insubstantial part of its activities:

- (a) to engage in activities that are not for religious, charitable, scientific, literary or educational purposes;
- or
- (b) to attempt to influence legislation, by propaganda or otherwise.

The laws and customs applicable to Grantee do not permit Grantee directly or indirectly to participate or intervene in any political campaign on behalf of, or in opposition to, any candidate for public office. Grantee is not controlled by or operated in connection with any other organization.

(9) Copies of the charter, bylaws and other documents pursuant to which Grantee is governed are attached hereto as Exhibit A.

The undersigned has executed this affidavit as of _____, _____, 2000.

_____ [Organization]

By: _____ [Signature]

Name: _____

Title: _____

Seal of the organization

ATTESTED

Page 7 of 22



Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI











ATTACHMENT D: SCHEDULE OF FUNDING SUPPORT BY CATEGORY OF INTERVENTION

FINANCIAL SUPPORT STRUCTURE:


Type of Intervention	Financial Support per Intervention (in Rupees)	Financial Support per Intervention (in US\$)	Number of Interventions likely to be funded		
			Year 1	Year 2	Year 3
Primary Lip Repair or Nose Revision with or without anterior palate	7,500	163	150	250	375
Primary Cleft Palate Repair	9,000	196	120	200	300
Secondary Rhinoplasty	6,500	141	15	25	40
Fistula Repair	6,000	130	5	10	15
Alveolar Bone Graft	7,000	152	5	5	10
'Whole-in-one'	12,000	261	5	10	10

* The figure is based on the approx. exchange rate prevailing at the time of signing this agreement; it is only an indicative figure, and the actual financial support will be computed on the basis of the figures in Indian Rupees

<p>Initialize for Smile Train:</p> <p> J. Baxter Urist Date: _____</p> <p> DeLois H. Greenwood Date: _____</p> <p> Satish Kalra Date: 14 March, 2001</p>	<p>Initialize for KLESH:</p> <p> Prabhakar Kore Date: 14 March, 2001</p> <p> Col. A.K. Singh Date: 14 March, 2001</p> <p> V.S. Sadhunavar Date: 14 March, 2001</p> <p> Rajesh Powar Date: 14 March, 2001</p> <p> Pradip R. Shetye Date: 14 March, 2001</p>
--	---

ATTESTED

Page 8 of 22


 Prof. Dr. V.A. KOTHIWALE
 Registrar
 KLE Academy of Higher Education
 and Research, BELAGAVI

66



**JAWAHARLAL NEHRU MEDICAL COLLEGE, BELGAUM
DEPARTMENT OF E.N.T & HEAD AND NECK SURGERY**

Extn. No: 1528, 2071

Ref. No: ENT/11-12/897

Date: 02-02-2012

To,

**The Registrar
KLE University,
Belgaum.**

Sub: Collabaration of Otology Centre of CAUSSE EAR CLINIC, FRANCE

Respected Sir,

I am very much thankful to you and Hon. Vice Chancellor for extending your support to collaboration of KLE University's, Department of ENT, J. N. Medical College, Belgaum with Causse Ear Clinic of France, again for next 5 years the MOU has signed on 22nd January- 2012 between KLE University and Causse Ear Clinic, France.

This will provide the opportunity for faculty exchange and joint research - publications between two institutes. It will also provide the "LION - LIVE INTERNATIONAL OTOLOGY NETWORK" twice a year connectivity of live surgeries run in 20 centres of Europe and USA to KLE Dr. Prabhakar Kore Hospital & Medical Research Centre. The Chief of the Causse Ear Clinic Dr. Robert Vilcent has expressed his desire to visit KLE University, Belgaum next year i.e 2013 for Live Surgical Workshop in our Hospital. I have extended the invitation to him on behalf of the KLE University.

Dr. Robert Vilcent has appreciated the KLE University for the Felicitation done to him on behalf of the KLE University at Chennai and I am herewith sending the copy of MOU with photographs.

Thanking you,

Yours faithfully,

**PROFESSOR & HOD
DEPARTMENT OF ENT
J. N. MEDICAL COLLEGE, BELGAUM.**

**&
OFFICER INCHARGE COLLABARATION**

- C.C To:
- 1) The Special Officer to Vice Chancellor, KLE University, Belgaum
 - 2) The Principal, J. N. Medical College, Belgaum.
 - 3) ✓ The Medical Director & CE, KLE Dr. Prabhakar Kore Hospital & MRC, Bgm

Sir original copy deposited to library

... .. forward to Secretary to M.D

ATTESTED

**Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI**

MEMORANDUM OF UNDERSTANDING
(ACADEMIC COLLABORATION)



KLE UNIVERSITY, BELGAUM

WITH




CLINIQUE DU DOCTEUR JEAN CAUSSEE
(CAUSSE EAR CLINIC, BEZIERS, FRANCE)

For

FELLOWSHIP PROGRAM IN OTOLOGY,
NETWORKING CENTRE FOR LIVE INTERNATIONAL OTOLOGY NETWORK (LION)
&
JOINT RESEARCH PUBLICATIONS

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

MEMORANDUM OF UNDERSTANDING

(ACADEMIC COLLABORATION)

This Memorandum of Understanding (this 'Understanding') for academic collaboration is executed on 22nd January 2012 by and between the **KLE University**, established u/s 3 of the UGC Act, 1956 having its registered office at 'JNMC Campus, Nehru Nagar, Belgaum - 590 010, Karnataka, India (hereinafter referred to as 'the University' which expression shall, unless repugnant to the subject or context thereof, be deemed to include and mean its nominees, successors and permitted substitutes or assigns) of the

ONE PART.

With

Clinique Du Docteur Jean Causee (Causee Ear Clinic, Beziers, France), (Hereinafter referred as 'Collaborator', which expression shall, unless repugnant to the subject or context thereof, be deemed to include and mean its nominees, successors and permitted substitutes or assigns) on another PART either or both of which may be referred to as a 'Party' or the 'Parties', respectively as the context demands.

WHEREAS

- A. The University and the Collaborator desire to provide training / education / academic collaboration for Fellowship Program in Otolaryngology every year.
- B. The KLE University will depute one faculty and one Post-Graduate Resident or as decided by the University for the Fellowship Program every year at the Collaborator Institute.
- C. The Duration of the Fellowship Program will be 2 to 3 weeks.
- D. Both the institutions will be jointly conducting clinical research and make international scientific/research publications together.
- E. The Collaborator will coordinate with KLES Prabhakar Kore Hospital & MRC, Belgaum to be one of the networking centers for the Live International Otolaryngology Network (LION) every year.
- F. Dr.R.S.Mudhol, Professor & HoD of ENT in the University's J.N.Medical College, Belgaum shall be the Officer Incharge for this academic collaboration with the collaborator institute.

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI


Any variation or amendment or addition of / to this Understanding shall be mutually agreed to in writing and executed by or on behalf of each of the parties, University and the Collaborator.

IN WITNESS WHEREOF, the parties hereto have executed this Understanding as of the date first above written.

Signed for and on behalf of
KLE University,
Belgaum.

Signed for and on behalf of
Clinique du Docteur Jean Caussee
(Causse Ear Clinic, Beziers, France)

Signature :



Signature :



Name : Prof. (Dr.) P.F. Kotur

Name : Dr. Robert Vincent

Designation : Registrar

Designation: Chief Otologist



ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

**MEMORANDUM OF UNDERSTANDING
(ACADEMIC COLLABORATION)**



KLE ACADEMY OF HIGHER EDUCATION AND RESEARCH
(Formerly known as KLE University)
(Deemed University established u/s.3 of the UGC Act, 1956)

WITH




**CLINIQUE DU DOCTEUR JEAN CAUSSEE
(CAUSSE EAR CLINIC, BEZIERS, FRANCE)**

For

**FELLOWSHIP PROGRAM IN OTOLOGY,
NETWORKING CENTRE FOR LIVE INTERNATIONAL OTOLOGY NETWORK (LION)
&
JOINT RESEARCH PUBLICATIONS**

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

MEMORANDUM OF UNDERSTANDING

(ACADEMIC COLLABORATION)

This Memorandum of Understanding (this 'Understanding') for academic collaboration is executed on 23rd January 2017 by and between the **KLE Academy of Higher Education and Research, Deemed University**, established u/s 3 of the UGC Act, 1956 having its registered office at JNMC Campus, Nehru Nagar, Belagavi - 590 010, Karnataka, India (hereinafter referred to as '**the Deemed University**' which expression shall, unless repugnant to the subject or context thereof, be deemed to include and mean its nominees, successors and permitted substitutes or assigns) of the ONE PART.


With

Clinique Du Docteur Jean Causee (Causee Ear Clinic, Beziers, France), (Hereinafter referred as '**Collaborator**', which expression shall, unless repugnant to the subject or context thereof, be deemed to include and mean its nominees, successors and permitted substitutes or assigns) on another PART either or both of which may be referred to as a 'Party' or the 'Parties', respectively as the context demands.

WHEREAS

- A. The Deemed University and the Collaborator desire to provide training / education / academic collaboration for Fellowship Program in Otolaryngology every year.
- B. The Deemed University will depute one faculty and one Post-Graduate Resident or as decided by the Deemed University for the Fellowship Program every year at the Collaborator Institute.
- C. The Duration of the Fellowship Program will be 2 to 3 weeks.
- D. Both the Institutions will be jointly conducting clinical research and make international scientific/research publications together.
- E. The Collaborator will coordinate with KLES Prabhakar Kore Hospital & MRC, Belagavi to be one of the networking centers for the Live International Otolaryngology Network (LION) every year.
- F. Dr.R.S.Mudhol, Professor of ENT in the Deemed University's J.N.Medical College, Belagavi shall be the Officer Incharge for this academic collaboration with the collaborator Institute.
- G. The duration of the MoU shall be for a period of five years from the date of its execution i.e. 23rd January 2017.


ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

Any variation or amendment or addition of / to this Understanding shall be mutually agreed to in writing and executed by or on behalf of each of the parties, Deemed University and the Collaborator.

IN WITNESS WHEREOF, the parties hereto have executed this Understanding as of the date first above written.


Signed for and on behalf of
KLE Academy of Higher Education & Research
Belagavi.

Signature : 

Name : Prof. Dr. V.D. PATIL

Designation : Registrar

Signed for and on behalf of
Clinique du Docteur Jean Caussee
(Causse Ear Clinic, Beziers, France)

Signature : 

Name : Dr. Robert Vincent

Designation: Chief Otologist

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

MEMORANDUM OF UNDERSTANDING



KLE University

(Formerly known as KLE Academy of Higher Education and Research),

herein represented by

Dr. V.D.Patil,

Registrar, KLE University

A Deemed University u/s 3 of the UGC Act 1956

vide Government of India notification No.9-19/2000-U.3A

Belagavi-590010, Karnataka, India

AND

Vijaya ENT Care Centre Super-Specialty Otolaryngology Centre,

herein represented by

Dr. H. Vijayendra,

Director and Chief Consultant,

#1, 9th Cross, Malleshwaram Bangalore-560 003

ATTESTED

Prof. Dr. V.A.KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

MEMORANDUM OF UNDERSTANDING

BETWEEN



KLE University,

herein represented by

Dr. V.D.Patil,

Registrar, KLE University

A Deemed University u/s 3 of the UGC Act 1956

vide Government of India notification No.9-19/2000-U.3A

Belagavi-590010, Karnataka, India

AND

Dr. H. Vijayendra,

Director and Chief Consultant,

Vijaya ENT Care Centre Super-Specialty Otolaryngology Centre,

1, 9th Cross, Malleshwaram Bangalore-560 003

The KLE University (KLEU), Belagavi, Karnataka, India and Vijaya ENT Care Centre Super-Specialty Otolaryngology Centre, Bengaluru recognize the benefits to their respective Institute / Centre from the establishment of collaborations and proceed to have a Memorandum of Understanding (MoU). Both the independent Institution / centre are committed to mutual and common goals of generating new knowledge towards academic collaborations in Otolaryngology and Micro-Ear Surgery.

PREAMBLE:

KLE Society established in the year 1916 is successfully running more than 255 institutions in the field of healthcare (Medical, Dental, Pharmacy, Ayurveda, Physiotherapy and Nursing Science), Information Technology, Law and many more conventional and non-conventional disciplines. Currently, the KLE University has been accredited with 'A' Grade by National Assessment and Accreditation Council (NAAC) in the 2nd Cycle and has been placed in Category 'A' by the Ministry of Human Resource Development (MHRD), Government of India.

Vijaya ENT Care Centre Super-Specialty Otolaryngology Centre, having its Centre at #1, 9th Cross, Malleshwaram Bangalore-560 003 caters to the needs of Post-Graduate students of ENT and Fellowship in Micro-Ear Surgery through advanced training program / practical aspects.

The respective University / Centre jointly recognize this MoU to mutually cooperate in the areas of advanced training and practical exposure in the field of Micro-Ear Surgery and Otolaryngology for the benefit of Post-Graduate students of ENT of J.N.Medical College, Belagavi, a constituent unit of the KLE University.

ATTESTED

A handwritten signature in black ink, appearing to read 'V.A. Kothiwale'.

Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

PURPOSE / OBJECTIVE

The primary purpose of this MoU is to build academic research / training capacity including research publications and to promote mutual understanding between the University /Centre. The MoU shall formally set out the terms of co-operative relationship between the parties, establish their respective roles, and facilitate the function of each party in relation to collaborative research / academic training.

Both University / Centre agree to develop collaborative activities in academic areas of mutual interest / advanced practical training and as equal partners with reciprocity. All academic and research training events are expected to reflect the Post-Graduate students and faculty members in the area of Micro-Ear Surgery, Otolaryngology and research publications particularly in the area of ENT and HNS.

The development and implementation of specific activities based on this MoU shall be negotiated and agreed upon with mutually accepted terms and conditions.

This MOU is agreed on the basis of cooperation between the University/Centre. Includes the following:


- A. The University and the Centre desire to provide training /education /academic collaboration for Fellowship Program in Micro-Ear Surgery every year and research publications.
- B. The KLE University will depute Post Graduate students and Fellowship students of Micro-Ear Surgery as decided by the University for the Fellowship Program every year at the Collaborator Centre.
- C. Both the institutes will be jointly conducting clinical research and make national and international scientific /research publications together.
- D. HOD of ENT in the University's J.N. Medical College, Belagavi shall be the Officer Incharge for this collaboration with the Collaborator institute.


TERMS OF AGREEMENT

Both University / Centre agree to carry out the above mentioned activities in accordance with laws and regulations of respective university/centre after full consultation and approvals.


The term of this agreement shall be valid for a period of five years commencing from the date of signature hereof. This agreement can be extended for further terms on mutual agreement. This agreement may be terminated by giving 6 months prior notice from either parties.


In witness whereof, the parties have executed this document by signing on the day of 2nd November 2013.


Dr. V. D. Patil
Registrar
KLE University
Belagavi, Karnataka
KLE UNIVERSITY
BELAGAVI


Dr. H. Vijayendra,
Director and Chief Consultant,
Vijaya ENT Care Centre
Super-Specialty Otolaryngology,
Bengaluru-560 003

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI



MEMORANDUM OF UNDERSTANDING



KLE Academy of Higher Education and Research (Formerly known as KLE University)

herein represented by
Dr. V.A.Kothiwale,
Registrar, KAHER

A Deemed University u/s 3 of the UGC Act 1956
vide Government of India notification No.9-19/2000-U:3A.
Belagavi-590010, Karnataka, India

AND

Vijaya ENT Care Centre Super-Specialty Otology Centre,

herein represented by

Dr. H. Vijayendra,

Director and Chief Consultant,

#1, 9th Cross, Malleshwaram Bangalore-560 003

ATTESTED

Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

MEMORANDUM OF UNDERSTANDING

BETWEEN



KLE Academy of Higher Education and Research

herein represented by

Dr. V.A.Kothiwale,

Registrar, KAHER

A Deemed University u/s 3 of the UGC Act 1956
vide Government of India notification No.9-19/2000-U.3A
Belagavi-590010, Karnataka, India

AND

Dr. H. Vijayendra,

Director and Chief Consultant,

Vijaya ENT Care Centre Super-Specialty Otolaryngology Centre,
1, 9th Cross, Malleshwaram Bengaluru-560 003

The **KLE Academy of Higher Education and Research (KAHER)**, Belagavi, Karnataka, India and **Vijaya ENT Care Centre Super-Specialty Otolaryngology Centre**, Bengaluru recognize the benefits to their respective Institute / Centre from the establishment of collaborations and proceed to have a Memorandum of Understanding (MoU). Both the independent institution / centre are committed to mutual and common goals of generating new knowledge towards academic collaborations in Otolaryngology and Micro-Ear Surgery.

PREAMBLE:

KLE Society established in the year 1916 is successfully running more than 255 institutions in the field of healthcare (Medical, Dental, Pharmacy, Ayurveda, Physiotherapy and Nursing Science), Information Technology, Law and many more conventional and non-conventional disciplines. Currently, the KLE University has been accredited with 'A' Grade by National Assessment and Accreditation Council (NAAC) in the 2nd Cycle and has been placed in Category 'A' by the Ministry of Human Resource Development (MHRD), Government of India.

Vijaya ENT Care Centre Super-Specialty Otolaryngology Centre, having its Centre at #1, 9th Cross, Malleshwaram Bengaluru-560 003 caters to the needs of Post-Graduate students of ENT and Fellowship in Micro-Ear Surgery through advanced training program / practical aspects.

The respective University / Centre jointly recognize this MoU to mutually cooperate in the areas of advanced training and practical exposure in the field of Micro-Ear Surgery and Otolaryngology for the benefit of Post-Graduate students of ENT of J.N.Medical College, Belagavi, a constituent unit of the KLE University.

ATTESTED

Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

PURPOSE / OBJECTIVE

The primary purpose of this MoU is to build academic research / training capacity including research publications and to promote mutual understanding between the University / Centre. The MoU shall formally set out the terms of co-operative relationship between the parties, establish their respective roles, and facilitate the function of each party in relation to collaborative research / academic training.

Both University / Centre agree to develop collaborative activities in academic areas of mutual interest / advanced practical training and as equal partners with reciprocity. All academic and research training events are expected to reflect the Post-Graduate students and faculty members in the area of Micro-Ear Surgery, Otology and research publications particularly in the area of ENT and HNS.

The development and implementation of specific activities based on this MoU shall be negotiated and agreed upon with mutually accepted terms and conditions.

This MOU is agreed on the basis of cooperation between the University/Centre includes the following:


- A. The University and the Centre desire to provide training / education / academic collaboration for Fellowship Program in Micro-Ear Surgery every year and research publications.
- B. The KLE University will depute Post Graduate students and Fellowship students of Micro-Ear Surgery as decided by the University for the Fellowship Program every year at the Collaborator Centre.
- C. Both the institutes will be jointly conducting clinical research and make national and international scientific / research publications together.
- D. HOD of ENT in the University's J.N. Medical College, Belagavi shall be the Officer Incharge for this collaboration with the Collaborator institute.


TERMS OF AGREEMENT

Both University / Centre agree to carry out the above mentioned activities in accordance with laws and regulations of respective university/centre after full consultation and approvals.


The term of this agreement shall be valid for a period of five years commencing from the date of signature hereof. This agreement can be extended for further terms on mutual agreement. This agreement may be terminated by giving 6 months prior notice from either parties.

In witness whereof, the parties have executed this document by signing on the day of 2nd November 2018.


Dr. V. A. Kothiwale
Registrar, KAHER
Belagavi, Karnataka
KLE Academy of Higher Education
and Research, BELAGAVI


Dr. H. Vijayendra,
Director and Chief Consultant,
Vijaya ENT Care Centre
Super-Specialty Otology,
Bangaluru-560 003

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI



सत्यमेव जयते




INDIA NON JUDICIAL

Government of Karnataka

e-Stamp

Certificate No.	IN-KA10294635850517S
Certificate Issued Date	18-Feb-2020 03:01 PM
Account Reference	: NONACC (FI)/ kacrsf08/ BELGAUM3/ KA-BL
Unique Doc. Reference	: SUBIN-KAKACRSFL0831151765944855S
Purchased by	: KLES DR PRABHAKAR KORE CHARITABLE HOSPITAL BGM
Description of Document	: Article 12 Bond
Description	: MOU
Consideration Price (Rs.)	: 0 (Zero)
First Party	: KLES DR PRABHAKAR KORE CHARITABLE HOSPITAL BGM
Second Party	: DISTRICT HEALTH AND FAMILY WELFARE OFFICE BELAGAVI
Stamp Duty Paid By	: KLES DR PRABHAKAR KORE CHARITABLE HOSPITAL BGM
Stamp Duty Amount(Rs.)	: 100 (One Hundred only)

Shri Siddhivinayak Banjara M...
C/o. K. T. Patil Building Chavat Galli, BGM



Please write or type below this line

Memorandum of Understanding (MOU) between District Health Society and participating Non Government Organization.

1. Preamble:
 - 1.1. WHEREAS the Union Cabinet has approved continuation of National Programme of control of Blindness, hereafter referred to as NPCB for implementation in all the states of the country during the YEAR (2017-2020).
 - 1.2. WHEREAS NPCB aims to reduce prevalence of blindness by implementing various activities through state and District Health societies established in all the districts of the country.

Statutory Alert:

1. The authenticity of this Stamp Certificate should be verified at www.stamps.gov.in for its genuineness in the details on this Certificate and as available on the website india.gov.in.
2. The onus of checking the legitimacy is on the users of the certificate.
3. In case of any discrepancy please inform the Competent Authority.

ATTESTED

Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

1.3. WHEREAS the NPCB seeks to involve eye care facilities in Government Non-Government and Private sectors having capacity to perform various activities under Nation programme for Control of Blindness

1.4. AND WHEREAS schemes for Non Government Organizations (hereafter referred as NGO/Private practitioner) providing eye care services as implemented as per pattern of assistance approved by the cabinet:

1.5. NOW THEREFORE the signatories of Memorandum of Understanding (MOU) have agreed as set out here in below.

2. Parties to MOU

This MOU is an agreement between District Health Society of Belagavi (Name of District) of the state of Karnataka (Name of the state) hereafter called District Health Society and KLE Prabhakar Kore Charitable Hospital, Belagavi (Name of NGO/Private Practitioner).

3. Duration of MOU

This MOU will be operative from the date of its signing by the parties and remain in force till 31ST March 2020 to 31ST March 2022. The MOU shall be renewed for further periods of two years every time by the .


DPM on request/application for extension by the applicant NGO/Private Practitioner as per.

(Annexure XVII) one month before expiry of Validity

Details of the schemes

i. Screening of the population of all ages with emphasis on 50 years in all the villages / townships including the area allotted for the NGOs. The NGO has to maintain village wise blind registers annually.
I. Identification of cases fit for cataract surgery, motivation thereof and transportation to the base hospital.
ii. Pre operative examination and investigation as required.
iii. Performance of cataract surgery preferably IOL, implantation through ECCE IOL, small incision cataract surgery (SICS) or phaco emulsification and diabetic Retinopathy, Glaucoma, keratoplasty, vitreoretinal surgery & childhood Blindness of patients identified in allotted areas, self motivated walk in cases and those referred by District Health Society (ASHA etc.
IV. Post-operative case including management of complications, if any and post operative counseling regarding use of glasses if required.
V. Follow up service including refraction and provision of glasses, if required providing best possible correction including presbyopic correction

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

4. Commitments of District Health Society

Through this MOU, the District Health Society agrees to provide following support to participating NGO/private Practitioner to facilitate service delivery (write Yes Against applicable clauses).

Clause	Clause of Agreement	Yes / No.
5.1	Issue a certificate of recognition about participation in NPCB (Annexure XVIII)	Yes
5.2	Undertake random verification of operated cases not exceeding 5% before discharge of patients DBCS to verify (5%) the camp or surgery activities through personal visits of deputing PMOA as per the NPCB guidelines ideally at the base hospital itself. Or the verification can be done at the time of follow up as informed by the NGO to DBCS.	Yes
5.3	Sanction cost of there cataract operations and management of Diabetic RRetinopathy, Glaucoma, Keratoplasty, Vitreoretinal surgery & childhood Blindness performed by the NGO / Private practitioner as per GOI guidelines indicated within month of submission of claim along the cataract surgery records.	Yes
5.4	Make payment of the sanctioned amount to the NGO/Private practitioner on monthly /quarterly basis	Yes
5.5	Regularly disseminate literature, guidelines or any other relevant information to participating NGO/private practitioner	Yes



5. Termination of MOU

Commitments agreed to by the parties are meant for prevention and control of blindness and therefore MOU should generally not be suspended or terminated. However, both parties can decide to suspend or terminate the MOU.

Signed 1st April 2020

For and on behalf of
NGO / Private Practitioner


For and on behalf of
District Health Society

[Signature]

Medical Superintendent
KLES Dr. Prabhakar Kore Charitable Hospital
Belagavi


[Signature]
27/02/2020

District Programme Manager
District Blindness Control Society
District Blindness Control Society
Belagavi



ATTESTED BY
SURESH. N. JALIHAL
Advocate & Notary
BELAGAVI.

Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI





INDIA NON JUDICIAL

Government of Karnataka

e-Stamp

Certificate No.	IN-KA92046213864478R
Certificate issued Date	13-Apr-2019 10:47 AM
Account Reference	NONACC (FI)/ kacrsf108/ BELGAUM3/ KA-BL
Unique Doc. Reference	SUBIN-KAKACRSFL0814348358464178R
Purchased by	KLE DR PRABHAKAR KORE CHARITABLE HOSPITAL BELGAVI
Description of Document	Article 12 Bond
Description	MOU
Consideration Price (Rs.)	0 (Zero)
First Party	KLE DR PRABHAKAR KORE CHARITABLE HOSPITAL BELGAVI
Second Party	DISTRICT HEALTH AND FAMILY WELFARE OFFICER BGM
Stamp Duty Paid By	KLE DR PRABHAKAR KORE CHARITABLE HOSPITAL BELGAVI
Stamp Duty Amount (Rs.)	100 (One Hundred only)



Shree Siddhivinayak Banjara
Multi Purpose Co-Op Society Ltd.
A. T. Patti Building Court Compound BGV



Memorandum of Understanding (MOU) between District Health Society and participating Non Government Organization.

1. Preamble:

- 1.1. WHEREAS the Union Cabinet has approved continuation of National Programme of control of Blindness, hereafter referred to as NPCB for implementation in all the states of the country during the 12th plan (2013-2017).
- 1.2. WHEREAS NPCB aims to reduce prevalence of blindness by implementing various activities through state and District Health societies established in all the districts of the country.

ATTESTED

Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

1.3. WHEREAS the NPCB seeks to involve eye care facilities in Government Non Government and Private sectors having capacity to perform various activities under Nation programme for Control of Blindness AND WHEREAS schemes for Non Government Organizations (hereafter referred as NGO/Private practitioner) providing eye care services as implemented as per pattern of assistance approved by the cabinet;

1.4. NOW THEREFORE the signatories of Memorandum of Understanding (MOU) have agreed as set out here in below.

2. Parties to MOU

This MOU is an agreement between District Health Society of Belagavi (Name of District) of the state of Karnataka (Name of the state) hereafter called District Health Society and K.L.E. D.C. Prabhakar Kore Charitable Hospital, Belagavi (Name of NGO/Private Practitioner).

Duration of MOU

This MOU will be operative from the date of its signing by the parties and remain in force till 31st March 2020. Period of two years. The MOU shall be renewed for further periods of two years every time by the

DPM on request/application for extension by the applicant NGO/Private Practitioner as per

(Annexure XVII) one month before expiry of Validity

Details of the schemes


<p>I. Screening of the population of all ages with emphasis on 50 years in all the villages / townships including the area allotted for the NGOs. The NGO has to maintain village wise blind registers annually.</p> <p>1. Identification of cases fit for cataract surgery, motivation thereof and transportation to the base hospital.</p>
<p>ii. Pre operative examination and investigation as required.</p>
<p>iii. Performance of cataract surgery preferably IOL, implantation through ECCE IOL, small incision cataract surgery (SICS) or phaco emulsification and diabetic Retinopathy, Glaucoma, keratoplasty, vitreoretinal surgery & childhood Blindness of patients identified in allotted areas, self motivated walk in cases and those referred by District Health Society (ASHA etc.</p>
<p>IV. Post-operative case including management of complications, if any and post operative counselling regarding use of glasses if required.</p>
<p>V. Follow up service including refraction and provision of glasses, if required providing best possible correction including presbyopic correction</p>

ATTESTED

Prof. Dr. V.A. KOTHIMWALE

Registrar


KLE Academy of Higher Education and Research, BELAGAVI



4. Commitments of District Health Society

Through this MOU, the District Health Society agrees to provide following support to participating NGO/private Practitioner to facilitate service delivery (write Yes Against applicable clauses).

Clause	Clause of Agreement	Yes/No
5.1	Issue a certificate of recognition about participation in NPCB (Annexure XVIII)	Yes
5.2	Undertake random verification of operated cases not exceeding 5% before discharge of patients DBCS to verify (5%) the camp or surgery activities through personal visits of deputing PMOA as per the NPCB guidelines ideally at the base hospital itself. Or the verification can be done at the time of follow up as informed by the NGO to DBCS.	Yes
5.3	Sanction cost of there cataract operations and management of Diabetic RRetinopathy, Glaucoma, Keratoplasty, Vitreoretinal surgery & childhood Blindness performed by the NGO / Private practitioner as per GCI guidelines indicated within month of submission of claim along the cataract surgery records.	Yes
5.4	Make payment of the sanctioned amount to the NGO/Private practitioner on monthly / quarterly basis	Yes
5.5	Regularly disseminate literature, guidelines or any other relevant information to participating NGO/ private practitioner	Yes



5. Termination of MOU

Commitments agreed to by the parties are meant for prevention and control of blindness and therefore MOU should generally not be suspended or terminated. However, both parties can decide to suspend or terminate the MOU.


Signed 2nd April 2019

For and on behalf of
NGO / Private Practitioner

For and on behalf of
District Health Society

[Signature]
Medical Superintendent
KLES Dr. Prabhakar Kore Charitable Hospital
Belagavi

[Signature]
District Programme Manager
District Blindness Control Society
Belagavi



BEFORE ME

[Signature]
SURESH N. JALIHAL
Advocate & Notary
BELAGAVI

15 APR 2019

Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research; BELAGAVI



सत्यमेव जयते


INDIA NON JUDICIAL Government of Karnataka

e-Stamp

Certificate No.	: IN-KA33831743045592Q
Certificate Issued Date	: 02-Apr-2018 03:24 PM
Account Reference	: NONACC (FI)/kacrsf108/ BELGAUM3/ KA-BL
Unique Doc. Reference	: SUBIN-KAKACRSFL0814036045530672Q
Purchased by	: KLE DR PRABHAKAR KORE CHARITABLE HOSPITAL BELAGAVI
Description of Document	: Article 12 Bond
Description	: M O U
Consideration Price (Rs.)	: 0 (Zero)
First Party	: KLE DR PRABHAKAR KORE CHARITABLE HOSPITAL BELAGAVI
Second Party	: DIST HEALTH AND FAMILY WELFARE OFFICER BELAGAVI
Stamp Duty Paid By	: KLE DR PRABHAKAR KORE CHARITABLE HOSPITAL BELAGAVI
Stamp Duty Amount(Rs.)	: 100 (One Hundred only)

Sree Sri Vinayak Banjara
Multi Purpose Co-Op Society Ltd.
K T Patil Building Court Compound BGV

Authorized Signatory



-----Please write or type below this line-----

Memorandum of Understanding (MOU) between District Health Society and participating Non Government Organization

1. Preamble:

1.1 WHEREAS the Union Cabinet has approved continuation of National Program for Control of Blindness, hereafter referred to as NPCB, for implementation in all the States of the country during the 12th Plan (20013-2017);

Medical Superintendent.

KLE Dr. P. K. Charitable Hospital,
Belgaum

ATTESTED

Statutory Alert:

1. The authenticity of this Stamp Certificate should be verified at www.shcesstamp.com. Any discrepancy in the details on this Certificate and as available on the website renders it invalid.
2. The onus of checking the legitimacy is on the users of the certificate.
3. In case of any discrepancy please inform the Competent Authority.

Prof. Dr. V.A.KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

1.2 WHEREAS NPCB aims to reduce prevalence of blindness by implementing various activities through State and District Health Societies established in all the districts of the country;

1.3 WHEREAS the NPCB seeks to involve eye care facilities in Government, Non Government and Private sectors having capacity to perform various activities under National Program for Control of Blindness;

1.4 AND WHEREAS schemes for Non Government Organizations (hereafter referred as NGO/Private Practitioner) providing eye care services are implemented as per pattern of assistance approved by the Cabinet;

1.5 NOW THEREFORE the signatories of Memorandum of Understanding (MOU) have agreed as set out here in below.

2. Parties of MOU:

This MOU is an agreement between District Health Society of **Belagavi** (Name of District) of the State of **Karnataka** (Name of the State); hereafter called District Health Society and **KLE's Dr. Prabhakar Kore Charitable Hospital, Belagavi**. (Name of NGO/Private Practitioner).

3. Duration of MOU:

This MOU will be operative from the date of its signing by the parties and remain in force till 31st March 2018.

period of two years. The MOU shall be renewed for further periods of two years every time by the

DPM on request/application for extension by the applicant NGO/Private Practitioner as per

(Annexure XVII) ONE MONTH BEFORE EXPIRY OF VALIDITY.


Details of The Schemes

i. Screening of the population of all ages with emphasis on 50+ years in all the villages / townships including the area allotted for the NGOs. The NGO has to maintain village wise blind registers annually.


i. Identification of cases fit for cataract surgery, motivation thereof and transportation to the base hospital

ii. Pre operative examination and investigation as required

iii. Performance of cataract surgery preferably IOL, implantation through ECCE-IOL, Small incision cataract surgery (SICS) or phaco emulsification and Diabetic Retinopathy, Glaucoma, Keratoplasty, Vitreoretinal surgery & Childhood Blindness of patients identified in allotted areas, self motivated walk in cases and those referred by District Health Society /ASHA etc.


Medical Superintendent,
KLE Dr. P. K. Charitable Hospital,
Belgaum

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

iv. Post-operative care including management of complications, if any and post-operative counseling regarding use of glasses if required.
v. Follow up service including refraction and provision of glasses, if required providing best possible correction including presbyopic correction
vi. Submission of cataract surgery records of operated cases online through the MIS-NPCB


4. Commitments of District Health Society

Through this MOU, the District Health Society agrees to provide following support to participating NGO/Private Practitioner to facilitate service delivery (Write 'YES' against applicable clauses).

Clause	Clause of agreement	Yes/no
5.1	Issue a certificate of recognition about participation in NPCB (Annexure XVIII)	yes
5.2	Undertake random verification of operated cases not exceeding 5% before discharge of patients DBCS to verify (5%) the camp or surgery activity through personal visits or deputing PMOA as per the NPCB guidelines-ideally at the base hospital itself. Or the verification can be done at the time of follow up as informed by the NGO to DBCS.	yes
5.3	Sanction cost of here cataract operations and management of Diabetic Retinopathy, Glaucoma, Keratoplasty, Vitreoretinal Surgery & Childhood Blindness performed by the NGO/Private Practitioner as per GOI guidelines indicated within month of submission of claim along with cataract surgery records.	Yes
5.4	Make payment of the sanctioned amount to the NGO/Private practitioner on monthly/quarterly basis	yes
5.5	Regularly disseminate literature, guidelines or any other relevant information to participating NGO/Private practitioner.	yes


Medical Superintendent,
KLE Dr. P. K. Charitable Hospital,
 Belgaum

ATTESTED


 Prof. Dr. V.A. KOTHIWALE
 Registrar
 KLE Academy of Higher Education
 and Research, BELAGAVI

Termination of MOU

Commitments agreed to by the Parties are meant for prevention and control of blindness and there fore MOU should generally not be suspended or terminated. However, both parties can decide to suspend or terminate the MOU.

Signed this day, the 2nd of April 2018.


For and on behalf of
NGO/Private Practitioner





Medical Superintendent
KLES Dr. Prabhakar Kore Charitable Hospital
Belagavi

Medical Superintendent.
KLE Dr. P. K. Charitable Hospital,
Belgaum

For and on behalf of
District Health Society



DISTRICT PROGRAMME MANAGER
DISTRICT BLINDNESS CONTROL SOCIETY
BELAGAVI



Executed before me



R. G. HULIKATTI
B. Sc., LL.B. (Spl)
Advocate & Notary, Belagavi.

1 JUN 2018

TRUE-COPY



R. G. HULIKATTI
B.Sc., LL.B. (Spl.)
Advocate & Notary Belgaum

ATTESTED

1 JUN 2018

Prof. Dr. V.A. KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI




सत्यमेव जयते

Government of Karnataka

e-Stamp

Certificate No.	: IN-KA263617701197780
Certificate Issued Date	: 31-Mar-2016 02:58 PM
Account Reference	: NONACC (FI)/ kaksfcl08/ TILAKWADI1/ KA-BL
Unique Doc. Reference	: SUBIN-KAKAKSFCL08021354803347390
Purchased by	: KLES DR PRABHAKAR KORE CHARITABLE HOSPITAL BELGAVI
Description of Document	: Article 12 Bond
Description	: MOU
Consideration Price (Rs.)	: 0 (Zero)
First Party	: KLES DR PRABHAKAR KORE CHARITABLE HOSPITAL BELGAVI
Second Party	: D P M DISTRICT BLINDNESS CONTROL SOCIETY BELGAVI
Stamp Duty Paid By	: KLES DR PRABHAKAR KORE CHARITABLE HOSPITAL BELGAVI
Stamp Duty Amount (Rs.)	: 100 (One Hundred only)



For CHANCE TO PURCHASE AND TO PURCHASE
 'SUDHAKAR' AND 'ROYASHI'

PAAL
 SUPERVISOR E-STAMP

Please write or type below this line.....

MEMORANDUM of understanding (MOU) between District Blindness Control Society and Participating Non Government Organization.

1) **Preamble**

- 1.1 WHEREAS the Union Cabinet has approved continuation of National program for Control of Blindness hereafter referred to as NPCB, for implementation in all the states of the country during the 10th Plan (2002-07)

No of Corrections

25/03/16
Govt
 District Leprosy Officer
 Belagavi

NOTARY Statutory Alert:

- The authenticity of this Stamp Certificate should be verified at "www.e-stamp.com". Any discrepancy found leads on this Certificate and its availability on the website renders it invalid.
- The onus of checking the legitimacy is on the users of the certificate.
- In case of any discrepancy please inform the Competent Authority.

ATTESTED

Kothiwale
 Prof. Dr. V.A.KOTHIWALE
 Registrar

KLE Academy of Higher Education
 and Research, BELAGAVI

1.2. WHEREAS the Cabinet has also agreed to follow the strategies of "Vision 2020- The Right to Sight" in NPCB as per plan of Action developed for the country.

1.3. WHEREAS NPCB aims to reduce prevalence of blindness by implementing various activities through state and district Blindness Control Societies established in all the districts of the country.

1.4. WHEREAS the NPCB seeks to involve eye care facilities in Government, Non Government and Private sectors having capacity to perform various activities under National program for Control of Blindness.

1.5. AND whereas schemes for Non Government Organizations (hereinafter referred as NGO) providing sectors eye care services are implemented as per pattern of assistance approved by the Cabinet.

NOW THEREFORE the signatories of Memorandum of understanding (MOU) have agreed as set out here in below.

Parties of MOU

This MOU is an agreement between District Blindness Control Society of Belgaum of the State of Karnataka, hereafter called District Blindness Society and "KLE Dr. Prabhakar Kore Charitable Hospital, Belgaum".

3. Duration of MOU

This MOU will be operative from the date of its signing by the parties and remain in force till 31st March 2017 MOU can be renewed through mutual agreement by the parties.

4. General Guidelines for Diabetic Retinopathy, Glaucoma, Keratoplasty and Childhood Blindness- Squint, ROP, Retinoblastoma, Congenital Ptosis, Intra Ocular Trauma in Children and low vision.

- i) Beneficiaries to include all patients irrespective of Religion, Caste, Sex and Economic status.
- ii) Cost of the patients :- Totally free of cost to the Beneficiaries.
- iii) Eligible Patient:- Either through screening camps or OPC or walk-in Patient, Referrals, etc.
- iv) Amount payable to NGO/Pvt. Practitioner:- Rs. 1,500/- (For Glaucoma, Diabetic Retinopathy, Keratoplasty and Childhood Blindness) per case.
- v) Copy of valid photo ID of beneficiaries should be kept as record (Voters II) card, Ration card and PAN card etc any other Govt. Provided ID, Employees Certificate).
- vi) Verification of cases should be done by the DPM BCD and/ or District Ophthalmic Surgeon, and Ophthalmic Assistant. If verified by PMOA then the records need to be further counter signed by the DPM BCD.
- vii) A minimum of 5% of the cases under diseases should be verified by DPM BCD/ District Ophthalmic Surgeon and Ophthalmic Assistant. If verified by PMOA then the records need to be further counter signed by the DPM BCD/ District Ophthalmic Surgeon on a monthly basis for release of GIA.

No. of Corrections

NOTARY

ATTESTED



Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

DIABETIC RETINOPATHY (DR)

- GIA of Rs. 1,500/- will be paid for the complete treatment per case.
- Verifiable Evidence.
- Laser Sitzings record should be maintained.
- DR register to be maintained by the NGO/ Private Practitioner (Annexure-XII)
- Fundus photograph/ fundus drawing as evidence along with medical record should be produced.

GLAUCOMA

- GIA of Rs. 1,500/- per case one time as reimbursement towards cost of laser and/ or surgery.
- Verifiable Evidence.
- Glaucoma Register to be maintained by reimbursement claiming NGO/ Private practitioner (Annexure-XIII).

KERATOPLASTY/ VITREO RETINAL OPERATION:

- GIA of Rs. 5,000/- to be paid per case after surgery and follow up.
- Keratoplasty Register to be maintained by reimbursement claiming organization. (Annexure-XY)
- Surgery record to be maintained.

CHILDHOOD BLINDNESS : (AGE 0- 16 YEARS)

- All children have to be included for the purpose of the scheme.
- a) **Congenital Cataract and Glaucoma**, Dev. Cataract and Glaucoma will be covered under new component of childhood blindness, will be reimbursed GIA of Rs. 1,500/- per eye.
 - b) **Squint**
 - Surgical Treatment will be eligible.
 - Pre-Op and Post a Photograph as evidence along with Medical record.
 - Payment after surgery and follow up.
 - c) **Retinopathy of Prematurely (ROP)**
 - Complete treatment, including laser sitting up to a maximum GIA of Rs. 1,500/- per case.
 - d) **Retinoblastoma**
 - Complete treatment including laser sitting up to a maximum GIA of Rs. 1,500/- per case
 - e) **Congenital Patois**
 - Pre-Op and Post-Op photograph as evidence along with Medical record.
 - f) **Intraocular Trauma in Children.**
 - GIA of Rs. 1,500/- per case for removal under GA under children of 16 years.
 - Details of the surgical records to be maintained.

No of Corrections

NOTARY

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research; BELAGAVI

Low Vision

Up to a maximum GIA of Rs. 500/- for any type of low visual aid provided to the patient.

The Cost of spectacles for students under school eye screening programme should not exceed Rs. 275/- per spectacle and better quality lens/frame design be ensured so as to make the spectacle attractive to the students.

5. Commitments of NGO

Through this MOU, the NGO agrees to provide following service Under National Program for Control of Blindness:

Activities	Yes/No
a) Screening of Population (50 + years) in all the village/township in the area allotted to the NGO and preparation of Village wise blind register.	Yes
b) Identification of cases, fit for cataract surgery, motivation thereof and transportation to the base hospital.	Yes
c) Pre-Operative examination and investigation if required.	Yes
d) Performance of cataract surgery preferable IOL implantation through ECCE/IOL, Small Incision Cataract Surgery(SICS) or Phaco-emulsification of patient identified in allotted area, self motivated walk in cases and those referred by DBCS.	Yes
e) Post operative care including management of complication, if any post operative counseling regarding use of glasses.	Yes
f) Submission of cataract surgery record of operated cases.	Yes

6. Commitments of DBCS


Through this MOU, the DBCS agrees to provide following support to participating NGO to facilitate service delivery (write yes against applicable clauses)

Clause	Clause of Agreement	Yes/No
5.1	Issue a Certificate of Recognition about participation in NPCB	Yes
5.2	Undertake random verification of operated cases not exceeding 5% before discharge of patients.	
5.3	Sanction cost of fee cataract operation performed by the NGO as per GOI guidelines indicated in Para 6 below within one month of submission of claim along with Cataract Surgery Records.	Yes
5.4	Make payment of the sanctioned amount to the NGO on monthly/ quarterly basis.	Yes
5.5	Regularly disseminate literature, guidelines or any other relevant information to participating NGO.	Yes

No of Corrections

NOTARY

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

7. Grant-in-Aid to NGO for this Scheme is governed by the following table.

(Rupees per operation)

Items	ICCE	ECCE/IOL	Price
Drugs & Consumables			
Status			
Spectacles			
Transport/ IOP			
Organization Lens, Visco-clastics and additional consumables			
Total		1000=00	1000=00

8. Termination of MOU

Commitments agreed to by the Parties are meant for prevention for Control of Blindness and therefore MOU should generally not be suspended or terminated. However, both parties can decide to suspend or terminate the MOU.

Signed this Day, the Day of 1st April-2016.

[Signature]
District Programme Manager
 DISTRICT BLINDNESS CONTROL SOCIETY
Belagavi.

[Signature]
 FOR KLE DR. PRABHAKAR
 KORE CHARITABLE HOSPITAL
Medical Superintendent.
 KLE Dr. P. K. Charitable Hospital,
 Belgaum


Identified By

[Signature]
 (Anil S. Sarikop)
 Advocate, Belgaum
 KAR-2464/99



Attested By

[Signature]
R. R. PATIL
 B.A., LL.B. (Spl.)
 Advocate & Notary, Belgaum



[Signature]

TRUE COPY

[Signature]
R. R. PATIL
 B.A., LL.B. (Spl.)
 Advocate & Notary Belgaum

No of Corrections

NOTARY

15 APR 2016

[Signature]
 Prof. Dr. V.A. KOTHIWALE
 Registrar
 KLE Academy of Higher Education
 and Research, BELAGAVI



Government of Karnataka



सत्यमेव जयते

e-Stamp

Certificate No.	: IN-KA263617701197780
Certificate Issued Date	: 31-Mar-2016 02:58 PM
Account Reference	: NONACC (FI)/kaksfcl08/ TILAKWADI1/ KA-BL
Unique Doc. Reference	: SUBIN-KAKAKSFCL08021354803347390
Purchased by	: KLES DR PRABHAKAR KORE CHARITABLE HOSPITAL BELGAVI
Description of Document	: Article 12 Bond
Description	: MOU
Consideration Price (Rs.)	: 0 (Zero)
First Party	: KLES DR PRABHAKAR KORE CHARITABLE HOSPITAL BELGAVI
Second Party	: D P M DISTRICT BLINDNESS CONTROL SOCIETY BELGAVI
Stamp Duty Paid By	: KLES DR PRABHAKAR KORE CHARITABLE HOSPITAL BELGAVI
Stamp Duty Amount(Rs.)	: 100 (One Hundred only)



For CHARGING THIS DOCUMENT WITH E-STAMP
SUBMITTED TO THE NOTARY

Patil
SUPERVISOR E-STAMP

Please write or type below this line.

MEMORANDUM of understanding (MOU) between District Blindness Control Society and Participating Non Government Organization.

1) Preamble

- 1.1 WHEREAS the Union Cabinet has approved continuation of National program for Control of Blindness hereafter referred to as NPCB, for implementation in all the states of the country during the 10th Plan (2002-07)

No of Corrections

Patil
District Leprosy Officer
Belagavi

NOTARY Statutory Alert:

1. The authenticity of this Stamp Certificate should be verified at www.shrestamp.com. Any discrepancy reported on this Certificate and as available on the website renders it invalid.
2. The onus of checking the legitimacy is on the users of the certificate.
3. In case of any discrepancy please inform the Competent Authority.

ATTESTED

Kothiwale
Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

1.2. WHEREAS the Cabinet has also agreed to follow the strategies of "Vision 2020- The Right to Sight" in NPCB as per plan of Action developed for the country.

1.3. WHEREAS NPCB aims to reduce prevalence of blindness by implementing various activities through state and district Blindness Control Societies established in all the districts of the country.

1.4. WHEREAS the NPCB seeks to involve eye care facilities in Government, Non Government and Private sectors having capacity to perform various activities under National program for Control of Blindness.

1.5. AND whereas schemes for Non Government Organizations (hereinafter referred as NGO) providing sectors eye care services are implemented as per pattern of assistance approved by the Cabinet.

NOW THEREFORE the signatories of Memorandum of understanding (MOU) have agreed as set out here in below.

Parties of MOU

This MOU is an agreement between District Blindness Control Society of Belgaum of the State of Karnataka, hereafter called District Blindness Society and "KLE Dr. Prabhakar Kore Charitable Hospital, Belgaum".

3. Duration of MOU

This MOU will be operative from the date of its signing by the parties and remain in force till 31st March 2017 MOU can be renewed through mutual agreement by the parties.

4. General Guidelines for Diabetic Retinopathy, Glaucoma, Keratoplasty and Childhood Blindness- Squint, ROP, Retinoblastoma, Congenital Ptosis, Intra Ocular Trauma in Children and low vision.

- i) Beneficiaries to include all patients irrespective of Religion, Caste, Sex and Economic status.
- ii) Cost of the patients :- Totally free of cost to the Beneficiaries.
- iii) Eligible Patient:- Either through screening camps or OPC or walk-in Patient, Referrals, etc.
- iv) Amount payable to NGO/Pvt. Practitioner:- Rs. 1,500/- (For Glaucoma, Diabetic Retinopathy, Keratoplasty and Childhood Blindness) per case.
- v) Copy of valid photo ID of beneficiaries should be kept as record (Voters II) card, Ration card and PAN card etc any other Govt. Provided ID, Employees Certificate).
- vi) Verification of cases should be done by the DPM BCD and/ or District Ophthalmic Surgeon, and Ophthalmic Assistant. If verified by PMOA then the records need to be further counter signed by the DPM BCD.
- vii) A minimum of 5% of the cases under diseases should be verified by DPM BCD/ District Ophthalmic Surgeon and Ophthalmic Assistant. If verified by PMOA then the records need to be further counter signed by the DPM BCD/ District Ophthalmic Surgeon on a monthly basis for release of GIA.

No. of Corrections


NOTARY

ATTESTED

Kelle

Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

DIABETIC RETINOPATHY (DR)



- GIA of Rs. 1,500/- will be paid for the complete treatment per case.
- Verifiable Evidence.
- Laser Sitzings record should be maintained.
- DR register to be maintained by the NGO/ Private Practitioner (Annexure-XII)
- Fundus photograph/ fundus drawing as evidence along with medical record should be produced.

GLAUCOMA

- GIA of Rs. 1,500/- per case one time as reimbursement towards cost of laser and/ or surgery.
- Verifiable Evidence.
- Glaucoma Register to be maintained by reimbursement claiming NGO/ Private practitioner (Annexure-XIII).

KERATOPLASTY/ VITREO RETINAL OPERATION:

- GIA of Rs. 5,000/- to be paid per case after surgery and follow up.
- Keratoplasty Register to be maintained by reimbursement claiming organization. (Annexure-XV)
- Surgery record to be maintained.

CHILDHOOD BLINDNESS : (AGE 0- 16 YEARS)

- All children have to be included for the purpose of the scheme.
- a) **Congenital Cataract and Glaucoma**, Dev. Cataract and Glaucoma will be covered under new component of childhood blindness, will be reimbursed GIA of Rs. 1,500/- per eye.
- b) **Squint**
- Surgical Treatment will be eligible.
 - Pre-Op and Post a Photograph as evidence along with Medical record.
 - Payment after surgery and follow up.
- c) **Retinopathy of Prematurely (ROP)**
- Complete treatment including laser sitting up to a maximum GIA of Rs. 1,500/- per case.
- d) **Retinoblastoma**
- Complete treatment including laser sitting up to a maximum GIA of Rs. 1,500/- per case
- e) **Congenital Ptosis**
- Pre-Op and Post-Op photograph as evidence along with Medical record.
- f) **Intraocular Trauma in Children.**
- GIA of Rs. 1,500/- per case for removal under GA under children of 16 years.
 - Details of the surgical records to be maintained.

No of Corrections

NOTARY

ATTESTED

Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

Low Vision

- Up to a maximum GIA of Rs. 500/- for any type of low visual aid provided to the patient.

The Cost of spectacles for students under school eye screening programme should not exceed Rs. 275/- per spectacle and better quality lens/frame design be ensured so as to make the spectacle attractive to the students.

5. Commitments of NGO

Through this MOU, the NGO agrees to provide following service Under National Program for Control of Blindness.

Activities	Yes/No
a) Screening of Population (50 + years) in all the village/township in the area allotted to the NGO and preparation of Village wise blind register.	Yes
b) Identification of cases, fit for cataract surgery, motivation thereof and transportation to the base hospital.	Yes
c) Pre-Operative examination and investigation if required.	Yes
d) Performance of cataract surgery preferable IOL implantation through ECCE/IOL, Small Incision Cataract Surgery(SICS) or Phaco-emulsification of patient identified in allotted area, self motivated walk in cases and those referred by DBCS.	Yes
e) Post operative care including management of complication, if any post operative counseling regarding use of glasses.	Yes
f) Submission of cataract surgery record of operated cases.	Yes

6. Commitments of DBCS

Through this MOU, the DBCS agrees to provide following support to participating NGO to facilitate service delivery (write yes against applicable clauses)

Clause	Clause of Agreement	Yes/No
5.1	Issue a Certificate of Recognition about participation in NPCB Undertake random verification of operated cases	Yes
5.2	not exceeding 5% before discharge of patients.	
5.3	Sanction cost of fee cataract operation performed by the NGO as per GOI guidelines indicated in Para 6 below within one month of submission of claim along with Cataract Surgery Records.	Yes
5.4	Make payment of the sanctioned amount to the NGO on monthly/ quarterly basis.	Yes
5.5	Regularly disseminate literature, guidelines or any other relevant information to participating NGO.	Yes

No of Corrections

NOTARY

ATTESTED

Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

7. Grant-in-Aid to NGO for this Scheme is governed by the following table.
(Rupees per operation)

Items	ICCE	ECCE/IOL	Price
Drugs & Consumables			
Status			
Spectacles			
Transport/ IOP			
Organization Lens, Visco-clastics and additional consumables			
Total		1000=00	1000=00

8. Termination of MOU

Commitments agreed to by the Parties are meant for prevention for Control of Blindness and therefore MOU should generally not be suspended or terminated. However, both parties can decide to suspend or terminate the MOU.


Signed this Day, the Day of 1st April-2016.

[Signature]
District Programme Manager
District Blindness Control Society
Belagavi.

[Signature]
FOR KLE DR. PRABHAKAR
KORE CHARITABLE HOSPITAL
Medical Superintendent
KLE Dr. P. K. Charitable Hospital,
Belgaum

Identified By

[Signature]
(Anil Sarikop)
Advocate, Belagavi
KAR-2464/93



Attested By

[Signature]
R. R. PATIL
B.A., LL.B. (Spl.)
Advocate & Notary, Belgaum

[Signature]
Today at Belgaum



TRUE COPY

[Signature]
R. R. PATIL
B.A., LL.B. (Spl.)
Advocate & Notary Belgaum

No of Corrections

4
NOTARY

15 APR 2016

[Signature]
Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI




सत्यमेव जयते

INDIA NON JUDICIAL Government of Karnataka

e-Stamp

Certificate No.	: IN-KA975890740787240
Certificate Issued Date	: 22-Aug-2016 12:10 PM
Account Reference	: NONACC (FI)/ kacrsf108/ BELGAUM6/ KA-BL
Unique Doc. Reference	: SUBIN-KAKACRSFL08454052136070720
Purchased by	: PRINCIPAL KLE V K INSTITUTE OF DENTAL SCIENCES BGM
Description of Document	: Article 4 Affidavit
Description	: MOU
Consideration Price (Rs.)	: 0 (Zero)
First Party	: PRINCIPAL SINHGAD DENTAL COLLEGE AND HOSPITAL PUNE
Second Party	: PRINCIPAL KLE V K INSTITUTE OF DENTAL SCIENCES BGM
Stamp Duty Paid By	: PRINCIPAL KLE V K INSTITUTE OF DENTAL SCIENCES BGM
Stamp Duty Amount(Rs.)	: 20 (Twenty only)



WAS
Authorised Signatory
 For, Shree Hasavanna Mahadev
 Co-op. Credit Society Ltd.
 2nd Cross, Anmol Plaza
 Nehru Nagar, Belgaum-590010

-----Please write or type below this line.-----

**Memorandum of Understanding (MoU) Between
 Sinhgad Dental College & Hospital, Vadgaon Budruk-Pune, Maharashtra
 and
 KLE VK Institute of Dental Sciences, Belagavi, Karnataka
 for
 Collaboration in the field of Research, Academics (Education, Preventive,
 Interceptive & Rehabilitative Patient Care)
 and
 Student & Faculty Exchange**

M. J.

Shale
ATTESTED

Page 1 | 6

Statutory Alert:

1. The authenticity of this Stamp Certificate should be verified at www.shrestamp.com. Any discrepancy in the details on this Certificate and as available on the website renders it invalid.
2. The onus of checking the legitimacy is on the users of the certificate.
3. In case of any discrepancy please inform the Competent Authority.

ROTHIWALE
 Registrar

KLE Academy of Higher Education
 and Research. BELAGAVI

100

Preamble:

The Memorandum of Understanding is a bridge made between the Sinhgad Dental College and Hospital (SDC&H), VadgaonBudruk-Pune, Maharashtra and "KLEVK Institute of Dental Sciences, Belagavi, Karnataka" is witnessed as follows:

Recognizing the mutual interest in the fields of research, development, educational training, preventive, interceptive, rehabilitative patient care and other facilities & dissemination of knowledge on long term non-profit basis.

Recognizing the importance of the role of an Institute in research and as a tertiary care center in promoting National and International collaboration and increased contribution to social development services.

Hereby, the Institutes agree to establish collaboration in terms of Academics and Research (preventive, interceptive and rehabilitative patient care) during the pendency of MoU according to terms and conditions set out in the articles following hereunder.

The words "The two Institutions" and "collaborating Institution" in the Memorandum of Understanding refer to Sinhgad Dental College & Hospital, VadgaonBudruk and KLEVK Institute of Dental Sciences, Belagavi, Karnataka.

Hereafter Sinhgad Dental College & Hospital, VadgaonBudruk' will be referred as "Part I" and 'KLEVK Institute of Dental Sciences, Belagavi, Karnataka' will be referred as "Part II".

Article-1: FIELD OF COLLABORATION

Collaboration between the two Institutions may be established within any field related to health science and technology of mutual interest and in particular research and patient care. Extensions to other areas will be made through further amendments to the present Memorandum of Understanding.

Article-2: EXCHANGE OF STAFF AND STUDENTS

2.1 Faculty and students of either Institute, who wish to undertake a short term programme or field work/research work at the other Institution, will be assisted by the host Institution in getting authorization, finding accommodation, library and laboratory facilities; provided the programme is accepted by the home Institution and has at least one supervisor from each Institution. The externship of such student/faculty will be equal / more or less in number for the exchange. The cost of travel and accommodation will be borne by individuals/home institution.

2.2 Parties will exchange proposals concerning the topics, persons, type of research, tests and periods of specific research reasonably in advance of the proposed visit.

2.3 The facilities available in the respective institution shall be extended for the patient care to the referred patients in the subsidized manner or as per prevailing practices at the host Institution offering the facilities.

Article-3: **TRAINING OF STUDENTS**

3.1 Both parties (I & II) will provide facilities for observation and practical training for students of other party. This training will be for a minimum duration of one month. The training fees, travel and/or living allowances to these students will be provided by the student/home institution. The selection of the student will be need based. Suitable and adequate accommodation will be provided, subject to the availability. In any case there shall be no financial liability on part of the host Institute.

Article-4: **JOINT SUPERVISION OF STUDENT PROJECT**

4.1 As a part of collaboration, the faculty of both Institutes may jointly supervise projects of students.

4.2 The details of the project of students will be worked out by the respective persons of both the Institutions.

4.3 The student should first submit the project proposal which has to be authorized by both the institutions.


Article-5: **RESEARCH PROJECTS**

There is possibility of twinning faculty and students of the two Institutions in common research. The expenditure incurred for the Post Graduate Training, Projects and Research will be borne by the Postgraduate Students / faculty of the respective Institute/home institution.

- a. The proposal of any research project to be taken up by either of the parties should be discussed and approved well in advance by both the parties. Research projects and the composition of research teams will be approved by both the institutions. Efforts will be made to evaluate the need for participating staff and location of the research activity.
- b. Institutional Ethics Board clearance of both the Institutes should be obtained from both the parties before taking up any research work.
- c. **Party I and II** are permitted to access all the details on the progress of the study, data and results on the joint studies or projects undertaken under this venture.

ATTESTED

Page 3 | 6


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

102

- d. Each research project will be jointly led by both institutions' team leader, who will be responsible for reporting on the project status. Concerned postgraduate and faculty shall submit progress report at periodical intervals (in case of Research, once in three months) to the collaborating institutes.
- e. Both the parties will put all efforts inviting grants for various research projects from funding sources. Efforts will be made to write and conduct research project by both institutions and provide information about ongoing research activities in order to establish contacts and collaborations between professionals working within the same field.
- f. For externally funded project, rules and regulations of both the parties will be strictly adhered to depending upon the Institute of the principal investigator (PI).
- g. The **attendance** of externship student and faculty during the posting at the **either of the Institute** will be maintained by both parties and shall be exchanged.

Article-6: **INTELLECTUAL PROPERTY RIGHTS (IPR)**

All Intellectual property solely conceived and/or developed by Party I during the course of this agreement shall be owned by Party I. All intellectual property solely conceived and/or developed by Party II during the course of this agreement shall be owned by Party II. Intellectual property jointly conceived and/or developed by Party I and Party II will be jointly owned by Party I and Party II. Both Party I and Party II agree towards the protection when the application of such intellectual property for commercial or other purposes on mutually acceptable terms with equal shares. All the provisions of this article hold true only for exchange of the students/faculty to other institution.

Article-7: **FUNDING AND FINANCE**

The party doing the research project will have the responsibility to finance the project & the other party in which the project is been carried out will provide the infrastructure and other related facilities. The exact nature of funding and finance to be decided mutually at the starting of each project with a separate MoU as mentioned in "Article.13".

Externally funded projects would be as per "Article 5 (f)".

[Handwritten signature]

[Handwritten signature]

ATTESTED

[Handwritten signature]

Article-8: **LINK MANAGEMENT AND ADMINISTRATION**

Negotiation, implementation and co-ordination of the Memorandum of Understanding falls under the responsibility of both, the Principal of the Party I and the Principal of Party II. The MoU will take effect from the date it is signed by the Principal of the Party I and the Principal of the Party II.

Article-9: **GENERAL PROVISIONS**

9.1 Party I and II will carry out joint research as a follow up to this Memorandum of Understanding. The activities must be carried out in accordance with appropriate laws and regulations existing in country and will undertake to not violate any of the statutory requirements as laid by the concerned bodies appointed by the Government of India for time to time.

9.2 Party I and II shall initiate an exchange of research publications, publication lists and other official publications. This will be provided with adequate security as for as intellectual property laws are concerned as mentioned in article No. 6.

9.3 All publications resulting from the collaboration between the two institutions will be mentioned in the scientific reports of the institutions. Likewise, this MoU must also be mentioned in all formal presentation, which results from the collaboration under the terms of this MoU.

9.4 This MoU is signed subject to appropriate authorization of both sides.

Article-10: **NON-DISCLOSURE**

In case of joint research and consultancy projects taken up by Party I and Party II, no party will disclose any investigation to media/any unauthorized person from each institute in any form whether electronic/print without mutual consent and approval by coordination committee.


Article-11: **SETTLEMENT OF DISPUTES**

Any difference or dispute between the parties concerning the interpretation and/or implementation and/or application of any of the provision of the MoU shall be settled amicably through mutual consultation and/or negotiation between the parties. In case, the dispute occurs between both the parties and if the same is not resolved through negotiations or by adopting amicable measures, in that case the matter will be settled through arbitration and the Arbitrator will be appointed with the mutual consent of both the parties, without reference to any tribunal or court.

Article-12: **VALIDITY PERIOD**

This MoU shall be valid for a period of three years from the date of signing. At the end of validity period, a fresh MoU with similar/modified terms may be considered for signing.

ATTESTED





DR. DR. VANKOTHIWALE
Registrar


KLE Academy of Higher Education
and Research, BELAGAVI

Page 5 | 6

Article-13: A separate MoU will be made for each research project at the start of the project and will be valid till the project is completed as mutually decided by both the parties.



Dr. Sameer Patil_{MDS}
Principal
Sinhgad Dental College and Hospital, Pune.
(Party I)





Dr. Alka Kale_{MDS, Ph.D}
Principal
KLE VK Institute of Dental Sciences, Belagavi.
(Party II)

Signed and delivered by within named Sinhgad Dental College and Hospital at Pune through the hands of Dr. Sameer Patil its authorized official in presence of:

Witness: 1



(Signature with date)
Dr. Sangeetha Palaskar
Convener
Curriculars Activity Committee
Sinhgad Dental College and Hospital, Pune.

Witness: 2



(Signature with date)
Dr. Kumudihi Borole
Member Secretary
Scientific Advisory Committee
Sinhgad Dental College and Hospital, Pune.

Signed and delivered by within named KLE VK Institute of Dental Sciences, Belagavi, Karnataka through the hands of Dr. Alka Kale, Principal, KLE VK Institute of Dental Sciences, Belagavi its authorized official in presence of:

Witness: 1



(Signature with date)
Dr Anjana Bagewadi,
Vice - Principal
KLE VK Institute of Dental Sciences Belagavi-
590010.

Witness: 2


(Signature with date)
Dr K. M. Keluskar
Director, Dental Hospital
KLE VK Institute of Dental Sciences Belagavi-
590010.

Page 6 | 6

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

105




सत्यमेव जयते

INDIA NON JUDICIAL
Government of Karnataka

e-Stamp

Certificate No. : IN-KA975918785157730
Certificate Issued Date : 22-Aug-2016 12:11 PM
Account Reference : NONACC (FI) kacrsf108/ BELGAUM6/ KA-BL
Unique Doc. Reference : SUBIN-KAKACRSFL08454076513533390
Purchased by : PRINCIPAL KLE V K INSTITUTE OF DENTAL SCIENCES BGM
Description of Document : Article 4 Affidavit
Description : MOU
Consideration Price (Rs.) : 0
(Zero)
First Party : PRINCIPAL SINHGAD DENTAL COLLEGE AND HOSPITAL PUNE
Second Party : PRINCIPAL KLE V K INSTITUTE OF DENTAL SCIENCES BGM
Stamp Duty Paid By : PRINCIPAL KLE V K INSTITUTE OF DENTAL SCIENCES BGM
Stamp Duty Amount(Rs.) : 20
(Twenty only)



[Handwritten signatures]

[Handwritten signature]
Authorised Signatory
For Shree Basavanna Mahadev
Co op. Credit Society Ltd.
2nd Cross, Anmol Plaza
Nehru Nagar, Belgaum-590010

Please write or type below this line.....

Memorandum of Understanding (MoU) Between
Sinhgad Dental College & Hospital, Vadgaon Budruk-Pune, Maharashtra
and
KLE VK Institute of Dental Sciences, Belagavi, Karnataka
for
Collaboration in the field of Research, Academics (Education, Preventive,
Interceptive & Rehabilitative Patient Care)

and
Student & Faculty Exchange

ATTESTED

[Handwritten signature]

Prof. Dr. V.A.KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

Page 1 | 6

106



KLE University, Belagavi, Karnataka
www.kleuniversity.edu.in

Memorandum of Understanding (MoU) for
Academic Research and Development in Health Sciences
and knowledge exchange with



Regional Medical Research Centre; ICMR, Belagavi, Karnataka
www.icmr.nic.in

Signed on: 06.1.2015
Valid up to: 05.1.2020

ATTESTED

Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

MEMORANDUM OF UNDERSTANDING (MoU)

Between

**REGIONAL MEDICAL RESEARCH CENTRE
(INDIAN COUNCIL OF MEDICAL RESEARCH)
BELAGAVI - 590010, KARNATAKA**

And

**KLE ACADEMY OF HIGHER EDUCATION & RESEARCH,
(KLE UNIVERSITY)
BELAGAVI - 590 010, KARNATAKA**

Regional Medical Research Centre, Belagavi, one of the research Centres of the Indian Council of Medical Research, a society established under the Societies Registration Act, 1860; an autonomous body under and fully funded by the Department of Health Research, Ministry of Health & FW, Govt of India, having its research facility at Nehru Nagar, Belagavi, and its head/registered office at V.Ramalingaswami Bhawan, Ansari Nagar, New Delhi-110 029 (hereinafter referred to 'RMRC, ICMR' as the context permits).

KLE University, Belagavi, Karnataka, a Deemed University, established u/s 3 of the UGC Act, having its office at Belagavi, Karnataka (hereinafter referred to as 'KLEU' as the context permits). The KLE University has been accredited placed in 'A' Category by the Government of India (Ministry of Human Resource Development) and has also been accredited with 'A' Grade by National Assessment and Accreditation Council (NAAC).

Indian Council of Medical Research (ICMR) established in 1911, is an apex body in India for the formulation, co-ordination and promotion of biomedical research. The Council is engaged in conducting and promoting research in various areas of bio-medical science through its 31 permanent institutes / centres and through Headquarters using task force approach as well as providing financial assistance to *ad hoc* research studies submitted by individual scientists from different parts of the country. The Council's priorities coincide with National Health Policies such as control and management of communicable diseases, fertility control, maternal and child health, nutrition and research on major non-communicable diseases like cancer, cardiovascular diseases, diabetes and other metabolic and hematological disorders, mental health research and drug research (including traditional remedies).

KLE Academy of Higher Education & Research (KLE University), Belagavi, Karnataka has been established u/s 3 of the UGC Act, 1956 vide Government of India [Ministry of Human Resource Development] Notification F.9-19/2000-U.3(A) dated 13th April

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

2

108

2006 and imparting education in Under-Graduate / Post-Graduate / Super-specialty / Post-doctoral courses and Doctor of Philosophy (Ph.D) in the disciplines of Health Science viz. Medical, Dental, Pharmacy, Ayurveda, Physiotherapy and Nursing Science including Inter-disciplinary Studies / Research. At present, there are eight constituent units under the ambit of the KLE University as detailed below:

1. Jawaharlal Nehru Medical College, Belagavi (Estd. 1963).
2. KLE VK Institute of Dental Sciences, Belagavi (Estd. 1985).
3. KLES College of Pharmacy, Belagavi (Estd. 1968).
4. KLES College of Pharmacy, Bengaluru(Off-campus Centre) (Estd. 1976)
5. KLES College of Pharmacy, Hubballi (Off-campus Centre) (Estd. 1985)
6. KLES Shri BMK Ayurveda Mahavidyalaya, Belagavi (Off-campus Centre) (Estd. 1933)
7. KLES Institute of Physiotherapy, Belagavi (Estd. 1994)
8. KLES Institute of Nursing Sciences, Belagavi (Estd. 1987)
9. KLES Dr.Prabhakar Kore Basic Sciences Research Centre, Belagavi (Estd. 2012)

The bed strength of the Hospitals of the KLE University is 2,600 which provides ample clinical material for various research studies. The KLE University's Basic and Applied Science Research Centre is set up in an area of 10,000 sq ft and focuses on Molecular Biology (including stem cell research), Medical microbiology, Pharmaceutical Analysis and Natural product research. In addition, this Centre is established to gear-up the research capacity through a series of highly focused workshops that will create critical pool of scientists, thus, providing the edge to keep up with current research and also engage with institutions of excellence on an equal platform.

The KLE University Research Foundation has the unique distinction of being selected as one of the Global Network Sites under the aegis of National Institutes of Health, USA for Woman and Child Health. The Research Foundation is dedicated towards woman and child health.

Principles of Co-operation:

It is imperative that RMRC (ICMR) and KLE University share common goals of working towards finding solutions of various communicable and non-communicable diseases through mutual co-operation by utilizing strengths of respective organizations.

RMRC (ICMR), Belagavi and KLE University, Belagavi agree to develop their academic links especially in the fields of Health Care, Nutrition and Life Sciences under the Principles of mutual understanding, common interest and mutually complementary activities.

1. To work in the areas benefiting the community at large.
2. To identify common thrust areas of research keeping in mind the Millennium Development Goals and national priorities in the field of health sciences and health-care.

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

3. To promote individual contacts among research scholars, students and faculty of both the institutions.
4. To provide opportunities for the faculty members, research scholars and students to use the expertise and facilities available in both the organizations
5. To work jointly for the common research interests. This includes preparation and submission of proposals / protocols and their implementation by making use of the clinical material / facilities at KLE University and RMRC (ICMR), Belagavi.
6. To mutually acknowledge the experience, expertise and capabilities of RMRC(ICMR), Belagavi and KLE University and give due importance in collaboration, resource sharing and partnership.
7. To publish reports of sponsored projects / papers and disseminate results.
8. To organize seminars and workshops to deliberate on important issues and also to organize training / sensitization programs for health and social sciences professionals.
9. To support the exchange of academic, research and training material to each other, available in the respective institutions.
10. To support the exchange of academic, research and training material.
11. To encourage any other activities that both the institutions agreed to be on mutual benefit.

Terms of Reference:

1. To jointly undertake research activities, submit grants proposals to various funding agencies.
2. Once MoU is signed, KLE University shall grant, after due consideration of facilities and competencies, recognition as guides to scientists of RMRC, ICMR for Ph.D. Program.
3. Students of RMRC, Belagavi will be allowed to register for Ph.D. program of the KLE University and will also be eligible for scholarships and contingencies as stipulated by the University from time to time.
4. The Ph.D. program will be governed by the Rules & Regulations specified by the KLE University which are in accordance with UGC Regulations, 2009 for Ph.D. Program which are to be mandatorily followed by all Universities.
5. The number of seats /intake can be decided by consensus each year before notification for admissions.
6. The Ph.D. Supervisors / Co-Supervisors (Guide) / Co-Guides may be from either of the institutions, subject to fulfilling the criteria specified in Ph.D. Regulations.

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

4

Ph.D students working at KLE University will be allowed to utilize the facilities available in both the institutions at RMRC, Belgaum and vice-versa depending upon requirements.

Scientists of RMRC, Belagavi and other ICMR institutes/Centres may deliver lectures in areas of their specialization to students of KLE University as 'Visiting Faculty' on days and timings pre-arranged, on mutual consent.

Termination and Termination of the MoU

1. This MoU is effective as of the date of signatures by the authorities of RMRC (ICMR) and KLE University, Belagavi
2. This MoU is valid from the date of execution by the parties and shall remain in effect for FIVE Years, and thereafter can be renewed.
3. This MoU may be amended at any time by written mutual consent.
4. This MoU may be terminated by either party by the provision of written notice of termination not less than three months prior to the desired termination date. However, both parties agree that all continuing obligations to students, staff, funding bodies or other entities are met in full subsequent to the notice of termination.
5. The termination of this MoU shall not affect the rights or obligations of either party regarding any binding offer or firm obligation approved and agreed to either party prior to the termination date.
6. In event of any dispute/s arising between the parties hereto, it shall be endeavour of both the parties to first make an attempt to resolve the dispute amicably by mutual discussion and deliberation, failing which the dispute shall be amicably resolved through mutual discussion and deliberation, failing which the dispute shall be referred to arbitration. The arbitration shall be conducted as per the provisions of arbitrator, to be appointed mutually by both the parties. The venue of arbitration shall be Belgaum. The language of arbitration shall be English. The award of the tribunal shall be final and binding on the parties.

Miscellaneous:

1. If any provision of this Memorandum is held by any court or the competent authority to be illegal, void or unforceable in whole or in part, this Memorandum shall continue to be valid as to the other provisions therefore and the remainder of the affected provision.
2. Nothing in this MoU constitutes or to be construed a party, partner, agent employee or representative of the other party. A party must not act independently of the other

ATTESTED



Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

5

111

Scanned by CamScanner

party and does not have the right or power of or pledge the credit of the other party without the prior written approval of the other party.

3. The parties agree to comply with all laws applicable within the jurisdiction of the signatories below.
4. Data generated through such collaborative research will be published in scientific journals jointly.

IN WITNESS Whereof the parties hereto have executed this MoU or caused it to be executed in their names and on their behalf by their duty authorized representatives on the date set forth:

For RMRC (ICMR), Belagavi

For K L E University, Belagavi

Signature:

प्रभारी अधिकारी / Officer-in-Charge

Name: क्षेत्रीय आयुर्विज्ञान अनुसंधान केंद्र (भा.आयु.अनु.प.)
Regional Medical Research Centre (ICMR)

Designation: नेहरु नगर, बेलगाम - ५९० ०१०
Nehru Nagar, Belgaum - 590 010

Date:

6 JAN 2015

Signature:

Name:

Designation

Date:

PROF. C-K. KOKATE

Vice-Chancellor
KLE University
BELAGAVI

6 JAN 2015

Witnesses:



1.

[Signature]

2.

[Signature]
6-1-15

[Signature]
DR. S. D. KHOLKUTE
Scientist 'G' & Director
Regional Medical Research Centre (ICMR),
Nehru Nagar, Belgaum - 590 010

ATTESTED

[Signature]

Prof. Dr. V.A.KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

6

Scanned by CamScanner

Memorandum of Understanding (MoU)

Between

University of Agricultural Sciences

Dharwad, Karnataka, India

And

K.L.E.Society's College of Pharmacy

Vidyanagar, Hubli. Karnataka, India.

ATTESTED




Prof. Dr. V.A.KOTHIWALE

Registrar

**KLE Academy of Higher Education
and Research, BELAGAVI**

Scanned with CamScanner



MEMORANDUM OF UNDERSTANDING

THIS MEMORANDUM OF UNDERSTANDING made on this the 6th day of November month 2007 between the UNIVERSITY OF AGRICULTURAL SCIENCES, DHARWAD, an autonomous body came in to existence with an act of Legislature viz., the University of Agricultural Sciences Act, 1963 and amended UAS Act 1986-87 and carrying on Research, Development, Teaching and imparting training in Agricultural and Horticultural Produce and its allied activities having its office at UAS, DHARWAD, herein after called the "UNIVERSITY" (which expression shall, whatever the context so requires or admits be deemed to mean and include the UAS, its scientists etc.) represented by Dr. J. H. Kulkarni, Vice Chancellor and Dr. Vijaykumar N. Torgal, Registrar, on one part.

AND

K.L.E. Society's College of Pharmacy, Hubli which was established in 1985 by the foresighted ALMA MATER, the Karnataka Lingayath Education Society, herein called "Pharmacy College" (which expression shall unless excluded for by or repugnant to the subject or context, be deemed to include its successors) represented by Sri. M.C. Kolli, Chairman, Governing Body and Dr B.M. Patil, Principal, on the other part.

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

Scanned with CamScanner

Aims and Objectives of the MoU

The aim of the Memorandum of Understanding is to set up a framework to encourage and develop collaboration between the two institutions in areas of mutual interest in the fields of Microbiology, Chemistry, Pharmacology and Agricultural Sciences. There are no pre-determined limits to the activities which might be involved in the collaboration but they will be directed towards the following specific objectives:

- To raise the research profile of both institutions, by developing collaborative research projects that utilizes the expertise and environment of the two institutions.
- To facilitate the greater involvement of research students and academic members of staff at both the institutions in research area, such as the development of drugs from medicinally valuable plants, bacteria and fungi for which there is a wealth of resources.
- To exploit the synergy arising from joint initiatives to improve the effectiveness and efficiency of teaching in both institutions.
- To attract higher levels of 'Reach-Out' funding and other support from industry through the higher critical mass of research and teaching activity created by the collaboration.



ATTESTED



Prof. Dr. V.A.KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI



Scanned with CamScanner

Terms of Reference under the MoU:

1. The highest priority will be given to the preparation of joint funding applications.
2. Senior and junior academic staff in full-time permanent employment may undertake exchange visit that contribute to the aims and objectives of the MoU.
3. High priority will be given to the publications of a quality appropriate for submission to major national and international journals with a higher citation index.
4. Any patenting out of collaborative research will be shared by both the Institutions.
5. Any financial benefit or loss out of collaborative research will be jointly shared by the Institutions.
6. Joint research out put will also be presented orally and in national publications.
7. There is no financial commitment on either of the partners.

ARBITRATION CLAUSE

In the event of any dispute or differences between the parties, hereto such disputes or differences shall be resolved amicably on the basis of mutual discussions by the signatories or their designated nominees and in the event of failure the matter may be referred to arbitration in accordance with Arbitration and Conciliation Act 1996 as amended from time to time and shall be subjected to exclusive jurisdiction of courts at Karnataka.


N.C.U.

ATTESTED



Prof. Dr. V.A.KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI



Scanned with CamScanner

FORCE MAJEURE

Neither of the parties hereto shall be considered in default performance under the contract if such performance is prevented or delayed by events such as war, civil war (whether declared or not), civil commotion, insurgency, hostilities, evolution, riots, strikes, lockouts, conflagration, epidemics, accidents, fire, flood, drought, earthquakes, or any act of god or cause beyond reasonable control of the party affected provided notice in writing within ten days, failing which, in shortest period by the First party to the Second party and vice versa. Soon after the cause of force majeure has ceased, the party whose ability to perform its obligation has been affected shall notify the other of such cessation and of the actual delay occurred in the affected activity, abducting necessary evidence in support thereof. From the date of occurrence of force majeure, the obligation under this agreement shall stand extended by a period equal to the period of delay occasioned by such events.

DURATION OF THE MoU

This MoU shall be in operation for a period of 10 years from the date of signing.



ATTESTED



Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

Scanned with CamScanner

Signed on behalf of UAS, Dharwad


Vice-Chancellor



Registrar

Signed on behalf of
K.L.E.S' College of Pharmacy, Hubli





Chairman, Governing Body




Principal

Witnesses

1) 

2) 

ATTESTED



Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

Scanned with CamScanner



HICURE PHARMACEUTICALS PRIVATE LIMITED

MEMORANDUM OF UNDERSTANDING

This Memorandum of Understanding on 22nd day of January, 2011 between the Hicure Pharmaceuticals Pvt Ltd., Kadanakoppa, Karnataka engaged in Pharmaceuticals production of small volume parenterals herein called Industry represented by B.F.Ningangoudar (Production Manager) on one part.

And

KLES College of Pharmacy, Hubli which is established 1985 carrying on Teaching, Training and Research, herein called Institute represented by Dr.B.M.Patil, Principal on the other part.


Aims and objectives of the MoU

The aim of MoU is to set up a frame work to encourage and develop collaboration between Industry and Institute in the areas of mutual interest in the field of Pharmaceutical Science and following are specific objectives:


- To raise the research profile of both Industry and Institute by developing collaboration research projects that utilize the expertise and environment of both industry and Institute.
- To provide an opportunity to students to learn and develop specific research skills.
- To exploit the synergy arising from joint initiatives to improve the Industry of student training.


This MoU shall be operation for period of 05 years from the date of signing.

Signed on behalf of
Hicure Pharmaceuticals Pvt Ltd


(B.F.Ningangoudar)
Production Manager

Signed on behalf of
KLES College of Pharmacy, Hubli.


(Dr.B.M.Patil)
Principal



Regd. Office & Factory : Hubli-karwar National Highway, Kadanakoppa, Tq. Kalgatagi, Dist. Dharwad- 580 204.(Karnataka)
Tel. : 08370-210275. Telefax: 08370-283543. E-mail: hicure@indiatimes.com

Administrative Office : Chandrika, Chitaguppi Park, Pinto Road, HUBLI - 580 020. Dist. Dharwad. (Karnataka)
Tel : 0836 - 2356237. Fax : 0836 - 4253532. E-mail : hicure@indiatimes.com



CamScanner

KLE Academy of Higher Education
and Research, BELAGAVI



सत्यमेव जयते

INDIA NON JUDICIAL
Government of Karnataka

e-Stamp

Certificate No. : IN-KAS32731059576L
 Certificate Issued Date : 23-Sep-2019 12:53 PM
 Account Reference : SHCL (FD) RAN IN SICIL HUBLI KA-DIV
 Unique Doc. Reference : 8UBIN KAKA-SICIL-274866466324954
 Purchased by : PRINCIPAL KLE'S COLLEGE OF PHARMACY HUBLI
 Description of Document : Article 12 Dohd
 Description : MEMORANDUM OF UNDERSTANDING
 Consideration Price (Rs.) : 0
 (Zero)
 First Party : PRINCIPAL, KLE'S COLLEGE OF PHARMACY HUBLI
 Second Party : MANAGING TRUSTEE VIVEKANAND GENERAL HOSPITAL HUBLI
 Stamp Duty Paid By : PRINCIPAL, KLE'S COLLEGE OF PHARMACY HUBLI
 Stamp Duty Amount (Rs.) : 100
 (One Hundred only)

Authorized Signatory
 For Stock Holding Corporation of India Ltd.
 1st Floor, VARDHA COMPLEX,
 Behind Haveli Area, Near to Gramina Bank,
 Near Old Bus Stand, HUBLI-580 029.

Please write or type below this line

MEMORANDUM OF UNDERSTANDING

This memorandum of understanding is made on 23rd Day September month 2019 Year between Vivekanand General Hospital, Deshpande Nagar, Hubli - 580 029, which is represented by its Managing Trustee herein named as party one and KLE University's College of Pharmacy, Vidyanagar, Hubli - 580 031, represented by its Principal herein named as party two.

For Vivekanand General Hospital

N. M. Shambhu
 Signature
 Managing Trustee,
 (N. M. Shambhu)



hnd
 Signature
 PRINCIPAL KLE UNIVERSITY'S
 COLLEGE OF PHARMACY
 HUBLI.

The parties hitherto agree as follows:

1. Party one declares that Vivekanand General Hospital, Deshpande Nagar, Hubli - 580 029 is a 300 bedded hospital, with a minimum of 120 beds for General Medicine Department.
2. Party one agrees to provide to party two the minimum space necessary of 1200 square feet in the hospital building to establish Pharmacy Practice department for the conduct of Pharma.D programs.
3. Party one agrees to provide preceptors required to train the Pharma.D students.
4. Party one agrees that, it will not enter into similar agreement with any other Pharmacy institution/s or department/s offering or intend to offer Pharma.D programs.
5. The prospective students will be allowed to undergo training in the following specialty departments
 - Medicine
 - Surgery
 - Pediatrics
 - Gynecology and Obstetrics
 - Psychiatry
 - Skin and VD
 - Orthopedics
6. Party two will provide the academic staff and necessary infrastructure for Pharma. D course as per the PCI norms and takes the overall responsibility for smooth conduct of the programs.
7. This agreement is to be in effect at least for ten years from the time of its endorsement by both the parties.
8. The officials representing Vivekanand General Hospital, Deshpande Nagar, Hubli - 580 029 and KLE University's College of Pharmacy, Vidyanagar, Hubli - 580 031 are signing this MOU to achieve the beneficial objectives of Pharma.D programs.

N. M. Shambhu

Signature
 Hospital authority (party one)
 with seal and date

For Vivekanand General Hospital

Managing Trustee,
 (N. M. Shambhu)

hnd

Signature
 Principal, (party two)
 College of Pharmacy
 with seal and date
 KLE UNIVERSITY'S
 COLLEGE OF PHARMACY
 HUBLI.



Scanned with
CamScanner

ATTESTED

Kothiwale

Prof. Dr. V.A KOTHIWALE
 Registrar
 KLE Academy of Higher Education
 and Research, BELAGAVI



सत्यमेव जयते

INDIA NON JUDICIAL Government of Karnataka

e-Stamp

Certificate No.	: IN-KA063478196061190
Certificate Issued Date	: 07-Sep-2016 02:35 PM
Account Reference	: NONACC (FI)/ kacrs108/ HUBLI/ KA-DW
Unique Doc. Reference	: SUBIN-KAKACRSFL08627884312157010
Purchased by	: DEPARTMENT OF CHEMISTRY PC JABIN SCIENCE COLLEGE
Description of Document	: Article 6 Agreement relating to Deposit of Title Deed
Description	: M O U
Consideration Price (Rs.)	: 0 (Zero)
First Party	: DEPARTMENT OF CHEMISTRY PC JABIN SCIENCE COLLEGE
Second Party	: K.L.E UNIVERSITY COLLEGE OF PHARMACY
Stamp Duty Paid By	: DEPARTMENT OF CHEMISTRY PC JABIN SCIENCE COLLEGE
Stamp Duty Amount(Rs.)	: 20 (Twenty only)

Hubli Advocate's Urban
Co-op Credit Society (R)
Court Complex, HUBLI



-----Please write or type below this line-----

MEMORANDUM OF UNDERSTANDING
FOR THE PERIOD OF FIVE YEARS FROM 2016, BETWEEN
DEPARTMENT OF CHEMISTRY, P.C. JABIN SCIENCE COLLEGE, HUBBALLI
AND
K.L.E. UNIVERSITY'S COLLEGE OF PHARMACY
VIDYANAGAR, HUBBALLI.

NO. OF CORRECTIONS

NOTARY

ATTESTED

Statutory Alert:

1. The authenticity of the Stamp Certificate should be verified at www.threstamp.com. Any discrepancy in the details on this Certificate and as available on the website renders it invalid.
2. The onus of checking the legitimacy is on the users of the certificate.
3. In case of any discrepancy please inform the Competent Authority.

Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

The aim of the MOU is to set up a framework to encourage and develop collaboration between the two institutions in areas of mutual interest in the fields of chemistry and pharmacology.

Whereas


Party No. 1, is the Department of Chemistry, P.C. Jabin Science College, Hubballi.

Whereas

Party No. 2, is K.L.E. University's College of Pharmacy, Vidyanagar, Hubballi.

In PURSUANCE of negotiation between both the parties the following terms and conditions are agreed by the parties.

- > To raise the research profile of both the institutions by developing collaborative research projects that utilizes the expertise and environment of the two institutions.
- > To facilitate the greater involvement of research students and academic members of staff at both the institutions in research areas.
- > To exploit the synergy arising from joint initiatives to improve the effectiveness and efficiency of teaching in both institutions.
- > To attract higher levels of "Reach-Out" funding and other support from industry through the higher critical mass of research and teaching activities created by the MOU.



NO. OF COPIES

NOTARY

[Handwritten signature]

[Handwritten signature]

ATTESTED

[Handwritten signature]

Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

IN WITNESS WHEREOF BOTH THE PARTIES HAVE SIGNED THIS MEMORANDUM OF UNDERSTANDING VOLUNTARILY.

Signed on behalf of the Department of Chemistry P.C. Jabin Science College, Hubballi.

[Signature]
H.O.D. OF CHEMISTRY

[Signature]
PRINCIPAL
P. C. Jabin Science College
Vidyanagar, HUBBALLI - 31

Signed on behalf of the K.L.E. University's College of Pharmacy, Vidyanagar Hubballi




[Signature]
PRINCIPAL
PRINCIPAL, KLE UNIVERSITY'S COLLEGE OF PHARMACY HUBLI.

WITNESSES

[1] *[Signature]* (V. P. Gaonkar)

[2] *[Signature]* (Mahabaleshwar B)



Date: 07-09-2016

Place: Hubballi.

Identified by me

[Signature]
(F.C. Bhandiwad)
Advocate, Hubballi

SOLEMNLY AFFIRMED BEFORE ME

[Signature]
NOTARY

NO. OF COPIES

NOTARY

17 SEP 2016

ATTESTED

[Signature]
Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI



British Council Division
British High Commission
17 Kasturba Gandhi Marg
New Delhi 110 001 India

T +91 (0)11 2371 1401
F +91 (0)11 2371 0717

www.britishcouncil.in

GRANT BY THE BRITISH COUNCIL

The British Council:	THE BRITISH COUNCIL, incorporated by Royal Charter and registered as a charity (under number 209131 in England & Wales and number SC037733 in Scotland), <i>operating through its local office at 17 Kasturba Gandhi Marg, New Delhi - 110001</i>
The Recipient: A	University of East Anglia (UEA) Norwich Research Park Norwich NR4 7TJ
The Recipient: B	Institute of Nursing Sciences, K.L.E. University Nehru Nagar Belgaum-590-010 Karnataka State India
Date:	

This Agreement is made on the date set out above subject to the terms set out in the schedules listed below which both the UK India and Education Research Initiative (UKIERI) through British Council and the Recipient undertake to observe in the performance of this Agreement.

UKIERI through British Council shall award the Grant to the Recipient for the purposes of funding the UKIERI- Institutional Capacity Building described in Schedule 1 on the terms and conditions of this Agreement.

[Where the Recipient comprises more than one organisation, each of Recipients A and Recipient B shall be deemed to be bound by the terms of this Agreement jointly and severally, and all references to "Recipient" shall be construed accordingly. Where the context so implies, a reference to "Recipient" shall be deemed to include each of Recipient A and Recipient B as individual entities.]


ATTESTED

Prof. Dr. V.A. KOTHIWALE
Registrar


KLE Academy of Higher Education
and Research, BELAGAVI

This Agreement shall only become binding on the British Council upon its signature by an authorised signatory of the British Council subsequent to signature by or on behalf of the Recipient.


Signed by the duly authorised representative of THE BRITISH COUNCIL

Name:	Richard Everitt	Signature:	
Position:	Director Education & Society India		
Date:			

Signed by UK Institution: (University of East Anglia)

Name:	Signature:	
Position:		
Date:			

Signed by Indian Institution (Institute of Nursing Sciences, K.L.E. University)

Name:	Dr. V.D Patil	Signature:	
Position:	Registrar, KLE University		
Date:	02/04/2014		

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

Schedule 1

Special Terms

Terms defined in this Schedule 1 shall have the same meanings when used throughout this Agreement.

In the event of any conflict between the terms set out in the various Schedules, the Schedules shall prevail in the order in which they appear in the Agreement.

For the purposes of the Project and the Grant, the terms of this Agreement shall prevail over any other terms and conditions issued by the British Council.

1 The Project

- 1.1 The British Council awards the Grant for the purposes conducting activities under UKIERI Institutional Capacity Building proposal titled (Enhancing midwifery and neonatal care through capacity building of midwifery lecturers) (the "Project").

2 Commencement and Duration

- 2.1 This Agreement shall come into force on 15th March 2014 till 28th February, 2016 and this Agreement shall continue in full force and effect for a fixed period of 24 months or such other date as may be agreed between the parties in writing from time to time (the "Term").
- 2.2 Notwithstanding anything to the contrary elsewhere in this Agreement, the British Council shall be entitled to terminate this Agreement by serving not less than 30 days' written notice on the Recipient.

3 The Grant

- 3.1 The amount of the grant awarded to the Recipient is (Total amount of funding requested in the proposal to be mentioned in words and figures)

(University of East Anglia): GBP 26,670 (Twenty thousand, six hundred and seventy Pounds)

(Institute of Nursing Sciences, K.L.E. University): INR 14,46,480 (Fourteen lakh, forty six thousand, four hundred and eighty Rupees)

- 3.2 In consideration of the Recipient's delivery of the Project, the Grant shall be paid by the British Council to the Recipient by BACS transfer on yearly basis respective currencies and as per British Council prevailing exchange rate. The disbursement of funds will be as per

ATTESTED
Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

the decision and sole discretion of UKIERI board and depend on the availability of funds with the UKIERI project.

- 3.3 The recipient will meet all costs and expenses necessary to provide the services contracted for under this Agreement including the costs of salaries, bonuses, superannuation, overseas inducements and leave allowances, clothing, passports, etc., of any staff employed by both the Institutes. These costs can not be charged to the grant money awarded under UKIERI Institutional Capacity Building awards.

All travel carried under the project plan will be at Economy class. All travel arrangements are the responsibility of the individual party concerned and it will be their responsibility to ensure that all entry requirements of the overseas government are met.

4 Service of notices

- 4.1 For the purposes of clause 18.4 of Schedule 3, notices are to be sent to the following addresses:

To the British Council	To the Recipient
UKIERI Secretariat British Council Division 17 K.G Marg New Delhi-110001	University of East Anglia (UEA) Norwich Research Park Norwich NR4 7TJ Institute of Nursing Sciences, K.L.E. University Nehru Nagar Belgaum-590 010 Karnataka State India

5 Locations

- 5.1 The Project will be carried out in India and United Kingdom or such other locations as may be agreed between the parties in writing from time to time.

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

**UKIERI APPLICATION FORM
Institutional Capacity Building (ICB)
Strand 3: Skills Development**

Official Use Only
Proposal Reference No:

- i. Please complete this form after reading:
- UKIERI Guidelines

Please send all completed documents to: ukieri@in.britishcouncil.org

A. General Details

1. Project Title	Enhancing midwifery and neonatal care through capacity building of midwifery lecturers
2. Proposed Start Date	1 st January 2014
3. Proposed End Date	1 st January 2016
4. UK Lead Institution Name	University of East Anglia
5. UK Project Leader	Ms Jayne Randall, Midwifery lecturer
6. UK Postal Address	School of Nursing Sciences, Faculty of Medicine and Health Sciences, Edith Cavell Building, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ
7. UK Telephone Number	01603 597079
8. UK Email Address	J.Randall@uea.ac.uk
9. Indian Lead Institution Name	Institute of Nursing Sciences, K.L.E. University, Nehru Nagar, Belgaum-590 010
10. Indian Project Leader	Professor Sudha A. Raddi, Principal, Institute of Nursing Sciences, KLEU
11. India Postal Address	K.L.E. University's Institute of Nursing Sciences, Nehru Nagar, Belgaum-590 010, Karnataka State, India
12. India Telephone Number	Ph. No. +91-831-2472303 Fax. +91 831-2475103 Mob. +91 9448354712
13. India Email Address	srdrishti@gmail.com
14. Other UK Partners	None ATTESTED

UKIERI Application Form – Institutional Capacity Building (ICB)

Kelly
Registrar
KLE Academy of Higher Education,
and Research, BELAGAVI

UKIERI
UK-India Education
and Research Initiative

Project Title	WIFERY AND NEONATAL CARE THROUGH CAPACITY BUILDING OF MIDWIFE		
UK Lead Institution	UNIVERSITY OF EAST ANGLIA (UEA)		
Indian Lead Institution	KLE UNIVERSITY, BELGAUM, KARNATAKA, INDIA		
Project start date	Jan-2014		
Project end date	Jan-2018		
Reference No/for/contractus			
Project Activities	Timeline	Impact/Outcomes	Risks/Assessment
Members of Faculty from KLE University to visit UK and observe clinical practice on Midwifery led birthing units, home births if possible and UEA develops teaching materials	months 1-2	2 faculty members from KLE will have completed the visit	<p>1. May not obtain consent from women or midwifery managers to visit units</p> <p>2. Changes to staffing in NSC or in KLE University may mean loss of key players, especially the Project Coordinators</p> <p>3. Risks associated with travel to and from India as well as whilst traveling within the country</p> <p>4. Heavy reliance on communication and information technologies for the activities related to the project</p> <p>5. Difficulties in staff attending study sessions due to staff shortages in the workplace or heavy workload activity in the hospitals and health centres</p> <p>6. Changes in costs of travel and other items due to inflation and any excess is not sufficiently covered by the contingency fund</p> <p>7. Will attempt to gain consent in months prior to visit and find alternative sites if necessary</p> <p>8. Involve the wider school community to engage and thus build succession planning should project needs leave current employment</p> <p>9. Comprehensive travel insurance policies will be in place for all participants</p> <p>10. To use 3G phones as an alternative. To prepare study packs as a back up</p> <p>11. Advance and forward planning of teaching sessions to give managers time to plan. Where possible, to conduct the teaching sessions in the workplace e.g. health centres rather than in the university buildings</p> <p>12. Project team to revisit at the activities end then to negotiate with UKIERI to seek approval for any changes</p>
UEA develops evaluation questionnaire	months 1-2	Teaching materials have been developed	
UEA develops evaluation questionnaire	months 2-4	Questionnaire developed	
Visit by UEA to KLE University to develop teaching, maternal and neonatal care emergencies around childbirth and to conduct 3x monthly meetings with steering group	month 4-5	Skills gap analysis completed, A minimum of 60 students, staff and faculty will have attended the sessions Minutes of meeting produced and approved	
KLE University develops a plan to cascade teaching materials onto website	month 6-7	Plan for cascading of teaching developed by KLE	
Further visit by UEA to conduct teaching- maternal and neonatal care, demonstrate referral	month 4-5	Teaching materials by UEA staff	
Conference to launch further teaching strategies	month 12-11	A minimum of 60 students, staff and faculty will have attended the sessions	
Development of mentorship teaching materials and link lecturer model by UEA	month 12-13	Conference planned and completed	
Final project review and evaluation and dissemination of work to date	month 13-14	Teaching materials by UEA staff	
Further visit by UEA to conduct teaching on mentorship and LL model	month 12-13	Review completed and report is disseminated to all stakeholders	
During the visit to KLE conduct teaching sessions in the rural health centres to the	month 16-18	A minimum of 60 students, staff and faculty will have attended the sessions	
Evaluation and conclusions	month 23-24	A minimum of 30 Angerwadi women volunteers will have attended the sessions	
UEA and KLE University to jointly write up the project and make plans to disseminate to wider KLE University faculty to deliver keynote lectures at UEA to staff and students	month 23-24	Evaluation completed and report disseminated to all stakeholders	
Observing emergency workshops with simulation and real time emergency scenarios	month 21-24	Report completed	
Evaluations using nominal group technique/formative questionnaires	month 21-23	Lectures delivered by KLE faculty	
	month 22-24	A minimum of 60 students, staff and faculty will have attended the sessions	
	month 23-24	Evaluation completed and report disseminated to all stakeholders	

ATTESTED

(Signature)

Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

UKIERI
UK-India Education
and Research Initiative

Reference No (for official purpose only)

UK Costs


Expenditure	Number of Units	Per Unit	Total
Travel (including visa fees) - Eight trips UK to Belgaum, including visas	8	1325	10600
Travel associated costs	1	800	800
Accommodation - 10 nights per trip at £70/night	8	700	5600
Monthly Allowances/Subsistence - 10 days per trip at £30/day	8	300	2400
Project costs (include purchase of any software/books relevant to project)	2	500	1000
Marketing & Promotion - project workshop	1	5000	5000
Staff Development			
Contingency		1270	1270
Total UKIERI funding requested			26670

India Costs

Expenditure	Number of Units	Per Unit	Total
Travel (including visa fees) Four trips India to UK	4	1280	5120
Accommodation - 10 nights per trip at £70/night	4	700	2800
Monthly Allowances/Subsistence			
Subsistence - 10 days per trip at £30/day	4	300	1200
Project costs (include purchase of any software/books relevant to project)	2	500	500
Marketing & Promotion - project workshop	1	3000	3000
Staff Development			
Contingency		656	656
Total UKIERI funding requested			13776

External Funding Contributions (from Institution or other Sources)	Number of Units	Per Unit	Total
Direct investment from institution (can include staff time)			
Direct investment from other partners eg commercial sponsor			
Indirect contributions from institution – student fee and other discounts			
Indirect contributions from institution – project costs			
Other indirect or direct contributions (please specify) Jayne			23320
Randal's time 1day/week			17559
Anna Harris's time 5 hours/week			
Total			40879

ATTESTED




Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

UKIERI
UK-India Education
and Research Initiative

UKIERI AWARDS
2013-14

www.ukieri.org



About UKIERI

UKIERI is being implemented with the aim to bring forth a unique initiative that strengthens the bilateral relationship between India and the UK and set an example of best practice in international cooperation. The initiative is working towards developing programmes that meets the priorities and needs of both India and the UK and bring about a systemic change in the educational sector of both India and the UK.

Phase Two of UKIERI was announced by the UK Prime Minister David Cameron and Indian Prime Minister Dr. Manmohan Singh in July 2010. This phase is being jointly funded by the Indian and UK Government. The main activities under the phase two of UKIERI have been identified based on the experience of UKIERI in phase one, deliberations during various policy dialogue events, outcomes from consultations, roundtable discussions and scoping for the next phase of activity.

UKIERI is a multi-stakeholder partnership programme supported from the UK by Department for Business, Innovation and Skills, Foreign and Commonwealth Office, British Council, Department for Employment and Learning, Scottish Government, Welsh Government and by Ministry of Human Resource Development, Department for Science and Technology, Ministry of Labour and Employment, University Grants Commission and All India Council for Technical Education from India respectively.

Long term Objectives

- Bringing India and UK together through academic engagement
- Developing long term sustainable partnerships with institutions, centres of excellence and knowledge hubs
- Successful integration between research, education and business needs
- Enhancing capacities of institutions through development of sustainable initiatives in leadership, skills development and innovation
- Providing opportunities for joint learning through adapting models, standards and practices prevalent in both India and the UK across sectors

Strand 1: Leadership Development

- Develop and implement an academic Higher Education Leadership programme training over 250 Higher Education institutional heads
- Develop and implement a sustainable and scalable School Leadership Development programme training over 1250 high performing school principals
- Develop and implement an academic Further Education Leadership programme training over 250 technical and vocational college principals and institutional heads

Strand 2: Innovation Partnerships

- Develop institutional partnerships with the aim of stimulating innovation in science, research and knowledge transfer in emerging areas of importance in partnership with DST and UGC
- Support capacity building workshops, conferences and seminars on quality assurance and assessment
- Set up the India UK Joint Working Group on Innovation to provide a strategic direction on activities to be undertaken under this strand

Strand 3: Skills Development

- Support Further Education institutes and SMEs in the UK and India to partner and form consortia for setting up of sustainable partnerships and deliver training and activities in line with Sector Skills Councils (SSCs)
- Enable the development of a strong Indian sector skills infrastructure focusing on employer engagement approaches, developing curriculum and qualifications, certification and assessment and thereby strengthening leadership and delivery capacity of FE institutions, focusing on 21 high growth sectors
- Set up the India UK Joint Working Group on Skills Development to provide a strategic direction on activities to be undertaken under this strand

Strand 4: Enhancing Mobility

- Develop mobility programmes for staff, faculty and students from India to the UK and from UK to India
- Develop institutional partnerships supporting mobility through shared learning, curriculum development and thematic study missions
- Support Work placement programmes to provide opportunity to UK graduates to work with companies and Indian graduates to work with UK businesses
- Develop policies and framework to support mutual recognition and equivalence of learning and achievement through India UK Qualification recognition Taskforce

Policy Dialogues

UKIERI works with key stakeholders, government agencies, thought leaders and partners on policy dialogues to contribute to developing and implementing education policies both in the UK and India. These policy dialogues aim to bring together decision makers and decision influencers to discuss key issues around the Education sector. UKIERI facilitates these dialogues through meetings, consultations, delegation visits, commissioned research and knowledge sharing workshops across both countries and provide a platform for sharing of learning, experiences and best practices.

Key Achievements

- 209 Higher Education Partnerships involving over 400 institutions to undertake joint research and programme delivery
- 56 Skills Partnerships to support curriculum development and deliver industry relevant training
- 216 Facilitation travel grants for partnership development, sharing of best practices on curriculum & pedagogy and professional development
- Opportunity to 522 British Students to visit India under the Study India Programme
- Constitution of the India –UK Qualification Recognition taskforce
- 22 events in policy dialogue and networking

Strand 1 : Leadership Development

At the India UK Education Forum in January, 2013 Memorandum of Understanding was signed with All India Council for Technical Education (AICTE) in the presence of the Education Ministers from the UK and India. All India Council for Technical Education through the MoU agreed to partner with UKIERI for implementation and delivery of the programme.

Dudley College, UK in consultation with AICTE has been awarded to design and deliver the programme. The programme will be developed in the Indian context and will work with high performing heads in India and the UK to identify specific requirements for developing leadership capacities of individuals that would help in effective management of FE institutions. The FE Leadership Development Programme is focusing towards building and implementing a strategic plan to transform leadership and management in Indian Further Education institutions.

Leadership skills of 250 Principals, Directors and Institutional Heads of Polytechnics and State Technical Departments will be developed under this programme. After the first year of delivery of the programme, participants of the programme will also be given an opportunity to visit the UK and work shadow FE Leaders in the UK.

Strand 2: Innovation Partnerships

UGC Thematic Partnerships Awards 2013-14

S.No	UK Partner	Indian Partner	Project Title	Project Description
1	Edinburgh Napier University	Shant Niketan West Bengal	The Scotland-India Continuum of Ideas: The Relevance of Tagore and his Circle	The main aim of the project is to trace the exchange of ideas and people between Scotland and India from mid-nineteenth to mid-twentieth century and reaffirm the relevance of the work and ideas of Tagore and his circle
2	University of Southampton	Indian Institute of Technology, Bhubaneswar	Chemical and Biosensors based on two dimensional layered structures and their graphene based hybrids	The main aim of the project plan is to fabricate efficient chemical and biosensors based on graphene transition metal dichalcogenides (TMDCs) and their hybrids with Au, Ag, Pt nanoparticles
3	University College London	Indian Institute of Technology, Delhi	Imaging technologies to understand bioprocesses	The main objective of the project is to investigate how advanced imaging techniques can enhance our understanding of the fundamental mechanisms causing aging and fouling phenomena
4	University of Bristol	Osmania University, Hyderabad	Status, taxonomy and conservation of bats in the Andaman Islands	The project aims at filling the lacunae of bat studies in the Andaman Islands by understanding current status, taxonomy, diversity and distribution, and to create awareness among stakeholders to conserve bats including two globally threatened species and 6 endemic taxa (including one species)
5	Hull University Business School	Indian Institute of Management, Bangalore	Building sustainable agricultural supply chains in India	The aim of the project is to provide a forum for researchers and practitioners to meet and share current developments and major challenges in the creation of sustainable agricultural supply chains in the Indian context
6	University of Bath	CSIR-Central Electro Chemical Research Institute, Karaikudi	Metal-Organic Redox Frameworks (MORs) for Photochemical Textile Processes	The main aim is to synthesise and study new types of dye-loaded MORs via (i) physiosorption and (ii) via post-synthetic covalent attachment and to employ conformal transformation of MORs for the production of novel low density photo-absorber materials based on oxides

S.No	UK Partner	Indian Partner	Project Title	Project Description
7	Cardiff University	CSIR-Structural Engineering Research Centre (SERC), Chennai	Retrofitting and rehabilitation of reinforced concrete beams using ultra high performance concrete and basalt reinforced concrete overlay	The main aim is development of methodologies for Retrofitting and Rehabilitation of Reinforced Concrete (RC) beams using Ultra High Performance Concrete (UHPC) and basalt reinforced concrete (BRC) overlay
8	University of Warwick	Jawahar Lal Nehru University, Delhi	Gendered citizenship: manifestations and performance	The main aim of the project is to apply multidisciplinary research to look at legal, socio-cultural and performative aspects of construction of gender, violence against women, victimhood and public opinion in contemporary times.
9	University of Leeds	National Institute of Technology, Rourkela	Flow modeling for compound channels with non-prismatic floodplains	The main objective is enhanced understanding of flow processes in a two stage non-prismatic compound channel flow having convergent and divergent geometry along the longitudinal sections and to quantify the influence of change in geometry, surface and flow conditions in predicting flow profiles, discharge distribution, boundary shear stress distribution, stage-discharge prediction etc.
10	Imperial College London	Indian Institute of Science, Bangalore	Local and Remote influences on Rainfall over India (LORRI)	The aim of the project is to understand how short-lived climate pollutants (SLCPs) such as aerosols and ozone precursors affect South Asian climate in general, and rainfall in particular.
11	University of Cambridge	Indian Institute of Technology Madras	The interaction of ICT networks structure and downstream trade flows: two case studies from India (IRuralNet)	This project will examine how to remove bottlenecks to Internet access for rural agricultural production and of community based tourism.
12	University of Greenwich	Gujarat Institute of Desert Ecology (GUIDE)	Ecosystem Assessment of the habitats in the Kachchh District: planning for biodiversity and livelihoods into the future	The main aim of the project is the rapid spread of the introduced tree Prosopis, which has become important for livelihoods but is simultaneously replacing native vegetation and altering habitats.
13	Queen's University Belfast	Indian Institute of Science Education and Research Thiruvananthapuram	Physics and applications of high-aspect ratio Schottky Junction Devices	This project addresses fabrication of high aspect ratio metal-semiconductor nano-scale Schottky junction (nSJ) devices to investigate electrical transport along these devices and to study their response for developing gas sensors with ultra-high sensitivity (<1ppm for hydrogen).

S.No	UK Partner	Indian Partner	Project Title	Project Description
14	University of St. Andrews	Presidency University, Kolkata	Narratives of Migration and Exchange	This interdisciplinary research project will explore, from a variety of approaches, the complicated network of exchange of people, ideas, technologies and capital which mark the colonial legacy in India and in Europe.
15	London School of Economics and Political sciences	University of Hyderabad	Urban Water Supply and Governance: Study of Four Indian Cities	The objective of this project is to evaluate the institutional arrangements of urban water service delivery and governance in India.
16	University of Leicester	National Museum Institute of History of Art, Delhi	Things Encountered: Object Engagements in Museums in India and the UK	Project aims to exchange and share training of museum studies researchers, in the process widening the scope of tomorrow's leading museum studies academics and frontline professionals in both India and the UK.
17	Anglia Ruskin University	ABV Indian Institute of Information Technology and Management (IIITM), Gwalior	Interfacing ad-hoc mobile networks with IP mobile systems	The aim of project is Design and construct a platform framework capable of aggregating together networking resources pertaining to wireless communication devices and develop a Mobile Ad-Hoc Resource Sharing Network (MARS-NET) Protocol
18	Loughborough University	Indian Institute of Technology Delhi	Improving road safety in India and the UK – in-depth investigation and analysis of crashes involving vulnerable road users	This project will focus on developing an engineering perspective to accident causation by combining the accident analysis capabilities of Loughborough University in the UK with the simulation and engineering skills of IIT Delhi.
19	University of Reading	Indian Institute of Technology Bombay	Goal-directed future cognition: neural and cognitive mechanisms underpinning the successful completion of planned and intended behaviour and actions	The aim of the project is to examine the impact of imagery perspective in two exemplars of goal-directed thinking to explore the developmental time course of goal-directed future thinking and to investigate the neural correlates of visual imagery perspective in future thinking.
20	London School of Hygiene and Tropical Medicine	Institute of Home Economics, Delhi University	Statistical and epidemiological capacity building to enhance India-UK collaborations	The main aim of project is to provide Indian researchers with current statistical knowledge and skills for evidence-based health care decision making.
21	Cranfield University	Jadavpur University	Significance of pharmaceuticals in the aqueous environment: A global catchment comparison and assessment of treatment processes	The main aim of project is to develop a robust analytical methodology for the determination of pharmaceuticals in wastewaters and surface waters.

S.No	UK Partner	Indian Partner	Project Title	Project Description
22	King's College, London	Institute of Social and Economic Change, Bangalore	Changing nature of the public and the private in school education	The project is envisaged as part of a research study that examines the changing nature of the public and the private in the school education system in India.
23	University of Edinburgh	CSIR- National Chemical Laboratory, Pune	NCL-EaStCHEM Network on Sustainable Chemistry	The project will build multifaceted interactions to jointly address key global challenges in sustainable chemistry.
24	University of Oxford	Tata Institute of Fundamental Research, Mumbai	Carbon Flux Measurement in Island Rainforest ecosystems	The main objective is to quantify the aboveground carbon efflux rates from soil and tree stem surfaces within two recently-established forest census plots in the Andaman and Nicobar Union Territory.
25	The University of Sheffield	Indian Institute of Management Ahmdabad	Green design to green disposal: Designing the green supply chain for the next generation	The project aims to investigate the current state of green supply various stages of the product life cycle from product design to disposal.
26	University of Manchester	Indian Institute of Technology Kanpur	Adaptive and Reconfigurable Multiband, Multimode and Multifunction Monolithic Millimetre-wave Integrated Circuits (MMICs) Technologies for 5G Wireless Communications	The aim of this project is to nurture the cooperation between the named HEIs in the important research area that brings expertise together to address challenges in millimeter-wave monolithic integrated circuits (MMICs), characterisation and sub-systems design for 5G wireless communications systems.
27	Unversit of St. Andrews	Jadavpur University	Comparing Comparative Literature	This is envisaged as the first phase of a long-term project whose aim is to establish (in tandem) lasting research and educational links on comparative literature.
28	Swansea University	The University of Burdwan West Bengal	A Gerontology Research Centre for the Study of the Impact of Population Ageing, Migration, Environmental and Social Change on Older People and their Families in India	The project aims to establish a Centre of Gerontological Research in Burdwan University by sharing examples of good practice from the Centre of Innovative Ageing (CIA), develop post-graduate research in Ageing Studies in Burdwan by establishing the infrastructure to support research students and initiating a PhD research programme building on existing research conducted by the CIA.
29	University of Southampton	Tezpur University, Assam	Fabrication of p-i-n photovoltaic devices hybridized with core-shell CdSe/TiO ₂ nanostructures for enhanced quantum efficiency.	The aim is to fabricate CdSe/TiO ₂ core-shell nanostructures using colloidal chemistry and to incorporate them in p-i-n structures for making cost effective and environment-friendly solar cell devices.

S.No	UK Partner	Indian Partner	Project Title	Project Description
30	University of Birmingham	Anna University	Performance enhancement of solar water heater integrated with latent heat thermal storage system using nano-enhanced phase change materials.	The main aim is to develop a suitable design methodology for the selected solar water heaters integrated with nano-enhanced PCM based storage system.
31	University of Bath	Indian Institute of Technology Delhi	Electro-optical Properties of Magnetically Modulated Graphene	The main objectives are fabrication of nanomagnets at the surface of graphene and 2D electron gases, theoretical and experimental demonstration of magnetic confinement of charge carriers in graphene and high mobility electron transistors, demonstration of transistor action in graphene. Hall bars modulated by single and double magnetic barrier structures, obtained by gating graphene with micro-magnets and theoretical and experimental demonstration of the interactions of Dirac fermions with microwaves.
32	University of Southampton	Indian Institute of Technology Delhi	A comparative study of hierarchical materials for biomedical and lightweight applications: manufacture, characterisation and modelling	The main objective of the proposed research is to manufacture and model novel materials having porous architecture for biomedical implants and lightweight structural applications.
33	The Open University	Jamia Millia Islamia University	Intergroup Contact and Collective Action in Educational Settings in India	The aim is to investigate how intergroup contact and collective action tendencies interact in multiple group settings where individuals share a multiplicity of social identities.

Strand 2: Innovation Partnerships

DST Thematic Partnerships Awards 2013-14

S.No	UK Partner	Indian Partner	Project Title	Project Description
1	Loughborough University	Institute for Plasma Research Gujarat	Plasmonics incorporated CZTS based solar cells	The aim is to develop a CZTS based solar cell and incorporate the plasmonic layers for higher efficiency and develop a bottom-up process to produce ordered silver nanoparticles arrays over large area for enhanced light trapping and to grow mechanism of various CZTS layers
2	University of Oxford	All India Institute of Medical Sciences, Delhi	Safety, Suitability and Clinical Effectiveness of Unicompartmental Knee Replacement in the Indian population	The purpose of the project is to establish the pattern of knee OA in Indian setting and to assess the suitability, safety and clinical effectiveness of UKR for managing end-stage knee OA in the Indian population for the transfer of technology to assess implant position
3	Queen's University Belfast	CSIR-Central Salt & marine Chemicals Research Institute, Gujrat	Development of domestic and -selective electro dialysis unit for community supply of desalinated potable water enriched with essential minerals	The aim of the project is to modify the ion-exchange membrane (IEM) by conducting polymer and develop the selective electro dialysis unit for producing nutritious ions (Ca ²⁺ , Mg ²⁺ , HCO ₃ ⁻ and SO ₄ ²⁻ etc) enriched desalinated water.
4	Queen Mary University of London	CSIR-Central Electronics Engineering Research Institute, Rajasthan	Micro/Nano fluidics for Health and diagnostics	The project aims to explore the possibility of developing an integrated microfluidic platform for health monitoring and diagnostic applications and to explore different technologies for the realization of microfluidic system components such as micropumps, reservoirs, filters, sensors, electrodes and mixers and Simulations for mixing applications, electrokinetic flow control using gate electrodes, FET (field effect transistor) based bio-sensing with fluidics integration
5	University of Cambridge	Indian Institute of Science, Bangalore	Multiple Carrier Generation in Fission Enhanced Polymer Solar Cells	In this project the aim is to develop and characterize singlet fission-enhanced organic solar cells. The future performance of conventional solar cells is constrained by the Shockley-Queisser efficiency limit, Substitution of polymers for nanocrystals would lead to easier fabrication and reduces toxicity, but requires polymers with efficient electron transport and suitable energy levels, which will be developed at IISc Bangalore

S.No	UK Partner	Indian Partner	Project Title	Project Description
6	University of London College London	Indian Institute of Technology Kanpur	Direct scaffolding with living cells	The major aim of the project is the development of novel nanocomposites together with exploration of nanomaterials in the area of tissue engineering and regenerative medicine and to measure the effects of varying voltage, eedle size and configuration (single versus concentric) on fibre direction and dynamics, and the biomechanical properties of cellularised constructs prepared using cell electrospinning. The viability and behavior of different cell types of interest.
7	University of Nottingham	Indian Institute of Technology Delhi	Nanoscale Surface Engineering in Organic Hetero-structures with Photocatalysts	The project aims to develop low cost and high performance visible light active novel nano-catalysts for photoelectrochemical splitting of water for solar hydrogen production. The approach consists of layer-by-layer deposition of material combinations and surface modifications for achieving the desired characteristics. Sustainable Activity for Solar Hydrogen Production
8	Loughborough University	KVSR Sridhartha College of Pharmaceutical Sciences, Vijayawada	Microemulsion Assisted Transdermal Delivery of Antihypertensive drugs	The partnership proposal aims to develop microemulsion systems for transdermal delivery of anti-migraine and anti-hypertensive drugs for better therapeutic efficacy. Hence, alternate route of administration, e.g., transdermally, is an ideal choice for these drugs
9	Coventry University	Indian Institute of Technology Mandi	Smart Multi-Terminal DC Grids for autonomous Zero-Net Energy Buildings	The main objective to enable the development of autonomous zero net energy building.
10	University of Leicester	CSIR-Institute of Genomics and Integrative Biology, Delhi	Study of the molecular basis of the choice between miRNA mediated suppression and RNA instability in neural cell types.	This proposal aims to address a lacuna in our understanding of the mechanism by which microRNAs regulate targets.
11	University of Hertfordshire	Indian Agricultural Research Institute, New Delhi	Understanding Pasteuria spore attachment for exploitation as a natural control agent of root-knot and cyst nematode crop pests	This project aims to focus on their interactions with the bacterial group of parasites closely related to Pasteuria penetrans which has potential as a biological control agent.

S.No	UK Partner	Indian Partner	Project Title	Project Description
12	University of Reading	Indian Association for the Cultivation of Science, Kolkata	To study the gelation mechanism of self-assembling peptide based new hydrogelators for the application of sustain release of drugs	The purpose of the project is to make peptide hydrogel based new biomaterials with greater enzymatic (present inside the human body) stability (due to the presence of naturally occurring non-protein amino acid residues) compare to those of existing peptide hydrogel based biomaterials and to use these biomaterials for sustained release of cancer drugs and also to explore the in depth knowledge of hydrogel formation by different techniques.
13	Queen's University Belfast	Indian Institute of Chemical Technology, Hyderabad	Novel Biomaterials for localised drug delivery for bone regeneration	The main aim of the project is Design, development and delivery of bisphosphonate anchored / immobilized mesoporous silica materials for effective bone tissue repair and regeneration
14	University of Cambridge	Indian Institute of Science, Bangalore	Design and Prototype Development of an Active Matrix Sensor-Actuator User Interface for Social HealthCare	The project proposed involves the development of a large area sheet (flexible or rigid) with an array of pixels with each pixel having a sensor, a circuit that takes information from the sensor, and an actuator that is driven by the circuit in response to the sensor input.
15	Heriot Watt University	Centre for Nano Science and Engineering, Indian Institute of Science Bangalore	Femtosecond laser micromachined microfluidics, integrated Surface Enhanced Raman Scattering (SERS) sensors for point-of-care diagnostics	The main objective of this proposed collaboration is to develop a novel platform for early disease detection and diagnosis.
16	University of Sheffield	Indian Institute of Science, Bangalore	Integrative In vitro and In silico Modelling of Arterial Mechanobiology for Health and Disease	This project brings together two leading experimental and computational AM research groups. This synergistic research collaboration will enable: (i) the establishment of a research collaboration between the INSIGNEO institute of in silico medicine (University of Sheffield) and the Indian Institute of Science; (ii) novel experimental and computational research on arterial mechanobiology; (iii) transfer of knowledge and expertise between institutes.
17	Heriot Watt University	National Institute of Science & Technology, Odisha	Development of solution processed CdTe@ZnTe core/shell nanocomposite plasmonic solar cells	The aim of the project is to develop low cost, high efficient solar cells that can facilitate widespread commercialization to address the world's energy and environmental challenges.

S.No	UK Partner	Indian Partner	Project Title	Project Description
18	University of Bath	National Centre for Cell Sciences, Pune	A Novel strategy for Reprogramming of somatic cells to induced pluripotent stem (iPS) cells by a single Non-coding RNA-Gimir for applications in regenerative medicine	The aim of the project is to develop methodologies for establishment of iPS cells from fibroblasts using nc RNA Gimir and compare attributes of iPS generation achieved through ncRNA-Gimir with known cocktail of transcription factors like Oct4, Sox2, Klf-4 and c-myc
19	University College London	National Chemical Laboratory, Pune	Efficient Waste Water treatment using Novel Catalysts	This project aims to develop a treatment approach that can simultaneously remove multi-contaminants such as methaldhyde, synthetic colour and pathogens from water.
20	University of Manchester	National Institute of Pharmaceutical Education and Research, Hyderabad	To evaluate the role of AMPK mediated signal transduction in models of chemotherapy induced peripheral neuropathy (CIPN) using pharmacological approaches	This Project leads to enhanced axonal protein synthesis and activation of channel subunits responsible for excitatory neurotransmission in pain signaling pathways
21	The Open University	National Institute of Technology Durgapur	Graphene Assisted Low cost Energy efficient Solar cell (GALES)	The main of the project is to produce functionalised graphene nanosheets (FGNS)-based dye synthesised solar cells. This work identifies a new class of electro-catalysts with potential of low cost photovoltaic devices both the partners propose a novel approach that opens new means to efficiently harvest energy by using a combination of chemical synthesis and atmospheric plasma functionalisation to achieve desired properties.
22	John Innes Centre	Indian Institute of Science, Bangalore	Developing topoisomerase targets for TB therapy	The project will involve knowledge and personnel exchange to capitalise on opportunities for developing gyrase and topo I as TB targets. Thus, the main aim of this proposal is to exploit and expand our current knowledge-base on these essential enzymes (TB gyrase and topo I) in order to develop them further as drug targets and to find new inhibitors that affect their function.
23	Queen Mary University of London	Postgraduate Institute of Medical Education and Research, Chandigarh	Identification and characterization of novel germline mutations causing pituitary disease	To identify novel gene mutation causing pituitary adenoma and to perform in vitro functional studies on the identified mutations.

S.No	UK Partner	Indian Partner	Project Title	Project Description
24	University of Surrey	University of Hyderabad	The Energy Cube of the Future	This project will demonstrate an integrated, inexpensive allotropic carbon system-based "energy cube" solution, for organic photovoltaic (OPV) energy harvesting, nanotechnology-enabled energy storage, and its energy-efficient utilisation using nanomaterials throughout.
25	Northumbria University	Sri Venkateswara University, Tirupati	Development of Efficient low-Cost Photovoltaic Solar Cells Based on the use of Tin Sulphide Absorber Layers	This aim will be achieved through study of deposit layers of SnS using thermal evaporation (UNN task) and using wet chemical processes, spray pyrolysis (SVU task) and to optimize the layers for PV solar energy conversion, deposit a range of Cd-free buffer layers e.g. ZnIn ₂ Se ₄ , ZnMgO and ZnS, and to optimize these materials for use as buffer layers in SnS based solar cells and to produce PV devices using the optimized layers and characterization of the devices with the aim of maximizing the solar conversion efficiency.
26	University of Southampton	Tea Research Association, Assam	Climate-smartening Assam's tea plantation landscapes; defining socio-ecological 'safe spaces' for future sustainability	This research will investigate the nexus of livelihoods, climate change and agricultural practice to locate "safe spaces" for tea plantation landscapes in Assam, India.
27	Heriot-Watt University	Thapar University, Patiala	Green Polymers for Waterborne Pathogen Detection and Treatment	The main aim of this project is to identify natural biopolymers (i.e. green) polymers for waterborne pathogen monitoring and treatment applications and to employ the high-throughput arrays systems for the identification of natural biopolymers which promote or prevent adhesion of waterborne protozoan pathogens.
28	University of Ulster	Indian Institute of Technology Kanpur	A BCI Operated Hand Exoskeleton based Neurorehabilitation System for Movement Restoration in Paralysis	Develop a lightweight three-finger exoskeleton with embedded sensors, capable of replicating human motion for physical practice. It will be controlled by users' EMG and EEG signals in assist-as-needed mode and develop a novel brain-computer interface (BCI) that facilitates EMG and EEG for controlling the exoskeleton and provides visual neurofeedback to ensure focused physical and MI practices.
29	University College London	Indian Space Research Organisation, Thiruvananthapuram	Collaborative scientific and mission definition studies and development of space plasma and planetary instrumentation for future space missions	A collaborative study of an innovative mission concept involving a piggy back nano-satellite on-board future space and planetary missions of ISRO, ESA and the UK. Also identify related technology requirements for scientific payloads such as plasma analysers and for the nano-satellite.

S.No	UK Partner	Indian Partner	Project Title	Project Description
30	University of Central Lancashire	Indian Association for the Cultivation of Science, Kolkata	Multifunctional hybrid nanocomposites for the separation of toxic and microbial contaminants from water	The specific objective of the project is to exploit multifunctional hybrid nanocomposites for the removal of toxic (arsenic) and using the recently developed novel surface chemistry to tackle the bacterial contaminants such as Legionella, E-coli, Shigella and Salmonella from water.
31	University of Exeter	CSIR-Central Salt & Marine Chemicals Research Institute, Gujarat	Sustainable Energy Production Through Biomass Gasification Integrated With Solar Thermal Conversion	The broad objective of this proposal is to develop a technology package for economic production of energy carrier through hydrogen gas from biomass integrated concentrating solar thermal system.
32	University of Exeter	Indian Institute of Science, Bangalore	Water Security and Infrastructure Resilience under Climate Change	Aims to improve the understanding and knowledge for managing water security and infrastructure resilience in a changing climate by investigating new methods and further developing the expertise at both institutions.
33	University of Bradford	National Chemical Laboratory, Pune	Morphological structuring of polymeric matrices as a novel approach for controlled drug release	To develop a detailed understanding of the effects of semi-crystalline polymer morphology on the release of a bioactive agent from such polymer matrices and to share cross-disciplinary expertise, infrastructure and networks across the proposed complementary groups for the development of platform technologies.

Strand 3: Skills Development

Institutional Capacity Building Awards 2013-14

S.No	UK Partner	Indian Partner	Project Title	Project Description
1	Dudley College UK	Mahatma Gandhi International School Sheth Hirabhai Motilal Bhavan Mithakali Ahmedabad	To establish Skill Based Teacher's Training documented and supported by Multi Media at MGIS	Through this project proposal MGIS will design and articulate Teacher's Training methodology which identifies dry areas of teaching such as science and sex education. All the teaching aids would be Multi Media based like - films and Documentaries implementing the vocational element of studies.
2	Burton and South Derbyshire College (BSDC)	MAEER'S Maharashtra Institute of Technology, MIT Academy of Skill Development Pune	International Curriculum Development In Construction	This project will equip the workforce with construction vocational skill and employability skills, each individual will have Individual Learning Plan (ILP) to ensure that they gain vocational qualification and soft skills such as communication, interview techniques, application forms. Additional health and safety skills/ qualification will also be offered that are required in the construction industry
3	City College Plymouth	Future Sharp Skills Limited Mumbai	Hospitality Entrepreneurship Employability and Enterprise Partnership (HEEEP)	Project partners will share good practice regarding embedding employability, and entrepreneurial spirit, whilst ensuring that learners gain the best opportunity to enter Tourism and Hospitality sector. Through this project project partners will to increase quality measures, build a sustainable and relevant curriculum, meeting the needs of employers and to share good practice regarding new and inspiring teaching methodologies.
4	Bradford College	Kannur Government Polytechnic Kerala	Skills Development in Garment Manufacture (SDGM)	The project is aimed to develop innovative approaches for employer engagement and develop technical and entrepreneurial skills for employment and progression purposes and to also work with leading fashion & textile companies in both regions on applications of the latest technology for commercial products.

S.No	UK Partner	Indian Partner	Project Title	Project Description
5	Pearson Education Ltd	MART Advance Training Institute Noida	Creation of Vocational Trainers in rural India	The broad aim of this project is that Pearson will work with MART to build capabilities through curriculum and academic framework design, content development and delivery of programs, facilitate collaborations and connect with the larger international community. The overarching aim of the project is to introduce vocational qualifications for trainers in rural India
6	Reid Kerr College	National Accreditation Board for Education and Training (NABET), Quality Council of India (QCI) New Delhi	Building Training Capacity in Central and State Government Funded Industrial Training Institutes (Reporting to Directorate General of Employment and Training, Ministry of Labour and Employment, Government of India)	The objective of the project is to create a local capacity of qualified and trained master trainers for Government Industrial Training Institutes in line with International Standards. SQA Certified Master Trainers will be utilized for training of faculties, students etc. in the identified 5 sectors. 5 identified sectors are – Retail, Construction, Food Processing, Healthcare and Telecom
7	Colleges Northern Ireland	Mechatronics Department, TeamLease Skills University Bangalore	Mechatronics Curriculum and Faculty Development for Greater Employability and Enterprise among Formal and Informal Sector Workforces	This project will see Colleges NI and Team Lease work together to benchmark, review and re-engineer Mechatronics curriculum and training methodologies which are relevant for the needs of industry in the India
8	Belfast Metropolitan College (Belfast Met)	Bombay Chamber of Commerce & Industry (Bombay Chamber) Mumbai	Building Organisational Efficiencies for Small and Medium Enterprises (SMEs)	The project will improve organisational efficiencies by developing effective and efficient business and operational processes which will enhance business and financial performance. These processes will be integrated and embedded through the development and implementation of series of workshops and master classes utilising a business process manual. This will be further enhanced by the development of a training module specifically focused on marketing and supply chain management.

S.No	UK Partner	Indian Partner	Project Title	Project Description
9	Hackney Community College	Mehr Chand Polytechnic College Jalandhar	Community College for Skills Development in Punjab.	The main focus of this project is to provide thorough practical training and skill knowledge to the intended staff group. A Faculty exchange and training program between India and UK will be the key towards development of intellectual capital, promoting knowledge and effective management and staff skills.
10	Edinburgh College	Government Women's Polytechnic College, Bhopal	Scottish Textiles, Indian Textiles - Collaborative Hub (STITCH)	The aim is to expand and enhance the Textile and Fashion Curriculum through training of staff and students by UK and Indian experts; Create new delivery materials in the form of 'you-tube' style video demonstrations and e-booklets. Offer training, networking and web based marketing opportunities to local industry and retail and facilitate the development of micro businesses
11	University of East Anglia	Institute of Nursing Sciences, K.L.E. University Belgaum	Enhancing midwifery and neonatal care through capacity building of midwifery lecturers	The project will involve enhancing the maternal and neonatal educational provision in Belgaum, India whilst developing research in the arena of women and child health in both institutions. The project will also aim to develop UK midwifery and nursing education by giving students the tools to understand and engage in global responsibilities for health.
12	NESCOT, Epsom, Surrey	Govt. Polytechnic College, Palakkad	Pedagogical Strategies in Skill Development	The project will focus on Pedagogical strategies in skill development. It will look into ways to develop strategies to enhance student skills by inspiring and engaging students both inside and outside the classroom.
13	Stow College	Ludhiana Polytechnic College, Ludhiana	The delivery of UK TVET qualifications in the Punjab, India.	The primary aim of this project is to work with Indian colleges to build their capacity to deliver internationally recognised qualifications alongside their existing local qualifications. The project will undertake pilot work on the introduction of a UK (Scottish Qualifications Authority) Higher National Certificate into Indian colleges. This will involve staff development for the Indian faculty, sharing of curriculum materials and establishment of SQA assessment and quality assurance processes.

S.No	UK Partner	Indian Partner	Project Title	Project Description
14	Highbury College	Larsen & Toubro Limited Construction Skills Training Institute Kanchipuram	Institutional strengthening and building capacity to deliver holistic vocational programs within the Construction Sector in India	The partnership will focus on: Skill standards, Training curriculum, Training the trainers and create master trainers, Training pathways and progression plan, Introduction of new tools, technology and facilities on campus, Introduction of eLearning and technology-aided blended learning pedagogy at CSTI, Apprenticeships and accreditation.
15	City & Islington College	TSEI - Town Schools Education Initiatives New Delhi	Impact	Project will create collaboration by forming partnerships between vocational education & skill development institutions from India & UK, with the objective of development of industry driven Indian Skills, and their standardized quality delivery capacity, thereby contributing towards building capacity in vocational education in the country.
16	Bournville College of Further Education	Confederation Of Indian Industry New Delhi	Capacity Building for Entrepreneurship Development for Marginalised Sections of India	The programme aims to help entrepreneurs succeed by filling this gap and mentoring them through robust programme for 100 entrepreneurs from marginalized sections by inculcating leadership skills and creating platforms for networking and Liaoning with relevant target customers.
17	Exeter College	BigSpring Pvt. Ltd. Mumbai	Beyond Borders - A Transnational Approach to Skills Training	The proposed project aims to develop and pilot a range of parallel and integrated vocational and English skills development programmes that will be used by trainees in both the UK and India.
18	Superact UK CIC	Don Bosco, Tech Society New Delhi	Women Empowerment	Developing employability and personal effectiveness amongst unemployed women in India through team and individual study using the performing arts.
19	Bradford College	Lucknow Excellence Cluster, Lucknow	Enhancing Employability Skills for SME's in the Automotive Sector.	The project aims on building & improving the craftsmanship, technical, communication, behavioural and managerial skills of workforce in order to improve competency and capability of enterprise. It aims to develop curriculum related to these training. It also aims to produce highly skilled trainers/trainers using latest pedagogical methods and equipped to deliver industry relevant training that enhances employability and enterprise capability.

S.No	UK Partner	Indian Partner	Project Title	Project Description
20	University of Bath Innovation Centre	Centre of Management Studies, Dibrugarh University, Assam	UK-India Entrepreneurship Programme	The proposed Project will fund the customisation of the Bath entrepreneurship Programme for nascent entrepreneurs who want to create ambitious high-growth businesses in India and the UK. The Project will train an initial cohort of internationalised entrepreneurs and provide a legacy of teaching materials and relationships that will be the foundation of future exchanges of Indian and British entrepreneurs who will go on to create innovation, business growth and wealth in and between our respective economies.
21	Worktree, Milton Keynes, UK	Gram Tarang Employability Training Services Pvt Ltd, Odisha	Work Tarang Job Readiness Partnership	The project brings together two partners with the same goal to assist young people, without the advantage of quality and higher education, to succeed in the job market. Through this partnership, the two organisations will meet their respective goals through a mix of exposure visits, product testing and development, and training of trainers.
22	Edinburgh College	Sardar Vallabh Bhai Polytechnic College, Bhopal	Renewables Industry Partnership Project for Learning Exchange (RIPPLE)	The design of this project is to facilitate the widest possible dissemination through the spoke and hub model, by training the trainer. In Madhya Pradesh alone there are over 60 polytechnics who can quickly develop the capacity to deliver future training, similarly in Scotland our participation in Colleges Scotland's Energy
23	Rural Skills Training Centre, Royal Agricultural University,	National Skills Foundation of India (NSFI), Gurgaon	Evaluation of the "UK Agricultural Training Group model" for local delivery of training, education and knowledge transfer to learners in the agriculture and food chain, and its opportunity to transfer to India to facilitate sector up skilling	The project will suggest the methodology in line with UK Agricultural Training Group Model for the Indian Agriculture Sector. In India, agriculture is much diversified and a large number of organisations are working on various training models. This gives an added advantage to the Indian Agriculture Sector for exploring the opportunity of adopting the Agricultural Training Group Model, by exploring UK best practices simultaneously

S.No	UK Partner	Indian Partner	Project Title	Project Description
24	Asset Skills (UK Sector Skills Council)	All India Management Association (AIMA), New Delhi	Creation of a Management and General Skills SSC	This project aims to work with key stakeholders such as existing SSC's, Confederation of Indian Industry (CII) and Federation of Indian chambers of Commerce and Industry (FICCI) to establish AIMA as the Sector Skills Council for Management and General skills (including employability skills) to underpin the economic goals and ambitions of India.
25	Department of Architecture and Civil Engineering, University of Bath	Government Polytechnic, Mayem, Goa	Development of structural concrete with the help of plastic waste as partial replacement for sand	The proposal looks to utilise these waste plastics as a replacement for up to 10% of the sand in concrete, with a small effect on compressive strengths. This has the dual benefits of using a waste product in a new way while reducing the damaging mining of sand from riverbeds (the indiscriminate mining of which is banned in most states). In addition, studies on workability, durability and crack control will be undertaken by considering the utilisation of chemical admixtures as well as plastics.

Strand 3: Skills Development


Sector Skills Collaboration Awards 2013-14

S.No	UK Partner	Indian Partner	Project Title	Project Description
1	Skills of Logistics	Sectors Skills councils for logistics chennai	Sharing best practice and opening up future partnerships in logistics skill development-India/UK collaboration.	This project will develop a key relationship which will support India SSC and UK counterparts by drawing on the experience of SFL-UK, CII will be well placed to create a SSC which will effectively develop National Occupational Standards, a Qualification reform and to develop activities around certification, accreditation and centres of excellence.
2	Lantra (UK Sector Skills Council for Land-based & Environmental Industries)	Rubber Skill Development Centre (India Sector Skill Council for Rubber Sector) New Delhi	Supporting innovation in understanding the labour market and occupational requirements of the Rubber producing and manufacturing sector in India	Development of integrated systems for skills management and occupational data significant benefits for the ongoing activities related to developing occupational standards, defining curricula and collecting information on skills gaps and shortages in the rubber plantation and manufacturing sectors increased levels of engagement with businesses in the sector impact on skills development within the workforce.
3	Lantra (UK Sector Skills Council for the Land-based & Environmental Sector)	Agriculture Skill Council of India (ASCI) Gurgaon	Promoting the take up of Occupational Standards in the Indian Agriculture Sector through developing a unique system for managing their development and review.	The project will help utilize the best practices of UK SSC for occupational standards development and utilization and suggest the model for Indian SSC in terms of occupational standards development and utilization. This will also create the opportunity to share such best practice with other Indian SSCs.
4	Skills for Health	Healthcare Sector Skill Council New Delhi	Development of Competency based Curriculum and Course. Content aligned with Occupational Standards, developed by HSSC for Healthcare Job-Roles	The Healthcare Sector Skill Council wishes to accelerate the pace of development in Occupational Standards across all job roles, supported by building the capacity of Indian Health Care trainers to deliver high quality training which meets national standards. Furthermore, there are no benchmarks for Train-the-Trainers with regard to teaching methodologies. This has resulted in poor quality of allied health and paramedics professionals, leading to compromises in patient care, health and safety. This project will focus on these.

Future Opportunities

1. **Higher Education Leadership and Development Programme** – UKIERI in partnership with Ministry of Human Resource Development will be working to support leadership and capacity building initiatives under RUSA (Rashtriya Uchattar Shiksha Abhiyan). RUSA is India's flagship mission on Higher Education which is a centrally sponsored scheme proposed by the Ministry of Human Resource Development to ensure holistic planning at the state level and enhancement of allocations for the state institutions with focus on state higher educational institutions. Through UKIERI, we aim to support the capacity building initiatives by facilitating a consortium of UK universities and agencies like QAA, HEFCE and LFHE for developing leadership modules, quality assurance mechanisms and professional development of state higher education institutions.
2. **School Leadership Research** – UKIERI through the school leadership development programme has been working successfully with National College for Teaching and Leadership and National University of Administration and Planning (NUEPA) to build and enhance the leadership capability of current and aspiring school leaders in state schools. Currently the programme is being piloted in Rajasthan and Tamil Nadu. The four strands of Leadership development are: curriculum and material development, capacity building, institutional development and networking, and research and development. Through UKIERI, we now aim to bring together a consortium of UK universities to jointly partner with Indian agencies and organisations on school leadership themes specifically to create a research consortium and develop a systemic approach to school leadership and share learning's.
3. **Partnership Opportunities** – Through Knowledge Transfer Partnerships, we aim to facilitate the transfer of knowledge, technology and skills from the academic institute to the company, which would otherwise have no access to this information. It benefits the academic institution through applying their knowledge and expertise to important business problems, developing business-relevant teaching and research materials, identifying new research themes and undergraduate and postgraduate projects, gaining a relevant and improved understanding of business requirements and operations etc. Through Community college partnerships, UKIERI is looking at supporting mentoring and capacity building partnerships with 25 identified Community colleges under MHRD.
4. **Study India Programme** – Study India Programme is a flagship programme under UKIERI that enables undergraduate students from UK universities and colleges to visit India for three weeks to gain experience of Indian culture, way of life, people, arts, politics, economy and language and it also provides opportunity to the UK undergraduate students to explore for further study or work in India. The SIP students also get an opportunity for a one-week work placement or internship with Indian companies during their visit. The UKIERI Study India programme started in 2009 and till date 915 UK students have got a chance to travel to India and learn about new culture and enterprise skills. The marketing and promotion for SIP 2014 will commence in February and March.

5. **Faculty exchange programmes** – UKIERI is looking at providing short term faculty and programme development exchange visits in partnership with Indian agencies like DST and UGC. This will provide access and capacity building for staff, researchers and enhance professional and thematic capacities.
6. **FE Leadership Development Programme** – UKIERI in partnership with All India Council for Technical Education (AICTE) will be working to support development of leadership skills of 250 Principals, Directors and Institutional Heads of Polytechnics and State Technical Departments. Dudley College, UK has been selected as the delivery partner and the participants for the programme will be selected in consultation with AICTE. Upon successful completion of the training programme, participants will be assessed and will be accredited for the training programme. After first year of the delivery selected participants of the programme will also be given an opportunity to visit the UK and work shadow FE Leaders in the UK.
7. **National Career Services** - UKIERI in partnership with Ministry of Labour and Employment will be working to support development of employment services in India on the lines of Careers Service in the UK. UKIERI will be working closely with Ministry of Labour and Employment and with Employment exchanges across the country for designing a mechanism to provide Career Services to the India youth either in training or looking for employment.
8. **Community Colleges** – UKIERI in partnership with MHRD will facilitate development of links between Indian community colleges in the priority states and sectors as recommended by MHRD and further education colleges in the UK. A maximum of 25 partnerships will be supported and these would be developed as models for replication
9. **Policy Dialogues & Capacity building workshops** – UKIERI will be partnering with Indian government agencies and Ministries to debate, discuss and brainstorm on areas around quality assurance, research performance, teacher training, industry & employer engagement, sector skill councils, leadership development, Employment Services, sustainable development etc which will provide a platform for UK and Indian institutions to share their ideas and models for best practice.



Contact Us:

UKIERI Secretariat-India

British Council Division

British High Commission

17, Kasturba Gandhi Marg

New Delhi 110001

Tel: +91 (0)11 41497453/7361/7336/7441

UKIERI Secretariat-UK

British Council

10 Spring Gardens



London SW1A 2BN

Tel: +44 (0)20 7389 4639

Email: ukieri@britishcouncil.org

Website: www.ukieri.org

Published in January 2014



Ministry of
Human Resource
Development (MHRD)



Llywodraeth Cymru
Welsh Government



158





KLE UNIVERSITY

(Formerly known as KLE Academy of Higher Education & Research, Belgaum)
Accredited 'A' Grade by NAAC Placed in Category 'A' by MHRD (Govt)

Office of the Registrar, KLE University,
KLE Campus, KLE Hospital, Belgaum-591 016, Karnataka State, India
Ref. No. KLE/HR-15/D-1393-15th July 2014

CIRCULAR

Sub: MoU between the KLE University and Gujarat Forensic Sciences University, Gandhinagar, Gujarat.

It is hereby informed that the KLE University has signed a Memorandum of Understanding (MoU) with Gujarat Forensic Sciences University, Gandhinagar, Gujarat on 10th July 2014. A copy of the MoU is enclosed herewith for your information.

The contents of this Circular be brought to the notice of all the faculty members, Post-Graduate students and the Research Scholars of the University.

OFFICE OF THE PRINCIPAL KLEU SHRI
B.M.K. AYURVEDA MAHAVIDYALAYA,
BELGAUM.
12⁵ JUL 2014
Inward No. 714 Sign.



Prof. Dr. V.D. Patil
Registrar

To
The Principals,
All Constituent Units,
KLE University, Belgaum.

ORE
ORE
circulate
SIB
Ch

- CC to:
1. The PA to Hon. Chancellor, KLE University, Belgaum.
 2. The Special Officer to Hon. Vice-Chancellor, KLE University, Belgaum.
 3. The Secretary, Board of Management, KLE Society, Belgaum.
 4. The Director, KLES Health Science Institutions, Belgaum.
 5. The Director, KLE University Research Foundation, Belgaum.
 6. The MD & CP, KLE Dr. PK Hospital & MRC, Belgaum.
 7. The Medical Superintendent, KLE Dr. PK Charitable Hospital, Belgaum.
 8. The University Officials.
 9. The Deputy Director, KLE Dr. PK BELASRI, Belgaum.

Copy to
Documents
Unit
DE Circulate
Ph

ATTESTED
[Signature]
Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

MEMORANDUM OF UNDERSTANDING

BETWEEN

Gujarat Forensic Sciences University

A State University under section 22 of UGC Act 1956, vide letter no. F.9-7/2013 (CPP-UPU)
Gandhinagar, Gujarat, India

AND

KLE University

A deemed University under sec 3 of the UGC Act 1956 vide
Government of India notification No. 9-19/2000-USA
Belgaum, Karnataka, India

The KLE University (KLEU), Belgaum, Karnataka, India and Gujarat Forensic Sciences University (GFSU), Gandhinagar, Gujarat, recognize the benefits to their respective Universities from the establishment of collaborations and proceed to have a memorandum of understanding (MOU). Both the independent institutions are committed to mutual and common goals of generating new knowledge towards improvement of science to betterment of the society we serve.

PREAMBLE:

KLE Society established in the year 1915, is successfully running more than 235 institutions in the field of healthcare (Medical, Dental, Pharmacy, Ayurveda, Physiotherapy and Nursing science), Information Technology, Law and many more conventional and non-conventional disciplines. Currently KLE University has been accredited A -Grade by NAAC (National Academic Accreditation Council, India)

The Government of Gujarat established Gujarat Forensic Sciences University, a super specialized University by passing an Act in the Legislative Assembly in the year 2003, which is unique and the first of its kind in the world, dedicated to only Forensic and other Investigative Sciences. The GFSU comprises of three Institutes, namely: Institute of Research & Development Institute of Forensic Science, and Institute of Behavioural Science. It currently offers only postgraduate level academic programs.

The respective Universities jointly recognize the MOU to mutually cooperate in the areas of Health Education and Research including other health sciences.

PURPOSE / OBJECTIVE

The primary purpose of this MOU is to build Academic research capacity and to promote mutual understanding between the Universities. The MOU shall formally set out the terms of co-operative relationship between the parties, establish their respective roles, and facilitate the function of each party in relation to collaborative research. Both Universities agree to develop collaborative activities in academic areas of mutual interest and as equal partners with reciprocity. All educational events are expected to reflect the faculty member's areas of research and expertise.

The development and implementation of specific activities based on this MOU shall be negotiated and agreed between individual faculty members through the Director of Hostel Department.

ATTESTED

Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

This MOU is agreed on the basis of cooperation between the Universities and includes, but is not limited to the following options


- a. Exchange of faculty members and research scholars between the Universities
- b. Exchange of students based on the projects and research needs
- c. Jointly apply for research funds to conduct collaborative research projects
- d. Conducting colloquiums
- e. Exchange of academic/research information and related materials to facilitate joint publications by collaborating faculty members
- f. Promoting any related academic activities based on mutual agreement


TERMS OF AGREEMENT

Both universities agree to carry out the above mentioned activities in accordance with laws and regulations of respective countries after full consultation and approvals.


The term of this agreement shall be valid for a period of three years commencing from the date of signature hereof. This agreement can be extended for further terms on mutual agreement. This agreement may be terminated by giving 6 months prior notice from either parties.

In witness whereof, the parties have executed this document on the day of 17th 0 JUL 2014



.....
Prof. C. Kokate
Vice Chancellor
KLE University
Belgaum, Karnataka
India


.....
Dr. J. M. Vyas
Director General
Gujarat Forensic Sciences University
Gandhinagar, Gujarat
India


Witness 1 :


.....
Registrar
KLE University
Belgaum, Karnataka
India

Witness 1 :


.....
Prof. Y.K. Agrawal
Director
Institute of R & D,
Gujarat Forensic Sciences University
Gandhinagar-382007

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI



KLE UNIVERSITY

(Formerly known as KLE Academy of Higher Education & Research, Belgaum)

Recognized as Deemed to be University under Section 3 of the UGC Act, 1956 and Government of India Notification No. 19/2009-11/16511

Accredited 'A' Grade by NAAC

Placed in Category 'A' by MHRD (Govt)

Office of the Registrar, KLE University,

NAAC Campus, Nehru Nagar, Belgaum-590 010, Karnataka State, India

Ph: 0831-2444444 FAX: 0831-2493777 Web: <http://www.kleuniversity.edu.in> E-mail: info@kleuniversity.edu.in

Ref. No. KLEU/14-15/ID-11763

22nd July 2014

CIRCULAR

Sub: MoU between the KLE University and Manipal University, Manipal.

It is hereby informed that the KLE University has signed a Memorandum of Understanding (MoU) with Manipal University, Manipal. A copy of the MoU is enclosed herewith for your information.

The contents of this Circular be brought to the notice of all the faculty members, Post-Graduate students, Course Co-ordinators of Allied Health Sciences of your Institution and Ph.D. Research Scholars of the University.

OFFICE OF THE PRINCIPAL, KLEU SHRI
D.R.K. AYURVEDA MAHAVIDYALAYA,
BELGAUM.



Prof. Dr. V.D. Patil
Registrar

To

The Principals,
All Constituent Units,
KLE University,
Belgaum.

24 JUL 2014

Inward No. 700 Sign.

UC to:

1. The PA to Hon. Chancellor, KLE University, Belgaum.
2. The Special Officer to Hon. Vice-Chancellor, KLE University, Belgaum.
3. The Secretary, Board of Management, KLE Society, Belgaum.
4. The Director, KLES Health Science Institutions, Belgaum.
5. The Director, KLE University Research Foundation, Belgaum.
6. The Professor & HoD, University Dept. of Allied Health Sciences, Belgaum
7. The MD & CE, KLE Dr. PK Hospital & MRC, Belgaum.
8. The Medical Superintendent, KLE Dr. PK Charitable Hospital, Belgaum
9. The University Officials.
10. The Deputy Director, KLE Dr. PK B&ASRC, Belgaum.

20/08/14
Srinivas
CRP
Ch
24/7/14

COPT
TO.
Document Unit
and
D: Girdhar
M

ATTESTED

[Signature]

Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

AND

KLE University, herein represented by
Registrar, KLE University,
A deemed University under (s) 3 of the UGC Act 1956 vide Government of India notification
No. 9-19/2000-U,3A
Belgaum, Karnataka, India

The KLE University (KLEU), Belgaum, Karnataka, India and Manipal University Manipal, Karnataka, recognize the benefits to their respective Universities from the establishment of collaborations and proceed to have a memorandum of understanding (MoU). Both the independent institutions are committed to mutual and common goals of generating new knowledge towards improvement of science to betterment of the society we serve.

PREAMBLE:


- KLE Society, established in the year 1916 is successfully running more than 259 institutions in the field of healthcare (Medical, Dental, Pharmacy, Ayurveda, Physiotherapy and Nursing sciences), Information Technology, Law, and many more conventional and non-conventional disciplines. Currently KLE University has been accredited A-Grade by NAAC (National Academic Accreditation Council-India).
- Manipal University is providing education, training and also conducting research in the field of Medicine, Pharmacy, Dentistry, Allied Health, Engineering, Information Sciences, Nursing, Media & communication, Management, Jewellery Management, Life Sciences, Hotel Management, Regenerative Medicine, etc.

The respective Universities jointly recognize this MoU to mutually cooperate in the area of Health Education and Research including allied health sciences.

PURPOSE / OBJECTIVE

The primary purpose of this MoU is to build academic research capacity and to promote mutual understanding between the Universities. The MoU shall formally set out the terms of co-operative relationship between the parties, establish their respective roles, and delineate the function of each party in relation to collaborative research.

Both Universities agree to develop collaborative activities in academic areas of mutual interest and as equal partners with reciprocity. All educational events are expected to reflect the faculty member's area of research and expertise.



2

ATTESTED

Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

The development and implementation of specific activities based on this MOU shall be negotiated and agreed between individual faculty members through the Deans or Heads of Department.

This MOU is agreed on the basis of cooperation between the Universities and includes, but is not limited to the following spheres:


- a. Exchange of faculty members and research scholars between the Universities.
- b. Exchange of students based on the projects and research needs.
- c. Jointly apply for research funds to conduct collaborative research projects.
- d. Conducting colloquiums.
- e. Exchange of academic/research information and related materials to facilitate joint publications by collaborating faculty members.
- f. Promoting any related academic activities based on mutual agreement.

TERMS OF AGREEMENT


Both universities agree to carry out the above mentioned activities in accordance with laws and regulations of respective countries after full consultation and approvals.

The term of this agreement shall be valid for a period of three years commencing from the date of signature hereof. This agreement can be extended for further terms on mutual agreement. This agreement may be terminated by giving 6 months prior notice from either parties.

In witness whereof, the parties have executed this document on the day of 12th July, 2016.



Dr. V. D. Patil
Registrar
KLE University
Belgaum, Karnataka
India





Dr. G. K. Prabhu
Registrar
Manipal University
Manipal, Karnataka,
India


REGISTRAR
MANIPAL UNIVERSITY
MANIPAL

Witness


Dr. B. S. Kothhany
Emeritus Professor and Director
KLE University Research Foundation,
Belgaum, Karnataka, India


Dr. N. Udupa
Professor and Research Director
School of Allied Health Science
Manipal University, Karnataka, India

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

MEMORANDUM OF UNDERSTANDING

BETWEEN



KLE University,
herein represented by

Dr. V.D.Patil,

Registrar, KLE University

A Deemed University u/s 3 of the UGC Act 1956
vide Government of India notification No.9-19/2000-U.3A
Belagavi-590010, Karnataka, India

AND



Maharashtra Institute of Medical Education and Research (MIMER)

herein represented by

Prof. Dr. Virendra Ghaisas,

Executive Director, Professor, Department of Otorhinolaryngology,
MIMER, Telegoan, Pune

ATTESTED

Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

MEMORANDUM OF UNDERSTANDING

BETWEEN



KLE
UNIVERSITY
EMPOWERING PROFESSIONALS

KLE University,
herein represented by
Dr. V.D.Patil,

Registrar, KLE University
A Deemed University u/s 3 of the UGC Act 1956
vide Government of India notification No.9-19/2000-U.3A
Belagavi-590010, Karnataka, India

AND



Maharashtra Institute of Medical Education and Research (MIMER)
herein represented by

Prof. Dr. Virendra Ghaisas,
Executive Director, Professor, Department of Otorhinolaryngology,
MIMER, Telegoan, Pune

The **KLE University (KLEU)**, Belagavi, Karnataka, India and **Maharashtra Institute of Medical Education and Research (MIMER)** recognize the benefits to their respective Universities / Institutes/Research Centres from the establishment of collaborations and proceed to have a Memorandum of Understanding (MoU). Both the independent institutions are committed to mutual and common goals of generating new knowledge towards improvement of science for the betterment of the society we serve.

PREAMBLE:

KLE Society established in the year 1916 is successfully running more than 245 institutions in the field of healthcare (Medical, Dental, Pharmacy, Ayurveda, Physiotherapy and Nursing Science), Information Technology, Law and many more conventional and non-conventional disciplines. Currently, the KLE University has been accredited with 'A' Grade by National Assessment and Accreditation Council (NAAC) and has been placed in **Category 'A'** by the Ministry of Human Resource Development (MHRD), Government of India.

K.P.L.
Prof. Dr. V.A. KOTHIWALE

Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

MIMER (Maharashtra Institute of Medical Education and Research) caters for undergraduate as well as postgraduate training programs and motto of the institution being to harness the knowledge of science and technology for the welfare of society. It has research facilities and catering all the sub-specialities of the department and especially has famed as an Rhinoplasty centre.

The respective Universities/institutes jointly recognize this MoU to mutually cooperate in the areas of Health Care, Education and Research including Life Sciences.

PURPOSE / OBJECTIVE

The primary purpose of this MoU is to build academic research capacity and promote mutual understanding between the Universities /Research establishments. The MoU shall formally set out the terms of co-operative relationship between the parties, establish their respective roles, and facilitate the function of each party in relation to collaborative research.


Both Universities/Institutes agree to develop collaborative activities in academic areas of mutual interest and as equal partners with reciprocity. All educational events are expected to reflect the faculty members' area of research and expertise.

The development and implementation of specific activities based on this MoU shall be negotiated and agreed upon between individual faculty members through the Deans or Heads of Department.

This MoU is agreed on the basis of cooperation between the University/Research Institution and includes, but is not limited to the following options.

- A. The University and the collaborator desire to provide training /education /academic collaboration for Fellowship Program in Rhinoplasty every year.
- B. The KLE University will depute one faculty and one Post Graduate Resident or as decided by the University for the Fellowship Program every year at the Collaborator Institute.
- C. Both the institutes will be jointly conducting clinical research and make national and international scientific /research publication together.
- D. HOD of ENT in the University's J.N. Medical College, Belagavi shall be the Officer Incharge for this collaboration with the Collaborator institute.

ATTESTED




Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

TERMS OF AGREEMENT


Both Universities / Institutes agree to carry out the above mentioned activities in accordance with laws and regulations of respective university/institution after full consultation and approvals.

The term of this agreement shall be valid for a period of **five** years commencing from the date of signature hereof. This agreement can be extended for further terms on mutual agreement. This agreement may be terminated by giving 6 months prior notice from either parties.

In witness whereof, the parties have executed this document by signing on the day of 2nd November 2015.




Dr. V. D. Patil
Registrar
KLE University
Belagavi, Karnataka



Prof. Dr. Virendra Ghaisas
Professor and Executive Director
Dept. of Otorhinolaryngology
MIMER, Telegoan, Pune



ATTESTED



Prof. Dr. V. A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI



JAWAHARLAL NEHRU MEDICAL COLLEGE

(A constituent unit of KLE Academy of Higher Education & Research Deemed-to-be University)

Accredited 'A' Grade by NAAC (2nd Cycle)

Placed in Category "A" by MHRD (GoI)

Nehru Nagar, Belagavi-590 010, Karnataka-India



Website : <http://www.jnmc.edu>

E-Mail : Principai@jnmc.edu

Office : +91-(0)831 2471350

FAX : +91 (0)831-2470759

Ref. No. : MOC/PG/888

Date : 03/06/2019

To,

The Administrative Officer (A&E),
National Institute of Mental Health & Neurosciences,
Bangalore-560 029.

Sub: Request for Permission to undergo training.

Ref: Letter No. NIMH:A&E:TM:TRG-NEURO :2019/194 dated 12-02-2019.

Sir,

With reference to the above, this is to bring to your kind notice that, we thank you very much for considering our request and permitting our D.M. (Neurology) students to undergo training at your institution.

However, as per your letter, students have to attend their postings during 01-03-2019 to 30-04-2019. But unfortunately we received the letter late due to postal delay. Hence we request you to kindly allot new dates to the following students of our Institution and confirm the same well in advance, and also by email to the email id principal@jnmc.edu.

So kindly consider our request and give our students future dates. Hence, we request you to kindly permit us to post the students as under.

Name of the Student	Period	Name of the Posting
1. Dr. Siddharth Singh	One month	Neurology
	15 days	Neuropathology
2. Dr. Shilpa.	15 days	Clinical Psychology (Neuropsychology)

We once again request you to kindly consider our request and allot a new dates to our above students.

Thanking you,

Yours faithfully,


PRINCIPAL,

J. N. MEDICAL COLLEGE, BELAGAVI.

Copy to : 1. The Hon'ble Vice Chancellor, National Institute of Mental Health & Neurosciences, Bangalore-560 029 for information.

2. The Professor & Head Department of Neurology, J. N. Medical College, Belagavi.

Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

**NATIONAL INSTITUTE OF MENTAL HEALTH & NEUROSCIENCES
(INSTITUTE OF NATIONAL IMPORTANCE) BENGALURU - 560 029**



NIMH:A&E:TM:TRG:NEURO:2019/857

Date: 27.06.2019

The Principal
Jawaharlal Nehru Medical College
Nehru Nagar, Belagavi - 590 010

Sir/Madam,

Sub: Request for Permission to undergo training at this institute - reg.
Ref: Your letter dated 03.06.2019

With reference to the above, I am directed to convey the permission of the Competent Authority for the students of your institute to undergo training at this Institution as follows:

1	Number of trainees	02
2	Name of the trainees	Dr. Siddharth Singh Dr. Shilpa
3	Department at which training permitted	Duration
	Neurology	01.08.2019 to 31.08.2019
	Neuropathology	01.02.2020 to 15.02.2020
	Clinical Psychology (Neuropsychology)	01.09.2019 to 15.09.2019
4	Training fee	Rs.10,000/- per month or part thereof per trainee

Note: Permission is subject to written assurance by Director/Dean/Principal/HOD of the above mentioned college/university that all the students who are posted will attend activity/duties of Neurology department everyday as per the timings of the department and will not take any planned leave during the period of posting.

- The trainees should compulsorily carry their college ID cards while posted at NIMHANS.
- One stamp size photo should be given at the time of joining for issue of temporary ID card. (ID card should be returned at the end of training without fail)
- Trainees should carry a copy of this letter without fail.
- **The training fee for the whole duration of training has to be paid by Debit/Credit Card on the day of joining. The training fee once paid will not be refunded.**

I am also directed to inform you that the visiting students/trainees should make their own arrangement for accommodation. However all efforts will be made to provide hostel accommodation, but this will be subject to availability, based on Manager, Hostel report (080-26995095)/Supervisor, Cauvery Hostel, (080-26995092) as on the date of joining and on payment of charges as below, Accommodation will not be provided to the candidates coming earlier than the scheduled date of training.

1. Hostel Rent: Rs.100/- per day

NOTE: *In case of any damage of assets/property in the Hostels i.e., movable and immovable property of NIMHANS by the trainees, the college shall be directly responsible for such act of the trainees. The loss incurred has to be borne by the Institution/College deputing the trainees. Further, the attendance certificate for training of such trainees will be withheld.*

On arrival, the trainees must contact the undersigned for further needful.

Yours faithfully,

[Signature]
ADMINISTRATIVE OFFICER (A&E)
Administrative Officer (A & E)
National Institute of Mental Health &
Neuro Sciences, Bengaluru - 560 029

Copy to: The HOD of Neurology, NIMHANS
The HOD of Neuropathology, NIMHANS
The HOD of Clinical Psychology, NIMHANS
The Manager/Supervisor, NIMHANS Hostels, NIMHANS




K.L.E. ACADEMY OF HIGHER EDUCATION AND RESEARCH
(Deemed - to -be -University)

Jawaharlal Nehru Medical College

Nehrunagar, Belgaum, Karnataka. INDIA. 590010

DEPARTMENT OF NEUROLOGY

Phone: 0831-2473777 ext:1388; 0831-2409-1388



J.N.M.C./ Neurology /2018

Date: 01/06/2018

To,

The Principal
JN Medical College,
Belagavi.

Respected Madam,

Sub: External posting to NIMHANS,

The DM Neurology residents who are admitted in this academic year need to be posted to NIMHANS, Bengaluru for additional training as per the University syllabus.

- | | |
|------------------------------|-----------|
| 1) Neurology | One month |
| 2) Neuropathology | 15 days |
| 3) Neuropsychology (MH & SP) | 15 days |

Name of the students

1. Dr. Manoj Kumar
2. Dr. Preeti Komireddy

I request you to kindly communicate to the Vice Chancellor, NIMHANS, Bengaluru for allotting the time slot for the posting.

Thanking you,

Yours truly

PRINCIPAL AND HEAD OF THE
DEPT. OF NEUROLOGY
J. N. MEDICAL COLLEGE,
BELGAUM-590010

RECEIVED

Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI



JAWAHARLAL NEHRU MEDICAL COLLEGE



(A constituent unit of KLE Academy of Higher Education & Research Deemed-to-be-University)
Accredited 'A' Grade by NAAG (2nd Cycle) Placed in Category "A" by MHRD (Govt)
Nehru Nagar, Belagavi-590 010, Karnataka-India.

Website : <http://www.jnmc.edu>
E-mail : principal@jnmc.edu

Office : +91 (0) 831 2471350
Fax : +91 (0) 831 2470759

Ref: MDC/PG/ 805

Date: 11-6-2018

To,
The Vice Chancellor,
National Institute of
Mental Health & Neurosciences
Post Box No.2900, Hosur Road,
BANGALORE - 560029.

Sub : Deputation for training of D.M. (Neurology) student.

Sir,

With reference to the above subject, the D.M. (Neurology) course students admitted in this college for the academic year 2016-17, have to undergo training as shown below for external postings at NIMHANS, Bangalore.

The posting allotted to our students at your institution as detailed below as per the request letter receive from the Head of the Department of Neurology of our college (copy enclosed).

Name of the Students	Name of the Postings	Period
1. Dr.Komireddy Preeti Reddy	Neurology	One Month
2. Dr.Manoj Kumar	Neuropathology	15 Days
	Neuropsychology (MH & SP)	15 Days

I request you to inform us the month in which we have to post our above said students to your institution for the said postings.

Kindly acknowledge the same and do the needful.

Thanking you,

Yours faithfully,

PRINCIPAL,
J. N. MEDICAL COLLEGE, BELAGAVI.

Copy to: The Head of the Department of Neurology, J.N. Medical College,
Belagavi, for information.

ATTESTED

Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

**NATIONAL INSTITUTE OF MENTAL HEALTH & NEUROSCIENCES
(INSTITUTE OF NATIONAL IMPORTANCE) BENGALURU - 560 029**



NIMH:A&E:TM:TRG-NP:2018/1038

Office of the
J. N. MEDICAL COLLEGE
BELAGAVI
06 OCT 2018
Inward.....
Sign.....

Date: 29.09.2018

The Principal
Jawaharlal Nehru Medical College,
Nehru Nagar
Belagavi - 590 010.

Sir/Madam,

Sub: Request for Permission to undergo training at this institute - reg.
Ref: Your letter dated 25.08.2018

With reference to the above, I am directed to convey the permission of the Competent Authority for the student/students of your Institution to undergo training at this Institution as follows:

1	Number of trainees	02(Two) - PG students
2	Name of trainees	Dr.K.Precty Reddy and Dr.Manoj Kumar
3	Training fee	Rs. 10000/- per month or part thereof per trainee
	Department of Neurology	01.01.2019 to 31.01.2019
	Department of Neuropathology	01.02.2019 to 15.02.2019
	Department of Psychology (Neuropsychology)	16.02.2019 to 28.02.2019

- The trainees should compulsorily carry their college ID cards while posted at NIMHANS.
- One stamp size photo should be given at the time of joining for issue of temporary ID card. (ID card should be returned at the end of training without fail)
- Trainees should carry a copy of this letter without fail.

The Training fee for the whole duration of training has to be paid by Cash Debit/Credit Card on the day of joining. The Training fee once paid will not be refunded.

I am also directed to inform you that the visiting students/trainees should make their own arrangement for accommodation. However all efforts will be made to provide hostel accommodation, but this will be subject to availability, based on Manager, Hostel report-(080-26995095)/Supervisor, Cuvvery Hostel, (080-26995092), as on the date of joining and on payment of charges as below. Accommodation will not be provided to the candidates coming earlier than the scheduled date of training.

1. Hostel Rent: Rs.100/- per day

NOTE: In case of any damage of assets/property in the Hostels i.e., movable and immovable property of NIMHANS by the trainees, the college shall be directly responsible for such act of the trainees. The loss incurred has to be borne by the Institution/College deputed the trainees. Further the attendance certificate for training of such trainees will be withheld.

On arrival, the trainee must contact the undersigned for further needful.

Yours faithfully

Rev. A. S. M.
ADMINISTRATIVE OFFICER(A&E)

Administrative Officer (A & E),
National Institute of Mental Health &
Neuro Sciences, Bangalore - 560 029

Copy to: The HOD of Neuropathology, NIMHANS
The HOD of Neurology, NIMHANS
The HOD of Clinical Psychology, NIMHANS
The Manager/Supervisor, NIMHANS Hostels

ATTESTED:

☎: 08026995015

Email: training@nimhans.ac.in

Website: <http://www.nimhans.ac.in>

V.A. Kothiwale
Prof. Dr. V.A.KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI



K.L.E. University's
Jawaharlal Nehru Medical College / 48
Nehrunagar, Belgaum, Karnataka. INDIA. 590010
DEPARTMENT OF NEUROLOGY

Phone: 0831-2473777 ext.1388; 0831-2409-1388

18/04/17

J.N.M.C / Neurology /2017

Date: 18/04/2017

To,

The Principal
JN Medical College,
Belagavi

Respected Madam,

Sub: External posting of DM Neurology students to NIMHANS

Ref: NIMH: ACA-B:TRG - NP: 2017/302 dt 05/04/2017

The DM Neurology students' posting to NIMHANS was requested recently. I am in receipt of the forwarded letter from NIMHANS dated 05/04/2017. As per the letter students one posted in three sessions of (two of 15 days and one of 30 days) and the first session starting on 16/04/2017. This become rather impractical in view of logistics of the postings and the students attending the posting. I request you to the NIMHANS authorities for modification of the postings as listed below:

From	To	Postings
01.01.2018	31.01.2018	Neurology
01.02.2018	15.02.2018	Neuropathology
16.02.2018	28.02.2018	Neuropsychology

Thanking you,

Yours truly

Sanjay Marawar

[Signature]
PROF. AND HEAD OF THE
DEPT. OF NEUROLOGY
J. N. MEDICAL COLLEGE,
BELGAUM-590010

ATTESTED

[Signature]
Prof. Dr. V.A.KOTHIWALE

Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

**NATIONAL INSTITUTE OF MENTAL HEALTH & NEUROSCIENCES
(INSTITUTE OF NATIONAL IMPORTANCE) BENGALURU - 560 029**




NIMH:ACA-B:TRG-NP:2017/302

Date: 05.04.2017

The Principal
JN Medical College
Nehru Nagar
Belagavi - 590 010

Sir/Madam,



Sub: Request for Permission to undergo training at this institute - reg.
Ref: Your letter dated 11.03.2017

With reference to the above, I am directed to convey the permission of the Competent Authority for the student/students of your Institution to undergo training at this institution as follows:

1	Number of trainees	02(Two)
2	Name of Trainees	Dr. Shah Naman Mahesh & Dr. Torat Ninad Nandkumar
3	Training fee	Rs. 5000/- per month per trainee or part thereof
4	Dept. of Clinical Psychology (Neuropsychology)	16.04.2017 to 30.04.2017
	Department of Neurology	01.06.2017 to 30.06.2017
	Department of Neuropathology	01.02.2018 to 15.02.2018

- The trainees should compulsorily carry their college ID cards while posted at NIMHANS.
- One stamp size photo should be given at the time of joining for issue of temporary ID card. (ID card should be returned at the end of training without fail)
- Trainees should carry a copy of this letter without fail.
- *The request letter (hard copy or soft copy of scanned letter) should reach the undersigned one month in advance to enable this office to process your request. Letters received with a shorter time span will not be entertained. Students coming with request letter without prior permission will not be entertained. Any queries related to training/visit, please call on working days between 2:30 pm to 4:00 pm only on 080-26995015.*
- The Training fee for the whole duration of training has to be paid by Debit/Credit Card on the day of joining. The Training fee once paid will not be refunded.

I am also directed to inform you that the visiting students/trainees should make their own arrangement for accommodation. However all efforts will be made to provide hostel accommodation, but this will be subject to availability as on the date of joining and on payment of charges as below:-

1. <u>Hostel Rent:</u> Rs.100/- per day	2. <u>Caution Money Deposit:</u> Rs.1000/- (refundable)
---	---

Further, allotments, payment, check-outs, refunds and other official transactions are possible only on working days between 10 am to 3 pm. Accommodation will not be provided to the candidates coming earlier than the scheduled date of training.

On arrival, the trainees must contact the undersigned for further needful.

Yours faithfully

Kenathi Bala

ASST. ADMINISTRATIVE OFFICER (A&E)

Copy to: The HOD of Neuropathology, NIMHANS
The HOD of Neurology, NIMHANS
The HOD of Clinical Psychology, NIMHANS
Asst. Administrative Officer (A & E)
National Institute of Mental Health &
Neuro Sciences, Bangalore-560 029

☎ : 08026995015

Email: academic@nimhans.ac.in
Prof. Dr. V.A. KOTHIWALE

Website : <http://www.nimhans.ac.in>

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI



Accredited 'A' Grade by NAAC



K.L.E. UNIVERSITY'S

Placed in Category 'A' by MHRD (Govt)

JAWAHARLAL NEHRU MEDICAL COLLEGE

NEHRU NAGAR, BELAGAVI-590 010. KARNATAKA, INDIA.



website: <http://www.jnmc.edu>
e-mail: principal@jnmc.edu

☎ : +91-(0)831 Office : 2471350
☎ : +91-(0)831 Fax : 2470759

Ref: MDC/PG/214

Date: 18-4-2017.

To,

The Vice Chancellor,
National Institute of
Mental Health & Neurosciences
Post Box No.2900, Hosur Road,
BANGALORE - 560029.

Sub: Permission to Modification of Postings.


Sir,

With reference to your office letter No.NIMH:ACA-B:TRG-NP:2017/302 dated 5-4-2017, I request your kindness to Modify the postings allotted to our students at your institution as detailed below as per the request letter received from the Head of the Department of Neurology of our college (Copy enclosed).

From	To	Name of the Postings
1-1-2018	31-1-2018	Neurology
1-2-2018	15-2-2018	Neuropathology
16-2-2018	28-2-2018	Neuropsychology

Kindly acknowledge the same and do the needful.

Thanking you,


Yours faithfully,



PRINCIPAL,

J. N. MEDICAL COLLEGE, BELAGAVI.

Copy to: 1. The Asst. Administrative Officer (A&E), National Institute of Mental Health & Neurosciences Post Box No.2900, Hosur Road, BANGALORE - 560029, for information and with a request to do the needful.

2. The Head of the Department of Neurology, J.N. Medical College, Belagavi, for information.

ATTESTED


Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI


NATIONAL INSTITUTE OF MENTAL HEALTH & NEUROSCIENCES
(INSTITUTE OF NATIONAL IMPORTANCE) BELAGAVI - 580 029



NIMH/ACA-B/TRG-NP:2017/456

Date: 08.05.2017

The Principal
 JN Medical College
 Nehru Nagar
 Belagavi - 590 010
 Email: principal@jnm.edu
 Sir/Madam,



Sub: Request for Permission to undergo training at this institute - reg.
 Ref: Your letter dated 11-03-2017 18/04/17

With reference to the above, I am directed to convey the permission of the Competent Authority for the student/students of your Institution to undergo training at this Institution as follows:

1	Number of trainees	02(Two)
2	Name of Trainees	Dr.Shah Naman Mahesh & Dr.Torat Ninad Nandkumar
3	Training fee	Rs.5000/- per month or part thereof per trainee
4	Dept.of Neurology	01.01.2018 to 31.01.2018
	Department of Neuropathology	01.02.2018 to 15.02.2018
	Dept. of Clinical Psychology (Neuropsychology)	16.02.2018 to 28.02.2018

- The trainees should compulsorily carry their college ID cards while posted at NIMHANS.
- One stamp size photo should be given at the time of joining for issue of temporary ID card. (ID card should be returned at the end of training without fail)
- Trainees should carry a copy of this letter without fail.
- The Training fee for the whole duration of training has to be paid by Debit/Credit Card on the day of joining. The Training fee once paid will not be refunded.

I am also directed to inform you that the visiting students/trainees should make their own arrangement for accommodation. However all efforts will be made to provide hostel accommodation, but this will be subject to availability as on the date of joining and on payment of charges as below:-

1. <u>Hostel Rent:</u> Rs.100/- per day	2. <u>Caution Money Deposit:</u> Rs.1000/- (refundable)
---	---

Further, allotments, payment, check-outs, refunds and other official transactions are possible only on working days between 10 am to 3 pm. Accommodation will not be provided to the candidates coming earlier than the scheduled date of training.

On arrival, the trainees must contact the undersigned for further needful.

Yours faithfully

Renukesh
 ASST.ADMINISTRATIVE OFFICER (A&E)


Copy to: The HOD of Neuropathology, NIMHANS
 The HOD of Neurology, NIMHANS
 The HOD of Clinical Psychology, NIMHANS
 Asst. Administrative Officer (A & E)
 National Institute of Mental Health &
 Neuro Sciences, Bangalore-580 029

ATTESTED

[Signature]
 Prof. Dr. V.A.KOTHIWALE
 Registrar
 KLE Academy of Higher Education
 and Research, BELAGAVI



Olc



K.L.E. University's
Jawaharlal Nehru Medical College

Nehrunagar, Belgaum, Karnataka. INDIA. 590010

DEPARTMENT OF NEUROLOGY

Phone: 0831-2473777 ext 1388; 0831-2409-1388

J.N.M.C / Neurology /2016

Date: 04/08/2016

To,

The Principal
JN Medical College,
Belagavi

Respected Madam,

Sub: External posting to NIMHANS,

The DM Neurology residents who are admitted in this academic year need to be posted to NIMHANS, Bangalore for additional training in the following specified fields as per the University syllabus.

- | | |
|------------------------------|-----------|
| 1) Neurology | One month |
| 2) Neuropathology | 15 days |
| 3) Neuropsychology (MH & SP) | 15 days |

Name of the students

1. Dr. Naagbushan Hesarur
2. Dr. Aditya Kulkarni

I request you to kindly communicate to Vice Chancellor, NIMHANS, Bangalore for allotting the time slot for the posting.


Thanking you,

Yours truly

PROF. DR. V.A. KOTHIWALE OF THE
DEPT. OF NEUROLOGY
J.N.M. MEDICAL COLLEGE,
ATTESTED

Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

**NATIONAL INSTITUTE OF MENTAL HEALTH & NEUROSCIENCES
(INSTITUTE OF NATIONAL IMPORTANCE) BENGALURU 560 029**



No.NIMH:ACA-B:TRG-NP/2016/905

Date: 23.09.2016

The Principal
Jawaharlal Nehru Medical College
Nehru Nagar
Belgaum - 590 010

Sir,

Sub: Request for permission to undergo training at this Institute - reg.
Ref: Your letter dated 05.08.2016

With reference to the subject cited above, I am directed to convey the permission of the Competent Authority for **Dr.Nagabushan Hesarur and Dr.Kulkarni Aditya Prakash -DM Neurology students** of your Institution to undergo training in the departments of Neurology, Clinical Psychology and Neuropathology of this Institute for the period mentioned below, subject to making payment of Rs.5000/- per month or part thereof per trainee towards training fee.

Department of Neurology	- 01.03.2017 to 31.03.2017
Department of Neuropathology	- 01.04.2017 to 15.04.2017
Department of Clinical Psychology	- 16.04.2017 to 30.04.2017

The training fee for the whole duration of training has to be paid by cash on the day of joining. The training fee once paid will not be refunded at any cost


I am also directed to inform you that the visiting students/trainees should make their own arrangement for accommodation. However efforts will be made to provide hostel accommodation only in Men's Hostel for Men and Cauvery Hostel for Women, but this will on payment of charges as below:-

Hostel Rent	- Rs.100/- per day
Caution Money Deposit	- Rs.1000/- (refundable)

Further, allotments, payment, check-outs, refunds and other official transactions are possible only on working days between 10 am to 3 pm.


- On arrival, the trainees must contact the undersigned for further needful along with photo copy of this letter.

Yours faithfully


ASST.ADMINISTRATIVE OFFICER (A&E)

Copy to: The HOD of Neuropathology, NIMHANS
The HOD of Neurology, NIMHANS
The HOD of Clinical Psychology, NIMHANS

☎ : 26995012, 26995013, 26995014, 26995015. Email: academic@nimhans.kar.nic.in
Fax : 91-80-26564830, 91-80-26562121. Website : <http://www.nimhans.kar.nic.in>


Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI



KLE UNIVERSITY'S
JAWAHARLAL NEHRU MEDICAL COLLEGE,
NEHRU NAGAR, BELGAUM-590 010, KARNATAKA, INDIA.
Accredited 'A' Grade by NAAC

☎ : 0831-2471350 / 2471701 ■ website: http://www.jnmc.edu ■ Fax : 0831-2470759 ■ E-mail : principal@jnmc.edu

Ref. No : NMC/PG/16SD.

Date : 5/8/2016.

To,

The Vice Chancellor,
National Institute of
Mental Health & Neurosciences
Post Box No.2900, Hosur Road;
BANGALORE - 560029.

Sub: Deputation for training of DM Neurology Students.

Sir,

With reference to the above subject, I am deputing following students of D.M.(Neurology) course of our college to undergo training in the following departments of your institution for the period shown as below:

Name of the Students	Name of the Departments	Period
1. Dr. Nagabushan Hesarur	Neurology	30 Days
2. Dr. Kulkarni Aditya Prakash	Neuropathology	15 Days
	Neuropsychology (MH & SP)	15 Days

I request you to kindly accord your permission to undergo training of our above students in your institution.

Thanking you,


Yours faithfully,


PRINCIPAL,

J. N. MEDICAL COLLEGE, BELAGAVI.

Copy to: The Head of the Department of Neurology, J.N. Medical College,
Belagavi, for information.

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

Principal

From: academic@nimhans.ac.in on behalf of Academic Section NIMHANS
<academic@nimhans.ac.in>
Sent: Monday, September 26, 2016 9:45 AM
To: principal@jnmc.edu
Subject: Order Letter for Dr. Nahabhushan Hesarur and Dr. Kulkarni Aditya Prakash to undergo training in NIMHANS
Attachments: jnmc belgaum.pdf

Sir/ Madam,

Please find attached the order letter for Dr. Nagabhushan Hesarur and Dr. Kulkarni Aditya Prakash, DM Neurology Students of your institution, to undergo training in the Departments of Neurology, Clinical Psychology and Neuropathology, NIMHANS, Bengaluru, from 01.03.2017 onwards.

Regards,

AAO (A &E),
NIMHANS, Bengaluru-29.

Office of the
J. N. MEDICAL COLLEGE
BELGAUM
26 SEP 2016
1429
Neurology Dept
Signature

1
ATTESTED

[Signature]

Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI



सत्यमेव जयते


INDIA NON JUDICIAL Government of Karnataka

e-Stamp






Certificate No.	: IN-KA139027537715940
Certificate Issued Date	: 08-Mar-2016 03:06 PM
Account Reference	: NONACC (BK)/ kakscub08/ BELGAUM2/ KA-BL
Unique Doc. Reference	: SUBIN-KAKAKSCUB08770294634118560
Purchased by	: SANKALP INDIA FOUNDATION
Description of Document	: Article 37 Note or Memorandum
Description	: MOU
Consideration Price (Rs.)	: 0 (Zero)
First Party	: SANKALP INDIA FOUNDATION
Second Party	: KLE UNIVERSITY JNMC BELAGAVI
Stamp Duty Paid By	: SANKALP INDIA FOUNDATION
Stamp Duty Amount(Rs.)	: 100 (One Hundred only)

Issued By
The Belgaumi District Revenue
Employees Co-operative Bank
Ltd. Belgaum


Authorised Signature



Memorandum of Understanding and Cooperation between
Sankalp India Foundation,
Bangalore-India, KLE University's Jawaharlal Nehru Medical
College, Belgaum-India &
KLE's Dr. Prabhakar Kore Hospital & Medical Research Centre,
Belgaum-India

MoU between Sankalp India Foundation, Jawaharlal Nehru Medical College and KLE's Prabhakar Kore Hospital & Medical Research Centre - February 2016 page 1

ATTESTED



K.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI


Statutory Alert:

1. The authenticity of this Stamp Certificate should be verified at the Registrar's Office, Belgaum.

PARTIES

This document constitutes an agreement between the Sankalp India Foundation (SIF, www.sankalpindia.org) Bangalore-India, represented by its President Lalith Parmar. KLE University's represented by Registrar Dr. V D Patil, Jawaharlal Nehru Medical College, Belgaum-India (JNMC) represented by Principal Dr. (Mrs) N S Mahantashetti, KLE's Prabhakar Kore Hospital & Medical Research Centre, Belgaum - India, represented by Its Dr. M V Jali, Medical Director & Chief Executive Officer and Co-ordinator for the project Dr. (Mrs) S M Jali, Professor of Pediatrics, J N Medical College, Belagavi.

This agreement expresses a convergence of will between the parties, indicating an intended common line of action.



MOU between Sankalp India Foundation, Jawaharlal Nehru Medical College and KLE's Prabhakar Kore Hospital & Medical Research Centre - February 2016 page 1

ATTESTED





Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

Article 1. Purpose

Sankalp India Foundation (SIF) is an apolitical, voluntary, non-profit secular organization working for the cause of voluntary blood donation and better healthcare to the needy since 23rd May 2003. The organization has been helping people who are in need of blood in emergencies, networking blood banks and providing access to safe blood through a single helpline number (9480044444), supporting the blood banks with voluntary blood donation drives, organizing workshops and seminars for the purpose of betterment of the blood banking facilities in the state of Karnataka and providing systematic care and management for the treatment of thalassemia and related hemoglobinopathies in its 2 day care centres in Bangalore. Eligible children are also being offered permanent cure through Bone Marrow Transplantation.

Jawaharal Nehru Medical College is a constituent **medical school** of KLE's University. The college was earlier affiliated to the state unitary **Rajiv Gandhi University of Health Sciences**. The college has been adjudged among the top twenty medical schools in the country as per a questionable national survey done in year 2007. The college has a 1200-bed free charitable block as well as the 1000-beds **KLE Society's Prabhakar Kore Hospital and Medical Research Centre** on campus.

The hospital provides state of the art healthcare facilities in multiple domains on par with national and international standards. The hospital has shown a service oriented mindset and has a good academic and professional blend thanks to the associated medical college. It is currently a 2200 bedded hospital that envisages and yearns to provide the most comprehensive medical care for the entire region of North Karnataka and has constantly evolved and adapted itself to the current disease management systems.



MoU between Sankalp India Foundation, Jawaharal Nehru Medical College and KLE's Prabhakar Kore Hospital & Medical Research Centre - February 2016 page 3




Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

Whereas SIF has initiated a project to support a "Thalassemia Day Care Centre" at K.L.E Hospital for streamlining both care and treatment of the children who are receiving treatment for Thalassemia by providing necessary resources and expertise in term of technology, protocols, training by professionals and patient support on a case to case basis. Article 2.

Commitments

SIF will commit to provide professional, technical assistance leading to prevention, management and cure of thalassemia major with the following components. Help with specialist lab resources and financial support to patients shall be enabled on a case to case basis:

- 1. Professional assistance and capacity building:** Sankalp India Foundation (S.I.F.) will provide a professional assistance to get the unit started, organize for the training and capacity building of the staff, providing necessary protocols, treatment plans and access to experts in the field. S.I.F. will organize a training program and academic interactions which will be conducted by experts with relevant experience for the staff.
- 2. Provide Technology Platform:** SIF will provide an online application - ThalCare which will enable effective tracking of the patients and the treatment being offered to them. The system will ensure that team from KLE's Hospital and Sankalp India Foundation will have all information relating to the activities around day care centre accessible to them. ThalCare is an internationally recognized award winning platform for better management of Thalassemia Major.



ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

3. **Financial and Resource Assistance to Patients:** Financial assistance shall be provided on a case to case basis. The following shall be the guiding principles.

- o The organization will provide limited and selective access to chelation therapy and external or internal lab investigations. The price sheet for lab investigations is mentioned in Appendix A.
- o The organization will also provide access to consultation with experts outside the institute wherever necessary.

4. **Blood Donation Drives:** Sankalp India Foundation will organize more voluntary blood donation drives for KLE Hospital Blood Bank on need basis.


5. **Thalassemia Prevention:** S.I.F. will assist the prevention of Thalassemia by supporting Antenatal screening.

6. **Thalassemia Cure:** S.I.F. will assist in enabling Thalassemia cure to the patients in the following ways.

- o S.I.F. will organize for the identification of children who are eligible for BMT by offering HLA typing.
- o S.I.F. will enable capacity building of the medical team for pre- and post-transplant management of the patients undergoing bone marrow transplantation.


Whereas JNMC by its staff has interest to collaborate with SIF to realize the project as above described, with the following actions:

1. **Physical Setup and Personnel:** The medical college should setup the day care center for thalassemia and provide the equipment and personnel for it. The physical facility must be of exclusive use by the patients who come to seek treatment for thalassemia at the hospital.



MOU between Sankalp India Foundation, Jawaharlal Nehru Medical College and KLE's Prabhakar Kore Hospital & Medical Research Centre - February 2016 page 5

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

2. **Training, Capacity Building and Professional Collaboration:** Participate in onsite and offsite training and capacity building programs for the staff. Participate in reviews, studies and analysis of performance of the centre in order to foster learning and sharing of best practices. Use the technology available to the institute to seek and leverage international expertise for better management and cure for thalassemia. Also contribution to the continuing update of protocols, recommendations and training material will be a good value addition to thalassemia management as a whole.
3. **Patient Selection:** Enroll patients in the day care center with no discrimination of caste, creed, religion, sect, language, origin, financial status, physical disability, etc. into the program.
4. **Prevention of Thalassemia:** Organize for the screening of thalassemia for the 'at risk' families and enable counseling of parents on pre-natal screening.
5. **Multi Center Studies:** Will participate in multi center studies for Thalassemia. One doctor from hospital will be represented in every paper published through these studies.

Whereas KLE by its staff has interest to collaborate with SIF to realize the project as above described, with the following actions:

1. **Service:** Provide free blood products (double saline washed and leuko depleted) and transfusions. Lab investigations (CBC, Biochemistry, Ferritin etc.) on not for profit basis the cost of which will be reimbursed by SIF on monthly basis. The rate card for lab tests is mentioned in Appendix A.


Article 3. Duration

The Agreements will take effect at its signing and will remain so for two years. The parties by common consent may extend the duration of the collaboration by a new written agreement.



Mol) Between Sankalp India Foundation, Jawaharlal Nehru Medical College and KLE's Prabhakar Kore Hospital & Medical Research Centre - February 2016 page 6

ATTESTED


 Prof. Dr. V.A. KOTHIWALE
 Registrar
 KLE Academy of Higher Education
 and Research, BELAGAVI

Article 4. Place of jurisdiction and applicable law

The exclusively place of Jurisdiction will be India.

Article 5: Data and Treatment Protocols

All medical data generated at the Center shall be jointly owned by KLE's team and Sankalp India Foundation in this agreement.

Any publications in science or medical journals with respect to the Center and the treatments being provided therein; where authored by KLE University's Jawaharlal Nehru Medical College shall be subject to final review by Sankalp prior to submission. Further, Sankalp or persons identified by Sankalp shall be named as co-authors on all such publications. Similarly, similar publication by Sankalp with reference to the Center shall be subject to final review by KLE University's Jawaharlal Nehru Medical College prior to submission and KLE's team or such persons identified by KLE's team shall be named as co-authors on any such publications.

AGREEMENT

IN WITNESS WHEREOF, the parties hereto have authorized their officers or representatives, the underlying signatories, to execute and bind the parties to this Agreement as of the Effective Date.

<p>Sankalp India Foundation</p> <p>Lalith Parmar President Bangalore- India Date: 8/3/2016</p>	<p>KLE University, Belagavi</p> <p>Dr. V D Patil Registrar, KLE University, Belgaum Date: 8/3/16</p> <p>Prof. (Dr.) V.D. PATIL, Registrar KLE UNIVERSITY BELAGAVI</p>
<p>KLE's Prabhakar Kore Hospital & M R C</p> <p>Dr. M V Jali Medical Director & Chief Executive KLE's Dr. Prabhakar Kore Hospital & Medical Research Centre, Belagavi. Date:</p>	<p>Jawaharlal Nehru Medical College</p> <p>Dr. (Mrs) N S Mahantashetti Principal J.N. Medical College, Belgaum Date: 8/3/16</p> <p>PRINCIPAL Jawaharlal Nehru Medical College BELGAUM,</p>
<p>Project Co-ordinator</p> <p>Dr. (Mrs) S M Jali Project Co-ordinator Date: 8/3/16</p> <p>Professor Department of Pediatrics KLE University's J.N. Medical College, Belagavi</p>	

MOU between Sankalp India Foundation, Jawaharlal Nehru Medical College and KLE's Prabhakar Kore Hospital & Medical Research Centre - February 2016, page 7

[Signature]

[Signature]

[Signature]






[Signature]

Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

APPENDIX A






TESTS	PRICING (INR Per Test)
CBC	FREE
Ferritin	INR 250 – INR 450
Biochemistry	FREE
Total Protein, ALB, ALP, Ionised Calcium, SDB and SIB	INR 310
Serology	FREE
Thyroid Baseline Profile	INR 250 – INR 450
Testosterone	INR 460
LH	INR 350
FSH	INR 350
GH	INR 560
Estrogen	INR 460
MRI (Liver and Cardiac)	INR 4000
Echo	INR 1250
ECG	INR 150
Dexa Scan	Whole Body: INR 2300 Lt Femur : INR 950 Rt Femur: INR 950 Spine: INR 950

MoU between Sankalp India Foundation, Jawaharlal Nehru Medical College and KLE's Prabhakar Kore Hospital & Medical Research Centre – February 2016 Page 8

Prof. Dr. V.A.KOTHIWALE
 Registrar
 KLE Academy of Higher Education
 and Research, BELAGAVI

	Rt for ARM: INR 950 Lt for ARM: INR 950
X Ray	INR 230
Abdominal Sonogram	INR 550

ATTESTED



Prof. Dr. V.A.KOTHIWALE
 Registrar
 KLE Academy of Higher Education
 and Research, BELAGAVI

MEMORANDUM OF UNDERSTANDING

KLE UNIVERSITY, BELGAUM

WITH

GSR Institute of Craniomaxillofacial and Facial Plastic Surgery,
17-1-383/55, Vinay nagar colony,
I.S.Sadan, Saidabad,
Hyderabad 500059
Telangana,India.

From 2015-2020

ATTESTED



Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

For

TRAINING POST GRADUATES IN CLEFT AND CRANIOFACIAL SURGERY IN
COLLABORATION WITH GSR INSTITUTE OF CRANIOMAXILLOFACIAL AND
FACIAL PLASTIC SURGERY

MEMORANDUM OF UNDERSTANDING

This memorandum of understanding (this 'Understanding') is executed on 1st October 2013 by and between

KLE University, established u/s 3 of the UGC Act, 1956 having its registered offices at 'JNMC Campus, Nehru Nagar, Belgaum- 590 010, Karnataka (hereinafter referred to as 'the University' which expression shall, unless repugnant to the subject or context thereof, be deemed to include and mean its nominees, successors and permitted substitutes or assigns) of the ONE PART:


With

GSR Institute of Craniomaxillofacial and Facial Plastic Surgery, 17-1-383/55, Vinay nagar colony, I.S.Sadan, Saidabad, Hyderabad 500059 Andhra Pradesh, India a premier hospital and Institute. (Hereinafter referred as 'GSR Institute', which expression shall, unless repugnant to the subject or context thereof, be deemed to include and mean its nominees, successors and permitted substitutes or assigns) on another PART either or both of which may be referred to as a 'Party' or the 'Parties', respectively as the context demands.

WHEREAS

- A. The university desires to provide training and education in the field of Craniomaxillary and Facial Plastic Surgery. The training for the postgraduates will be for a duration of 1 to 2 month during their 3rd year of Post graduation

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

- b. KLE University is committed to promote & develop higher education and impart education & qualification in the medical technology. The University has conceded to GSR Institute on the terms and subject to the conditions container herein.
- c. Based on the complementary strengths of the University and GSR Institute, the University is desirous of collaborating with GSR Institute, which would provide education, research and training to the postgraduates

NOW THIS MOU WITNESSES AS FOLLOWS THE ROLES AND RESPONSIBILITIES OF EITHER PARTY

Roles and Responsibilities of the University:

The University & GSR Institute will collaboratively arrange for the training to be conducted at GSR Hospital based at Hyderabad, India by faculty that includes Dr S M Kotrashetti, Professor, Department of Oral & Maxillofacial Surgery, in-house faculty, and the surgical faculty of GSR Hospital, Hyderabad.

1. The University & GSR Institute appoint Dr S M Kotrashetti and Dr Gosla Reddy as Course Coordinators in order to facilitate proper coordination between the University and GSR Institute covering all aspects training. Dr S M Kotrashetti will be permitted to travel to GSR Institute for Coordinating and training on need basis not more than 40 days in a year by the KLE University
2. Faculty of the Department of Oral & Maxillofacial Surgery, KLE VK Institute of Dental Sciences can also visit and train in the GSR Institute with prior permission from the KLE University and GSR Institute
3. All students shall be governed by the academic regulation framed by the University, which shall be provided by the University to the students at the start of the Course.
4. The GSR Institute shall arrange to provide a certificate of completion of training for the students. Assessment of the students shall be solely carried out by the University.
5. The University shall maintain both in physical as well as in an electronic format (wherever possible or available) the details, (including academic records) of all students enrolled for the training and shall provide the same to KLE University on request.

Roles and Responsibilities of GSR Institute:

1. GSR Institute shall ensure necessary facilities are provided for surgical training
2. GSR Institute undertakes to strictly follow the Course Curriculum and the teaching plan approved by the University.

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

Team Termination and Liability:

This understanding shall come into force and take effect from the date first written above and shall be valid for a period of five (5) years and may be renewed thereafter by the parties upon mutual consent.

This understanding may be terminated by either party by providing 60 (Sixty) days written notice to the other party before the beginning of the academic year, and the termination would be effective at the end of the notice period.

Any termination of the Understanding shall be on the understanding that students who have already enrolled in any of the courses as at the date of termination shall remain entitled to complete their respective training. The obligation of the parties shall continue to be in force during such period, notwithstanding any termination of the understanding.

Miscellaneous:

A coordination committee consisting of the following shall coordinate and monitor the academic and research programs and all related operational details.

- | | |
|--|---------------------|
| 1. Vice-Chancellor | Chairman |
| 2. Director (Academic), KLE University | Co-Chairman |
| 3. Registrar, KLE University | Member |
| 4. Nominees of the University | Dr S M Kotrashetti, |
| 5. Nominees of the GSR Institute | Dr Rajgopal Reddy, |

Any variation or amendment or addition of / to this Understanding shall be mutually agreed to in writing and executed by or on behalf of each of the parties, University and GSR Institute.

This understanding represents the entire understanding as to the subject matter hereof and supersedes any prior understanding between the parties on the subjects matter hereof.

In witness whereof, the parties hereto have executed this understanding as of the date first above written.

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

Signed for and on behalf of
KLE University,
Belgaum.

Signature :



Name :

Dr S.M. Kondaiah

Designation:

Professor,
Dept. of Oral & Max. Surgery
KLE University, Belgaum.


Signed in presence of:

1.

2.

Signed for and on behalf of
GSR Institute,

Signature :




Name :

Dr. Srinivas Gosla Reddy

Designation: Former Director, GSR
Institute, Hyderabad

ATTESTED


Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI




सत्यमेव जयते


INDIA NON JUDICIAL
Government of Karnataka

e-Stamp

Certificate No.	: IN-KA76852609710974N
Certificate Issued Date	: 17-Jun-2015 12:58 PM
Account Reference	: NONACC (FY) kactr106, BELGAUM/ KA-BL
Unique Doc. Reference	: SUBIN-KAKACRCFL0803000000353624N
Purchased by	: K L E S DR P K HOSPITAL AND M R C BELAGAVI
Description of Document	: Article 12 Bond
Description	: AGREEMENT
Consideration Price (Rs.)	: 0 (Zero)
First Party	: K L E UNIVERSITY AYURVED HOSPITAL BELAGAVI
Second Party	: K L E S DR P K HOSPITAL AND M R C BELAGAVI
Stamp Duty Paid By	: K L E S DR P K HOSPITAL AND M R C BELAGAVI
Stamp Duty Amount(Rs.)	: 100 (One Hundred only)



MH
Authorized Signatory
For Shree Kavyanna Alankar
Co-op. Credit Society Ltd
and Union, Annapal, Plesha
Begur Taluk, Belgaum-590016



Statutory Alert:

1. The authenticity of the Stamp Certificate should be verified at www.karnataka.gov Any discrepancy at the Service till the Certificate and its proceeds on the website remains 1 month.
2. The onus of checking the authenticity is on the users of the Certificate.
3. In case of any discrepancy please inform the Subscribed Authority.

ATTESTED

Prof. Dr. V.A. KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

MEMORANDUM OF UNDERSTANDING

WITH

KLE UNIVERSITY'S AYURVED HOSPITAL, & MEDICAL RESEARCH
CENTRE

SHAHAPUR BELAGAVI

THIS MEMORANDUM OF UNDERSTANDING ENTERED THIS
1ST DAY OF JUNE 2015 AT BELAGAVI.


BETWEEN

1] K.L.E.S. Dr. Prabhakar Kore Hospital and Medical Research Centre, Belagavi represented by its Medical Director, and Chief Executive [Herein after referred to as PARTY No. I of the FIRST PART, which expression shall mean, & include its legal heirs, Administrators, successors].

AND


1] K.L.E. University's Ayurved Hospital & MRC, Belagavi represented by its Medical Director [Herein after referred to as PARTY No. II of the SECOND PART, which expression shall mean & include its legal heirs, administrators, successors].


Medical Director & Chief Executive
KLES Dr. Prabhakar Kore Hospital &
Medical Research Centre, BELAGAVI.


Medical Director
K.L.E. University's
Ayurved Hospital
Shahapur, Belagavi

Notary
Notary

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI


WHEREAS, The PARTY NO II is running and managing Ayurved Hospital and M.R.C., Belagavi desirous of availing the services like Diagnostic Imaging, CT Scanning, DSA LAB, MRI,PET, Gamma camera, Laboratory services like, Histopathology, Cytopathology, Genetics, Molecular Biology, Blood bank services, Emergency services, and Support services like, Mortuary services etc.; which the Party No I is having.

WHEREAS PARTY NO I has consented and agreed to provide the services like Diagnostic Imaging, CT scanning, DSA LAB, MRI,PET, Gamma camera, Laboratory services like, Histopathology, Cytopathology, Genetics, Molecular Biology, Blood bank services, Emergency services, etc., having in the Hospital of Party No 1 taking into consideration the need necessity of Party No II, on the following terms & conditions.

THIS DEED WITNESETH AS UNDER:

1] The PARTY NO I has agreed to provide the services like Diagnostic Imaging, CT scanning, DSA LAB, MRI,PET, Gamma camera, Laboratory services like, Histopathology, cytopathology, Genetics, Molecular Biology, Blood bank services, Emergency services, and Support services like, Mortuary services continuously to party no II.


2] The PARTY NO II has agreed to refer the it's patients to Party No I to avail services mentioned above in clause No 1 of this memorandum of understanding.


Medical Director & Chief Executive
KLES Dr. Prabhakar Kore Hospital &
Medical Research Centre, BELAGAVI


Medical Director
K.L.E. University's
Ayurved Hospital
Shahapur, Belagavi

No. of Correction
NIL
Notary

ATTESTED


Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI


3] The PARTY NO I shall charge the patient's referred by Party No II as per the standard tariff list as agreed in between Party No I & II and as per existing rates of Hospital, which will be in force from time to time.


4] The PARTY NO I shall collect charge for carrying out the procedure from the patients referred by Party No II and the Party No II is as no way responsible for the nonpayment of charges by the carried out by the Party No I referred by Party no II.

5] The Patients of Party No II who avail services of Party No I shall pay the charges for the same and the Party No II is in no way responsible for the nonpayment of the charges for having availed the facility by the patient referred by Party No II.

6] It is the sole discretion of PARTY NO I i.e., Medical Director and Chief Executive of the Hospital to give concession to the patient's referred by Part No II in carrying out any required procedure to the patients referred by Party No II.


7] It is the sole discretion of PARTY NO I Medical Director & Chief Executive of the Hospital to fix the charges for carrying out any of the procedure referred above from time to time with notice to Party No II, which are binding on Party No II.


Medical Director & Chief Executive
KLES Dr. Prachakar Kore Hospital &
Medical Research Centre, BELAGAVI.


Medical Director
K.L.E. University's
Ayurved Hospital
Shahapur, Belagavi

No. of Correction
= Nil
Notary

ATTESTED


Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI


8] The period of memorandum of understanding is for a period of 5 years commencing from the date of execution of this deed which is further extendable at the sole discretion of PARTY NO.1 on those terms and conditions which are agreeable to both the parties.


9]. If parties to this memorandum of understanding intend to terminate the agreement it shall give one month notice in advance in writing by either side without assigning any reasons.


10] If any dispute arises regarding the interpretation of the terms and conditions of this memorandum of understanding and its implementation the same shall be referred to the Chairman, Board of Management, KLE Society, Belagavi, whose decision shall be final and conclusive.

EXECUTED, SIGNED & SEALED ON THIS 1ST DAY OF JUNE 2015.


WITNESSES.

1] 
(R. B. Srinivas)



Medical Director & Chief Executive
KLES Dr. Prabhakar Kore Hospital &
Medical Research Centre, BELAGAVI.

2] 
NABH Coordinator
KLE University's
Ayurved Hospital & MRC
Shahapur-Belagavi-3


NABH Coordinator
K.L.E. University's
Ayurved Hospital
Shahapur, Belagavi



ATTESTED BY



ADVOCATE & NOTARY
BELAGAVI

- 6 JUL 2015

No. of Correction

Notary


ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

MEMORANDUM OF UNDERSTANDING



BETWEEN



K.L.E. UNIVERSITY'S

SHRI B. M. KANKANAWADI AYURVEDA MAHAVIDYALAYA,

SHAHAPUR, BELAGAVI, KARNATAKA, INDIA,

(CONSTITUENT UNIT OF KLE UNIVERSITY - DEEMED TO BE UNIVERSITY U/S 3 OF
THE UGC ACT ;

ACCREDITED 'A' GRADE BY NAAC, &

PLACED IN CATEGORY "A" BY MHRD, GOVT. OF INDIA)

&

INTERNATIONAL UNIVERSITY OF YOGA AND AYURVEDA, INC.

23855 NE HWY 314 SALT SPRINGS, FL 32134,

FLORIDA, USA

ATTESTED

DR. D. V. S. SHIVALE

MEMORANDUM OF UNDERSTANDING

This memorandum of understanding (MOU) is made on 28th November 2015 between K.L.E. University's Shri B.M. Kankanawadi Ayurveda Mahavidyalaya, a Constituent Unit of KLE University (Declared as Deemed to be University U/s 3 of the UGC Act vide Government of India Notification No.F-9-19/2000-U 3 (A) Accredited 'A' Grade by NAAC, Placed in Category "A" by MHRD (G&T), Shahapur, Belagavi, Karnataka, India, hereinafter referred as KLEU SBMK, Belagavi, represented by its Principal, Dr. B.Sreenivasa Prasad (which expression shall meet and include its successors and assigns) on the FIRST PART.

And

International University of Yoga and Ayurveda, Inc. Florida USA represented by Dr. Shekhar Annambhotla (Ayurveda Director), here after referred as IUYA, Florida, USA, which expression shall meet and include its successors and assigns) on the OTHER PART.

Whereas

- a. KLEU SBMK Belagavi is an institute for higher learning offering educational programs in the areas of Ayurveda science. It has also established health care services in region by running Charitable hospitals of Ayurveda Sciences.
- b. International University of Yoga and Ayurveda, Inc. is offering educational programs in Ayurveda, Yoga Vastu, Jyotish (Vedic Sciences) through its accredited schools and institutions around the globe.
- c. KLEU SBMK Belagavi and IUYA, Florida, USA have agreed to collaborate closely to provide quality programs including clinical training, internship facility and teaching in the science of Ayurveda for mutual benefit including academic research collaboration as per the following terms and conditions.

TERMS & CONDITIONS:

1. IUYA, Florida, USA and its accredited schools and institutions of Ayurveda and Yoga will depute its students who have interest in KLEU SBMK Belagavi to learn Ayurveda through clinical training / internship.
2. KLEU SBMK Belagavi will provide Clinical Training / Internship Facilities to IUYA, Florida, USA students at its KLEU SBMK Belagavi, Karnataka (India) campus as per the schedule mutually agreed upon by both the parties from time to time.
3. Fees for Clinical Training / Internship Facilities will be mutually discussed and agreed by both parties and payment will be made to KLEU SBMK Belagavi by attending student from IUYA, Florida, USA.
4. Two Types of educational programs will be available: Short Visit Training and Internship.
5. The Clinical Training / Internship / Teaching of IUYA, Florida, USA students will be undertaken by KLEU SBMK Belagavi in batches of minimum of 4 students and vice-versa applies to KLEU SBMK Belagavi students towards IUYA, Florida, USA.
6. The International and domestic travel arrangements will be the responsibility of students only either from IUYA, Florida, USA or from KLEU SBMK Belagavi.
7. Boarding and lodging arrangements for the students during their training / internship will be made by KLEU SBMK Belagavi on specific request by IUYA, Florida, USA and its accredited schools of Ayurveda and Yoga, on mutually acceptable terms.



ATTESTED



Dr. SHEKHAR ANNAMBHOTLA
Registrar

PRINCIPAL

K.L.E. University
Shri B. M. Kankam
Ayurved Mahavidya
Shahapur-BELAGAVI

8. Payment should be made by the students in advance before the commencement of the program for boarding and lodging facility and training fee. And vice versa applies to the students from KLEU SBMK Belagavi who would like to utilise the facilities of IUYA, Florida, USA.
9. KLEU SBMK Belagavi can provide its faculty/experts for curriculum design and as members of Board of Studies, if required at IUYA, Florida, USA.
10. KLEU SBMK Belagavi could also provide faculty for short term (1-2 weeks) and long term (3-12 months) teaching assignments if needed, subject to the approval of statutory authorities with advance intimation of 3 months.
11. KLEU SBMK Belagavi can provide services of faculty through online video-conference system (e.g. Skype) if required by IUYA, Florida, USA and its accredited schools and institutions, after due intimation in advance with payment of mutually agreed remuneration.
12. Both the parties for the training / internship program will decide the financial terms and obligations mutually whenever needed.
13. This MoU does not hinder either KLEU SBMK or IUYA, Florida, USA to have direct collaboration or MoU with any educational or research institute for Ayurveda education or research.

This MOU will be valid for three years from the date of signing by both the parties. This MOU may be terminated by either party with written notice of 90 days.


IN WITNESS WHEREOF both the parties have set hands today and agreed to sign this MOU the day, year and month mentioned above.

On the behalf of
KLEU Shri BMKAM, Belagavi

On the behalf of
International University of Yoga & Ayurveda Inc.

Ch
28/11/15
Dr. B. Sreenivasa Prasad,
Principal
KLEU's University's
KLEU's Shri B.M.K. Ayurved Mahavidyalaya,
Shri B. M. Kankarwadi
Belagavi, Karnataka, India
Ayurved Mahavidyalaya
Shahapur-BELAGAVI-03

Dr. Shekhar
Dr. Shekhar Annambhotla
Ayurveda Director,
IUYA, Florida, USA



WITNESS:

① *Giridhar*
28/11/2015
Dr. Vedantam Giridhar

WITNESS:

Debra
Debra Hougard
Delaware, USA


ATTESTED

[Signature]
Prof. Dr. V. A. KOTHIMBLE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

MEMORANDUM OF UNDERSTANDING



BETWEEN



K.L.E. UNIVERSITY'S

SHRI B. M. KANKANAWADI AYURVEDA MAHAVIDYALAYA,

SHAHAPUR, BELAGAVI, KARNATAKA, INDIA,

(CONSTITUENT UNIT OF KLE UNIVERSITY - DEEMED TO BE UNIVERSITY U/S 3 OF
THE UGC ACT ;

ACCREDITED 'A' GRADE BY NAAC, &

PLACED IN CATEGORY "A" BY MHRD, GOVT. OF INDIA)

&

INTERNATIONAL UNIVERSITY OF YOGA AND AYURVEDA, INC.

23855 NE HWY 314 SALT SPRINGS, FL 32134,

FLORIDA, USA

ATTESTED

A handwritten signature in black ink, appearing to read "V.A. Kothiwale".

Prof. Dr. V.A. KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

MEMORANDUM OF UNDERSTANDING

This memorandum of understanding (MOU) is made on 28th November 2015 between K.L.E. University's Shri B.M. Kankanawadi Ayurveda Mahavidyalaya, a Constituent Unit of KLE University (Declared as Deemed to be University U/s 3 of the UGC Act vide Government of India Notification No.F-9-19/2000-U 3 (A) Accredited 'A' Grade by NAAC, Placed in Category "A" by MHRD (GoI), Shahapur, Belagavi, Karnataka, India, hereinafter referred as KLEU SBMK, Belagavi, represented by its Principal, Dr. B.Sreenivasa Prasad (which expression shall meet and include its successors and assigns) on the FIRST PART.

And

International University of Yoga and Ayurveda, Inc. Florida USA represented by Dr. Shekhar Annambhotla (Ayurveda Director), here after referred as IU YA, Florida, USA, which expression shall meet and include its successors and assigns) on the OTHER PART.


Whereas

- a. KLEU SBMK Belagavi is an institute for higher learning offering educational programs in the areas of Ayurveda science. It has also established health care services in region by running Charitable hospitals of Ayurveda Sciences.
- b. International University of Yoga and Ayurveda, Inc. is offering educational programs in Ayurveda, Yoga Vastu, Jyotish (Vedic Sciences) through its accredited schools and institutions around the globe.
- c. KLEU SBMK Belagavi and IU YA, Florida, USA have agreed to collaborate closely to provide quality programs including clinical training, internship facility and teaching in the science of Ayurveda for mutual benefit including academic research collaboration as per the following terms and conditions.

TERMS & CONDITIONS:

1. IU YA, Florida, USA and its accredited schools and institutions of Ayurveda and Yoga will depute its students who have interest in KLEU SBMK Belagavi to learn Ayurveda through clinical training / internship.
2. KLEU SBMK Belagavi will provide Clinical Training / Internship Facilities to IU YA, Florida, USA students at its KLEU SBMK Belagavi, Karnataka (India) campus as per the schedule mutually agreed upon by both the parties from time to time.
3. Fees for Clinical Training / Internship Facilities will be mutually discussed and agreed by both parties and payment will be made to KLEU SBMK Belagavi by attending student from IU YA, Florida, USA.
4. Two Types of educational programs will be available: Short Visit Training and Internship.
5. The Clinical Training / Internship / Teaching of IU YA, Florida, USA students will be undertaken by KLEU SBMK Belagavi in batches of minimum of 4 students and vice-versa applies to KLEU SBMK Belagavi students towards IU YA, Florida, USA.
6. The International and domestic travel arrangements will be the responsibility of students only either from IU YA, Florida, USA or from KLEU SBMK Belagavi
7. Boarding and lodging arrangements for the students during their training / internship will be made by KLEU SBMK Belagavi on specific request by IU YA, Florida, USA and its accredited schools of Ayurveda and Yoga, on mutually acceptable terms.

Dr. B. Sreenivasa Prasad



ATTESTED

Dr. Shekhar Annambhotla

Dr. SHEKHAR ANNAMBHOTLA

KLE Academy of Higher Education
and Research, BELAGAVI

Chr
PRINCIPAL
K.L.E. University
Shri B. M. Kankam
Ayurved Mahavidya
Shahapur-BELAGAVI

8. Payment should be made by the students in advance before the commencement of the program for boarding and lodging facility and training fee. And vice versa applies to the students from KLEU SBMK Belagavi who would like to utilise the facilities of IUYA, Florida, USA.
9. KLEU SBMK Belagavi can provide its faculty/experts for curriculum design and as members of Board of Studies, if required at IUYA, Florida, USA.
10. KLEU SBMK Belagavi could also provide faculty for short term (1-2 weeks) and long term (3-12 months) teaching assignments if needed, subject to the approval of statutory authorities with advance intimation of 3 months.
11. KLEU SBMK Belagavi can provide services of faculty through online video-conference system (e.g. Skype) if required by IUYA, Florida, USA and its accredited schools and institutions, after due intimation in advance with payment of mutually agreed remuneration.
12. Both the parties for the training / internship program will decide the financial terms and obligations mutually whenever needed.
13. This MoU does not hinder either KLEU SBMK or IUYA, Florida, USA to have direct collaboration or MoU with any educational or research institute for Ayurveda education or research.

This MOU will be valid for three years from the date of signing by both the parties. This MOU may be terminated by either party with written notice of 90 days.


IN WITNESS WHEREOF both the parties have set hands today and agreed to sign this MOU the day, year and month mentioned above.

On the behalf of
KLEU Shri BMKAM, Belagavi

On the behalf of
International University of Yoga & Ayurveda Inc.

Ch
28/11/15
Dr. B. Sreenivasa Prasad,
Principal
KLEU's University's
Shri B. M. Ranganwadi
Ayurved Mahavidyalaya
Belagavi, Karnataka, India
Shahapur-BELAGAVI-03

Dr. Shekhar
Dr. Shekhar Annambhotla
Ayurveda Director,
IUYA, Florida, USA



WITNESS:

① *Giridhar*
28/11/2015
Dr. Vedantam Giridhar

WITNESS:

Debra
Debra Haugaard
Delaware, USA

ATTESTED

K. S. H.

UBMTA Implementing Letter

The purpose of this letter is to provide a record of the biological material transfer, to memorialize the agreement between the PROVIDER SCIENTIST (identified below) and the RECIPIENT SCIENTIST (identified below) to abide by all terms and conditions of the Uniform Biological Material Transfer [[Page 12775]] Agreement ("UBMTA") March 8, 1995, and to certify that the RECIPIENT (identified below) organization has accepted and signed an unmodified copy of the UBMTA. The RECIPIENT organization's Authorized Official also will sign this letter if the RECIPIENT SCIENTIST is not authorized to certify on behalf of the RECIPIENT organization. The RECIPIENT SCIENTIST (and the Authorized Official of RECIPIENT, if necessary) should sign both copies of this letter and return one signed copy to the PROVIDER. The PROVIDER SCIENTIST will forward the material to the RECIPIENT SCIENTIST upon receipt of the signed copy from the RECIPIENT organization.

Please fill in all of the blank lines below:

1. PROVIDER: Organization providing the ORIGINAL MATERIAL:

Organization: KLE University's College of Pharmacy-Bengaluru
Address: 2nd Block, Rajajinagar, Bengaluru, PIN-560010,
Karnataka State, INDIA

2. RECIPIENT: Organization receiving the ORIGINAL MATERIAL:

Organization: The Board of Trustees of the University of Illinois
Address: 1737 W. Polk St.,
414 AOB,
Chicago, IL 60612-7228

3. ORIGINAL MATERIAL (Enter description):

Synthesized compounds

4. Termination date for this letter (optional): _____

5. Transmittal Fee to reimburse the PROVIDER for preparation and distribution costs (optional). Amount: 0


ATTESTED




Prof. Dr. V.A KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

This Implementing Letter is effective when signed by all parties. The parties executing this Implementing Letter certify that their respective organizations have accepted and signed an unmodified copy of the UDMTA, and further agree to be bound by its terms, for the transfer specified above.

PROVIDER SCIENTIST


Name: Dr. Subhas S. Karki
Title: Vice Principal, Professor & Head
Address: 2nd Block, Rajajinagar, Bengaluru
Karnataka State, INDIA. PIN-560010
Signature: 
Date: December 9, 2016

PROVIDER ORGANIZATION

Authorized Official: Prof. (Dr.) SM. Hippargi
Title: Principal
Address: 2nd Block, Rajajinagar,
Bengaluru, PIN-560010
Signature: 
Date: December 9, 2016



RECIPIENT SCIENTIST

Name: Scott Franzblau
Title: Professor and Director
Address: Institute for Tuberculosis Research, MC 964 College of Pharmacy,
Rm 425 University of Illinois at Chicago
833 S. Wood St. Chicago, Illinois 60621-7231 USA
www.tuberculosisdrugresearch.org
Tel: 312-355-1715, Fax: 312-355-2693
Signature: 
Date: 12/12/16

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

13. 11. 2011
14. 11. 2011
15. 11. 2011
16. 11. 2011
17. 11. 2011
18. 11. 2011
19. 11. 2011
20. 11. 2011
21. 11. 2011
22. 11. 2011
23. 11. 2011
24. 11. 2011
25. 11. 2011
26. 11. 2011
27. 11. 2011
28. 11. 2011
29. 11. 2011
30. 11. 2011
31. 11. 2011
32. 11. 2011
33. 11. 2011
34. 11. 2011
35. 11. 2011
36. 11. 2011
37. 11. 2011
38. 11. 2011
39. 11. 2011
40. 11. 2011
41. 11. 2011
42. 11. 2011
43. 11. 2011
44. 11. 2011
45. 11. 2011
46. 11. 2011
47. 11. 2011
48. 11. 2011
49. 11. 2011
50. 11. 2011
51. 11. 2011
52. 11. 2011
53. 11. 2011
54. 11. 2011
55. 11. 2011
56. 11. 2011
57. 11. 2011
58. 11. 2011
59. 11. 2011
60. 11. 2011
61. 11. 2011
62. 11. 2011
63. 11. 2011
64. 11. 2011
65. 11. 2011
66. 11. 2011
67. 11. 2011
68. 11. 2011
69. 11. 2011
70. 11. 2011
71. 11. 2011
72. 11. 2011
73. 11. 2011
74. 11. 2011
75. 11. 2011
76. 11. 2011
77. 11. 2011
78. 11. 2011
79. 11. 2011
80. 11. 2011
81. 11. 2011
82. 11. 2011
83. 11. 2011
84. 11. 2011
85. 11. 2011
86. 11. 2011
87. 11. 2011
88. 11. 2011
89. 11. 2011
90. 11. 2011
91. 11. 2011
92. 11. 2011
93. 11. 2011
94. 11. 2011
95. 11. 2011
96. 11. 2011
97. 11. 2011
98. 11. 2011
99. 11. 2011
100. 11. 2011

08/5752 - 0001, 12/11

ATTESTED

Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

MEMORANDUM OF UNDERSTANDING



BETWEEN



K.L.E. UNIVERSITY'S

SHRI B. M. KANKANAWADI AYURVEDA MAHAVIDYALAYA,

SHAHAPUR, BELAGAVI, KARNATAKA, INDIA,

(CONSTITUENT UNIT OF KLE UNIVERSITY - DEEMED TO BE UNIVERSITY U/S 3 OF
THE UGC ACT ;

ACCREDITED 'A' GRADE BY NAAC, &

PLACED IN CATEGORY "A" BY MHRD, GOVT. OF INDIA)

&

INTERNATIONAL UNIVERSITY OF YOGA AND AYURVEDA, INC.

23855 NE HWY 314 SALT SPRINGS, FL 32134,

FLORIDA, USA

ATTESTED

A handwritten signature in black ink, appearing to read "V.A. Kothiwale".

Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education,
and Research, BELAGAVI

MEMORANDUM OF UNDERSTANDING

This memorandum of understanding (MOU) is made on 28th November 2015 between K.L.E. University's Shri B.M. Kankanawadi Ayurveda Mahavidyalaya, a Constituent Unit of KLE University (Declared as Deemed to be University U/s 3 of the UGC Act vide Government of India Notification No.F-9-19/2000-U 3 (A) Accredited 'A' Grade by NAAC, Placed in Category "A" by MHRD (GoI), Shahapur, Belagavi, Karnataka, India, hereinafter referred as KLEU SBMK, Belagavi, represented by its Principal, Dr. B.Sreenivasa Prasad (which expression shall meet and include its successors and assigns) on the FIRST PART.

And


International University of Yoga and Ayurveda, Inc. Florida USA represented by Dr. Shekhar Annambhotla (Ayurveda Director), here after referred as IUYA, Florida, USA, which expression shall meet and include its successors and assigns) on the OTHER PART.

Whereas

- KLEU SBMK Belagavi is an institute for higher learning offering educational programs in the areas of Ayurveda science. It has also established health care services in region by running Charitable hospitals of Ayurveda Sciences.
- International University of Yoga and Ayurveda, Inc. is offering educational programs in Ayurveda, Yoga Vastu, Jyotish (Vedic Sciences) through its accredited schools and institutions around the globe.
- KLEU SBMK Belagavi and IUYA, Florida, USA have agreed to collaborate closely to provide quality programs including clinical training, internship facility and teaching in the science of Ayurveda for mutual benefit including academic research collaboration as per the following terms and conditions.

TERMS & CONDITIONS:

- IUYA, Florida, USA and its accredited schools and institutions of Ayurveda and Yoga will depute its students who have interest in KLEU SBMK Belagavi to learn Ayurveda through clinical training / internship.
- KLEU SBMK Belagavi will provide Clinical Training / Internship Facilities to IUYA, Florida, USA students at its KLEU SBMK Belagavi, Karnataka (India) campus as per the schedule mutually agreed upon by both the parties from time to time.
- Fees for Clinical Training / Internship Facilities will be mutually discussed and agreed by both parties and payment will be made to KLEU SBMK Belagavi by attending student from IUYA, Florida, USA.
- Two Types of educational programs will be available: Short Visit Training and Internship.
- The Clinical Training / Internship / Teaching of IUYA, Florida, USA students will be undertaken by KLEU SBMK Belagavi in batches of minimum of 4 students and vice-versa applies to KLEU SBMK Belagavi students towards IUYA, Florida, USA.
- The International and domestic travel arrangements will be the responsibility of students only either from IUYA, Florida, USA or from KLEU SBMK Belagavi
- Boarding and lodging arrangements for the students during their training / internship will be made by KLEU SBMK Belagavi on specific request by IUYA, Florida, USA and its accredited schools of Ayurveda and Yoga, on mutually acceptable terms.



ATTESTED

Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

PRINCIPAL

K.L.E. University
Shri B. M. Kankani
Ayurved Mahavidya
Shahapur-BELAGAVI

8. Payment should be made by the students in advance before the commencement of the program for boarding and lodging facility and training fee. And vice versa applies to the students from KLEU SBMK Belagavi who would like to utilise the facilities of IUYA, Florida, USA.
9. KLEU SBMK Belagavi can provide its faculty/experts for curriculum design and as members of Board of Studies, if required at IUYA, Florida, USA.
10. KLEU SBMK Belagavi could also provide faculty for short term (1-2 weeks) and long term (3-12 months) teaching assignments if needed, subject to the approval of statutory authorities with advance intimation of 3 months.
11. KLEU SBMK Belagavi can provide services of faculty through online video-conference system (e.g. Skype) if required by IUYA, Florida, USA and its accredited schools and institutions, after due intimation in advance with payment of mutually agreed remuneration.
12. Both the parties for the training / internship program will decide the financial terms and obligations mutually whenever needed.
13. This MoU does not hinder either KLEU SBMK or IUYA, Florida, USA to have direct collaboration or MoU with any educational or research institute for Ayurveda education or research.

This MOU will be valid for three years from the date of signing by both the parties. This MOU may be terminated by either party with written notice of 90 days.


IN WITNESS WHEREOF both the parties have set hands today and agreed to sign this MOU the day, year and month mentioned above.

On the behalf of
KLEU Shri BMKAM, Belagavi

On the behalf of
International University of Yoga & Ayurveda Inc.

Ch
28/11/15
Dr. B. Sreenivasa Prasad,
Principal,
KLEU Shri BMKAM Ayurved Mahavidyalaya,
Shri B. W. Ranganwadi
Belagavi, Karnataka, India
Ayurved Mahavidyalaya
Shahapur-BELAGAVI-03

Dr. Shekhar
Dr. Shekhar Annambhotla
Ayurveda Director,
IUYA, Florida, USA



WITNESS:

① *Giridhar*
28/11/2015
Dr. Vedantam Giridhar

WITNESS:

Debra
Debra Hougard
Delaware, USA

ATTESTED

[Signature]
Prof. Dr. V. A. KOTHAWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

UBMTA Implementing Letter

The purpose of this letter is to provide a record of the biological material transfer, to memorialize the agreement between the PROVIDER SCIENTIST (identified below) and the RECIPIENT SCIENTIST (identified below) to abide by all terms and conditions of the Uniform Biological Material Transfer ([Page 12775]) Agreement ("UBMTA") March 8, 1995, and to certify that the RECIPIENT (identified below) organization has accepted and signed an unmodified copy of the UBMTA. The RECIPIENT organization's Authorized Official also will sign this letter if the RECIPIENT SCIENTIST is not authorized to certify on behalf of the RECIPIENT organization. The RECIPIENT SCIENTIST (and the Authorized Official of RECIPIENT, if necessary) should sign both copies of this letter and return one signed copy to the PROVIDER. The PROVIDER SCIENTIST will forward the material to the RECIPIENT SCIENTIST upon receipt of the signed copy from the RECIPIENT organization.

Please fill in all of the blank lines below:

1. PROVIDER: Organization providing the ORIGINAL MATERIAL:

Organization: KLE University's College of Pharmacy-Bengaluru
Address: 2nd Block, Rajajinagar, Bengaluru, PIN-560010,
Karnataka State, INDIA

2. RECIPIENT: Organization receiving the ORIGINAL MATERIAL:

Organization: The Board of Trustees of the University of Illinois
Address: 1737 W. Polk St.,
414 AOB,
Chicago, IL 60612-7228

3. ORIGINAL MATERIAL (Enter description):

Synthesized compounds

4. Termination date for this letter (optional): _____

5. Transmittal Fee to reimburse the PROVIDER for preparation and distribution costs (optional). Amount: \$ _____


ATTESTED




Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

This Implementing Letter is effective when signed by all parties. The parties executing this Implementing Letter certify that their respective organizations have accepted and signed an unmodified copy of the UBMTA, and further agree to be bound by its terms, for the transfer specified above.

PROVIDER SCIENTIST


Name: Dr. Subhas S. Karki
Title: Vice Principal, Professor & Head
Address: 2nd Block, Rajajinagar, Bengaluru
Karnataka State, INDIA. PIN-560010
Signature: 
Date: December 9, 2016

PROVIDER ORGANIZATION

Authorized Official: Prof. (Dr.) SM. Hippargi
Title: Principal
Address: 2nd Block, Rajajinagar,
Bengaluru, PIN-560010
Signature: 
Date: December 9, 2016



RECIPIENT SCIENTIST


Name: Scott Franzblau
Title: Professor and Director
Address: Institute for Tuberculosis Research, MC 964 College of Pharmacy,
Rm 425 University of Illinois at Chicago
833 S. Wood St. Chicago, Illinois 60621-7231 USA
www.tuberculosisdrugresearch.org
Tel: 312-355-1715, Fax: 312-355-2693
Signature: 
Date: 12/12/16

ATTESTED



ATTESTOR

KLE Academy of Higher Education
and Research, BELAGAVI



Faint, illegible text, possibly a certificate or official letter, located in the upper left quadrant of the page.

Walter K. Kothiwale
12/20/12

08/5/52 - 00001, 12-20

ATTESTED

Kothiwale

Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI



ગુજરાત ગુજરાત GUJARAT

43AA 431601

મંચુ. નં. ૧૯૮૩૦ તા. ૧૨/૬/૨૦૧૫ રા. ૨૦/

12 JUN 2015

પરીક્ષારત્નું નામ **VASU RESEARCH CENTRE**
(A Division of Vasu Healthcare Pvt. Ltd.)

સરનામું ૬૦૬/૪, G.I.D.C., Makarpura,
Vadodara-390010

ધર્મચામ હરીભાઈ પટેલ (રહેવા વેન્ડરની સહી) કન્ટિસા
જી. રોબલ પ્લાઝા, સંપતરાંપ કોલોની, વેલપુર રોડ,
મલકાપુરી, વડોદરા-૭ લા. નં. ૬૬/૯૦ તા. ૧૮/૦૪/૧૦

MEMORANDUM OF UNDERSTANDING

This memorandum of understanding is entered into on this 18th day of month September, 2015

BETWEEN

M/s Vasu Research Center (A Division of Vasu Healthcare Pvt. Ltd.), Vadodara, a company incorporated under the Indian Companies Act, having its registered office at 967/4, GIDC, Makarpura, Vadodara – 390 010, Gujarat, India, through its authorized signatory Shri Haribhai B. Patel, Managing Director authorized by the Board Resolution dated 02/10/2013, hereinafter referred to as the company, which expression shall unless repugnant to the context and meaning thereof include its heirs, successors and assignees of the one Part.

AND

KLE University's Shri B M Kankanawadi Ayurved Mahavidyalaya - Medical Research Centre, Shahapur, Belagavi, Karnataka - 590003, India, through its Principal, Dr. B. Sreenivas Prasad hereinafter referred to as the Institute, which expression shall unless repugnant to the context and meaning thereof include its heirs, successors and assignees of the Second Part.

Page 1 of 4

ATTESTED

Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

WHERE AS the company is engaged, interalia, in research and development of various Ayurvedic drugs,
AND WHERE AS the Institute has fully established good research facilities and hospital facility for the clinical studies in the field of Ayurved and Ayurvedic Drugs.

WHERE AS the company has developed a drug in its laboratory for the management of Stress and wants a clinical assessment for its efficacy and safety in Generalized Anxiety Disorder, to be done in the lab & hospital of the Institute, to which the Institute has agreed.

NOW, THEREFORE, in consideration of the representations, warranties, covenants and agreements set forth herein and other valuable consideration and subject to the terms and conditions set forth herein, the Lessor and the Lessee hereby agree as follows

1. That the Institute has agreed to conduct a clinical assessment of the drug *Alert Capsule*, developed by the company.
2. That the company has agreed to provide to the Institute detail ingredients of the drugs, type of investigation required in the clinical trial, brief detail of the products, copy of certificate of analysis of used raw materials and ingredient pharmacology of used raw materials.
3. That the company has also agreed to utilize the result of the clinical study for the benefit of patients and undertakes that the company shall only be responsible / liable for any legal or other requirement arising out of the application of the result of the project.
4. That the clinical study would require certain amount of expenditure as per details attached herewith in the project proposal (including financial) to which both the parties have agreed. Total amount of project is Rs. 4, 74,210/- only (In words: Four lakhs seventy four thousand two hundred ten only), after deduction of 10% TDS it will be Rs. 4, 26,789/- only (In words: Four lakhs twenty six thousand seven hundred eighty nine).
Out of the above proposed fixed expenditure of Rs. 4, 26,789/-, the company has agreed to make 10% non-refundable amount (Rs. 42,679/- via cheque no. 739847... dated 11/09/2015) along with application which will be adjustable in total project cost, 50% (2, 13,395/-) of payment will be made after ethical clearance as part of project initiation, and 30% (1, 28,036/-) payment will be made once the 50% of sample size is reached. Remaining 10% (Rs. 42,679/-) of the project cost should be paid after the completion of the project.
5. That the said trial shall be completed in a period of 24 months.
6. The Institute has agreed to provide trimonthly basis progress report of the clinical trial of the said drug.
7. The company has agreed to provide all detail of work, raw drugs, finished drugs and all other necessary co-operation in order to complete the research activities of the drugs.
8. *It has been agreed between the parties that all rights arising out of research and clinical activities of the said drug, including patent right shall vest with the company and the Institute shall never claim any right over the drugs any time in future.*
9. *Important research findings arising out of the activities covered under this MOU will be published in/presented at National/International journals/conferences with joint authorship of both the parties.*
10. All notices and other communication required to be served on parties under the terms of this agreement shall be considered duly served if the same have been delivered to or posted by registered mail to:

In case of Vasu Research Center:

Manager – R&D,
Vasu Research Centre
(A Division of Vasu Healthcare Pvt. Ltd.)
896/A, GIDC, Makarpura, Vadodara-390010, Gujarat, India
Tel.: 91-265-2657701/2 Fax: 91-265-2647331
Web.: www.vasuresearch.com; www.vasuhealthcare.com

J.P. Patil

Chr

ATTESTED

M. K. Kothiwale
Prof. Dr. V.A. KOTHIWALE
Registrar


KLE Academy of Higher Education
and Research, BELAGAVI

- (ii) The Institute undertakes to keep confidential all information provided by the company to the Institute whether related to the drugs under trial or otherwise.
- (iii) The Institute undertakes do not disclose to any third party about the present Agreement understanding.
12. None of the Parties to this MOU shall make any public disclosure in any form relating to this MOU without the prior written consent of the other party : provided, the party shall be permitted to make such disclosures to the Public or to Government agencies as the party shall deem necessary to comply with any applicable law, rule or regulation or to Governmental Reviews or approvals of the proposed business arrangement discussed in this MOU
13. This MOU can be terminated by either of the party by giving 30 days of notice to the other party for the reasons stated below:
 (i) Any material breach of terms of the agreement
 The termination shall not affect the parties' liability for its unperformed obligations which have accrued prior to the date of termination and hence the parties shall fulfill its obligation under the agreement till the date of termination.
14. The parties to the MOU agree that the present MOU can be modified, varied, changed or otherwise in whole or in part only with mutual consent, in writing and executed by or on behalf of the parties.
15. Time is the essence of this agreement.
16. Any dispute, difference or claim arising out of or in connection with this Agreement including the construction, validity, execution, performance, termination or breach hereof (a "Dispute"), that is not settled within fifteen (15) business days of the date on which such dispute, difference or claim is raised, shall be referred to final and binding arbitration under the Indian Arbitration and Conciliation Act, 1996, as amended (the "Arbitration Act"). Such arbitration shall be held at Vadodara, Gujarat. All proceedings of such arbitration shall be in the English language.
17. The courts of Vadodara shall have the sole and exclusive jurisdiction to resolve any dispute if not solved amicably between the Parties

In witness whereof the parties hereto have signed this agreement on the day, month and year mentioned hereinabove.

PARTIES

For and on behalf of
 Vasu Research Center
 (A Division of Vasu Healthcare Pvt. Ltd.)




Mr. Haribhai B. Patel

For and on behalf of
 KLE University's Shri B M Kankanawadi
 Ayurved Mahavidyalaya




Dr. B. Sreenivas Prasad

WITNESSES




Mr. Vikram Trivedi



Dr. Hardik Soni



Dr. A. R. Tushar



Dr. Nandhigam

ATTESTED



Prof. Dr. V.A. KOTHIWALE
 Registrar
 KLE Academy of Higher Education
 and Research, BELAGAVI



MEMORANDUM OF UNDERSTANDING

Between

**K.L.E. UNIVERSITY'S
SHRI B. M. KANKANAWADI AYURVEDA MAHAVIDYALAYA,**

SHAHAPUR, BELAGAVI, KARNATAKA, INDIA,

(CONSTITUENT UNIT OF KLE UNIVERSITY -
DEEMED TO BE UNIVERSITY U/S 3 OF THE UGC ACT ;
ACCREDITED 'A' GRADE BY NAAC, &
PLACED IN CATEGORY "A" BY MHRD, GOVT. OF INDIA)


&

RASAYANI BIOLOGICS PVT. LTD. (RBPL)

48/7, MHALUNGE-NANDE ROAD,

PUNE 411 045

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar

MEMORANDUM OF UNDERSTANDING

This Memorandum of Understanding ("MOU") dated this 28th day of November 2015

by and between:

KLE University's BMK Ayurveda Mahavidyalaya, Belagavi, is a leading institute in the education field of Ayurveda in India, having its office at Nathpai circle, Shahapur, Belagavi (here in after referred to as 'B.M.K Ayurved Mahavidyalaya) which expression shall unless it be repugnant to the context or meaning thereof shall be deemed to mean and include its successors and permitted assigns) of the **One Part**

AND

Rasayani Biologics Pvt. Ltd. (RBPL) having its place of business at 48/7, Mhalunge-Nande Road, Pune 411 045 (hereinafter referred to as 'RBPL' which expression shall unless it be repugnant to the context or meaning thereof shall be deemed to mean and include its successors and permitted assigns) of the **Other Part**

B.M.K AYURVED MAHAVIDYALAYA and RBPL shall be individually hereinafter referred to as 'Party' and collectively as 'Parties'.

Whereas


A. 'B.M.K AYURVED MAHAVIDYALAYA' is an educational Institute in Ayurveda also carrying on research and development in the field of Ayurveda.

B. 'RBPL' is engaged in Research and Development of newer range of Biotech and Nanotech products. RBPL is proving multidimensional use of Ayurveda and weaves a net of collaborative research with multiple scientific disciplines for translating it in modern medicine terminology.

C. The parties are interested in exploring possible opportunities of establishing a mutually cooperative and beneficial relationship, including the carrying out of Projects relevant to their respective capabilities in India.

D. B.M.K Ayurved Mahavidyalaya and RBPL acknowledge, confirm and understand that this MOU is not intended to provide and set out any contractual terms binding or otherwise governing the terms and conditions or the manner of conduct of any Projects and that may necessarily require the Parties to:

- share relevant information on a confidential basis with the aim and objective of identifying their requirements, needs and capabilities;
- establish a working relationship between themselves (which is targeted to the parties' specific needs);
- establish Projects which maybe of mutual benefits and interest ;
- Determine the details of Projects, their scope and purview, Project work plan, funding of the Project, their rights, duties and obligations in relation to the Project and its outcome.



ATTESTED

Prof. Dr. V. K. Kulkarni

Registrar

PRINCIPAL
K.L.E. University
Shri B. M. Kankal
Ayurved Mahavidyalaya
Shahapur-BELAGAVI

For the purposes of each Project, the Parties shall enter into separate Agreements.

For the purposes of this MOU, "Project" shall mean a collaboration relating to research and business management in the fields of Ayurvedic products related to medicines with focus on immunomodulatory and nano materials.

1. SCOPE OF THE MOU

1.1 The Parties will co-operate to:

- (a) identify Projects of mutual interests;
- (b) facilitate the development of proposals for Projects between the two organizations including exploring possibilities for grants and other forms of funding;
- (c) determine the terms and conditions of the specific agreements under which each Project will be conducted ("Collaboration Agreements") and the ownership of the intellectual property rights arising from the Project ;
- (d) execute those Projects; and
- (e) Conduct an annual review of current and future Projects approximately one (1) week prior to the anniversary of the execution of this MOU.

1.2 Subject to the terms and conditions of any Collaboration Agreement agreed to and executed, each Party will have the right, in any field related to the Project or otherwise, to:

- (a) conduct business or research independently, whether or not with third parties;
- (b) continue existing commitments, or make new ones; and
- (c) Exploit or otherwise take advantage of its intellectual property.


2. COLLABORATION AGREEMENT

2.1 The Parties acknowledge and confirm their intention to negotiate and settle the terms and conditions of a Collaboration Agreement in respect of each Project.

2.2 The parties agree that the ownership of the intellectual property generated during the project shall be owned by RBPL only, if the project is wholly funded by RBPL. In IPRs (patent etc.) and in publications, relevant investigators/contributors names from both parties, who had contributed significantly in designing, conceptualization, scientific implementation etc., shall be included, but without any financial rights. Appropriate authorship or co-authorship will be decided with mutual understanding between two parties. If funding is from both parties or from any funding agency, then IPRs etc. will be based on mutual agreement or based on funding agency's guidelines.


2.3 Each Collaboration Agreement will include provisions relating amongst other things to:

- (a) a Project plan pursuant to which the Project will be carried out which will include information pertaining to technical objectives, statement of work, deliverables, schedule, decision gates, resource requirements and costs;
- (b) funding arrangements for the Project;
- (c) Holding by the Parties of periodic Project review meetings to assess the management and the progress of the Project and the status of any expenditure;
- (d) Exploitation of Intellectual property and rights arising from the same including their protection, enforcement and commercialization.



Dr. V.A. KOTHIKAR
Registrar

ATTESTED


PRINCIPAL
K.L.E. University
Shri B. M. Kankar
Ayurved Mahavidya
Shahapur-BELAGAVI

(e) Commercial arrangements between the B.M.K Ayurved Mahavidyalaya and RBPL.

2.4 The Parties agree, acknowledge and confirm that for any agreement to be binding on them, it must be in writing and shall be executed by a duly authorized representative of each of the B.M.K AYURVED MAHAVIDYALAYA and RBPL.

3. REPRESENTATIVE

3.1 For the term and purposes of this MOU, each party shall appoint a designated representative ("the Representative").

3.2 The Representative of the appointing Party will be responsible for:

- (a) managing, overseeing or coordinating that Party's relationship with the other Party;
- (b) identifying any commercial issues that arise between the Parties and refer them to the **Competent Authority** within the Representative's organization;
- (c) discussing any issues arising out of this MOU or a Collaboration Agreement with the Representative of the other party; and
- (d) Co-coordinating the exchange of information between the Parties.

3.3 The Representatives designated at the time of signing this MOU by the parties are:

(a) for B.M.K Ayurved Mahavidyalaya:

Name : Dr. B. Sreenivasa Prasad
Designation : Principal
Email : dr_bsprasad@rediffmail.com
Mob. : +919448569289


(b) for RBPL

Name: Dr. Rammesh Natu
Designation: Research Coordinator
Email: drrammeshnatu390@gmail.com
Mob. 08605066700

4. CONFIDENTIAL INFORMATION


4.1 **Definition:** As used herein "Confidential Information" shall mean and include all information and data which has been provided/disclosed/shared by B.M.K AYURVED MAHAVIDYALAYA to RBPL prior and post the execution of this MOU and/or the Collaboration Agreement either written or oral or in any other form or manner of communication or which has been acquired or will be acquired by either Party such as designs, drawings, specifications, technical information, documents and know-how, designs, manufacturing processes, ideas, data, financial information and other technologies, whether patentable, copyrightable or susceptible to any other form of protection. The terms and existence of this MOU, the fact that Confidential Information has been shared and/or made available, that discussions or negotiations pertaining to the technology are taking place between the Parties shall also be considered Confidential Information for the purposes of this MOU.

4.2 **Purpose:** The Parties shall use the Confidential Information strictly and solely for the purposes for which the Confidential Information is provided under this MOU and none other.



ATTESTED

Dr. V.A. KOTHIWALE
Registrar



PRINCIPAL
K.L.E. University
Shri B. M. Kankani
Ayurved Mahavidya
Shahapur-BELAGAVI

4.3 Ownership: The Parties hereby understand, acknowledge, and confirm that the Confidential Information is a valuable trade secret owned by each Party and which retains all right, title, and interest in and unto the same. Neither Party shall have any right, title and interest in the Confidential Information of the other Party. By virtue of either Party disclosing the Confidential Information, no license to such Confidential Information or any Intellectual Property rights owned by that Party is or are granted to the other Party. Neither Party shall directly or indirectly, through its directors, employees or agents, at any point of time, do any acts, things or deeds that may prejudicially affect the proprietary right, title and interests of either Party in and unto the Confidential Information.

4.4 No Warranties: At no point of time shall either Party be responsible for any loss or damages which may be suffered by the Party receiving the Confidential Information or for that matter by its customers or any third parties on account of or arising from the use of the Confidential Information. Neither Party makes any representations or warranties of any kind, whether expressed or implied as to the accuracy or completeness of the Confidential Information.


4.5 Use of Confidential Information: Each Party may use the Confidential Information for the purposes stated in Clause 4.2 above only. Each Party recognizes that this MOU imposes an affirmative duty on the other Party to hold such information in confidence and to protect it from dissemination to and use by any and all unauthorized parties. In the absence of any prior written consent neither Party shall copy, reproduce or disclose the Confidential Information to any third party in any manner whatsoever.

4.6 Further Responsibility: The Parties agree and undertake to use the same degree of care to protect the confidentiality of the Confidential Information as it would exercise to protect its own trade secrets and information but in no case less than a reasonable degree of care. Each Party may grant access to the Confidential Information to its directors, officers, employees, advisors and consultants ("related parties") who have a clear need to know, for purposes of this MOU and shall advise such related parties of the existence and terms of this MOU and of its obligations of confidentiality herein.

4.7 Return of Confidential Information: Promptly following the request of either Party the receiving Party will return to the disclosing Party or certify in writing to the disclosing Party as to the destruction of (without retaining any copy in any form or manner) all Confidential Information including copies and extracts thereof as may have been or will be furnished as by the disclosing Party to the receiving Party.

4.8 Remedies: The Parties acknowledge, understand and confirm that the disclosing Party is the proprietor of the Confidential Information and that any unauthorized disclosure, misappropriation or unauthorized use of such Confidential Information by the receiving Party in any manner whatsoever will cause serious irreparable loss and harm

4.9 to disclosing Party. The receiving Party expressly agrees that the disclosing Party shall be entitled to seek injunctive and other equitable relief against it to prevent the breach or further breaches of any of its confidentiality obligations under this MOU and



ATTESTED
5
[Signature]
Dr. V.A. KOTHIWALE

Registrar

[Signature]
PRINCIPAL
K.L.E. University
Shri B. M. Kankanv
Ayurved Mahavidya
Shahapur-BELAGAVI


which it will not dispute by challenging the jurisdiction of the competent Courts where injunctive or equitable relief is being sought at by the disclosing Party.

5. TERMINATION AND AMENDMENT

- 5.1 The term of this MOU is a period of one (1) year from the date of execution. The MOU will be automatically renewed for a further period of one (1) year unless one Party notifies the other Party in writing 30 days in advance that they do not wish to renew the MOU at the completion of the annual review of current and future Projects.
- 5.2 This MOU may be terminated by mutual consent of the parties. Either party may terminate this MOU upon one (1) month written notice to the other.
- 5.3 A Collaboration Agreement made pursuant to clause 2 of this MOU shall survive termination or expiration of this MOU.
- 5.4 This MOU may be amended only by an agreement in writing between the Parties and not otherwise.

6. GENERAL

- 6.1 B.M.K AYURVED MAHAVIDYALAYA and RBPL agree that each of them is free to undertake R&D and business projects on their own or in conjunction with third party, and that the Parties will co-operate only in circumstances where each of them agrees if co-operation is for their mutual benefit and each is satisfied that the specific provisions covering their co-operation are appropriate and will not adversely or prejudicially affect their interests.
- 6.2 With the exception of Clause 4 herein, this MOU is not binding and the Parties do not intend that it or any part of it be binding. It serves only as a record of the understanding between the Parties' intentions pending possible execution of a Collaboration Agreement as contemplated by Clause 2 herein.
- 6.3 Nothing in this MOU will oblige or cast any obligation upon either Party to enter into a Collaboration Agreement with the other Party or to conduct any Project.
7. This MOU constitutes the entire understanding between the Parties regarding the subject matters contained herein. Any prior agreements, commitments or negotiations concerning the subject matters herein are superseded.
8. The headings contained herein are for the purposes of convenience only and are not intended to define or limit the contents of the provisions contained therein.
9. If one or more provisions of this MOU are held to be illegal or unenforceable, such provisions will be limited or excluded to the minimum extent required so that this MOU will otherwise remain enforceable in accordance with the remaining terms.
10. The rights of the Parties hereto shall not be prejudiced or restricted by any indulgence or forbearance extended to the other party and no waiver by the parties hereto of any breach of the other party of any of the terms hereunder shall operate as a waiver in respect of any subsequent breach. No variation of this MOU shall be effective unless it is in writing and duly signed by both parties.
11. **FORCE MAJEURE:** Neither party shall be liable for any delay in or failure of discharging respective obligations under this MOU caused by occurrence beyond the control of B.M.K AYURVED MAHAVIDYALAYA or RBPL as the case may be, including but not limited to fires, floods, explosions, power shortage, failure/breakdown of UPS/DG set/computer etc. or of GOD, hostility, acts of public enemy



6 ATTESTED

V. A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

PRINCIPAL
K.L.E. University
Shri B. M. Kankan
Ayurved Mahavidya
Shahapur-BELAGAVI

insurrections, riots, strikes, lockouts, sabotage. Either parties shall promptly but not later than 10 days of the commencement thereof notify the other in writing of such contingency and prove that such is beyond the control and affects the implementation of this MOU adversely and materially. If such contingency continues beyond 30 days both the parties agree to discuss and agree upon an equitable solution.

12. **ARBITRATION:** For any interpretation of clauses in this MOU or in case of any dispute during implementation, such matter will be jointly discussed by representative of B.M.K AYURVED MAHAVIDYALAYA and RBPL. In case of disagreement, the matter would be referred to the International Centre for Alternative Dispute Resolution (ICADR, an autonomous organization working under the aegis of the Ministry of Law and Justice, Govt. of India) New Delhi-110 070. ICADR decision would be binding on both parties.


IN WITNESS WHEREOF, the parties have executed this MOU as of the date first above written

SIGNED AND DELIVERED BY
KLEU Sri B.M.K Ayurved
Mahavidyalaya, Belagavi, Karnataka
through its Authorized Signatory

SIGNED AND DELIVERED BY
RBPL, Pune, Maharashtra
through its Authorized Signatory

Signature _____
Dr. B. S. Prasad
Principal, KLE University's
KLEU Sri B.M.K Ayurved
Mahavidyalaya, BELAGAVI-03.

Signature Dr. Yogesh Bendale
Dr Yogesh Bendale
Chairman and MD (RBPL)



in the presence of Dr. Vedantam Giridhar
28/11/2015



in the presence of Dr. Arinash Kodam

in the presence of _____


in the presence of _____

ATTESTED
7
[Signature]
Prof. Dr. V.A. KOTHWALE
Registrar

Research Subaward Agreement Amendment

Pass-through Entity (PTE)		Subrecipient	
PTE Thomas Jefferson University		Subrecipient KLE Society's Jawaharlal Nehru Medical College	
Address 125 South 9th St. 2nd Floor Sheridan Building		Address Nehru Nagar, Old Poona-Bangalore Rd	
City, State, Zip+4 (Country) Philadelphia, PA 19107		City, State, Zip+4 (Country) BELAGAVI, KARNATAKA	
PTE Principal Investigator (PI) Dr. Richard Derman		Subrecipient Principal Investigator (PI) Dr. Bhalachandra S. Kodkany	
PTE Federal Award No: 5U10HD0076457-05 REVISED	FAIN: U10HD076457	Federal Awarding Agency: NIH/Eunice Kennedy Shriver NICHD	
Project Title: CCHS-INMC Global Network for Women's & Children Health Research Unit			
Subaward Period of Performance: Start Date: 5/1/2017 End Date: 6/30/2018		Amount Funded This Action: \$20,169	Amendment No: 3 Subaward No: n80-70000-S22901
Effective Date of Amendment: 7/20/2018	Total Amount of Federal Funds Obligated to date \$808,407	Subject to FFATA <input checked="" type="checkbox"/> Yes or <input type="checkbox"/> No	
Amendment(s) to Original Terms and Conditions This Amendment revises the above-referenced Research Subaward Agreement as follows:			
<p>Action: To add funding of \$20,169 for the approved carryforward. Total authorized amount is increased to \$808,407 as per Attachment 1 of Amendment 3, the Notice of Award.</p> <p>Action: To extend the Period of Performance from April 30, 2018 to June 30, 2018</p>			
All other terms and conditions of this Subaward Agreement remain in full force and effect.			
By an Authorized Official of Pass-through Entity:  Name: Timothy Schaeley Date: 8/2/18 Title: Director, Office of Research Administration		By an Authorized Official of Subrecipient:  Name: Dr. (Mrs.) Niranjana S Mahantashuti Date: Aug 2, 2018 Title: Principal	

FDP Version 03 18 2015


 Prof. Dr. V.A. KOTHIWALE
 Registrar
 KLE Academy of Higher Education
 and Research, BELAGAVI

Attachment 1



Notice of Award
COOPERATIVE CLINICAL RESEARCH AGREEMENT Federal Award Date: 08/22/2018
Department of Health and Human Services
National Institutes of Health



EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT

Grant Number: 5U10HD076457-05 REVISED
FAIN: U10HD076457

Principal Investigator(s):
RICHARD J DERMAN, MD

Project Title: CCHS-JNMC Global Network for Women's & Children's Health Research Unit

Margaret Burwell
125 S. 8th Street
2nd Floor, Sheridan Bldg
Philadelphia, PA 19107

Award e-mailed to: resadmin@jefferson.edu

Period Of Performance:
Budget Period: 05/01/2017 – 04/30/2019
Project Period: 07/01/2013 – 04/30/2019

Dear Business Official:

The National Institutes of Health hereby revises this award (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to THOMAS JEFFERSON UNIVERSITY in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 31 USC 6306 42 CFR 82 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the National Institutes of Health under Award Number U10HD076457. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 60 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/efci/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Page 1
ATTESTED

Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

Kimberly Durkin
Grants Management Officer
EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN
DEVELOPMENT

Additional information follows

Page-2 ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

SECTION I - AWARD DATA - 5U10HD076457-05 REVISED

Award Calculation (U.S. Dollars)

Salaries and Wages	\$43,283
Fringe Benefits	\$11,219
Personnel Costs (Subtotal)	\$54,472
Consultant Services	\$24,700
Travel	\$14,424
Subawards/Consortium/Contractual Costs	\$834,847

Federal Direct Costs	\$928,543
Federal F&A Costs	\$54,052
Approved Budget	\$982,595
Total Amount of Federal Funds Obligated (Federal Share)	\$982,595
Less Unobligated Balance	\$264,477
TOTAL FEDERAL AWARD AMOUNT	\$718,118

AMOUNT OF THIS ACTION (FEDERAL SHARE) \$0

SUMMARY TOTALS FOR ALL YEARS		
YR	THIS AWARD	CUMULATIVE TOTALS
5	\$718,118	\$718,118

Fiscal Information:

CFDA Name: Child Health and Human Development Extramural Research
 CFDA Number: 93.865
 EIN: 1231352851A1
 Document Number: UHD076457B
 PMS Account Type: P (Subaccount)
 Fiscal Year: 2017

IC	CAN	2017
HD	8014707	\$718,118

NIH Administrative Data:

PCC: FPB -TR / OC: 414P / Released: SHAWK00 08/21/2018
 Award Processed: 06/22/2018 12:05:10 AM

SECTION II - PAYMENT/HOTLINE INFORMATION - 5U10HD076457-05 REVISED

For payment and HHS Office of Inspector General Hotline Information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

SECTION III - TERMS AND CONDITIONS - 5U10HD076457-05 REVISED

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.
- b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- c. 45 CFR Part 75.
- d. National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
- f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

Page-3

ATTESTED



Prof. Dr. V. A. KOTHIWALE
 Registrar
 K. J. Somaiya Institute of Higher Education
 and Research, BELAGAVI

230

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

Research and Development (R&D): All awards issued by the National Institutes of Health (NIH) meet the definition of "Research and Development" at 45 CFR Part § 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

Carry over of an unobligated balance into the next budget period requires Grants Management Officer prior approval.

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) U10HD076457. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see <http://grants.nih.gov/grants/policy/awardconditions.htm> for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

This award provides support for one or more clinical trials. By law (Title VIII, Section 801 of Public Law 110-85), the "responsible party" must register "applicable clinical trials" on the ClinicalTrials.gov Protocol Registration System Information Website. NIH encourages registration of all trials whether required under the law or not. For more information, see http://grants.nih.gov/ClinicalTrials_fdaee/

This award provides support for one or more NIH defined Phase III Clinical Trials. The NIH Policy for research supported as an NIH Phase III Clinical Trial has been amended in Section II.B. of the NIH Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research - Amended October 2001 (see http://grants.nih.gov/grants/funding/women_mfn/guidelines_amended_10_2001.htm).

A description of plans to conduct analyses, as appropriate, by sex/gender and racial/ethnic groups must be included in clinical trial protocols. Cumulative subject accrual and progress in conducting subset analyses must be reported to NIH in the annual Progress Reports. Final analyses of sex/gender and racial/ethnic differences must be reported in the required Final Progress Report or Compellive Renewal Applications (or Contract Renewals/Extensions) as stated in Section II.B. of the Guidelines.

This award represents the final year of the compellive segment for this grant. See the NIH Grants Policy Statement Section 8.6 Closeout for complete closeout requirements at: <http://grants.nih.gov/grants/policy/policy.htm#gps>.

Page-4

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

231

A final expenditure Federal Financial Report (FFR) (SF 425) must be submitted through the eRA Commons (Commons) within 120 days of the period of performance end date; see the NIH Grants Policy Statement Section 8.6.1 Financial Reports, <http://grants.nih.gov/grants/policy/policy.htm#qps>, for additional information on this submission requirement. The final FFR must indicate the exact balance of unobligated funds and may not reflect any unliquidated obligations. There must be no discrepancies between the final FFR expenditure data and the Payment Management System's (PMS) quarterly cash transaction data. A final quarterly federal cash transaction report is not required for awards in PMS B subaccounts (i.e., awards to foreign entities and to Federal agencies). NIH will close the awards using the last recorded cash drawdown level in PMS for awards that do not require a final FFR on expenditures or quarterly federal cash transaction reporting. It is important to note that for financial closeout, if a grantee fails to submit a required final expenditure FFR, NIH will close the grant using the last recorded cash drawdown level. If the grantee submits a final expenditure FFR but does not reconcile any discrepancies between expenditures reported on the final expenditure FFR and the last cash report to PMS, NIH will close the award at the lower amount. This could be considered a debt or result in disallowed costs.

A Final Invention Statement and Certification form (HHS 568), (not applicable to training, construction, conference or cancer education grants) must be submitted within 120 days of the expiration date. The HHS 568 form may be downloaded at: <http://grants.nih.gov/grants/forms.htm>. This paragraph does not apply to Training grants, Fellowships, and certain other programs—i.e., activity codes C06, D42, D43, D71, DP7, G07, G08, G11, K12, K16, K30, P09, P40, P41, P51, R13, R25, R28, R30, R90, RL6, RL9, S10, S14, S15, U13, U14, U41, U42, U45, UC6, UC7, UR2, X01, X02.

Unless an application for competitive renewal is submitted, a Final Research Performance Progress Report (Final RPPR) must also be submitted within 120 days of the period of performance end date. If a competitive renewal application is submitted prior to that date, then an Interim RPPR must be submitted by that date as well. Instructions for preparing an Interim or Final RPPR are at: https://grants.nih.gov/grants/rppr/rppr_instruction_guide.pdf. Any other specific requirements set forth in the terms and conditions of the award must also be addressed in the Interim or Final RPPR. Note that data reported within Section I of the Interim and Final RPPR forms will be made public and should be written for a lay person audience.

NIH strongly encourages electronic submission of the final invention statement through the Closeout feature in the Commons, but will accept an email or hard copy submission as indicated below.

Email: The final invention statement may be e-mailed as PDF attachments to: NIHCloseoutCenter@mail.nih.gov.

Hard copy: Paper submissions of the final invention statement may be faxed to the NIH Division of Central Grants Processing, Grants Closeout Center, at 301-480-2304, or mailed to:

National Institutes of Health
Office of Extramural Research
Division of Central Grants Processing
Grants Closeout Center
6705 Rockledge Drive
Suite 6016, MSC 7988
Bethesda, MD 20892-7988 (for regular or U.S. Postal Service Express mail)
Bethesda, MD 20817 (for other courier/express deliveries only)

NOTE: If this is the final year of a competitive segment due to the transfer of the grant to another institution, then a Final RPPR is not required. However, a final expenditure FFR is required and should be submitted electronically as noted above. If not already submitted, the Final Invention Statement is required and should be sent directly to the assigned Grants Management Specialist.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that

Page-5

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

232

reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

Treatment of Program Income:
Additional Costs

SECTION IV – HD Special Terms and Conditions – 6U10HD076457-05 REVISED

Clinical Trial Indicator: Yes

This award supports one or more NIH-defined Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

REVISION: This revised award authorizes a carryover of funds in the amount of \$ 2,688 total costs (\$ 2688 direct costs + \$ 0.00 facilities and administrative costs) as requested in the correspondence dated 06/11/2016. The carryover is approved based on the unobligated balance as shown on the year 04 Federal Financial Report (REVISED). These funds are restricted and may not be used for any other purpose without the written prior approval of NICHHD.

The previous terms and conditions of award remain in effect as stated below.

.....
REVISION: This revised award authorizes a carryover of funds in the amount of \$ 44,043 total costs (\$ 36,125 direct costs + \$ 7,918 facilities and administrative costs) as requested in the correspondence dated 2/20/18. The carryover is approved based on the unobligated balance as shown on the year 04 Federal Financial Report. These funds are restricted and may not be used for any other purpose without the written prior approval of NICHHD.

The previous terms and conditions of award remain in effect as stated below.

.....
This award includes a carryover of funds in the amount of \$ 217,768 total costs (\$ 217,768 direct costs + \$ 0.00 facilities and administrative costs). These funds are to be used as requested in the correspondence dated 8/7/2017. The carryover is approved based on the unobligated balance as shown on the year 04 Federal Financial Report. These funds are restricted and may not be used for any other purpose without the written prior approval of NICHHD.

The previous terms and conditions of award remain in effect as stated below.

.....
REVISION: In accordance with the NIH fiscal policy for FY2017, this non-competing award is restored to the originally committed level.

The previous terms and conditions of award remain in effect as stated below.

.....
REVISION: This revised award reflects NICHHD acceptance of the justification for meals at Refresher Trainings as provided in the correspondence dated 05/05/17, and releases the restriction of \$1607.00 on the Notice of Award issued on 04/29/2017.

Page-8

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

The previous terms and conditions of award remain in effect as stated below.

NIH staff has determined that the submitted Continuation Progress Report is within the approved scope of work.

This award includes a base budget as described in the RFA HD-13-008 and fixed protocol-specific funding. The average protocol funding rate was calculated based on budgets submitted by the Research Units on the estimated cost per patient for enrollment and conduct of the individual research protocol. Protocol costs include funds for study start up, e.g., training expenses to implement the study, and funds for the conduct of the study (which requires IRB approval).

Based on participation, compliance, and performance in protocol activities by the network sites, the protocol funds may be reduced and/or redistributed depending on the needs of the Global Network as a whole.

This award includes funding for the following sites: Jawaharal Nehru Medical College of KLE University in Belgaum, INDIA

This award is issued as a cooperative agreement, a financial assistance mechanism in which substantial NIH scientific and/or programmatic involvement is anticipated in the performance of the activity. This award is subject to the terms and conditions of award as set forth in the SPECIAL REQUIREMENTS section of RFA-HD-13-008, "Global Network for Women's and Children's Health Research U10" posted date May 31st, 2012, which are hereby incorporated by reference as special terms and conditions of award.

Copies of this RFA are available at <http://www.nih.gov/grants/guide/index.html>

These special terms and conditions of award are in addition to, and not in lieu of, otherwise applicable OMB administrative guidelines; Federal Regulations, including HHS Grant Administration Regulations at 45 CFR Part 75; other HHS regulations; and the NIH Grants Policy Statement (rev. 11/15).

Project Scientist Contact Information:

Project Scientist: Dr. Marion Koso-Thomas
Email: kosomark@mail.nih **Phone:** (301) 435-8878


STAFF CONTACTS

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

Grants Management Specialist: Kimberly Durkin
Email: kimberly.durkin@nih.gov **Phone:** 301-451-0820


Program Official: Tonse N. Raju
Email: raju1@mail.nih.gov **Phone:** (301) 402-1872 **Fax:** (301) 498-3790

Page-7
ATTESTED




Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELASAVI

HP LaserJet Pro

M402/M403 Series



Optimize your day-to-day workflow with this reliable, high-performance black and white printer designed for work teams of 3 to 10 people. Share printing resources on a network¹ and take advantage of fast printing speeds. Be productive and save paper using automatic two-sided printing.² Embedded PIN printing helps keep confidential documents safe.³ The easy-to-use two-line control panel lets you start printing right away.



2-sided printing²



Auto On/Off Technology



Wireless direct printing⁴



PIN printing³



NFC touch to print⁵

Original HP Toner Cartridges with

JETINTELLIGENCE

More. Pages, performance and protection.

¹ Available only on HP LaserJet Pro M402 and M403 n/dn/dw. ² Available only on HP LaserJet Pro M402 and M403 d/dn/dw. ³ Requires purchase and installation of separate USB drive and available only on HP LaserJet Pro M402 and M403 n/dn/dw. ⁴ Print without a router and available only on HP LaserJet Pro M402 and M403 dw. ⁵ Available only on HP LaserJet Pro M402 and M403 dw.

Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

www.hp.com

SUB-GRANT AGREEMENT (July 16, 2012)

Between
KLE University's JAWAHARLAL NEHRU MEDICAL COLLEGE, BELGAUM, INDIA
and
THE UNIVERSITY OF BRITISH COLUMBIA

- I. This is a Sub-grant Agreement ("Agreement") under an Agreement (the "Prime Agreement") dated 5 November 2010 (with effect from 12 November 2010) between the Bill & Melinda Gates Foundation (the "Prime Sponsor") and the University of British Columbia, a corporation existing under the *University Act* of British Columbia with offices at 103 – 6190 Agronomy Road, Vancouver, British Columbia, V6T 1Z3, Canada, for the project PRE-EMPT (Pre-eclampsia, Eclampsia, Monitoring, Prevention & Treatment) (the "Prime Project").
The parties to this Agreement are The University of British Columbia (hereinafter referred to as "UBC") and the KLE University's Jawaharlal Nehru Medical College, Belgaum, India, (hereinafter referred to as "SUB-AWARDEE").

Further, SUB-AWARDEE will execute a separate subcontract with S Nijalingappa Medical College, Bagalkot "SNMC" for providing personnel and other resources for implementation of activities related to the research project .

UBC and SUB-AWARDEE are each referred to herein as a "Party" and jointly as "the Parties".

This Agreement sets forth the terms for a sub-grant by UBC to SUB-AWARDEE in the amount of **USD \$195,230.00** in support of the research project to test new community level strategies for the monitoring, prevention, and treatment of pre-eclampsia, as more fully described in Annex 1 hereto (the "Project"). Specifically, the Agreement pertains to the CLIP Feasibility Study Project Plan.

The Sub-grant Agreement between the Parties comprises:

This Agreement;

Annex 1 – Original BMGF PRE-EMPT PROPOSAL Research Proposal and Budget; and

Annex 2 – PROPOSAL CLIP FEASIBILITY STUDY

Annex 3 – PRIME AGREEMENT

- II. The budget for the activities to be reimbursed by UBC is set out in Annex 1. Should major changes between categories of expenditure become necessary in the course of implementing the activities, SUB-AWARDEE shall proceed in accordance with the provision set forth in Article IV. 3(i) below.

III. Responsibility

1. SUB-AWARDEE Co-Principal Investigators are responsible for the proper management and conduct of the Project.
2. The UBC Principal Investigator shall be responsible for directing the Project, reviewing, evaluating and monitoring SUB-AWARDEE's technical, scientific and programmatic performance under this Agreement.
3. UBC shall be responsible for the provision of funds to SUB-AWARDEE for the Project, in accordance with the terms of this Agreement and its Annexes.

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

July 16, 2012

IV. Financial arrangements

1. Schedule of payments

The total amount of the funds to be provided by UBC to SUB-AWARDEE (the "contribution") is USD \$195,230.00. The amount of \$170,230.00 will be paid upon signing of this agreement, and USD \$ 25,000.00 will be paid within 30 days of receipt of the final report.

2. Payment of the contribution

Payments shall be deposited according to the above schedule of payments in the SUB-AWARDEE's bank account:

ACCOUNT DETAILS FOR USD PAYMENT

CORRESPONDENT BANK NAME AND ADDRESS:

**BENEFICIARY BANK
NAME AND ADDRESS:**

Syndicate Bank, JNMC Campus, Nehru Nagar, Belgaum, Karnataka – India, PIN: 590010.

BANK ROUTING NO (SORT CODE, SWIFT CODE OR IBAN): SYNBINBB155

DEUTSCH BANK TRUST COMPANY AMERICAS NEWYORK


ACCOUNT NAME (IN THE NAME OF THE INSTITUTE): **Principal, J. N. Medical College, Belgaum.**

ACCOUNT NUMBER: **05043030000042**

3. Utilization of funds and accounting

- (i) The payment shall be used and for the purposes indicated in Annex 1 hereto and shall be administered in accordance with the terms of this Agreement and the SUB-AWARDEE Financial Regulations and Rules as contained in Annex 4. Any budget cost category change of more than 10% must be approved in writing by UBC in advance. No grant funds may be used to reimburse expenses incurred prior to the starting date of the Project.
- (ii) Any interest earned on the cash balance of the contribution shall be used in accordance with SUB-AWARDEE Financial Regulations and Rules, and financial and administrative rules and practices of SUB-AWARDEE.
- (iii) Any balance of the contribution that is outstanding at the time of expiration of the Project, or of termination of this Agreement, and after all properly incurred

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

2

237

July 16, 2012

obligations by SUB-AWARDEE prior to expiration or termination have been fully liquidated, shall be repaid to UBC.

V. Implementation

1. **Period of implementation**

The starting date of the Project shall be **July 20, 2012**.

The completion date of the Project shall be **August 31, 2013**, with a Preliminary Feasibility Study report due **January 15, 2013**, an interim Feasibility Study report due by **March 31, 2013** and a final report due by **September 30, 2013**.

SUB-AWARDEE will use reasonable efforts to perform the Project substantially in accordance with the terms and conditions of this Agreement.

SUB-AWARDEE shall have no obligation to implement the Project unless all necessary and sufficient funds for the implementation have been received by SUB-AWARDEE.

A period of up to 12 months shall be allowed after completion of the Project, or of any termination of this Agreement, to liquidate all obligations for activities completed by SUB-AWARDEE prior to expiration or termination of this Agreement.

2. **Completion of Deliverables**

During the term of the Project and by agreement of the Party Scientific Contacts, the Parties will enter into a further agreement to conduct the CLIP RCT in India.

This commitment will be voided in case of events beyond the control of the SUB-AWARDEE. These events may include, but are not restricted to: acts of God, acts of local or provincial governments, fires, floods, epidemics, quarantine restrictions, strikes or labour unrest, freight embargoes, war or political instability and unusually severe weather.

VI. Reporting

1. **Technical**

SUB-AWARDEE shall transmit to UBC at quarterly intervals, a technical report on the progress in the activities financed by the contribution.

Technical Reports are due on the Target Dates outlined above, with a Preliminary Feasibility Study report due **January 15, 2013**, an interim Feasibility Study report due by **March 31, 2013** and a final report due by **September 30, 2013**.

The parties will engage in regular monthly teleconference calls during the course of the Project.

2. **Financial**

The income and expenditure recorded in respect of the contribution under this Agreement shall be indicated in the SUB-AWARDEE Financial Reports on an annual and biennial basis. Certified financial statements of income and expenditure shall be provided to UBC on a yearly basis. A final certified statement of income and expenditure will be provided by SUB-

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLF Academy of Higher Education
and Research, BELAGAVI

July 16, 2012

AWARDEE, after settlement of all obligations for activities started by SUB-AWARDEE prior to expiration or early termination of the Agreement.

All reports will be submitted to the UBC Principal Investigator at the address set forth in Section XXI below.

VII. Audit

It is understood that all agreements with SUB-AWARDEE are subject exclusively to its internal and external auditing procedures.

VIII. Change of SUB-AWARDEE Co-Principal Investigators

If the SUB-AWARDEE Co-Principal Investigators become unable or unwilling to continue the Project, SUB-AWARDEE will use all reasonable endeavors to find a replacement within a period not exceeding three (3) months. SUB-AWARDEE shall promptly inform UBC of any change of the SUB-AWARDEE Co-Principal Investigators.

IX. Acknowledgement

Neither party shall use the name or emblem of the other in any form of advertising or promotion without the prior written approval of the other party.

SUB-AWARDEE may not make any statement or otherwise imply to the media, the general public or any other donor or investor that SUB-AWARDEE's participation in this Project is supported by any organization other than UBC, unless SUB-AWARDEE has directly received funds from the other organization (prime sponsor). SUB-AWARDEE may state that UBC is the grantee of the Bill & Melinda Gates Foundation and that SUB-AWARDEE is a sub-grantee of UBC for the Project.

SUB-AWARDEE shall obtain advance approval from UBC for any use of the name or logo of the Prime Sponsor:

X. Termination

Either party may terminate this Agreement upon written notification to the other. Such termination shall enter into effect three months after notice has been received subject to the settlement of any outstanding obligations.

XI. Global Access

SUB-AWARDEE's activities pursuant to this Agreement must be consistent with and in furtherance of Global Access and the scientific and charitable objectives of the Prime Project, as more fully described in the Prime Agreement.

XII. Publications

SUB-AWARDEE has the right to publish and otherwise publicly disclose information it has

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KJ Somaiya Academy of Higher Education
and Research, BELAGAVI

July 16, 2012

gained in the course of the conduct of the Project in accordance with the terms of this Agreement. The Parties agree with, and will give effect to, the publication provisions contained in the Prime Agreement.

XIII. Intellectual Property Rights

All rights in the work emanating from the Project under this Subgrant Agreement, including ownership of the SUB-AWARDEE background intellectual property and copyright thereof, shall be vested in SUB-AWARDEE. SUB-AWARDEE hereby grants UBC a royalty-free, non-exclusive license to use and reproduce the work for UBC's educational, scientific or research purposes, including the right of publication thereof, subject to an appropriate acknowledgement of SUB-AWARDEE's copyright (unless SUB-AWARDEE indicates that it does not wish to be associated with any such publication). UBC shall provide SUB-AWARDEE with an advance copy of any material intended to be published in sufficient time to allow SUB-AWARDEE to review such material, and UBC shall consider seriously and in good faith any comments offered by SUB-AWARDEE as long as they are received in sufficient time so as not to delay publication.

XIV. Data Sharing

SUB-AWARDEE grants to UBC the right to use data and other information created in the performance of this Agreement and the right to authorize others to use such data or information for non-commercial purposes in order to enable (i) the knowledge gained during the Project to be promptly and broadly disseminated, and (ii) the intended product(s) to be made available and accessible at reasonable cost to people most in need within developing countries. The foregoing is subject to any requirement for confidentiality.

XV. Human Subjects

It is understood that no clinical research involving the use of human subjects will be conducted under this Agreement.

XVI. Terrorism

The paragraph entitled "Anti-Terrorism" in the Prime Agreement shall not apply to SUB-AWARDEE. Nevertheless, SUB-AWARDEE confirms that it is the SUB-AWARDEE's policy not to engage in, support or promote terrorism, either directly or indirectly through another organization or individual.


XVII. Liability

Each Party shall be solely responsible for the manner in which it carries out its part of the collaborative activities under this Agreement. Thus, a Party shall not be responsible for any loss, accident, damage or injury suffered or caused by another Party, or that other Party's staff or sub-contractors, in connection with, or as a result of, the collaboration under this Agreement.

XVIII. Independent Contractor

For the purposes of this Agreement and all work to be performed hereunder, each Party shall be,

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

5

240

July 16, 2012

and shall be deemed to be, an independent contractor and not an agent or employee of the other Party. Neither Party shall have authority to make any statements, representations, nor commitments of any kind, or to take any action, which shall be binding on the other Party, except as may be explicitly provided for herein or authorized by the other Party in writing.

XIX. Assignment

This Agreement shall not be assignable by either Party without the prior written consent of the other Party. Any and all assignments not made in accordance with this Section shall be void.

XX. Settlement of disputes

Any dispute relating to the interpretation or application of this Agreement shall, unless amicably settled, be subject to conciliation. In the event of failure of the latter, the dispute shall be settled by arbitration. The arbitration shall be conducted in accordance with the modalities to be agreed upon by the Parties, or in the absence of agreement, with the rules of arbitration of the International Chamber of Commerce. The Parties shall accept the arbitral award as final.

XXI. Contact Information

Administrative Contacts

SUB-AWARDEE

Dr Shivaprasad S Goudar,
Professor of Physiology,
JN Medical College

sgoudar@jnmc.edu; +91 94481 26371

UBC

Mario Kasapi, Associate Director
University-Industry Liaison Office
#103 – 6190 Agronomy Road
Vancouver, British Columbia
Canada V6T 1Z3
Telephone: (604) 822-8580
Email: Mario.kasapi@uilo.ubc.ca

Scientific Contacts

SUB-AWARDEE

Dr Shivaprasad S Goudar,
Professor of Physiology,
JN Medical College

sgoudar@jnmc.edu; +91 94481 26371

UBC

Dr Peter Von Dadelszen
Maternal Fetal Medicine
The University of British Columbia
Room 426B, 4500 Oak Street,
Vancouver, British Columbia V6H 3N1
Telephone: +1 875-3054
Email: pvd@cw.bc.ca

ATTESTED



Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI


July 16, 2012


XXII. Entire Agreement

This Agreement constitutes the entire agreement between UBC and SUB-AWARDEE. Any changes or modifications shall be made by amendment to this Agreement in writing executed by the duly authorized representatives of the Parties.

Accepted on behalf of the
The University of British Columbia

Accepted on behalf of the
KLE University and JN Medical College



.....
Dr. Mario Kasapi,
University-Industry Liaison Office


.....
Dr Shivaprasad S Goudar,
Professor and Head, Department of Physiology,
KLE University's JN Medical College,
Belgaum 590010 Karnataka India

Date: July 31/12

Date: July 20, 2012


By: _____
Name: _____
Title: _____


.....
Dr V D Patil
Principal,
JN Medical College,
Belgaum 590010 Karnataka India

Date: Aug 2/12

Date: 20/7/2012



ATTESTED

Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

CLINICAL STUDY SUB-SITE AGREEMENT

This clinical study sub-site agreement (the "Agreement") is made effective as of September 2, 2013 (the "Effective Date")

AMONG:

THE UNIVERSITY OF BRITISH COLUMBIA, a corporation continued under the *University Act* of British Columbia with offices at 103 - 6190 Agronomy Road, Vancouver, British Columbia, Canada V6T 1Z3 ("UBC"), and CHILDREN'S & WOMEN'S HEALTH CENTRE OF BRITISH COLUMBIA BRANCH, a public hospital having its administrative offices at 4500 Oak Street, Vancouver, British Columbia, Canada V6H 3N1 ("C&W")

(UBC and C&W will be referred to in the Agreement collectively as the "Coordinating Institution")

AND:

DR. PETER VON DADELSZÉN, having an address at Rm V3-339, 950 West 28th Avenue, Vancouver, British Columbia, Canada V5Z 4H4 (the "Principal Investigator")

AND:

KLE UNIVERSITY'S JAWAHARLAL NEHRU MEDICAL COLLEGE, WOMEN'S AND CHILDREN'S HEALTH RESEARCH UNIT BELGAUM, having its administrative offices at Jawaharlal Nehru Medical college Nehru Nagar Belgaum 590010, Karnataka India (the "Site")

AND:

Dr. M.B. BELLAD, having an address at Department of OBGYN, KLE University's J N Medical College, Belgaum, 590010 Karnataka India

AND:

DR. SHIVAPRASAD S. GOUDAR, having an address at Department of Physiology, KLE University's J N Medical College, Belgaum, 590010 Karnataka India

(Dr. M.B. Bellad and Dr. Shivaprasad S. Goudar will be referred to in the Agreement collectively as the "Site Investigator")

(the Coordinating Institution, the Principal Investigator, the Site, and the Site Investigator are referred to in the Agreement individually as a "Party" and collectively as the "Parties")

WHEREAS:

The term "UBC" includes both UBC-Vancouver and UBC-Okanagan campuses.

ATTESTED



It is UBC's objective to exploit its technology for the public benefit in harmony with the UBC Global Access Principles, outlined at www.uilo.ubc.ca/global.asp, and to generate further research in a manner consistent with UBC's status as a non-profit, tax-exempt educational institution. Under UBC research policy and in agreement with its affiliated hospitals, UBC owns inventions, results, and/or data that arise from research performed by UBC and which are conceived and/or made by researchers who have an appointment with UBC.

The Principal Investigator designed and developed the protocol for a clinical study titled "**The CLIP (Community Level Interventions for Pre-eclampsia) Cluster Randomized Controlled Trial**" (the "**Study**").

UBC has received a grant for the Study from the Bill & Melinda Gates Foundation (the "**Foundation**").

The Principal Investigator and the Coordinating Institution wish to engage the services of the Site Investigator and the Site for the Study, and the Site Investigator and the Site wish to be so engaged.

THE PARTIES AGREE AS FOLLOWS:

1.0 Definitions

1.1 In the Agreement:

(a) "**Confidential Information**" means the Protocol (as defined below) and all information, regardless of its form, that is disclosed by one Party (the "**Discloser**") to another Party (the "**Recipient**") and which is clearly identified in writing as being confidential either at the time of disclosure, or if disclosed other than in writing, then the Discloser will identify such information as confidential at the time of disclosure and will summarize such disclosure in writing and label it "**Confidential**" within 30 days of the original disclosure, except that Confidential Information does not include information:

- (i) possessed by the Recipient prior to receipt from the Discloser, other than through prior confidential disclosure by the Discloser, as evidenced by the Recipient's business records;
- (ii) published or otherwise made available to the general public, other than through a breach of the Agreement;
- (iii) obtained by the Recipient from a third party with a valid right to disclose it, provided that the third party is not under a confidentiality obligation to the Discloser in respect of the same; or
- (iv) Independently developed by employees, agents, or consultants of the Recipient who had no knowledge of or access to the Discloser's information, as evidenced by the Recipient's business records.

"**Contract Period**" means the time period ranging from the Effective Date

(b) "**Contract Period**" means the time period ranging from the Effective Date through May 31, 2017 (the "**End Date**").

ATTESTED

CONFIDENTIAL

J N Medical College UBC File No. F13-03649
Prof. Dr. V.A. KOTHIWALE

Page 2 of 21

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

244

(c) "Data" means any and all data generated or collected during the Contract Period in the performance of the Study, including, but not limited to, medical information, diagnoses, and analyses of medical records.

(d) "Data Collection Forms" means the documents attached to the Agreement as Schedule "A", as well as the mHealth data fields embedded in PIERS on the Move, as per the Protocol (defined below). The full implementation of PIERS on the Move on the mHealth platform is contingent on its feasibility as assessed during the CLIP Pilot Study.

(e) "Inventions" means any and all knowledge, know-how, techniques, technologies, or other intellectual property that is conceived, invented, developed, improved, or acquired during the Contract Period in the performance of the Study.

(f) "Protocol" means the protocol for the Study that is attached to the Agreement as Schedule "B".

(g) "Site Data" means all Data solely generated or developed by the Site Investigator or the Site Researchers (as defined below).

(h) "Site Researchers" means any agents, employees, representatives, or sub-investigators of the Site.

(i) "Study Budget" means the description of compensation that is attached to the Agreement as Schedule "C".

2.0 SCOPE OF WORK AND FUNDING

2.1 The Site Investigator will conduct the Study at the Site in accordance with the Protocol and any approved amendments, which will form an integral part of the Agreement. The Principal Investigator and/or the Coordinating Institution may amend the Protocol from time to time during the Contract Period, and a copy of any such amendment will be promptly provided by the Principal Investigator to the Site Investigator. The implementation of any such amendment by the Site Investigator and the Site will be preceded by any approval that may be required by the Site's Research Ethics Board ("REB").

2.2 The Site and Site Investigator will also ensure that the Study is conducted in accordance with the Protocol and any approved amendments at S. N. Medical College, Bagalkot ("SNMC"). The Site and Site Investigator will enter into an agreement (the "SNMC Agreement") with SNMC and investigators participating in the Study at SNMC (the "SNMC Investigators"), as applicable, and otherwise ensure that SNMC and the SNMC Investigators (a) are bound by the same obligations and responsibilities by which the Site and Site Investigator are bound under the Agreement; (b) agree to the terms and conditions of the Agreement as if SNMC and the SNMC Investigators were parties to the Agreement; (c) fulfill all their obligations in order to allow the Site and Site Investigator to fulfill their obligations under the Agreement.

2.3 The Coordinating Institution will provide funds to the Site for the performance of the Study by the Site Investigator in accordance with the Study Budget. The Principal Investigator and the Coordinating Institution, acting reasonably, reserve the right to withhold payment or request the return of funds to the extent that Study participants were not properly enrolled under the terms of the Protocol or the Study was otherwise not conducted in accordance with this Agreement or the Protocol. The Parties acknowledge and agree that the funding of the Site is contingent upon the receipt of grant funding from the Foundation by the Coordinating Institution.

The funding provided by the Coordinating Institution to the Site will be deemed inclusive of costs associated with the research at the Site, including any indirect costs or administrative charges of the Site.

2.4 By January 15 of each year during the Contract Period, the Site will submit to the Coordinating Institution, and will ensure that SNMC will submit to the Coordinating Institution, a CLIP Annual Progress Report and completed Budget Report for the previous fiscal year (November 1 to October 31) in accordance with the Foundation reporting format requirement included in the Study materials provided to the Site.

2.5 The Site has been selected to participate in the Study at UBC's discretion. The Site may not make, and will ensure that SNMC does not make, any statement or otherwise imply to donors, investors, media, or the general public that the Site is a direct grantee of the Foundation. The Site may state that UBC is the Foundation's grantee and that the Site is a subgrantee or subcontractor of UBC for the Study.

2.6 Except as stated above, the Site may not issue, and will ensure that SNMC will not issue, a press release or announcement regarding the award of the subgrant by UBC to the Site or SNMC, or a press release or announcement that is directly related to the subgrant, without obtaining advance approval from the Coordinating Institution of the press release or announcement and the date of release. The Site also agrees to obtain, and will ensure that SNMC agrees to obtain, advance approval from the Coordinating Institution for any other use of the Foundation's name or logo.

2.7 The Site and Site Investigator will not expend, and will ensure that neither SNMC nor the SNMC Investigators expend, any funds to enroll human subjects in the Study until the necessary ethical bodies' approvals are obtained by the Site, the Coordinating Institution, and SNMC, and copies of the Site's and SNMC's approvals are provided to the Coordinating Institution.

2.8 Funding provided by UBC to the Site may be used only for the Study. Any funds unexpended or uncommitted at the end of the Contract Period must be promptly returned to UBC. Any budget cost category change of more than 10% must be approved in writing by the Coordinating Institution in advance. No funds may be used to reimburse expenses incurred prior to the Effective Date.

2.9 Funds originating from the Foundation may be invested in highly liquid investments with the primary objective of preservation of principal so that they are available for the Study. The Coordinating Institution requires that the Site report the amount of any interest or other income generated by the grant funds, including currency conversion gains (collectively "Interest"). Any Interest must be used for the Study.

2.10 The Site and Site Investigator will maintain, and will ensure that SNMC and the SNMC Investigators maintain, adequate financial records for the Study in order to enable the Coordinating Institution to easily determine how the Study funds were expended. The Parties agree that the Site and Site Investigator's books and records must be made available for inspection, and that the Site and Site Investigator will ensure that the SNMC and SNMC Investigators' books and records are made available for inspection, by the Coordinating Institution or its designee at reasonable times to permit the Coordinating Institution to monitor and conduct an evaluation of operations under the Study.

ATTESTED

CONFIDENTIAL

J N Medical College

UBC File No. F13-03649

Page 4 of 21

Prof. Dr. V.A.KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

246

3.0 PERIOD OF PERFORMANCE

3.1 The Agreement will continue in full force and effect for the duration of the Contract Period; or if the Study is completed prior to the End Date, until the date on which the Study is completed at the Site; or if the Parties agree to extend the Study at the Site beyond the End Date, until such date as is mutually agreed upon in writing; or if the Study is terminated in accordance with Section 10.0 of the Agreement, until the date on which the Study is terminated.

4.0 RESPONSIBILITIES OF THE SITE AND/OR SITE INVESTIGATOR

4.1 The Site and/or Site Investigator, as applicable, will, and will ensure that SNMC and the SNMC Investigators will:

(a) comply with the Protocol and with all applicable laws, rules, guidelines, and regulations in the performance and documentation of the Study, including, but not limited to: the generally accepted principles of "Good Clinical Practices" as defined by the International Conference on Harmonisation (ICH) E-6 Standard (the "ICH/GCP"), the United States Food and Drug Administration, or the European Agency for the Evaluation of Medicinal Products, as applicable; the Canadian Institutes of Health Research: Best Practices for Protecting Privacy in Health Research; the Declaration of Helsinki; the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans; and all applicable Health Canada regulations and other applicable federal, provincial, and local laws, rules, regulations, procedures, and guidelines.

(b) provide to the Coordinating Institution, prior to screening Study participants or enrolling Study participants into the Study: (i) a copy of the Study participant informed consent form, written in the Site's local language, that will be used in the Study and that has been approved by the Site's REB (the "ICF"), as well as a copy of the ICF that has been translated into English and a signed certificate of translation which certifies that the ICF in English is a true and accurate translation of the ICF in the Site's local language; and (ii) a copy of the Data Collection Forms formatted for the local site and written in the English language that will be used in the Study and that has been approved by the Site's REB. Any changes to the ICF or Data Collection Forms will be reported to the Coordinating Centre, with justification for each change, prior to the UBC REB renewal.

(c) provide to the Coordinating Institution, prior to screening Study participants or enrolling Study participants into the Study, a copy of the *curriculum vitae* of the Site Investigator, SNMC Investigators, and any key Study personnel at the Site and SNMC; and written evidence of all applicable legal, regulatory, and ethical bodies' approvals for the Study, including written approval from the appropriate REB and ethical committee for the Protocol and the conduct of the Study at the Site and SNMC. The Site will promptly notify, and will ensure that SNMC will promptly notify, the Coordinating Centre if the facts and/or circumstances change regarding the approval status of the REB or ethical committee for the Protocol.

(d) provide to the Coordinating Institution, for trial monitoring purposes, the certificate of analysis for the drugs to be used in the Study (the "Study Drugs"; methyl dopa, MgSO₄), including the batch number, expiry date, where the Study Drugs will be stored, and who will be responsible for handling the Study Drugs (e.g., pharmacist).

ATTESTED

CONFIDENTIAL

J N Medical College


—UBC File No. F13-03649

Page 5 of 21

Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

247

(e) assume responsibility for the conduct of the Study at the Site or SNMC, as applicable, and conduct the Study at the Site or SNMC, as applicable, in accordance with the Protocol (subject to any amendments approved by the Site's REB or SNMC's REB, as applicable). Any changes in procedure set out in the Protocol will be made by the Site Investigator only if considered necessary by the Site Investigator to protect the safety, rights, or welfare of Study participants, provided that the Site Investigator promptly notify the Principal Investigator of any such deviation. Such deviations from the terms of the Protocol will not constitute negligence, error, omission, malfeasance, or material breach of the Agreement on the part of the Site Investigator or the Site.

(f) ensure that any sub-investigators and any support staff who are participating in the Study at the Site and SNMC will comply with the terms of the Protocol and any amendments to the same extent as the Site Investigator. The Site Investigator will take appropriate steps to inform, and will ensure that the SNMC Investigators will take appropriate steps to inform, each such person of his/her obligations and to obtain his/her agreement to abide by the terms and conditions of the Agreement.

(g) complete accurately and promptly the Data Collection Forms in accordance with the Protocol and submit completed Data Collection Forms and any other Study data on a timely basis through the customized Study database. Clinical PIERS on the Move cleaned data will be sent monthly, and Surveillance cleaned data will be sent at the completion of each Surveillance cycle. ~~The Site will provide all translation services for paper copy and mHealth Data Collection Forms.~~

(h) disclose to Study participants and the REB what care and/or referrals will be available through participation in the Study. Institutional policies regarding what care will be provided to personnel who are injured as a result of their work on the Study should be similarly developed, approved, and implemented with notice to the employees.

(i) conduct and manage the Study, and Study technologies, biological samples, and information, in a manner that enables (i) the knowledge gained during the Study, including but not limited to data and biological samples, to be promptly and broadly disseminated; and (ii) the intended product(s) to be made available and accessible at reasonable cost to people most in need within developing countries.

(j) agree that the Site and/or Site Investigator, as applicable, will source and purchase, in country, all Study package materials, including (i) all Study Drugs, and (ii) all devices and equipment to be used in the Study (collectively, the "Study Devices"). The Study Devices will exclude blood pressure monitoring devices (BP 3AS-2), which will be purchased from Microlife by the Coordinating Institution and provided by the Coordinating Institution to the Site for use in the Study. The blood pressure monitoring devices will be provided by the Coordinating Institution to the Site in quantities sufficient for use in the Study. The Site will be responsible for replacing any blood pressure monitoring devices and mobile devices that are misplaced, stolen, damaged, or lost. All Study Drugs and Study Devices sourced and purchased by the Site must meet quality standards established by the Coordinating Institution. The Coordinating Institution will reimburse the Site for the Study Drugs and Study Devices listed in Table A below. The Coordinating Institution will pay to the Site up to the Amounts specified in Table A plus 15% in indirect costs upon invoice, with the exception of cell phone minutes/data plan, indicated in Table A as "Mobile Minutes", for which the Coordinating Institution will provide to the Site a one-time payment in the amount of \$22,500 USD (including indirect

ATTESTED

costs) at the first quarterly invoice. The Coordinating Institution will also provide the Site with funds plus 15% in indirect costs to purchase the Android operating system-based mobile devices and SD cards upon receipt of the quote from the mobile device vendor. In the event that the Coordinating Institution is able to purchase the mobile devices directly, the Coordinating Institution will notify the Site. Accurate records of the costs of all Study Drugs and Study Devices, including receipts, will be provided by the Site to the Coordinating Institution upon request by the Coordinating Institution for the purposes of (i) reimbursement, and (ii) conducting the Study cost analysis. The Coordinating Institution will reimburse the Site on a quarterly basis for the Study Devices within sixty (60) days of receipt of an invoice with receipts. The total payment by the Coordinating Institution to the Site for the direct costs of the Study Drugs and Study Devices will not exceed \$33,454 USD. The total payment by the Coordinating Institution to the Site for the indirect costs of the Study Drugs and Study Devices will not exceed \$1,643 USD.

Table A

Sl.N O	Particulars	Quant ity	Rate (in Rupees)	Amount (in Rupees)	Amount (in USD)
1	Clip Box	50	200	10000	167
2	Clip Box Cardboard box with Stickers	1500	30	45000	750
3	Stickers Cardboard box	1500	30	45000	750
4	Gloves Pair	1500	20	30000	500
5	Syringe 10ml *3	4500	20	90000	1500
6	Magnesium sulfate 10ml 2	3000	40	120000	2000
7	Methyldopa, 3 tablet per Women	4500	3	13500	225
8	Alcohol swabs	4500	1.5	6750	113
9	Community engagement handbook or Pamplet 3 Fold	2000		30000	500
10	PHC Posters- 200 quantity , Size 2'X4' flex- Color	200	150	30000	500
11	Paper Posters A3 size	1000	15	15000	250
12	Fram with board for 200 Paperposter A3 Size	200	100	20000	333
ATTESTED					

13	Mobile Minutes - 2gb Limited usage Rs 250 for 3g Plan for 150 Devices over a period on 36 months	150	250	1350000	22500	
14	Dip Sticks (Protein)	1500	100	150000	2500	
15	CLIP Protocol Over View	600	30	18000	300	
16	LMP EDD Card	600	30	18000	300	
17	Sharps Box for Syringe Disposal	40	400	16000	267	

In United States Dollars **\$33,454**

In Rupees **2,007,250**

5.0. RECORD KEEPING

5.1 The Site and Site Investigator will maintain, and will ensure that SNMC and the SNMC Investigators maintain, adequate and accurate records relating to the Study, including the Study participant informed consent and treatment records of the Study participants, for the minimum period following completion or termination of the Study that is required by Health Canada regulations or such other period required by local laws, regulations, or guidelines.

6.0 CONFIDENTIALITY

6.1 The Recipient will keep and use the Discloser's Confidential Information in confidence and will not, without the Discloser's prior written consent, disclose the Discloser's Confidential Information to any person or entity, except to the Recipient's directors, officers, employees, faculty, students, and professional advisors who require the Confidential Information in order to assist the Recipient in performing its obligations and/or exercising its rights under the Agreement.

6.2 If the Recipient is required by judicial or administrative process to disclose the Discloser's Confidential Information, the Recipient will promptly notify the Discloser of the requirement and allow the Discloser reasonable time to oppose the process before disclosing the Confidential Information.

6.3 The Parties agree that the provisions of this Section 6.0 will not prevent the Recipient from disclosing the Discloser's Confidential Information to: (i) the Recipient's REB; (ii) the REB of another site participating in the Study if it is necessary for the performance of the Study or for the safety of Study participants, provided that the Recipient notifies the Discloser in writing in advance of the Recipient's intention to do so; or (iii) Study participants, their doctors, or their legal representatives if required for the clinical or medical care or safety of the Study participants.

ATTESTED



CONFIDENTIAL

J N Medical College

UBC File No. F13-03649

Page 8 of 21

Prof. Dr. V.A.KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

250

6.4 Notwithstanding any termination or expiration of the Agreement, the obligations set out in this Section 6.0 survive and continue to bind the Parties and their successors and assigns until 5 years after the date of such termination or expiration.

7.0 PRIVACY

7.1 The Parties agree that all personal information and personal health information (the "Information") provided by a Party to any other Party under the Agreement is subject to Canada's *Personal Information Protection and Electronic Documents Act* ("PIPEDA"), the text of which is available at the following web address: <http://laws-lois.justice.gc.ca/PDF/P-8.6.pdf>. Each Party warrants that the Party and its employees and designee(s) will adhere to and comply with all applicable laws and regulations regarding protection of the Information, including but not limited to PIPEDA. In the event that a Party is subject to a substantially similar provincial legislation as acceptable under the terms of PIPEDA, the Party will comply with such provincial legislation in its use, retention, and destruction of all Information provided to it under the Agreement. Notwithstanding anything to the contrary in the Agreement, the Parties will treat as confidential, and will continue to treat as confidential following the ending or termination of the Agreement, all the Information of Study participants as set out in this Section 7.1 and as required by law.

8.0 DATA AND INVENTIONS

8.1 Subject to Section 9 (Publication), the Parties agree, and the Site and Site Investigator will ensure that SNMC and the SNMC Investigators agree, that the Coordinating Institution and the Principal Investigator own all right, title, and interest in any and all Data, Site Data, Data Collection Forms, and Data generated or developed by SNMC, SNMC Investigators, and any agents, employees, representatives, or sub-investigators of SNMC (the "SNMC Researchers").

8.2 The Coordinating Institution and the Principal Investigator hereby grant to the Site and the Site Investigator a non-exclusive, royalty-free, irrevocable, perpetual right to use any and all Site Data for the purpose of the Study and internal and academic research purposes.

8.3 The Site and the Site Investigator will promptly disclose, and will ensure that SNMC and the SNMC Investigators will promptly disclose, to the Principal Investigator and the Coordinating Institution any Inventions made or conceived by the Site Investigator and/or the Site Researchers. Inventorship will be determined in accordance with United States patent law and ownership will follow inventorship. Where a joint Invention is made by naming at least one entity as inventor from each Party, the Site and the Site Investigator agree, and will ensure that SNMC and the SNMC Investigators agree, to enter into an agreement with the Coordinating Institution to administer such joint Inventions (the "Joint Inventions Agreement"). The Joint Inventions Agreement will specify, among other terms, the respective responsibilities of the Parties regarding patent costs and other reasonable costs, and a reasonable and equitable revenue sharing mechanism.

8.4 Each Party hereby grants to the other Parties a non-exclusive, royalty-free license to use Inventions for internal and academic research purposes.

9.0 PUBLICATION

9.1 The Parties agree, and the Site and Site Investigator will ensure that SNMC and the SNMC Investigators agree, that one publication of the Study will be a joint, multi-centre

publication involving all the investigators and sites that participated in the Study, and that authorship of the multi-centre publication will be determined in accordance with academic standards for authorship. Prior to this multi-site publication, the Site Investigator may publish any Site Data, and the Parties agree that the SNMC Investigators may publish all Data solely generated or developed by the SNMC Investigators (the "SNMC Data"), in accordance with Section 9.2. The Site Investigator will have the right to disclose information resulting from the Study or any background information provided by the Principal Investigator or the Coordinating Institution that is necessary to allow other scholars to verify research results.

9.2 Subject to Section 9.1, the Site Investigator and the Site Researchers will not be restricted from presenting Site Data, and the Parties agree that the SNMC Investigators will not be restricted from presenting the SNMC Data, at symposia or national or regional professional meetings or from publishing Site Data or SNMC Data, as applicable, in journals or other publications (collectively, the "Proposed Disclosure"), provided that any Proposed Disclosure is submitted to the Principal Investigator for review for Confidential Information and for comment at least 30 days before the date of presentation of the Proposed Disclosure or the date of submission of the Proposed Disclosure for publication. The Parties agree, and the Site and Site Investigator will ensure that SNMC and the SNMC Investigators agree, that any information identified by the Principal Investigator or the Coordinating Institution as being Confidential Information will be deleted from the Proposed Disclosure, provided that the Principal Investigator and the Coordinating Institution will not request the deletion of, and the Site Investigator, the Site Researchers, or the SNMC Investigators will not be required to delete, any data, results, or information related to research methods used in the Study. The Parties agree, and the Site and Site Investigator will ensure that SNMC and the SNMC Investigators agree, that at the request of the Principal Investigator or the Coordinating Institution, any Proposed Disclosure will be delayed for a further period not exceeding 60 days to enable the Coordinating Institution to protect its rights in such Confidential Information. If the Site Investigator, the Site Researchers, or the SNMC Investigators do not wish to delay the Proposed Disclosure, the Site Investigator, the Site Researchers, or the SNMC Investigators, as applicable, will delete the Confidential Information identified by the Principal Investigator or the Coordinating Institution from the Proposed Disclosure prior to its presentation or submission for publication.

9.3 Other than with respect to Confidential Information, nothing in the Agreement will be construed as granting to the Principal Investigator or the Coordinating Institution any right to edit the Proposed Disclosure. The final analysis and interpretation of the Site Data remain with the Site Investigator and the Site Researchers.

9.4 The Parties agree that any publication that arises from the Study will be in accordance with Schedule "D" ("Community Level Interventions for Pre-Eclampsia (CLIP) Authorship Agreement").

10.0 TERMINATION

10.1 The Parties agree, and the Site will ensure that SNMC agrees, that any Party may terminate the Agreement upon 30 days' prior written notice to the other Parties and that the 30-day notice will not be required if the Party wishing to terminate the Agreement, in its sole opinion, deems that the safety of the Study participants is a concern, provided that the Party wishing to terminate the Agreement due to safety concerns promptly notifies the other Parties of its decision to do so.

ATTESTED



CONFIDENTIAL

J N Medical College

UBC File No. F13-03649

Page 10 of 21

Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

252

10.2 If a Party (the "Breaching Party") breaches the Agreement, the Agreement will be terminated, provided that a non-breaching Party provides written notice of the breach to the Breaching Party and the Breaching Party fails to remedy such breach within 15 days after receiving such notice, or such longer period as the Parties may agree to in writing, acting reasonably and giving consideration to the nature of the breach and time reasonably required to cure the same.

10.3 No termination of the Agreement, however effectuated, will release the Parties from their rights and obligations under Sections 5.0 (Record Keeping), 6.0 (Confidentiality), 7.0 (Privacy), 8.0 (Data and Inventions), 9.0 (Publication), 10.3, 10.4, 11.0 (Disclaimer of Warranty and Liability), 12.0 (Insurance), 13.0 (Use of Name), and 15.0 (General).

10.4 In the event of termination, the Coordinating Institution will reimburse the Site for all payments owing to the Site up to the Site's receipt of the written notice of termination, in accordance with the Study Budget, except that no such payment will be made in the event that the Agreement is terminated because of the Site's, Site Investigator's, SNMC's, or the SNMC Investigators' failure to adhere to the Protocol. The Site shall take all reasonable steps to minimize further costs after receiving notice of termination, regardless of the grounds for such termination.

11.0 DISCLAIMER OF WARRANTY AND LIABILITY

11.1 The Parties will perform the Study in accordance with the Protocol and the terms of the Agreement. However, no Party promises success in achieving any particular result. Except as expressly provided in the Agreement, no Party gives any warranty whatsoever, express or implied, as to any matter, including, without limitation, as to the results of the Study or regarding Confidential Information that a Party may disclose to another Party. No Party will be responsible for any lost profits, lost opportunities, or other indirect or consequential damages suffered by any other Party as a result of the conduct of the Study or the performance of the Agreement.

11.2 The Parties acknowledge and agree that each Party will be responsible and liable for any damage or loss to the extent that such damage or loss arises as a result of its own negligence or willful or wrongful acts or omissions in conducting the Study, such as a failure by that Party to: (a) adhere to the material terms of the Protocol; (b) comply with applicable governmental requirements or regulations of Canada or the province in which a Party operates; and (c) conduct the Study in accordance with the medical standards set out in the ICH-GCP. No Party ("the First Party") will be liable to any other Party (the "Second Party") or third party for any damage or loss that results from the use by the Second Party or third party of the Data or Inventions developed under the Agreement, Protocol, or Study, except to the extent that the damage or loss arises from the gross negligence or willful misconduct of the First Party.

11.3 The Site assumes liability, or will otherwise require that SNMC assumes liability, for any costs, suits, or claims on account of injuries (including death) to persons participating in the Study at SNMC arising from their participation in the Study or damage to property which may arise as a result of SNMC's or the SNMC Investigators' participation in the Study. Neither the Coordinating Institution nor the Principal Investigator will assume liability for any costs, suits, or claims on account of injuries (including death) to persons participating in the Study or damage to property which may arise as a result of the participation of SNMC or the SNMC Investigators in the Study.

ATTESTED

CONFIDENTIAL

J N Medical College

UBC File No. F13-03649

Page 11 of 21

Prof. Dr. V A KOTHIMALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

253

12.0 INSURANCE

12.1 The Coordinating Institution and the Site will each maintain, and the Site will ensure that SNMC will maintain, appropriate policies of liability insurance against any and all foreseeable risks of loss arising out of the Agreement or the Study, with the Coordinating Institution having limits of no less than \$3,000,000 CAD per occurrence, the Site having limits of no less than INR 10,000,000 per occurrence, and SNMC having limits of no less than INR 4,000,000 per occurrence, to cover the activities of their directors, officers, employees, faculty, students, and agents. The Coordinating Institution and the Site will provide, and the Site will ensure that SNMC will provide, evidence of such insurance to each other upon written request, and will provide each other 30 days' prior written notice of cancellation or non-renewal of their respective coverage.

12.2 The Site Investigator represents and warrants that they are, and that any other licensed physician involved in the Study at the Site, including any co-investigator and sub-investigator, is, a member in good standing of the applicable professional medical organization and will maintain such standing during the conduct of the Study. The Site will also ensure that the SNMC Investigators represent and warrant that they are, and that any other licensed physician involved in the Study at SNMC, including any co-investigator and sub-investigator, is, a member in good standing of the applicable professional medical organization and will maintain such standing during the conduct of the Study.

13.0 USE OF NAME

13.1 Notwithstanding anything to the contrary in the Agreement and without further notice, the Parties agree that each Party may disclose the existence of the Agreement, the Contract Period, the Parties to the Agreement, the amount of funding received by the Site from the Coordinating Institution and the title of the Study in annual reports or in any publication or presentation relating to the results of the Study. However, no Party may use the name, trademarks, or insignia of any other Party in any publication, news release, promotion, advertisement, or other public announcement, whether written or oral, that endorses services, organizations, or products, or for any other purpose other than that expressly permitted by the Agreement, without the other Party's prior written consent.

14.0 NOTICES

14.1 All payments, reports, notices, or other documents that a Party is required or wishes to deliver to any other Party will be delivered:

- (a) in writing, and
- (b) either by personal delivery or by registered or certified mail (with all postage and other charges prepaid) at the address for the receiving Party as set out in Section 14.2 or as varied by any notice.

Any notice that is personally delivered is deemed to have been received at the time of delivery. Any notice that is mailed in accordance with this Section 14.0 is deemed to have been received at the end of the fifth business day after it is posted.

14.2 Addresses for delivery of notices:


ATTESTED

CONFIDENTIAL

J N Medical College

JBC File No. F13-03649

Page 12 of 21


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

254

To the Coordinating Institution
If to UBC:

Managing Director, UILO
UBC File No.
The University of British Columbia
University-Industry Liaison Office
#103 - 6190 Agronomy Road
Vancouver, British Columbia
Canada V6T 1Z3
Tel: (604) 822-8580
Fax: (604) 822-8589

If to C&W

Dr. Michael O'Shaughnessy
Acting Executive Director, Child and Family Research Institute
Children's and Women's Health Centre of B.C. Branch
A2-146
950 West 28th Avenue
Vancouver, British Columbia
Canada V5Z 4H4
Tel: (604) 875-2404
Fax: (604) 875-2496

To the Site:

KLE University's
Jawaharlal Nehru Medical College
Women's and Children's Health Research Unit
Belgaum 590010 Karnataka India
Tel: 91-831-2474200
Fax: 91-831-2472891

To the Principal Investigator

Dr. Peter von Dadelszen
Rm V3-339, 950 West 28th Avenue
Vancouver, British Columbia
Canada V5Z 4H4
Tel: (604) 875-3054
Fax: (604) 875-3212

To the Site Investigator:

Dr. M.B. Bellad
Professor, Department of OBGYN,
KEL University' J N Medical College
Belgaum, 590010 Karnataka India
Tel: 91+94481 24893
Fax: 91-831-2472891

Dr. Shivaprasad S Goudar
Professor, Department of Physiology
KEL University' J N Medical College
Belgaum, 590010 Karnataka India
Tel: 91+94481 26371
Fax: 91-831-2472891

15.0 GENERAL

15.1 Nothing contained in the Agreement is to be deemed or construed to create between the Parties a partnership or joint venture. No Party has the authority to act on behalf of any other Party, or to commit any other Party in any manner at all or cause any other Party's name to be used in any way not specifically authorized by the Agreement.


ATTESTED

CONFIDENTIAL

J N Medical College

UBC File No. F13-03649

Page 13 of 21


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

255

15.2 The Agreement is governed by, and will be construed in accordance with, the laws of British Columbia and the laws of Canada in force in that province, without regard to its conflict of law rules. The Parties agree that by executing the Agreement, they have attorned to the exclusive jurisdiction of the Supreme Court of British Columbia.

15.3 No condoning, excusing, or overlooking by any Party of any default, breach, or non-observance by any other Party at any time or times regarding any terms of the Agreement operates as a waiver of that Party's rights under the Agreement. A waiver of any term or right under the Agreement will be in writing signed by the Party entitled to the benefit of that term or right, and is effective only to the extent set out in the written waiver.

15.4 No exercise of a specific right or remedy by any Party precludes it from or prejudices it in exercising another right or pursuing another remedy or maintaining an action to which it may otherwise be entitled either at law or in equity.

15.5 No right or license is granted under the Agreement by any Party to any other Party either expressly or by implication, except as specifically set out in the Agreement. Nothing contained in the Agreement will impose an obligation of exclusivity on one Party by any other Party. Each Party reserves the right to enter into and participate in other activities (either alone or with a third party), including, but not limited to, clinical trials and other research projects.

15.6 All terms in the Agreement which require performance by the Parties after the expiry or termination of the Agreement will remain in force despite the Agreement's expiry or termination for any reason.

15.7 Part or all of any section of the Agreement that is indefinite, invalid, illegal, or otherwise voidable or unenforceable may be severed from the Agreement, and the balance of the Agreement will continue in full force and effect.

15.8 Each Party will execute and deliver such further agreements and other documents and do such further acts and things as the other Parties reasonably request to evidence, carry out, or give full force and effect to the intent of the Agreement.

15.9 The Agreement and the Schedules set out the entire understanding between the Parties and no changes to the Agreement are binding unless in writing and signed by the Parties to the Agreement. The Parties will be bound by the Schedules, except to the extent that they may conflict with the terms and conditions contained in the Agreement, in which case the terms and conditions of the Agreement will govern.

15.10 The Parties are independent contractors. No Party has the authority to act on behalf of any other Party, or to commit any other Party in any manner at all.

15.11 Each Party acknowledges that it/he/she has been advised by the other Parties to seek independent legal advice with respect to the Agreement and that it/he/she has not relied upon any of the other Parties for any advice, whether legal or otherwise, with respect to the Agreement.

15.12 The Agreement may be executed in counterparts by the Parties, either through original copies or by facsimile or electronically, each of which will be deemed an original and all of which will constitute the same instrument.

15.13 In the Agreement, the term "days" means calendar days, unless otherwise indicated.

ATTESTED

CONFIDENTIAL

J N Medical College  UBC File No. F13-03649

Page 14 of 21

Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI


256

SIGNED BY THE PARTIES AS AN AGREEMENT and effective as of the Effective Date.

Signed for and on behalf of
THE UNIVERSITY OF BRITISH COLUMBIA
by its authorized signatories:



Signature **MARIO A. KASAPI**
Associate Director
Name: University - Industry Liaison Office
Title:

Date Sept. 16, 2013


Signature **J. P. Heale, PhD, MBA**
Associate Director
Name: University-Industry Liaison Office
Title:

Date Sept 17/13

Signed for and on behalf of
**CHILDREN'S & WOMEN'S HEALTH
CENTRE OF BRITISH COLUMBIA
BRANCH** by its authorized signatory:


Signature **Stuart Turvey**
Director of Clinical Research
Child & Family Research Institute
Name: *Dr. Michael O'Shaughnessy*
Title: Acting Executive Director
CFRI

Date 18 Sept. 2013

PRINCIPAL INVESTIGATOR

Signature _____
Name: Dr. Peter von Dadelszen
Date _____


Signed for and on behalf of
**KLE UNIVERSITY'S
JAWAHARLAL NEHRU MEDICAL COLLEGE,
WOMEN'S AND CHILDREN'S HEALTH RESEARCH
UNIT BELGAUM**
by its authorized signatory:

SITE INVESTIGATOR

Signature _____
Name: Dr. Ashok S. Godhi
Title: Principal
Date _____

Signature _____
Name: Dr. M. B. Bellad
Title: Professor
Date _____
ATTESTED

CONFIDENTIAL


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

SIGNED BY THE PARTIES AS AN AGREEMENT and effective as of the Effective Date.

Signed for and on behalf of
THE UNIVERSITY OF BRITISH COLUMBIA
by its authorized signatories:

Signed for and on behalf of
**CHILDREN'S & WOMEN'S HEALTH
CENTRE OF BRITISH COLUMBIA
BRANCH** by its authorized signatory:

Signature

Signature

Name:
Title:

Name:
Title:

Date

Date

Signature

PRINCIPAL INVESTIGATOR



Name:
Title:

Signature

Name: Dr. Peter von Dadelszen

Date

Date

September 13/2018

Signed for and on behalf of
**KLE UNIVERSITY'S
JAWAHARLAL NEHRU MEDICAL COLLEGE,
WOMEN'S AND CHILDREN'S HEALTH RESEARCH
UNIT BELGAUM**
by its authorized signatory:

SITE INVESTIGATOR

Signature

Signature


Name: Dr. Ashok S. Godhi
Title: Principal

Name: Dr. M. B. Bellad
Title: Professor

Date

Date

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

SIGNED BY THE PARTIES AS AN AGREEMENT and effective as of the Effective Date,

Signed for and on behalf of
THE UNIVERSITY OF BRITISH COLUMBIA
by its authorized signatories:

Signed for and on behalf of
**CHILDREN'S & WOMEN'S HEALTH
CENTRE OF BRITISH COLUMBIA
BRANCH** by its authorized signatory:

Signature

Signature

Name:
Title:

Name:
Title:

Date

Date

Signature

PRINCIPAL INVESTIGATOR:

Name:
Title:

Signature

Name: Dr. Peter von Dadelszen

Date

Date

Signed for and on behalf of
**KLE UNIVERSITY'S
JAWAHARLAL NEHRU MEDICAL COLLEGE,
WOMEN'S AND CHILDREN'S HEALTH RESEARCH
UNIT BELGAUM**
by its authorized signatory:

SITE INVESTIGATOR

Signature

Signature

Name: Dr. Ashok S. Godhi
Title: Principal

Name: Dr. M. B. Bellad
Title: Professor

September 21, 2013
Date

September 21, 2013
Date

CONFIDENTIAL

J N Medical College

ATTESTED

UBC File No. F13-03649


Page 15 of 21


Prof. Dr. V.A. KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

259

SITE INVESTIGATOR


Signature

Name: Dr. Shivaprasad S. Goudar
Title: Professor


Date

Subaward Agreement

Organization ("Organization") Name: Christiana Care Health Services, Inc. (CCHS) Address: Office of Sponsored Programs, Suite 2400 200 Hygeia Drive, Newark, DE 19713	Institution ("Collaborator") Name: Jawaharlal Nehru Medical College (JNMC), KLE Organization Address: Nehru Nagar, Belgaum – 590010 Karnataka, India TIN.: BLRK04603E
---	---

Prime Award No. Thrasher Award #: 10326 Matthew Hoffman	Subaward No. 601465
---	-------------------------------

Awarding Agency Thrasher Research Fund	CFDA No. NA
--	-----------------------



Subaward Period of Performance June 22, 2013 – June 21, 2014	Amount Funded this Action \$155,873	Est. Total (if incrementally funded) \$298,541
--	---	--


Project Title
Clindamycin to reduce preterm birth in a low resource setting: a randomized placebo-controlled trial

Reporting Requirements/Payment Schedule [Check here if applicable: See Attachment 4]

Terms and Conditions

- 1) Organization hereby awards a (choose one): cost reimbursable firm-fixed-price subaward, as described above, to Collaborator. The statement of work and budget for this subaward are shown in Attachment 5. In its performance of subaward work, Collaborator shall be an independent entity and not an employee or agent of Organization.
 - 2) Organization shall (choose one):
 issue an advance payment of \$53,717 U.S dollars upon execution of this Agreement. Organization shall thereafter reimburse Collaborator on a monthly basis for allowable costs based on invoices submitted in accordance with sample invoice shown in Attachment 6.
 pay Collaborator according to the payment schedule in Attachment 4.
- Expenditures of Collaborator shall conform to budget in Attachment 5. All payments will be in U.S. dollars. Questions concerning payments should be directed to the appropriate party's Financial Contact, as shown in Attachment 3.
- 3) A final statement of cumulative costs incurred, including cost sharing, marked "FINAL," must be submitted to the Organization's Financial Contact NOT LATER THAN forty-five (45) days after subaward end date. The final statement of costs shall constitute Collaborator's final financial report.
 - 4) All payments shall be considered provisional and subject to adjustment within the total estimated cost in the event such adjustment is necessary as a result of an adverse audit finding against the Collaborator.
 - 5) Matters concerning the technical performance of this subaward should be directed to the Organization Principal Investigator,, as shown in Attachment 3. Technical reports are required as shown above, "Reporting Requirements."
 - 6) Matters concerning the request or negotiation of any changes in the terms, conditions, or amounts cited in this subaward agreement, and any changes requiring prior approval, should be directed to the appropriate party's Administrative Contact, as shown in Attachment 3. Any such changes made to this subaward agreement require the written approval of each party's Authorized Official, as shown in Attachment 3.
 - 7) Each party shall be responsible for its negligent acts or omissions and the negligent acts or omissions of its employees, officers, or directors, to the extent allowed by law.
 - 8) Either party may terminate this agreement with thirty days written notice to the appropriate party's Administrative Contact, as shown in Attachment 3.
 - 9) No-cost extensions require the approval of Organization and the Awarding Agency. Any requests for a no-cost extension should be addressed to and received by the Administrative Contact, as shown in Attachment 3, not less than thirty days prior to the desired effective date of the requested change.
 - 10) The Subaward is subject to the terms and conditions of the Award Letter (Attachment 1) and other special terms and conditions, as identified in Attachment 2.
 - 11) By signing below Collaborator makes the certifications and assurances shown in Attachment 2.

By an Authorized Official of ORGANIZATION:  Thomas L. Corrigan Date: 8/21/13	By an Authorized Official of COLLABORATOR:  Dr. Ashok S. Godhi, Principal Date: 8/26/13
--	--

APPROVED BY LEGAL

Prof. Dr. V.A. KOTHIWALE
 Registrar
 KLE Academy of Higher Education and Research, BELAGAVI

**ATTACHMENT 1
EXECUTED LETTER, CONDITIONS OF AWARD**

ATTESTED



Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI



Thrasher Research Fund
Medical Research for Children
68 S. Main Street, Suite 400
Salt Lake City, UT 84101
Phone: 801-240-4753
Fax: 801-240-1625
ThrasherResearch.org

November 7, 2012


Matthew K. Hoffman, M.D., MPH
Director, Division of Education & Research
Dept. of Obstetrics & Gynecology
Christiana Care Health Services, Inc.
4755 Ogletown-Stanton Rd.
Newark, DE 19718

Dear Dr. Hoffman:

This Award Letter is to advise you that the Thrasher Research Fund ("Fund") has approved your application for a grant (the "Grant") described below, to be made upon the following terms and conditions:

1. The Principal Investigator is **Matthew K. Hoffman, M.D., MPH**. The project name is **"Clindamycin to reduce preterm birth in a low resource setting: A randomized placebo-controlled trial."** The total project grant award for the period of April 1, 2013 to March 31, 2016 is \$418,262. The Supervising Institution is **Christiana Care Health Services, Inc.**
2. This Grant is awarded on the condition that proof of IRB approval is received, proof of registration as a clinical trial at <https://register.clinicaltrials.gov>, or equivalent, is provided and the enclosed budget supersedes any previous requests. These requirements must be met and the project must begin by **June 22, 2013**.
3. By acceptance of the Grant, the Principal Investigator and the Supervising Institution expressly acknowledge and accept all of the conditions in this Award Letter as well as the conditions stated in the document entitled Conditions of Grant, a copy of which is enclosed and made part of this Grant by this reference. Please pay particular attention to the details stated in this Award Letter as well as in the Conditions of Grant, and retain them for future reference. Unauthorized reallocation of funds or failure to submit semiannual reports as required will give the Fund the right, but not the obligation, to suspend the Grant. If suspended, the Grant can only be reinstated upon written authorization from the Fund. Unless otherwise specifically stated in this Award Letter, this Grant shall be paid to the Supervising Institution under whose supervision the Principal Investigator shall be responsible for the research and other activities required to complete the project.
4. The Principal Investigator and Supervising Institution agree to adhere to this Award Letter and the Conditions of Grant, the violation of any provision of which shall be reason for suspension of the Grant for which reinstatement shall require written appeal from the Principal Investigator and Supervising Institution.

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

263

5. The Supervising Institution agrees to disclose promptly and in confidence to the Fund any patentable inventions conceived and reduced to practice in the performance of research funded in whole or in part by the Grant (hereinafter referred to as "Inventions"). The Supervising Institution has the right to obtain letters patent or design patent in the name of the Supervising Institution or otherwise of any Inventions in the United States or in any applicable foreign countries covering such, all costs for such patenting to be paid by the Supervising Institution. The Supervising Institution agrees to grant to the Fund a paid-up, non-exclusive license to any Inventions for internal, non-commercial research purposes only.

6. To accomplish the purposes set forth above, the Principal Investigator in accordance with the Supervising Institution's policies and practices will (a) disclose promptly and report fully all Inventions to the Supervising Institution; (b) cooperate with the Supervising Institution in securing intellectual property protection for such Inventions; (c) deliver to the Supervising Institution copies of all relevant notes, drawings, blueprints and papers upon request and give other reasonable assistance in the preparation or defense of patents or patent applications for such Inventions; and (d) sign all papers as appropriate for the filing of any application for such letters patent or design patent.

7. Income received by Supervising Institution from commercially licensing any Invention shall be shared with the Fund. The Fund's share shall be determined by mutual agreement between Supervising Institution and the Fund after a license has been executed for such Invention. The Fund's share will be determined on a case-by-case basis and be proportional to the level of support provided by the Fund to the research that resulted in such Invention and will begin when Net Income on any license exceeds \$250,000. Net Income is defined to be gross income less unreimbursed expenses for obtaining and maintaining patent rights and mandatory distributions under the Policy of the Supervising Institution (to include distributions to inventors).

8. If the Supervising Institution decides to abandon the commercialization or licensing activities associated with a disclosed Invention, the Fund will be notified and given the option to execute a license to Invention (under standard Supervising Institution terms), with rights to sublicense. At Fund request and expense, the Supervising Institution will continue the patent or patent application process.

9. Any activities associated with a Thrasher Research Fund Grant conducted in, or affiliated with, a country outside the United States, must be performed in accordance with U.S. export control and trade sanctions laws and regulations. The Supervising Institution agrees to take full responsibility for ensuring that any necessary U.S. Government export control or trade sanctions authorizations are obtained and maintained throughout the duration of the project. The Supervising Institution assumes responsibility for (and, to the extent allowable by law, shall indemnify Thrasher Research Fund from and against) any and all liability, loss, expense, or claims for injury or damages arising out of the Supervising Institution's performance of this Grant, but only in proportion to and to the extent such liability, loss, expense or claims for injury or damages are caused by or result from the negligent or intentional act or omissions of the Supervising Institution, its officers, employees, or agents.

10. This Grant supersedes your Grant proposal application and all other prior dealings between you and the Fund regarding your proposal.

ATTESTED



Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

11. In the event the Principal Investigator transfers from the within-named Supervising Institution to another institution, this Grant or the project funded thereunder may be continued with such other institution, and such other institution may become a Successor Supervising Institution, only if (a) such Successor Supervising Institution agrees to be bound by the terms and conditions of an amended Award Letter and Conditions of Grant reflecting such transfer, and (b) all of the parties hereto and the Successor Supervising Institution mutually agree upon the allocation of Grant Award funds between the respective institutions. Except as provided herein, the parties hereto may not assign, encumber or otherwise transfer this Grant, and any such attempt at assignment, encumbrance, or transfer will be void.


When both the Supervising Institution and Principal Investigator have executed this Grant, please return one fully executed copy of this Agreement to each of the parties.

We wish you success in your research.

Sincerely,

THRASHER RESEARCH FUND

By


R. Justin Brown, MPH
President


CHRISTIANA CARE HEALTH SERVICES, INC.

By _____

Title _____

Dated this ____ day of _____, 2012

MATTHEW K. HOFFMAN, M.D., MPH

By  _____

Dated this ____ day of _____, 2012

Revised May, 2010

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

265

Administration

Grant monies awarded by the Thrasher Research Fund (the Fund) are to be used only for the purposes described in the Grant application. The study must begin within one year of the Award Letter date or the award will be withdrawn.

Although the term "co-principal investigator" may be used, one principal investigator will be responsible for completion of all required reports. This individual will be responsible for direct supervision of all Grant activities and may make minor changes in emphasis or direction of the work as necessary. However, contemplated changes in research site or key personnel, or major changes in Grant focus or direction, must have prior written approval from the Fund.

Budget

Written approval by the Fund is required prior to any changes in the budget. Failure to obtain prior authorization may result in suspension of the grant.

The Fund will participate in the payment of indirect costs up to an amount of seven percent of the yearly Grant budget excluding equipment allocations. When collaborating institutions receive a portion of a grant award, indirect cost payments will be shared proportionately, based on the division of the award amount.

Use of Grant Funds

Grant monies are to be used only during the period indicated in the notice-of-award letter. Any deviation from this schedule must have prior approval from the Fund. Extensions will be considered but will require prior approval by the Fund before the scheduled end date. All unexpended monies must be returned to the Fund within 90 days following conclusion of the Grant.

Disbursements

Payment of Grant monies are made at the beginning of the Grant period and semiannually if all required reports are received and acceptable. Payments are subject to compliance with these Conditions of Grant and satisfactory project performance. The Fund reserves the right to terminate any project that, in the Fund's sole discretion, is not satisfactorily pursuing and fulfilling stated project goals and objectives. The Fund shall reimburse for uncancellable obligations properly incurred prior to termination notice.

The Fund will retain ten percent or \$5,000 (whichever is less) of the total Grant amount until all final reports are received.

Reports

Report forms will be sent to the principal investigator and the institution's financial officer at the end of each semiannual project period. These must be completed and returned to the Fund within 60 days following each semiannual period. Failure to provide progress and financial reports will give the Fund the right, but not the obligation, to suspend the Grant upon the issuance of written notice from the Fund to the Principal Investigator and/or the Supervising Institution, in which case no further disbursements will be made unless the Grant is reinstated by the written authorization of the Fund. During the suspension period, no further expenditures can be made for a project without written approval of the Research Manager. If a

project is terminated, the remaining balance of the award is deemed forfeit by the Supervising Institution after meeting the outstanding current obligations of the grant.

A final project report and final financial report must be completed and returned within 90 days following conclusion of the project. Failure to provide these reports by the deadline may result in the forfeiture of the retainer.

Individuals who receive Grants and are not affiliated with a legally recognized institution are under the same obligations as detailed above.

Equipment

Equipment purchased with money awarded by the Fund shall be the property of the Fund, which has authority to determine disposition of the equipment at the conclusion of the project. Equipment is defined as any item costing more than \$4,000 with useful life beyond the term of the project. Authorized equipment purchases include only those items specifically listed in the Equipment section of the approved grant proposal budget.

Human Subjects

Projects involving human subjects must obtain informed consent of the subject or legal guardian(s) and provide information about potential risks, and they must provide for the safeguard of human rights and welfare at a standard equivalent to that prescribed by the U.S. Department of Health and Human Services. Satisfactory evidence indicating approval of the protocols and procedures by appropriate ethical review boards must be submitted before any monies will be disbursed.

Investigational New Drug (IND)

If the proposed study requires an Investigational New Drug application from the FDA, the IND should be received from the FDA prior to submitting the application to the Thrasher Research Fund. Include with this application all written correspondence with the FDA relating to the IND. Upon submission to the Fund, all FDA correspondence will be forwarded to the Fund, including future annual reviews, to Fund as part of the semi-annual reports.

Royalties and Publications

With each Grant, the Fund secures the rights to an assignment of a share of royalties from marketable products related to the project as outlined in the Award Letter.

Publication of project results in peer-reviewed scientific or professional journals is encouraged. Any publications or other dissemination arising from research supported by the Fund must acknowledge assistance received from the Fund and copies or notification must be submitted to the Fund. The correct name for acknowledgment is the Thrasher Research Fund.

Principal Investigator Initial _____

Supervising Institution Initial _____

Revised July, 2010

ATTESTED



Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

First Year Budget Request

Thrasher Research Fund
15 W. South Temple St. #1650
Salt Lake City, UT 84101

IMPORTANT: Complete this form and return it with the signed Award Letter and Conditions of Grant page. A disbursement will not be made until ALL forms are completed and returned.

Principal investigator: Matthew K. Hoffman, M.D., MPH
Project name: Clindamycin to reduce preterm birth in a low resource setting: A randomized placebo-controlled trial

First six months disbursement request (NO MORE THAN 60%)
Second six months disbursement request
Total first year budget (same as on budget sheet)

Financial Contact: (This is the person to whom semiannual reports are sent and who is responsible for said forms.)

Name and Title

Full Mailing Address

Telephone: Fax: E-mail address:

Payment Information: (Institutional information necessary for disbursement.)

Disbursement payable to:

Wire transfers are an option for international grantee. If your institution is able to accept them, please provide ALL of the following information. If any information is not provided, a transfer cannot and will not be accepted or completed.

Institutional reference number

Bank routing number (9 digit number)

Attention to and Full mailing address

Transfer account number:

US bank affiliate:

Telephone Fax

Equipment Needs for Project (These items have been given prior approval.)

Date needed: Equipment item

Date needed: Equipment item

Equipment Acquisition Procedure

As stated in the "Conditions of Grant," all equipment purchased in behalf of grantees shall be the property of the Thrasher Research Fund. Equipment is defined as any item costing more than \$4000.00 with a useful life beyond the term of the project, unless otherwise specified at the time of the award. Authorized equipment purchases include only those items specifically listed in the equipment budget section of an approved grant proposal.

Financial contact signature _____

Principal investigator signature _____

ATTESTED

Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI



World Health
Organization

WHO/GSC/GPL
BLOCK 3510
JALAN TEKNOKRAT 6
CYBERJAYA 63000
Malaysia

WHO Reference/ Référence OMS

WHO Reference	2014/432421-0
Purchase Order	201019382
Reg. File	R15-TSA-006
Unit Reference	A65780/India

COVERING LETTER
LETTRE D'ACCOMPAGNEMENT

Dr Shivaprasad Goudar
PRINCIPAL, J.N. MEDICAL COLLEGE,
BELGAUM (JAWAHARLAL NEHRU MEDICAL
COLLEGE, BELGAUM)
KARNATAKA
Nehru Nagar
Belgaum
Karnataka
India

Téléphone Central/Exchange: +60 3 8871 7111
Email / Courriel: GSCprocurement@who.int

Re: As part of multi-country study (India) Project A65780 - Carbetoicin RTS for preventing postpartum haemorrhage: a randomized non-inferiority controlled trial.

We are enclosing the Technical Services Agreement between the World Health Organization and PRINCIPAL, J.N. MEDICAL COLLEGE, BELGAUM (JAWAHARLAL NEHRU MEDICAL COLLEGE, BELGAUM), KARNATAKA, in the amount of INR 12,348,393.12 (Twelve Million Three Hundred Forty-Eight Thousand Three Hundred Ninety-Three), for conducting the above-mentioned work. We also enclose three attachment(s) referenced in the Agreement.

We kindly request that you return, duly signed, a copy of the Agreement, keeping one copy for your files.

For any technical or scientific questions, please contact Mariana WIDMER, widmERM@who.int.

On behalf of the World Health Organization, we thank you for your collaboration.

Cc: WHO Representative, India

WHO Global Service Centre

Concern: As part of multi-country study (India) Project A65780 - Carbetoicin RTS for preventing postpartum haemorrhage: a randomized non-inferiority controlled trial.

Veillez trouver ci-joint l'Accord de Services Techniques entre l'Organisation Mondiale de la Santé et PRINCIPAL, J.N. MEDICAL COLLEGE, BELGAUM (JAWAHARLAL NEHRU MEDICAL COLLEGE, BELGAUM), KARNATAKA, pour un montant de INR 12,348,393.12 (Twelve Million Three Hundred Forty-Eight Thousand Three Hundred Ninety-Three), vous permettant de mener à bien le travail susmentionné. Veillez également trouver trois pièces jointes mentionnées dans l'Accord.

Veillez nous retourner, dûment signée, une copie de l'Accord et en garder une pour vos dossiers.

Pour toutes questions à caractère scientifique ou technique, veuillez contacter Mariana WIDMER, widmERM@who.int.

Au nom de l'Organisation Mondiale de la Santé, nous vous remercions de votre collaboration.

Centre de Soutien Administratif Mondial de l'OMS

Cc: Représentant de l'OMS, India

ATTESTED

Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

268



**TECHNICAL SERVICES
AGREEMENT
ACCORD DE SERVICES
TECHNIQUES**

The WORLD HEALTH ORGANIZATION hereby agrees to provide to
L'ORGANISATION MONDIALE DE LA SANTÉ s'engage par la présente à fournir à
INSTITUTION:

PRINCIPAL, J.N. MEDICAL COLLEGE, BELGAUM
(JAWAHARLAL NEHRU MEDICAL COLLEGE, BELGAUM)
KARNATAKA
Karnataka
India

Principal Investigator: Dr Shivaprasad Goudar
Telephone: +918312444194
Fax:
Email/Courriel: gshivaprasad@hotmail.com

The Amount of/Un Montant de: INR 12,348,393.00 (Twelve Million Three Hundred Forty-Eight Thousand Three Hundred Ninety-Three)

In respect of/en vue de: As part of multi-country study (India) Project A65780 - Carbetocin RTS for preventing postpartum haemorrhage: a randomized non-inferiority controlled trial.

For the period financed by this Agreement From/De : 15-JUN-2014
Période du projet financée par le présent accord To/A : 30-NOV-2015

Summary of work/ Description sommaire des travaux:

1. Description of work under this Agreement/ Description des travaux faisant l'objet du présent accord:

The objectives are:

- i) To evaluate non-inferiority of carbetocin RTS 100 µg IM versus oxytocin 10 IU IM in the prevention of the composite outcome blood loss ≥500 mL or the use of additional uterotonic drugs following vaginal delivery of the baby;
- (ii) To evaluate non-inferiority of carbetocin RTS 100 µg IM versus oxytocin 10 IU IM in the prevention of blood loss ≥1000 mL.

2. Contribution of the Institution and/or other sources for the project (Staff, equipment, supplies, etc. excluding general facilities). The Institute will provide all facilities, equipment and personnel not covered by this Agreement.
Contribution de l'institution ou de tout autre organisme à l'exécution du projet (personnel, matériel, fournitures, etc. à l'exclusion des services d'ordre général). L'institution s'engage à fournir les locaux, équipement et personnels non couverts par cet accord.

The Institute will provide all other facilities not provided for under this Agreement.

Financial Arrangements/ Dispositions financières:

1. Payments will be made as follows/Les versements seront effectués comme suit:

	Deliverable/ Résultat	Due Date/ Date Remise	%	Currency Amount/ Montant en Devise
1	Upon receipt of countersigned contract	15-JUN-2014	100.00	12,348,393.12
2	Upon receipt financial report	30-NOV-2015	0.00	0.00
3	Upon receipt of technical report	30-NOV-2015	0.00	0.00

2. INR 0.00 will be used by WHO for the purchase of equipment and supplies to be ordered by the Institution as soon as practicable, but not beyond 31 December of the year following the end of the Agreement period as indicated above at which time any uncommitted balance will revert to WHO.

INR 0.00 seront affectés par l'OMS à l'achat de matériels et de fournitures à commander par l'institution dès que possible, mais au plus tard avant le 31 décembre de l'année suivant la fin de la période susmentionnée d'exécution de l'accord, étant entendu qu'à ce moment tout solde non engagé fera retour à l'OMS.

Annexes

The following annexes form an integral part of this Agreement/ Les annexes listées ci-dessous font partie intégrante de cet accord:

Annex	File Description/Description de fichier
1	Cover letter for TSA Issued for clinical trial from Legal Office
2	Main protocol
3	Project budget

In the event that the terms of the annexes contain any provisions which are contrary to the terms of this Agreement, the terms of this Agreement shall take precedence/ En cas de contradiction entre les termes apparaissant sur les annexes et ceux de l'Accord, les dispositions de l'Accord prévaudront dans tous les cas.

WHO Financial References/ Références financières de l'OMS



World Health Organization

WHO/GSC/GPL
BLOCK 3510
JALAN TEKNOKRAT 6
CYBERJAYA 63000
Malaysia

WHO Reference/ Référence OMS	
WHO Reference	2014/432421-0
Purchase Order	201019382
Reg. File	R15-TSA-006
Unit Reference	A65780/India

**TECHNICAL SERVICES AGREEMENT
ACCORD DE SERVICES TECHNIQUES**

	Project	Task	Award	Expenditure Type	Expenditure Organization	%	USD
1	HQRHR1409029	4.2	61980	512-Consulting, Research Serv.	HQ	100	209,153.00

General

The parties accept the "General Conditions" overleaf, which constitute an integral part of this Agreement. The Institution certifies the correctness of the banking instructions provided on Page 1. All necessary arrangements to comply with national regulations relating to this project and relevant to the Institution's responsibilities shall have been under-taken by the Institution; failure to do so will nullify this Agreement. The responsibility of the World Health Organization is limited only to the financial support as specified in this Agreement.

Généralités

Les parties acceptent les "Conditions générales" reproduites au verso, lesquelles font partie intégrante du présent accord. L'Institution certifie l'exactitude des instructions bancaires indiquées à la page 1. Toutes les dispositions relevant des responsabilités de l'Institution et nécessaires à la mise en conformité de ce Projet avec la réglementation nationale, devront avoir été prises par l'Institution, faute de quoi l'accord sera nul. La responsabilité de l'Organisation Mondiale de la Santé se limite au soutien financier spécifié dans le présent accord.

ON BEHALF OF WHO/ POUR L'OMS

Responsible WHO Technical Officer;
Fonctionnaire technique responsable de l'OMS:

Mariana Widmer
Technical Officer
HQ/RHR - Reproductive Health and Research

Responsible Divisional Director
Directeur de division responsable

Flavia BUSTREO
Asst Director-General
HQ/FWA FWC ADGO Office of the Assistant DG

Authorized Signatory:
Signataire autorisé:

Mr. Motohiro Ogita
Coordinator
Global Procurement and Logistics
(WHO/GMG/GSC/GPL)

Motohiro Ogita
Coordinator
HQ/GSC Global Service Centre
13-JUN-2014

PRINCIPAL INVESTIGATOR/ CHERCHEUR PRINCIPAL

Principal Investigator or Technical Officer responsible for the project.
Chercheur Principal ou membre du personnel technique responsable de l'exécution du projet.

Signature :
Dr Shrivprasad Goudar

ON BEHALF OF THE INSTITUTION/ POUR L'INSTITUTION

Responsible Administrative Authority*
*Autorité administrative responsable**

Signature :
Name/nom : Dr. A.S. Eodhi
Division :
Date : 13/06/2014

**PRINCIPAL
JNMO, BELGAUM**

* An official of the Institution - other than the Principal Investigator - fully empowered to enter into contracting arrangements on behalf of the Institution. *Un responsable de l'Institution autre que le Chercheur principal - ayant pleins pouvoirs pour passer un contrat au nom de l'Institution.*

ATTESTED

Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI



World Health
Organization

COVERING LETTER
LETTRE D'ACCOMPAGNEMENT

WHO/GSC/GPL
BLOCK 3510
JALAN TEKNOKRAT 6
CYBERJAYA 63000
Malaysia

WHO Reference/ Référence OMS

WHO Reference	2016/647688-0
Purchase Order	201544467
Reg. File	n/a
Unit Reference	A65670

DR. Shivaprasad Goudar
PRINCIPAL, J.N. MEDICAL COLLEGE,
BELGAUM (JAWAHARLAL NEHRU MEDICAL
COLLEGE, BELGAUM)
KARNATAKA
Nehru Nagar
Belgaum
Karnataka
India

Téléphone Central/Exchange: +60 3 8871 7111
Email / Courriel: GSCprocurement@who.int

Re: CHAMPION TRIAL

We are enclosing the Technical Services Agreement between the World Health Organization and PRINCIPAL, J.N. MEDICAL COLLEGE, BELGAUM (JAWAHARLAL NEHRU MEDICAL COLLEGE, BELGAUM), KARNATAKA, in the amount of USD 302,410.00 (Three Hundred Two Thousand Four Hundred Ten), for conducting the above-mentioned work. We also enclose two attachment(s) referenced in the Agreement.

We kindly request that you return, duly signed, a copy of the Agreement, keeping one copy for your files.

For any technical or scientific questions, please contact Mariana WIDMER, widmem@who.int.

On behalf of the World Health Organization, we thank you for your collaboration.

Cc: WHO Representative, India

WHO Global Service Centre

Concerne: CHAMPION TRIAL

Veillez trouver ci-joint l'Accord de Services Techniques entre l'Organisation Mondiale de la Santé et PRINCIPAL, J.N. MEDICAL COLLEGE, BELGAUM (JAWAHARLAL NEHRU MEDICAL COLLEGE, BELGAUM), KARNATAKA, pour un montant de USD 302,410.00 (Three Hundred Two Thousand Four Hundred Ten), vous permettant de mener à bien le travail susmentionné. Veillez également trouver two pièces jointes mentionnées dans l'Accord.

Veillez nous retourner, dûment signée, une copie de l'Accord et en garder une pour vos dossiers.

Pour toutes questions à caractère scientifique ou technique, veuillez contacter Mariana WIDMER, widmem@who.int.

Au nom de l'Organisation Mondiale de la Santé, nous vous remercions de votre collaboration.

Centre de Soutien Administratif Mondial de l'OMS

Cc: Représentant de l'OMS, India

ATTESTED

Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

271



**World Health
Organization**

WHO/GSC/GPL
BLOCK 3510
JALAN TEKNOKRAT 6
CYBERJAYA 63000
Malaysia

WHO Reference/ Référence OMS

WHO Reference 2016/647688-0
Purchase Order 201544467
Reg. File n/a
Unit Reference A65870

**TECHNICAL SERVICES
AGREEMENT
ACCORD DE SERVICES
TECHNIQUES**

The WORLD HEALTH ORGANIZATION hereby agrees to provide to
L'ORGANISATION MONDIALE DE LA SANTÉ s'engage par la présente à fournir à
INSTITUTION:

PRINCIPAL, J.N. MEDICAL COLLEGE, BELGAUM
(JAWAHARLAL NEHRU MEDICAL COLLEGE, BELGAUM)
KARNATAKA
Karnataka
India

Principal Investigator: DR.Shivprasad Goudar
Telephone:
Fax:
Email/Courriel: sgoudar@jnmc.edu

The Amount of/Un Montant de: USD 302,410.00 (Three Hundred Two Thousand Four Hundred Ten)
In respect of/en vue de: CHAMPION TRIAL

For the period financed by this Agreement From/De : 25-JUL-2016
Période du projet financée par le présent accord To/A : 24-JUL-2017

Summary of work/ Description sommaire des travaux:

1. Description of work under this Agreement/ Description des travaux faisant l'objet du présent accord:

A phase III, randomized, double-blind, active, controlled, multinational, multicentre, non-inferiority trial using carbococin room temperature stable (RTS) for the prevention of postpartum haemorrhage during the third stage of labour in women delivering vaginally.

Objective: To implement trial A65870 according to GCP guidelines.

2. Contribution of the Institution and/or other sources for the project (Staff, equipment, supplies, etc. excluding general facilities). The Institute will provide all facilities, equipment and personnel not covered by this Agreement.
Contribution de l'institution ou de tout autre organisme à l'exécution du projet (personnel, matériel, fournitures, etc. à l'exclusion des services d'ordre général). L'institution s'engage à fournir les locaux, équipement et personnels non couverts par cet accord.

The Institute will provide all other facilities not provided for under this Agreement.

Financial Arrangements/ Dispositions financières:

1. Payments will be made as follows/Les versements seront effectués comme suit:

	Deliverable/ Résultat	Due Date/ Date Remise	%	Currency Amount/ Montant en Devise
1	Countersigned contract	25-JUL-2016	100.00	302,410.00
2	Receipt of final financial report	24-JUL-2017	0.00	0.00
3	Receipt of final technical report	24-JUL-2017	0.00	0.00

2. USD 0.00 will be used by WHO for the purchase of equipment and supplies to be ordered by the Institution as soon as practicable, but not beyond 31 December of the year following the end of the Agreement period as indicated above at which time any uncommitted balance will revert to WHO.

USD 0.00 seront affectés par l'OMS à l'achat de matériels et de fournitures à commander par l'institution dès que possible, mais au plus tard avant le 31 décembre de l'année suivant la fin de la période susmentionnée d'exécution de l'accord, étant entendu qu'à ce moment tout solde non engagé fera retour à l'OMS.

Annexes

The following annexes form an integral part of this Agreement/ Les annexes listées ci-dessous font partie intégrante de cet accord:

Annex	File Description/Description de fichier
1	2016/647688 Contractual - Budget Breakdown
2	2016/647688 Contractual - Terms of Reference

In the event that the terms of the annexes contain any provisions which are contrary to the terms of this Agreement, the terms of this Agreement shall take precedence/ En cas de contradiction entre les termes apparaissant sur les annexes et ceux de l'Accord, les dispositions de l'Accord prévaudront dans tous les cas.

WHO Financial References/ Références financières de l'OMS

	Project	Task	Award	Expenditure Type	Expenditure Organization	%	USD
1	HQRHR1612205	10.1	61980	512-Consulting,	HQ	100	302,410.00

ATTESTED

Technical Services Agreement

Page 1 of 5

Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

272



World Health Organization

WHO/GSC/GPL
BLOCK 3510
JALAN TEKNOKRAT 8
CYBERJAYA 63000
Malaysia

WHO Reference/ Référence OMS	
WHO Reference	2016/647688-0
Purchase Order	201544467
Reg. File	n/a
Unit Reference	A65870

**TECHNICAL SERVICES AGREEMENT
ACCORD DE SERVICES TECHNIQUES**

				Research Serv.		
--	--	--	--	----------------	--	--

General

The parties accept the "General Conditions" overleaf, which constitute an integral part of this Agreement. The Institution certifies the correctness of the banking instructions provided on Page 1. All necessary arrangements to comply with national regulations relating to this project and relevant to the Institution's responsibilities shall have been undertaken by the Institution; failure to do so will nullify this Agreement. The responsibility of the World Health Organization is limited only to the financial support as specified in this Agreement.

Généralités

Les parties acceptent les "Conditions générales" reproduites au verso, lesquelles font partie intégrante du présent accord. L'Institution certifie l'exactitude des instructions bancaires indiquées à la page 1. Toutes les dispositions relevant des responsabilités de l'Institution et nécessaires à la mise en conformité de ce Projet avec la réglementation nationale, devront avoir été prises par l'Institution, faute de quoi l'accord sera nul. La responsabilité de l'Organisation Mondiale de la Santé se limite au soutien financier spécifié dans le présent accord.

ON BEHALF OF WHO/ POUR L'OMS

Responsible WHO Technical Officer:
Fonctionnaire technique responsable de l'OMS:

Mariana Widmer
Technical Officer
HQ/RHR - Reproductive Health and Research

Responsible Divisional Director
Directeur de division responsable

Flavia BUSTREO
Asst Director-General
HQ/FWA FWC ADGO Office of the Assistant DG

Authorized Signatory:
Signataire autorisé:

Mr Motohiro Ogita
Coordinator
Global Procurement and Logistics
(WHO/GMG/GSC/GPL)

Motohiro Ogita
Coordinator
HQ/GSC Global Service Centre
21-JUL-2016

PRINCIPAL INVESTIGATOR/ CHERCHEUR PRINCIPAL

Principal Investigator or Technical Officer responsible for the project.
Chercheur Principal ou membre du personnel technique responsable de l'exécution du projet.

Signature :
DR. Shivaprasad Goudar

ON BEHALF OF THE INSTITUTION/ POUR L'INSTITUTION

Responsible Administrative Authority*
*Autorité administrative responsable**

Signature :
Name/nom : DR. N. S. MAHANTSHETTI
Division : PRINCIPAL
Date : 22 July 2016

* An official of the Institution - other than the Principal Investigator - fully empowered to enter into contracting arrangements on behalf of the Institution. *Un responsable de l'Institution autre que le Chercheur principal - ayant pleins pouvoirs pour passer un contrat au nom de l'institution.*

Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI



TECHNICAL SERVICES
AGREEMENT
ACCORD DE SERVICES
TECHNIQUES

GENERAL CONDITIONS

The following are the general conditions relating to this Agreement concerning WHO support for research or other technical services. The purpose of such support is to assist an Institution to undertake, for WHO, investigations on a particular problem or other work which has been agreed upon by the Institution and WHO.

1 INSTITUTION AND PRINCIPAL INVESTIGATOR

1.1 The Institution and the Principal Investigator (or Responsible Technical Officer), who must be an employee of the Institution, shall be jointly responsible for all the technical and administrative aspects of the work referred to in this Agreement.

1.2 The Institution is required to notify WHO immediately of knowledge that the Principal Investigator will cease or ceases to be an employee of the Institution or is no longer continuing the responsibilities covered by this Agreement. Under such circumstances WHO has the right to:

- a. cancel this Agreement or
- b. agree to continue the project under a new Principal Investigator proposed by the Institution and approved by WHO.

2. FINANCIAL ARRANGEMENTS

2.1 Payments shall be made to the bank account(s) of the Institution as specified in this Agreement and in accordance with the schedule of payments contained therein. If, after the submission of the final financial report referred to in paragraph 4.3 below, there remains an unused balance of funds with the Institution, this balance shall be due to WHO. In the event of this Agreement being cancelled under any circumstances, the Institution shall refund to WHO the balance of uncommitted funds. The funds provided under this Agreement shall be spent only in accordance with its terms.

2.2 The funds transferred to the Institution under this Agreement may not be used to meet any form of emoluments, travel costs or any other reimbursements of expenditure to a staff member of WHO.

2.3 Unless otherwise provided in this Agreement the funds may not be used to cover:

- a. normal administrative and overhead expenses of the Institution;
- b. cost of maintenance, repair, running or insurance of existing equipment and machinery belonging to the Institution;
- c. cost of construction of new buildings or alterations and modifications of existing buildings and premises;
- d. salary support of the Principal Investigator.

3. EQUIPMENT AND SUPPLIES

3.1 Unless otherwise agreed, and subject to subparagraph 3.2 below, any equipment acquired under this Agreement shall become the property of the Institution. The Institution and the Principal Investigator shall be jointly responsible for the proper safeguard, maintenance and care of all equipment acquired under this Agreement.

3.2 Notwithstanding subparagraph 3.1 above, the Institution shall transfer ownership of any equipment acquired under this Agreement to WHO. If so requested by WHO, upon termination or expiry of this Agreement. In such cases the Institution shall dispatch the equipment to any destination chosen by WHO, the cost of which will be borne by WHO.

4. REPORTS

The Institution shall submit technical and financial reports to WHO on the work as required, or at least annually, in accordance with the following provisions:

4.1 Technical reports shall be prepared by the Principal Investigator and forwarded through and countersigned by the authorized official of the Institution or his authorized representative. Each annual report shall summarize the results of the project and give in sufficient detail its positive and negative findings so that the value of the work can be assessed.

4.2 Financial reports shall be forwarded after being jointly certified by the Institution's Chief Financial Officer and the Principal Investigator, using form WHO 782. The reports must show the use of the funds provided by WHO compared with the original budget expenditure pattern agreed between the Institution and WHO.

4.3 All Financial and Technical reports are subject to audit by WHO, including examination of supporting documentation and relevant accounting entries in the Institution's books. In order to facilitate such reporting and audit, the Institution shall ensure that accurate and systematic accounts and records are kept in respect of the project. The final Technical and Financial reports must be submitted within 90 days after the expiry of this Agreement.

5. RELATIONSHIP AND RESPONSIBILITY OF PARTIES

The relationship of the Institution to WHO shall be that of an independent contractor. The employees of the Institution are not entitled to describe themselves as staff members of WHO. The Institution shall be solely responsible for the manner in which work on the project is carried out and accordingly shall assume full liability for any damage arising from research or other technical services under this Agreement. No liability shall attach to WHO, its advisers, agents or employees.

6. USE OF RESULTS, EXPLOITATION OF RIGHTS, AND PUBLICATION

6.1 The results of the project funded under this Agreement may be freely used or disclosed by either party provided that, without the consent of the other party, no use may be made for commercial purposes and confidentiality shall be maintained with respect to results that may be eligible for protection by proprietary rights. The Institution shall provide WHO with the results, in the form of relevant know-how and other information, and to the extent feasible, tangible products.

6.2 The industrial or commercial exploitation of any intellectual property rights,

including the ownership of know-how, arising from the project shall be designed to achieve, in so far as circumstances permit, the following objectives in the following order of priority:

- a. the general availability of the products of creative activity;
- b. the availability of those products to the public health sector on preferential terms, particularly in developing countries;
- c. the grant to each party of additional benefits, including royalties, account being taken of the relative value of each party's financial, intellectual and other contribution to the research.

6.3 The rights referred to in para. 6.2 shall belong to the Institution, or to the Principal Investigator if the Institution and WHO so agree. To the extent that the former do not intend to exercise them, the rights shall be promptly transferred to WHO, if it so requests. Each party shall provide the other with its full cooperation to permit the effective exercise of the rights. The party in which the corresponding rights are vested may file applications for industrial property protection, promptly furnishing copies of the applications and other patent documents to the other party. All rights other than the right to file applications shall be exercised in accordance with an agreement which shall be negotiated in good faith between the Institution and WHO.

6.4 In any publication by the Institution or the Principal Investigator relating to the results of the project, the responsibility for the direction of the work shall not be ascribed to WHO. Unless WHO advises otherwise, all publications shall include a notice indicating that the underlying investigation received financial support from WHO. Two off-prints or copies shall be sent to WHO unless another number is stipulated. WHO funds may not be used for publication costs unless specifically authorized.

7. RESEARCH INVOLVING HUMAN SUBJECTS

7.1 Ethical Aspects

It is the responsibility of the Institution and the Principal Investigator to safeguard the rights and welfare of human subjects involved in research supported in whole or in part by funds from WHO, in accordance with the appropriate national code of ethics or legislation, if any, and in the absence thereof, the Helsinki Declaration and any subsequent amendments. Such funds may be used only to support investigations where (a) the rights and welfare of the subjects involved in the research are adequately protected, (b) freely given informed consent has been obtained, (c) the balance between risk and potential benefits involved has been assessed and deemed acceptable by a panel of independent experts appointed by the Institution and (d) any special national requirements have been met.

7.2 Regulatory Requirements

It is the responsibility of the Institution and the Principal Investigator to comply with the relevant national regulations pertaining to research involving human subjects.

7.3 Protection of Subjects

Without prejudice to obligations under applicable laws, the Institution shall make appropriate arrangements to eliminate or mitigate the consequences to subjects or their families in the case of death, injury or illness resulting from the conduct of research referred to in paragraph 7.1. Such arrangements shall, to the extent feasible, include medical treatment and financial relief. The Institution and Principal Investigator undertake to protect the confidentiality of the information relating to the possible identification of subjects involved in the research involving human subjects conducted under the auspices of this Agreement.

8. RESEARCH INVOLVING THE USE OF LABORATORY ANIMALS

The Institution undertakes that living vertebrate animals, required for use as laboratory animals for the research to be carried out under this Agreement, shall be handled in accordance with generally accepted principles for the humane treatment of such animals and the avoidance of unnecessary suffering.

9. RESEARCH SAFETY

It is the responsibility of the Institution to establish and implement policies and practices to assure and provide for the safety of its employees, the public, and the environment during the conduct of the supported research. If the supported research involves the use of dangerous biological agents, the Institution shall establish and implement an appropriate safety plan.

10. PUBLICITY

The Institution and the Principal Investigator shall not refer to the relationship of WHO to the project, or to products or processes connected with the project, in any statement or material of a publicity or promotional nature issued for commercial purposes, or with a view to financial benefit.

11. SETTLEMENT OF DISPUTES

Any matter relating to the interpretation or application of this Agreement which is not covered by its terms shall be resolved by reference to Swiss law. Any dispute relating to the interpretation or application of this Agreement shall, unless amicably settled, be subject to conciliation. In the event of failure of the latter, the dispute shall be settled by arbitration. The arbitration shall be conducted in accordance with the modalities to be agreed upon by the parties or, in the absence of agreement, with the Rules of Arbitration of the International Chamber of Commerce. The parties shall accept the arbitral award as final.

12. PRIVILEGES AND IMMUNITIES

Nothing contained in or relating to this Agreement shall be deemed to constitute a waiver of any of the privileges and immunities enjoyed by WHO and/or as submitting WHO to any national court jurisdiction.

Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI



**TECHNICAL SERVICES
AGREEMENT
ACCORD DE SERVICES
TECHNIQUES**

CONDITIONS GENERALES

Les conditions générales énoncées ci-après s'appliquent au présent Accord sur l'appui de l'OMS aux recherches ou autres services techniques. Cet appui vise à aider une Institution à entreprendre pour le compte de l'OMS, des investigations portant sur un problème particulier ou des travaux convenus entre l'Institution et l'OMS.

1. INSTITUTION ET CHERCHEUR PRINCIPAL

1.1 L'Institution et le Chercheur principal (ou l'Administrateur technique responsable), lequel doit être employé par l'Institution, sont conjointement responsables de l'ensemble des aspects techniques et administratifs des travaux visés par le présent Accord.

1.2 L'Institution est tenue d'aviser immédiatement l'OMS lorsqu'elle apprend que le Chercheur principal va cesser, ou a cessé, d'être employé par elle, ou bien qu'il ne continue pas à exercer les fonctions visées par le présent Accord. En pareil cas, l'OMS peut :

- a. soit annuler le présent Accord;
- b. soit accepter de poursuivre le projet sous la conduite d'un nouveau Chercheur principal proposé par l'Institution et approuvé par l'OMS.

2. DISPOSITIONS FINANCIERES

2.1 Des versements seront faits au(x) compte(s) bancaire(s) de l'Institution comme il est stipulé dans le présent Accord et conformément au calendrier qui y figure. Si, après communication du rapport financier final mentionné plus loin au paragraphe 4.3, il apparaît que l'Institution détient un solde non utilisé, ce solde reste payable à l'OMS. En cas d'annulation du présent Accord, quelles qu'en soient les circonstances, l'Institution restituera à l'OMS les sommes non encore engagées. Les sommes fournies en vertu du présent Accord ne pourront être dépensées que conformément aux dispositions dudit Accord.

2.2 Les fonds versés à l'Institution en vertu du présent Accord ne peuvent être utilisés pour verser des émoluments quelconques à un fonctionnaire de l'OMS, couvrir ses frais de voyage ou lui rembourser toute autre dépense.

2.3 Sauf dispositions contraires du présent Accord, ces fonds ne peuvent être utilisés pour couvrir :

- a. les dépenses administratives et les frais généraux normaux de l'Institution;
- b. le coût de l'embauche, de la réparation, de l'exploitation ou de l'assurance de matériels ou d'appareils existants qui appartiennent à l'Institution;
- c. le coût de la construction de nouveaux bâtiments, ou de la transformation ou de la modification de bâtiments et locaux existants;
- d. le versement d'un complément de traitement au Chercheur principal.

3. MATERIEL ET FOURNITURES

3.1 Sauf convention contraire, et sous réserve des dispositions de l'alinéa 3.2 ci-après, tout matériel obtenu en vertu du présent Accord sera la propriété de l'Institution. L'Institution et le Chercheur principal seront conjointement responsables du bon état de conservation et d'entretien de tout matériel acquis en application du présent Accord.

3.2 Nonobstant les dispositions de l'alinéa 3.1 ci-dessus et si l'OMS en fait la demande, l'Institution transférera à celle-ci, lors de la résiliation ou de l'expiration du présent Accord les droits de propriété afférents à tout matériel acquis au titre dudit Accord. L'Institution expédiera alors ce matériel vers toute destination que lui aura indiquée l'OMS, les frais d'expédition étant à la charge de cette dernière.

4. RAPPORTS

L'Institution soumettra à l'OMS des rapports techniques et financiers concernant ses travaux, chaque fois qu'il y a lieu et au moins une fois par an, selon les modalités suivantes.

4.1 Les rapports techniques seront établis par le Chercheur principal, envoyés sous couvert du responsable de l'Institution ou de son représentant l'un et l'autre dûment autorisés, et contre-signés par eux. Chaque rapport annuel résumera les résultats du projet et en exposera les conclusions positives ou négatives de façon assez détaillée pour permettre d'apprécier la valeur des travaux.

4.2 Les rapports financiers devront être envoyés, après avoir été visés conjointement par le Chef des Services financiers de l'Institution et par le Chercheur principal qui utilisera à cette fin le formulaire WHO 782. Les rapports devront indiquer l'utilisation des fonds provenant de l'OMS au regard des prévisions de dépenses initiales dont étaient convenues l'Institution et l'OMS.

4.3 Tous les rapports financiers et techniques sont soumis par l'OMS à une vérification comprenant l'examen de toutes pièces justificatives ainsi que des écritures comptables correspondantes dans les livres de l'Institution. En vue de faciliter l'établissement et la vérification de ces rapports, l'Institution veillera à la tenue de comptes et de registres exacts et systématiques pour tout ce qui concerne le projet. Les rapports techniques et financiers finaux devront être présentés dans les 90 jours suivant l'expiration du présent Accord.

5. RELATIONS ENTRE LES PARTIES ET LEURS RESPONSABILITES

L'Institution agit à l'égard de l'OMS en tant qu'entrepreneur indépendant; ses employés ne pourront se prévaloir de la qualité de membres du personnel de l'OMS. L'Institution sera seule responsable de la façon dont s'exécute le projet et, partant, assumera l'entière responsabilité de tout dommage résultant de recherches ou d'autres services techniques visés par le présent Accord. Aucune responsabilité ne pourra incomber à l'OMS, ses conseillers, agents ou employés.

6. UTILISATION DES RESULTATS, EXPLOITATION DES DROITS, ET PUBLICATION

6.1 Les résultats du projet financé en vertu du présent Accord pourront être librement utilisés ou divulgués par l'une ou l'autre partie. Toutefois, à défaut de l'assentiment de l'autre partie, les résultats ne pourront être utilisés à des fins commerciales et, s'ils sont susceptibles d'être protégés par des droits de propriété, ils conserveront leur caractère strictement confidentiel. L'Institution communiquera à l'OMS les résultats des recherches, sous forme de savoir-faire et autres

intellectuelle, y compris les droits qui s'attachent au savoir-faire, découlant du projet, devra permettre, dans toute la mesure du possible, d'atteindre les objectifs suivants énoncés par ordre de priorité :

- a. mise à la disposition de tous les produits de l'activité créatrice;
- b. leur mise à la disposition du secteur de la santé publique, notamment dans les pays en développement à des conditions préférentielles;
- c. accès à chaque partie d'avantages additionnels, y compris sous formes de redevances, compte tenu de la valeur relative de ses contributions financières, intellectuelles et autres.

6.3 Les droits mentionnés plus haut au paragraphe 6.2 seront la propriété de l'Institution, ou du Chercheur principal si l'Institution et l'OMS en conviennent ainsi. Dans la mesure où l'Institution n'entend pas les exercer, les droits seront promptement transmis à l'OMS, si celle-ci le demande. Chaque partie coopérera pleinement avec l'autre pour lui permettre d'exercer effectivement ses droits. La partie détentrice des droits pourra déposer des demandes de propriété industrielle et devra alors remettre à l'autre partie copie de ces dépôts et des autres documents relatifs au brevet. Tous les droits autres que celui de déposer des demandes s'exercent aux termes d'un accord qui sera négocié de bonne foi entre l'Institution et l'OMS.

6.4 Dans aucune de ses publications concernant les résultats du projet, l'Institution ou le Chercheur principal n'attribuera à l'OMS la responsabilité de la direction des travaux. Sauf instructions contraires de l'OMS, toutes les publications comporteront une note indiquant que les recherches qui sont à l'origine des résultats ont reçu un appui financier de l'OMS. A moins qu'un autre chiffre n'ait été stipulé, deux exemplaires ou tirés à part de ces publications seront envoyés à l'OMS et, sauf autorisation expresse, les fonds de l'OMS ne pourront être utilisés pour couvrir les coûts de publication.

7. RECHERCHES IMPLIQUANT L'ETUDE DE SUJETS HUMAINS.

7.1 Aspects éthologiques

Il incombe à l'Institution et au Chercheur principal de s'assurer qu'au cours des travaux financés totalement ou en partie par l'OMS et impliquant l'étude de sujets humains, les droits et la santé de ces derniers soient protégés conformément au code de déontologie ou à la législation du pays, ou, à défaut, à la Déclaration d'Helsinki et aux amendements qui pourraient lui être ultérieurement apportés. Les fonds ne peuvent être utilisés pour financer des recherches que si les conditions suivantes sont remplies :

- a. les droits et le bien-être des sujets impliqués sont suffisamment protégés;
- b. le consentement libre et éclairé des intéressés a été obtenu;
- c. des experts indépendants désignés par l'Institution ont passé les risques et les avantages potentiels et ont jugé qu'ils s'équilibrent de manière acceptable; et
- d. il est satisfait à toute exigence particulière de la réglementation nationale.

7.2 Dispositions réglementaires

Il incombe à l'Institution et au Chercheur principal de respecter la réglementation nationale relative aux recherches impliquant l'étude de sujets humains.

7.3 Protection des sujets d'expérience

Sans préjudice des obligations qui lui incombent aux termes des lois en vigueur, l'Institution prendra des mesures appropriées en vue d'éliminer ou d'atténuer les conséquences des expériences pour les sujets ou leur famille en cas de décès, de traumatisme ou de maladie résultant de la conduite des recherches mentionnées au paragraphe 7.1. Ces mesures comprendront, dans la mesure du possible, un traitement médical et un dédommagement financier. L'Institution et le Chercheur principal s'engagent à protéger le caractère confidentiel des informations qui pourraient permettre d'identifier les sujets impliqués dans les études effectuées en vertu du présent Accord.

8. RECHERCHES IMPLIQUANT L'UTILISATION D'ANIMAUX DE LABORATOIRE

L'Institution s'engage à veiller à ce que les animaux vertébrés vivants qu'il sera nécessaire d'utiliser comme animaux de laboratoire pour des recherches entreprises en vertu du présent Accord soient traités conformément aux principes universellement reconnus qui veulent que l'on épargne à ces animaux toute souffrance inutile.

9. SECURITE DES RECHERCHES

Il incombe à l'Institution d'arrêter et d'appliquer des politiques et pratiques préservant et garantissant la sécurité de ses employés et du public ainsi que celle de l'environnement pendant les recherches soutenues par l'OMS. Si les travaux impliquent l'utilisation de substances biologiques dangereuses, l'Institution établira et appliquera un plan de sécurité approprié.

10. PUBLICITE

L'Institution et le Chercheur principal ne pourront faire mention, dans un quelconque écrit ou déclaration à caractère publicitaire ou promotionnel diffusé à des fins commerciales, ou en vue d'un avantage financier, du lien existant entre l'OMS et le projet ou les produits ou procédés en découlant.

11. REGLEMENT DES LITIGES

Toute question concernant l'application ou l'interprétation du présent Accord que les dispositions de ce dernier ne permettent pas de résoudre doit être résolue par référence au droit suisse. Tout différend relatif à l'application ou à l'interprétation du présent Accord qui n'aurait pu être résolu à l'amiable, fera l'objet d'une conciliation. En cas d'échec de celle-ci, le différend sera réglé par arbitrage. Les modalités de l'arbitrage seront convenues entre les parties ou, en absence d'accord, seront déterminées selon le règlement d'arbitrage de la Chambre de Commerce Internationale. Les parties reconnaissent que la sentence arbitrale sera finale.

12. PRIVILEGES ET IMMUNITES

Aucun des termes du présent Accord ne sera considéré comme constituant une

Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI



**World Health
Organization**

**TECHNICAL SERVICES
AGREEMENT
ACCORD DE SERVICES
TECHNIQUES**

Informations pertinentes et, dans la mesure du possible, lui fournira des produits concrets.
6.2 L'exploitation industrielle ou commerciale de tout droit de propriété

WHO/GSC/GPL
BLOCK 3510
JALAN TEKNOKRAT 6
CYBERJAYA 63000
Malaysia

WHO Reference/ Référence OMS

WHO Reference	2016/647688-0
Purchase Order	201544467
Reg. File	n/a
Unit Reference	A65870

renonciation à quelque privilège ou immunité que ce soit dont jouit l'OMS et/ou comme constituant une soumission de l'OMS à la compétence d'un quelconque tribunal national.

ATTESTED

Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

**SUBCONTRACT
AMENDMENT NUMBER FOUR (4)**

Prime Recipient	Subcontractor	
Institution/Organization ("Prime Recipient") Name: Regents of the University of Colorado, a body corporate, for and on behalf of the University of Colorado Denver Address: University of Colorado Denver, Office of Grants and Contracts, Anschutz Medical Campus Bldg. 500, W1126, 13001 E 17 th Place, Mail Stop F428, Aurora, Colorado 80045	Institution/Organization ("Subcontractor") Name: Jawaharlal Nehru Medical College Address: Nehru Nagar, Belgaum Karnataka, India, PIN 590010	
Prime Award No. <p style="text-align: center;">OPP1055867_YR4</p>	Subcontract No. <p style="text-align: center;">FY13.040.002</p>	Amount Funded This Action: <p style="text-align: center;">US\$442,578</p>
Prime Recipient's Principal Investigator <p style="text-align: center;">Nancy Krebs, MD (PI Change)</p>	Amendment No. <p style="text-align: center;">FY16.115.004 AMD4</p>	Project No. <p style="text-align: center;">2-5-81932</p>

This Amendment modifies the following to the Original Terms and Conditions

1. PERIOD

The Current Period of Performance applicable to the Subcontract is extended to cover the Budget Period November 1, 2014 to October 31, 2016.

2. COMPENSATION

The budget available for the Budget Period is revised as follows:

Personnel	US\$249,394
Consultant Costs	US\$28,560
Supplies	US\$62,200
Travel	<u>US\$44,696</u>
Total Direct Costs	US\$384,850
F&A Costs @ 15%	<u>US\$57,728</u>
Total Costs	US\$442,578
Cumulative Costs	US\$1,462,955
(Amount Funded to Subcontractor through the end of the Budget Period)	

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

**SUBCONTRACT
AMENDMENT NUMBER FIVE (5)**

Prime Recipient	Subcontractor	
Institution/Organization ("Prime Recipient") Name: Regents of the University of Colorado, a body corporate, for and on behalf of the University of Colorado Denver Address: University of Colorado Denver, Office of Grants and Contracts, Anschutz Medical Campus Bldg. 500, W1126, 13001 E 17 th Place, Mail Stop F428, Aurora, Colorado 80045	Institution/Organization ("Subcontractor or Subrecipient") Name: Jawaharlal Nehru Medical College Address: Nehru Nagar, Belgaum Karnataka, India, PIN 590010 DUNS: 650251213	
Prime Award No.: OPP1055867_AMD03	Subcontract No.: FY13.040.002	Amount Funded This Action: USD\$160,736
Prime Recipient's Principal Investigator: Nancy Krebs, MD	Amendment No.: FY17.115.007_AMD5	Project No.: 2-5-81932
Project Title: Implementing Integrated Maternal Nutrition Interventions		

1. PERIOD

The Current Period of Performance applicable to the Subcontract is extended to cover the Budget Period November 1, 2014 to October 31, 2017.

2. COMPENSATION

The budget available for the Budget Period is revised as follows:

Personnel	USD\$15,050.93
Consultation Costs	USD\$38,102
Supplies	USD\$79,169.91
Travel	USD\$7447.07
Total Direct Costs	USD\$139,770
F&A Costs @ 15%	USD\$20,966
Total Costs	USD\$160,736
Total Cumulative Costs (Total amount funded through the budget period)	USD\$1,623,691

3. PAYMENT

Subcontractor may submit invoices to Prime Recipient, for costs incurred. Said invoices should include:

- (a) Subcontract Amendment number: FY17.115.007_AMD5 JNMC
- (b) Prime Award number: OPP1055867_AMD03
- (c) Project number: 2-5-81932
- (d) The period for which reimbursement is being requested.
- (e) An itemization of current and cumulative costs in accordance with the categories in the budget.
- (f) Telephone number for Subcontractor's certifying officer.
- (g) All invoices should be signed by Subcontractor's authorized official and include the following statement: "I certify that all expenditures reported (or payments requested) are for appropriate purposes and in accordance with the provisions of the application and award document." Promptly after approval of each invoice, Prime Recipient shall make payment thereof.

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

A final invoice for the Budget Period must be submitted within sixty (60) calendar days after termination or expiration of this Subcontract or the Budget Period, whichever is first, and must be marked "Final Invoice".

Invoices should be mailed to the attention of: Jamie Westcott, University of Colorado Denver, 12700 E, 19th Ave., Campus Box C225, Aurora, Colorado 80045. Jamie Westcott may be reached by telephone at (303) 724-3265.

4. REVISED TERM

Paragraph 3 of the Subcontract terms and conditions is deleted in its entirety and is replaced with the following:

A final statement of cumulative costs incurred, including cost sharing, marked "FINAL," must be submitted to UCD's Financial Contact, as shown in Attachments 3A, before the earlier of sixty (60) days after Subaward end date or fifteen (15) days prior to the date UCD's final invoice is required by the Sponsor in the Prime Award. The final statement of costs shall constitute Subcontractor's final financial report.

UNIFORM GUIDANCE/FULL FORCE AND EFFECT

The Subcontract is hereby revised to include any and all applicable changes required by the implementation of 2 C.F.R § 200 UNIFORM ADMINISTRATIVE REQUIREMENTS, COST PRINCIPLES, AND AUDIT REQUIREMENTS FOR FEDERAL AWARDS.

All other terms and conditions of the Subcontract remain in full force and effect.

By an Authorized Official of Prime Recipient: (UCD OGC) <i>Thomas Keith</i> 1/31/17 Name Date	By an Authorized Official of Subcontractor: (JNMC) * <i>[Signature]</i> 2/01/17 Name DR. N. S. Mahantshetti Date
Acknowledged by Principal Investigator of Prime Recipient (UCD PI): <i>[Signature]</i> 1/23/17 Name Date	

ATTESTED

[Signature]

Prof. Dr. V.A.KOTHIWALE
 Registrar
 KLE Academy of Higher Education
 and Research, BELAGAVI

Non-Federal Research Subcontract Amendment



Contractor		Subcontractor	
Institution/Organization ("Contractor") Name: Regents of the University of Colorado, a body corporate, for and on behalf of the University of Colorado Denver Address: University of Colorado Denver, Office of Grants and Contracts, Anschutz Medical Campus Bldg. 500, W1126, 13001 E 17 th Place, Mail Stop F428, Aurora, Colorado 80045-2571		Institution/Organization ("Subcontractor") Name: Jawaharlal Nehru Medical College Address: Nehru Nagar, Belgaum Karnataka, India, PIN 590010 Award: OPP1055867	
Contractor Principal Investigator: Nancy Krebs, MD		Subcontractor Principal Investigator: Dr. Shivaprasad S. Goudar	
Amendment No.: FY18.115.011_AMD6		Subcontract No.: FY13.040.002	Contractor Project No.: 2-5-81932
Project Title: Implementing Integrated Maternal Nutrition Interventions			
Subcontract Period of Performance: Budget Period: Start: 11/1/2017 • End: 10/31/2018 Total Anticipated Project Period: Start: 12/1/2012 • End: 10/31/2018		Contract Value: Funding This Action: \$ 144,176 (USD) Total Funding to Date: \$ 1,767,867 (USD)	
Amendment(s) to Original Terms and Conditions			

1. PERIOD
 The Subcontract Period of Performance is revised to cover November 1, 2017 to October 31, 2018.

2. BUDGET
 The cumulative budget available for the Subcontract Period of Performance is attached.

3. INVOICING
 Subcontractor's invoicing requirements are revised to include the following information as it appears in this Amendment: Subcontract Amendment Number; Contractor Project Number; Subcontract Period of Performance; and Contractor Purchase Order Number (if provided by Contractor).

All other terms and conditions of the Subcontract remain in full force and effect.

By an Authorized Official of Contractor: Ryan Holland <small>Digitally signed by Ryan Holland DN: cn=Ryan Holland, o=University of Colorado Denver, ou=Office of Grants and Contracts, email=ryan.holland@ucdenver.edu, c=US Date: 2018.01.04 12:14:03 -0700</small> <div style="text-align: right;">01/04/18 Date</div>	By an Authorized Official of Subcontractor:  (Dr. S. Mahantscheki) <div style="text-align: right;">01/12/17 Date</div>
Acknowledged by Contractor Principal Investigator:  <div style="text-align: right;">12/14/17 Date</div>	

ATTESTED



Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
 and Research, BELAGAVI

Budget Period:	11/1/2017 to 10/31/2018
Personnel	\$53,704.00
<i>Salary</i>	\$53,704.00
<i>Benefits</i>	\$0.00
Equipment	
Supplies	\$70,412.00
Travel	-\$420.00
Other Expenses	\$1,675.00
Consulting	
Total Direct Costs	\$125,371.00
Total BASE for F&A	\$125,371.00
F&A Costs	\$18,805.00
15.00%	
*Exclusions	
TOTAL COSTS	\$144,176.00
TOTAL CUMULATIVE	\$1,767,867.00

ATTESTED



Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

Non-Federal Research Subcontract Amendment



Contractor	Subcontractor
Institution/Organization ("Contractor") Name: Regents of the University of Colorado, a body corporate, for and on behalf of the University of Colorado Denver Address: University of Colorado Denver, Office of Grants and Contracts, Anschutz Medical Campus Bldg. 500, W1126, 13001 E 17 th Place, Mail Stop F428, Aurora, Colorado 80045-2571	Institution/Organization ("Subcontractor") Name: Jawaharlal Nehru Medical College Address: Nehru Nagar, Belgaum Karnataka, India, PIN 590010 Award: OPP1055867
Contractor Principal Investigator: Nancy Krebs, MD	Subcontractor Principal Investigator: Dr. Shivaprasad S. Goudar
Amendment No.: FY19.115.007_AMD7	Subcontract No.: FY13.040.002 Contractor Project No.: 2-5-81932
Project Title: Implementing Integrated Maternal Nutrition Interventions	
Subcontract Period of Performance: Budget Period: Start: 11/1/2018 End: 1/31/2019 Total Anticipated Project Period: Start: 12/1/2012 End: 1/31/2019	Contract Value: Funding This Action: \$ 29,302 (USD) Total Funding to Date: \$ 1,797,169 (USD)
Amendment(s) to Original Terms and Conditions	

1. PERIOD
 The Subcontract Period of Performance is revised to cover November 1, 2018 to January 31, 2019.


2. BUDGET
 The cumulative budget available for the Subcontract Period of Performance is attached.

3. INVOICING
 Subcontractor's invoicing requirements are revised to include the following information as it appears in this Amendment: Subcontract Amendment Number; Contractor Project Number; Subcontract Period of Performance; and Contractor Purchase Order Number (if provided by Contractor).

All other terms and conditions of the Subcontract remain in full force and effect.

By an Authorized Official of Contractor: Digitally signed by Ryan Holland DN: cn=Ryan Holland, o=University of Colorado Denver, ou=Office of Grants and Contracts, email=ryan.holland@ucdenver.edu, c=US Date: 2018.10.26 15:58:45 -06'00' Ryan Holland Date: 10/26/18	By an Authorized Official of Subcontractor:  (Dr. N.S. Mahantshetti) Date: 5/10/18
Acknowledged by Contractor Principal Investigator:  _____ Date: 10-22-18	

ATTESTED



Prof. Dr. V.A.KOTHIWALE
 —Registrar—
 KLE Academy of Higher Education
 and Research, BELAGAVI

Budget Period:		11/1/2018 to 1/31/2019
Personnel		\$7,520.00
<i>Salary</i>	\$7,520.00	
Supplies		\$13,520.00
Travel		\$4,440.00
Total Direct Costs		\$25,480.00
Total BASE for F&A		\$25,480.00
F&A Costs		\$3,822.00
	15.00%	
*Exclusions		
TOTAL COSTS		\$29,302.00
TOTAL CUMULATIVE		\$1,797,169.00

ATTESTED



Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

Non-Federal Research Subcontract Amendment



Contractor	Subcontractor		
Institution/Organization ("Contractor") Name: Regents of the University of Colorado, a body corporate, for and on behalf of the University of Colorado Denver Address: University of Colorado Denver, Office of Grants and Contracts, Anschutz Medical Campus Bldg. 500, W1126, 13001 E 17 th Place, Mail Stop F428, Aurora, Colorado 80045-2571	Institution/Organization ("Subcontractor") Name: Jawaharlal Nehru Medical College Address: Nehru Nagar, Belgaum Karnataka, India, PIN 590010 Award: OPP1055867		
Contractor Principal Investigator: Nancy Krebs, MD	Subcontractor Principal Investigator: Dr. Shivaprasad S. Goudar		
Amendment No.: FY19.115.011_AMD8	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Subcontract No.: FY13.040.002</td> <td style="width: 50%;">Contractor Project No.: 2-5-81932</td> </tr> </table>	Subcontract No.: FY13.040.002	Contractor Project No.: 2-5-81932
Subcontract No.: FY13.040.002	Contractor Project No.: 2-5-81932		
Project Title: Implementing Integrated Maternal Nutrition Interventions			
Subcontract Period of Performance: Budget Period: Start: 11/1/2018 End: 10/31/2019 Total Anticipated Project Period: Start: 12/1/2012 End: 10/31/2019	Contract Value: Funding This Action: \$ 16,100 (USD) Total Funding to Date: \$ 1,813,269 (USD)		
Amendment(s) to Original Terms and Conditions			


1. PERIOD
 The Subcontract Period of Performance is revised to cover November 1, 2018 to October 31, 2019.

2. BUDGET
 The cumulative budget available for the Subcontract Period of Performance is attached.

3. INVOICING
 Subcontractor's invoicing requirements are revised to include the following information as it appears in this Amendment: Subcontract Amendment Number; Contractor Project Number; Subcontract Period of Performance; and Contractor Purchase Order Number (if provided by Contractor).

All other terms and conditions of the Subcontract remain in full force and effect.

By an Authorized Official of Contractor: Eric Maize <small>Digitally signed by Eric Maize DN: cn=Eric Maize, ou=University of Colorado, an=Anschutz Medical Campus, o=University of Colorado and Contracts, ou=University of Colorado, email=maize@regents.edu, c=US Date: 2019.03.28 10:53:11 -0700</small> Date: 4/3/2019	By an Authorized Official of Subcontractor:  Date: 28/03/2019 (DR N.S. MAHANTSHETTI)
Acknowledged by Contractor Principal Investigator:  Date: 3/29/19	

ATTESTED

 Prof. Dr. V.A. KOTHIWALE
 Registrar
 KLE Academy of Higher Education
 and Research, BELAGAVI

Budget Period:	11/1/2018 to 10/31/2019
Travel	\$4,000.00
Other Expenses (List below)	\$10,000.00
Consulting	
Total Direct Costs	\$14,000.00
Total BASE for F&A	\$14,000.00
F&A Costs	\$2,100.00
15.00%	
*Exclusions	
TOTAL COSTS	\$16,100.00
TOTAL CUMULATIVE	\$1,813,269.00

ATTESTED


Prof. Dr. V.A.KOTHIWALE
 Registrar
 KLE Academy of Higher Education
 and Research, BELAGAVI

Non-Federal Research Subcontract Amendment



Contractor	Subcontractor
Institution/Organization ("Contractor") Name: Regents of the University of Colorado, a body corporate, for and on behalf of the University of Colorado Denver Address: University of Colorado Denver, Office of Grants and Contracts, Anschutz Medical Campus Bldg. 500, W1126, 13001 E 17 th Place, Mail Stop F428, Aurora, Colorado 80045-2571.	Institution/Organization ("Subcontractor") Name: Jawaharlal Nehru Medical College Address: Nehru Nagar, Belgaum Karnataka, India, PIN 590010 Award: OPP1055867
Contractor Principal Investigator: Nancy Krebs, MD	Subcontractor Principal Investigator: Dr. Shivaprasad S. Goudar
Amendment No.: FY20.115.006_AMD9	Subcontract No.: FY13.040.002 Contractor Project No.: 2-5-81932
Project Title: Implementing Integrated Maternal Nutrition Interventions	
Subcontract Period of Performance: Budget Period: Start: 11/01/2019 End: 10/31/2020 Total Anticipated Project Period: Start: 12/1/2012 End: 10/31/2020	Contract Value: Funding This Action: \$ 0 (NCE) Total Funding to Date: \$ \$1,813,269
Amendment(s) to Original Terms and Conditions	

1. PERIOD
The Subcontract Period of Performance is extended to cover November 1st, 2019 to October 31st, 2020.


2. BUDGET
This is a no cost extension. No additional monies will be provided. For the services provided hereunder during the Budget Period, Contractor will reimburse Subcontractor for all reasonable, allocable, and allowable costs incurred up to, but not to exceed One Million, Eight Hundred and Thirteen Thousand, Two Hundred and Sixty-Nine (\$1,813,269.00). Under no circumstances shall Contractor be responsible for paying Subcontractor in excess of \$1,813,269.00 for the Budget Period, November 1st, 2019 to October 31st, 2020.

3. INVOICING
Subcontractor's invoicing requirements are revised to include the following information as it appears in this Amendment: Subcontract Amendment Number; Contractor Project Number; Subcontract Period of Performance; and Contractor Purchase Order Number (if provided by Contractor).

All other terms and conditions of the Subcontract remain in full force and effect.

By an Authorized Official of Contractor: Ryan Holland <small>Digitally signed by Ryan Holland DN: cn=Ryan Holland, o=University of Colorado Denver, ou=Office of Grants and Contracts, email=ryan.holland@ucdenver.edu, c=US Date: 2019.11.12 08:27:23 -0700</small> _____ Date	By an Authorized Official of Subcontractor:  _____ Date <u>21/10/2019</u>
Acknowledged by Contractor Principal Investigator:  _____ Date <u>10/23/19</u>	

ATTESTED




 Prof. Dr. V.A. KOTHIWALE
 Registrar
 KLE Academy of Higher Education
 and Research, BELAGAVI

FDP Cost Reimbursement Foreign Research Subaward Agreement

Pass-through Entity (PTE): Thomas Jefferson University		Subrecipient: KLE Society's Jawaharlal Nehru Medical College	
PTE Principal Investigator (PI): Richard Derman, MD, MPH		Subrecipient Principal Investigator (PI): Dr. Bhalanchandra S. Kodkany	
PTE Federal Award No: 7U10HD076457-04	FAIN: U10HD076457	Federal Awarding Agency: NIHEunice Kennedy	
Federal Award Issue Date: 6/15/2016	Total Amount of Federal Award to PTE: \$ 742,841	CFDA No: 93.865	CFDA Title: Shriver NICHD Child Health & Human Development Extramural Research
Project Title: CCHS-JNMC Global Network for Women's & Children's Health Research Unit			
Subaward Period of Performance: Start: 6/16/2016 End: 4/30/2017		Amount Funded This Action: \$ 570,454	Subaward No. 080-70000-S22901
Estimated Project Period (if incrementally funded): Start: 6/16/2016 End: 4/30/2018		Incrementally Estimated Total: \$ 1,140,908	Is this Award R & D <input checked="" type="checkbox"/> Yes or <input type="checkbox"/> No
Check all that apply <input type="checkbox"/> Reporting Requirements (Attachment 4) <input type="checkbox"/> Subject to FFATA (Attachment 3B) <input type="checkbox"/> Cost Sharing (Attachment 5)			


Terms and Conditions

- 1) PTE hereby awards a cost reimbursable subaward, as described above, to Subrecipient. The statement of work and budget for this subaward are (check one) as specified in Subrecipient's proposal dated _____ or as shown in Attachment 5. In its performance of subaward work, Subrecipient shall be an independent entity and not an employee or agent of PTE.
- 2) PTE shall reimburse Subrecipient not more often than monthly for allowable costs. All invoices shall be submitted using Subrecipient's standard invoice, but at a minimum shall include current and cumulative costs (including cost sharing), subaward number, and certification, as required in 2 CFR 200.415 (a). Invoices that do not reference PTE Subaward number shall be returned to Subrecipient. Invoices and questions concerning invoice receipt or payments should be directed to the appropriate party's Financial Contact, as shown in Attachments 3A.
- 3) A final statement of cumulative costs incurred, including cost sharing, marked "FINAL" must be submitted to PTE's Financial Contact, as shown in Attachments 3A, NOT LATER THAN 60 days after subaward end date. The final statement of costs shall constitute Subrecipient's final financial report.
- 4) All payments shall be considered provisional and subject to adjustment within the total estimated cost in the event such adjustment is necessary as a result of an adverse audit finding against the Subrecipient. PTE reserves the right to reject an invoice, in accordance with 2 CFR 200.305.
- 5) Matters concerning the technical performance of this subaward should be directed to the appropriate party's Principal Investigator as shown in Attachments 3A and 3B. Technical reports are required as shown above, "Reporting Requirements."
- 6) Matters concerning the request or negotiation of any changes in the terms, conditions, or amounts cited in this subaward agreement, and any changes requiring prior approval, should be directed to the appropriate party's Administrative Contact, as shown in Attachments 3A and 3B. Any such changes made to this subaward agreement require the written approval of each party's Authorized Official, as shown in Attachments 3A and 3B.
- 7) Substantive changes made to this subaward agreement require the written approval of each party's Authorized Official as shown in Attachments 3A and 3B. The PTE may issue non-substantive changes to the Period of Performance (check one) Bilaterally, or Unilaterally. Unilateral modifications shall be considered valid 14 days after receipt unless otherwise indicated by Subrecipient.
- 8) Each party shall be responsible for its negligent acts or omissions and the negligent acts or omissions of its employees, officers, or directors, to the extent allowed by law.
- 9) Either party may terminate this subaward with thirty days written notice to the appropriate party's Administrative Contact, as shown in Attachments 3A and 3B. PTE shall pay Subrecipient for termination costs as allowable under Uniform Guidance, 2 CFR 200, or 45 CFR Part 74 Appendix E, "Principles for Determining Costs Applicable to Research & Development under Grants and Contracts with Hospitals, as applicable.
- 10) No-cost extensions require the approval of the PTE. Any requests for a no-cost extension should be addressed to and received by the Administrative Contact, as shown in Attachments 3A, not less than 30 days prior to the desired effective date of the requested change.
- 11) The Subaward is subject to the terms and conditions of the PTE Award and other special terms and conditions, as identified in Attachment 2.
- 12) By signing this Research Subaward Agreement Subrecipient makes the certifications and assurances shown in Attachments 1 and 2.
- 13) Research Terms & Conditions - RESERVED

By an Authorized Official of Pass-through Entity:  Name: Margaret Burwell Date: 7/22/2016 Title: Associate Director, Pre-Award Grants	By an Authorized Official of Subrecipient:  Name: Dr. (Mrs) Niranjana S Mahantashetti Date: Jul 22, 2016 Title: Principal
--	--

FDP Version 2.9.15

ATTESTED


 Prof. Dr. V.A. KOTHIWALE
 Registrar
 KLE Academy of Higher Education
 and Research, BELAGAVI

Notice of Award



COOPERATIVE CLINICAL RESEARCH AGREEMENT Federal Award Date: 06/27/2016
Department of Health and Human Services
National Institutes of Health



EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT

Grant Number: 7U10HD076457-04 REVISED
FAIN: U10HD076457

Principal Investigator(s):
RICHARD J DERMAN, MD

Project Title: CCHS-JNMC Global Network for Women's & Children's Health Research Unit

Margaret Burwell
125 S. 9th Street
2nd Floor, Sheridan Bldg
Philadelphia, PA 19107

Award e-mailed to: resadmin@jefferson.edu

Period Of Performance:
Budget Period: 06/16/2016 – 04/30/2017
Project Period: 07/01/2013 – 04/30/2018

Dear Business Official:

The National Institutes of Health hereby revises this award (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to THOMAS JEFFERSON UNIVERSITY in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 31 USC 6305 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the National Institutes of Health under Award Number U10HD076457. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

ATTESTED

Page 1

NIH NGA R | VET 3011 - 02/17/2016 - 15:00:00 - 06/27/2016 12:02:19 AM

Prof. Dr. V. A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

ORDER

In continuation of this Department's sanction order of even number dated 02nd March, 2016. Sanction of the President is hereby accorded, under Rule 18 of the Delegation of Financial Power Rules, 1978 for the release of Rs. 25.14 lakhs (Rupees Twenty five lakhs and fourteen thousand only) being the 1st year release towards the Recurring head for the Indian component of the joint project titled "Evaluation of the Introduction of a novel device in the management of hypertension and shock in pregnancy in low-resource settings" executed by Dr. Shivaprasad S. Goudar, Principal Investigator, Department of Physiology, K.L.E. University's Jawaharlal Nehru Medical College, JN Medical College, Belgaum, Karnataka as per the break up given below:

Recurring Head		(Rs. in lakhs)
S. No.	Head	Year I
1.	Consumables/ research expenses (incl. internet connections, communication expenses, reimbursements (Data capitation) and translation of forms)	3.0
2.	Manpower	
	Study Personnel	
	i. Project Administrator (Sr. RS)	7.20
	ii. Data Entry Operator	2.30
	iii. Field Monitoring (LHV)	1.32
	iv. Training Coordinator (Sr. SN)	2.30
	v. Field Assistant I	0.96
	Pilot Study Personnel	
	vi. Research Assistant	1.12
	vii. Field Assistant I	0.44
	Total Manpower	15.64
3.	Travel	
	i. Domestic	1.0
	ii. International	3.0
	iii. Local hospitality for visiting scientist	1.0
	Total Travel	5.0
4.	Contingency (Incl. printing and stationery supplies and printing of DCI)	0.50
5.	Overheads	1.0
	Total A (1+2+3+4+5)	25.14

Total amount to be released under recurring head = Rs. 25.14 lakhs

- The other terms and conditions governing the financial sanction will remain unaltered.
- The amount of Rs. 25.14 lakhs (Rupees Twenty five lakhs and fourteen thousand only) will be drawn by the DDO, DBT from PAO, DBT and will be disbursed to the Registrar K.L.E. University, Belgaum, Karnataka as per details given below:

Name of the Bank : Syndicate Bank, K.L.E. University, Jawaharlal Nehru Medical College
 Campus, Belgaum, Karnataka
 Bank A/c No. : 05042170000039
 IFSC Code : SYNB0000504
 MICR Code : 590025005

- As per rule 211(1) of GFR, the accounts of all grantee Institutions shall be open to inspection by the sanctioning authority / audit.

Shrip


Contd. 2/-

ATTESTED

Walter

Prof. Dr. V.A.KOTHIWALE
 Registrar
 KLE Academy of Higher Education
 and Research, BELAGAVI


5. The expenditure involved is debitable to:
- | | | |
|-----------------|---|---|
| Demand No.79 | : | Department of Biotechnology |
| 3425 | : | Other Scientific Research (Major Head) |
| 60 | : | Others (Sub Major Head) |
| 60.200 | : | Assistance to other scientific bodies |
| 60.200.29 | : | Biotechnology Research and Development |
| 60.200.29.17 | : | Assistance for Research and Development |
| 60.200.29.17.31 | : | Grant in aid General 2016-17 (Plan) |
6. This is first release of the project so no UC/SE is pending with the project.
7. In case the whole or a part of the amount of the grant-in-aid is being refunded, as an interest at the rate of ten per cent per annum thereon shall be recovered.
8. This issues under the powers delegated to this Department with the concurrence of IFD, DBT vide their Dy. No. 102/IFD/SAN/ 199 /2016-2017 dated 26.04.2016.
9. This sanction order has been entered at Serial No. 45 in the register of grants.


(Dr. Sanjay Kalia)
Scientist 'D'

To
The Pay & Accounts Officer
Department of Biotechnology
C.G.O. Complex, Lodhi Road
New Delhi-110 003

Copy to:

1. The Principal Director of Audit (Scientific Departments), IP Estate, AGCR Building, New Delhi-2.
2. Cash Section, DBT (2 copies)
3. IFD, DBT.
4. Dr. Shivaprasad S. Goudar, Principal Investigator, Department of Physiology, K.L.E. University's Jawaharlal Nehru Medical College, JN Medical College, Belgaum, Karnataka.
5. The Registrar K.L.E. University, Belgaum, Karnataka.
6. Sanction folder.
7. File.


(Dr. Sanjay Kalia)
Scientist 'D'

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

BT/IN/DBT-MRC/DFID/22/SSG/2015-16
 Ministry of Science & Technology
 Department of Biotechnology
 Government of India

Block 2, 8th Floor
 CGO Complex, Lodhi Road
 New Delhi 110 003
 Dated: 31st May, 2016

ORDER

In continuation of this Department's sanction order of even number dated 02nd March, 2016. Sanction of the President is hereby accorded, under Rule 18 of the Delegation of Financial Power Rules, 1978 for the release of Rs. 25.14 lakhs (Rupees Twenty five lakhs and fourteen thousand only) being the 1st year release towards the Recurring head for the Indian component of the joint project titled "Evaluation of the Introduction of a novel device in the management of hypertension and shock in pregnancy in low-resource settings" executed by Dr. Shivaprasad S. Goudar, Principal Investigator, Department of Physiology, K.L.E. University's Jawaharlal Nehru Medical College, JN Medical College, Belgaum, Karnataka as per the break up given below:

Recurring Head		(Rs. in lakhs)
S. No.	Head	Year I
1.	Consumables/ research expenses (incl. internet connections, communication expenses, reimbursements (Data capitation) and translation of forms)	3.0
2.	Manpower Study Personnel i. Project Administrator (Sr. RS) ii. Data Entry Operator iii. Field Monitoring (LHV) iv. Training Coordinator (Sr. SN) v. Field Assistant I Pilot Study Personnel vi. Research Assistant vii. Field Assistant I	7.20 2.30 1.32 2.30 0.96 1.12 0.44
Total Manpower		15.64
3.	Travel i. Domestic ii. International iii. Local hospitality for visiting scientist	1.0 3.0 1.0
Total Travel		5.0
4.	Contingency (Incl. printing and stationery supplies and printing of DCI)	0.50
5.	Overheads	1.0
Total A (1+2+3+4+5)		25.14

Total amount to be released under recurring head = Rs. 25.14 lakhs


- The other terms and conditions governing the financial sanction will remain unaltered.
- The amount of Rs. 25.14 lakhs (Rupees Twenty five lakhs and fourteen thousand only) will be drawn by the DDO, DBT from PAO, DBT and will be disbursed to the Registrar K.L.E. University, Belgaum, Karnataka as per details given below:

Name of the Bank : Syndicate Bank, K.L.E. University, Jawaharlal Nehru Medical College
 Campus, Belgaum, Karnataka
 Bank A/c No. : 05042170000039
 IFSC Code : SYNB0000504
 MICR Code : 590025005


- As per rule 211(1) of GFR, the accounts of all grantee Institutions shall be open to inspection by the sanctioning authority / audit.

Contd. 2/-

ATTESTED


 Prof. Dr. V.A. KOTHIWALE
 Registrar
 KLE Academy of Higher Education
 and Research, BELAGAVI


5. The expenditure involved is debitable to:
- | | | |
|-----------------|---|---|
| Demand No.79 | : | Department of Biotechnology |
| 3425 | : | Other Scientific Research (Major Head) |
| 60 | : | Others (Sub Major Head) |
| 60.200 | : | Assistance to other scientific bodies |
| 60.200.29 | : | Biotechnology Research and Development |
| 60.200.29.17 | : | Assistance for Research and Development |
| 60.200.29.17.31 | : | Grant in aid General 2016-17 (Plan) |
6. This is first release of the project so no UC/SE is pending with the project.
7. In case the whole or a part of the amount of the grant-in-aid is being refunded, as an interest at the rate of ten per cent per annum thereon shall be recovered.
8. This issues under the powers delegated to this Department with the concurrence of IFD, DBT vide their Dy. No. 102/IFD/SAN/ 199 /2016-2017 dated 26.04.2016.
9. This sanction order has been entered at Serial No. 45 in the register of grants.


(Dr. Sanjay Kalia)
Scientist 'D'


To
The Pay & Accounts Officer
Department of Biotechnology
C.G.O. Complex, Lodhi Road
New Delhi-110 003

Copy to:

1. The Principal Director of Audit (Scientific Departments), IP Estate, AGCR Building, New Delhi-2.
2. Cash Section, DBT (2 copies)
3. IFD, DBT.
4. Dr. Shivaprasad S. Goudar, Principal Investigator, Department of Physiology, K.L.E. University's Jawaharlal Nehru Medical College, JN Medical College, Belgaum, Karnataka.
5. The Registrar K.L.E. University, Belgaum, Karnataka.
6. Sanction folder.
7. File.


(Dr. Sanjay Kalia)
Scientist 'D'

ATTESTED


Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI



**KLE Academy of Higher Education and Research
Jawaharlal Nehru Medical College, Belagavi
Women's and Children's Health Research Unit**

Ref No. MDC/JNMC/2020-21/

Date:28.01.2021

TO WHOMSOEVER IT MAY CONCERN

Women's and Children's Health Research Unit, Jawaharlal Nehru Medical College, KLE Academy of Higher Education and Research, Belagavi has conducted a research project titled – “**Evaluation of the introduction of a novel device in the management of hypertension and shock in pregnancy in low-resource settings**” in collaboration with King's College, London co-funded by UK Medical Research Council and Department of Biotechnology, Govt. of India.

Project Period: July 2015 to March 2018

National Collaborators: S N Medical College, Bagalkot, Karnataka



Dr Shivaprasad S Goudar

Professor of Physiology, J N Medical College &
Director-Research, KLE Academy of Higher Education and Research
(Deemed-to-be-University)

Nehru Nagar, Belagavi-590010

Mobile: +91-94481 26371

Email: sgoudar@jnmc.edu




Address for Correspondence:

KLE Academy of Higher Education and Research, J.N. Medical College,
Nehru Nagar, Belagavi-590 010, Karnataka

Phone: +91-831-2474200 / +91 831 244 4190

Fax: +91-831-2472891


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

RESEARCH SUB AGREEMENT

This Research Sub Agreement is made and executed on this the 15th day of October 2019 by and between

KLE Academy of Higher Education & Research
Women's and Children's Health Research Unit
Jawaharlal Nehru Medical College,
Nehru Nagar, Belagavi,
Represented by the Principal
Dr N. S. Mahantshetti

Hereinafter referred to as "JNMC"

AND

Shri B M Patil Medical College
Bijapur,
Represented by its Principal
Dr. Aravind. V. Patil

(Hereinafter referred to as "BLDE")

Eunice Kennedy Shriver National Institutes of Child Health
and Human Development
Global Network for Women's and Children's Health Research

(Hereinafter referred to as "Sponsor").

Title : **"The A-PLUS Study on Infection"**

Award Title: This Community-based Trial Contract (the "Contract"), effective as of October 15, 2019 (the "Effective Date") is by and between TJU / GLOBAL NETWORK and Jawaharlal Nehru Medical College located at Belgaum 590010 in Karnataka, India ("JNMC"), represented by its employee Dr Shivaprasad Goudar, MD (the "Principal Investigator").

Prime Award: PTE Federal Award No - 2UG1HD076457-07,
Sub-award No: - 080-70000-S22902

Principal Investigator Name : Dr Shivaprasad S Goudar (JNMC)
Facility Director Name : Dr Shailaja Bidari (BLDE)

Preamble:

WHEREAS, JNMC and Sponsor entered into an agreement on 15 October 2019, attached hereto (Attachment A) and incorporated by this reference, wherein JNMC

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI



295

was to provide certain services to Sponsor for "**Prevention of maternal and neonatal death/infections with a single oral dose of azithromycin in women in labor (in low- and middle-income countries)**"; titled as The A-PLUS Study on Infection" in Bijapur sub-site. India.

FURTHER BLDE will participate in the conduct of the project and agrees to abide by all the terms and conditions of the Sponsor. Pursuant to the Protocol, BLDE agrees to provide data entry, data management, and data quality control services and to dedicate an employee to serve as a Co-Investigator for the Community-based Trial.

WHEREAS, the Agreement is for work approved by Sponsor as a portion of the statement of work shown in Attachment A & Attachment B;

NOW, THEREFORE, the parties agree that the foregoing statements of fact are true and correct and are incorporated herein by this reference. In consideration of the covenants and conditions contained in this Agreement ("the Agreement"), and other good and valuable consideration, the adequacy and receipt of which are acknowledged, JNMC and BLDE agree as follows:

Definitions:

1. "JNMC" means the Jawaharlal Nehru Medical College, which has its principal office in Belgaum, India
2. TJU / GLOBAL NETWORK
3. "BLDE" means Shri B M Patil Medical College, which has its principal office in Bijapur, India,

Article I. Scope of Work

BLDE, as a Sub-Contractor of JNMC, agrees to provide all the necessary qualified personnel, equipment, materials (except as otherwise may be provided herein), and facilities to perform the work as described in its proposal, which by this reference is incorporated into this Agreement, Attachment A & Attachment B.

JNMC shall provide the upgraded equipment and material to BLDE for performance of the said project as and when required.

Article II. Period of Performance

The period of this Agreement shall be from November 1, 2019 to May 31, 2020 unless extended by written amendment to this Agreement.

Article III. Consideration

BLDE shall deploy its qualified personnel for accomplishment of the said project. The salaries and other expenses shall be credited directly to the personal account of the employees. BLDE shall provide the details of bank accounts, salary statement and invoices for any incidental expenses incurred by BLDE. JNMC shall reimburse

2

ATTESTED



Prof. Dr. V.A.KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI



296

the incidental expenses unconnected with the Prime Award, if any, incurred by BLDE, through cheque/DD drawn in favour of "The Principal, BLDE. BLDE is not entitled to 8% of Indirects' received by the Sponsor, due to amendments to the FCRA Regulations.

Article IV. Authorized Representatives

The authorized representatives of JNMC and BLDE for technical and administrative matters shall be:

Shri B M Patil Medical College, Bijapur

J N Medical College, Belgaum

Technical Representative:

Dr Shailaja Bidari;

Technical Representative:

Dr Shivaprasad S Goudar

Administrative Representative:

Dr Aravind P Patil
Principal

Administrative Representative:

Dr.N S Mahantshetti
Principal

Article V. Reports

Final Progress Report - A Final Progress Report shall be submitted to the JNMC Technical Representative within sixty (60) days of the close of the final project period for inclusion in the Principal Investigator's Final Progress Report.

Article VI. General Provisions

The work to be performed under this Agreement is being supported by the Sponsor under Agreement Attachment B. Therefore, wherever applicable, the rules and regulations governing the award to JNMC are by this reference hereby incorporated into this Agreement, including, but not limited to, provisions governing care and treatment of laboratory animals, civil rights and equal employment opportunity, protection of human subjects, patents and inventions, publications and rights in data.

Article VII. Additional General Provisions

The following general provisions shall apply to this Agreement:

3

ATTESTED



Prof. Dr. V.A.KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI



A. Allowable Costs

Allowable costs shall be determined by JNMC in accordance with cost principles generally accepted by, or required to be used by, similar institutions or organizations, that are in effect as of the effective date of this Agreement.

B. Billing

JNMC shall reimburse the BLDE 's payment within forty (40) days after receipt of an acceptable invoice provided in accordance with the terms and conditions of this Agreement.

The performance of JNMC of any of its obligations under this Agreement shall be subject to and contingent upon the availability of funds, and the obligation of funds by the prime funding agency (Sponsor), or otherwise lawfully expendable for the purposes of this Agreement for the current and future periods. JNMC shall give notice to BLDE of the non-availability of such funds when JNMC has knowledge of such fact. Upon receipt of such notice by BLDE, the employees of BLDE shall be entitled to payment only for those services performed and expenses incurred prior to the date notice is received.

C. Equipment

JNMC and BLDE agree that if BLDE purchases permanent equipment under this Agreement, title to such equipment will vest in the JNMC under the same conditions as apply under JNMC's grant with the Sponsor and that JNMC shall have the same rights to require transfer of equipment as the Sponsor has.

Further if JNMC provides any equipment to BLDE for implementation of the present agreement, the title to such equipment shall vest in BLDE exclusively and BLDE shall not transfer such equipment to JNMC upon accomplishment of the project.


D. Indemnification

Each party hereby assumes any and all risk of personal injury and property damage attributable to the negligent acts or omissions of that party and the officers, employees and agents thereof. BLDE will assure that persons subcontracting with or otherwise acting or engaged to act at the instance of BLDE in furtherance of BLDE fulfilling its obligations under this Agreement will assume such risk with respect to the willful or negligent acts or omissions of their personnel. BLDE shall provide professional liability coverage for its employees discharging services as per the provisions of this contract and accident insurance coverage for all equipment/material procured for conducting the trial as specified in Attachment B.

4
ATTESTED



Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI



E. Amendments

Any amendments, including renewals, alterations or modifications to the Agreement must be signed by the signatories to this Agreement.

F. Governance

The validity, construction and effect of this Agreement shall be governed by the prevailing laws. In the event either party is required to obtain from any governmental authority any permit, license or authorization as a prerequisite to perform its obligations under this Agreement, the cost shall be borne by the party required to obtain such permit, license or authorization.

BLDE shall allow access to all documents, papers, letters or other material subject to the provisions of this Contract, and made or received by BLDE in conjunction with this Agreement to JNMC or its representatives, the regulatory authorities or the representatives of the sponsor as specified in Attachment B. Refusal by BLDE to allow such access shall be grounds for cancellation of this Agreement by JNMC.

BLDE may not, without the advance written approval of JNMC, assign any right or delegate any duties under this Agreement nor may it transfer, pledge, surrender or otherwise encumber or dispose of its interest in any portion of this Agreement

It is understood and agreed that nothing contained in this Agreement is intended, or should be construed, as creating or establishing the relationship of partners between the parties, or as constituting BLDE as the agent or representative of JNMC for any purpose in any manner whatsoever. BLDE is not authorized to bind JNMC to any contracts or other obligations. BLDE shall not expressly or impliedly represent to any party that University of British Columbia and JNMC are partners or that JNMC is the agent or representative of TJU / GLOBAL NETWORK for any purpose or in any manner whatsoever.

G. Termination

JNMC or BLDE may terminate this Agreement upon thirty (30) days written notice to the other party. However, in the event that the Sponsor terminates the Agreement with JNMC prior to the period end date, this Agreement will be immediately terminated. In the event of termination JNMC will pay for costs incurred and non-cancelable commitments through the date of termination, contingent upon JNMC having received sufficient funds from Sponsor. BLDE will furnish all necessary reports of research completed or in progress through the date of termination.

H. Publications


Any publications resulting from this Agreement shall be governed by the policies laid out in Attachment B.

5

ATTESTED



Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI



299

I. Arbitration

If any dispute arises in between JNMC and BLDE the same should be referred to Chancellor, KLE University and Chairman, KLE Society, Belgaum and President, BLDE University's Bijapur and the decision of the Arbitrators shall be final and the same shall be binding on the both the parties.

BLDE certifies that to the best of its knowledge and belief that it and its principals will abide by the payment Standard Operating Procedures in Attachment A and Attachment B

This Contract includes the following Appendices (incorporated herein):
Attachment A: Prime Award Title no: 2UG1HD076457-07 FOR A-PLUS study
Attachment B: Protocol Version, Number:1.4.1
Attachment C: Budget Sheet for 07months version 1.4.1

IN WITNESS WHEREOF, JNMC and BLDE have executed and delivered this agreement by and through their duly authorized representatives below

Jawaharlal Medical College (JNMC)
(BLDE)

Shri B M Patil Medical College

By: _____

By: _____

Name: Dr N S Mahantshetti

Name: Dr Aravind V Patil

Title: Principal

Title: Principal

Date: 15/10/2019

Date: 15/10/2019

Principal Investigator

By: _____

By: _____

Name: Dr Shivaprasad S Goudar

Name: Dr. Shailaja Bidari

Title: Professor Department of
Department of
PHYSIOLOGY

Title: Asst. Professor and Head,
OBGYN .

Date: 15/10/2019

Date: 15/10/2019



6

ATTESTED

[Signature]
Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

300

Gynae NO. 16-17/14/2

date - 16/9/16

**KLE University's
Women's and Children's Health Research Unit
JN Medical College
COST REIMBURSABLE RESEARCH SUBCONTRACT
"CARBETOCIN RTS"**

This contract Agreement for "**Carbetocin RTS for preventing postpartum haemorrhage**" in Varanasi Sub-site, India hereafter referred to as the "**CARBETOCIN RTS**" is entered into in order to specify the terms and conditions under which the KLE University's, Women's and Children's Health Research Unit, JN Medical College, (hereinafter referred to as "JNMC") and Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh (hereinafter referred to as "BHU") will participate in the conduct of a project supported by the World Health Organization (WHO) (hereinafter referred to as "Sponsor").

General Information:

Title: Research Subcontract in between Jawaharlal Nehru Medical College, Belgaum and Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh for the "**CARBETOCIN RTS**"

Award Title: This Community-based Trial Contract (the "Contract"), effective as of July 01, 2015 (the "Effective Date") is by and between WHO and Jawaharlal Nehru Medical College located at Belgaum 590010 in Karnataka, India ("JNMC"), represented by its employee Dr Shivaprasad Goudar, MD (the "Principal Investigator").

Prime Award: WHO Reference - 2014/432421-0,
Purchase Order - 201019382
Reg. File - R15-TSA-006
Unit Reference - A65780/India

Principal Investigator Name: Dr Shivaprasad S Goudar (JNMC)
Facility Director Name: Dr. Uma Pandey (BHU)

WHEREAS, JNMC and Sponsor entered into an agreement on 15 June 2014, attached hereto (Attachment A) and incorporated by this reference, wherein JNMC was to provide certain services to Sponsor for the "**CARBETOCIN RTS**"


WHEREAS, JNMC and BHU wish to enter into a subcontract wherein BHU will provide certain services to JNMC in JNMC's performance of the contract with World Health Organization (WHO);

WHEREAS, BHU agrees to abide by all of the terms and conditions of the Sponsor- World Health Organization (WHO) agreement;

WHEREAS, the Agreement is for work approved by Sponsor as a portion of the statement of work shown

1

ATTESTED


Prof. Dr. V.A. KOTHIWALE

Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

301

in Attachment A & Attachment B;

NOW, THEREFORE, the parties agree that the foregoing statements of fact are true and correct and are incorporated herein by this reference. In consideration of the covenants and conditions contained in this Agreement ("the Agreement"), and other good and valuable consideration, the adequacy and receipt of which are acknowledged, JNMC and BHU agree as follows:

Definitions:

1. "JNMC" means the Jawaharlal Nehru Medical College, which has its principal office in Belgaum, India
2. "WHO" means World Health Organization
3. "BHU" means Institute of Medical Sciences, Banaras Hindu University, Varanasi, which has its principal office in Varanasi, India, and which pursuant to the Protocol, agrees to provide data entry, data management, and data quality control services and to dedicate an employee to serve as a Co-Investigator (as defined below) for the Community-based Trial.

Article I. Scope of Work

BHU, as a Sub-Contractor of JNMC, agrees to provide all the necessary qualified personnel, equipment, materials (except as otherwise may be provided herein), and facilities to perform the work as described in its proposal, which by this reference is incorporated into this Agreement, Attachment A & Attachment B.

Article II. Period of Performance

The period of this Agreement shall be from June 1, 2016 to November 30, 2017 unless extended by written amendment to this Agreement.

Article III. Estimated Cost

JNMC agrees to pay BHU an amount not to exceed Rs. 15,35,336 =00 for the work described in Article I. **Payment will be made in advance by JNMC, six monthly subject to utilization certificate from BHU.**

WHO does not pay any indirect cost as per the Prime Award to JNMC, hence JNMC will not pay any indirect to BHU for the conduct of the "CARBETOCIN RTS" study. We have made provision in Budget (Attachment C) which could be treated as indirect under the heads Utility Expenses & Accounting services amounting to 1,80,000/-

BHU 's budget is incorporated into this Agreement as Attachment C. The allowance of costs will be determined in accordance with JNMC's methods of determining costs under its grants and contracts with the Sponsor, and with the Sponsor's policies applicable to research projects as in effect on the beginning date of

2


ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

302

1



ATTESTED

Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

the budget period of this Agreement. Where BHU is normally required by these current policies to seek prior approval for actions from the Sponsor, BHU shall direct its request to the Administrative Representative of JNMC

JNMC will provide advance **funds amounting six months** as per Attachment C to **BHU every six monthly** for the duration of the study, BHU will submit audited statement of expenses to JNMC every six months. Required supporting documentation, to be submitted with invoices, is clearly detailed and incorporated into this Agreement as Attachment A

The project funds will be transferred to BHU

INSTITUTION DETAILS

Name of Institution : BANARAS HINDU UNIVERSITY
Address of institution : Registrar Office, BHU, Varanasi, Pin Code – 221005
✓ Bank Account Holder's Name / Beneficiary Name : Registrar, BHU
Bank Account No. (for NEFT/RTGS/E-Payment) : 27790200000003
Type of Account (Current A/c) : Current Account
Bank IFCS Code : BARBOBHUVAR
Bank MICR Code : 221012011
Bank Code : 012

Article IV. Authorized Representatives

The authorized representatives of JNMC and BHU for technical and administrative matters shall be:

**Institute of Medical Sciences, Banaras,
Hindu University Varanasi**

J N Medical College, Belgaum

Technical Representative:
Dr Uma Pandey

Technical Representative:
Dr Shivaprasad S Goudar

Administrative Representative:
Registrar

Administrative Representative:
Dr.N S Mahantshetti
Principal

Article V. Reports

As stated in Article VII Section C paragraph 3 BHU must submit its most recent audit report to the JNMC

3

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

304



Audit Representative.

Half year financial reports are required by BHU if it is not required under Article VII, entitled "Additional General Provisions", Section C paragraph 3, to submit its most recent audit report. The financial reports must be submitted to the JNMC Audit Representative.

Final Progress Report - A Final Progress Report shall be submitted to the JNMC Technical Representative within sixty (60) days of the close of the final project period for inclusion in the Principal Investigator's Final Progress Report.

Article VI. General Provisions

The work to be performed under this Agreement is being supported by the Sponsor under Agreement Attachment B. Therefore, wherever applicable, the rules and regulations governing the award to JNMC are by this reference hereby incorporated into this Agreement, including, but not limited to, provisions governing care and treatment of laboratory animals, civil rights and equal employment opportunity, protection of human subjects, patents and inventions, publications and rights in data.

Article VII. Additional General Provisions

The following general provisions shall apply to this Agreement:

A. Allowable Costs

Allowable costs shall be determined by JNMC in accordance with cost principles generally accepted by, or required to be used by, similar institutions or organizations, that are in effect as of the effective date of this Agreement.

B. Billing

BHU agrees that bills and invoices for fees or other compensation for services or expenses shall cite the Title: "CARBETOCIN RTS"

The performance of JNMC of any of its obligations under this Agreement shall be subject to and contingent upon the availability of funds, and the obligation of funds by the prime funding agency (Sponsor), or otherwise lawfully expendable for the purposes of this Agreement for the current and future periods. JNMC shall give notice to BHU of the non-availability of such funds when JNMC has knowledge of such fact. Upon receipt of such notice by BHU, BHU shall be entitled to payment only for those services performed and expenses incurred prior to the date notice is received.

If this Agreement includes travel expenditures, any such expenditure, including reimbursement, must comply

ATTESTED

Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

with University or JNMC rules and itemized in detail.

Dr Shivaprasad S Goudar
Co-Principal Investigator, "CARBETOCIN RTS",
KLE University's Women's and Children's Health Research Unit
J N Medical College
Nehru Nagar,
Belgaum, 590010
sgoudar@jnmc.edu

C. Audit

BHU shall maintain and have available for audit and inspection all administrative and financial documents, and all other records, pertinent to the financial costs allocated to this agreement for a period of three years following the termination date except that, if an audit is initiated before the expiration of the three year period, the records shall be retained until audit findings have been resolved. The above records are subject to inspection and audit by JNMC, its designated representatives or representatives of Sponsor at all reasonable times during the life of the grant and for three years thereafter.

Any costs reimbursed by JNMC which are subsequently found to be disallowed under audit shall be refunded to JNMC by BHU. BHU agrees to comply with the requirements. In cases of non-compliance with Indian laws and regulations, BHU will also provide copies of responses to auditor's reports and a plan for corrective action. All records and reports prepared in accordance with the requirements shall be available for inspection by JNMC, its designated representatives or representatives of Sponsor at all reasonable times during the life of the grant and for three years thereafter.

If BHU is required to perform an Audit, BHU must provide JNMC with a copy of its most recent audit report.

D. Equipment

JNMC and BHU agree that if BHU purchases permanent equipment under this Agreement, title to such equipment will vest in the JNMC under the same conditions as apply under JNMC's grant with the Sponsor and that JNMC shall have the same rights to require transfer of equipment as the Sponsor has.

E. Indemnification

Each party hereby assumes any and all risk of personal injury and property damage attributable to the negligent acts or omissions of that party and the officers, employees and agents thereof. BHU will assure that persons subcontracting with or otherwise acting or engaged to act at the instance of BHU in furtherance of BHU fulfilling its obligations under this Agreement will assume such risk with respect to the willful or negligent acts or omissions of their personnel. BHU shall provide professional liability coverage for its employees discharging services as per the provisions of this contract and accident insurance coverage for all equipment/material procured for conducting the trial as specified in Attachment B. + B¹

F. Amendments

5

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

306

Any amendments, including renewals, alterations or modifications to the Agreement must be signed by the signatories to this Agreement.

G. Governance

The validity, construction and effect of this Agreement shall be governed by the prevailing laws. In the event either party is required to obtain from any governmental authority any permit, license or authorization as a prerequisite to perform its obligations under this Agreement, the cost shall be borne by the party required to obtain such permit, license or authorization.

BHU shall allow access to all documents, papers, letters or other material subject to the provisions of this Contract, and made or received by BHU in conjunction with this Agreement to JNMC or its representatives, the regulatory authorities or the representatives of the sponsor as specified in Attachment B. Refusal by BHU to allow such access shall be grounds for cancellation of this Agreement by JNMC.

BHU may not, without the advance written approval of JNMC, assign any right or delegate any duties under this Agreement nor may it transfer, pledge, surrender or otherwise encumber or dispose of its interest in any portion of this Agreement

It is understood and agreed that nothing contained in this Agreement is intended, or should be construed, as creating or establishing the relationship of partners between the parties, or as constituting BHU as the agent or representative of JNMC for any purpose in any manner whatsoever.

H. Termination

JNMC or BHU may terminate this Agreement upon thirty (30) days written notice to the other party. However, in the event that the Sponsor terminates the Agreement with JNMC prior to the period end date, this Agreement will be immediately terminated. In the event of termination JNMC will pay for costs incurred and non-cancelable commitments through the date of termination, contingent upon JNMC having received sufficient funds from Sponsor. BHU will furnish all necessary reports of research completed or in progress through the date of termination.

I. Publications

Any publications resulting from this Agreement shall be governed by the policies laid out in Attachment B.

J. Arbitration

If any dispute arises in between JNMC and BHU the same should be referred to Chancellor, KLE University and Chairman, KLE Society, Belgaum and Vice-Chancellor, Banaras Hindu University, Varanasi and the decision of the Arbitrators shall be final and the same shall be binding on the both the

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

(1)



ATTESTED

Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

BHU certifies that to the best of its knowledge and belief that it and its principals will abide by the payment Standard Operating Procedures in Attachment A and Attachment B.

This Contract includes the following Appendices (incorporated herein):

Attachment A: Cover Letter for TAS issued for Clinical Trial, WHO Covering letter, Technical Services Agreement and Budget Sheet Version 3,

Attachment B: Protocol Version 28 April 2014, Forms WHO Trial A65870 SCR, DEL3, AER, SAE2, CON and Flow Chart,

Attachment C: Budget Sheet for BHU

IN WITNESS WHEREOF, JNMC and BHU have executed and delivered this Contract by and through their duly authorized representatives below

Jawaharlal Medical College (JNMC)

Institute of Medical Sciences, Banaras Hindu University, Varanasi (BHU)

By: [Signature]

By: [Signature] संयुक्त कुलसचिव (विकास, Joint Registrar (Development) काशी हिन्दू विश्वविद्यालय Banaras Hindu University Varanasi-221005

Name: Dr N S Mahantshetti

Name: कुलसचिव Registrar

Title: Principal

Title: काशी हिन्दू विश्वविद्यालय Banaras Hindu University Varanasi-221005 (Dr. Uma Pandey)

Date: 01/06/2016 DD/MM/YYYY

Date: Varanasi-221005 DD/MM/YYYY

Principal Investigator

By: [Signature]

By: Uma Pandey

Name: Dr Shivaprasad S Goudar

Name: Dr Uma Pandey

Title: Professor Department of PHYSIOLOGY

Title: Associate Professor, Department of OBGYN

Date: 01/06/2016 DD/MM/YYYY

Date: 08/07/2016 DD/MM/YYYY

Forwarded with the remarks that safety of patients and consultants involved in the project should be

[Signature] 20-8-16
संकाय प्रमुख
आयुर्विज्ञान संकाय
काशी हिन्दू विश्वविद्यालय

Uma Pandey
Dr. UMA PANDEY
ASSOCIATE PROFESSOR
DEPT. OF OBS & GYN
Institute of Medical Sciences
Banaras Hindu University
Varanasi-221005

Comprehensively ensured by PI / university and a legal cell opinion should be taken

[Signature] 22-8-16
निदेशक
DIRECTOR
विज्ञान विज्ञान संस्थान
INSTITUTE OF MEDICAL SCIENCES
काशी हिन्दू विश्वविद्यालय
Varanasi-221005

ATTESTED
Department of Obst. & Gynaecology
Institute of Medical Sciences
Banaras Hindu University
Varanasi-221005

[Signature]
Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

[Signature] 16/9/16

**KLE University's
Women's and Children's Health Research Unit
J N Medical College
COST REIMBURSABLE RESEARCH SUBCONTRACT
"CARBETOCIN RTS"**

This contract Agreement for "**Carbetocin RTS for preventing postpartum haemorrhage**" in Nagpur Sub-site, India hereafter referred to as the "**CARBETOCIN RTS**" is entered into in order to specify the terms and conditions under which the KLE University's, Women's and Children's Health Research Unit, J N Medical College, (hereinafter referred to as "JNMC") and Lata Medical Research Foundation Trust, Nagpur, Maharashtra (hereinafter referred to as "LMRF") will participate in the conduct of a project supported by the World Health Organization (WHO) (hereinafter referred to as "Sponsor").

General Information:

Title: Research Subcontract in between Jawaharlal Nehru Medical College, Belgaum and Lata Medical Research Foundation Trust, Nagpur, Maharashtra for the "**CARBETOCIN RTS**"

Award Title: This Hospital-based Trial Contract (the "Contract"), effective as of July 01, 2015 (the "Effective Date") is by and between WHO and Jawaharlal Nehru Medical College located at Belgaum 590010 in Karnataka, India ("JNMC"), represented by its employee Dr Shivaprasad Goudar, MD (the "Principal Investigator").

Prime Award: WHO Reference - 2014/432421-0 & 2016/647688-0
Purchase Order - 201019382 & 201544467
Reg. File - R15-TSA-006
Unit Reference - A65780/India & A65870

Principal Investigator Name: Dr Shivaprasad S Goudar (JNMC)
Facility Director Name: Dr. Archana Patel (LMRF)

WHEREAS, JNMC and Sponsor entered into an agreement on 15 June 2014 with amendment on , attached hereto (Attachment A) and incorporated by this reference, wherein JNMC was to provide certain services to Sponsor for the "**CARBETOCIN RTS**"

WHEREAS, JNMC and LMRF wish to enter into a subcontract wherein LMRF will provide certain services to JNMC in JNMC's performance of the contract with World Health Organization (WHO);


WHEREAS, LMRF agrees to abide by all of the terms and conditions of the Sponsor- World Health Organization (WHO) agreement;

WHEREAS, the Agreement is for work approved by Sponsor as a portion of the statement of work shown in Attachment A & Attachment B;

NOW, THEREFORE, the parties agree that the foregoing statements of fact are true and correct and are incorporated herein by this reference. In consideration of the covenants and conditions contained in this

Page 1 of 11

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

310

Agreement ("the Agreement"), and other good and valuable consideration, the adequacy and receipt of which are acknowledged, JNMC and LMRF agree as follows:

Definitions:

1. "JNMC" means the Jawaharlal Nehru Medical College, which has its principal office in Belgaum, India
2. "WHO" means World Health Organization
3. "LMRF" means Lata Medical Research Foundation Trust, which has its principal office in Nagpur, India, and which pursuant to the Protocol, agrees to provide data entry, data management, and data quality control services and to dedicate an Consultant to serve as a Co-Investigator (as defined below) for the Hospital-based Trial. LMRF has entered in a memorandum of understanding with DAGA Memorial Govt. Women's Hospital, Nagpur; an undertaking by Govt. of Maharashtra (1956) situated at Ganjakhel, Gandhi Baug, Nagpur, 440002 (herein after referred to as DMH as the context permits)- (Attachment D- MOU between LMRF & DMH on March 14,2015)

Article I. Scope of Work

LMRF, as a Sub-Contractor of JNMC, agrees to provide all the necessary qualified personnel, equipment, materials (except as otherwise may be provided herein), and facilities to perform the work as described in its proposal, which by this reference is incorporated into this Agreement, Attachment A & Attachment B.

LMRF will facilitate the implementation of research protocol (Attachment B) at DAGA Memorial Govt. Women's Hospital, Nagpur, an undertaking by Govt. of Maharashtra (1956) situated at Ganjakhel, Gandhi Baug, Nagpur, 440002. Designated place will be provide for storage and administration of the research protocol at DMH. Study documents will be stored at DMH under lock and key.

Article II. Period of Performance

The period of this Agreement shall be from September 1, 2016 to November 30, 2017 unless extended by written amendment to this Agreement.

Article III. Estimated Cost

JNMC agrees to pay LMRF an amount not to exceed Rs.43,11,724=00 for the work described in Article I.

Payment will be made in advance by JNMC, six monthly subject to utilization certificate from LMRF.

WHO does not pay any indirect cost as per the Prime Award to JNMC, hence JNMC will not pay any indirect to LMRF for the conduct of the "CARBETOCIN RTS" study. We have made provision in Budget (Attachment C) which could be treated as indirect under the heads Utility Expenses & Accounting services amounting to 1,80,000/-

Page 2 of 11

ATTESTED



Prof. Dr. V.A.KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

311

LMRF's budget is incorporated into this Agreement as Attachment C. The allowance of costs will be determined in accordance with JNMC's methods of determining costs under its grants and contracts with the Sponsor, and with the Sponsor's policies applicable to research projects as in effect on the beginning date of the budget period of this Agreement. Where LMRF is normally required by these current policies to seek prior approval for actions from the Sponsor, LMRF shall direct its request to the Administrative Representative of JNMC

JNMC will provide advance funds amounting six months as per Attachment C to LMRF every six monthly for the duration of the study, LMRF will submit audited statement of expenses to JNMC every six months. Required supporting documentation, to be submitted with invoices, is clearly detailed and incorporated into this Agreement as Attachment A

The project funds will be transferred to LMRF

INSTITUTION DETAILS

Name of Institution : LATA MEDICAL RESEARCH FOUNDATION TRUST

Address of institution : 9/1, Kinkine Kutir, Vasant Nagar, Near Dikshabhoomi Square, Nagpur-440022

Bank Account Holder's Name / Beneficiary Name : Lata Medical Research Foundation Trust.

Bank Account No. (for NEFT/RTGS/E-Payment) : 100041805557

Type of Account (Current A/c) : Saving.

Bank IFCS Code : INDB0000561

Bank MICR Code : SWIFT: INDBINBBNAS

Bank Code : _____

Article IV. Authorized Representatives

The authorized representatives of JNMC and LMRF for technical and administrative matters shall be:

**Lata Medical Research Foundation Trust,
Nagpur**

**J N Medical College,
Belgaum**

Technical Representative:

Dr Archana Patel

Technical Representative:

Dr Shivaprasad S Goudar

Administrative Representative:

Ms. Smita Puppalwar

Administrative Representative:

Dr.N S Mahantshetti
Principal

Page 3 of 11

ATTESTED



Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

312

Article V. Reports

As stated in Article VII Section C paragraph 3 LMRF must submit its most recent audit report to the JNMC Audit Representative.

Half-year financial reports are required, by LMRF if it is not required under Article VII, entitled "Additional General Provisions", Section C paragraph 3, to submit its most recent audit report. The financial reports must be submitted to the JNMC Audit Representative.

Final Progress Report - A Final Progress Report shall be submitted to the JNMC Technical Representative within sixty (60) days of the close of the final project period for inclusion in the Principal Investigator's Final Progress Report.

Article VI. General Provisions

The work to be performed under this Agreement is being supported by the Sponsor under Agreement Attachment B. Therefore, wherever applicable, the rules and regulations governing the award to JNMC are by this reference hereby incorporated into this Agreement, including, but not limited to, provisions governing care and treatment of laboratory animals, civil rights and equal employment opportunity, protection of human subjects, patents and inventions, publications and rights in data.

Article VII. Additional General Provisions

The following general provisions shall apply to this Agreement:

A. Allowable Costs

Allowable costs shall be determined by JNMC in accordance with cost principles generally accepted by, or required to be used by, similar institutions or organizations, that are in effect as of the effective date of this Agreement.

B. Billing

LMRF agrees that bills and invoices for fees or other compensation for services or expenses shall cite the Title: "CARBETOCIN RTS"

The performance of JNMC of any of its obligations under this Agreement shall be subject to and contingent upon the availability of funds, and the obligation of funds by the prime funding agency (Sponsor), or otherwise lawfully expendable for the purposes of this Agreement for the current and future periods. JNMC shall give notice to LMRF of the non-availability of such funds when JNMC has knowledge of such fact. Upon receipt of such notice by LMRF, LMRF shall be entitled to payment only for those services performed and expenses incurred prior to the date notice is received.

If this Agreement includes travel expenditures, any such expenditure, including reimbursement, must comply with University or JNMC rules and itemized in detail.

Page 4 of 11

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

313

Dr Shivaprasad S Goudar
Co-Principal Investigator, "CARBETOCIN RTS",
KLE University's Women's and Children's Health Research Unit
JN Medical College
Nehru Nagar,
Belgaum, 590010
sgoudar@jnmc.edu

C. Audit

LMRF shall maintain and have available for audit and inspection all administrative and financial documents, and all other records, pertinent to the financial costs allocated to this agreement for a period of three years following the termination date except that, if an audit is initiated before the expiration of the three year period, the records shall be retained until audit findings have been resolved. The above records are subject to inspection and audit by JNMC, its designated representatives or representatives of Sponsor at all reasonable times during the life of the grant and for three years thereafter.

Any costs reimbursed by JNMC which are subsequently found to be disallowed under audit shall be refunded to JNMC by LMRF. LMRF agrees to comply with the requirements. In cases of non-compliance with Indian laws and regulations, LMRF will also provide copies of responses to auditor's reports and a plan for corrective action. All records and reports prepared in accordance with the requirements shall be available for inspection by JNMC, its designated representatives or representatives of Sponsor at all reasonable times during the life of the grant and for three years thereafter.

If LMRF is required to perform an Audit, LMRF must provide JNMC with a copy of its most recent audit report.

D. Equipment

JNMC and LMRF agree that if LMRF purchases permanent equipment under this Agreement, title to such equipment will vest in the JNMC under the same conditions as apply under JNMC's grant with the Sponsor and that JNMC shall have the same rights to require transfer of equipment as the Sponsor has.

E. Indemnification


Each party hereby assumes any and all risk of personal injury and property damage attributable to the negligent acts or omissions of that party and the officers, employees and agents thereof. LMRF will assure that persons subcontracting with or otherwise acting or engaged to act at the instance of LMRF in furtherance of LMRF fulfilling its obligations under this Agreement will assume such risk with respect to the willful or negligent acts or omissions of their personnel. LMRF shall provide professional liability coverage for its employees discharging services as per the provisions of this contract and accident insurance coverage for all equipment/material procured for conducting the trial as specified in Attachment B.

F. Amendments

Any amendments, including renewals, alterations or modifications to the Agreement must be signed by the signatories to this Agreement.

Page 5 of 11

ATTESTED


KLE Academy of Higher Education
and Research, BELAGAVI

314

G. Governance

The validity, construction and effect of this Agreement shall be governed by the prevailing laws. In the event either party is required to obtain from any governmental authority any permit, license or authorization as a prerequisite to perform its obligations under this Agreement, the cost shall be borne by the party required to obtain such permit, license or authorization.

LMRF shall allow access to all documents, papers, letters or other material subject to the provisions of this Contract, and made or received by LMRF in conjunction with this Agreement to JNMC or its representatives, the regulatory authorities or the representatives of the sponsor as specified in Attachment B. Refusal by LMRF to allow such access shall be grounds for cancellation of this Agreement by JNMC.

LMRF may not, without the advance written approval of JNMC, assign any right or delegate any duties under this Agreement nor may it transfer, pledge, surrender or otherwise encumber or dispose of its interest in any portion of this Agreement

It is understood and agreed that nothing contained in this Agreement is intended, or should be construed, as creating or establishing the relationship of partners between the parties, or as constituting LMRF as the agent or representative of JNMC for any purpose in any manner whatsoever. LMRF is not authorized to bind JNMC to any contracts or other obligations. JNMC are partners or that JNMC is the agent or representative of World Health Organization (WHO) for any purpose or in any manner whatsoever.

H. Termination

JNMC or LMRF may terminate this Agreement upon thirty (30) days written notice to the other party. However, in the event that the Sponsor terminates the Agreement with JNMC prior to the period end date, this Agreement will be immediately terminated. In the event of termination JNMC will pay for costs incurred and non-cancelable commitments through the date of termination, contingent upon JNMC having received sufficient funds from Sponsor. LMRF will furnish all necessary reports of research completed or in progress through the date of termination.

I. Publications

Any publications resulting from this Agreement shall be governed by the policies laid out in Attachment B.

J. Arbitration


If any dispute arises in between JNMC and LMRF the same should be referred to Chancellor, KLE University and Chairman, KLE Society, Belgaum and Dr Hemant Kulkarni , President , LMRF Trust, Nagpur and the decision of the Arbitrators shall be final and the same shall be binding on the both the parties.

LMRF certifies that to the best of its knowledge and belief that it and its principals will abide by the payment Standard Operating Procedures in Attachment A and Attachment B.

This Contract includes the following Appendices (incorporated herein):

Page 6 of 11

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

315

ATTESTED



Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI



Attachment A: Cover Letter for TAS issued for Clinical Trial, WHO Covering letter, Technical Services Agreement and Budget Sheet Version 3,


Attachment B: Protocol Version 07 March 2016, Forms WHO Trial A65780/India & A65870 SCR, DEL3, AER, SAE2, CON and Flow Chart,

Attachment C: Budget Sheet for LMRF

Attachment D: MOU between LMRF & DMH on March 14,2015

IN WITNESS WHEREOF, JNMC and LMRF have executed and delivered this Contract by and through their duly authorized representatives below

**Jawaharlal Medical College (JNMC)
Belgaum**

By: 

Name: **Dr N S Mahantshetti**

Title: Principal
Date: 23/09/2016
DD/MM/YYYY

Principal Investigator

By: 

Name: **Dr Shivaprasad S Goudar**

Title: Professor Department of
PHYSIOLOGY

Date: 23/09/2016
DD/MM/YYYY


**Lata Medical Research Foundation Trust,
Nagpur**

By: 

Name: **Dr. Archana Patel**

Title: Program Director and CFO
Date: 26/09/2016
DD/MM/YYYY

Principal Investigator


By: 

Name: **Dr Archana Patel**

Title: **Principal Investigator**

Date: 26/09/2016
DD/MM/YYYY

Administrator and Study Coordinator

By: 

Name: **Ms. Smita Puppalwar**

Title: **Administrator and Study Coordinator**

Date: 26/09/2016
DD/MM/YYYY



Page 7 of 11

ATTESTED



Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

317

**Terms and condition between the Principal Investigator of JNMC , Belgaum and
Principal Investigator SCBMCH, Cuttack for
"CARBETOCIN RTS"**

This is a Hospital based project supported by the World Health Organization (WHO) represented in India by Dr Shivaprasad Goudar, MD, the "Principal Investigator"(PI), an employee of JNMC (Jawaharlal Nehru Medical College) Belgaum.

Article I

This is effective as of June 01, 2016 (the "Effective Date") is by and between WHO and Jawaharlal Nehru Medical College located at Belgaum 590010 in Karnataka, India ("JNMC"),

Prime Award: WHO Reference - 2014/432421-0 & 2016/647688-0
Purchase Order - 201019382 & 201544467
Reg. File - R15-TSA-006
Unit Reference - A65780/India

SCB Medical College and Hospital (SCBMCH) Cuttack, Orissa, is selected as a centre, under Dr Sujata Misra as the Facility Director (FD), Associate professor, OBGYN SCBMCH to conduct the trial and provide data entry, data management, data quality control services and to dedicate an employee to serve as a Co-Investigator for the Community-based Trial.

Article II Period of Performance

The period of this Agreement shall be from June 1, 2016 to November 30, 2017 unless extended by written amendment to this terms and condition.

Article III. Estimated Cost

The FD will be paid through the Dean and Principal, SCBMCH an amount not to exceed Rs. 14,68,672=00 for the work upon receipt of invoices. The 'budget' for the FD SCBMCH is incorporated as Attachment C

The indirect expenses under the heads Utility Expenses & Accounting services shall amount to 1,80,000/-

PI at JNMC will provide advance funds accounting for three months as per Attachment C to FD SCBMCH every quarter for the duration of the study.

FD of SCBMCH will submit audited statement of expenses to PI JNMC every six months. Required supporting documentation, to be submitted with invoices, is clearly detailed and incorporated into this Agreement as Attachment A


The project funds will be transferred to the account of Dean and Principal, SCBMCH, Cuttack.

INSTITUTION DETAILS

Name of Institution : S.G.B. Medical College & Hospital, Cuttack
Address of Institution : S.C.B. Medical College & Hospital, Manglabag,
Cuttack, Odisha, Pin Code: 753007
Bank Account: Holder's Name/ Beneficiary Name : Dean and Principal, SCB Medical College, Cuttack

1

ATTESTED



Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

Bank Account No. (for NEFT/RTGS/E-Payment) : 10145480088
Type of Account (Current A/c) : S.B Account
Bank IFCS Code : SBIN0005760
Bank MICR Code : 753002018
Bank Code : 005760

FD of SCBMCH is to submit monthly invoices to PI at JNMC on a cost reimbursable basis. Required supporting documentation, to be submitted with invoices, is clearly detailed and incorporated into this document as Attachment A

Remuneration to all Consultants will be paid through PI JNMC as per WHO contract amounting of - Rs 13,05,321

Article IV. Authorized Representatives

The authorized representatives of JNMC and SCBMCH for technical and administrative matters shall be:

SCB-Medical College & HOSPITAL, Cuttack, Odisha	J N Medical College, Belgaum
<i>Technical Representative:</i> Dr Sujata Misra	<i>Technical Representative:</i> Dr Shivaprasad S Goudar
<i>Administrative Representative:</i> Prof Dr Sidhartha Das Dean & Principal	<i>Administrative Representative:</i> Dr.N S Mahantshetti Principal

Article V. Reports

As stated in Article VII Section C paragraph 3 FD of SCBMCH must submit its most recent audit report to the PI at JNMC Audit Representative.

Quarterly financial reports are required from the FD, SCBMCH. The financial reports must be submitted to the PI at JNMC or his Audit Representative.

Final Progress Report - A Final Progress Report shall be submitted to the PI, JNMC Technical Representative within sixty (60) days of the close of the final project period for inclusion in the Principal Investigator's Final Progress Report.

Article VI. General Provisions

The work to be performed is being supported by the Sponsor under Agreement Attachment B. Therefore, wherever applicable, the rules and regulations governing the award to PI at JNMC are by this reference.


Article VII. Additional General Provisions

The following general provisions shall apply to this study.

A. Allowable Costs

Allowable costs shall be determined as per WHO guide lines for this study by the PI, JNMC in accordance

2

ATTESTED

Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

with cost principles generally accepted by, or required to be used by, similar institutions or organizations, that are in effect as of the effective date of this Agreement.

B. Billing

PI, JNMC shall reimburse the payment to FD at SCBMCH within forty (40) days after receipt of the invoice and after inspection and acceptance of the research deliverables provided in accordance with the terms and conditions decided hereby.

FD at SCBMCH agree that bills and invoices for fees or other compensation for services or expenses shall cite the Title: "CARBETOCIN RTS"

All travel expenditures, any such expenditure, including reimbursement, must comply with the rules and itemized in detail.

The FD at SCBMCH shall submit invoices based on the payment schedule specified in Article III, Cost. A final invoice must be received within 30 days after the budget period end date. Please forward all invoices to the following address:

Dr Shivaprasad S Goudar
Principal Investigator, "CARBETOCIN RTS",
KLE University's Women's and Children's Health Research Unit
J N Medical College
Nehru Nagar,
Belgaum, 590010
sgoudar@jnmc.edu

C. Audit

The FD at SCBMCH shall maintain and have available for audit and inspection all administrative and financial documents, and all other records, pertinent to the financial costs allocated to this agreement for a period of three years following the termination date except that, if an audit is initiated before the expiration of the three year period, the records shall be retained until audit findings have been resolved. The above records are subject to inspection and audit by designated representatives or representatives of Sponsor at all reasonable times during the life of the grant and for three years thereafter.

Any costs reimbursed by PI at JNMC which are subsequently found to be disallowed under audit shall be refunded to PI, JNMC by the FD at SCBMCH during the life of the grant.

D. Equipment

PI at JNMC and FD at SCBMCH agree that if she purchases permanent equipment, title to such equipment will vest in the JNMC under the same conditions as apply under JNMC's grant with the Sponsor

E. Indemnification

Each party hereby assumes any and all risk of personal injury and property damage attributable to the negligent acts or omissions of that party and the officers, employees and agents thereof. Attachment B.

F. Modifications

Any modification, including renewals, alterations or changes to the terms and conditions must be signed by both the signatories.

3

ATTESTED



Prof. Dr. V.A.KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELGAVI

320

G. Governance

The validity, construction and effect of this terms and condition shall be governed by the prevailing terms and conditions. In the event either party is required to obtain from any governmental authority any permission, license or authorization as a prerequisite to perform its obligations, the cost shall be borne by the party required to obtain such permission, license or authorization.

FD, SCBMCH shall share documents, papers, letters or other material subject to the provisions of this terms and condition, and made or received by FD, SCBMCH in conjunction with PI, JNMC or its representatives, the regulatory authorities or the representatives of the sponsor as specified in Attachment B.

H. Termination

PI, JNMC or FD, SCBMCH may terminate this study upon thirty (30) days written notice to the other party. However, in the event that the Sponsor terminates the Agreement with JNMC prior to the period end date, this study will be immediately terminated. In the event of termination PI, JNMC will pay for costs incurred and non-cancelable commitments through the date of termination, contingent upon PI, JNMC having received sufficient funds from Sponsor. FD, SCBMCH will furnish all necessary reports of research completed or in progress through the date of termination.

I. Publications

Any publications resulting from this study shall be governed by the policies laid out in Attachment B.

J. Arbitration

If any dispute arises in between PI, JNMC and FD, SCBMCH the same should be referred to Chancellor, KLE University and Chairman, KLE Society, Belgaum and Dean and Principal, SCB Medical and Hospital College, Cuttack, Odisha and the decision of the Arbitrators shall be final and the same shall be binding on the both the parties.

These terms and conditions includes the following Appendices (incorporated herein):


Attachment A: Cover Letter for TAS issued for Clinical Trial, WHO Covering letter, Technical Services Agreement and Budget Sheet Version 3,

Attachment B: Protocol Version 28 April 2014, Forms WHO Trial A65870 SCR, DEL3, AER, SAE2, CON and Flow Chart,

Attachment C: Budget Sheet for SCBMCH


IN WITNESS WHEREOF, JNMC and SCBMCH have executed and delivered this understanding by and through their duly authorized representatives below

Principal Investigator

By: 

Name: Dr Shivaprasad S Goudar
Title: Professor Department of
PHYSIOLOGY

Date: 01/08/2016
DD/MM/YYYY

By: 

Name: Dr. Sujata Misra
Title: Associate Professor and unit Head
Dept. of Obst. & Gyn.

Date: 22/07/2016
DD/MM/YYYY

4


ATTESTED



Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI





KLE Academy of Higher Education and Research
Jawaharlal Nehru Medical College, Belagavi
Women's and Children's Health Research Unit

Ref.No. MDC/JNMC/2020-21/

Date:28.01.2021


TO WHOMSOEVER IT MAY CONCERN

Women's and Children's Health Research Unit, Jawaharlal Nehru Medical College, KLE Academy of Higher Education and Research, Belagavi has conducted a research project titled – “**Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)**” funded by the Global Network for Women's and Children's Health Research of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, USA.

Project Period: May 2015 to May 2020

National Collaborators: S N Medical College, Bagalkot, Karnataka

Dr Shivaprasad S Goudar
Professor of Physiology, J N Medical College &
Director-Research, KLE Academy of Higher Education and Research
(Deemed-to-be-University)
Nehru Nagar, Belagavi-590010
Mobile: +91-94481 26371
Email: sgoudar@jnmc.edu



Address for Correspondence:

KLE Academy of Higher Education and Research, J.N. Medical College,
Nehru Nagar, Belagavi-590 010, Karnataka
Phone: +91-831-2474200 / +91 831 244 4190

ATTESTED

Fax: +91-831-2472891

Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

MEMORANDUM OF UNDERSTANDING

BETWEEN

**KLE University's
Shri B. M. Kankanawadi Ayurveda
Mahavidyalaya
Belgaum, Karnataka**

AND

**CSIR's Ayurgenomics Unit-TRISUTRA
IGIB, DELHI**

REGARDING

COLLABORATIVE RESEARCH

May 2012

ATTESTED

V.A. Kothiwale

Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

**MEMORANDUM OF UNDERSTANDING
BETWEEN
KLE UNIVERSITY'S
SHRI B. M. KANKANAWADI AYURVEDA MAHAVIDYALAYA
BELGAUM, KARNATAKA**

**AND
CSIR -TRISUTRA, DELHI
FOR
COLLABORATIVE RESEARCH**

KLEU's Shri B. M. Kankanawadi Ayurveda Mahavidyalaya, will be hereinafter referred to as **BMK Ayurveda Mahavidyalaya** and the CSIR's Ayurgenomics unit TRISUTRA at Institute of Genomics and Integrative Biology, Delhi, a unit of Council of Scientific and Industrial Research as **CSIR-TRISUTRA**.

This **MOU** sets down the mutually agreed broad framework for joint research and academic activities in various fields of interest. It also incorporates the modalities for collaboration.

1. PREAMBLE:

- 1.1 BMK Ayurveda Mahavidyalaya is a premier Ayurvedic Medical Research Institute/hospital, having extraordinary infrastructure, specialized medical/paramedical staff, management and facilities for patient care, training programmes and research activities.
- 1.2 CSIR-IGIB is one of the premier research laboratories of the CSIR, with an extensive array of sophisticated equipment and highly qualified staff, carrying out advanced research in biochemical technology and genomics including various aspects of molecular medicine. Scientists at CSIR- IGIB have been pursuing research integrating Ayurveda with Modern Genomics and have established a new field of research called Ayurgenomics. This has led to the set up of a new unit CSIR-TRISUTRA dedicated for the research in the field of Ayurgenomics. This

ATTESTED



Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

unit would aim to develop affordable health care solutions based on traditional knowledge of Ayurveda and modern genomic knowledge and medicine. This interdisciplinary networked unit would enable cross talk between Ayurveda, modern medicine and genomic science.

- 1.3 The activities of BMK Ayurveda Mahavidyalaya and CSIR-TRISUTRA are in several ways complementary. It is therefore felt that initiating collaborative research programmes would be of considerable mutual benefit.

2. PURPOSE:

BMK Ayurveda Mahavidyalaya and CSIR-TRISUTRA desire to implement, in the areas of mutual interest, cooperative and collaborative activities, which would address multidisciplinary scientific, technological and educational problems of relevance to the country. This is facilitated by the instrument of this MOU as follows:

ARTICLE - 1

Consistent with the goals and purpose of the collaboration, BMK Ayurveda Mahavidyalaya and CSIR-TRISUTRA propose to initiate joint multidisciplinary research, to begin with in the area given below:

1. To conduct research aimed at validation and providing scientific evidence to principles/concepts described in Ayurveda for predictive, personalized and pre-emptive approach to health and diseased conditions
2. To develop data and sample repositories for prospective research studies
3. To develop interdisciplinary human resources

Other projects would be taken up to include other areas as mutually agreed upon involving faculty, research scholars and students from different departments/ divisions of both the Institutes.

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

ARTICLE - 2

- a) The faculty and staff of BMK Ayurveda Mahavidyalaya and CSIR-TRISUTRA will hold regular meetings on problems of mutual interest.
- b) The faculty and research scholars of BMK Ayurveda Mahavidyalaya and CSIR-TRISUTRA will have access to the facilities of both Institutes, subject to their respective rules and regulations.
- c) The faculty and staff of BMK Ayurveda Mahavidyalaya and CSIR-TRISUTRA will jointly apply to the funding agencies for financial support for the collaborative research and academic programmes undertaken under this MoU.
- d) The faculty and staff will jointly report progress and accomplishment annually.

ARTICLE - 3

Provision is hereby made for:

- a) The exchange of Faculty, research scholars, staff and students between the two institutes.
- b) The joint organization of Symposia, Seminars, Workshops and Lectures; and mutual sharing of data on collaborative projects.
- c) No formal day-to-day permission will be necessary for the faculty, research scholars, staff and students of the two institutes to work in the laboratories of other institute in connection with the research work/ projects approved jointly by the heads of the respective departments of BMK Ayurveda Mahavidyalaya and CSIR-TRISUTRA.

ARTICLE - 4

INTELLECTUAL PROPERTY:

- a) Important research findings arising out of the activities covered under this MOU may be published in/presented at national and international Journals/Conferences jointly with the mutual consent of collaborators.
- b) Knowledge developed, which can result in commercial exploitation would be IPR protected and filed jointly by both the institutes. The expenses involved in

ATTESTED



Prof. Dr. V.A.KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

protecting the IPR shall be shared equally. However, if one of the institute decides not to share the expenses for protecting IPR, then it should assign its rights to the other institute to enable the other institute to file for IPR protection

- c) Neither party shall reveal intellectual property belonging to the other to any third party without the prior written concurrence of the other party.
- d) Any returns arising of commercialization of the Intellectual Property generated out of the programmes undertaken under this MoU, will be shared in proportion to be decided mutually by both the parties, on case-to-case basis and through exchange of letters.
- e) Both parties shall abide by the Government Rules as applicable time-to-time.

ARTICLE - 5

NON-EXCLUSIVITY OF THE MOU

Notwithstanding anything contained in the provisions excepting Article - 4 of the MOU, either party or both parties together have the unrestricted right to seek additional funds for and/or to cooperate with any agency/institute for any of the projects covered by the MOU.

ARTICLE - 6

Any article of the MOU may be modified or changed by mutual agreement of the parties hereto in writing. The modifications/changes shall be effective from the date on which they are modified/extended unless otherwise agreed to.

ARTICLE - 7

All disagreements/differences of opinion/disputes regarding the interpretation of the provisions of this MOU shall be resolved by mutual consultation by the signatories. However, in case the dispute persists, the matter shall be referred jointly to the DG-CSIR and the Secretary, Health, Government of India, Delhi, whose decision shall be final and binding on both the parties.

ATTESTED



Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

ARTICLE -8


GOVERNING LAW:

All research activities undertaken jointly by BMK Ayurveda Mahavidyalaya and CSIR-TRISUTRA under this MOU will be governed by the Laws of the Republic of India.

ARTICLE -9

The tenure of the MOU shall be for three years from the date of signing the MOU. Unless opted otherwise by either of the signatory parties to this MOU, the tenure shall be renewed automatically for another three years from the date of expiry of the first tenure.

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

In witness whereof the undersigned, duly authorized thereto, have signed this MOU on this day, _____

Ch
11/6/12

PRINCIPAL
BMK Ayurveda Mahavidyalaya
Address:
BMK Ayurveda Mahavidyalaya
Shahapur
Belgaum-590003
Karnataka

Jyotav
24/5/2012

Head PME Division
CSIR-IGIB
Address:
CSIR-Institute of Genomics and Integrative Biology
Near Jubilee Hall,
Mall Road, Delhi-110 007

डॉ० ज्योति यादव/Dr. JYOTI YADAV
वैज्ञानिक एवं प्रमुख पी० एन० ई०
Scientist & Head P. M. E.
जीनोमिक्स और समन्वित जीवविज्ञान संस्थान
Integrative Biology, दिल्ली-110007/Mall Road, Delhi-110007

Witnesses : (Name & Address)

Witnesses : (Name & Address)

1. *Dr R C Mathad*
KLEVBMK AYU COL Belgaum.

Dr S. L. Patil
Dr - S. L. Patil
KLEVBMK. V. V. College Belgaum.

Date : 11.6.12

2. *Rakum Kapur*
(Rakum Kapur
STO- PMEDIC
CSIR-IGIB)

Manish Patidar
(Manish patidar)
T.O CSIR-IGIB

Date : _____

ATTESTED

V.A. Kothiwale

Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI



MEMORANDUM OF UNDERSTANDING BETWEEN

**GOVINDRAM SEKSARIA SCIENCE COLLEGE
AND
K.L.E.UNIVERSITY'S
SHRI.B.M.K.AYURVEDA MAHAVIDYALAYA**

DATE: 27-01-2014

ATTESTED

Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Education, Health
and Research, BELGAUM

MEMORANDUM OF UNDERSTANDING

This Memorandum of Understanding ("MOU") is made, effective as of the Monday 27th day of the month of January 2014 ("Effective Date"),

Between

Govindram Seksaria Science College Geology department, Belgaum, Karnataka, (hereinafter called "GSS College" which expression shall where the context so admits include its successors and permitted assigns) of the one part;

And

KLE University's SHRI B. M. KANKANWADI AYURVEDA MAHAVIDYALAYA, a Company registered in India under the Companies Act, 1956 and having its registered office at SHAHPUR, BELGAUM, (hereinafter called "BMK", which expression shall, where the context so admits, include its successors and permitted assigns) of the second part.

PREAMBLE

It is the need of hour to work in collaborations to achieve and maintain the Education and Research standards in any institute. Individual academicians from University campus schools and constituent/private Institute should join their hands in academics and research. This helps to increase the academic and research standards as well as the student quality. This also helps in tackling the local problems and work towards the sustainable development of the region.

SKE Society and Govindram Seksaria Science College, Belgaum:

South Konkan Education Society (commonly known as SKE Society) had started the Rani Parvati Devi College with Arts and Science course way back in 1945 at Savantwadi, Maharashtra. Later the Rani Parvati Devi College was relocated to Belgaum in 1948. Durig 1966 due to increase in student strength the college was bifurcated as Rani Parvati Devi College of Arts and Govindram Seksaria Science College. Presently, GSS College is affiliated to Rani Channamma University, Belagavi (RCU), and is a premier educational institute in North Karnataka imparting quality education in Science and committed to overall development of students. The college is re-accredited with "A" Grade (3.10 CGPA) by NAAC and enjoys CPE status of UGC. The college has a proud track record of consistent high results at degree level.

It is engaged in providing quality education through well qualified and dedicated teaching staff. Several departments have shown high quality research by receiving funding from UGC, DST, MoES etc. Through this MoU these departments will be strengthened further in their researches. The department of Geology, Chemistry, Zoology and Physics are engaging major and minor projects. Department of Chemistry also has a PG programme in Organic Chemistry.

The Geology Department especially has completed four major and one minor research projects. 18 students have bagged gold medals at Karnataka University, Dharwad for securing highest marks in Geology since 1984. The students of this department are settled worldwide. The faculty of the school is having expertise in Sedimentation, sediment transport, coastal dynamics,

CONFIDENTIAL

Prof. Dr. V.A.KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

watershed development, Geological mapping, geophysical exploration, geochemical modeling, remote sensing; Environmental aspects such as pollution assessment, land use-land cover changes, etc. The department is equipped with geophysical resistivity meter, surveying equipment, Sieve analyses, heavy mineral analysis, ERDAS Imagine Remote Sensing software, Binocular petrological microscope with photographic attachment etc., to cater the training and research needs of the students. The department also has collaborative research with Department of Rasashastra, BMK Ayurveda Mahavidyalaya for their MD dissertations. Till now, 5 collaborative MD dissertations have been completed.

About KLEUniversity's Shri.BMK Ayurveda Mahavidyalaya:

Inspired by the way an Ayurvedic Physician diagnosed the miserable condition of wife, Late Sri Basappanna Mallappanna Kankanwadi, a retired Police Officer established this institute in 1933 by donating all his retirement earnings of Rs.50,000/-. Presently the institute is spread in 12 acres of land under three major establishments

- Shri B.M.K Ayurved Mahavidyalaya
- KLE Ayurveda Hospital
- KLE Ayurveda Pharmacy

The college is imparting Ayurveda education up to Post Doctoral Level. Graduation i.e. BAMS (75 intake), Post Graduation in Nine disciplines viz. Rasashastra, DravyaGuna, Shalya Tantra, Agada Tantra, Kayachikitsa, Kaumarabhritya, Panchakarma, Bhaishajya Kalpana & Sagnyaharana. The institute is well established with well equipped laboratories including Digital Library. Central Research Facility comprising of Analytical Laboratory, Microbiology Laboratory, Medical Research Center and Animal House are main attraction for research scholars. Herbal garden spread with rare and endangered species is the special feature of this institute.

The hospital worth six crores spread over 67,000 sq.ft with state of art facilities offering clinical training to UG, PG students as well as research scholars. All specialty OPD including super specialty OPD and various classical treatments are made available for health seekers. Panchakarma with all the modern gadgets and learned therapists offers panchakarma treatments for about 80 to 100 patients per day. Rejuvenation programmes through department of Swasthavritta are being offered for health promotion. Apart from these the hospital is having physiotherapy, OT complex, Labour Theater, Kangaroo Mother Care Center, NICU, Dental Wing, Ayurveda Fertility Center. Suvarnabindu an Ayurveda immunization is attracting large group of people and around 3000 kids attend the programme on every PushyaNakshatra day. Garbhasanskar is another unique approach of Ayurveda through which pregnant women will be taken care by Ayurveda management, yoga, medication, music therapy and mantra therapy. Samvardhana a rehabilitation center for mentally and physically challenged children is an added advantage of Kaumarabhritya department. Priyangu a Skin & Hair Care Clinic deals with skin analysis, hair analysis, relaxing head massage etc. Obesity Cell offers multi dimension approach like Panchakarma, Physiotherapy, Yoga & Naturopathy. Separate Chakshushya & Kankayana units offer special Kriyakalpa procedures for the ailments of Eye & ENT.

The pharmacy with GMP certification is producing quality medicines to meet the demands of KLE Ayurveda Hospital. Well established quality control laboratory is assuring the quality of the products. The pharmacy is manufacturing 70 classical and 7 proprietary products.

ATTESTED

CONFIDENTIAL

Prof. Dr. V.A.KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

New Library & PG Block:

To meet the increase demand of the Post Graduates and Doctoral Research requirements, the new Library & PG Block worth Rs.4 Crores has been constructed with the financial aid of Rs.1.2 Crore by Department of AYUSH, Ministry of Health & Family Welfare, Government of India, New Delhi under the Centre of Excellency Scheme.

The block contains spacious well furnished Library with huge number of literature i.e. about more than 16000 books. The accommodating capacity of the library is around 125. A provision of round the clock reading room has been made. Digital Lab with 30 High Configured Systems provides e-literature and web browsing to the students. Sound Proof discussion room in library is a unique feature which facilitates the research scholars to discuss the critical points in the library without disturbing others.

The PG Block accommodates Nine PG Departments, each having Department PG Seminar Hall, Museum cum Laboratory. All Seminar Halls are well equipped with proper audio-visual aids.

Department of Rasashastra:

Inorganic matter in fact provides in ways that are still not fully understood, an extremely powerful source of energy, not only for plants but for all living beings. However, inorganic matter in its natural form cannot be easily metabolized by humans unlike plants and other autotrophs. A special branch of Ayurveda pharmacy called Rasashastra developed around the 8th century, innovated and introduced complex process (using the then available primitive technologies), to convert ingeniously, outside of biological systems, metals and minerals into bio available drugs for powerful curative, preventive and health promoting uses. Today, Rasashastra is considered as a specialized, almost secretive branch of Ayurvedic pharmacy and therapeutics. It is Ayurveda's most powerful pharmaceutical form. It is a complex branch of pharmacy and designed to be practiced only by experts: It requires several years of training under expert teachers. It deals with the medicinal uses of around 70 different metals and minerals, along side organic substances (herbs), to make extremely potent medicines.

In the context of Ayurveda, the 'rasa' refers to 'Parad' or 'mercury'. This is because the science of Rasashastra is centrally based on the use of mercury. Mercury is known by the name 'Rasa' or 'Rasendra' and 'Parada'. It is called 'Rasa' because it has the power to transform various metals and minerals. It is used for both loha siddhi (conversion of base metals) and deha siddhi (used in the preparation of medicines for prevention and treatments). Rasashastra is considered as superior to all forms of medicine as it is fast acting and medicines prepared with strict adherence to methods prescribed in texts of Ayurveda alleviate many complex disorders. Metal and mineral preparations are therapeutically effective even when administered in small doses (unlike plant origin drugs which are generally required to be administered in a much larger dose). Properly prepared mineral drugs are bio- assimilable and produce their intended therapeutic results instantaneously. Improperly prepared drugs can however be toxic and harmful. This is the reason why only experts are advised to practice Rasashastra.

While mercury is the most important metal used in Rasashastra, there are other metals and minerals also used. They are grouped under Maharasa and Sadharana Rasa. Maharasa are the drugs that are widely used in formulations and are used in processing mercurial preparations, Uparasas are slightly lower in the effect, compared to the Maharasa and Sadharanarasas have limited power of

[Signature]

CONFIDENTIAL

Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

transformation. The Maharasa are Abhraka (Mica), Vaikranta (Tourmaline), SvarnaMakshika (Chalcopyrites), Vimala (Iron pyrites), Shilajit (Bitumen), Tutha (Copper sulphate), Bismuth and Zinc oxidw. The Uparasas are Gandhaka (Sulphur), Gairika (Red ochre), Kasisa (Iron sulphate), Kankshi (Alum), Talak (Orpiment), Manashila (Realgar), Anjana (Stibnite) and Kankushta (Gamboze). The Sadharana rasas consists of Kampillaka (obtained from fruits of mallotus trees), Arsenic oxide, Ammonium chloride, Cowrie, Ambergris, Red oxide of mercury, Mercury sulphide and Lead oxide.

Ayurveda obtained global recognition as science of life. Though people understand Ayurveda is an herbal medicine yet several preparations are Herbo mineral and Mineral formulations. The safety of the mineral ingredients in various formulations has been questioned and has become the concern of all Ayurvedic fraternity. Considering the global demand of Ayurvedic medicine, several business people started adulterating raw materials and this has contributed some more controversy to the existing controversies in raw material identification. Hence, this is the right time to identify genuine raw materials to preserve the global faith in Ayurveda.

In this aspect, the Department of Geology has made several advances and developed various methodologies for identification of Minerals and ores. Considering the need of identification, the Rasashastra department and department of Geology G.S. Science College, Tilakwadi-Belgaum has decided to make MoU.

1. Objectives

The objectives of the MoU are the following:

- (i) Collaborative research by sharing knowledge and research facilities.
- (ii) Conducting workshops/seminars/group discussions/ crash courses/bridge courses/ field visits etc.
- (iii) Guiding research and publishing the data.
- (iv) Up gradation of knowledge and technology development.

2. Financial Arrangements

Each party shall bear its own expenses incurred in the course of its performance under this Agreement.

3. Intellectual property (IP)

Credit of outcome of the collaboration should accrue credit to both the institutions.

4. Confidentiality

The parties understand that in the course of their association, they shall have access to confidential information provided by the other party. Accordingly, the parties agree that such information shall be maintained in the strictest confidence and trust, except such information which is by its nature, not confidential or which is in the public domain or which the party comes to know about other than through violation of any law of legal obligation, provided that such party may be entitled to disclose such information if legally required to be disclosed to a competent authority. Failure to maintain confidentiality shall entitle the affected party to terminate the MoU.

- (i) During and for a period of 3 year from the date of termination of this MOU, each party undertakes on their behalf and on the behalf of their subcontractors

ALIGNED

CONFIDENTIAL

Prof. Dr. V.A.KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

/employees /representatives/ associates to maintain strict confidentiality and prevent disclosure of the information/data exchanged / generated pursuant to this MOU for any purpose other than in accordance with this MOU.

- (ii) Upon termination or dissolution of this MOU, or upon earlier determination thereof, each party shall return to the other party all disclosing party's known tangible forms of the confidential information and copies thereof in the receiving party's possession and shall delete or erase all tangible/intangible confidential information of the disclosing party in its possession. If requested by the disclosing party an officer of the receiving party shall certify in writing that all such confidential information of the other was returned, erased or deleted.

5. Term of MoU and termination

- a. GSS College and BMK Ayurveda Mahavidyalaya, agree to enter into detailed agreements on case-to-case basis, with a defined objective, specifying the scope of work and mutual obligations, terms and conditions, financial arrangements, Intellectual Property Rights and similar contractual obligations.
- b. Both the Institutes agree to obtain prior permission from each other for using the infrastructural or intellectual facilities.
- c. Both the Institutes agree to obtain prior permission from each other to state in any project proposal that the project would be carried out by using the Institutes infrastructural or intellectual facilities.
- d. In case either party wins a consultancy project by projecting this MOU, a liability is created immediately in respect of royalty/premium/over head expenses due to either party. Either party shall concur with the liability to the extent of contribution to the output of the project. Both the parties will arrive at the exact amount of liability after mutual consent.

This MoU unless extended by a mutual written agreement of both the parties shall expire 5 years after the effective date specified in the opening paragraph. This MoU may be amended or terminated earlier by mutual written consent by both the parties at any time. Either party shall have the right to unilaterally terminate this MoU upon 30 days prior written notice to the other party. Failure of either party to terminate the MoU on account of breach or default by the other party shall not constitute a waiver of that party's right to terminate this MoU.


Upon Termination or Expiration of this MoU, any equipment, data, literature, books, journals, dissertations, thesis etc., shall be returned to the respective institutions, within 15 working days.

6. Representations, Warranties and Liability

GSS College and BMK will hold each other unconditionally harmless from any possible claims or damages brought by THIRD PARTIES against each other in connection with the performance of this Agreement.

GSS College shall not be responsible or liable for any damage to the property, material or personnel of the **BMK** or any monetary losses to the **BMK**, in consequence of the jobs taken up by **BMK**, as a result of this MoU. GSS

CONFIDENTIAL


Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

College shall also not be responsible for any procedural or legal matters pertaining to this assignment.

7. Rights in Results

- 7.1 Copyright in the generated Results shall vest with both the parties.
- 7.2 Each Party shall be free to use the Results as it deems fit and to grant use rights in respect of the Results to whomsoever they want without any liability, financially or otherwise, to other party, but with prior consent of both the parties.
- 7.3 The weight age for the order of authorships in the publications arisen out of the collaboration depends upon the amount and importance of the data used in the paper.

8. Relationship

Nothing in this MoU shall be construed to make party a partner, an agent or legal representative of the other party for any purpose. Neither party has any right or authority to accept any service, or receive any notices on behalf of the other party or to enter into any commitments, undertakings, or agreements purporting to obligate such other party in any way, or to amend, modify or vary any existing agreements to which such other party may be a party.

9. Assignment

The rights and/or liabilities arising to any party to this MoU shall not be assigned except with the written consent of the other party and subject to such terms and conditions as may be mutually agreed upon.

10. Force Majeure

Neither party shall be held responsible for non-fulfillment of their respective obligations under this MOU due to the exigency of one or more of the force majeure events such as but not limited to acts of god, war, flood, earthquakes, strike, lockouts, epidemics, riots, civil commotion, etc. provided on the occurrence and cessation of any such events, the party affected thereby shall give a notice in writing to the other party within one month of such occurrence or cessation. If the force majeure conditions continued beyond six months, the parties shall then mutually decide about the future course of action.

11. Arbitration

Any disputes arising out of this MoU shall be settled amicably through negotiations in good faith failing which the same shall be referred to and settled in accordance with the provisions of Arbitration & Conciliation Act, 1996 or any amendment thereof. This clause shall survive expiration or earlier determination of this MOU.

12. Jurisdiction

This MOU shall be subject to the jurisdictions of the courts in Belgaum only.

ATTESTED

CONFIDENTIAL


Prof. Dr. V.A. KOTHIWALE
Registrar

Academy of Higher Education
and Research, BELAGAVI

College shall also not be responsible for any procedural or legal matters pertaining to this assignment.

7. Rights in Results

- 7.1 Copyright in the generated Results shall vest with both the parties.
- 7.2 Each Party shall be free to use the Results as it deems fit and to grant use rights in respect of the Results to whomsoever they want without any liability, financially or otherwise, to other party, but with prior consent of both the parties.
- 7.3 The weight age for the order of authorships in the publications arisen out of the collaboration depends upon the amount and importance of the data used in the paper.

8. Relationship

Nothing in this MoU shall be construed to make party a partner, an agent or legal representative of the other party for any purpose. Neither party has any right or authority to accept any service, or receive any notices on behalf of the other party or to enter into any commitments, undertakings, or agreements purporting to obligate such other party in any way, or to amend, modify or vary any existing agreements to which such other party may be a party.

9. Assignment

The rights and/or liabilities arising to any party to this MoU shall not be assigned except with the written consent of the other party and subject to such terms and conditions as may be mutually agreed upon.

10. Force Majeure

Neither party shall be held responsible for non-fulfillment of their respective obligations under this MOU due to the exigency of one or more of the force majeure events such as but not limited to acts of god, war, flood, earthquakes, strike, lockouts, epidemics, riots, civil commotion, etc. provided on the occurrence and cessation of any such events, the party affected thereby shall give a notice in writing to the other party within one month of such occurrence or cessation. If the force majeure conditions continued beyond six months, the parties shall then mutually decide about the future course of action.

11. Arbitration

Any disputes arising out of this MoU shall be settled amicably through negotiations in good faith failing which the same shall be referred to and settled in accordance with the provisions of Arbitration & Conciliation Act, 1996 or any amendment thereof. This clause shall survive expiration or earlier determination of this MOU.

12. Jurisdiction

This MOU shall be subject to the jurisdictions of the courts in Belgaum only.

ATTESTED

CONFIDENTIAL


Prof. Dr. V.A. KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

In witness whereof the parties intending to be legally bound have caused this MOU to be duly executed in two originals by their authorized representatives, each to be version of equal authenticity as of the date first written above.

GSS College

KLEU's BMK AYURVEDA MAHAVIDYALAYA

Signature: M Mense

Name: Prof.A.K.MENSE

Designation: Principal

Date: 27-01-2014

Signature: Ch

Name: Dr. B.SREENIVAS PRASAD

Designation: Principal

Date: 27-01-2014

Witnesses:

[Signature]
27/1/14
1. Dr.P.T.Hanamgond

[Signature]
2. Dr.P.G.Jadar

~~7~~ ATTESTED CONFIDENTIAL

[Signature]
Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

MEMORANDUM OF UNDERSTANDING

BETWEEN

Interactive Research School for Health Affairs,

Bharati Vidyapeeth Deemed University,

Pune, Maharashtra

(Re-Accredited 'A' Grade NAAC & placed in 'A' Category by MHRD)

AND

KLE University's

Shri B. M. Kankanawadi Ayurved Mahavidyalaya

Belgaum, Karnataka

(Accredited 'A' Grade NAAC & placed in 'A' Category by MHRD)

REGARDING

Collaborative Research

2014-2018

ATTESTED



Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

MEMORANDUM OF UNDERSTANDING (MOU)

BETWEEN

Interactive Research School for Health Affairs,
Bharati Vidyapeeth Deemed University,
Pune, Maharashtra

AND

KLE University's
Shri B. M. Kankanawadi Ayurved Mahavidyalaya
Belgaum, Karnataka

FOR

COLLABORATIVE REASERCH

The Interactive Research School for Health Affairs, Bharati Vidyapeeth Deemed University, Pune, Maharashtra hereinafter referred to as IRSHA, while KLE University's Shri B. M. Kankanawadi Ayurved Mahavidyalaya, Belgauni, Karnataka will be referred as KLEU BMKAM.

This MOU sets down the mutually agreed broad framework for joint/collaborative research and academic activities in various fields of interest. It also incorporates the modalities for collaboration.

PREAMBLE:

IRSHA, a constituent unit of Bharati Vidyapeeth Deemed University, is a premier research institute totally dedicated to research on human health and nutrition with a special attention on Mother and Child Health and adult disorders. It has a team of Scientists with diverse expertise in Biochemistry, Molecular Biology, Ayurveda, Ethnobotany and Taxonomy, Biotechnology and Cell Biology. IRSHA has In-campus facility for animal experiments and clinical trials along with well Equipped Research Lab with State of Art facilities. There is a vibrant inhouse Ph.D program with full time Ph.D students working under various research programs.

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

KLEU BMKAM is a premier Ayurved Medical Research Institute/Hospital, having extraordinary infrastructure, specialized medical/paramedical staff, management and facilities for patient care, training programmes and research activities.

The activities of IRSHA and KLEU BMKAM could be successfully and complementarily conducted in areas of mutual interest and benefit.

PURPOSE: IRSHA and KLEU BMKAM desire to implement cooperative and collaborative activities, which would address multidisciplinary scientific, technological and educational issues/problems/challenges of relevance to the country. This is facilitated by the instrument of this MOU as follows:

ARTICLE-1

Consistent with the goals and purpose of the collaboration, IRSHA and KLEU BMKAM propose to initiate joint multidisciplinary research to begin with in areas given below:

- a) Metabolic syndrome with special focus on Obesity
- b) Other projects/studies would be taken up to include areas as mutually agreed upon involving faculty, research scholars and students from different departments/divisions of both the institutes.

ARTICLE-2

- a) The faculty and staff of IRSHA and KLEU BMKAM will hold regular meetings on research issues of mutual interest.
- b) The faculty and research scholars of IRSHA and KLEU BMKAM will have access to the facilities of both institutes, subject to their respective rules and regulation.
- c) The faculty and staff of IRSHA and KLEU BMKAM will jointly apply to the funding agencies for financial support for the collaborative research and academic program undertaken under this MOU.
- d) The faculty and staff will jointly report progress and accomplishment annually. As of now Dr. Prabhakar Ranjekar, Director, IRSHA and Dr. BS

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

Prasad, Principal, KLEU BMKAM shall co-ordinate the research work embodied in this MOU.

ARTICLE-3

Provision is hereby made for:

- a) The exchange of faculty, research scholars, staff and students between the two institutes
- b) The IRSHA staff based at KLEU BMKAM shall primarily report to Principal, KLEU BMKAM and report to Director, IRSHA as may be needed by the study. Likewise, the KLEU BMKAM staff based at IRSHA shall primarily report to Director, IRSHA and report to his/her Principal, KLEU BMKAM as may be needed by respective study.
- c) The joint organization of Symposia, Seminars, Workshops, trainings and Lectures; and mutual sharing of data on collaborative projects
- d) Collaborate/work jointly with other national and international partners of each other's institutions in mutual consultation and agreement time to time for conducting collaborative research.
- e) No formal day to day permission will be necessary for the faculty, research scholars, staff and students of the two institutes to work in the laboratories of other institute in connection with the research work/ projects approved jointly by the Heads/Coordinators of the respective departments of IRSHA and KLEU BMKAM.

ARTICLE-4

INTELLECTUAL PROPERTY:

- a) Research findings arising out of the activities covered under this MOU may be published in/presented at national and international journals/conferences jointly with the mutual consent of collaborators.
- b) Knowledge developed which can result in commercial exploitation would be Intellectual Property Rights act (IPR) Protected and filed jointly by both the institutes. IPR shall be based on contributions made by each party. However, the expenses involved in protecting the IPR shall be shared equally. However, if one of the institutes decides not to share the expenses for protecting IPR.

ATTESTED



Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

then it should assign its rights to other institute to enable the other institute to file the IPR protection.

- c) Either party may make use of, for its own internal purpose, all information and data generated during this program of collaborative work. However neither party shall reveal intellectual property belonging to the other to any third party without the prior written concurrence of the other party.
- d) Any returns arising of the commercialization of the Intellectual Property generated out of the programs undertaken under this MOU, will be shared in proportion to be decided mutually by both the parties, on case to case basis and through exchange of letters.

ARTICLE-5

NON-EXCLUSIVITY OF THE MOU

Notwithstanding anything contained in the provisions excepting Article-4 of the MOU, either party or both parties together have the unrestricted right to seek additional funds for and/or cooperate with any agency/institute for any of the projects covered by the MOU.


ARTICLE-6

Any article of the MOU may be modified or changed by mutual agreement of the parties here to in writing. The modification/changes shall be effective from the date on which they are modified/extended unless otherwise agreed to.

ARTICLE-7

All disagreements/differences of opinion /disputes regarding the interpretation of the provision of this MOU shall be resolved by mutual consultation by the signatories. However, in case the dispute persists, the matter shall be referred jointly to Prof. Sahebrao Mahadik, Advisor, IRSHA and Dr B.S.Prasad, Principal whose decision shall be final and binding on both the parties.

ATTESTED



Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

ARTICLE-8

GOVERNING LAW

All research activities undertaken jointly by IRSHA and KLEU BMKAM under this MOU will be governed by the laws of Republic of India.


ARTICLE-9

The tenure of the MOU shall be for five years from the date of signing the MOU unless opted otherwise by either of the signatory parties to this MOU. The tenure may be renewed for further period provided both parties agree in writing.

In witness where of the undersigned, duly authorized there to, have signed this MOU on this Tuesday, the 17th day of June 2014.







Dr. Prabhakar Ranjekar
Director, IRSHA



Dr. B.S. Prasad 17/6/2014
Principal, KLEU BMKAM

Witness

1. 
Dr. Supriya Bhalekar
2. 
DR. OMKAR KULKARNI

- Witness*
1. 
Dr. Geethika Vedantam
 2. 
Dr. S.K. Patil

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

Tel : 283650
Telefax : 08370-283651
Email : elegant@bsnl.in

ELEGANT DRUGS PVT. LTD.
PHARMACEUTICAL MANUFACTURERS

Manufacturing Unit : R. S. No. 59/3A, HUBLI-KARWAR HIGHWAY,
CHALMATTI - 581 196.
(Dist : Dharwad, Taluk : Kalghatagi, State : Karnataka)

Ref. No.: MISC/EDPL/092/16-17

Date: 17/06/2016

TO WHOMSOEVER IT MAY CONCERN


This is to certify that **Mr. AZHAR AHMED N. KHALASI**, student of KLEU'S COLLEGE OF PHARMACY, VIDYANAGAR, HUBLI has successfully completed 50 hours in plant training in our organization between 02.06.2016 to 16.06.2016. He has worked in all departments related to Tablets & Capsules.

His conduct and performance during above period was found to be satisfactory.

This certificate is issued to **Mr. AZHAR AHMED N. KHALASI**, only to complete the formalities of the academic course.

We wish all the best for his future.

FOR ELEGANT DRUGS PVT. LTD.,


Mr. Mahadev Chougule
Plant Manager


PRINCIPAL, KLE UNIVERSITY'S
COLLEGE OF PHARMACY
HUBLI.

ATTESTED



Corporate Office
New Cotton Market, HUBLI - 580 029 (Karnataka)
Tel : 2253607, 2253609 Fax : 0836-2253304 Email : elegant@bsnl.in

CamScanner

Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

345

Tel : 283650
Telefax : 08370-283651
Email : elegant@bsnl.in

ELEGANT DRUGS PVT. LTD.
PHARMACEUTICAL MANUFACTURERS

Manufacturing Unit : R. S. No. 59/3A, HUBLI-KARWAR HIGHWAY,
CHALMATTI - 581 196.
(Dist : Dharwad, Taluk : Kalghatagi, State : Karnataka)

Ref. No.MISC/EDPL/025/16-17

Date : 17.06.2016

TO WHOM SO EVER IT MAY CONCERN

This is to certify that Ms.JERUSHA JOSEPH IRUDAYARAJ, student of COLLEGE OF PHARMACY, VIDYANAGAR, HUBLI has successfully completed 15 days (50 hours) in plant training in our organization between 01.06.2016 to 15.06.2016. She has worked in all departments related to Tablets & Capsules.

Her conduct and performance during above period was found to be satisfactory.

This Certificate is issued to Ms.JERUSHA JOSEPH IRUDAYARAJ, only to complete the formalities of the academic course.

We wish all the best for her future.


Thanking you,

Yours faithfully,

For ELEGANT DRUGS PVT.LTD.,


Rajashekar C.Pattanshetty

(Managing Director)


19/6/16
PRINCIPAL KLE UNIVERSITY'S
COLLEGE OF PHARMACY
HUBLI.



ATTESTED



Corporate Office

New Cotton Market, HUBLI-580 029, (Karnataka)

Tel: 2252201, 2250603, Fax: 0836-2252186, Email: elegant@bsnl.in

CamScanner

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

346



**KLE UNIVERSITY'S
COLLEGE OF PHARMACY**

(A constituent unit of KLE Academy of Higher Education & Research- Deemed University)

Vidyanagar, HUBBALLI-580 031. Karnataka, India

Recognised by Government of Karnataka

Approved by Pharmacy Council of India (PCI) & All India Council for Technical Education (AICTE), New Delhi

(Accredited by NBA, AICTE, New Delhi)



Ref. No. : IP(KCOP HBC/IT/2016-17) 139(A)

Date : 23/02/2016

To,

The Production Manager,
Elegant Drugs Pvt. Limited,
R.S.No.59/3A,
Hubli-Karwar Highway,
CHALAMATTI - 581 204.

Sub: Permission to visit your esteemed Industry
by the final year B.Pharm. & M.Pharm. Students.

Sir,

We are pleased to inform you that, we are running B.Pharm. & M.Pharm. Courses since 1991 & 1999 respectively. These courses are approved by AICTE & PCI, New Delhi and Institution is reaccredited by NBA, AICTE, New Delhi. As per the regulations of B.Pharm. Course, the students studying in Final year B.Pharm are required to visit several Pharmaceutical manufacturing units and laboratories as supplement to their academic training and they are required to submit the report to the Head of the institution where he / she is studying.

In this context, our Final year B.Pharm. & M.Pharm. students intend to visit your esteemed Industry / Laboratory in third week of February, 2016. We will be grateful to you, if you permit us to visit your Industry / Laboratory. I am confident that your good self will permit us and widen the knowledge.

Hoping for your early and favorable reply.

Thanking you,



Yours faithfully,

PRINCIPAL

Note: 15 students and 2 staff members will be visiting in one batch or as per your convenience.

ATTESTED



Scanned with CamScanner
E : 0836-2373174, Fax No. 0836-2371694/2371048, Web : <http://www.klescoph.org> Email : principal.klescoph@gmail.com

Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

Tel : 283650
Telefax : 08370-283651
Email : elegant@bsnl.in



ELEGANT DRUGS PVT. LTD.
PHARMACEUTICAL MANUFACTURERS

Manufacturing Unit : R. S. No. 59/3A, HUBLI-KARWAR HIGHWAY,
CHALMATTI - 581 196.
(Dist : Dharwad, Taluk : Kalghatagi, State: Karnataka)

Ref. No.: MISC/EDPL/090/16-17

Date: 17/06/2016

TO WHOMSOEVER IT MAY CONCERN

This is to certify that Mr. **SACHIN HAVERI ASHOK**, student of COLLEGE OF PHARMACY, VIDYANAGAR, HUBLI has successfully completed 50 hours in plant training in our organization between 02.06.2016 to 16.06.2016. He has worked in all departments related to Tablets & Capsules.


His conduct and performance during above period was found to be satisfactory.

This certificate is issued to Mr. **SACHIN HAVERI ASHOK**, only to complete the formalities of the academic course.

We wish all the best for his future.

FOR ELEGANT DRUGS PVT. LTD.,



Mr. Mahadev Chougule
Plant Manager


PRINCIPAL, KLE UNIVERSITY'S
COLLEGE OF PHARMACY
HUSLL

ATTESTED

Corporate Office
New Cotton Market, HUBLI - 580 028 (Karnataka)
Tel: 2257637, 2250300, Fax: 0836-2253386, Email: elegant@bsnl.in

CamScanner


Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

348

Tel : 283650
Fax : 08370-283651
Mail : elegant@bsnl.in

ELEGANT DRUGS PVT. LTD.
PHARMACEUTICAL MANUFACTURERS

Manufacturing Unit : R. S. No. 59/JA, HUBLI-KARWAR HIGHWAY,
CHALMATTI - 581 196.
(Dist : Dharwad, Taluk : Kalghatagi, State : Karnataka)

Ref. No.MISC/EDPL/027/16-17

Date : 17.06.2016

TO WHOM SO EVER IT MAY CONCERN

This is to certify that Ms.PRATIBHA HUDED MALLAPPA, student of COLLEGE OF PHARMACY, VIDYANAGAR, HUBLI has successfully completed 15 days (50 hours) in plant training in our organization between 01.06.2016 to 15.06.2016. She has worked in all departments related to Tablets & Capsules.

Her conduct and performance during above period was found to be satisfactory.

This Certificate is issued to Ms. PRATIBHA HUDED MALLAPPA, only to complete the formalities of the academic course.

We wish all the best for her future.

Thanking you,


Yours faithfully,

For ELEGANT DRUGS PVT.LTD.,


Rajashekar C.Pattanshetty

(Managing Director)




PRINCIPAL, KLE UNIVERSITY'S
COLLEGE OF PHARMACY
HUBLI.

ATTESTED



Corporate Office
New Cotton Market, HUBLI - 580 029, (Karnataka)
Tel: 2252677, 2252678, 2252679, 2252680, 2252681, 2252682, 2252683, 2252684, 2252685, 2252686, 2252687, 2252688, 2252689, 2252690, 2252691, 2252692, 2252693, 2252694, 2252695, 2252696, 2252697, 2252698, 2252699, 2252700, 2252701, 2252702, 2252703, 2252704, 2252705, 2252706, 2252707, 2252708, 2252709, 2252710, 2252711, 2252712, 2252713, 2252714, 2252715, 2252716, 2252717, 2252718, 2252719, 2252720, 2252721, 2252722, 2252723, 2252724, 2252725, 2252726, 2252727, 2252728, 2252729, 2252730, 2252731, 2252732, 2252733, 2252734, 2252735, 2252736, 2252737, 2252738, 2252739, 2252740, 2252741, 2252742, 2252743, 2252744, 2252745, 2252746, 2252747, 2252748, 2252749, 2252750, 2252751, 2252752, 2252753, 2252754, 2252755, 2252756, 2252757, 2252758, 2252759, 2252760, 2252761, 2252762, 2252763, 2252764, 2252765, 2252766, 2252767, 2252768, 2252769, 2252770, 2252771, 2252772, 2252773, 2252774, 2252775, 2252776, 2252777, 2252778, 2252779, 2252780, 2252781, 2252782, 2252783, 2252784, 2252785, 2252786, 2252787, 2252788, 2252789, 2252790, 2252791, 2252792, 2252793, 2252794, 2252795, 2252796, 2252797, 2252798, 2252799, 2252800, 2252801, 2252802, 2252803, 2252804, 2252805, 2252806, 2252807, 2252808, 2252809, 2252810, 2252811, 2252812, 2252813, 2252814, 2252815, 2252816, 2252817, 2252818, 2252819, 2252820, 2252821, 2252822, 2252823, 2252824, 2252825, 2252826, 2252827, 2252828, 2252829, 2252830, 2252831, 2252832, 2252833, 2252834, 2252835, 2252836, 2252837, 2252838, 2252839, 2252840, 2252841, 2252842, 2252843, 2252844, 2252845, 2252846, 2252847, 2252848, 2252849, 2252850, 2252851, 2252852, 2252853, 2252854, 2252855, 2252856, 2252857, 2252858, 2252859, 2252860, 2252861, 2252862, 2252863, 2252864, 2252865, 2252866, 2252867, 2252868, 2252869, 2252870, 2252871, 2252872, 2252873, 2252874, 2252875, 2252876, 2252877, 2252878, 2252879, 2252880, 2252881, 2252882, 2252883, 2252884, 2252885, 2252886, 2252887, 2252888, 2252889, 2252890, 2252891, 2252892, 2252893, 2252894, 2252895, 2252896, 2252897, 2252898, 2252899, 2252900, 2252901, 2252902, 2252903, 2252904, 2252905, 2252906, 2252907, 2252908, 2252909, 2252910, 2252911, 2252912, 2252913, 2252914, 2252915, 2252916, 2252917, 2252918, 2252919, 2252920, 2252921, 2252922, 2252923, 2252924, 2252925, 2252926, 2252927, 2252928, 2252929, 2252930, 2252931, 2252932, 2252933, 2252934, 2252935, 2252936, 2252937, 2252938, 2252939, 2252940, 2252941, 2252942, 2252943, 2252944, 2252945, 2252946, 2252947, 2252948, 2252949, 2252950, 2252951, 2252952, 2252953, 2252954, 2252955, 2252956, 2252957, 2252958, 2252959, 2252960, 2252961, 2252962, 2252963, 2252964, 2252965, 2252966, 2252967, 2252968, 2252969, 2252970, 2252971, 2252972, 2252973, 2252974, 2252975, 2252976, 2252977, 2252978, 2252979, 2252980, 2252981, 2252982, 2252983, 2252984, 2252985, 2252986, 2252987, 2252988, 2252989, 2252990, 2252991, 2252992, 2252993, 2252994, 2252995, 2252996, 2252997, 2252998, 2252999, 2253000, 2253001, 2253002, 2253003, 2253004, 2253005, 2253006, 2253007, 2253008, 2253009, 2253010, 2253011, 2253012, 2253013, 2253014, 2253015, 2253016, 2253017, 2253018, 2253019, 2253020, 2253021, 2253022, 2253023, 2253024, 2253025, 2253026, 2253027, 2253028, 2253029, 2253030, 2253031, 2253032, 2253033, 2253034, 2253035, 2253036, 2253037, 2253038, 2253039, 2253040, 2253041, 2253042, 2253043, 2253044, 2253045, 2253046, 2253047, 2253048, 2253049, 2253050, 2253051, 2253052, 2253053, 2253054, 2253055, 2253056, 2253057, 2253058, 2253059, 2253060, 2253061, 2253062, 2253063, 2253064, 2253065, 2253066, 2253067, 2253068, 2253069, 2253070, 2253071, 2253072, 2253073, 2253074, 2253075, 2253076, 2253077, 2253078, 2253079, 2253080, 2253081, 2253082, 2253083, 2253084, 2253085, 2253086, 2253087, 2253088, 2253089, 2253090, 2253091, 2253092, 2253093, 2253094, 2253095, 2253096, 2253097, 2253098, 2253099, 2253100, 2253101, 2253102, 2253103, 2253104, 2253105, 2253106, 2253107, 2253108, 2253109, 2253110, 2253111, 2253112, 2253113, 2253114, 2253115, 2253116, 2253117, 2253118, 2253119, 2253120, 2253121, 2253122, 2253123, 2253124, 2253125, 2253126, 2253127, 2253128, 2253129, 2253130, 2253131, 2253132, 2253133, 2253134, 2253135, 2253136, 2253137, 2253138, 2253139, 2253140, 2253141, 2253142, 2253143, 2253144, 2253145, 2253146, 2253147, 2253148, 2253149, 2253150, 2253151, 2253152, 2253153, 2253154, 2253155, 2253156, 2253157, 2253158, 2253159, 2253160, 2253161, 2253162, 2253163, 2253164, 2253165, 2253166, 2253167, 2253168, 2253169, 2253170, 2253171, 2253172, 2253173, 2253174, 2253175, 2253176, 2253177, 2253178, 2253179, 2253180, 2253181, 2253182, 2253183, 2253184, 2253185, 2253186, 2253187, 2253188, 2253189, 2253190, 2253191, 2253192, 2253193, 2253194, 2253195, 2253196, 2253197, 2253198, 2253199, 2253200, 2253201, 2253202, 2253203, 2253204, 2253205, 2253206, 2253207, 2253208, 2253209, 2253210, 2253211, 2253212, 2253213, 2253214, 2253215, 2253216, 2253217, 2253218, 2253219, 2253220, 2253221, 2253222, 2253223, 2253224, 2253225, 2253226, 2253227, 2253228, 2253229, 2253230, 2253231, 2253232, 2253233, 2253234, 2253235, 2253236, 2253237, 2253238, 2253239, 2253240, 2253241, 2253242, 2253243, 2253244, 2253245, 2253246, 2253247, 2253248, 2253249, 2253250, 2253251, 2253252, 2253253, 2253254, 2253255, 2253256, 2253257, 2253258, 2253259, 2253260, 2253261, 2253262, 2253263, 2253264, 2253265, 2253266, 2253267, 2253268, 2253269, 2253270, 2253271, 2253272, 2253273, 2253274, 2253275, 2253276, 2253277, 2253278, 2253279, 2253280, 2253281, 2253282, 2253283, 2253284, 2253285, 2253286, 2253287, 2253288, 2253289, 2253290, 2253291, 2253292, 2253293, 2253294, 2253295, 2253296, 2253297, 2253298, 2253299, 2253300, 2253301, 2253302, 2253303, 2253304, 2253305, 2253306, 2253307, 2253308, 2253309, 2253310, 2253311, 2253312, 2253313, 2253314, 2253315, 2253316, 2253317, 2253318, 2253319, 2253320, 2253321, 2253322, 2253323, 2253324, 2253325, 2253326, 2253327, 2253328, 2253329, 2253330, 2253331, 2253332, 2253333, 2253334, 2253335, 2253336, 2253337, 2253338, 2253339, 2253340, 2253341, 2253342, 2253343, 2253344, 2253345, 2253346, 2253347, 2253348, 2253349, 2253350, 2253351, 2253352, 2253353, 2253354, 2253355, 2253356, 2253357, 2253358, 2253359, 2253360, 2253361, 2253362, 2253363, 2253364, 2253365, 2253366, 2253367, 2253368, 2253369, 2253370, 2253371, 2253372, 2253373, 2253374, 2253375, 2253376, 2253377, 2253378, 2253379, 2253380, 2253381, 2253382, 2253383, 2253384, 2253385, 2253386, 2253387, 2253388, 2253389, 2253390, 2253391, 2253392, 2253393, 2253394, 2253395, 2253396, 2253397, 2253398, 2253399, 2253400, 2253401, 2253402, 2253403, 2253404, 2253405, 2253406, 2253407, 2253408, 2253409, 2253410, 2253411, 2253412, 2253413, 2253414, 2253415, 2253416, 2253417, 2253418, 2253419, 2253420, 2253421, 2253422, 2253423, 2253424, 2253425, 2253426, 2253427, 2253428, 2253429, 2253430, 2253431, 2253432, 2253433, 2253434, 2253435, 2253436, 2253437, 2253438, 2253439, 2253440, 2253441, 2253442, 2253443, 2253444, 2253445, 2253446, 2253447, 2253448, 2253449, 2253450, 2253451, 2253452, 2253453, 2253454, 2253455, 2253456, 2253457, 2253458, 2253459, 2253460, 2253461, 2253462, 2253463, 2253464, 2253465, 2253466, 2253467, 2253468, 2253469, 2253470, 2253471, 2253472, 2253473, 2253474, 2253475, 2253476, 2253477, 2253478, 2253479, 2253480, 2253481, 2253482, 2253483, 2253484, 2253485, 2253486, 2253487, 2253488, 2253489, 2253490, 2253491, 2253492, 2253493, 2253494, 2253495, 2253496, 2253497, 2253498, 2253499, 2253500, 2253501, 2253502, 2253503, 2253504, 2253505, 2253506, 2253507, 2253508, 2253509, 2253510, 2253511, 2253512, 2253513, 2253514, 2253515, 2253516, 2253517, 2253518, 2253519, 2253520, 2253521, 2253522, 2253523, 2253524, 2253525, 2253526, 2253527, 2253528, 2253529, 2253530, 2253531, 2253532, 2253533, 2253534, 2253535, 2253536, 2253537, 2253538, 2253539, 2253540, 2253541, 2253542, 2253543, 2253544, 2253545, 2253546, 2253547, 2253548, 2253549, 2253550, 2253551, 2253552, 2253553, 2253554, 2253555, 2253556, 2253557, 2253558, 2253559, 2253560, 2253561, 2253562, 2253563, 2253564, 2253565, 2253566, 2253567, 2253568, 2253569, 2253570, 2253571, 2253572, 2253573, 2253574, 2253575, 2253576, 2253577, 2253578, 2253579, 2253580, 2253581, 2253582, 2253583, 2253584, 2253585, 2253586, 2253587, 2253588, 2253589, 2253590, 2253591, 2253592, 2253593, 2253594, 2253595, 2253596, 2253597, 2253598, 2253599, 2253600, 2253601, 2253602, 2253603, 2253604, 2253605, 2253606, 2253607, 2253608, 2253609, 2253610, 2253611, 2253612, 2253613, 2253614, 2253615, 2253616, 2253617, 2253618, 2253619, 2253620, 2253621, 2253622, 2253623, 2253624, 2253625, 2253626, 2253627, 2253628, 2253629, 2253630, 2253631, 2253632, 2253633, 2253634, 2253635, 2253636, 2253637, 2253638, 2253639, 2253640, 2253641, 2253642, 2253643, 2253644, 2253645, 2253646, 2253647, 2253648, 2253649, 2253650, 2253651, 2253652, 2253653, 2253654, 2253655, 2253656, 2253657, 2253658, 2253659, 2253660, 2253661, 2253662, 2253663, 2253664, 2253665, 2253666, 2253667, 2253668, 2253669, 2253670, 2253671, 2253672, 2253673, 2253674, 2253675, 2253676, 2253677, 2253678, 2253679, 2253680, 2253681, 2253682, 2253683, 2253684, 2253685, 2253686, 2253687, 2253688, 2253689, 2253690, 2253691, 2253692, 2253693, 2253694, 2253695, 2253696, 2253697, 2253698, 2253699, 2253700, 2253701, 2253702, 2253703, 2253704, 2253705, 2253706, 2253707, 2253708, 2253709, 2253710, 2253711, 2253712, 2253713, 2253714, 2253715, 2253716, 2253717, 2253718, 2253719, 2253720, 2253721, 2253722, 2253723, 2253724, 2253725, 2253726, 2253727, 2253728, 2253729, 2253730, 2253731, 2253732, 2253733, 2253734, 2253735, 2253736, 2253737, 2253738, 2253739, 2253740, 2253741, 2253742, 2253743, 2253744, 2253745, 2253746, 2253747, 2253748, 2253749, 2253750, 2253751, 2253752, 2253753, 2253754, 2253755, 2253756, 2253757, 2253758, 2253759, 2253760, 2253761, 2253762, 2253763, 2253764, 2253765, 2253766, 2253767, 2253768, 2253769, 2253770, 2253771, 2253772, 2253773, 2253774, 2253775, 2253776, 2253777, 2253778, 2253779, 2253780, 2253781, 2253782, 2253783, 2253784, 2253785, 2253786, 2253787, 2253788, 2253789, 2253790, 2253791, 2253792, 2253793, 2253794, 2253795, 2253796, 2253797, 2253798, 2253799, 2253800, 2253801, 2253802, 2253803, 2253804, 2253805, 2253806, 2253807, 2253808, 2253809, 2253810, 2253811, 2253812, 2253813, 2253814, 2253815, 2253816, 2253817, 2253818, 2253819, 2253820, 2253821, 2253822, 2253823, 2253824, 2253825, 2253826, 2253827, 2253828, 2253829, 2253830, 2253831, 2253832, 2253833, 2253834, 2253835, 2253836, 2253837, 2253838, 2253839, 2253840, 2253841, 2253842, 2253843, 2253844, 2253845, 2253846, 2253847, 2253848, 2253849, 2253850, 2253851, 2253852, 2253853, 2253854, 2253855, 2253856, 2253857, 2253858, 2253859, 2253860, 2253861, 2253862, 2253863, 2253864, 2253865, 2253866, 2253867, 2253868, 2253869, 2253870, 2253871, 2253872, 2253873, 2253874, 2253875, 2253876, 2253877, 2253878, 2253879, 2253880, 2253881, 2253882, 2253883, 2253884, 2253885, 2253886, 2253887, 2253888, 2253889, 2253890, 2253891, 2253892, 2253893, 2253894, 2253895, 2253896, 2253897, 2253898, 2253899, 2253900, 2253901, 2253902, 2253903, 2253904, 2253905, 2253906, 2253907, 2253908, 2253909, 2253910, 2253911, 2253912, 2253913, 2253914, 2253915, 2253916, 2253917, 2253918, 2253919, 2253920, 2253921, 2253922, 22539

Tel : 283650
Telefax : 08370-283651
Email : elegant@bsnl.in

ELEGANT DRUGS PVT. LTD.
PHARMACEUTICAL MANUFACTURERS

Manufacturing Unit : R. S. No. 59/3A, HUBLI-KARWAR HIGHWAY,
CHALMATTI - 581 196.
(Dist : Dharwad, Taluk : Kalghatagi, State : Karnataka)

Ref. No.MISC/EDPL/029/16-17

Date : 17.06.2016

TO WHOM SO EVER IT MAY CONCERN

This is to certify that Mis.SONAM NANDGERIKAR VINAYAK, student of COLLEGE OF PHARMACY, VIDYANAGAR, HUBLI has successfully completed 15 days (50 hours) in plant training in our organization between 01.06.2016 to 15.06.2016. She has worked in all departments related to Tablets & Capsules.

Her conduct and performance during above period was found to be satisfactory.

This Certificate is issued to Ms. SONAM NANDGERIKAR VINAYAK, only to complete the formalities of the academic course.

We wish all the best for her future.


19/8/16
PRINCIPAL, KLE UNIVERSITY'S
COLLEGE OF PHARMACY
HUBLI

Thanking you,




Yours faithfully,

For ELEGANT DRUGS PVT.LTD.,


Rajashekar C.Pattanshetty

(Managing Director)

ATTESTED


Corporate Office
New Cotton Market, HUBLI - 580 029 (Karnataka)
Tel : 2252677350/08 / Fax : 0836-2253386 Email : elegant@bsnl.in

CamScanner

SHIVWALE,
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

350

Tel : 283650
Telefax : 08370-283651
Email : elegant@bsnl.in

ELEGANT DRUGS PVT. LTD.
PHARMACEUTICAL MANUFACTURERS

Manufacturing Unit : R. S. No. 59/3A, HUBLI-KARWAR HIGHWAY,
CHALMATTI - 581 196.
(Dist : Dharwad, Taluk : Kalghatagi, State : Karnataka)

Ref. No.MISC/EDPL/026/16-17

Date : 17.06.2016

TO WHOM SO EVER IT MAY CONCERN

This is to certify that Mis.AKSHATA. MENSINKAI, student of COLLEGE OF PHARMACY, VIDYANAGAR, HUBLI has successfully completed 15 days (50 hours) in plant training in our organization between 01.06.2016 to 15.06.2016. She has worked in all departments related to Tablets & Capsules.

Her conduct and performance during above period was found to be satisfactory.

This Certificate is issued to Ms. AKSHATA. MENSINKAI, only to complete the formalities of the academic course.

We wish all the best for her future.


Thanking you,

Yours faithfully,

For ELEGANT DRUGS PVT.LTD.,


Rajashekar C.Pattanshetty

(Managing Director)


PRINCIPAL, KLE UNIVERSITY'S
COLLEGE OF PHARMACY
HUBLI.



ATTESTED


Corporate Office

New Cotton Market, HUBLI - 580 028 (Karnataka)

Tel : 283650, 283651, 283652, 283653, 283654, 283655, 283656, 283657, 283658, 283659, 283660, 283661, 283662, 283663, 283664, 283665, 283666, 283667, 283668, 283669, 283670, 283671, 283672, 283673, 283674, 283675, 283676, 283677, 283678, 283679, 283680, 283681, 283682, 283683, 283684, 283685, 283686, 283687, 283688, 283689, 283690, 283691, 283692, 283693, 283694, 283695, 283696, 283697, 283698, 283699, 283700, 283701, 283702, 283703, 283704, 283705, 283706, 283707, 283708, 283709, 283710, 283711, 283712, 283713, 283714, 283715, 283716, 283717, 283718, 283719, 283720, 283721, 283722, 283723, 283724, 283725, 283726, 283727, 283728, 283729, 283730, 283731, 283732, 283733, 283734, 283735, 283736, 283737, 283738, 283739, 283740, 283741, 283742, 283743, 283744, 283745, 283746, 283747, 283748, 283749, 283750, 283751, 283752, 283753, 283754, 283755, 283756, 283757, 283758, 283759, 283760, 283761, 283762, 283763, 283764, 283765, 283766, 283767, 283768, 283769, 283770, 283771, 283772, 283773, 283774, 283775, 283776, 283777, 283778, 283779, 283780, 283781, 283782, 283783, 283784, 283785, 283786, 283787, 283788, 283789, 283790, 283791, 283792, 283793, 283794, 283795, 283796, 283797, 283798, 283799, 283800, 283801, 283802, 283803, 283804, 283805, 283806, 283807, 283808, 283809, 283810, 283811, 283812, 283813, 283814, 283815, 283816, 283817, 283818, 283819, 283820, 283821, 283822, 283823, 283824, 283825, 283826, 283827, 283828, 283829, 283830, 283831, 283832, 283833, 283834, 283835, 283836, 283837, 283838, 283839, 283840, 283841, 283842, 283843, 283844, 283845, 283846, 283847, 283848, 283849, 283850, 283851, 283852, 283853, 283854, 283855, 283856, 283857, 283858, 283859, 283860, 283861, 283862, 283863, 283864, 283865, 283866, 283867, 283868, 283869, 283870, 283871, 283872, 283873, 283874, 283875, 283876, 283877, 283878, 283879, 283880, 283881, 283882, 283883, 283884, 283885, 283886, 283887, 283888, 283889, 283890, 283891, 283892, 283893, 283894, 283895, 283896, 283897, 283898, 283899, 283900, 283901, 283902, 283903, 283904, 283905, 283906, 283907, 283908, 283909, 283910, 283911, 283912, 283913, 283914, 283915, 283916, 283917, 283918, 283919, 283920, 283921, 283922, 283923, 283924, 283925, 283926, 283927, 283928, 283929, 283930, 283931, 283932, 283933, 283934, 283935, 283936, 283937, 283938, 283939, 283940, 283941, 283942, 283943, 283944, 283945, 283946, 283947, 283948, 283949, 283950, 283951, 283952, 283953, 283954, 283955, 283956, 283957, 283958, 283959, 283960, 283961, 283962, 283963, 283964, 283965, 283966, 283967, 283968, 283969, 283970, 283971, 283972, 283973, 283974, 283975, 283976, 283977, 283978, 283979, 283980, 283981, 283982, 283983, 283984, 283985, 283986, 283987, 283988, 283989, 283990, 283991, 283992, 283993, 283994, 283995, 283996, 283997, 283998, 283999, 284000, 284001, 284002, 284003, 284004, 284005, 284006, 284007, 284008, 284009, 284010, 284011, 284012, 284013, 284014, 284015, 284016, 284017, 284018, 284019, 284020, 284021, 284022, 284023, 284024, 284025, 284026, 284027, 284028, 284029, 284030, 284031, 284032, 284033, 284034, 284035, 284036, 284037, 284038, 284039, 284040, 284041, 284042, 284043, 284044, 284045, 284046, 284047, 284048, 284049, 284050, 284051, 284052, 284053, 284054, 284055, 284056, 284057, 284058, 284059, 284060, 284061, 284062, 284063, 284064, 284065, 284066, 284067, 284068, 284069, 284070, 284071, 284072, 284073, 284074, 284075, 284076, 284077, 284078, 284079, 284080, 284081, 284082, 284083, 284084, 284085, 284086, 284087, 284088, 284089, 284090, 284091, 284092, 284093, 284094, 284095, 284096, 284097, 284098, 284099, 284100, 284101, 284102, 284103, 284104, 284105, 284106, 284107, 284108, 284109, 284110, 284111, 284112, 284113, 284114, 284115, 284116, 284117, 284118, 284119, 284120, 284121, 284122, 284123, 284124, 284125, 284126, 284127, 284128, 284129, 284130, 284131, 284132, 284133, 284134, 284135, 284136, 284137, 284138, 284139, 284140, 284141, 284142, 284143, 284144, 284145, 284146, 284147, 284148, 284149, 284150, 284151, 284152, 284153, 284154, 284155, 284156, 284157, 284158, 284159, 284160, 284161, 284162, 284163, 284164, 284165, 284166, 284167, 284168, 284169, 284170, 284171, 284172, 284173, 284174, 284175, 284176, 284177, 284178, 284179, 284180, 284181, 284182, 284183, 284184, 284185, 284186, 284187, 284188, 284189, 284190, 284191, 284192, 284193, 284194, 284195, 284196, 284197, 284198, 284199, 284200, 284201, 284202, 284203, 284204, 284205, 284206, 284207, 284208, 284209, 284210, 284211, 284212, 284213, 284214, 284215, 284216, 284217, 284218, 284219, 284220, 284221, 284222, 284223, 284224, 284225, 284226, 284227, 284228, 284229, 284230, 284231, 284232, 284233, 284234, 284235, 284236, 284237, 284238, 284239, 284240, 284241, 284242, 284243, 284244, 284245, 284246, 284247, 284248, 284249, 284250, 284251, 284252, 284253, 284254, 284255, 284256, 284257, 284258, 284259, 284260, 284261, 284262, 284263, 284264, 284265, 284266, 284267, 284268, 284269, 284270, 284271, 284272, 284273, 284274, 284275, 284276, 284277, 284278, 284279, 284280, 284281, 284282, 284283, 284284, 284285, 284286, 284287, 284288, 284289, 284290, 284291, 284292, 284293, 284294, 284295, 284296, 284297, 284298, 284299, 284300, 284301, 284302, 284303, 284304, 284305, 284306, 284307, 284308, 284309, 284310, 284311, 284312, 284313, 284314, 284315, 284316, 284317, 284318, 284319, 284320, 284321, 284322, 284323, 284324, 284325, 284326, 284327, 284328, 284329, 284330, 284331, 284332, 284333, 284334, 284335, 284336, 284337, 284338, 284339, 284340, 284341, 284342, 284343, 284344, 284345, 284346, 284347, 284348, 284349, 284350, 284351, 284352, 284353, 284354, 284355, 284356, 284357, 284358, 284359, 284360, 284361, 284362, 284363, 284364, 284365, 284366, 284367, 284368, 284369, 284370, 284371, 284372, 284373, 284374, 284375, 284376, 284377, 284378, 284379, 284380, 284381, 284382, 284383, 284384, 284385, 284386, 284387, 284388, 284389, 284390, 284391, 284392, 284393, 284394, 284395, 284396, 284397, 284398, 284399, 284400, 284401, 284402, 284403, 284404, 284405, 284406, 284407, 284408, 284409, 284410, 284411, 284412, 284413, 284414, 284415, 284416, 284417, 284418, 284419, 284420, 284421, 284422, 284423, 284424, 284425, 284426, 284427, 284428, 284429, 284430, 284431, 284432, 284433, 284434, 284435, 284436, 284437, 284438, 284439, 284440, 284441, 284442, 284443, 284444, 284445, 284446, 284447, 284448, 284449, 284450, 284451, 284452, 284453, 284454, 284455, 284456, 284457, 284458, 284459, 284460, 284461, 284462, 284463, 284464, 284465, 284466, 284467, 284468, 284469, 284470, 284471, 284472, 284473, 284474, 284475, 284476, 284477, 284478, 284479, 284480, 284481, 284482, 284483, 284484, 284485, 284486, 284487, 284488, 284489, 284490, 284491, 284492, 284493, 284494, 284495, 284496, 284497, 284498, 284499, 284500, 284501, 284502, 284503, 284504, 284505, 284506, 284507, 284508, 284509, 284510, 284511, 284512, 284513, 284514, 284515, 284516, 284517, 284518, 284519, 284520, 284521, 284522, 284523, 284524, 284525, 284526, 284527, 284528, 284529, 284530, 284531, 284532, 284533, 284534, 284535, 284536, 284537, 284538, 284539, 284540, 284541, 284542, 284543, 284544, 284545, 284546, 284547, 284548, 284549, 284550, 284551, 284552, 284553, 284554, 284555, 284556, 284557, 284558, 284559, 284560, 284561, 284562, 284563, 284564, 284565, 284566, 284567, 284568, 284569, 284570, 284571, 284572, 284573, 284574, 284575, 284576, 284577, 284578, 284579, 284580, 284581, 284582, 284583, 284584, 284585, 284586, 284587, 284588, 284589, 284590, 284591, 284592, 284593, 284594, 284595, 284596, 284597, 284598, 284599, 284600, 284601, 284602, 284603, 284604, 284605, 284606, 284607, 284608, 284609, 284610, 284611, 284612, 284613, 284614, 284615, 284616, 284617, 284618, 284619, 284620, 284621, 284622, 284623, 284624, 284625, 284626, 284627, 284628, 284629, 284630, 284631, 284632, 284633, 284634, 284635, 284636, 284637, 284638, 284639, 284640, 284641, 284642, 284643, 284644, 284645, 284646, 284647, 284648, 284649, 284650, 284651, 284652, 284653, 284654, 284655, 284656, 284657, 284658, 284659, 284660, 284661, 284662, 284663, 284664, 284665, 284666, 284667, 284668, 284669, 284670, 284671, 284672, 284673, 284674, 284675, 284676, 284677, 284678, 284679, 284680, 284681, 284682, 284683, 284684, 284685, 284686, 284687, 284688, 284689, 284690, 284691, 284692, 284693, 284694, 284695, 284696, 284697, 284698, 284699, 284700, 284701, 284702, 284703, 284704, 284705, 284706, 284707, 284708, 284709, 284710, 284711, 284712, 284713, 284714, 284715, 284716, 284717, 284718, 284719, 284720, 284721, 284722, 284723, 284724, 284725, 284726, 284727, 284728, 284729, 284730, 284731, 284732, 284733, 284734, 284735, 284736, 284737, 284738, 284739, 284740, 284741, 284742, 284743, 284744, 284745, 284746, 284747, 284748, 284749, 284750, 284751, 284752, 284753, 284754, 284755, 284756, 284757, 284758, 284759, 284760, 284761, 284762, 284763, 284764, 284765, 284766, 284767, 284768, 284769, 284770, 284771, 284772, 284773, 284774, 284775, 284776, 284777, 284778, 284779, 284780, 284781, 284782, 284783, 284784, 284785, 284786, 284787, 284788, 284789, 284790, 284791, 284792, 284793, 284794, 284795, 284796, 284797, 284798, 284799, 284800, 284801, 284802, 284803, 284804, 284805, 284806, 284807, 284808, 284809, 284810, 284811, 284812, 284813, 284814, 284815, 284816, 284817, 284818, 284819, 284820, 284821, 284822, 284823, 284824, 284825, 284826, 284827, 284828, 284829, 284830, 284831, 284832, 284833, 284834, 284835, 284836, 284837, 284838, 284839, 284840, 284841, 284842, 284843, 284844, 284845, 284846, 284847, 284848, 284849, 284850, 284851, 284852, 284853, 284854, 284855, 284856, 284857, 284858, 284859, 284860, 284861, 284862, 284863, 284864, 284865, 284866, 284867, 284868, 284869, 284870, 284871, 284872, 284873, 284874, 284875, 284876, 284877, 284878, 284879, 284880, 284881, 284882, 284883, 284884, 284885, 284886, 284887, 284888, 284889, 284890, 284891, 284892, 284893, 284894, 284895, 284896, 284897, 284898, 284899, 284900, 284901, 284902, 284903, 284904, 284905, 284906, 284907, 284908, 284909, 284910, 284911, 284912, 284913, 284914, 284915, 284916, 284917, 284918, 284919, 284920, 284921, 284922, 284923, 284924, 284925, 284926, 284927, 284928, 284929, 284930, 284931, 284932, 284933, 284934, 284935, 284936, 284937, 284938, 284939, 284940, 284941, 284942, 284943, 284944, 284945, 284946, 284947, 284948, 284949, 284950, 284951, 284952, 284953, 284954, 284955, 284956, 284957, 284958, 284959, 284960, 284961, 284962, 284963, 284964, 284965, 284966, 284967, 284968, 284969, 284970, 284971, 284972, 284973, 284974, 284975, 284976, 284977, 284978, 284979, 284980, 284981, 284982, 284983, 284984, 284985, 284986, 284987, 284988, 284989, 284990, 284991, 284992, 284993, 284994, 284995, 284996, 284997, 284998, 284999, 285000, 285001, 285002, 285003, 285004, 285005, 285006, 285007, 285008, 285009, 285010, 285011, 285012, 285013, 285014, 285015, 285016, 285017, 285018, 285019, 285020, 285021, 285022, 285023, 285024, 285025, 285026, 285027, 285028, 285029, 285030, 285031, 285032, 285033, 285034, 285035, 285036, 285037, 285038, 285039, 285040, 285041, 285042, 285043, 285044,

Tel : 283650
Telefax : 08370-283651
Email : elegant@bsnl.in

ELEGANT DRUGS PVT. LTD.
PHARMACEUTICAL MANUFACTURERS

Manufacturing Unit : R. S. No. 59/3A, HUBLI-KARWAR HIGHWAY,
CHALMATTI - 581 196.
(Dist : Dharwad, Taluk : Kalghatagi, State : Karnataka)

Ref. No.MISC/EDPL/028/16-17

Date : 17.06.2016

TO WHOM SO EVER IT MAY CONCERN

This is to certify that **Mis.MANJULA CHIKKAMATH KUMARSWAMY**, student of **COLLEGE OF PHARMACY, VIDYANAGAR, HUBLI** has successfully completed **15 days (50 hours)** in plant training in our organization between **01.06.2016 to 15.06.2016**. She has worked in all departments related to **Tablets & Capsules**.

Her conduct and performance during above period was found to be satisfactory.


This Certificate is issued to **Ms. MANJULA CHIKKAMATH KUMARSWAMY**, only to complete the formalities of the academic course.


We wish all the best for her future.

Thanking you,

Yours faithfully,

For **ELEGANT DRUGS PVT.LTD.,**


Rajashekar C.Pattanshetty
(Managing Director)


**PRINCIPAL, KLE UNIVERSITY'S
COLLEGE OF PHARMACY
HUBLI.**



ATTESTED



Corporate Offices

New Cotton Market, HUBLI - 580 029, (Karnataka)

Tel : 2252877 / 2252878, Fax : 0836-2253386, Email : elegant@bsnl.in

CamScanner

Prof. Dr. V.A.KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

352

Tel : 283650
Fax : 08370-283651
Mail : elegant@bsnl.in

ELEGANT DRUGS PVT. LTD.
PHARMACEUTICAL MANUFACTURERS

Manufacturing Unit : R. S. No. 59/3A, HUBLI-KARWAR HIGHWAY,
CHALMATTI - 581 196.
(Dist : Dharwad, Taluk : Kalghatagi, State : Karnataka)

Ref. No.MISC/EDPL/027/16-17

Date : 17.06.2016

TO WHOM SO EVER IT MAY CONCERN

This is to certify that Ms.PRATIBHA HUDED MALLAPPA, student of COLLEGE OF PHARMACY, VIDYANAGAR, HUBLI has successfully completed 15 days (50 hours) in plant training in our organization between 01.06.2016 to 15.06.2016. She has worked in all departments related to Tablets & Capsules.

Her conduct and performance during above period was found to be satisfactory.

This Certificate is Issued to Ms. PRATIBHA HUDED MALLAPPA, only to complete the formalities of the academic course.

We wish all the best for her future.

Thanking you,


Yours faithfully,

For ELEGANT DRUGS PVT.LTD.,


Rajashekar C.Pattanshetty

(Managing Director)




PRINCIPAL, KLE UNIVERSITY'S
COLLEGE OF PHARMACY
HUBLI

ATTESTED



Corporate Offices
New Cotton Market, HUBLI - 580 029. (Karnataka)
Tel: 2252057, 2250108, Fax: 0837-2253386, Email: elegant@bsnl.in

CamScanner

Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

353



Prajna Biosciences Pvt. Ltd.

Center for Technology Entrepreneurship
BVD College of Engineering & Technology, Hubli - 580 031, Karnataka, India.

Cell: +91 9686145135 Email: vineeth@prajna.bio.com Web: www.prajna.bio.com

80
Dr. P. S. Patil
to Director

Ref:

Date:

To

The Principal

KLE University's College of Pharmacy
Hubballi-580031.

OFFICE OF THE PRINCIPAL
K.L.E.S. COLLEGE OF PHARMACY
VIDYANAGAR HUBBALLI-58

Date 23/06/2016

Inward No. 130

Date: 22/06/2016

Sir,

SUB: Request for Development of Product Formulation

This is to bring to your kind notice that Prajna Biosciences, Hubballi has developed a product based on Microbial Consortium for environmental applications. The present formulation is in the form of liquid preparation and we need to formulate it into solid form (cake form / compact form). Hence we request your kind self to extend your technical expertise through faculty to develop an effective formulation.

We abide by the rules and regulations of KLE University and KLE Society.

Kindly do the needful.

Thanks and Regards,

Mr. Vineeth A. Shettar

Managing Director

Prajna Biosciences Pvt Ltd

Vidyanagar, Hubballi-580031.

ATTESTED

Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

354



Memorandum of Understanding

Between

KLE University's College of Pharmacy, Hubli

And

Agastya International Foundation's Science Center, Hubli

KLE University's College of Pharmacy is one amongst the many successful ventures of K.L.E. Society, which has a reputation for pioneering in pursuit of academic excellence. The college has achieved laurels worthy of creators and it is continuously striving for higher ground. It has gained appreciation from the top recognizing centers in India like: Pharmacy Council of India, All India Council for Technical Education and Government of Karnataka. College has the series of courses aimed at developing the best of pharma professionals. The courses are: B.Pharm, M.Pharm and Ph.D. For more details about College kindly follow the link <http://www.klescoph.org/>.

Agastya is a Non-profit, public charitable educational trust doing trans-formative work in grassroots education. Our mission is to **spark curiosity, creativity and innovation** through hands-on science, art and ecology. Today, we operate over **85 mobile labs and 40 science centers in 13 states** of India. We've reached over **4 million children and 200,000 teachers** through programs that impact attitudes to learning. For more details about Agastya kindly follow the link <http://www.agastya.org/>.

Understanding & recognizing need for the **resource collaboration** for the academic year 2014-2015, between KLE University's College of Pharmacy & Agastya International Foundation, to support Agastya team and networks schools & community through various capacity building activities, sharing Research labs for testing & Analyzing various R & D (Research & Development), PBL (Project Based Learning) activities. Here by declaring that Agastya International Foundation is collaborating with KLE University's College of Pharmacy, Hubli to bring a vital change in the society.

Professors and Resource persons of KLE University's College of Pharmacy can support Agastya team in building knowledge, lab development, awareness activities, focussed on health & hygienity for Govt' school students studying between 5-10th Std'. In turn this collaboration will bring long lasting change in popularizing science and innovation among students, teachers and community.

The activities planned are as follows:

- ✓ Health & hygienic activities; Conducting sessions to the school children and different communities
- ✓ Environmental activities; celebration of important days/special days.

ATTESTED



Prof. Dr. V.A.KOTHIWALE Scanned with CamScanner
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI



- ✓ Awareness campaigns for the community; conducting jathas (Processions) on various special days.
- ✓ Research based programs; supporting in making effective models like for IRIS, DFC, Google science fairs, NIF etc.
- ✓ Lab development; in setting up such as Chemistry and Biology labs.
- ✓ Herbal gardens; Creating at selected schools.
- ✓ Awareness classes on Nutrition & safe use of drugs; for the staff, school children & communities.
- ✓ Career counseling in regards to Pharmacy; For selected students of different High schools

The role of KLE University's College of Pharmacy as first party,

- Organizing a community programs,
- Sharing resources either knowledge or skills,
- Providing laboratories for testing & analyzing the data for R & D projects,
- Assisting for the lab set up such as Chemistry & Botany, herbal garden...
- Providing space for the students to interact with their RPs,
- Organizing career counseling for our students,

And

The role of Agastya International Foundation as second party,

- Getting permissions from educational authorities for organizing the programs,
- Providing platform for organizing school & community programs,
- Building linkage between community & their RPs and students,
- Mobilizing resources such as man power, vehicles, science experiments & other materials for conducting programs,

No financial commitments on either side apart from conducting activities for the school children, staff and community.

The Principal,



KLE University's College of Pharmacy,
Vidyanagar, Hubli - 580031

For



Mr. Anil Joshi
Program Manager, NK Operations
Agastya International Foundation
Vidyanagar, Hubli - 580031

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

Scanned with CamScanner



Memorandum of Understanding

Between

KLE University's College of Pharmacy, Hubli

And

Agastya International Foundation's Science Center, Hubli

KLE University's College of Pharmacy is one amongst the many successful ventures of K.L.E. Society, which has a reputation for pioneering in pursuit of academic excellence. The college has achieved laurels worthy of creators and it is continuously striving for higher ground. It has gained appreciation from the top recognizing centers in India like: Pharmacy Council of India, All India Council for Technical Education and Government of Karnataka. College has the series of courses aimed at developing the best of pharma professionals. The courses are: B.Pharm, M.Pharm and Ph.D.. For more details about College kindly follow the link <http://www.klescoph.org/>.

Agastya is a Non-profit, public charitable educational trust doing trans-formative work in grassroots education. Our mission is to **spark curiosity, creativity and innovation** through hands-on science, art and ecology. Today, we operate over **85 mobile labs and 40 science centers in 13 states** of India. We've reached over **4 million children and 200,000 teachers** through programs that impact attitudes to learning. For more details about Agastya kindly follow the link <http://www.agastya.org/>.

Understanding & recognizing need for the **resource collaboration** for the academic year 2014-2015, between KLE University's College of Pharmacy & Agastya International Foundation, to support Agastya team and networks schools & community through various capacity building activities, sharing Research labs for testing & Analyzing various R & D (Research & Development), PBL (Project Based Learning) activities. Here by declaring that Agastya International Foundation is collaborating with KLE University's College of Pharmacy, Hubli to bring a vital change in the society.

Professors and Resource persons of KLE University's College of Pharmacy can support Agastya team in building knowledge, lab development, awareness activities, focussed on health & hygienity for Govt' school students studying between 5-10th Std'. In turn this collaboration will bring long lasting change in popularizing science and innovation among students, teachers and community.

The activities planned are as follows:

- ✓ Health & hygienic activities; Conducting sessions to the school children and different communities
- ✓ Environmental activities; celebration of important days/special days.

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

Scanned with CamScanner



- ✓ Awareness campaigns for the community; conducting jathas (Processions) on various special days.
- ✓ Research based programs; supporting in making effective models like for IRIS, DFC, Google science fairs, NIF etc.
- ✓ Lab development; in setting up such as Chemistry and Biology labs.
- ✓ Herbal gardens; Creating at selected schools.
- ✓ Awareness classes on Nutrition & safe use of drugs; for the staff, school children & communities.
- ✓ Career counseling in regards to Pharmacy; For selected students of different High schools

The role of KLE University's College of Pharmacy as first party,

- Organizing a community programs,
- Sharing resources either knowledge or skills,
- Providing laboratories for testing & analyzing the data for R & D projects,
- Assisting for the lab set up such as Chemistry & Botany, herbal garden...
- Providing space for the students to interact with their RPs,
- Organizing career counseling for our students,

And

The role of Agastya International Foundation as second party,

- Getting permissions from educational authorities for organizing the programs,
- Providing platform for organizing school & community programs,
- Building linkage between community & their RPs and students,
- Mobilizing resources such as man power, vehicles, science experiments & other materials for conducting programs,

No financial commitments on either side apart from conducting activities for the school children, staff and community.

The Principal,



KLE University's College of Pharmacy,
Vidyanagar, Hubli - 580031

For,


26-8-14
Mr. Anil Joshi

Program Manager, NK Operations
Agastya International Foundation
Vidyanagar, Hubli - 580031

ATTESTED



Prof. Dr. V.A. KOTHIWALE Scanned with CamScanner
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI



KLE UNIVERSITY

(Formerly known as KLE Academy of Higher Education & Research)
[Declared as Deemed-to-be-University w/s 3 of the UGC Act, 1956 vide Government of India Notification No.F.9-19/2000-U.3(A)]
Accredited by NAAC Placed in Category 'A' by MHRD (GoI)

ಕೆ.ಎಲ್.ಇ ವಿಶ್ವವಿದ್ಯಾಲಯ

(ಕೆ.ಎಲ್.ಇ, ಎಕ್ಯಾಡಮಿ ಆಫ್ ಹೈಯರ್ ಎಜ್ಯುಕೇಶನ್ ಆಂಡ್ ರಿಸರ್ಚ್ ಎಂದು ಮುಂಚೆ ಗುರುತಿಸಿದ)
ಭಾರತ ಸರ್ಕಾರದ ಅಧಿಸೂಚನೆ ಶ್ರೀ ಎನ್.ಎ-೧೯/೨೦೦೦-ಮು.೩ (ಎ) ರನ್ವಯ ೧೯೫೬ರ ವಿ.ಭ.ಆ.ಕಲಂ ೩ರಡಿ ಸ್ವಾಯತ್ತ ವಿಶ್ವವಿದ್ಯಾಲಯವೆಂದು ಘೋಷಿಸಲ್ಪಟ್ಟಿದೆ
ಸ್ವಾತಂತ್ರ್ಯದ 'ಎ' ಶ್ರೇಣಿ ಮಾನ್ಯತೆ ಪಡೆದ ಮಾ.ಸಂ.ಅ.ಸ (ಭಾರತ ಸರ್ಕಾರ) ದಿಂದ 'ಎ' ವರ್ಗ ದಲ್ಲಿ ಸ್ಥಾನೀಕರಿಸಲಾಗಿದೆ

Ref. No.KLEU/14-15/D-2432

9th October 2014

CIRCULAR

Sub: MoU between the KLE University and Sinhgad Technical Education Society (STES), Pune.

It is hereby informed that the KLE University has signed Memorandum of Understanding (MoU) with Sinhgad Technical Education Society, Pune.

The contents of this Circular be brought to the notice of all the faculty members, Post-Graduate students, Course Co-ordinators of Allied Health Sciences of your Institution and Ph.D. Research Scholars of the University. A copy of each of the MoUs signed is enclosed herewith for information.



V.D. Patil
Prof. Dr. V.D.Patil
Registrar

To

The Principals,
KLE College of Pharmacy,
Belgaum / Hubli / Bengaluru.

The Professor and Head,
University Department of Allied Health Sciences,
Belgaum.

CC to:

1. The PA to Hon. Chancellor, KLE University, Belgaum.
2. The Special Officer to Hon. Vice-Chancellor, KLE University, Belgaum.
3. The Director, KLES Health Science Institutions, Belgaum.
4. The Director, KLE University Research Foundation, Belgaum.
5. The Director, Academic Affairs, KLE University, Belgaum.
6. The Deputy Director, KLE Dr. PK B&ASRC, Belgaum.

Manoj
Patil

ಜಿಎನ್‌ಎಸ್ ಆವರಣ, ನೆಹರು ನಗರ, ಬೆಳಗಾವಿ - ಪಿಒ ೦೧೦, ಕರ್ನಾಟಕ ರಾಜ್ಯ, ಭಾರತ JNMC Campus, Nehru Nagar, Belgaum-590 010, Karnataka State, India
:: 0831-2444444 / 2493779 FAX No. : 0831-2493777 Web : <http://www.kleuniversity.edu.in> E-mail : info@kleuniversity.edu.in

ATTESTED

V.A. Kothiwale

Prof. Dr. V.A.KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

359

The KLE University (KLEU), Belgaum, Karnataka, India and STES, recognize the benefits to their respective Universities from the establishment of collaborations and proceed to have a Memorandum of Understanding (MoU). Both the independent institutions are committed to mutual and common goals of generating new knowledge towards improvement of science to betterment of the society we serve.

PREAMBLE:

KLE Society established in the year 1916 is successfully running more than 239 institutions in the field of healthcare (Medical, Dental, Pharmacy, Ayurveda, Physiotherapy and Nursing science, Information Technology, law and many more conventional and non-conventional disciplines. Currently KLE University has been accredited A-Grade by NAAC (National Academic Accreditation Council-India).


Sinhgad Technical Education Society is a leading organization in Pune specialized in technical education. STES is well known in providing high quality education in the fields of Engineering, Technology, Architecture, Pharmacy, Science, commerce, and also school education. The Department of Biotechnology is part of Sinhgad College and it is affiliated to University of Pune and approved by AICTE.

STES and KLE jointly recognize this MoU to mutually cooperate in the Education and Research of areas of mutual interest such as Biotechnology and Health Sciences i.e. Dental, Medical, Pharmacy, Nursing, Physiotherapy & other allied Health Sciences.

PURPOSE/OBJECTIVE

The primary purpose of this MoU is to build academic research capacity and to promote mutual understanding between the universities. The MoU shall formally set out the terms of co-operative relationship between the parties, establish their respective roles, and facilitate the function of each party in relation to collaborative research.

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

Both Universities agree to develop collaborative activities in academic areas of mutual interest and as equal partners with reciprocity. All educational events are expected to reflect the faculty member's area of research and expertise.

The development and implementation of specific activities based on this MoU shall be negotiated and agreed between individual faculty members through the Deans or Heads of Department.

This MoU is agreed on the basis of cooperation between the Universities and includes, but is not limited to the following options.

- a. Exchange of faculty members and research scholars between the Universities.
 - b. Exchange of students based on the projects and research needs.
 - c. Jointly apply for research funds to conduct collaborative research projects.
 - d. Conducting colloquiums.
 - e. Exchange of academic/research information and related materials to facilitate joint publications by collaborating faculty members.
- Promoting any related academic activities based on mutual agreement.



TERMS OF AGREEMENT

Both universities agree to carry out the above mentioned activities in accordance with laws and regulations of respective university after full consultation and approvals.


The term of this agreement shall be valid for a period of three years commencing from the date of signature hereto. This agreement can be extended for further terms on mutual agreement. This agreement may be terminated by giving 6 months prior notice from either parties.

ATTESTED

Prof. Dr. V.A.KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

In witness whereof, the parties have executed this documented on the day of _____




[Handwritten signature]

Dr. V.D. Patil
Registrar
KLE University
Belgaum
Karnataka

[Handwritten signature]


Prof. M.N. Navale
Hon. President
Sinhgad Technical Education Society
Pune
Maharashtra.



Witness:

[Handwritten signature]


Dr. B.S. Kodkany
Emeritus Professor & Director
KLE University
Research Foundation



[Handwritten signature]

Dr. S.D. Lokhande
Principal
Sinhgad College of Engineering
Vajrapada (A.K.) Pune-411041.

ATTESTED BY
[Signature]
ASHOK MARUTRAO GALANDE
NOTARY
GOVT. OF INDIA



27 AUG 2016
Dr. Prasad ...
Research ...
ENBRC

ATTESTED

[Handwritten signature]

Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI



KLE UNIVERSITY

(Formerly known as KLE Academy of Higher Education & Research, Belgaum)

[Declared as Deemed-to-be-University w/s 3 of the UGC Act, 1956 vide Government of India Notification No F 9-19/2000-U 3 (A)]

Accredited 'A' Grade by NAAC

Placed in Category 'A' by MHRD (GoI)

Office of the Registrar, KLE University,

JNNIC Campus, Nehru Nagar, Belgaum-590 010, Karnataka State, India

☎: 0831-2444444 FAX: 0831-2493777 Web: <http://www.kleuniversity.edu.in> E-mail: info@kleuniversity.edu.in

Ref. No. KLEU/14-15/D-11763.

22nd July 2014

CIRCULAR

Sub: MoU between the KLE University and Manipal University, Manipal.

It is hereby informed that the KLE University has signed a Memorandum of Understanding (MoU) with Manipal University, Manipal. A copy of the MoU is enclosed herewith for your information.

The contents of this Circular be brought to the notice of all the faculty members, Post-Graduate students, Course Co-ordinators of Allied Health Sciences of your Institution and Ph.D. Research Scholars of the University..



Prof. Dr. V.D. Patil
Registrar

To

The Principals,
All Constituent Units,
KLE University,
Belgaum.

CC to:

1. The PA to Hon. Chancellor, KLE University, Belgaum.
2. The Special Officer to Hon. Vice-Chancellor, KLE University, Belgaum.
3. The Secretary, Board of Management, KLE Society, Belgaum.
4. The Director, KLES Health Science Institutions, Belgaum.
5. The Director, KLE University Research Foundation, Belgaum.
6. The Professor & HoD, University Dept. of Allied Health Sciences, Belgaum.
7. The MD & CE, KLE Dr. PK Hospital & MRC, Belgaum.
8. The Medical Superintendent, KLE Dr. PK Charitable Hospital, Belgaum.
9. The University Officials.
10. The Deputy Director, KLE Dr. PK B&ASRC, Belgaum.

BSRC/2014/122

ATTESTED

Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

363

AND

KLE University, herein represented by
Registrar, KLE University
A deemed University under u/s 3 of the UGC Act 1956 vide Government of India notification
No. 9-19/2000-U.3A
Belgaum, Karnataka, India

The KLE University (KLEU), Belgaum, Karnataka, India and Manipal University Manipal, Karnataka, recognize the benefits to their respective Universities from the establishment of collaborations and proceed to have a memorandum of understanding (MoU). Both the independent institutions are committed to mutual and common goals of generating new knowledge towards improvement of science to betterment of the society we serve.

PREAMBLE:

KLE Society established in the year 1916 is successfully running more than 239 institutions in the field of healthcare (Medical, Dental, Pharmacy, Ayurveda, Physiotherapy and Nursing science), Information Technology, Law and many more conventional and non-conventional disciplines. Currently KLE University has been accredited A -Grade by NAAC (National Academic Accreditation Council- India).


Manipal University is providing education, training and also conducting research in the field of Medicine, Pharmacy, Dentistry, Allied Health, Engineering, Information Sciences, Nursing, Media & communication, Management, Jewellery Management, Life Sciences, Hotel Management, Regenerative Medicine etc.

The respective Universities jointly recognize this MoU to mutually cooperate in the area of Health Education and Research including allied health sciences

PURPOSE / OBJECTIVE

The primary purpose of this MoU is to build academic research capacity and to promote mutual understanding between the Universities. The MoU shall formally set out the terms of co-operative relationship between the parties, establish their respective roles, and facilitate the function of each party in relation to collaborative research.

Both Universities agree to develop collaborative activities in academic areas of mutual interest and as equal partners with reciprocity. All educational events are expected to reflect the faculty member's area of research and expertise



2

ATTESTED

Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

364

The development and implementation of specific activities based on this MoU shall be negotiated and agreed between individual faculty members through the Deans or Heads of Department.

This MOU is agreed on the basis of cooperation between the Universities and includes, but is not limited to the following options


- a. Exchange of faculty members and research scholars between the Universities
- b. Exchange of students based on the projects and research needs
- c. Jointly apply for research funds to conduct collaborative research projects
- d. Conducting colloquiums
- e. Exchange of academic/research information and related materials to facilitate joint publications by collaborating faculty members
- f. Promoting any related academic activities based on mutual agreement

TERMS OF AGREEMENT


Both universities agree to carry out the above mentioned activities in accordance with laws and regulations of respective countries after full consultation and approvals.

The term of this agreement shall be valid for a period of three years commencing from the date of signature hereof. This agreement can be extended for further terms on mutual agreement. This agreement may be terminated by giving 6 months prior notice from either parties.

In witness whereof, the parties have executed this documented on the day of 12th July, 2014.



.....
Dr. V. D. Patil
Registrar
KLE University
Belgaum, Karnataka
India





.....
Dr. G. K. Prabhu
Registrar
Manipal University
Manipal, Karnataka,
India


REGISTRAR
MANIPAL UNIVERSITY
MANIPAL

Witness:


.....
Dr. B.S. Kodkany
Emeritus Professor and Director
KLE University Research Foundation
Belgaum, Karnataka, India


.....
Dr. N. Udupa
Professor and Research Director
School of Allied Health Science
Manipal University, Karnataka, India

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI





सत्यमेव जयते

INDIA NON JUDICIAL Government of Karnataka

e-Stamp

Certificate No. : IN-KA97144430181613N
 Certificate Issued Date : 22-Jul-2015 11:03 AM
 Account Reference : NONACC (FI)/ kasfinc01/ BANGALORE/ KA-BA
 Unique Doc. Reference : SUBIN-KAKASFINC0143359202469422N
 Purchased by : LOTUS LABS PVT LTD
 Description of Document : Article 12 Bond
 Description : AGREEMENT
 Consideration Price (Rs.) : 0
 (Zero)
 First Party : DR SMITHA K S
 Second Party : LOTUS LABS PVT LTD
 Stamp Duty Paid By : LOTUS LABS PVT LTD
 Stamp Duty Amount(Rs.) : 100
 (One Hundred only)



-----Please write or type below this line-----

CLINICAL TRIAL AGREEMENT

THIS AGREEMENT FOR "CLINICAL TRIAL" ("Agreement") is made and entered into this 24th day of July by and among Dr. Smitha KS, "KLES Dr. Prabhakar Kore Hospital and Medical Research Centre, Nehrunagar, Belgaum-590010. Karanataka, India" (hereinafter referred to as the "Principal Investigator" or "PI")

AND

KLE'S Dr. Prabhakar Kore Hospital and Medical Research Centre, Nehrunagar, Belgaum-590010. Karanataka, India herein after called the "Institution" (which expression shall wherever the context so admits include its successor and assignees) of the second part

Clinical Trial Agreement

ATTESTED



Page 1 of 24

1. The authenticity of the Stamp Certificate should be verified at www.shoestamp.co. Any discrepancy in the Stamp Certificate should be reported to the Registrar immediately.
 2. The validity of the Stamp Certificate is for a period of 30 days from the date of issue.
 3. The validity of the Stamp Certificate is for a period of 30 days from the date of issue.

Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

366

AND

CMS clinical research Pvt. Ltd, # 51, 3rd Floor, Paigah Colony, S P Road, Secunderabad—500003, Telangana, INDIA (SMO) (herein after called as "Site Management Organisation" which expression shall wherever the context so admits include its successor and assignees) of the Third Part

AND

Lotus Labs Pvt. Ltd, a company incorporated under the Companies Act, 1956 of India having its registered Office at No. 7, Jasma Bhavan Road, Millers Tank Bed Area, Opp. Gurunanak Bhavan, Vasanthnagar, Bangalore – 560 052, India ; and include its successors and assignees (hereinafter referred to as "Lotus") representing the interests of Sponsor Watson Pharma Pvt. Ltd., (hereinafter referred to as "Sponsor") in connection with conduct of clinical trial "An Open Label, Randomized, Multicentric, Two Treatment, Single Dose, Parallel Group Two Stage Adaptive Design Bioequivalence Study Of Loteprednol Etabonate Ophthalmic Suspension, 0.5 % In Aqueous Humor Of Patients Undergoing Indicated Cataract surgery." ("Study") bearing the protocol/study number: WAT/LTPNL/2015 ("Protocol") attached hereto as Exhibit A.

PI, Institution and Lotus hereinafter are individually referred to as "the Party" and are jointly referred to as "the Parties".

WHEREAS:

1. Sponsor is a pharmaceutical company and had engaged the services of Lotus for execution of a clinical trial in India.
2. Lotus is in the business of providing contract research services and has necessary infrastructure and facilities to provide such services for the clinical trial and in turn desires to engage the services of the Institution to conduct/assist in such a trial;
3. Institution represents that it has qualified personnel and adequate facilities and equipment to competently conduct the Study and is desirous of rendering such services upon such terms and conditions as envisaged below.
4. Institution and PI desires to engage SMO to provide qualified manpower services as required for conducting the clinical study under this agreement and rendering such services upon such terms and condition set forth herein.
5. SMO is a site management organization has qualified and trained personnel to competently conduct the Study and is desirous of rendering such services upon such terms and conditions as envisaged below.
6. SMO hereby agrees to provide its services in connection with the clinical trial and as per the approved study protocol and the terms and conditions set forth therein.

1. Provision of Services
- 1.1 Scope of Work.

Clinical Trial Agreement

KL

ATTESTED

[Handwritten signature]



Prof. Dr. V.A.KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

Page 2 of 24

[Handwritten signature]

367

The Study to be performed under this Agreement shall be performed in accordance with the terms of the final Protocol, including as it may be amended in accordance with the terms of this Agreement, for the Study. Institution and Principal Investigator agree that all aspects of the Study will be conducted in conformity with all applicable laws and regulations, the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice: Consolidated Guideline ("ICH Guideline,) and applicable requirements of the United States Food and Drug Administration ("FDA"). Institution and Principal Investigator further agree not to conduct any research activities with the Study Drug (as such term is defined below), which are contrary to the provisions of the Protocol or outside the scope of the Protocol.

Institution shall use best efforts to enrol up to 30 study participants capable of being evaluated and having analyzable data in the treatment portion of the Study, within 06 months of receipt of investigational supplies. The enrolment period may be extended or shortened at the sole discretion of Sponsor at any time.

1.2 Principal Investigator.

Institution shall appoint [Dr. Smitha KS] as Principal Investigator having the requisite education, experience and expertise to competently perform the Study according to the terms and conditions as hereafter set forth, and that said Principal Investigator shall act as representative of the Institution for medical and scientific matters arising under this Agreement. Principal Investigator will be responsible for the direction and supervision of all Study efforts in accordance with applicable Institution policies, the Protocol and this Agreement. Principal Investigator and Institution will ensure that any sub-investigators and any other staff comply with the terms of this Agreement and the Protocol. In the event that Principal Investigator leaves or is removed from the Institution, then institution shall, within ten (10) days of such departure by Principal Investigator, provide written notice of such event to Lotus and Sponsor. Any successor to Principal Investigator must be approved, in writing, by Lotus and Sponsor and such successor shall be required to agree to all the terms and conditions of the Protocol and this Agreement and to sign each such document as evidence of such agreement (although failure to so sign will not relieve such successor from abiding with the terms and conditions of the Protocol and this Agreement).


Institution and Principal Investigator represent and warrant that they will not use in any capacity, in connection with any services to be performed under this Agreement, any individual who has been debarred pursuant to any applicable laws or regulations, including debarments under the United States Federal Food, Drug and Cosmetic Act, or exclusion from a United States federal healthcare program.

Institution and Principal Investigator agree to immediately inform Lotus and Sponsor in writing if any person who is performing services hereunder is debarred or if any action, suit, claim, investigation or legal or administrative proceeding is pending, or, to the best of their knowledge, is threatened, relating to the debarment of Institution or any person performing services hereunder. Principal Investigator represents and

Clinical Trial Agreement



ATTESTED




Prof. Dr. V.A. KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI



Page 3 of 24



warrants that no action, suit, claim investigation or legal or administrative proceeding is pending or threatened relating to Principal Investigator's debarment and Principal Investigator agrees to immediately inform Lotus and Sponsor in writing if any such action, suit, claim, investigation or legal or administrative proceeding is threatened or commenced for Principal Investigator's debarment.

Details of Principal Investigator's responsibilities are set forth in the Protocol and on Exhibit A attached hereto.

1.3 SMO (Site Management Organisation)

SMO will provide the manpower services like clinical research co-ordinator(s) (hereinafter "co-ordinators") for clinical study. Such number of co-ordinators will be appointed by the institution and PI as and when required for the clinical study. All such co-ordinators will perform their services under the direction and supervision of the Institution and PI. The consultant will provide the number and details of the co-ordinators appointed for clinical study to the sponsor/Lotus.

1.4 Lotus will provide the PI with all the information, documents, and materials which, in Lotus' reasonable opinion, are required in order to carry out activities in a clinical trial.

Lotus transfers the obligations, explicitly detailed in Exhibit A to this Agreement, for this clinical study to the PI and the PI accepts the same and shall diligently carry them out along with other obligations under this Agreement. The PI will take all reasonable steps to ensure that personnel used to perform his/her obligations under this Agreement are appropriately trained and qualified.

1.5 Records and Reports.

Principal Investigator and Institution shall have the following record keeping and reporting obligations:

- (i) preparation and maintenance of complete, accurately written records, accounts, notes, reports and data relating to the Study under this Agreement; and
- (ii) preparation and submission to Lotus and Sponsor (in a periodic and timely manner during the term of this Agreement) of all raw data and other material called for in the Protocol in the form of properly completed patient case report forms ("Case Report Forms") or into an electronic database (i.e., remote data entry) supplied by Sponsor for each patient as provided in the Protocol. Case Report Forms and the electronic database shall be the exclusive property of Sponsor.

Principal Investigator and Institution agree to notify Sponsor and Lotus within one day after learning of any serious and/or unexpected adverse drug reaction affecting any patient in the Study. Principal Investigator and Institution further agree to follow up such notification of adverse drug reaction with appropriate reports in compliance with the Protocol and all applicable legal and regulatory requirements. In the event Principal Investigator and Institution become aware of any quality complaints

Clinical Trial Agreement




ATTESTED




Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI



Page 4 of 24



369

associated with the Study Drug provided under this Agreement, they agree to notify Sponsor in compliance with the Protocol.

Principal Investigator and Institution further agree to conduct the Study and maintain records and data during and after the term or early termination of this Agreement in compliance with all applicable legal and regulatory requirements, including without limitation, any applicable requirements of the FDA that are provided to Principal Investigator, local regulations, applicable GCP and per the directions of Lotus. Principal Investigator and Institution further agree to permit Sponsor or Sponsor's representatives to examine and audit all records and reports, with prior written notification from Sponsor and during normal business hours (subject to applicable patient confidentiality considerations). Principal Investigator and Institution agree to take any action necessary, as reasonably requested by Lotus and Sponsor, to properly correct or address any deficiencies noted during any audit and agree to cooperate with Lotus and Sponsor with respect to any action taken to address any such deficiencies.

Principal Investigator or Institution agree to notify Sponsor within twenty-four (24) hours in the event that the FDA or any other regulatory authority notifies the Study site of a pending inspection/audit. In addition, Principal Investigator and Institution will forward to Lotus and Sponsor any written communication received as a result of the inspection/audit within twenty-four (24) hours of receipt of such communication and agrees to allow Lotus and Sponsor to assist in responding to any citations. Such responses shall be made within two (2) weeks of issuance of any citations or within any earlier deadline set by the issuing regulatory authority. Principal Investigator and Institution shall also provide to Lotus and Sponsor copies of any documents provided to any inspector or auditor. In the event the FDA or other regulatory authority requests or requires any action to be taken to address any citations, Principal Investigator and Institution agree, after consultation with Lotus and Sponsor, to take such action as necessary to address such citations, and agree to cooperate with Lotus and Sponsor with respect to any such citation and/or action taken with respect thereto.

- 1.6 **Project Monitor and Inspection Rights.** It is agreed that the project monitor(s) and others designated by Lotus and/or Sponsor may, at mutually agreeable times during the Study and for a reasonable time after completion or early termination of the Study, arrange with Principal Investigator or his/her designee:
- (i) to examine and inspect, at regular business hours, Institution facilities required for performance of the Study; and
 - (ii) subject to applicable patient confidentiality considerations, to inspect, audit, and to copy or have copied, all data and work product relating to the Study conducted under this Agreement and to inspect and make copies of all data necessary for Lotus and Sponsor to confirm that the Study is being conducted in conformance with the Protocol and in compliance with all applicable legal and regulatory


WHL

ATTESTED

KOTHIWALE

Prof. Dr. V.A. KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI



Sudh

requirements, including without limitation, any applicable FDA requirements that Lotus and/or Sponsor has provided in writing.
Institution agrees to assist Lotus and Sponsor in order to facilitate the Lotus and Sponsor representatives' examination, inspection, auditing and copying of materials relating to the Study and in order to enforce the rights granted to Sponsor as per ICH Guidelines.

1.7 Clinical Trial Approvals.

Institution and Principal Investigator shall be responsible for obtaining the following:

- (i) approval of the Protocol, any informed consent relating to the Study and advertisement, if any, pertaining to the enrolment of subjects in the Study by the appropriate Ethics Committee ("EC") prior to beginning any Study on human subjects; and
- (ii) an informed consent which complies with all applicable laws and regulations signed by or on behalf of each human subject prior to the subject's participating in the Study. Additionally, Institution and Principal Investigator shall also obtain an audio-visual recording of the informed consent process of each Study subject while maintaining principles of confidentiality.

In the event the EC requires changes in the Protocol or informed consent, Lotus and Sponsor shall be advised in advance and all modifications to the Protocol and informed consent must be approved in advance by Sponsor. Institution and Principal Investigator shall not modify the Study described in the Protocol once finalized and after approval by the EC without the prior written approval of Sponsor.

2. Payment


- 2.1 The total fees and expenses payable by Lotus to the Institution/ SMO for the services set forth herein shall not exceed the Budget as per Exhibit B. However the payment to the SMO will be adjusted against the payment to the institution/site on a pro rata basis. The payments set forth in the budget are acknowledged by the Parties hereto to be adequate consideration for the work taken hereunder.
- 2.2 Lotus shall pay the Institution and SMO against the submission of the invoice in accordance with the terms set forth herein after deducting there from any tax as applicable.
- 2.3 Payment shall be made by account payee Cheque/ DD /NEFT only.
- 2.4 Institution agrees that, in the event of a dispute regarding Sponsor and Lotus' approval of documentation supporting costs incurred under this Agreement, data and information resulting from the Study cannot be withheld by Institution or Principal Investigator prior to the resolution of the dispute because such withholding of data may cause irreparable harm to Sponsor. The Institution further agrees to use reasonable efforts to resolve any disputes of this type in a timely manner.

3. Term


Clinical Trial Agreement



ATTESTED



Page 6 of 24



Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

This Agreement shall commence on the date of execution and shall continue until the date of payment of the last sum due hereunder or until the date when the last services required to be performed hereunder are performed, whichever date shall last occur, unless terminated earlier as provided herein.

4. Termination and Consequences of Termination

Termination:

- 4.1 Either Party may terminate this Agreement without any notice, only for subjects' safety or medical reasons.
- 4.2 Either Party may terminate this Agreement by written notice of sixty (60) days to the other Party without assigning any reason thereof and with no penalty on either side.
- 4.3 Either Party may terminate this Agreement for cause upon thirty (30) days prior written notice, provided the Party receiving such notice has neither remedied nor sufficiently explained the breach within the period specified in the notice. Notices shall be deemed delivered upon receipt by the recipient designated for each party. "Cause" shall be defined to include a material breach of this Agreement, a material violation of the Protocol, or a lack of enrolment of the stated study participant population, as described in Section 1.1.
- 4.4 Any failure by a Party to carry out all or part of its obligations under this Agreement resulting in such detriment to the other Party as to substantially deprive such other Party of what it is entitled to expect under this Agreement, shall be considered a substantial breach for the purpose of clause 4.3 above.
- 4.5 Upon receipt of a written termination notice, both the parties will work diligently, in good faith and in cooperation with each other, to conduct the orderly termination of the services set forth under this Agreement.


Consequences of Expiry or Termination:

- 4.6 Unless terminated pursuant to Section 4.3 above, upon the expiry or termination of this Agreement, Lotus shall, in accordance with the payment provisions of Clause 2, pay for all reasonable, verifiable and completed activities up to the date of actual termination. In no event will payments made by Lotus to the PI under this Agreement exceed the project costs as set forth in the Study Budget.
- 4.7 Upon expiry or termination of this Agreement, the Institution and PI shall, at Lotus' option, either immediately transfer to Lotus or destroy any or all Confidential Information, including any copies thereof, except for those materials or copies that are required by law or regulation or for archival purposes.
- 4.8 The expiry or termination of this Agreement shall not relieve any Party of its obligation to the other with respect to:

Clinical Trial Agreement




ATTESTED




Prof. Dr. V.A.KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI



Page 7 of 24



- (i) retaining in confidence all Confidential Information;
- (ii) complying with record keeping and reporting obligations;
- (iii) complying with any publication obligations and obtaining any written approval and consents for any publicity and promotional purposes;
- (iv) complying with obligations relating to clinical supplies;
- (v) indemnification and insurance obligations;
- (vi) inspection rights; and
- (vii) the obligation to assist in obtaining patent protection

all of which obligations are binding on the appropriate party and shall remain in full force and effect as set forth in this Agreement.

5. Intellectual Property Ownership, Invention & Discoveries and Publication

- 5.1 **Inventions and Patents.** The sole and exclusive right to any inventions, discoveries or innovations, whether patentable or not, arising from the performance of the Protocol and Study under this Agreement, and using Study funds or otherwise arising out of use, misuse or modification of the Study Drug provided under this Agreement (the "Inventions"), shall be the property of the Sponsor. Institution or Principal Investigator will promptly notify Sponsor in writing of any such Inventions, and at Sponsor's request and expense Institution and Principal Investigator will cause to be assigned to Sponsor all right, title and interest in and to any such Inventions and provide reasonable assistance to obtain patents, including causing the execution of any invention assignment or other documents.
- 5.2 **Data Ownership.** All case report forms and other data (including, without limitation, written, printed, graphic, video and audio material and information contained in any computer data base or computer readable form) generated by the Institution and the PI in the course of conducting the Study (the "Data") and results shall be the exclusive property of Sponsor, and Sponsor reserves the right to use the Data and results for any corporate purpose
- 5.3 The PI acknowledges that all the intellectual property rights in the Confidential Information of and belonging to Sponsor and/or Lotus which is disclosed to the PI is and shall always remain the sole and exclusive property of Sponsor and/or Lotus.
- 5.4 **Publication.** As this is a multi-center study, publications derived from this Study must include input from one or more investigators, their colleagues, Lotus and Sponsor personnel. Such input shall be reflected in publication authorship, and agreement regarding order of authors shall be established before writing a manuscript. Unless specifically approved by Sponsor, results from a single center in a multi-center study will not be submitted for publication separately before results of the multi-center study are published, unless (1) more than eighteen (18) months have elapsed since completion of the Study, and (2) the Institution provides Sponsor with a proposed manuscript for review

VAL


ATTESTED

Kille

Prof. Dr. V.A.KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI



[Handwritten signature]

and comment prior to publication. Sponsor shall complete review within sixty (60) days of receipt of a manuscript, during which time Institution shall not permit publication or presentation. Sponsor shall notify Institution of any comments, deletions or modifications requested in the proposed manuscript to protect its proprietary rights, and Institution shall make any such changes reasonably requested by Sponsor.

In the event Sponsor, pursuant to this Section elects to file one or more patent applications relating to any invention made in the course of the Study, any publications and presentations will be delayed for an additional ninety (90) days to permit the preparation and filing of such patent applications.

Subject to the publication restrictions in this Agreement, Institution shall have the right to use the results of the Study provided by Institution under this Agreement, including, but not limited to the results of tests and any raw data and statistical data generated therefrom, for its own internal teaching and research purposes.

6. Representations.

6.1 The PI hereby warrants and represents that the following are true and correct on the date of entering into this Agreement:

- (i) The PI is an individual and has the requisite qualification, legal power to enter into this Agreement and to perform his/her obligations hereunder. This Agreement, when duly executed, shall constitute the legal, valid and binding obligation on the PI and is enforceable against the PI in accordance with its terms;
- (ii) All acts and conditions required by the laws in force at the date thereof to be done, fulfilled and performed in order (i) to enable him/her lawfully to enter into this Agreement and to exercise his/her rights and perform his/her obligations under this Agreement and (ii) to make this admissible in evidence have been done, fulfilled and performed in strict compliance with the applicable laws.

7. Indemnification.

7.1 Sponsor shall indemnify, defend and hold harmless Institution, its trustees, officers, agents, employees and Principal Investigator, (and any named co-investigator) from and against any demands, claims, actions, proceedings or costs of judgments ("Claims") which may be made or instituted against any of them by reason of personal injury (including death) to any person, or damage to property, arising out of or connected with the performance of the activities to be carried out pursuant to the Protocol.

Notwithstanding the foregoing, Sponsor shall have no indemnification obligation or liability and Institution and Principal Investigator shall indemnify, defend and hold harmless Sponsor, its parent corporation, subsidiaries, affiliates, officers, directors, agents, and employees for loss or damage resulting from:

Clinical Trial Agreement

ATTESTED:

Prof. Dr. V.A.KOTHIVALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

Page 9 of 24

- (i) failure of Institution or Principal Investigator to adhere to the terms and provisions of the Protocol or agreed amendments thereto or Sponsor's written recommendations and instructions relative to the administration and use of any drug substances involved in the Study, including, but not limited to, the Study Drug, any comparative drug and any placebo;
 - (ii) failure of Institution or Principal Investigator to comply with any applicable FDA or other governmental or state requirements, law, rules, ICH Guidelines or regulations applicable to the performance of its obligations under this Agreement;
 - (iii) failure of Institution or Principal Investigator to render professional service or to conduct the Study in a normal, prudent manner; or
 - (iv) negligent act or omission or willful misconduct by Principal Investigator, Institution, its trustees, officers, agents or employees related to the performance of services under this Agreement.
- 7.2 Institution agrees to indemnify and hold Sponsor and Lotus harmless from liability for any claim, demand or lawsuit arising out of (i) the willful, reckless or negligent act or failure to act of Institution (including failure to comply with the terms of the Study Protocol), or (ii) the breach of any of the Institution's or PI's covenants or representations contained in this Agreement.
- 7.3 Institution and/or Principal Investigator shall secure and maintain in full force and effect through the performance of the Study (and following termination or early termination of the Study to cover any claims arising from the Study) insurance coverage in amounts as required by applicable legal requirements and appropriate to the conduct of Institution's and Principal Investigator's activities and the services contemplated by the Study. Upon request of Lotus or Sponsor, copies of certificates evidencing such insurance coverage will be made available to Sponsor. Institution and/or Principal Investigator shall provide thirty (30) days' prior written notice to Lotus and Sponsor in the event of cancellation or any material change in such insurance.
- 7.4 These indemnification obligations of the Parties shall only apply provided that in regards to the Claim (i) the indemnified party promptly notifies the indemnifying party of such Claim; (ii) the indemnified party allows the indemnifying party and/or its insurers the right to assume direction and control of the defense (including settlement) of any such claim, demand or lawsuit (the indemnifying party shall not admit fault on any one or all of the indemnified party's behalf without the indemnified party's advance written permission); (iii) the indemnified party cooperates fully with the indemnifying party and/or its insurers in the defense of such claim, demand or lawsuit; and (iv) the indemnified party agrees not to settle or

WAL

ATTESTED

[Signature]

Prof. Dr. V.A.KOTHIWALE
Registrar



[Signature]

compromise any claim, demand or lawsuit without prior written authorization of the indemnifying party.

8. Confidentiality

8.1 Upon execution of this Agreement a confidential relationship shall exist between Lotus, Sponsor, Institution and Principal Investigator and SMO, whereby Institution and Principal Investigator and SMO agree to hold in confidence confidential information disclosed by Lotus and/or Sponsor, in connection with the Study. As used in this Agreement "Confidential Information" shall be understood to include information disclosed by Lotus and/or Sponsor which is not in the public domain, including but not limited to: technical, scientific, market and marketing information, know-how, data, formulae, processes, plans, assessments and methods for Study Drug and/or its uses or modes of action, as well as similar information relating to any other Sponsor compound. Confidential Information shall also include all test articles and proprietary data and/or information generated pursuant to the Study, including, but not limited to the Protocol, the investigator's brochure, interim results and any other information or material disclosed under secrecy agreements previously entered into by the Parties. For purposes of this Agreement, Confidential Information supplied by Lotus and/or Sponsor to Institution shall be deemed to be in the public domain or in the possession of Institution only if the Confidential Information as a whole is in the public domain or in the prior possession of Institution.

Clinical Trial Agreement




ATTESTED



Prof. Dr. V.A.KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

Page 11 of 24



- 8.2 Confidential Information shall not be deemed to include information which: (i) is in or enters the public domain through no act or omission of Institution; (ii) is lawfully in Institution's or Principal Investigator's possession prior to disclosure, which possession can be documented through business records maintained in the ordinary course of Institution's business; (iii) is obtained by Institution or Principal Investigator from a third party having an apparent lawful right to provide such information and having no known obligation of confidentiality to Lotus or Sponsor; (iv) is independently developed by Institution personnel not privy to Lotus or Sponsor Confidential Information, as applicable, disclosed under this Agreement; or (v) is required by law to be disclosed.
- 8.3 Institution and Principal Investigator shall limit disclosure of Confidential Information received hereunder to only those of its (i) representatives, agents and officers bound by a written agreement with terms equivalent to or more stringent than this Agreement, and (ii) employees (collectively, "Agents") who are directly involved with the Study and only on a need to know basis. Institution and Principal Investigator shall advise its Agents upon disclosure to them of any Confidential Information of the proprietary nature thereof and the terms and conditions of this Agreement and shall use all reasonable safeguards to prevent unauthorized use or disclosure by such Agents. Institution and Principal Investigator shall be responsible for any breach of these confidentiality provisions by its Agents.
- 8.4 Institution and Principal Investigator acknowledge and expressly agree that any disclosure of Confidential Information in violation of this Agreement would be detrimental to Sponsor's business and cause it irreparable harm and damage. In accordance with applicable law and in addition to any other rights and remedies provided herein, Sponsor shall be entitled to seek equitable relief by way of injunction or otherwise.
- 8.5 The disclosure of Confidential Information to Institution and Principal Investigator shall not be construed in any way as a license or transfer of other rights.

9. **Miscellaneous**

9.1 **Governing Law**

This Agreement and the rights and obligations of the parties hereunder shall be governed by and construed in accordance with the laws of India.

9.2. **Arbitration**

Any dispute, controversy or claim arising out of or in connection with this agreement including any question regarding its existence, validity, interpretation or termination, shall be conclusively settled by referring the same to arbitration. The arbitration proceedings shall be conducted in the English language and be governed by the provisions of the Arbitration and Conciliation Act, 1996. The venue for arbitration proceedings shall be Bangalore.

Clinical Trial Agreement

ATTESTED



Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

Page 12 of 24

377

9.3 Force Majeure (Act of God)

In the event either Party is delayed or hindered in or prevented from the performance of any act required hereunder by reasons of restrictive government or judicial orders or decrees, riots, burglary, insurrection, war, acts of God, inclement weather or other similar reasons or causes beyond such Party's control, and such Party has exerted all reasonable efforts to avoid or remedy such event, then performance of such act shall be excused for the period of such delay (which is reasonable and consented by the other Party in writing). Notice of the start and stop of any such force majeure shall be provided to the other Party.

9.4 Record Keeping

During the term of this Agreement, PI shall maintain all materials and all other data obtained or generated by PI in the course of providing the services in a secure area reasonably protected from fire, theft and destruction.

9.5 Headings.

The headings used in this Agreement are for the sake of convenience and the same are not to be construed to define, limit or affect the construction of interpretation of this Agreement.

9.6 Publicity.

Except as required by applicable law, neither Institution nor PI shall use, or authorize others to use, the name, symbols, or marks of Sponsor in any advertising or publicity material or make any form of representation or statement in relation to the Study, which would constitute an express or implied endorsement by Sponsor of any commercial product or service without prior written approval from Sponsor.

9.7 Independent Contractors.

It is agreed by the parties that Institution and Principal Investigator are acting in the capacity of independent contractors hereunder and not as employees, agents or joint venturers of or with Sponsor. Neither Institution nor Principal Investigator shall have any authority to represent, bind or act on behalf of Sponsor. Institution represents that Principal Investigator is an employee of the Institution. Investigator acknowledges and agrees that Principal Investigator's sole recourse for compensation for his or her services, as well as the services of Principal Investigator's staff affiliated with the Study, shall be from Institution and not Watson.

9.8 Assignment.

This Agreement is, not assignable by Institution or Principal Investigator and any attempted assignment or delegation in violation hereof shall be void. Sponsor may assign this Agreement to an affiliated company without the prior consent of Institution or Principal Investigator. Notwithstanding such assignment, Sponsor shall remain liable for all of its obligations under this Agreement.

9.9 No Modifications.

Clinical Trial Agreement




ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

Page 13 of 24



Neither this Agreement nor the Protocol may be altered, amended or modified except by written document signed by the Parties.

9.10 Severability.

If any term or condition of this Agreement, the deletion of which would not adversely affect the receipt of any material benefit by a Party hereunder, shall be held illegal, invalid or unenforceable, the remaining terms and conditions of this Agreement shall not be affected thereby and such terms and conditions shall be valid and enforceable to the fullest extent permitted by law.

9.11 No Waiver.

Failure on the part of a Party to exercise or enforce any right conferred upon it hereunder shall not be deemed to be a waiver of any such right nor operate to bar the exercise or enforcement thereof at any time or times thereafter.

9.12 Compliance with Anti-Corruption Laws

- (i) PI, Institution and SMO agrees to comply with applicable anti-corruption laws such as the U.S. Foreign Corrupt Practices Act (FCPA) and the UK Bribery Act of 2010 as well as any laws implementing the U.N. Convention Against Corruption and the OECD Anti-bribery Convention (collectively, "Anti-Corruption Laws"). PI, Institution and SMO undertakes that, in connection with its performance of its obligations under this Agreement, they will not and shall not directly or indirectly (a) offer, provide, authorize for or promise to another person, or (b) request, accept or agree to accept from another person any financial or other advantage or anything of value ("Benefit"), if such Benefit is for the purpose of influencing the receiving person improperly in his or her official capacity for the purpose of obtaining a business advantage, or where such Benefit would constitute a violation of any applicable Anti-Corruption Law.
- (ii) In the event that PI, Institution and SMO is accused of or becomes subject to investigation by a governmental authority for an alleged violation of applicable Anti-Corruption Laws in connection with this Agreement, or LOTUS notifies PI and Institution that it has a reasonable basis for believing that PI, Institution and SMO has not complied with applicable Anti-Corruption Laws in connection with this Agreement (and discloses in reasonable detail the evidence underlying such belief), LOTUS shall have the right to request in writing that PI, Institution and SMO provide access to (either directly or through legal counsel or an internationally recognized independent auditor) such written records or other information reasonably required to credibly refute such alleged non-compliance.
- (iii) If, in connection with this agreement, PI and Institution breaches its obligations under Sections 9.12(i) and 9.12(ii) above or admits to a violation or is determined by a governmental authority to have violated applicable Anti-Corruption Law, then LOTUS shall be entitled to immediately terminate this Agreement upon written notice to PI, Institution and SMO

Clinical Trial Agreement



ATTESTED




Prof. Dr. V.A.KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI



Page 14 of 24



379

By signing this agreement "You are required to refer and adhere to our Business Partner Guide hosted on our website. URL for the same is http://www.lotuslabs.com/Uploads/Lotus_business_partner_guide.pdf. It gives our expectations with regard to your conduct as a Lotus Business Partner."

9.13. **Notices & Service of documents**


The notice and documents required to be given under this Agreement shall be deemed to be sufficiently given if hand delivered by one Party to the other or sent by Registered Mail with acknowledgement due.

Clinical Trial Agreement

VAK

ATTESTED

[Handwritten signature]



Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

Page 15 of 24

[Handwritten signature]













All the correspondence/ notices to be sent by the PI to Lotus shall be addressed to:

Lotus Labs Pvt. Ltd.
 No. 7, Jasma Bhavan Road,
 Millers Tank Bed Area,
 Opp. Gurunanak Bhavan,
 Vasanthnagar,
 Bangalore – 560 052
 Phone No. 080-22370982/22370912/13/14/15
 Fax No. 080-2237091

All the correspondence/ notices to be sent by Lotus to PI shall be addressed to:

Dr. Smitha KS, "KLES Dr. Prabhakar Kore Hospital and Medical Research Centre, Nehrunagar, Belgaum-590010.

For LOTUS LABS PVT LTD

	 12/08/2015	 07/08/15	
S. Hari Sankar Managing Director	Dr. Mallikarjun V. Jali Managing Director	Dr. Smitha K.S. Principal Investigator	A.V.A.Suresh Babu Director CMS Clinical Pvt. Ltd. (SMO)
Seal: 	Seal: 	Seal: 	Seal: 
Witness 	Witness 	Witness 	Witness 
Vesharesh Hegde Executive Legal	Prashant Bandari	Dr. Vishwanandra Socodia.	K. Keshavachan.

Clinical Trial Agreement


ATTESTED







Page 16 of 24



Prof. Dr. V.A.KOTHIWALE
 Registrar
 KLE Academy of Higher Education
 and Research, BELAGAVI

Exhibit A

Responsibilities of PI for

"An Open Label, Randomized, Multicentric, Two Treatment, Single Dose, Parallel Group Two Stage Adaptive Design Bioequivalence Study Of Loteprednol Etabonate Ophthalmic Suspension, 0.5 % In Aqueous Humor Of Patients Undergoing Indicated Cataract surgery." bearing the protocol / study number: WAT/LTPNL/2015.

1. PI has sufficient time, adequate staff, and appropriate facilities to conduct and complete the clinical study. PI agrees to make these resources available for the duration of the study and agrees that other studies will not divert essential subjects or facilities away from this trial.

PI assures Lotus Labs Pvt. Ltd., that no other clinical study conducted by him shall give rise to a conflict of interest or interfere with the clinical trial.

PI will endeavor to ensure an adequate recruitment rate during the clinical investigation.

2. Lotus Labs Pvt. Ltd. will furnish PI with copies of the Investigator's Brochure, the Study Plan and Protocol and agrees:
 - a. To become thoroughly familiar with the properties of the investigational product as described in the Investigator's Brochure, which provides full information concerning the pre-clinical investigations that justify clinical studies, together with informative material describing any prior investigations, side effects, and precautions to be taken into account in the course of the clinical investigation; and
 - b. To become well acquainted with the Study Plan before signing it.
3. PI agrees to make the necessary arrangements, including provisions for emergency treatment, to ensure the proper conduct of the study.
4. PI understands that along with the Institution, he will have primary responsibility for the accuracy, legibility, and security of all study data, documents, and subject records both during and after the study. PI will be responsible for electronic signature of the Electronic Case Report Forms (e-CRF).

PI agrees to abide by the following conditions governing his/her handling of the data associated with this study.

- a. PI is required to maintain adequate records regarding all investigational product received and used by him/her including batch numbers, dates, and quantities. If the study is terminated, suspended, discontinued, or completed, PI shall return to Lotus Labs Pvt. Ltd., any unused supplies other than retention samples unless other arrangements are made by Lotus Labs Pvt. Ltd.

Clinical Trial Agreement

VAC

ATTESTED



Prof. Dr. V.A.KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI


Page 17 of 24

[Signature]

- b. PI is required to prepare and maintain adequate and accurate patient case histories, recording all observations and other data pertinent to the clinical investigation of each subject in the clinical study.
- c. PI understands to furnish records of the study to Lotus Labs Pvt. Ltd./Sponsor.
- d. PI will maintain records of the disposition of the investigational product and other records for the longer of the following periods:
 - I. the period defined by national or local law and rules
 - II. five years after the study is terminated or completed, or
 - III. Five years after the records are no longer required for purposes of supporting the relevant United States, other national, European (EU), or other international regulatory applications.
 - IV. To avoid any possible errors PI will contact Lotus Labs Pvt. Ltd. prior to the destruction of records or in the event of accidental loss or destruction of any Study records.
- e. PI, along with Institution, agrees to provide accurate information to the Ethics Committee upon request. PI, along with Institution, also agrees to provide accurate information to the regulatory authorities upon their request and within the scope of the agencies' authorities and ethical obligations, as set forth below:
 - I. The patient's identity will not be released except under the following limited circumstances
 - i. Upon the request of a scientifically trained and specifically authorized employee of national or international regulatory agencies, PI will make records related to the clinical study available for inspection and copying
 - II. Where data verification procedures demand inspection of patient's personal identity or personal medical information, in which case this inspection may be performed only by a properly authorized person
 - III. The patient's identity shall not be released to third parties without the patient's and/ or impartial witness prior consent. Accordingly, the study patient's and/ or impartial witness consent to the potential release of patient identity information to regulatory bodies for data verification purposes will be obtained as part of the informed consent procedure.
- 5. PI agrees to be responsible for submitting the Investigational Protocol for opinion or approval, to an appropriate Ethics Committee and shall transmit the results to Lotus Labs Pvt. Ltd.


PI shall not commence the study without an approval or favorable opinion from the Ethics Committee of the Investigational Protocol, informed consent forms, subject

Clinical Trial Agreement

ATTESTED

 Prof. Dr. V.A. KOTHTWALE
 Registrar



Page 18 of 24



KLE Academy of Higher Education
 and Research, BELAGAVI

recruitment procedures, and any written material to be provided to the patient's and/ or impartial witness.

PI shall provide the Institutional Ethics Committee or Institutional Review Board with all required information.

6. PI certifies that the investigational products for clinical investigation will be provided only to patient under his personal supervision or under the supervision of the Co-investigator/ Sub-investigator (if any) responsible to him.

PI further certifies that the investigational products will not be supplied by him to any investigator, other than those listed above as Co-Investigator/ Sub-investigators, or to any clinic, medical facility, or study site for use.

7. No procedure will be performed until all personnel have been properly trained.
8. PI shall be responsible for completing and signing the FDA form 1572.
9. PI agrees to be responsible for the personal safety and well-being of the subjects. To this end, PI agrees to abide by the Declaration of Helsinki and their subsequent amendments, national policy, and the following conditions governing the ethical treatment of subjects in this clinical investigation:

Following national policy and the Declaration of Helsinki, informed consent shall be documented by the subject or subject's legal representative with dated signature:

- a. PI ensures that patient and/ or impartial witness or their guardians receive adequate information to make informed consents. This information will be provided both in oral and in written form and shall be in a form easily understood by the patient's and/ or impartial witness. Additionally, as required by Indian law, Principal Investigator shall also obtain an audio-visual recording of the informed consent process for each Study subject. Such process shall be undertaken while maintaining principles of confidentiality.


The informed consent information shall include the aims, expected benefits, risks and inconveniences of the clinical investigation, an explanation of any alternative methods or treatments available, and an explanation of possible consequences of any withdrawal from the clinical investigation.

- b. PI will ensure that the patient and/ or impartial witness are given the opportunity to inquire about the details of the clinical study. The information given to the subject /subject's legal representatives shall make clear to them that they remain free to refuse to participate in and free to withdraw from the clinical study at any time without any sanction. PI will make an effort to ascertain the reasons for any


Clinical Trial Agreement



ATTESTED



Page 19 of 24



Prof. Dr. V.A.KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

withdrawal while fully respecting the subject's and/ the subject's legal representative's rights.

- c. PI will ensure that the patient and/ or impartial witness are provided adequate time to decide whether or not they wish to participate/ wish their ward to participate in this clinical investigation.
10. PI will discuss with Lotus Labs Pvt. Ltd. any question of modification of the study plan and obtain Lotus Labs Pvt. Ltd./ Sponsor written agreement and also approval from the ethics committee prior to implementation of any modification. PI will not proceed with a non-emergency deviation from the Clinical Protocol without approval from Lotus Labs Pvt. Ltd. and as needed the Ethics Committee. It is PI's responsibility to inform the Ethics Committee about any protocol amendment or any significant change in the Investigational Plan or Protocol that has been approved by Lotus Labs Pvt. Ltd., including the reason for the change, and to obtain the Ethics Committee's approval or favorable opinion regarding the change.
11. PI will report all adverse events/ serious adverse events to Lotus Labs Pvt. Ltd./ Sponsor.
- a. PI will report within one day:
- Deviations from or changes to the protocol to eliminate immediate hazards to the study patients.
 - Changes increasing the risk to patients and/or affecting significantly the conduct of the study.
 - All adverse drug reactions (ADRs) and Adverse Events (AEs) those are both serious and unexpected.
 - New information that may affect adversely the safety of the patients or the conduct of the study.
- b. All staff in contact with the patient should be aware of their responsibility to note and report all adverse events reported by the patient's and/ or impartial witness
- c. The Principal Investigator or designate should assess the patient at each visit for adverse event or serious adverse event that may have occurred since the previous visit.
- d. All serious adverse events (SAEs) should be reported to Lotus within 24 hours.
- e. The immediate reports should be followed promptly by detailed written reports including the completed Adverse Event Forms.
- f. The immediate and follow-up reports should identify patients by unique code numbers assigned to the study patients rather than by the patients' names, personal identification numbers and/or addresses.

Clinical Trial Agreement

ATTESTED

Prof. Dr. V.A.KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI



Page 20 of 24

385

Date: 11-Sep-15

To:

Dr. Shailesh Veerbhadrappa Udupudi
K.L.E.S Dr. Prabhakar Kore Hospital &
Medical Research Centre
Nehrunagar, Belgaum - 590010
Karnataka.

7(P)

Sub: Status of Clinical Trial I4V-MC-JADX, I4V-MC-JADZ & I4V-MC-JADY

Dear Dr. Udupudi,

We would like to thank you for your active participation and continued interest in Eli Lilly Clinical Studies I4V-MC-JADX, I4V-MC-JADZ & I4V-MC-JADY as Principal Investigator.


The Current Status of these studies is as follows:

1. Protocol I4V-MC-JADX: LPV Achieved, Database Lock Completed and Site Closed
2. Protocol I4V-MC-JADZ: LPV Achieved, Database Lock Completed
3. Protocol I4V-MC-JADY: This is an 48 months Extension study of Feeder studies JADX and JADZ, All subjects who completed JADX and JADZ and given consent to participate in the extension has been enrolled into JADY study. JADY Study is expected to achieve LPV in India by September 2018.


From your site we currently have 3 Active Subjects in Trial I4V-MC-JADY.

We thank you and your entire team for the active participation and support in these studies.

Regards,



Sanjay Majumdar
Senior Manager, Clinical Research
Eli Lilly & Company (India) Pvt. Ltd
Phone: +91 9871707965
Mail: majumdar_sanjay_in@lilly.com


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

भारतीय नैसर्ग्यायिक

बीस रुपये

₹.20

Rs.20

TWENTY
RUPEES

INDIA

INDIA NON JUDICIAL

TELANGANA

S343 09/11/2015

T. Gayathri
0247 487792

CLINICAL STUDY AGREEMENT

This Clinical Study Agreement (the "Agreement") is made and entered into 18th day of December 2015 by and between:

CMS Clinical Research Pvt. Ltd, a company incorporated under the provisions of the Companies Act, 1956 and having its registered office at #51, 3rd Floor, Paigah Colony, S P Road, Secunderabad-500003, Telangana, India (hereinafter referred to as "CMS" which expression shall be deemed to mean and include its affiliates, successors and permitted assigns) of the **FIRST PART**

And

Dr. Rajesh Shankar Powar, Chief Consultant Plastic Surgeon, Department of Plastic Surgery, KLES Dr Prabhakar Kore Hospital & Medical Research Centre, Belgaum, Karnataka, INDIA. ("Investigator") **SECOND PART.**

ATTESTED

For The Site:



CONFIDENTIAL

1/13

387

For The Site:

Site Details:

Site No.	Name of the Principal Investigator	Institution Name	Location
Study Site	Dr. Rajesh Shankar Powar	KLES Dr Prabhakar Kore Hospital & MRC.	Belgaum, Karnataka

WHEREAS CMS Clinical Research a private limited company incorporated under the company's act 1956 is conducting a clinical study (the "Study") of the product Silver Sulfadiazine Cream (Nanonized) 0.5% w/w (Silver Sulphadiazine (Nanonized) 0.5% and Chlorhexidine Gluconate 0.2%) hereinafter referred as Study Drug ; and Silver Cream 1% w/w (Silver Sulphadiazine (Nanonized) 1% and Chlorhexidine Gluconate 0.2%) as comparator in patients with Burn Wounds.

WHEREAS the Study shall be conducted in full compliance with the SPONSOR's protocol "protocol number R2012003 and protocol title/name of Comparative Efficacy, Safety and Tolerability of Silver Sulfadiazine Cream (Nanonized) 0.5% w/w and Silverex Cream 1% w/w in the Prophylaxis of Infection in Burn Wounds – A Double-Blind, Randomized, Pivotal Study and any amendments there to (the "Protocol");

WHEREAS the Investigator agrees to act as the principal investigator for the Study at the Institution.


NOW, THEREFORE, in consideration of the terms and conditions set forth herein, the parties agree as follows:

1. SERVICES AND OBLIGATIONS

The Sponsor requires services relating to Site Management & Clinical Research Coordination activities generated in course of its business and wishes to outsource such services to SERVICE PROVIDER and SERVICE PROVIDER desires to be hired to perform such services regarding the Site Management & Administration (Clinical Research Coordinator) support for the *conduct of Comparative Efficacy, Safety and Tolerability of Silver Sulfadiazine Cream (Nanonized) 0.5% w/w and Silverex Cream 1% w/w in the Prophylaxis of Infection in Burn Wounds – A Double-Blind, Randomized, Pivotal Study* ("Services");

a) SMO (via Institution) and the Investigator hereby agree to conduct the study in accordance with this Agreement and the Protocol. SMO and the Investigator shall also follow, and shall ensure that the Study Personnel (defined below) and the SPONSOR's instructions as they relate to the Institution's and/or the Investigator's performance under this Agreement.

CONFIDENTIAL

ATTESTED
2/14

Prof. Dr. V. AKOTIA
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

388

b) The Study shall be conducted at **KLES Dr Prabhakar Kore Hospital & MRC**, Belgaum, Karnataka (the "Investigative Site"). SMO and the Investigator shall ensure that all individuals and entities that perform any portion of the study under the Investigator's supervision (the "Study Personnel") and conduct the study in accordance with the Protocol and the terms and conditions defined in this Agreement. Further, SMO and the Investigator shall ensure that all Study Personnel are trained in the Protocol and good clinical practices.

c) SMO (via Institution) and the Investigator shall start to conduct the study as soon as all of the following events have occurred: (i) The Protocol and Study have been approved by the responsible ethics committee(s) and the competent regulatory authority and registered under the Clinical Trial Registry-India; (ii) The site initiation visit at the Institution has been performed and (iii) Case Report Forms (as defined below) and the Study Drug have been delivered to the Institution and/or the Investigator.

1.1 Regulatory Compliance of Study

a) Each party shall perform its obligations under this agreement with due diligence and in strict compliance with: (i) All applicable laws and regulations applicable to the conduct of clinical trials, including without limitation the Drugs and Cosmetics Act 1940, the Drugs and Cosmetics, Rules 1945, the Indian Council of Medical research guidelines and the Medical Council of India Act, 1956, (ii) All generally accepted standards of good clinical practice, including without limitation the current Good Clinical Practices Guidelines of the International Conference on Harmonization and the Ethical Principles of the World Medical Association Declaration of Helsinki (iii) The applicable laws related to data protection and data privacy, including without limitation, and as applicable, the EU Data Protection Directive 95/46/EC and (iv) Any other applicable laws, rules, guidelines and regulations (collectively, as amended from time to time, the "Applicable Regulatory Requirements").

b) Any modifications to the Protocol, if required, must be made by the SPONSOR and in accordance with the Applicable Regulatory Requirements and approved by the SPONSOR.

1.2 Study Subjects

The estimated number of subjects to be enrolled by the Investigator need to be in compliance with study protocol and competitive. Detailed criteria of subjects to be enrolled in the study are to strictly in accordance with the Protocol. SPONSOR reserves the right to unilaterally reduce or increase the number of study subjects at any time and with immediate effect and/or to instruct the Investigator to discontinue recruiting study subjects. The Institution and the Investigator shall ensure that the rights and welfare of the study subjects are protected.

1.3 Study Drug and Study Supplies

a) Sponsor agrees to provide the Study Drug at no cost to the Institution or the Investigator in volumes sufficient for the conduct of the study. The SPONSOR may also, at its sole discretion, provide additional materials, supplies and equipment (the "Study Supplies"). Immediately upon receipt of the Study Drug and/or any study supplies, the Institution and/or the Investigator shall provide The SPONSOR with a written acknowledgement. The Institution and the Investigator shall maintain inventory and control the Study Drug in accordance with: (i) Applicable Regulatory Requirements; (ii) In the manner outlined in the Protocol; and, (iii) According to any additional documents provided by the SPONSOR related to the storage (including temperature monitoring, if applicable), preparation and/or dispensing of the Study Drug.

ATTESTED

CONFIDENTIAL

3/14



Prof. Dr. V. A. KOTHARE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

b) SMO (via Institution) and the Investigator shall ensure that the Study Drug and the Study Supplies are solely used for the purpose of conducting the Study in accordance with the Protocol and for no other purpose. Furthermore, SMO and the Investigator shall ensure that the Study Drug and the study supplies are not transferred to any third parties. Unless stated otherwise in writing by the SPONSOR, the Study Drug and the study supplies are and will remain the sole property of the SPONSOR (as the case may be). SMO and the Investigator shall be responsible to the SPONSOR for the Study Drug and the study supplies entrusted to them and shall notify SPONSOR immediately if any study drug or study supplies are lost, damaged or destroyed.

c) Upon completion or termination of the study or at SPONSOR's request, SMO/or the Investigator shall deliver all study supplies and/or all unused study drug to the address indicated by SPONSOR or destroy it/them, as instructed by SPONSOR and in accordance with the Applicable Regulatory Requirements. Neither SMO nor investigator shall destroy any study drug or study supplies without SPONSOR's written consent.

1.4 Informed Consent

a) The Investigator shall obtain in compliance with all applicable Regulatory requirements an informed consent properly signed by the or on behalf of each study subject prior to the subject's participation in the study.

The investigator or designated staff will obtain the subject's parent/subject's legally acceptable representative written and audio-visually recorded Informed Consent (As per latest DCGI guidelines) prior to any study-related procedures.

b) The Investigator shall use the form of the informed consent (the "Informed Consent Form") provided by SPONSOR and approved in compliance with all applicable regulatory requirements.

1.5 Case Report Forms and Study Data


a) SPONSOR shall supply (or if electronic, provide access to) the forms to be used and completed by the Investigator to document a study subject's participation in the study (the "Case Report Forms" or "CRFs"). The Investigator shall record all data generated as a result of conducting the Study (the "Study Data") in a timely, accurate and complete manner in the form described in the Protocol and shall ensure that the Case Report Forms for each study subject are duly signed and dated. To the extent the study requires completion of electronic Case Report Forms, the Institution and the Investigator shall ensure that they have implemented and maintain appropriate computer security sufficient to protect the confidentiality, integrity and availability of such Study Data in accordance with the Applicable Regulatory Requirements. The Investigator shall not grant unauthorized users access to the electronic data capture (EDC) system used in the Study, and in particular, shall not share or disclose his/her username and/or passwords only persons authorized to make entries and/or corrections on CRFs will use the system.

b) The Investigator and SMO shall take reasonable and customary precautions to prevent the loss or alteration of any Study Data and shall be liable for any loss or alteration of the same. SMO and the Investigator acknowledge and agree that the SPONSOR shall own all Study Data.

1.6 Adverse Events

In case of any adverse event/events Investigator agrees to immediately and fully inform SPONSOR, the ethics committee(s) and competent authorities, of any significant risks,

CONFIDENTIAL

4/14

Prof. Dr. V.A. KOTHAPALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

adverse events or unexpected results related to the study, according to the Applicable Regulatory Requirements and applicable Protocol provisions.

1.7 Financial Disclosure

The Investigator shall complete and return financial disclosure document provided, this document discloses the financial interests which the Investigator and/or his/her family members may have with the SPONSOR and/or the Study drug. The Investigator shall also ensure that all sub-investigators complete and provide SPONSOR with such financial disclosure forms. Such financial disclosure forms shall be kept updated for a period of one (1) year after Study completion.

2. STUDY GRANT AND INVESTIGATOR FEE

- a) The investigator fee for the conduct of the Study is set out in the **Fee and Payment Schedule** enclosed as **Attachment 1**.
- b) SMO and the Investigator acknowledge that SPONSOR may refuse to make payment in case of a Protocol violation or an incomplete CRF.

3. CONFIDENTIALITY

- a) **"Confidential Information"** means all confidential or proprietary information or data, of any kind whatsoever and however memorialized, that is: (i) Disclosed by or on behalf of SPONSOR and/or the SPONSOR to the SMO, the Investigator or the Study Personnel in connection with this Agreement or (ii) Obtained, developed or generated by the Institution, the Investigator and/or the Study Personnel as a result of performing the Study under this Agreement. The Confidential Information shall include, without limitation, the Study, the Study Drug, the Protocol, the Investigator's Brochure, the Study Data, the Intellectual Property (defined below) and information regarding the SPONSOR, and their affiliates. All confidential information shall belong solely and exclusively to the SPONSOR, as the case may be.
- b) Confidential Information does not include information (I) That is in the public domain at the time of its disclosure to SMO (II) Information that was evidenced by written records or other competent proof, in the SMO and/or Investigator's possession prior to its disclosure without obligations of confidentiality (excluding study data), or (III) Enters the public domain as a result of a third party's activities, through no act or omission by the Investigator, the SMO or any Study Personnel.
- c) The SMO and the Investigator shall hold all confidential information in strict confidence and use all reasonable safeguards to prevent unauthorized use or disclosure. The SMO and the investigator shall use the confidential information only as required for the purpose of this Agreement. The SMO and the investigator shall limit their disclosure of the confidential information to those members of the Study personnel who need to know the confidential information for the conduct of the Study and are subject to obligations of confidentiality not less stringent than those contained in this Agreement. The SMO and the Investigator shall advise the Study Personnel of the confidential nature of the confidential information and remain liable for any breach of the confidentiality provisions herein.
- d) Should the SMO or the investigator or any study personnel receive a court order or other legally binding request to disclose confidential information, the SMO or the investigator shall immediately inform SPONSOR upon the discovery of such request and before any confidential information is disclosed. The SMO and the investigator shall

CONFIDENTIAL

5/14 ATTESTED



Prof. Dr. V.A. KOTHIVALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

cooperate with the SPONSOR in any efforts to seek limitation or protection from the order demanding disclosure. In any case, the SMO and investigator shall disclose only the minimum amount of confidential information necessary to comply with such request only on the behest of the SPONSOR's legal counsel.

e) The obligations of confidentiality exist at all times during this agreement and shall survive the expiration or earlier termination of this agreement for a period of ten (10) years.

4. INTELLECTUAL PROPERTY

The SMO and the investigator acknowledge and agree that the SPONSOR shall have exclusive ownership rights to all Study data, improvements, developments, discoveries, inventions, work, know-how and other rights (whether or not patentable), created, developed, and/or reduced to practice as a result of or in connection with the conduct of the Study and/or the use of the Study drug or the confidential information, together with all intellectual property rights relating thereto ("Intellectual Property"). The SMO and the Investigator shall promptly disclose in writing to the SPONSOR all intellectual property made by the SMO, the Investigator and/or the Study personnel. All Intellectual Property and any information with respect thereto shall be confidential information subject to the obligations set forth in Article 3. At the SPONSOR's request, the SMO and the investigator shall cause all rights titles and interests in and to any such intellectual property to be assigned to the SPONSOR without additional investigator fee and provide reasonable assistance to obtain patents, including causing the execution of any invention assignment or other documents. In the event the SPONSOR is unable for any reason, after good faith and all reasonable effort, to secure the SMO's or the Investigator's signature on any document which the SMO or the Investigator is required to execute in accordance with the terms of this Article 4, the SMO and the Investigator hereby irrevocably designates and appoints the SPONSOR and its duly authorized officers and agents to act for and on their behalf to execute, verify and file any such documents with the same legal force and effect as if executed by the SMO or the Investigator. To the extent that the applicable law does not allow a the transfer of any of the intellectual property rights, the SMO and the investigator hereby grant the SPONSOR an exclusive, perpetual, irrevocable, worldwide, transferable, fully paid-up and royalty free license, with the right to sublicense to any third party, to use such intellectual property for any and all purposes.

5. PUBLICATION AND PUBLICITY

5.1 Publication

a) As this Study is part of a multicenter trial, publications derived from this Study may include input from the investigator, his/her colleagues, other investigators in this Study and the SPONSOR's personnel. Such input will be reflected in publication as an acknowledgement. Selection of authors will be at the sole discretion of the SPONSOR governed by the SPONSOR

CONFIDENTIAL

ATTESTED

6/14



Prof. Dr. V. A. KOTHAWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGALI

5.2 Publicity

The SMO and the Investigator shall not use SPONSOR's name, the names of any of their employees, symbols, or trademarks in any advertising, sales promotional material, or press release without the prior written permission of SPONSOR, as applicable.

6. INDEMNIFICATIONS, NOTIFICATION OF CLAIMS AND INSURANCE

6.1 SPONSOR's Indemnity Obligations and Disclaimer

a) SPONSOR undertakes to indemnify and hold harmless the SMO and the Investigator against any and all claims, damages, losses and costs arising out of (i) Any breach of this Agreement by SPONSOR or (ii) Any negligent or willful act or omission by SPONSOR, including by its officers, employees, contractors or other staff.

SPONSOR expressly disclaims any and all liability whatsoever in connection with the Study drug and the Protocol, except to the extent that such liability that arises from (i) Any negligent or willful act or omission of SPONSOR; or (ii) Any breach of this Agreement by SPONSOR.

6.2 The SMO's and the Investigator's Indemnity Obligations

The SMO and the Investigator undertake to indemnify and hold harmless the SPONSOR against any and all claims, damages, losses and costs (including reasonable attorneys' fees) arising out of (i) any breach of this Agreement by the SMO and/or the Investigator, or (ii) any negligence or willful act or omission of the SMO, the Investigator, study Personnel or any of their officers, employees, contractors or staff or (iii) any unauthorized warranties made by the SMO and/or the Investigator or any study personnel concerning the study Drug.

6.3 Notification of Claims

The SMO and the Investigator shall immediately serve a notice in writing to SPONSOR about any investigation, claim or legal proceedings related to the study against the SMO, the investigator, the study personnel or other staff in connection with the study. The SMO and the investigator shall fully cooperate in all reasonable aspects upon request and on behalf of SPONSOR in the investigation and/or defense of these claims or lawsuits.

6.4 Insurance

a) SPONSOR shall ensure it executes the mandatory clinical trial insurance (if any) required by the Applicable Regulatory Requirements.

b) The SMO shall subscribe to and maintain and shall ensure that the investigator subscribes to and maintains all insurance coverage, as required by law. They shall provide evidence of such insurance(s) upon request by SPONSOR.

ATTESTED

CONFIDENTIAL


Prof. Dr. V.A. KOTHAWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

7. INSPECTIONS, AUDITS, MONITORING AND RECORDS

7.1 Regulatory Inspections

The SMO and the investigator shall promptly notify SPONSOR of any inspection or investigation relating to the Study by any regulatory, governmental or law agency (including without limitation the Drug Controller General of India, the Ethics Committee, the Central Drugs Standard Control Organization, the State Drug Control, the EMEA and the US FDA) of which they become aware. SPONSOR, and/or their representatives shall have the right to be present at and/or participate in any such inspection or investigation. Before SMO or Investigator submit any materials or information to an agency in connection with an inspection or investigation, SPONSOR shall have the right, to review, provide and/or comment on any such materials and/or information.

7.2 Audit and Monitoring by SPONSOR

SPONSOR and their representatives may audit, monitor and/or meet with the investigator and the study personnel at the SMO and/or at the investigative site during normal business hours and with reasonable frequency for audits and visits to monitor the progress of the study and review study records, documents, information, data, and materials (including the Study Data). The SMO and the investigator shall assist SPONSOR and their representative(s) in scheduling such visits.

a) SPONSOR and their representative(s) shall be entitled to: (i) Examine and inspect the facilities required for the performance of the study; (ii) Inspect source documents; and (iii) inspect, request correction of and copy all study Data (including, without limitation, Case Report Forms, original reports of laboratory tests and examination findings, and all other notes, charts, reports, or memoranda related to the study subjects or to the conduct of the study), which SPONSOR are authorized to access by the signed Informed Consent Form, and/or the applicable regulatory requirements. The investigator shall cooperate with SPONSOR and their representatives during audits and monitoring visits and in the resolution of any questions regarding the study Data.

7.3 Record Keeping

The SMO and the Investigator shall maintain accurate, complete and current records of all study data, including the Case Report Forms (or equivalent electronic data), relevant source documents and any other essential documents or materials as required by the protocol, the applicable regulatory requirements and SPONSOR's instructions (collectively the "Records"). The SMO and the Investigator shall keep all the Records in a safe and secure location for the period required by the applicable regulatory requirements, or for a period of fifteen (15) years following the completion of the study, whichever is longer. The SMO and/or the investigator may destroy the records at the end of the records keeping period on the condition that the institution and/or the investigator sends written notice to the SPONSOR at least sixty (60) days prior to the date deletion/disposal will occur, and, if requested by the SPONSOR, cooperates with the SPONSOR in extending the record keeping period or shipping the records at another facility for storage, at the SPONSOR's reasonable expense.

CONFIDENTIAL

8/14 ATTESTED



Prof. Dr. V. V. KOTHAR
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

9. NON-DEBARMENT

The SMO and the Investigator represent and warrant that neither they nor any of the study personnel is or ever has been debarred, disqualified, excluded or suspended to participate in clinical research by any competent authority or agency in any country (including in particular but without limitation the US FDA), and that it shall not make use of, nor involve in this study any person or organization which is or has been debarred, suspended, excluded or disqualified by any regulatory authority to participate in clinical research. In the event the SMO or the Investigator or any person or organization involved in the study is or becomes threatened with or becomes debarred, disqualified, suspended or excluded during the study, the SMO and the Investigator shall notify SPONSOR in writing about this fact within five (5) days of its discovery.

10. DATA TRANSFER

a) The Investigator and the SMO undertake to protect the personal data of the study subjects and to process them in accordance with the applicable data protection laws and regulations.


b) Both prior to and during the course of the study, the investigator and the study personnel may provide SPONSOR with personal data. Such data may include names, contact information, bank account details, work experience, qualifications, publications, resumes, educational background, performance information, facilities, staff capabilities, and other information relating to the study (the "Personal Data"). The investigator hereby consents to the processing (including use, disclosure or transfer) of his/her personal data as required for the following purposes (the "Purposes"): (i) The conduct of clinical trials, (ii) Review by governmental or regulatory agencies, SPONSOR, and their agents, and affiliates, (iii) Compliance with legal or regulatory requirements, and (iv) Storage in databases for use in selecting investigators and institutions for future clinical trials. The Investigator also agrees to a transfer of his/her Personal Data abroad, even if such personal data is transferred to countries that do not ensure an equivalent level of protection as that provided in India. The Investigator and the SMO represent that all study Personnel have given express consent to the processing of their Personal Data for the Purposes and shall notify SPONSOR immediately if such consent has been withdrawn.

11. EXPERIMENTAL NATURE OF INVESTIGATIONAL PRODUCT

THE SMO AND THE INVESTIGATOR ACKNOWLEDGE THAT THE INVESTIGATIONAL MEDICINAL PRODUCT IS EXPERIMENTAL IN NATURE, AND SPONSOR WILL NOT MAKE ANY WARRANTIES, EXPRESS OR IMPLIED, REGARDING THE INVESTIGATIONAL PRODUCT, INCLUDING WITHOUT LIMITATION THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. THE INSTITUTION AND THE INVESTIGATOR ACKNOWLEDGE THAT SPONSOR CANNOT GUARANTEE THE SAFETY, NON-TOXICITY, FITNESS OR EFFICACY OF THE INVESTIGATIONAL MEDICINAL PRODUCT. THE FOREGOING IS NOT INTENDED TO, AND DOES NOT, NEGATE SPONSOR'S LIABILITY UNDER LAW FOR PRODUCT LIABILITY CLAIMS ARISING OUT OF THE USE OR ADMINISTRATION OF THE STUDY DRUG IN ACCORDANCE WITH THE PROTOCOL AND THIS AGREEMENT.

CONFIDENTIAL

10/14


Prof. Dr. M. A. N. S. Reddy
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

8. TERMINATION AND SUSPENSION

8.1 Term

The term of this agreement shall commence on the date of the last named party signature. Unless terminated earlier in accordance with this Section 8, this agreement shall remain in effect until the final study documentation required to be provided under the Protocol is received and accepted by SPONSOR, and SPONSOR has performed a closeout visit at the Institution.

8.2 Termination by the SPONSOR

SPONSOR, in consultation with the SMO, may terminate this agreement with immediate effect (i) If the SMO and/or the Investigator is in breach of this agreement and fails to address such breach within fifteen (15) calendar days from the receipt of written notice, (ii) If SPONSOR in good faith believe the study Drug or continuation of the study presents an unreasonable medical risk to the study subjects or if there are efficacy or safety concerns, (iii) If the study is terminated, suspended or not initiated at the institutions for any reason or (iv) If the agreement between the Investigator, SMO and SPONSOR regarding the study is terminated for whatsoever reason. SPONSOR, may also terminate this agreement without cause upon thirty (30) calendar days' notice.

8.3 Termination by the SMO or the Investigator

Either the SMO or the investigator may terminate this agreement: (i) If SPONSOR breaches this agreement and fails to address such breach within thirty (30) calendar days from the receipt of written notice, or (ii) If, following consultation with SPONSOR, the SMO and/or the investigator in good faith believe that the continuation of the study presents an unreasonable medical risk to the study subjects.

8.4 Surviving Clauses

The termination or expiration of this agreement shall not relieve either party of its obligation to the other with respect of the following provisions: Section 1.4 b) and c) [Study Drug and Study Supply], Section 1.8 [Financial Disclosure], Section 3 [Confidentiality], Section 4 [Intellectual Property], Section 5 [Publication and Publicity], Section 6 [Indemnification, Notification of Claims and Insurance], Section 7 [Inspections, Audits, Monitoring and Record Keeping], Section 8.3 [Surviving Clauses], Section 10 [Data Transfer], Section 11 [Anti-Bribery and Anti-Corruption], Section 12 [Experimental Nature Of Investigational Product], Section 13 [Miscellaneous] and Section 14 [Applicable Law and Place of Jurisdiction].

8.5 Suspension of the Study

The SPONSOR may suspend the study at any time for any reason upon written notice, such suspension shall not be deemed as a breach of this agreement by the SPONSOR.

CONFIDENTIAL

ATTESTED

9/14



KLE Academy of Higher Education
and Research, BELAGAVI

12. MISCELLANEOUS

- a) No amendment to this agreement (including its attachments) shall be effective unless such amendment is made in writing and signed by the parties hereto.
- b) If any provision(s) of this agreement shall be declared invalid by a court of competent jurisdiction, such determination shall not affect the remaining provisions of this agreement which shall remain in full force and effect. The parties hereto shall, however, attempt to replace the provision(s) declared invalid as aforesaid with legally valid provision(s) which reflect(s) the same purpose of the invalid provision(s) to the greatest extent possible.
- c) This agreement is entered into between the parties hereto on principal to principal basis. Nothing contained in this agreement shall be construed to imply a joint venture, employment, partnership, or principal agent relationship between the institution/investigator and SPONSOR; and neither party hereto by virtue of this Agreement shall have the right, power or authority to act or create any obligation, express or implied, on behalf of the other party.
- d) The SMO and the investigator may not assign any of their rights or subcontract obligations hereunder without the prior written consent of SPONSOR. Even if SPONSOR authorizes delegation or subcontracting in full or in part, the Institution and the Investigator remain fully responsible and liable for the performance of all delegated duties.

13. APPLICABLE LAW AND PLACE OF JURISDICTION

- a) This Agreement shall be governed by and construed in accordance with the laws of India, without regard to its conflict of law provisions.
- b) Any claim or controversy arising out of or related to this Agreement or any breach hereof shall be submitted to the exclusive jurisdiction of the competent courts located at Hyderabad, Telangana notwithstanding the foregoing, either party may seek injunctive relief in a court of competent jurisdiction.

CONFIDENTIAL

11/14

ATTESTED



Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

[SIGNATURE PAGE TO FOLLOW]

This Agreement has been executed two originals, one for each party.

SMO: CMS Clinical Research Pvt. Ltd.

For CMS Clinical Research Private Limited

Name: Ms. Anshula Gautam

Title: Director

Authorised Signatory

Dated: _____

Investigator:

Name: Dr. Rajesh Shankar Powar,

Title: Investigator

Dr. Rajesh S. Powar
Senior Consultant & Head
Dept. of Plastic & Reconstructive Surgery
KLES Dr. Prabhakar Kore Hospital &
MRC- Belgaum.

Dated: _____

CONFIDENTIAL

ATTESTED

12/14

Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

Attachment 1

Fee and Payment Schedule

I. Fees

The investigator fees shall be based on the number of study subjects randomized into the study in compliance with the protocol and the number of visits performed with respect to these study subjects in accordance with the following payments table:

All amounts stated in this Fee and Payment Schedule are inclusive of any value added tax.

A. Fixed Cost	Unit Cost (INR)	Amount (INR)
Ethics Committee Fee	@25,000/- per protocol	25,000/-
Study Equipments <ul style="list-style-type: none"> • BP Machine with calibration certificate - 1 • Height Measuring Scale with calibration certificate - 1 • Weighing Machine with calibration certificate - 1 • Clinical Thermometer with calibration certificate - 1 • Thermohygrometer without probe with calibration certificate - 1 • Video Camera* - 1 (*Video Camera to be returned to sponsor after the completion of study) 	<ul style="list-style-type: none"> • @ 2,260/- • @ 590/- • @ 2,333/- • @ 350/- • @ 915/- • @ 12,200/- 	18,648/-
Sub Total		43,648/-
B. Variable Costs	Unit Cost	
Investigator Research Grant - for 15 completed subjects	@ Rs. 15,000/- per completed patient	2,25,000/-
Investigator Research Grant in case of drop out after visit 2 for 2 drop out patients	@ Rs. 2000/- per drop out patient	4,000/-
Study Coordinator Grant - for 15 completed subjects	@ Rs. 3,000/- per	45,000/-
Study Coordinator Grant in case of drop out after visit 2 for 2 drop out patients	@ Rs. 1000/- per drop out patient	2,000/-
Institutional Overhead Charges (for subjects completing the study) @ 20% of research grant - for 15 completed subjects	@ Rs. 3,600/- per completed subject	54,000/-
Institutional Overhead Charges (for drop out subjects) @ 20% of research grant - for 2 drop out subjects	@ Rs. 600/- per drop out subject	1200/-
Laboratory Investigation Charges - for 15 completed patients	@ Rs. 5,450/- per completed patient as per Lab cost sheet signed (To be paid on actual as per the bills provided)	81,750/-
Photographic Charges- 60 photographs for 15 patients	@ 40/- per completed patient	600/-
Study subject travel allowance (60 visits for 15 subjects)	@ 100/- per completed visit	6000/-
Sub Total		4,19,550/-
Total		4,63,198/-

ATTESTED

CONFIDENTIAL

13/14


Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

II. Invoicing and Payments

- a) SPONSOR shall make the payments in Indian Rupees according to the grant/fee payment schedule on the date of invoicing. The Overall Budget will be shared equally between the CMS Clinical Research (SMO) & Investigator after deducting all the study related expenditure. CMS Clinical Research will pay to Investigator once fund released by sponsor.
- b) EC fees and institute overhead charges will not be paid to CMS clinical Research Pvt. Ltd.


III. Account Details

The SMO and the Investigator hereby instruct SPONSOR to pay the entire investigator fee under this Agreement to the following bank account:

Issuing Entity	Ranbaxy Laboratories Ltd.
Payee Name	CMS Clinical Research Pvt. Ltd.
Payee Address	#51, 3 rd Floor, Paigah Colony, S P Road, Secunderabad-500003, Telangana,
PAN No:	AAFCC 8457 M
Method of Payment	Cheque
Bank Name	HDFC Bank

CONFIDENTIAL

ATTESTED
14/14


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

CLINICAL STUDY AGREEMENT

This clinical study agreement ("Agreement") is executed as of the 17 day of July 2016 (Effective Date) by and between:

Sun Pharma Advanced Research Company Ltd. (CIN L73100GJ2006PLC047837), a company registered under the Companies Act, 1956 having its registered office at SPARC Ltd, Akota Road, Akota, Vadodara - 390020 India and having a business address at 17/B, Mahakali Caves Road, Andheri East, Mumbai 400093, India, which expression shall, where the context so permits include his successors in office and assigns (hereinafter referred to as the "Sponsor").

AND

KLEs Dr. Prabhakar Kore Hospital & Medical Research Centre, a hospital having its registered office at Nehrunagar, Belgaum - 590010, Karnataka, India, which expression shall, where the context so permits include his successors in office and permitted assigns (hereinafter referred to as the "Institution").

AND

Dr. Rohan Bhise, MBBS, MD (Oncology), Principal Investigator, at KLEs Dr. Prabhakar Kore Hospital & Medical Research Centre, Nehrunagar, Belgaum - 590010, Karnataka, India. (hereinafter referred as the "Investigator")

AND

Global Drug Development (GDD) Experts India Pvt. Ltd., Ground floor, Gulmohar Apartment, Opp. Hislop College, Civil Lines, Nagpur-440001, Maharashtra, India. Head Off.: 910 Seventeenth Street, NW Suite 312, Washington D.C. 20006 (hereinafter referred as the "Site Management Organization")

(each a "Party" and Sponsor, Investigator and Investigator collectively, the "Parties")

WHEREAS:

- A. The Institution is a health care and research organization engaged in the diagnosis, treatment and prevention of disease and clinical research for the improvement of healthcare, and has the facilities and personnel necessary to conduct the clinical trial;
 - B. Sponsor is a pharmaceutical company involved, inter alia, in the research, development and manufacture of medicines for use in humans and has developed Paclitaxel Injection Concentrate for Nano-dispersion (PICN) which is intended to be used for treatment of locally recurrent or metastatic breast cancer. Sponsor represents that it has applied for the necessary permissions and licenses required under the provisions of relevant Acts and Rules which are required for use of the same on subjects/ healthy human volunteers etc.
- Site Management Organization has agreed to provide a professionally trained and experienced Clinical Research Coordinator who will be responsible for delegated trial related activities and documentation from the start till close out of the trial

D-517P/W/C
 M.D.F.C. Bhatnagar
 Trade Tax Dept.
 Andheri East, Mumbai
 400093
 59302
 148564
 12-16
 95145
 06-06-2016
 12-16
 95145

Site Specific Final Version 01_02 Aug 2016
Master Version 01_24 Dec 2015

[Handwritten signatures]

ATTESTED

[Handwritten signature]

Prof. Dr. V.A.KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

at the Institute; a Project Manager to over-see & coordinate the progress & management of CRC activities and a Quality Control Associate to ensure adherence to the protocol, ICH-GCP, other applicable regulatory requirements and the relevant Standard Operating Procedures (SOPs). Hence GDD Experts will assist Investigator and institute for efficient Trial Management; Project Management and Quality Management.

- C. Sponsor desires Institution to study the bioavailability and bioequivalence of PICN and Institution is willing to perform a clinical study of the Investigational Product (IP).

NOW THEREFORE in consideration of the promises and mutual covenants herein contained, Parties including Site Management Organization hereby agree as follows:

1. SCOPE

1.1 The Study is of mutual interest and benefit to Sponsor and Institution, and will further the Institution's instructional and research objectives in a manner consistent with the terms and conditions of this Agreement.

1.2 The Institution shall exercise its best efforts to carry out the research ("Study") set forth in the Protocol CLR_16_13: A Randomized, Open Label, Two Period, Single Dose, Crossover, Bioavailability Study Of Paclitaxel Injection Concentrate For Nano-Dispersion (PICN) And Abraxane® In Subjects With Locally Recurrent Or Metastatic Breast Cancer, which has been provided prior to signing of this Agreement. In the event of any inconsistency between this Agreement and the Protocol, the terms of this Agreement shall govern. Changes in the Protocol may be made only through prior written agreement between the Sponsor and the Institution. The Study shall be conducted under the direction of Investigator in accordance with this Agreement, subject to review and prior approval by the institution's ethical committee.

2. CONDUCT OF THE CLINICAL TRIAL

2.1 The Investigator and the Institution shall conduct the Study in accordance with the Protocol. The Sponsor is responsible for obtaining and maintaining all applicable regulatory approvals for the Study in India. The Sponsor, Investigator and Institution shall perform the Clinical Study in accordance with all applicable laws, government regulations and guidelines including but not limited to the Drugs & Cosmetics Act 1940 and Rules, 1945 : Schedule-Y (as amended from time to time), The Indian Council of Medical Research (ICMR) guidelines, Good Clinical Practices (GCP) and the standards conforming to the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).

2.2 Site Management Organization will ensure to follow the Study Management Responsibilities Matrix which is a detail agreement to define the terms and condition and obligation of each Party between PI, Institute and Site Management Organization

2.3 It is explicitly agreed and acknowledged by the Parties including Site Management Organization that the Protocol for clinical trial/Study be reviewed and approved by the Ethical Committee ("EC") registered with DCGI before the commencement of the Study.

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

The Investigator shall obtain and deliver a copy of such approval to the Sponsor. The approval must indicate the date of issuance and bear the name and signature of the Chairperson or Secretary of the EC. If any such committee do not exist in the Institution, then the approval granted to a protocol by the ethics committee of another institution will be applicable to use of that protocol in the institution.

2.4 The Institution and Investigator agree that the Sponsor or its designee as clinical monitor will conduct routine monitoring visits at mutually convenient times and upon reasonable advance notice to the Investigator. The clinical monitor will have direct access to all original records and documents pertaining to the study to ensure that the study is conducted in accordance with the Protocol and applicable regulatory requirements and in terms of this Agreement. Similarly, sponsor may conduct audit at mutually convenient times and upon reasonable advance notice to the Investigator. The auditor will have direct access to all records and documents pertaining to the study.

2.5 It is explicitly agreed and acknowledged by the Parties including Site Management Organization that in case Investigator is unable to perform the study in accordance with this agreement, the Institution shall appoint another Investigator in consultation with the Sponsor. The Institution shall take written consent from the Sponsor prior to such appointment. The Sponsor retains the right to suggest Investigator(s) for appointment to conduct and perform the Study.

2.6 If any biological samples are to be tested as part of the Study, these are to be tested in accordance with the Protocol and at a central laboratory approved by Sponsor and with the Clinical Trial Subject's signed written informed consent form. If study requires local lab, the investigator would share applicable documents (viz. lab head CV, accreditation, Lab normal values). It is explicitly agreed and acknowledged by the Parties including Site Management Organization that Collection, Retention, Use and Destruction of Biological Samples by Institution or Investigator or Sponsor or either of the parties including Site Management Organization shall be in accordance with the applicable Protocol, acceptable clinical trial practices, applicable subject privacy and informed consent laws and in compliance with all applicable laws and regulations.

For the investigations required to be conducted at the local laboratory, the expenses will be reimbursed as per actuals, subject to submission of the original invoices and corresponding receipts for the same obliterating subject's identity.


3. OBLIGATIONS, REPRESENTATIONS & WARRANTIES OF THE PARTIES INCLUDING SITE MANAGEMENT ORGANIZATION

3.1 The Investigator shall be responsible for obtaining and maintaining all approvals from the appropriate EC for the conduct of the clinical Study and from time to time the Investigator shall inform Sponsor about the progress of EC submissions, and provide Sponsor and the Institution with all correspondences relating to such submissions. The institution shall ensure the proper conduct of Study.

3.2 The Investigator shall be responsible for obtaining a signed informed consent form from each Clinical Study Subject prior to the Clinical Study Subject's participation in the Clinical Study. For clarity "Clinical Trial Subject" means a person recruited to participate in the Clinical Trial. The investigator shall comply with the applicable regulatory requirement(s), and should adhere to GCP and to the ethical principles in

Site Specific Final Version 01_02 Aug 2016
Master Version 01_24 Dec 2015

Page 3 of 17



ATTESTED



obtaining and documenting informed consent. The Parties including Site Management Organization agree that in addition to the requirement of obtaining written informed consent, including the procedure of providing information to the subject and his/her understanding on such consent is required to be done while adhering to the principles of confidentiality. As per applicable regulatory requirement, it is agreed and acknowledged by the Parties including Site Management Organization that in case of certain clinical trials, audio-video recording of the informed consent process to be maintained by the investigator for certain subjects. In such event, the Parties including Site Management Organization will agree the necessary terms and conditions relating to the audio-video recording and incorporate the same in the informed consent form.

3.3 In addition, prior to the beginning of the Study, the Investigator must have the EC's written approval/favourable opinion of the written informed consent form and any other written information to be provided to Clinical Trial Subject. Neither the investigator, nor the trial staff, should coerce or unduly influence a Clinical Trial subject to participate or to continue to participate in a trial.

It is agreed and acknowledged by the Investigator and the Institution that when a clinical trial (therapeutic or non-therapeutic) includes Clinical Trial Subjects who can only be enrolled in the trial with the consent of the Clinical Trial Subject's legally acceptable representative (e.g., minors, or subjects with severe dementia), the Clinical Trial Subject should be informed about the trial to the extent compatible with the subject's understanding and, if capable, the subject should sign and personally date the written informed consent.

3.3 The Investigator shall take reasonable efforts to recruit the agreed number of Clinical Trial Subjects on a timely basis and the Parties including Site Management Organization shall take reasonable efforts to conduct the Clinical Study in accordance with the agreed time period.

Investigator shall target to enroll (randomize) at least 6-8 subjects in the study.

3.4 The Institution and Investigator shall not permit the use of IP for any purpose (whether directly or indirectly) other than the conduct of the clinical Study and upon termination or completion of study, all used and unused IP shall, at Sponsor's instructions, either be returned to Sponsor or destroyed in accordance with the Protocol or Sponsor's written instructions.

3.5 It is explicitly agreed and acknowledged by the Parties including Site Management Organization that the Study may involve the participation of multiple sites and recruitment and in such event, when the enrolment goal for the clinical Study as a whole is reached, enrolment will be closed at all sites, including the trial Site, regardless of whether the Institution has reached its individual enrolment goal.

3.6 To the extent permitted by law, the Institution and the Investigator shall immediately inform Sponsor of:

3.6.1 Any intended or actual inspection, written inquiry or visit to the trial Site by any regulatory authority; or



ATTESTED



Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

3.6.2 Any queries by State or Central Information Commission under Right to Information Act (amended up to date)

In connection with the clinical Study and forward promptly to Sponsor copies of any correspondence from any such authority.

The Institution or Investigator shall use its best efforts to obtain the approval of the regulatory authority (e.g. DCGI or state FDA personnel) to have a representative of Sponsor present during any such visit. If a representative of Sponsor is unable to be present during a visit, the Institution and the Investigator shall provide Sponsor with a prompt brief summary followed by a detailed written report following the visit.

3.7 The Institution and the Principal Investigator shall keep complete and accurate records of the conduct of the clinical Study and of all clinical Study data in accordance with generally accepted industry standards and practices and applicable Law. The Institution and the Investigator agree to retain all such records for a period of not less than fifteen (15) years from the date of completion of Study or termination of this Agreement, whichever is earlier, or any such period prescribed in the Sponsor's 'Document Retention & Destruction Policy' (the "Retention Period"). The Institution shall use reasonable efforts to give Sponsor written notice before destroying the Clinical trial documentation and clinical trial data. Any such destruction is subject to prior written consent of the Sponsor. In case, Institution and Principal Investigator do not have archival facility as per Sponsor's expectations, Institution and Principal Investigator agree to third party archival facilitated by the sponsor respecting confidentiality of subject's data.

For clinical/ therapeutic bioequivalence study, the Investigator and Institution agree to retention of Investigational Product (IP) as per regulatory requirements. In case, Institution and Principal Investigator do not have archival facility for IP as per Sponsor's expectations, Institution and Principal Investigator agree to third party archival by the sponsor respecting confidentiality of subject's data.

3.8 The Investigator undertakes to document all Adverse Events (AE) on adverse event page of Case Report Form (CRF). The investigator shall report all serious adverse events (SAE) to the licensing authority (DCGI), sponsor/ CRO (if applicable) and chairperson of ethics committee within 24 hour of SAE occurrence. The investigator shall report all SAE after due analysis to the licensing authority (DCGI), chairperson of ethics committee and head of the institution where the trial has been conducted within the timelines as per the applicable regulatory requirement. Subsequent follow-up information shall be reported to all stakeholders as mentioned above. In case, Investigator fails to report any SAE within stipulated period, the investigator shall have to furnish the reason for the delay to the satisfaction of licensing authority along with the report of SAE. Sponsor's safety physician/ CRO (if applicable) shall report all SAE after due analysis to licensing authority (DCGI), chairperson of ethics committee and head of the institution where the trial has been conducted within the timelines as per the applicable regulatory requirement. Subsequent follow-up information shall be reported to all stakeholders as mentioned above. Sponsor's safety physician/ CRO (if applicable) shall report all serious adverse events to other participating Investigators within the timelines as per the applicable regulatory



ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

requirement. (This shall be for multi centric studies). Sponsor's safety physician/ CRO (if applicable) shall notify SAE to other regulatory authorities as applicable.

As much information as possible shall be supplied by Investigator at the time of the initial report with at least the following information using SAE Report Form.

- Name, address, and telephone number of the reporting Investigator.
- Investigational product(s).
- Protocol number.
- Subject identification number, initials, sex and date of birth.
- Description of the AE, reason considered serious, measures taken and outcome (if resolved).
- Likelihood of drug causation of the adverse event assessed by the Investigator.

A SAE is any untoward medical occurrence that, at any dose:

- results in death;
- is life-threatening;
- requires in-subject hospitalization or prolongation of existing hospitalization; [For the avoidance of doubt, A planned hospitalization for pre-existing condition, or a procedure required by the Clinical Investigation Plan, without a serious deterioration in health or if the hospitalization is clearly not associated with an AE (e.g., social hospitalization) are not to be considered as SAEs.]
- results in persistent or significant disability/incapacity;
- is a congenital anomaly/birth defect;
- important medical event.

For the sake of clarity, the term "life-threatening" in the definition of "serious" refers to an event in which the subject was at risk of death at the time of the event; it does not refer to an event, which, hypothetically, might have caused death if it were more severe.

To the maximum extent permissible under applicable laws and DCGI regulation, the Sponsor shall pay all medical expenses pertaining to Study subject in the event of any AE or SAE. In case of trial related injury or death, the financial compensation will be paid to the subject/ nominee subject to the terms and conditions of this Agreement.

3.9 The Sponsor shall pay all medical management pertaining to Study subject in the event of any SAE, and any IP or study participation related AE, unless it has arisen due to non-adherence to the terms of the Protocol or Sponsor's written instructions on IP as agreed by Investigator EC and/or the same has resulted from the negligence or willful malfeasance or malpractices by Investigator and /or any trial staff or the Institution.

If Subject has a medical emergency, illness or injury that was caused by the research drug or study procedures, Sponsor will provide subject medical management as per the applicable regulatory requirement.

In case of Study related injury or death, to the maximum extent permissible under applicable laws and DCGI regulation, Sponsor will provide complete medical care along

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

with compensation for the injury or death. In case of any SAEs (death and other than death) EC will evaluate and give its opinion regarding compensation to DCGI. Subject will get an additional compensation will be over and above any expenses incurred on subject's medical management from Sponsor if recommended by DCGI. Subject or his/her nominee(s) has the right to contact the Sponsor or his representative, for the purpose of making claim in the case of trial related injury or death.

3.10 Investigator warrants and represents that:

3.10.1 He is free to participate in the clinical trial/ Study and there are no rights, which may be exercised by, or obligations owed to any third party, which might prevent or restrict his performance of the obligations detailed in this Agreement;

3.10.2 Where the Institution is not the Investigator's principal employer, he has notified his principal employer of his proposed participation in the clinical trial/Study and, where relevant, his supervision of trial site team members. He has obtained all necessary consents from his principal employer relating to this;

3.10.3 He is not involved in any regulatory or misconduct litigation or investigation by the Drugs Controller General of India, Food and Drug Administration, the Ministry of Health, or other regulatory authorities;

3.10.4 He is qualified to provide clinical Study services based on the skills and experience and has reviewed information regarding the Sponsor's IP and the Protocol for the proposed clinical Study and wishes to conduct the trial and to supervise the team members at the trial site; and

3.10.5 During the Clinical Trial, he will not serve as an investigator or other significant participant in any clinical trial/study for another sponsor or any CRO companies if such activity might adversely affect his ability to perform his obligations under this Agreement.

3.11 Institution certifies that neither Institution nor any person (including Investigator) employed or engaged by Institution in the conduct of the Study has been debarred pursuant to applicable provisions of law (whether state or central) and that no debarred person will in the future be employed or engaged by Institution in connection with conduct of the Study. Institution further certifies that it will notify Sponsor immediately in the event of any debarment or threat of debarment of any person employed or engaged by Institution in the conduct of the Study occurring during the period of this Agreement.

3.12 Sponsor, Institution and the Investigator represent and warrant that it has the right to enter into and fully perform this Agreement and, by entering into this Agreement it is not in violation of any law, statute, agreement or any other statute.

4. FINANCIAL ARRANGEMENTS

4.1 SPARC, as Sponsor, has agreed to provide financial support for the project. The Sponsor shall pay fees for the services of the Investigator in accordance with the budget as per Exhibit-A.

Site Specific Final Version 01_02 Aug 2016
Master Version 01_24 Dec 2015



Page 7 of 17

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

4.2 Sponsor shall make payments to Institution in accordance with the payment schedule set forth in Exhibit A and incorporated herein. Cheque (s) shall be made payable and sent to the:

Payee Name: GDD Experts India Private Limited
PAN: AADCG0363Q

4.3 The Investigator agrees to make every effort to supervise and lead the study to completion as planned and in time. Should any circumstances beyond his control delay the project or make it impossible to complete it, the Investigator shall give due notice to the Sponsor so as to minimize the overall project delay or the loss, and return funds to the sponsor on pro rata basis as per Exhibit A. The Investigator and Institution should facilitate return of unused IP to sponsor or other site as per sponsor's instructions.

4.4 The Payee shall raise invoice on the Sponsor and separately specify Service Tax payable, if applicable, on the services rendered and shall also show other necessary details such as Service Tax registration no. etc. so as to enable Sponsor to claim credit for the same as per law. The Sponsor shall verify the invoice and make the payment within 30 days from the receipt of the invoice submitted by Payee. However, if, upon verification by Sponsor, the invoice is found to be incorrect or inappropriate, the same shall be returned by Sponsor to the Payee for correction and revision. No other costs, payments and expenses would be borne by Sponsor unless specifically mentioned in this agreement or mutually agreed in writing in advance. Notwithstanding the foregoing, any payment under this Agreement is subject to deduction of applicable Tax-deduction-at-source (TDS). Sponsor shall deduct the amount and pay balance amount to the Institution.

4.5 The Parties including Site Management Organization hereby agree that Site Management Organization shall be responsible for payment of fees to Institution to performance of their obligation for conducting the clinical trial under this Agreement. The Parties including Institution further agree that SPARC shall not responsible for payment of any fees or cost to Institution. SPARC shall not be liable to pay any sum to Institution even in the event including the default of Site Management Organization in making payment to Institution SPARC shall not be liable to pay to Institution under this Agreement.

5. TERM AND TERMINATION

5.1 Unless otherwise terminated earlier, this Agreement shall commence upon Effective Date and will continue for a period of 5 years from the Effective Date or upon completion of the Clinical Study, whichever is earlier.

5.2 Parties may terminate this Agreement with immediate effect, at any time, if another Party is in breach of any of the defaulting Party's obligations hereunder (including a material failure without just cause to meet a timeline) and fails to remedy such breach, where it is capable of remedy, within thirty (30) days of a written notice from the terminating Party specifying the breach and requiring its remedy. Notwithstanding to the above, the Investigator may terminate the Study, if the Investigator suspects an adverse drug reaction / adverse drug event related to the Study related procedure and of serious nature to take its cognizance, after informing Institution, EC and Sponsor in writing. It is explicitly agreed and acknowledged by the Investigator and Institution that in case of termination of study, no further payment shall be made by Sponsor to Principal Investigator, Institution or any other person under this agreement.

ATTESTED


ATTESTOR

KLE Academy of Higher Education
and Research, BELAGAVI

5.3 Sponsor may terminate this Agreement upon thirty (30) days prior written notice to the Institution and the Principal Investigator, or such shorter notice period as required by a Regulatory Authority (whether State or Central), for any reason whatsoever.

5.4 Without limiting the generality of the foregoing, Sponsor may terminate this Agreement:

5.4.1 if the Investigator is not performing the Study as required in the protocol;

5.4.2 in case of failure of the Investigator and/ or Institution to provide access by Sponsor representatives /Clinical monitor all original medical records necessary to verify entries on study case report forms;

5.4.3 in case of an unauthorized replacement of Investigator;

5.4.4 if Sponsor determine that business or scientific considerations require termination of this Agreement (either full or in part);

5.4.5 if Case report forms provided to Investigator by Sponsor for use in the study are not legibly and/or accurately completed and forwarded the same to Sponsor or its designated representative persistently within 1 week of each Subject's visit date; or

5.4.6 if any malpractices adopted either by Investigator or Institution or both.

5.5 Within thirty (30) days after the termination of this Agreement, the Investigator shall deliver to Sponsor completed CRF pages on RDC.

6. INDEMNIFICATION

6.1 To the maximum extent permitted by applicable laws, the Institution agrees to defend, indemnify and hold harmless the Sponsor and its respective directors, officers, employees and agents (the "Indemnities") and those of its affiliates against all claims, actions, suits, proceedings, liability, losses, damages, charges, orders, fines and expenses, including assessable legal fees and disbursements made or brought by a third party against an Indemnity for harm:

6.1.1 Arising out of or relating to the negligence or willful misconduct or malpractices of the Institution, its employees and agents in performing their obligations under this Agreement;

6.1.2 Arising out of errors or omissions by Institution;

6.1.3 arising out of or relating to the failure of the Institution, its employees and agents to comply with the provisions of this Agreement, the Protocol, or any written instructions of Sponsor concerning the Clinical Study; or

6.1.4 Arising out of the violation of applicable Law related to the conduct of the Clinical Study by the Institution, its employees or agents.

6.2 The Investigator agrees to defend, indemnify and hold harmless the Sponsor and its respective directors, officers, employees and agents (the "indemnities") and those of its

Site Specific Final Version 01_02 Aug 2016
Master Version 01_24 Dec 2015



Page 9 of 17

ATTESTED



Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

affiliates against all claims, actions, suits, proceedings, liability, losses, damages, charges, orders, fines and expenses, including assessable legal fees and disbursements made or brought by a third party against an indemnity for harm:

6.2.1 arising out of or relating to the negligence or willful misconduct or malpractices of the Investigator, his study team member/employee or any person for whom the Investigator is responsible at law in performing their obligations under this Agreement;

6.2.2 arising out of or relating to the failure of the Investigator, his or her study team members or employees and any person for whom the Investigator is responsible at law to comply with the provisions of this Agreement, the Protocol, or any written instructions of Sponsor concerning the Clinical Study ;

6.2.3 arising from a violation of applicable laws and regulations related to the conduct of the Clinical Trial by the Investigator, his or her study team members/ employees or any person for whom the Investigator is responsible at law; or

6.2.4 arising out of from or by reason of any breach or non-frivolous of alleged breach of representation, warranty or covenant herein.


6.3 To the maximum extent permitted by applicable laws, SPONSOR agrees to indemnify and hereby indemnifies, defend and hold the Site; its Principal Investigator, Sub-Investigators and study team, directors, officers and the support staff, agents, the trustees of the Institution harmless from and against any proven liability, loss, damage, costs, expenses, claims, demands and suits (including reasonable attorney's fees and expenses) including arising from and resulting out of (i) the breach of any of Sponsor representations, warranties or covenants set forth in this Agreement or (ii) the performance of the Study or any of its results / outcome including, adverse drug experiences or an injury, death to/of a Study subject directly or indirectly caused by or attributed to the Study , (Iii) any injury or claim arising due to any defect / malfunction of the IP used during the Study in accordance with the provisions of the Protocol and this Agreement.

6.4 Each Party shall use reasonable efforts to inform the other Parties including Site Management Organization promptly of any circumstances of which it is aware that are reasonably likely to give rise to a claim or proceeding and shall keep the other Parties including Site Management Organization reasonably informed of developments in relation to any claim or proceeding, even where a Party decides not to make a claim for indemnification under this Section 5. The Parties including Site Management Organization further agree that they have a right to retain their own counsel to conduct a full defense of any such claim or proceeding.

6.5 The Institution, Investigator and Sponsor shall each give to the others such help as may reasonably be required for the efficient conduct and prompt handling of any claim or proceeding concerning the Clinical Study.

6.6 No settlement or compromise of a claim or proceeding subject to indemnification under this Section 6 shall be binding on a Party without the prior written consent of the other affected Party(s). A Party shall not unreasonably withhold such consent of a settlement or compromise. Without limiting the generality of the preceding, no Party shall admit fault on behalf of an indemnity or enter into a non-monetary settlement that places future obligations on an indemnity without the written approval of the indemnity.

Site Specific Final Version 01_02 Aug 2016
Master Version 01_24 Dec 2015



Page 10 of 17

ATTESTED



Prof. Dr. V.A.KOTHIWALE
Registrar.

KLE Academy of Higher Education
and Research, BELAGAVI

7. CONFIDENTIALITY.

"Confidential Information" means all information (including, without limitation, subject identity, Study Protocol(s), Investigator Brochure, informed consent form, subject diaries, case report forms, clinical data, other data, reports, specifications, computer programs or models and related documentation, know-how, trade secrets, or business or research plans) of Sponsor or Sponsor's Affiliates that are: (1) provided to Institution or Investigator in connection with this Agreement or a Study; (2) cumulative Study data, results, and reports from all sites conducting the Study.

7.1 Sponsor Confidential Information and all tangible expressions, in any media, of Sponsor Confidential Information are the sole property of Sponsor. Each party shall endeavor to identify tangible Confidential Information provided to the other party as "Confidential" given the understanding that failure to do so does not constitute a designation of non-confidentiality when the confidential nature is apparent from context and subject matter. Institution and Investigator agree to treat Sponsor's Confidential Information as it would its own proprietary and confidential information. Institution and Investigator will only accept information from Sponsor which is required for conduct of the Study and which must be maintained for Institution's records.


7.2 Investigator agrees for a period of ten (10) years after the expiration or termination of the Study not to use and disclose Sponsor Confidential Information to any third party. Institution and Investigator agrees not to disclose Sponsor Confidential Information to third parties including Site Management Organization or use except as necessary to conduct a Study and under an agreement by the third party to be bound by the obligations of this Section. Institution and Investigator shall safeguard Sponsor Confidential Information with the same standard of care that is used with own Confidential Information, but in no event less than reasonable care. The parties including Site Management Organization understand and agree that information communicated to EC is "Confidential and Privileged".

7.3 The Parties including Site Management Organization agree to abide by applicable Law relating to the protection of Clinical Trial Subject Personal Information and where Confidential Information is also Personal Information, the obligations in this Section 7 shall remain in force for the period required under such law. The Party that received Personal Information hereunder shall only use or disclose the Personal Information as set out in the Clinical Trial Subject's consent form or as required by applicable Law. Each Party shall give prompt notice to the other Parties including Site Management Organization of any privacy or security breach it has experienced that affects Clinical Trial Subject Personal Information.

8. PUBLICATION

8.1 Institution and/or Investigator shall have the right to publish his own site patients' data generated during the Study. Upon receipt of written instruction from Sponsor, Institution and/or Investigator shall have the right to publish the results of the Study subject to the terms and conditions of this Section 8. Prior to submission for Publication purpose, the Institution and/or Investigator shall provide Sponsor thirty (30) days to review a Publication. If Sponsor requests in writing, the Institution and/or the Investigator shall withhold any publication or presentation an additional sixty (60) days solely to permit Sponsor to seek patent protection and to remove any Confidential Information from all publications. For the purpose of this Section, "Publication"

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

means a paper, article, manuscript, report, poster, Internet posting, presentation slides, abstract, outline, video, instructional material, presentation (in the form of a written summary), or other disclosure of Study Results, in printed, electronic, oral or other form.

8.2 Inclusion of the Institution and/or Investigator in the authorship of any multi-center publication will be based upon substantial contribution to the design, analysis, interpretation of data, drafting and/or critically revising any Publication derived from the Study. The Institution and the Investigator agree that if a Study is part of a multi-center study, any Publication by the Institution and/or Investigator of the results of the Study conducted at Institution shall not be made before the first multi-center publication. In the event there is no multi-center publication within twelve (12) months after a Study has been completed or terminated at all Study sites, and all data has been received, Institution shall have the right to publish its results from the Study, subject to the notice requirements described above.

8.3 Any publication or disclosure by the Investigator contrary to the provisions of this section or without prior written consent of Sponsor shall be void-ab-initio. It is agreed and acknowledged by the Parties including Site Management Organization that in the event of any breach of this Section, Section (7) & (8), in addition to other legal remedies that may be available, Sponsor shall have the right to seek specific performance and other injunctive and equitable relief, in any court having jurisdiction over the Parties and the subject matter hereof.

9. INTELLECTUAL PROPERTY RIGHTS

9.1 All Intellectual Property Rights owned by or licensed to Sponsor prior to and after the date of this Agreement are and shall remain the exclusive property of Sponsor.


9.2 All Intellectual Property Rights owned by or licensed to the Institution or the Investigator prior to and after the date of this Agreement, other than any Intellectual Property Rights arising from the clinical Study, are and shall remain the exclusive property of the Institution or the Investigator, as applicable.

9.3 All Intellectual Property Rights (including Clinical trial data and clinical trial documentation) arising from and relating to the Clinical Study/trial, the Investigational drug or the Protocol (the "Clinical Trial Intellectual Property") shall be the exclusive property of Sponsor and for this purpose, the Institution and the Investigator hereby assign and transfer, and shall cause the trial site team members to assign and transfer, without additional consideration, to Sponsor (or its nominate designee), all their rights and title in and to the Clinical Trial Intellectual Property throughout the world on perpetual basis. The Institution and the Investigator shall execute and deliver, and shall cause the trial site team members to execute and deliver, all such documents and, at Sponsor's expense, do all such other acts as Sponsor may reasonably require in order to vest fully and effectively all Clinical Trial Intellectual Property in Sponsor or its nominate designee.

9.4 The Institution and the Investigator shall promptly disclose to Sponsor any Clinical Trial Intellectual Property generated pursuant to this Agreement and shall treat the Clinical Trial Intellectual Property as Confidential information.

10. MISCELLANEOUS

Site Specific Final Version 01_02 Aug 2016
Master Version 01_24 Dec 2015



Page 12 of 17

ATTESTED



Prof. Dr. V. A. KOTHIWALE

KLE Academy of Higher Education
and Research, BELAGAVI

10 .1 All notices required to be given by one Party to the other shall be deemed to have been properly served when sent by a registered post or any other means of communication acceptable in law to the addresses mentioned in the first page of this Agreement or such appropriate addresses available in public domain.

10 .2 No forbearance or tolerance on the part of the either Party of any breach of this Agreement by the other shall constitute waiver of the requirements of this Agreement.

10 .3 Each Party acknowledges that it is entering into this Agreement solely on its own behalf, and will perform any and all of its obligations or work under this Agreement as an independent contractor. Nothing under this Agreement shall create any other relationship between the Parties including Site Management Organization including without limitation one of principal and agent, employer and employee, or partnership.

10 .4 The Institution and Investigator will be responsible for payment to its employees, study team members and/or agents of all salaries, wages, benefits, workman compensations reimbursable travel, lodging, and other expenses to which the study team members or employees or agents may be entitled to receive for performing services. Investigator will be solely responsible for withholding and paying all applicable taxes of whatsoever in nature, statutory contributions, benefits, dues etc. that may be payable to its employees and/or agents.


10.5 This Agreement constitutes the entire Agreement between the Parties including Site Management Organization and supersedes all prior oral and written understandings between the Parties including Site Management Organization on the subject matter of this Agreement. Any Exhibit, Annexure or otherwise any documents, including but not limited amendment or modification made in reference with this Agreement shall be valid if the same is incorporated in writing on the terms that may be mutually agreed and signed by the authorized signatories of the respective parties including Site Management Organization.

10.6 The Parties including Site Management Organization hereby agree that any provision/s of this Agreement which is held to be invalid and unenforceable in law shall not by itself make this Agreement invalid nor effect the other provisions of this Agreement and the other terms shall remain fully enforceable and valid in law.

10.7 Neither the Investigator nor the Institution may assign this Agreement without the prior written consent of Sponsor. Sponsor may assign any or all of its rights and obligations under this Agreement at any time, provided that Sponsor ensures the assignee is bound by the terms hereof.

10.8 The Investigator and the Institution shall not subcontract the whole or any part of the performance of the clinical Study without the prior written consent of Sponsor. This Agreement ensures to the benefit of and binds the Parties including Site Management Organization and their respective administrators, successors and permitted assigns, and with respect to the Investigator, heirs and executors.

10.9 This Agreement and the obligations of the Parties including Site Management Organization shall be governed by and construed in accordance with the laws of India. The Parties including Site Management Organization agree to submit to the exclusive jurisdiction of courts at Mumbai in connection with this Agreement.



ATTESTED



Prof. Dr. V.A KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

10.10 Neither Party to this Agreement shall be liable for breach of this Agreement to the extent caused by or arising from prohibition or restriction by law or regulation of any Government, fire, flood, storms, weather, strike, lock-out or other labour problems, accident; riots, acts of God, breakdown of communication facilities, breakdown of web host; breakdown of Internet service provider or other events beyond that Party in breach. The Party affected by such circumstances shall promptly notify the other Parties including Site Management Organization in writing when such circumstances cause a delay or failure in performance and shall take whatever reasonable steps are necessary to relieve the effect of such cause as rapidly as reasonably possible. In the event of a delay lasting for four (4) weeks or more, the non-affected Parties shall have the right to terminate this Agreement in accordance the term of this Agreement.

10.11 The provisions of this Agreement which, by their terms, require performance after the termination or expiration of this Agreement; or have application to events that may occur after the termination or expiration of this Agreement, will survive the termination or expiration of this Agreement. All indemnity obligations and any applicable Indemnification procedures will be deemed to survive the termination or expiration of this Agreement.

11. INTERPRETATION

11.1 Unless the context requires otherwise:

11.1.1. references to this Agreement are to this Agreement as it is from time to time amended;

11.1.2. headings are for convenience only and shall not affect interpretation;

11.1.3. references to the singular include the plural and vice versa, and references to one gender include all genders;


11.1.4. any phrase introduced by the expressions "including", "include" or any similar expression shall be construed as illustrative and shall not limit the sense of the words preceding those terms;

11.1.5. reference to any law: shall be deemed to include any bye-laws, licences, statutory instruments, rules, regulations, orders, notices, directions, consents or permissions made under that law; and shall be construed as referring to any law which replaces, re-enacts, amends or consolidates such law (with or without modification) at any time;

11.1.6. references to "writing" or "written" include any modes of reproducing words in a legible and non transitory form but do not include writing on the screen of a visual display unit or other similar device;

11.1.7. references to a numbered clause are references to the clause of or to this Agreement so numbered.

11.2 The parties hereto have participated jointly in the negotiation and drafting of this Agreement and, in the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as jointly drafted by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of



ATTESTED



Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

the authorship of any provision of this Agreement.

IN WITNESS WHEREOF the parties have executed this Agreement after carefully reading the contents of this Agreement out of their free will and consent without any kind of force or coercion on them.

- Signature page follows-

BY SPONSOR:

Sun Pharma Advanced Research Company Ltd.

Signature: *Ajay Singh Solanki*

Name: Mr. Ajay Singh Solanki

Designation: GM, Clinical Operations

(who by his signature hereto warrants his authority)

Date: *22.08.2016*

Place: *MUMBAI.*

BY INSTITUTION:

KLEs Dr. Prabhakar Kore Hospital & Medical Research Centre

Signature:

Name: Dr. M. V. Jali

Designation: Medical Director

(who by his/her signature hereto warrants his/her authority)

Date:

Place:

BY INVESTIGATOR

KLEs Dr. Prabhakar Kore Hospital & Medical Research Centre

Signature:

Name: Dr. Rohan Bhise

Designation: Principal Investigator
(who by his signature hereto warrants his authority)

Date:

Place:

BY SITE MANAGEMENT ORGANIZATION

GDD Experts India Pvt. Ltd.

Signature: *Vinod Gyanchandani*

Name: Vinod Gyanchandani



Designation: Head-Clinical Operations
(who by his signature hereto warrants his authority)

Date: *21/Aug/2016*

Place: *Nagpur*

Site Specific Final Version 01_02 Aug 2016
Master Version 01_24 Dec 2015



ATTESTED

[Signature]

Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

EXHIBIT-A

Financial Grant

Protocol No.: CLR_16_13


Protocol Title: "A Randomized, Open Label, Two Period, Single Dose, Crossover, Bioavailability Study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) and Abraxane® in Subjects with Locally Recurrent or Metastatic Breast Cancer."

Investigator's Name: Dr. Rohan Bhise

Institute Name: KLEs Dr. Prabhakar Kore Hospital & Medical Research Centre

Heads	Amount in INR with breakup	Schedule for Generating Invoice
Screen failure cost up to 5 subjects	8000/subject	Monthly
Investigator fee per completed subjects	Screening Visit	Monthly
	Cycle 1 Day1	
	Cycle 1 Day 8	
	Cycle 1 Day 15	
	Cycle 2 Day 1	
	Cycle 2 Day 8	
	Cycle 2 Day 15	
	End of study visit	
Total	75000	
Study coordinator salary/month (From Site Initiation date till Site Close-out date)	15000	Monthly
Phlebotomist charges/ completed subject	Cycle 1	Monthly
	Cycle 2	
	Total	
IP reconstitute or charges per reconstitute	1000	Monthly
Subject travel reimbursement/visit	1000	Monthly
Subject study participation in period 1 and period 2 *	Cycle 1	Monthly
	Cycle 2	
	Total	
Administrative cost/ month (internet, courier, stationary etc.) (From Site Initiation date till Site Close-out date)	2500	Monthly
Ethics committee charges	As per actual	Monthly
Hospitalization charges for cycle 1 & cycle 2	As per actual	Monthly
SAE management	As per actual	Monthly
Local lab charges	As per actual	Monthly
Institutional overheads charges	20 %	Monthly


ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

CONFIDENTIAL

- 1) All invoices will be addressed to: Mr. Ashok Gupta, Sun Pharma Advanced Research Company Ltd., Clinical Research Dept., 17/B, Mahal Industrial Estate, Mahakali Caves Road, Andheri (E), Mumbai 400093, Maharashtra, India.
- 2) *As per Indian Council for Medical Research guidelines 2006 on "Ethical Guidelines for Biomedical Research on Human Participants"

Site Specific Final Version 01_02 Aug 2016
Master Version 01_24 Dec 2015



Page 17 of 17

ATTESTED



Prof. Dr. V. K. KOTHIWALE
Principal
KLE Academy of Higher Education
and Research, BELAGAVI

417



सत्यमेव जयते


INDIA NON JUDICIAL

Government of Karnataka

Rs. 300

e-Stamp

Certificate No. : IN-KA88069366324232R
Account Reference : NONACC (FI)/ kakstci08/ UTTARHALLI/KA-BA
Certificate Issued Date : 04-Apr-2019 03:30 PM
Unique Doc. Reference : SUBIN-KAKAKSFCL0806375160282325R
Purchased by : IQVIA RDS INDIA PRIVATE LIMITED
Description of Document : Article 12 Bond
Description : CLINICAL TRIAL AGREEMENT
Consideration Price (Rs.) : 0 (Zero)
First Party : IQVIA RDS INDIA PRIVATE LIMITED
Second Party : KLES KARNATAKA
Stamp Duty Paid By : IQVIA RDS INDIA PRIVATE LIMITED
Stamp Duty Amount (Rs.) : 300 (Three Hundred only)



Please write or type below this line

Statutory Alert:

1. The authenticity of this Stamp Certificate should be verified at "www.sticstamp.com". Any discrepancy in the details on this Certificate and as available on the website renders it invalid.
2. The onus of checking the legitimacy is on the users of the certificate.
3. In case of any discrepancy please inform the Competent Authority.

TESTED

Prof. Dr. V. A. KOTHIWALE
 Registrar
 KLE Academy of Higher Education
 and Research, BELAGAVI

**AMENDMENT NUMBER TWO
TO CLINICAL TRIAL AGREEMENT
PROTOCOL NO. K-877-302**

This Amendment Number Two to Clinical Trial Agreement ("Amendment No. 2") is entered by and among:

Dr. Veerappa Annasaheb Kothiwale, having a place of business at KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, NehruNagar, Belagavi- 590 010, Karnataka, India ("Investigator"), and;

KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, having a place of business at NehruNagar, Belagavi- 590 010, Karnataka, India ("Institution"), and;

GDD Experts India Pvt. Ltd having a place of business at Ground Floor, Gulmohar Apartment, Opposite Hislop College, Nagpur - 440 001, Maharashtra, India (the "Research Company"), and

IQVIA RDS (India) Private Limited, (formerly Quintiles Research (India) Private Limited) having a place of business at III Floor, Etamin Block, Prestige Technology Park, Sarape- Marathahalli Outer Ring Road Bangalore – 560103, Karnataka, India ("IQVIA"), representing the interests of Kowa Research Institute, Inc. (the "Sponsor"), and; is effective as of the date last signed below ("Effective Date").

WITNESSETH:

WHEREAS, IQVIA, Institution, Investigator and Research Company are parties to a Clinical Trial Agreement effective as of 25 November 2017, as amended by Amendment No. 1 dated 25 March 2019 (collectively referred to as the "Agreement") pursuant to which Institution and Investigator agreed to conduct a clinical trial in connection with the conduct of a study (the "Study") relating to Protocol No. K-877-302, Protocol entitled "Pemafibrate to Reduce cardiovascular Outcomes by reducing triglycerides in diabetic patients (PROMINENT)" (the "Protocol"), and the parties desire to amend such Agreement, and;

NOW THEREFORE, in consideration of the mutual promises and covenants set forth herein, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereby agree to amend the Agreement as follows:

1. **Additional Invoiceable Items.** The Agreement is hereby amendment to include the following invoiceable items:

Subject Identification Fees. Reimbursement for Subject identification in the amount of **Seven Thousand Indian Rupees (7,000.00 INR)** will be paid to the Investigator (Payee) to cover for the time and effort expended in Subject identification, data base search, laboratory result evaluation and medical chart review. Payment will be made for each screen failed patient provided approval is obtained from IQVIA India Medical Advisor prior to pre-screening the Subject and information is entered in the interactive web response system (IWRS).

Notwithstanding the Effective Date of this Amendment No. 2, payment for this invoiceable cost will be made retroactively from 26 February 2019

2. All terms and conditions of the Agreement not expressly amended by this Amendment #2 remain in full force and effect.

ATTESTED



Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI


419

IN WITNESS WHEREOF, this Amendment #2 has been executed by the parties hereto through their duly authorized officers on the date(s) set forth below.

**ACKNOWLEDGED AND AGREED BY IQVIA RDS (India) Private Limited
(formerly Quintiles Research (India) Private Limited)**

By: Shweta Pradhan

Title: Director, Clinical Site Management


Signature: 

Date: 29/Apr/2019.

**ACKNOWLEDGED AND AGREED BY KLES DR. PRABHAKAR KORE HOSPITAL &
MEDICAL RESEARCH CENTRE::**

By: Dr. M.V.Jali

Title: Medical Director


Signature: 

Date: 30/APR/2019

ACKNOWLEDGED AND AGREED BY THE INVESTIGATOR:

By: Dr. Veerappa Annasaheb Kothiwale

Title: Principal Investigator


Signature: 

Date: 24/APR/2019

Protocol Number: K-877-302_ Dr. Kothiwale _ CTA Amendment#2_ 06Mar2019
CONFIDENTIAL

Page 2 of 3

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

420

Research Company agrees to abide by all obligations placed on Institution in the provisions of this Agreement concerning Confidentiality (Section 3); Intellectual Property (Section 4); Publication Rights (Section 5); Debarment (Section 10); Anti Kickback and Anti Fraud (Section 12); and Anti-Bribery (Section 13)

By: Dr. Vinod Gyanchandani

Title: Head - Clinical Operations

Signature: 

Date: 11/ April 2019

Protocol Number: K-877-302_ Dr. Kothiwale _ CTA Amendment#2_ 06Mar2019
CONFIDENTIAL

Page 3 of 3



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

421






सत्यमेव जयते

INDIA NON JUDICIAL

Government of Karnataka

e-Stamp

Certificate No. : IN-KA65984783473227R
 Certificate Issued Date : 05-Mar-2019 01:01 PM
 Account Reference : NONACC (FI)/ kaksfcl08/ UTTARHALLI/ KA-BA
 Unique Doc. Reference : SUBIN-KAKAKSFCL0863928414111785R
 Purchased by : IQVIA RDS INDIA PRIVATE LIMITED
 Description of Document : Article 12 Bond
 Description : CLINICAL TRIAL AGREEMENT
 Consideration Price (Rs.) : 0
 (Zero)
 First Party : IQVIA RDS INDIA PRIVATE LIMITED
 Second Party : KLES KARNATAKA
 Stamp Duty Paid By : IQVIA RDS INDIA PRIVATE LIMITED
 Stamp Duty Amount(Rs.) : 300
 (Three Hundred only)



Please write or type below this line

Statutory Alert:

1. The authenticity of this Stamp Certificate should be verified at "www.shcilestamp.com". Any discrepancy in the details on this Certificate and as available on the website renders it invalid.
2. The onus of checking the legitimacy is on the users of the certificate.
3. In case of any discrepancy please inform the Competent Authority.

ATTESTED

V.A.KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

AMENDMENT NUMBER ONE TO CLINICAL TRIAL AGREEMENT

This Amendment to the Clinical Trial Agreement ("Amendment #1") is between IQVIA RDS (India) Private Limited, (formerly Quintiles Research (India) Private Limited) having a place of business at III Floor, Etamin Block, Prestige Technology Park, Sarjapur- Marathahalli Outer Ring Road Bangalore – 560103, Karnataka, India ("IQVIA") and KLES Dr. Prabhakar Kore Hospital & Medical Research Centre having a place of business at NehruNagar, Belgavi-590 010, Karnataka, India ("Institution") and Dr.Veerappa Annasaheb Kothiwale having a place of business at KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, NehruNagar, Belgavi-590 010, Karnataka, India ("Investigator") and GDD Experts India Pvt. Ltd having a place of business at Ground floor, Gulmohar Apartment, Opposite Hislop College, Nagpur-440 001, Maharashtra, India ("Research Company") and is effective as of the date last signed below.

WITNESSETH:

WHEREAS, IQVIA, Institution, Invstigator and Research Company are parties to an agreement entitled **PROMINENT "PEMAFIBRATE TO REDUCE CARDIOVASCULAR OUTCOMES BY REDUCING TRIGLYCERIDES IN PATIENTS WITH DIABETES"** bearing the Protocol number **K-877-302** effective as of 25 November 2017 (the "Agreement"), and the parties desire to amend such Agreement;

WHEREAS, IQVIA is providing clinical research organisation services to Kowa Research Institute, Inc. ("Sponsor") under a separate contract between IQVIA and Sponsor, and IQVIA's services include monitoring of the Study and contracting with clinical research sites;

NOW THEREFORE, in consideration of the mutual promises and covenants set forth herein, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereby agree to amend the Agreement as follows:

- Change in Quintiles' corporate name.** As of the Effective Date of this Amendment #1, following the name change described in the above recital, the parties acknowledge that:
 - all references to **Quintiles Research (India) Private Limited** in the Agreement shall be updated to refer to **IQVIA RDS (India) Private Limited** (formerly **Quintiles Research (India) Private Limited**) and
 - all references to the defined term "**Quintiles**" shall now be deemed replaced by references to "**IQVIA**".

Kowa Research Institute, Inc
Protocol Number: K-877-302
KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, Dr. Veerappa Annasaheb Kothiwale,
CTA Amendment #1_7 Mar 2019

CONFIDENTIAL

Page 1 of 4

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

423

2. **Change in the notice details.** Section K, on Invoices, as found in Attachment A, Budget and Payment Schedule portion of the Agreement is hereby amended by deleting it in its entirety and replacing it with the paragraph below:

K. INVOICES

Original Invoices pertaining to this Study for the following items must be submitted to IQVIA for reimbursement at the following address:

IQVIA RDS (India) Private Limited
 (formerly Quintiles Research (India) Private Limited)
 Attn: Accounts Payable
 Address: III Floor, Etamin Block, Prestige Technology Park,
 Sarjapur - Marathahalli Outer Ring Road Bangalore – 560103,
 Karnataka, India
 Phone: +91 80 71317779/78

Please note that invoices will not be processed unless they reference the Sponsor name, Protocol number, Investigator name, Site number and Payee GST registration number. Upon receipt and verification of the invoices, reimbursement for invoices will be included with the next regularly scheduled payment for subject activity.

1. Attachment A **BUDGET & PAYMENT SCHEDULE**, Section N. Budget Table of the Agreement shall be deleted in its entirety and replaced as follows, to reflect the Protocol Amendment Visit 4 change from a phone visit to an on-site visit with the addition of the following assessments:
- Blood sample collection
 - Lab handling and/or shipping of specimen
 - Physician, Simple (e.g. interim visits) - Per Visit
 - Patient Reimbursement, Expenses, Patient Travel - Per Visit


N- BUDGET TABLE:

Visit	Total Cost Per Visit including 20% Overhead (INR)
PreScreen	13,578
Screen	19,998
Visit 2	17,331
Visit 3	4,679
Visit 4	8,229
Visit 5	13,304
Visit 6	12,535
Visit 7	12,616
Visit 8	4,679

Kowa Research Institute, Inc
 Protocol Number: K-877-302
 KLES Dr. Prabhakar Kore Hospital & Medical Research Centre_ Dr. Veerappa Annasaheb Kothiwale_
 CTA Amendment #1_7 Mar 2019

CONFIDENTIAL

Page 2 of 4

ATTESTED

 Prof. Dr. V.A.KOTHIWALE
 Registrar
 KLE Academy of Higher Education
 and Research, BELAGAVI

Visit	Total Cost Per Visit including 20% Overhead (INR)
Visit 9	13,790
Visit 10	4,679
Visit 11	12,616
Visit 12	4,679
Visit 13	12,616
Visit 14	4,679
Visit 15	13,790
Visit 16	4,679
Visit 17	12,616
Visit 18	4,679
Visit 19	12,616
Visit 20	4,679
Visit 21	13,790
Visit 22	4,679
Visit 23	12,616
Visit 24	4,679
Visit 25	12,616
Visit 26	4,679
Visit 27	13,790
Visit 28	4,679
Visit 29	12,616
Visit 30	4,679
Visit 31	12,616
Visit 32	4,679
Visit 33	13,790
Visit 34	4,679
CSED Visit	15,515
Post Study Safety Call	4,060
Retest	8,169
Off*	11,931
Total Cost Per Patient (Rs)**	357,229

* Visit can occur more than once
 **The total does not include Retest & Off.

All terms and conditions of the Agreement not expressly amended by this Amendment #1 remain in full force and effect.

Kowa Research Institute, Inc
 Protocol Number: K-877-302
 KLES Dr. Prabhakar Kore Hospital & Medical Research Centre_ Dr. Veerappa Annasaheb Kothiwale_
 CTA Amendment #1_7 Mar 2019

CONFIDENTIAL

Page 3 of 4

ATTESTED



Prof. Dr. V.A. KOTHIVALE
 Registrar
 KLE Academy of Higher Education
 and Research, BELAGAVI

425

IN WITNESS WHEREOF, this Amendment #1 has been executed by the parties hereto through their duly authorized officers on the date(s) set forth below.

ACKNOWLEDGED AND AGREED BY IQVIA RDS (INDIA) PRIVATE LIMITED

By: Gaurav Mathur

Title: Director, India Regulatory Affairs


Signature: 

Date: 07th March 2019

ACKNOWLEDGED AND AGREED BY THE INVESTIGATOR:

Name: Dr. Veerappa Annasaheb Kothiwale

Title: Principal Investigator

Signature: 

Date: 12/ Mar / 2019

ACKNOWLEDGED AND AGREED BY KLES DR. PRABHAKAR KORE HOSPITAL & MEDICAL RESEARCH CENTRE:

By: Dr.M.V.Jali

Title: Medical Director

Signature: 

Date: 25/ Mar / 2019

ACKNOWLEDGED AND AGREED BY GDD EXPERTS INDIA PVT. LTD:

By: Dr. Vinod Gvanchandani

Title: Head-Clinical Operations

Signature: 

Date: 08/ March / 2019

Kowa Research Institute, Inc
Protocol Number: K-877-302
KLES Dr. Prabhakar Kore Hospital & Medical Research Centre_ Dr. Veerappa Annasaheb Kothiwale_
CTA Amendment #1_7 Mar 2019

CONFIDENTIAL

Page 4 of 4

ATTESTED



Prof. Dr. V A KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

426

AMENDMENT NUMBER ONE TO CLINICAL TRIAL AGREEMENT

This Amendment to the Clinical Trial Agreement ("Amendment #1") is between IQVIA RDS (India) Private Limited, (formerly Quintiles Research (India) Private Limited) having a place of business at III Floor, Etamin Block, Prestige Technology Park, Sarjapur- Marathahalli Outer Ring Road Bangalore - 560103, Karnataka, India ("IQVIA") and KLES Dr. Prabhakar Kore Hospital & Medical Research Centre having a place of business at NehruNagar, Belgavi-590 010, Karnataka, India ("Institution") and Dr. Veerappa Annasaheb Kothiwale having a place of business at KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, NehruNagar, Belgavi-590.010, Karnataka, India ("Investigator") and GDD Experts India Pvt. Ltd having a place of business at Ground floor, Gulmohar Apartment, Opposite Hislop College, Nagpur-440 001, Maharashtra, India ("Research Company") and is effective as of the date last signed below:

WITNESSETH:

WHEREAS, IQVIA, Institution, Investigator and Research Company are parties to an agreement entitled PROMINENT "PEMAFIBRATE TO REDUCE CARDIOVASCULAR OUTCOMES BY REDUCING TRIGLYCERIDES IN PATIENTS WITH DIABETES" bearing the Protocol number K-877-302 effective as of 25 November 2017 (the "Agreement"), and the parties desire to amend such Agreement;

WHEREAS, IQVIA is providing clinical research organisation services to Kowa Research Institute, Inc. ("Sponsor") under a separate contract between IQVIA and Sponsor, and IQVIA's services include monitoring of the Study and contracting with clinical research sites;

NOW THEREFORE, in consideration of the mutual promises and covenants set forth herein, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereby agree to amend the Agreement as follows:

- I. Change in Quintiles' corporate name. As of the Effective Date of this Amendment #1, following the name change described in the above recital, the parties acknowledge that:
 - (a) all references to Quintiles Research (India) Private Limited in the Agreement shall be updated to refer to IQVIA RDS (India) Private Limited (formerly Quintiles Research (India) Private Limited) and;
 - (b) all references to the defined term "Quintiles" shall now be deemed replaced by references to "IQVIA".

Kowa Research Institute, Inc
Protocol Number: K-877-302
KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, Dr. Veerappa Annasaheb Kothiwale,
CTA Amendment #1_22 Nov 2018

CONFIDENTIAL

Page 1 of 4

ATTESTED



Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

428

2. **Change in the notice details.** Section K, on Invoices, as found in Attachment A, Budget and Payment Schedule portion of the Agreement is hereby amended by deleting it in its entirety and replacing it with the paragraph below:

K. INVOICES

Original Invoices pertaining to this Study for the following items must be submitted to IQVIA for reimbursement at the following address:

IQVIA RDS (India) Private Limited
 (formerly Quintiles Research (India) Private Limited)
 Attn: Accbunts Payable
 Address: III Floor, Etamin Block, Prestige Technology Park,
 Sarjapur - Marathahalli Outer Ring Road Bangalore – 560103,
 Karnataka, India
 Phone: +91 80 71317779/78

Please note that invoices will not be processed unless they reference the Sponsor name, Protocol number, Investigator name, Site number and Payee GST registration number. Upon receipt and verification of the invoices, reimbursement for invoices will be included with the next regularly scheduled payment for subject activity.

1. Attachment A **BUDGET & PAYMENT SCHEDULE**, Section N. Budget Table of the Agreement shall be deleted in its entirety and replaced as follows, to reflect the Protocol Amendment Visit 4 change from a phone visit to an on-site visit with the addition of the following assessments:
- Blood sample collection
 - Lab handling and/or shipping of specimen
 - Physician, Simple (e.g. interim visits) - Per Visit
 - Patient Reimbursement, Expenses, Patient Travel - Per Visit

N- BUDGET TABLE:

Visit	Total Cost Per Visit including 20% Overhead (INR)
PreScreen	13,578
Screen	19,998
Visit 2	17,331
Visit 3	4,679
Visit 4	8,229
Visit 5	13,304
Visit 6	12,535
Visit 7	12,616
Visit 8.	4,679

Kowa Research Institute, Inc
 Protocol Number: K-877-302
 KLES' Dr. Prabhakar Kore Hospital & Medical Research Centre_ Dr. Veerappa Annasaheb Kothiwale_
 CTA Amendment #1_22 Nov 2018

CONFIDENTIAL

Page 2 of 4

ATTESTED



Prof. Dr. V.A. KOTHIWALE
 Registrar
 KLE Academy of Higher Education
 and Research, BELAGAVI

Visit	Total Cost Per Visit including 20% Overhead (INR)
Visit 9	13,790
Visit 10	4,679
Visit 11	12,616
Visit 12	4,679
Visit 13	12,616
Visit 14	4,679
Visit 15	13,790
Visit 16	4,679
Visit 17	12,616
Visit 18	4,679
Visit 19	12,616
Visit 20	4,679
Visit 21	13,790
Visit 22	4,679
Visit 23	12,616
Visit 24	4,679
Visit 25	12,616
Visit 26	4,679
Visit 27	13,790
Visit 28	4,679
Visit 29	12,616
Visit 30	4,679
Visit 31	12,616
Visit 32	4,679
Visit 33	13,790
Visit 34	4,679
CSED Visit	15,515
Post Study Safety Call	4,060
Retest	8,169
Off*	11,931
Total Cost Per Patient (Rs)**	357,229

* Visit can occur more than once

**The total does not include Retest & Off.

All terms and conditions of the Agreement not expressly amended by this Amendment #1 remain in full force and effect.

Kowa Research Institute, Inc

Protocol Number: K-877-302

KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, Dr. Veerappa Annasaheb Kothiwale,

CTA Amendment #1_22 Nov. 2018

CONFIDENTIAL

Page 3 of 4

ATTESTED



Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

430

IN WITNESS WHEREOF, this Amendment #1 has been executed by the parties hereto through their duly authorized officers on the date(s) set forth below.

ACKNOWLEDGED AND AGREED BY IQVIA RDS (INDIA) PRIVATE LIMITED

By: Gaurav Mathur

Title: Director, India Regulatory Affairs

Signature: _____

Date: 22nd Nov. 2018

ACKNOWLEDGED AND AGREED BY THE INVESTIGATOR:

Name: Dr. Veerappa Annasaheb Kothiwale

Title: Principal Investigator

Signature: _____

Date: 26/11/2018

ACKNOWLEDGED AND AGREED BY KLES DR. PRABHAKAR KORE HOSPITAL & MEDICAL RESEARCH CENTRE:

By: Dr. M.V. Jali

Title: Medical Director

Signature: _____

Date: 04/12/2018

ACKNOWLEDGED AND AGREED BY GDD EXPERTS INDIA PVT. LTD:

By: Dr. Vinod Gvanchandani

Title: Head-Clinical Operations

Signature: _____

Date: 07/Dec/2018

Kowa Research Institute, Inc
Protocol Number: K-877-302
KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, Dr. Veerappa Annasaheb Kothiwale
CTA Amendment #1_22 Nov.2018

CONFIDENTIAL

Page 4 of 4

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

431




सत्यमेव जयते

INDIA NON JUDICIAL Government of Karnataka

e-Stamp

Certificate No.	: IN-KA26553303732998P
Certificate Issued Date	: 03-Nov-2017 12:31 PM
Account Reference	: NONACC (FI)/kaksfcl08/ RAJARAJESHWARI NAGAR1/ KA-BN
Unique Doc. Reference	: SUBIN-KAKAKSFCL0803156565987465P
Purchased by	: QUINTILES RESEARCH INDIA PVT LTD
Description of Document	: Article 12 Bond
Description	: CLINICAL TRIAL AGREEMENT
Consideration Price (Rs.)	: 0 (Zero)
First Party	: QUINTILES RESEARCH INDIA PVT LTD
Second Party	: KLES KARNATAKA
Stamp Duty Paid By	: QUINTILES RESEARCH INDIA PVT LTD
Stamp Duty Amount(Rs.)	: 300 (Three Hundred only)



-----Please write or type below this line-----

Statutory Alert:

1. The authenticity of this Stamp Certificate should be verified at www.shclastamp.com. Any discrepancy in the details on this certificate and as available on the website renders it invalid.
2. The onus of checking the legitimacy is on the user of this certificate.
3. In case of any discrepancy please inform the Competent Authority.

ATTESTED

P. P. KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

432

CLINICAL TRIAL AGREEMENT

The Clinical Trial Agreement ("**Agreement**") is made by and between:

KLES Dr. Prabhakar Kore Hospital & Medical Research Centre having a place of business at NehruNagar, Belagavi - 590 010, Karnataka, India (the "**Institution**"), and

Dr. Veerappa Annasaheb Kothiwale having a place of business at KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, NehruNagar, Belagavi - 590 010, Karnataka, India (the "**Investigator**"), and

GDD Experts India Pvt. Ltd at Ground Floor, Gulmohar Apartment, Opposite Hislop College, Nagpur - 440 001, Maharashtra, India (the "**Research Company**"), and

Quintiles Research (India) Private Limited, having a place of business at B 101-106, Shapath IV, Opposite Karnavati Club, Sarkhej Gandhinagar Road,, Ahmedabad 380051, Gujarat, India ("**Quintiles**"),

Each a "**Party**" and together the "**Parties**".

Protocol Number:	K-877-302
Protocol Title:	PROMINENT PEMA FIBRATE TO REDUCE CARDIOVASCULAR OUTCOMES BY REDUCING TRIGLYCERIDES IN PATIENTS WITH DIABETES
Protocol Date:	16 November 2016
Sponsor:	Kowa Research Institute, Inc.
Country where Site is Conducting Study	India
Investigator:	Dr. Veerappa Annasaheb Kothiwale "an employee of Institution"
Key Enrollment Date:	100 Calendar Days after Site Initiation Visit date (being the date by which Site must enroll at least one [1] subject as more specifically set out in section 1.8 "Key Enrollment Date" below)
IRB/IEC	Ethics Committee of KLE University, Belagavi, JNMC Campus, NehruNagar, Belagavi-590 010, Karnataka, India EC chairperson name : Dr. Subarna Roy Contact No. of the EC chairperson: +91-9449033133

The following additional definitions shall apply to this Agreement:

Protocol: the clinical protocol referenced above as it may be modified from time to time by the Sponsor (defined below).

Case Report Form or **CRF:** paper or electronic document to be used by Site to record all applicable Protocol-required information to be reported to Sponsor on each Study Subject (defined below).

Study: the clinical trial that is to be conducted in accordance with this Agreement and the Protocol for purposes of gathering information about the Investigational Product identified in the Protocol.

Study Subject: an individual who participates in the Study, either as a recipient of the Investigational Product (defined below) or as a control.

Kowa Research Institute, Inc.
Protocol Number: K-877-302


CONFIDENTIAL

India Specific CTA template dated 07Jul2017

Page 1 of 24


KLES Dr. Prabhakar Kore Hospital & Medical Research Centre_Dr. Veerappa Annasaheb Kothiwale_10Nov2017
_AN_clean

ATTESTED


Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI


433

Study Staff: the individuals involved in conducting the Study under the direction of the Investigator.

Investigational Product: the investigational drug identified in the Protocol that is being tested in the Study.

Good Clinical Practices or GCPs: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Harmonised Tripartite Guideline for Good Clinical Practice as amended from time to time and the principles set out in the Declaration of Helsinki as revised from time to time.

Sponsor: an individual, institution, company or organization that takes the responsibility to initiate, manage or finance the Study, but does not actually conduct the Study.

Medical Records: the Study Subjects' primary medical records kept by the Institution on behalf of the Investigator.

Source Documents: all recorded original observations and notations of clinical activities and all reports and records necessary for the evaluation and reconstruction of the Study, regardless of form, as maintained by the Investigators, including all laboratory reports, ECG tracings, x-rays, radiologist reports, biopsy reports, ultrasound photographs, Study Subject progress notes, hospital charts, pharmacy records and any other similar reports or records of any procedure performed during the Study. Source Documents include workbooks only when information is recorded directly onto such forms. In the event that the workbook is used as a Source Document by a physician not identified as a primary or secondary investigator in the Protocol or not under the direct supervision of the Investigator, the workbook must be signed and dated by the individual making the entry.

MCI Regulations: Indian Medical Council (Professional Conduct, Etiquette and Ethics) (Amendment) Regulations, 2009 – Part -1, as may be amended from time to time or any replacement regulations.

Study Data: all data relating to Subjects that are, collected by or on behalf of the Site in connection with the Study.

Study Documentation: all (i) Source Documents, (ii) Study Data and, (iii) to the extent not included in (i) or (ii), all records, accounts, notes and reports relating to the Study, whether in written, electronic, video or other tangible form, including: Case Report Forms; data correction forms; monitoring logs; appointment schedules; case histories; informed consent forms and related documentation; records of receipt, use, processing and disposition of the Investigational Product approvals of (a) the applicable Protocol and any amendments thereto and (b) the informed consent forms by the Investigator, Site and the IRB/IEC; copies of all correspondence to or from Quintiles related to the Study; the Investigator, any other Study Staff, any IRB/IEC and any Governmental Official with respect to the Study; any other documentation required by the Protocol, this Agreement, or Applicable Law. While "Study Documentation" may include information derived from a Study Subject's Medical Record, "Study Documentation" does not include any portion of the Medical Record.

Government Official: any officer or employee of a government or of any ministry, department, agency, or instrumentality of a government; any person acting in an official capacity on behalf of a government or of any ministry, department, agency, or instrumentality of a government; any officer or employee of a company or of a business owned in whole or part by a government; any officer or employee of a public international organization such as the World Bank or the United Nations; any officer or employee of a political party or any person acting in an official capacity on behalf of a political party; and/or any candidate for political office; any doctor, pharmacist, or other

Kowa Research Institute, Inc.

Protocol Number: K-877-302

India Specific CTA template dated 07Jul2017


KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, Dr. Veerappa Annasaheb Kothiwale, 10Nov2017

_AN_clean

CONFIDENTIAL

Page 2 of 24

ATTESTED


Prof. Dr. V. A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

434

healthcare professional who works for or in any hospital, pharmacy or other healthcare facility owned or operated by a government agency, ministry or department.

Item(s) of Value: should be interpreted broadly and may include, but is not limited to, money or payments or equivalents, such as gift certificates; gifts or free goods; meals, entertainment, or hospitality; travel or payment of expenses; provision of services; purchase of property or services at inflated prices; assumption or forgiveness of indebtedness; intangible benefits, such as enhanced social or business standing (e.g., making donations to government official's favored charity); and/or benefits to third persons related to government officials (e.g., close family members).

Dual Capacity: the capacity of holding a Government Official position and being a party to this Agreement.

RECITALS:

WHEREAS, Quintiles is providing clinical research organisation services to Sponsor under a separate contract between Quintiles and Sponsor and Quintiles' services include monitoring of the Study and contracting with clinical research sites;

WHEREAS, the Institution and Investigator (hereinafter jointly the "Site") are willing to conduct the Study and Quintiles requests the Site to undertake such Study.

NOW THEREFORE, the following is agreed:

1. CONDUCT OF THE STUDY

1.1. Compliance with Laws, Regulations, and Good Clinical Practices

Site agrees that Site and Study Staff shall perform the Study at Institution in strict accordance with this Agreement, the Protocol, any and all applicable local, national and international laws, regulations and guidelines ("**Applicable Law**") including in particular, but without limitation, GCPs, MCI Regulations and state and local tax and finance regulations. Site and Study Staff acknowledge that Quintiles and Sponsor, and their respective affiliates, need to adhere to the provisions of (i) the Bribery Act 2010 of the United Kingdom (Bribery Act); (ii) the Foreign Corrupt Practices Act 1977 of the United States of America (FCPA) and (iii) any other applicable anti-corruption legislation.

1.2. Informed Consent Form

Site agrees to use an informed consent form ("**ICF**") that has been reviewed by Sponsor and is approved by and in accordance with applicable regulations and the requirements of the Institutional Review Board ("**IRB**") or Independent Ethics Committee ("**IEC**") that is responsible for reviewing the Study. Prior to a Study Subject participating in the Study, Site shall obtain from such Study Subject a properly executed ICF.

1.3. Medical Records and Study Documentation

1.3.1. Collection, Storage and Destruction: Site shall ensure the prompt, complete, and accurate collection, recording and classification of the Medical Records and Study Documentation.

Site shall

- (i) maintain and store Medical Records and Study Documentation in a secure manner with physical and electronic access restrictions, as applicable and environmental controls appropriate to the applicable data type and in accordance with Applicable Laws, and industry standards; and
- (ii) protect the Medical Records and Study Documentation from unauthorized use, access, duplication, and disclosure. If directed by Sponsor or Quintiles, Site will

Kowa Research Institute, Inc.

Protocol Number: K-877-302

India Specific CTA template dated 07Jul2017

KLES Dr. Prabhakar Kore Hospital & Medical Research Centre_ Dr. Veerappa Annasaheb Kothiwale_10Nov2017

_AN_clean

CONFIDENTIAL

Page 3 of 24

ATTESTED



Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

435

submit Study Documentation using the electronic system provided by Sponsor or Quintiles, or their designated representative and in accordance with Sponsor's instructions for electronic data entry. Site shall prevent unauthorized access to the Study Documentation by maintaining physical security of the electronic system and ensuring that Study Staff maintain the confidentiality of their passwords. Investigator agrees to collect all Study Documentation in Medical Records prior to entering it into the CRF. Site shall ensure the prompt submission of CRFs; and (iii) take measures to prevent accidental or premature destruction or damage of these documents, for as long as required by Applicable Law. . Neither Institution nor Investigator shall destroy or permit the destruction of any Medical Records or Study Documentation and Institution shall continue to store Medical Records and Study Documentation, at the Sponsor's expense, for any period that the Sponsor may request in writing after retention is no longer required by any Applicable Law.

If the Investigator leaves the Institution, then responsibility for maintaining Medical Records and Study Documentation shall be determined in accordance with Applicable Laws but Institution will not in any case be relieved of its obligations under this Agreement for maintaining the Medical Records and Study Documentation.

1.3.2. Ownership. Institution shall retain ownership of Medical Records. Subject to Applicable Laws, Sponsor shall have the right to access, use and disclose the Medical Records during the term of this Agreement and thereafter. The Institution and the Investigator hereby assign to Sponsor all of their rights, title and interest, including intellectual property rights, to all Confidential Information (as defined below) and any other Study Documentation.

1.3.3. Access, Use, Monitoring and Inspection. Upon Quintiles' or Sponsor's request, Site shall provide original or copies (as the case may be) of all Study Documentation to Quintiles and Sponsor. Site shall afford Sponsor and Quintiles and their representatives and designees reasonable access to Site's facilities and to Medical Records and Study Documentation so as to permit Sponsor and Quintiles and their representatives and designees to monitor the Study.

Site shall afford regulatory authorities reasonable access to Site's facilities and to Medical Records and Study Documentation, and the right to copy Medical Records and Study Documentation.

The Site agrees to cooperate with the representatives of Quintiles and Sponsor, and the Site agrees to ensure that the employees, agents and representatives of the Site do not harass, or otherwise create a hostile working environment for such representatives.


The Site shall immediately notify Quintiles of, and provide Quintiles copies of, any inquiries, correspondence or communications to or from any governmental or regulatory authority relating to the Study, including, but not limited to, requests for inspection of the Site's facilities, and the Site shall (i) cooperate with any regulatory authority regarding an audit or inspection related to such Study, including audit or inspection of Site, (ii) permit Quintiles and Sponsor to attend any such inspections or audits and permit Sponsor and Quintiles to assist Site in responding to any such inquiries, correspondence or communications, (iii) promptly provide copies of any documents, correspondence, reports and other materials to or from the regulatory authority and/or the institution relating to the audit, inspection, or regulatory action and (iv) keep apprised of the regulatory action, audit, or inspection and the accompanying findings and response in a timely manner. The Site will make reasonable efforts to separate, and not disclose, all Confidential Information that is not required to be disclosed during such inspections.


Kowa Research Institute, Inc.
Protocol Number: K-877-302
India Specific CTA template dated 07Jul2017
KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, Dr. Veerappa Annasaheb Kothiwale_10Nov2017
_AN_clean

CONFIDENTIAL

Page 4 of 24

ATTESTED


Dr. M.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI


436

1.3.4. License. Sponsor hereby grants to Institution a perpetual, non-exclusive, nontransferable, paid-up license, without right to sublicense, to use Study Documentation (i) subject to the obligations set forth in section 3 "Confidentiality", for internal, non-commercial research and for educational purposes, and (ii) for preparation of publications in accordance with Section 5 "Publication Rights".

1.3.5. Survival. This section 1.3 "Medical Records and Study Documentation" shall survive termination or expiration of this Agreement.

1.4. Duties of Investigator

Investigator is responsible for the conduct of the Study at Institution and for supervising any individual or party to whom the Investigator delegates Study-related duties and function. In particular, but without limitation, it is the Investigator's duty to review and understand the information in the Investigator's Brochure or device labeling instructions, to ensure that all informed consent requirements are met, to ensure that all required reviews and approvals by applicable regulatory authorities and IRBs or IECs are obtained, and to review all CRFs to ensure their accuracy and completeness. If Investigator is an employee of Institution or an affiliate of Institution, then Institution shall ensure that Investigator complies with the terms and conditions of this Agreement and shall be responsible for Investigator's performance of this Agreement and the Study.

If the Investigator and Institution retain the services of any individual or party to perform Study-related duties and functions, the Institution and Investigator shall ensure this individual or party is qualified to perform those Study-related duties and functions and shall implement procedures to ensure the integrity of the Study-related duties and functions performed and any data generated.

Investigator agrees to provide a written declaration revealing Investigator's possible economic or other interests, if any, in connection with the conduct of the Study or the Investigational Product before the Study starts.

Investigator agrees to provide a written declaration revealing Investigator's disclosure obligations, if any, with the Institution in connection with the conduct of the Study and the Investigational Product before the Study starts.

Site agrees to provide prompt advance notice) to Sponsor and Quintiles if Investigator will be leaving the Institution or is otherwise no longer able to perform the Study. The appointment of a new Investigator must have the prior approval of Sponsor and Quintiles.

1.5. Adverse Events

The Site shall report adverse events and serious adverse events as directed in the Protocol and by Applicable Law. The Site shall cooperate with Sponsor in its efforts to follow-up on any adverse events. The Site shall comply with the applicable IRB/IEC reporting obligations.

Sponsor will promptly report to the Site, the applicable IRB/IEC, and Quintiles, any finding that could affect the safety of participants or their willingness to continue participation in the Study, influence the conduct of the Study, or alter the IRB/IEC's approval to continue the Study.

1.6. Use and Return of Investigational Product and Equipment

Sponsor or a duly authorized agent of Sponsor, shall supply Institution or Investigator with sufficient amount of Investigational Product as described in the Protocol.

The Site shall use the Investigational Product and any comparator products provided in connection with the Study, solely for the purpose of properly completing the Study and shall

Kowa Research Institute, Inc.
Protocol Number: K-877-302
India Specific CTA template dated 07Jul2017
KLES Dr. Prabhakar Kore Hospital & Medical Research Centre_ Dr. Veerappa Annasaheb Kothiwale_10Nov2017
_AN_clean

CONFIDENTIAL

Page 5 of 24

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

437

maintain the Investigational Product as specified by Sponsor and according to Applicable Law, including storage in a locked, secured area at all times.

Upon completion or termination of the Study, the Site shall return or destroy, at Sponsor's option, the Investigational Product, comparator products, and materials and all Confidential Information (as defined below) at Sponsor's sole expense.

Institution and Investigator shall comply with all Applicable Laws and regulations governing the disposition or destruction of Investigational Product and any instructions from Quintiles that are not inconsistent with such laws and regulations.

Based on assessment of Site's facilities and needs in connection with the conduct of the Study, Sponsor may provide to Site certain electronic and other equipment as necessary (the "Equipment") solely for use in performance of the Study. Such Equipment may be leased by Sponsor and provided to Site through a third party ("Lessor") on behalf of Sponsor or provided directly by Sponsor to Site. Equipment shall be returned to Lessor or Sponsor, as applicable, at the expense of Sponsor, upon the completion or termination of the Study or upon Sponsor's request, or shall otherwise be disposed of pursuant to the written direction of Lessor or Sponsor as applicable. Site shall implement reasonable and appropriate administrative, physical and technical safeguards to protect the Equipment, shall at all times while the Equipment is in its possession maintain adequate and appropriate insurance coverage for the Equipment, and shall promptly notify Sponsor or its designee of any malfunctioning Equipment. Sponsor shall use reasonable efforts to repair or replace any malfunctioning Equipment at its own expense.

SPONSOR MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND CONCERNING THE EQUIPMENT, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR TITLE.

1.7. Enrollment of Patients

The Effective Date of this Agreement is as listed in Section 15. Consequently, the Site will not be permitted to screen patients, randomize patients, receive Investigational Product or receive any payment until the validity date of this Agreement is reached.

1.8. Key Enrollment Date

The Site understands and agrees that if Site has not enrolled at least one (1) Study Subject by the Key Enrollment Date then Quintiles may terminate this Agreement in accordance with Section 15 "Term & Termination" Sponsor/Quintiles has the right to limit enrollment at any time.

1.9. Minimum Goal

Site acknowledges that Site's minimum randomized goal is 13 subjects and that Site will use best efforts to reach the goal within a reasonable time after commencement of the Study at Site. If Site fails to adhere to this principle Quintiles may reconsider Site's suitability to continue participation in the Study.

1.10 Subcontracting. No rights or obligations of Site or Investigator under this Agreement may be assigned or subcontracted to others without Quintiles' prior written consent and pursuant to a written agreement approved by Quintiles. Site and Investigator shall ensure that all third parties who provide any services on their behalf relating to the Study comply with the terms of this Agreement, and Site and Investigator remain liable for any breach by such third parties. Site and Investigator shall cause each such subcontractor or third party to secure and maintain appropriate insurance to the reasonable satisfaction of Quintiles in amounts that will be adequate to cover the activities and obligations of the subcontractor or third party related to the Study.

Kowa Research Institute, Inc.
Protocol Number: K-877-302
India Specific CTA template dated 07Jul2017
KLES Dr. Prabhakar Kore Hospital & Medical Research Centre_ Dr. Veerappa Annasaheb Kothiwale_10Nov2017
_AN_clean

CONFIDENTIAL

Page 6 of 24

ATTESTED



Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

438

1.11. Biological Samples.

Investigator shall collect, retain, analyze and/or use biological samples from subjects enrolled in the Study solely according to the Protocol and consistent with the ICF. All biological samples shall be transferred to the organization identified in the Protocol. Sponsor shall own rights and interest in biological samples collected in connection with the Study and shall have the sole right to use the samples as permitted under the ICF and Applicable Law.

2. PAYMENT

2.1 Budget.

2.1.1 In full consideration for the performance of the Study, Quintiles shall pay Payee (as defined below in Attachment A) those fees, expenses and costs, at such times and in accordance with the payment schedule set forth in Attachment A of this Agreement. No payments shall be made for the conduct of the Study that are deemed violations or breaches of or deviations (unless approved by Sponsor or Quintiles) from the Protocol, this Agreement or Applicable Law. In no event shall the fees, expenses and costs exceed the amount set forth in Attachment A without the written prior consent of Quintiles. Institution and Investigator acknowledge and confirm that if Investigator is a named payee hereunder, such payment arrangement is in accordance with the modalities laid down by the Institution for receipt of funding for the Study and is not in violation of the MCI Regulations.

2.1.2 The Parties represent that the compensation provided for the conduct of the Study represents the fair market value of the fees, expenses and costs associated with the Study and has not been determined in a manner that takes into account the volume or value of any past, present or anticipated future referrals or business.

2.1.3 To the extent permissible under Applicable Law, budget information shall remain confidential and shall be considered Confidential Information (as defined below). Site acknowledges and agrees that in order to comply with certain legal requirements, Sponsor may be required to publicly disclose payments, gifts, and other transfers of value it provides to physicians and certain hospitals, regardless of whether such payment is remitted directly to such physicians or hospitals or passes through a separate legal entity and that Quintiles or Sponsor may report to relevant regulatory agencies the total amount paid by Quintiles for purposes of conducting the Study under this Agreement, including the estimated fair market value for Equipment and supplies provided under this Agreement. Claims for services and/or products in connection with the Study that Site and/or any Investigator may submit for reimbursement to government entitlement programs or third-party payors shall at all times be in compliance with Applicable Law, including notices, issuances and national and local coverage decisions. Neither Site nor any Investigator shall, under any circumstances, submit any invoice or charges to any subject, government entitlement program, insurer or any other person for payment with respect to the Investigational Product or any other procedures or products provided at no charge by Sponsor or Quintiles.

3. CONFIDENTIALITY

3.1 Definition

"**Confidential Information**" means the confidential and proprietary information of Sponsor and includes (i) all information disclosed by or on behalf of Sponsor to Institution, Investigator or other Institution personnel, including without limitation, the Investigational Product, technical information relating to the Investigational Product, all Pre-Existing Intellectual Property (as defined in Section 4) of Sponsor, and the Protocol; and (ii) Study enrollment information, information pertaining to the status of the Study, communications to

Kowa Research Institute, Inc.

Protocol Number: K-877-302

India Specific CTA template dated 07Jul2017

KLES Dr. Prabhakar Kore Hospital & Medical Research Centre_ Dr. Veerappa Annasaheb Kothiwale_10Nov2017

_AN_clean

CONFIDENTIAL

Page 7 of 24



ATTESTED



Prof. Dr. V.A.KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

439

and from regulatory authorities, information relating to the regulatory status of the Investigational Product, and Study Documentation and Inventions (as defined in Section 4).

Confidential Information shall not include information that:

- (i) can be shown by documentation to have been public knowledge prior to or after disclosure by Sponsor, other than through wrongful acts or omissions attributable to Investigator, Institution or any of its personnel;
- (ii) can be shown by documentation to have been in the possession of Investigator, Institution or any of its personnel prior to disclosure by Sponsor, from sources other than Sponsor that did not have an obligation of confidentiality to Sponsor;
- (iii) can be shown by documentation to have been independently developed by Investigator, Institution or any of its personnel; or
- (iv) is permitted to be disclosed by written authorization from Sponsor.

3.2 Obligations

Site and Site's personnel, including Study Staff shall not

- (i) use Confidential Information for any purpose other than the performance of the Study or
- (ii) disclose Confidential Information to any third party, except as permitted by this Section 3 or by Section 5 "Publication Rights", or as required by law or by a regulatory authority or as authorized in writing by the disclosing party.

To protect Confidential Information, Site agrees to:

- (i) limit dissemination of Confidential Information to only those Study Staff having a need to know for purposes of performing the Study;
- (ii) advise all Study Staff who receive Confidential Information of the confidential nature of such information; and
- (iii) use reasonable measures to protect Confidential Information from disclosure.

Nothing herein shall limit the right of Site to disclose Study Documentation as permitted by Section 5 "Publication Rights."

3.3 Compelled Disclosure

In the event that Institution or Investigator receives notice from a third party seeking to compel disclosure of any Confidential Information, the notice recipient shall provide Sponsor with prompt notice so that Sponsor may seek a protective order or other appropriate remedy. In the event that such protective order or other remedy is not obtained, the notice recipient shall furnish only that portion of the Confidential Information which is legally required to be disclosed, and shall request confidential treatment for the Confidential Information.

3.4 Return or Destruction

Upon termination of this Agreement or upon any earlier written request by Sponsor at any time, Site shall return to Sponsor all Confidential Information other than Study Documentation.

3.5 Survival

This Section 3 "Confidentiality" shall survive termination or expiration of this Agreement for ten (10) years.

4. INTELLECTUAL PROPERTY

4.1 Pre-existing Intellectual Property


Ownership of inventions, discoveries, works of authorship and other developments existing as of the Effective Date and all patents, copyrights, trade secret rights and other intellectual property rights therein (collectively, "**Pre-existing Intellectual Property**"), is not affected by this Agreement, and no Party or Sponsor shall have any claims to or rights in any Pre-

Kowa Research Institute, Inc.
Protocol Number: K-877-302
India Specific CTA template dated 07Jul2017
KLES Dr. Prabhakar Kore Hospital & Medical Research Centre_ Dr. Veerappa Annasaheb Kothiwale_10Nov2017
_AN_clean

CONFIDENTIAL

Page 8 of 24

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

440

existing Intellectual Property of another, except as may be otherwise expressly provided in any other written agreement between them.

4.2 Inventions

Sponsor shall own all right, title and interest in and to each invention, discovery, know-how, trade-secret and other intellectual property, including improvements, whether patentable or not, that is conceived, reduced to practice or otherwise made by Institution, the Investigator or any other person (other than Sponsor) who assists in performing the Study (whether solely or jointly with others) (each, an "Inventor") as a result of or in connection with the Study, the performance of obligations under this Agreement, or its/their access to or knowledge or use of Confidential Information or any drug or device which is the subject of the Study, including any patent, trade secret, trademark, copyright or other proprietary right with respect thereto (collectively, the "Invention(s)").

4.3 Assignment of Inventions

Site shall, and shall cause each inventor to, disclose all Inventions promptly and fully to Sponsor in writing, and Site, on behalf of itself, and Inventors, hereby assigns to Sponsor all of its rights, title and interest in and to Inventions, including all patents, copyrights and other intellectual property rights therein and all rights of action and claims for damages and benefits arising due to past and present infringement of said rights. Site shall cooperate and assist Sponsor by executing, and causing its personnel to execute, all documents reasonably necessary for Sponsor to secure and maintain Sponsor's ownership rights in Inventions.

4.4 Patent Prosecution

Site shall cooperate, at Sponsor's request and expense, with Sponsor's preparation, filing, prosecution, and maintenance of all patent applications and patents for Inventions.

4.5 Survival

This Section 4 "Intellectual Property" shall survive termination or expiration of this Agreement.

5. PUBLICATION RIGHTS

5.1 Publication and Disclosure

Institution and Investigator shall have the right to publish or present the results of Institution's and Investigator's activities conducted under this Agreement, including Study Documentation, only in accordance with the requirements of this Section. Institution and Investigator agree to submit any proposed publication or presentation to Sponsor for review at least sixty (60) calendar days prior to submitting any such proposed publication to a publisher or proceeding with such proposed presentation. Within thirty (30) calendar days of its receipt, Sponsor shall advise Institution and/or Investigator, as the case may be, in writing of any information contained therein which is Confidential Information (other than Study Documentation) or which may impair the availability of patent protection for Inventions. Sponsor shall have the right to require Institution and/or Investigator, as applicable, to remove specifically identified Confidential Information (other than Study Documentation) and/or to delay the proposed publication or presentation for an additional sixty (60) calendar days to enable Sponsor to seek patent protection for Inventions.

ATTESTED



KLES Dr. Prabhakar Kore Hospital
and Research, BELAGAVI

5.2 Multi-Center Publications

If the Study is a multi-center study, Institution and Investigator agree that they shall not, without the Sponsor's prior written consent, independently publish, present or otherwise disclose any results of or information pertaining to Institution's and Investigator's activities conducted under this Agreement until a multi-center publication is published; provided, however, that if a multi-center publication is not published within eighteen (18) months after completion of the Study and lock of the database at all research sites or any earlier termination or abandonment of the Study, Institution and Investigator shall have the right to publish and present the results of Institution's and Investigator's activities conducted under this Agreement, including Study Documentation, solely in accordance with the provisions of Section 5.3 "Confidentiality of Unpublished Data."

5.3 Confidentiality of Unpublished Data

Institution and Investigator acknowledges and agrees that Study Documentation that is not published, presented or otherwise disclosed in accordance with Section 5.1 or Section 5.2 ("**Unpublished Data**") remains within the definition of Confidential Information, and Institution and Investigator shall not, and shall require their personnel not to, disclose Unpublished Data to any third party or disclose any Study Documentation to any third party in greater detail than the same may be disclosed in any publications, presentations or disclosures made in accordance with Section 5.1 or Section 5.2.

5.4 Media Contacts

Institution and Investigator shall not, and shall ensure that its personnel do not engage in interviews or other contacts with the media, including but not limited to newspapers, radio, television and the Internet, related to the Study, the Investigational Product, Inventions, or Study Documentation without the prior written consent of Sponsor. This provision does not prohibit publication or presentation of Study Documentation in accordance with this Section.

5.5 Use of Name, Registry and Reporting

No Party hereto shall use any other Party's name, or Sponsor's name, in connection with any advertising, publication or promotion without prior written permission, except that the Sponsor and Quintiles may use the Site's name in Study publications and communications, including clinical trial websites and Study newsletters. Sponsor will register the Study with a public clinical trials registry in accordance with applicable laws and regulations and will report the results of the Study publicly when and to the extent required by applicable laws and regulations.

5.6 Survival

This Section 5 "Publication Rights" shall survive termination or expiration of this Agreement.

6. PERSONAL DATA

6.1 Study Team Member Personal Data

Both prior to and during the course of the Study, the Investigator and his/her teams may be called upon to provide personal data. This data falls within the scope of the law and regulations relating to the protection of personal data.

For the Investigator, this personal data may include names, contact information, work experience and professional qualifications, medical license, publications, resumes, educational background and information related to potential Dual Capacity conflict of interest, and payments made to Payee(s) under this Agreement for the following purposes:

- (i) the conduct of clinical trials;
- (ii) verification by governmental or regulatory agencies, the Sponsor, Quintiles, and their agents and affiliates;
- (iii) compliance with legal and regulatory requirements;

Kowa Research Institute, Inc.
Protocol Number: K-877-302
India Specific CTA template dated 07Jul2017
KLES Dr. Prabhakar Kore Hospital & Medical Research Centre_ Dr. Veerappa Annasaheb Kothiwale_10Nov2017
_AN_clean

CONFIDENTIAL

Page 10 of 24

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

442

- (iv) publication on www.clinicaltrials.gov and websites and databases that serve a comparable purpose;
- (v) storage in databases to facilitate the selection of investigators for future clinical trials; and
- (vi) anti-corruption compliance.

Names of members of Study Staff may be processed in Quintiles' study contacts database for study-related purposes only.

6.2 Study Subject Personal Data

The Investigator shall obtain Study Subject written consent for the collection and use of Study Subject personal data for Study purposes, including the disclosure, transfer and processing of data collected in accordance with the Protocol, in compliance with applicable data protection provisions.

6.3 Data Controller

The Sponsor shall be the data controller for such personal data except that, if Quintiles deals with any personal data under this Agreement in the manner of a data controller, Quintiles shall be the data controller of such personal data to the extent of such dealings.

Quintiles may process "personal data", as defined in the applicable data protection legislation enacted under the same or equivalent/similar national legislation (collectively "Data Protection Legislation"), of the Investigator and Study Staff for study-related purposes and all such processing will be carried out in accordance with the Data Protection Legislation.

6.4 Survival

This Section 6 "Personal Data" shall survive termination or expiration of this Agreement.

7. INDEMNIFICATION : STUDY SUBJECT INJURY

To the extent not expressly prohibited by state law, Institution shall indemnify and hold harmless Sponsor, its affiliates and their respective employees, officers, and directors ("Sponsor Indemnitees") from and against any claims, liabilities, losses, demands, causes of action, judgments, settlements and expenses (including, but not limited to, reasonable attorneys' fees and court costs) (each a "Claim(s)") arising out of (i) the failure of an Institutional Indemnitee to comply with Applicable Law, rule, or Good Clinical Practices or adhere to the terms of the Protocol or this Agreement, or (ii) the negligence or willful misconduct of Institution, Institution's affiliates, Investigator, GDD Experts India Pvt. Ltd., or its or their employees, agents or contractors, provided, however, that Institution shall have no such obligation with respect to Claims arising out of the negligence or willful misconduct of Sponsor or its employees, agents or contractors.

In the event a Study Subject requires medical treatment for physical injury, Sponsor shall reimburse Site for the direct, reasonable and necessary costs associated with the treatment of the physical injury sustained as a direct result of taking the Investigational Product or undergoing a procedure required by the Protocol ("Covered Injury"), provided that such injury does not arise out of the negligence, willful misconduct, breach of this Agreement, Applicable Law or failure to follow and comply with the Protocol by Institution, Investigator, the sub-investigator, the Study Staff, or their employees or agents. Site shall notify Sponsor in advance of treatment, whenever practicable, but in any event within twenty-four (24) hours of provision of treatment.

Site shall coordinate and manage the request from a Study Subject for treatment and reimbursement of a Covered Injury, and shall provide to Sponsor in a timely manner, such

Kowa Research Institute, Inc.
Protocol Number: K-877-302
India Specific CTA template dated 07Jul2017
KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, Dr. Veerappa Annasaheb Kothiwale, 10Nov2017
_AN_clean


CONFIDENTIAL

Page 11 of 24

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI



443

supporting documentation and reports as Sponsor may reasonably request. Such documentation and reports shall include, but not be limited to, the government entitlement program health insurance claim number or, if none is available, the social security number of the Study Subject and such other information relating to the treatment and insurance coverage of the Study Subject as may be reasonably requested by Sponsor and/or as Sponsor reasonably determines is required or appropriate under Applicable Law. Reimbursement by Sponsor for a Covered Injury or otherwise shall be limited to those costs not covered by such Study Subject's insurance, excluding government entitlement programs. No party shall submit any claim for reimbursement to government entitlement programs until Sponsor has satisfied its reimbursement obligations under this Agreement and Applicable Law.

This Section 7 "Study Subject Injury" shall survive termination or expiration of this Agreement.

8. QUINTILES DISCLAIMER

Quintiles expressly disclaims any liability in connection with the Investigational Product, including any liability for any claim arising out of a condition caused by or allegedly caused by any Study procedures associated with such product except to the extent that such liability is caused by the negligence, willful misconduct or breach of this Agreement by Quintiles.

This Section 8 "Quintiles Disclaimer" shall survive termination or expiration of this Agreement.

9. CONSEQUENTIAL DAMAGES

Neither Quintiles nor Sponsor shall be responsible to the Site for any lost profits, lost opportunities, or other consequential damages, nor shall Site be responsible to Quintiles or Sponsor for any lost profits, lost opportunities, or other consequential damages.

This Section 9 "Consequential Damages" shall survive termination or expiration of this Agreement.

10. DEBARMENT

The Site represents and warrants that neither Institution nor Investigator, nor any of Institution's or Investigator's employees, agents or other persons performing the Study at Institution, have been debarred, disqualified or banned from conducting clinical trials or are under investigation by any regulatory authority for debarment or any similar regulatory action in any country, and the Site shall notify Quintiles immediately if any such investigation, disqualification, debarment, or ban occurs.

This Section 10 "Debarment" shall survive termination or expiration of this Agreement.

11. FINANCIAL DISCLOSURE AND CONFLICT OF INTEREST

Upon Sponsor's or Quintiles' request, Site agrees that, for each listed or identified investigator or sub-investigator who is directly involved in the treatment or evaluation of Study Subjects, it shall promptly return to Quintiles a financial and conflict of interest disclosure form that has been completed and signed by such investigator or sub-investigator, which shall disclose any applicable interests held by those investigators or sub-investigators or their spouses or dependent children.

Kowa Research Institute, Inc.

Protocol Number: K-877-302

India Specific CTA template dated 07Jul2017

KLES Dr. Prabhakar Kore Hospital & Medical Research Centre_Dr. Veerappa Annasaheb Kothiwale_10Nov2017

_AN_clean

CONFIDENTIAL

Page 12 of 24

ATTESTED



Prof. Dr. V.A.KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

Quintiles may withhold payments if it does not receive a completed form from each such investigator and sub-investigator.

Site shall ensure that all such forms are promptly updated as needed to maintain their accuracy and completeness during the Study and for one (1) year after Study completion.

Site agrees that the completed forms may be subject to review by governmental or regulatory agencies, Sponsor, Quintiles, and their agents, and the Site consents to such review.

The Site further consents to the transfer of its financial disclosure data to the Sponsor's country of origin and to the U.S., even though data protection may not exist or be as developed in those countries as in the Site's own country.

This Section 11 "Financial Disclosure and Conflict of Interest" shall survive termination or expiration of this Agreement.

12. ANTI-KICKBACK AND ANTI FRAUD

Institution and Investigator agree that their judgment with respect to the advice and care of each Study Subject will not be affected by the compensation they receive from this Agreement, that such compensation does not exceed the fair market value of the services they are providing, and that no payments are being provided to them for the purpose of inducing them to purchase or prescribe any drugs, devices or products.

If the Sponsor or Quintiles provides any free products or items for use in the Study, Institution and Investigator agree that they will not bill any Study Subject, insurer or governmental agency, or any other third party, for such free products or items.

Institution and Investigator agree that they will not bill any Study Subject, insurer, or governmental agency for any visits, services or expenses incurred during the Study for which they have received compensation from Quintiles or Sponsor, or which are not part of the ordinary care they would normally provide for the Study Subject, and that neither Institution nor Investigator will pay another physician to refer subjects to the Study.

13. ANTI-BRIBERY

Institution and Investigator agree that the fees to be paid pursuant to this Agreement represent fair compensation for the services to be provided by Site. Institution and Investigator represent and warrant that payments or Items of Value received pursuant to this Agreement or in relation to the Study will not influence any decision that Institution, Investigator or any of their respective owners, directors, employees, agents, consultants, or any payee under this Agreement may make, as a Government Official or otherwise, in order to assist Sponsor or Quintiles to secure an improper advantage or obtain or retain business.

Institution and Investigator further represent and warrant that neither they nor any of their respective owners, directors, employees, agents, or consultants, nor any payee under this Agreement, will, in order to assist Sponsor or Quintiles to secure an improper advantage or obtain or retain business, directly or indirectly pay, offer or promise to pay, or give any Items of Value to any person or entity for purposes of (i) influencing any act or decision; (ii) inducing such person or entity to do or omit to do any act in violation of their lawful duty; (iii) securing any improper advantage; or (iv) inducing such person or entity to use influence with the government or instrumentality thereof to affect or influence any act or decision of the government or instrumentality.

In addition to other rights or remedies under this Agreement or at law, Quintiles may terminate this Agreement if Site breaches any of the representations or warranties contained in this Section

Kowa Research Institute, Inc.

Protocol Number: K-877-302

India Specific CTA template dated 07Jul2017

KLES Dr. Prabhakar Kore Hospital & Medical Research Centre_ Dr. Veerappa Annasaheb Kothiwale_10Nov2017

_AN_clean

CONFIDENTIAL

Page 13 of 24

ATTESTED



Prof. Dr. V.A.KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

445

or if Quintiles or Sponsor learns that improper payments are being or have been made to or by Institution or Investigator or any individual or entity acting on its or their behalf.

14. INDEPENDENT CONTRACTORS

The Investigator and Institution and GDD Experts India Pvt. Ltd and Study Staff are acting as independent contractors of Quintiles and Sponsor and shall not be considered the employees or agents of Quintiles or Sponsor.

Neither Quintiles nor Sponsor shall be responsible for any employee benefits, pensions, workers' compensation, withholding, or employment-related taxes as to the Investigator or Institution or GDD Experts India Pvt. Ltd or their staff.

It is hereby agreed and acknowledged by the Parties and Sponsor that Quintiles has no relationship whatsoever with the Research Company and that the Research Company is acting as an independent contractor of the Institution.

15. TERM & TERMINATION

15.1 Term

This Agreement will become effective on the date of approval of the Study by Drugs Controller General India or the date on which it is last signed by the parties, whichever date is later, (the "**Effective Date**") and shall continue until completion or until terminated in accordance with this Section 15 "Term & Termination". Quintiles shall attach a copy of the approval from the Drugs Controller General India approving the Study to this Agreement as Attachment B, and the Parties agree that such approval shall be incorporated by reference herein. If such approval has not been received as of the date the Parties sign this Agreement, Quintiles shall keep the original signed Agreements until receipt of such approval, and upon receipt of such approval, Quintiles shall attach a copy of the approval to each original Agreement as Attachment B and forward an original Agreement to each other Party thereafter, while retaining one original Agreement in its files. If such approval was received prior to the signatures of the Parties, Quintiles shall attach a copy of the approval hereto as Attachment B, and upon signature of all Parties, each Party shall receive an original of the Agreement, which shall include such approval as Attachment B.

15.2 Termination

Quintiles may terminate this Agreement for any reason effective immediately upon written notice. The Site may terminate upon written notice if at any time in the Investigator's professional judgment, a material adverse safety concern for the Study subjects makes continued testing inadvisable. Upon notice of termination or upon notice of suspension of the Study or this Agreement, Site shall immediately cease enrollment of subjects into the Study and, at the election of Quintiles shall (a) either (i) terminate the Agreement with respect to the enrolled subjects in an orderly and prompt manner and pursuant to consultation with Quintiles and Sponsor, including any required follow-up treatment with previously enrolled subjects, or (ii) transfer the enrolled subjects to another clinical site in accordance with Quintiles' instructions. Sponsor or its designee shall have the right to assume full control of the terminated Study and Site shall turn over all Study Documentation and materials in its possession associated with the Study, as expeditiously as possible, and shall provide such other assistance as is necessary to ensure a smooth and orderly transition of the Study without any disruption of the Protocol and (b). Site shall make all reasonable efforts to minimize further costs, and Quintiles shall make a final payment for visits or milestones properly performed pursuant to this Agreement in the amounts specified in Attachment A; provided, however, that ten percent (10%) of this final payment will be

Kowa Research Institute, Inc.

Protocol Number: K-877-302

India Specific CTA template dated 07Jul2017

KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, Dr. Veerappa Annasaheb Kothiwale, 10Nov2017

_AN_clean

CONFIDENTIAL

Page 14 of 24

ATTESTED


Prof. Dr. V.A.KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

446

withheld until final acceptance by Sponsor of all Study or data clarifications requested and satisfaction of all other applicable conditions set forth herein. If a material breach of this Agreement appears to have occurred and termination may be required, then, except to the extent that Study Subject safety may be jeopardized, Quintiles may suspend performance of all or part of this Agreement, including, but not limited to, subject enrollment.

16. NOTICE

Any notices required or permitted to be given hereunder shall be given in writing and shall be delivered

- (a) in person,
 - (b) by certified mail, postage prepaid, return receipt requested,
 - (c) by e-mail of .pdf/scan or other non-editable format notice with confirmed transmission report, or
 - (d) by a commercial overnight courier that guarantees next day delivery and provides a receipt,
- and such notices shall be addressed as follows:

To Sponsor:	Gary Gordon, M.B.A., M.D. President Kowa Research Institute, Inc. 430 Davis Drive, Suite 200 Morrisville, NC 27560 919-433-1600 phone 919-433-1620 fax
To Quintiles	Name: Quintiles Research (India) Private Limited Address: B 101-106, Shapath IV, Opposite Karnavati Club, Sarkhej Gandhinagar Road, Ahmedabad 380051, Gujarat, India Tel: +91-79-66303300
To Institution	Name: Dr. M. V. Jali Address: KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, NehruNagar, Belagavi – 590010, Karnataka, India Tel: +91-831-2473777
To Investigator	Name: Dr. Veerappa Annasaheb Kothiwale Address: KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, NehruNagar, Belagavi - 590010, Karnataka, India Tel: +91-9448119899
To Research Company	Name: Dr. Vinod Gyanchandani Address: GDD Experts India Pvt. Ltd, Ground Floor, Gulmohar Complex, Opposite Hislop College, Civil Lines, Nagpur-440001, Maharashtra, India Tel: +91 9923000560

17. FORCE MAJEURE

The performance by either Party of any obligation on its part to be performed hereunder shall be excused by floods, fires or any other Act of God, accidents, wars, riots, embargoes, delay of carriers, inability to obtain materials, failure of power or natural sources of supply, acts, injunctions, or restraints of government or other force majeure preventing such performance,

Kowa Research Institute, Inc.
Protocol Number: K-877-302
India Specific CTA template dated 07Jul2017
KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, Dr. Veerappa Annasaheb Kothiwale_10Nov2017
_AN_clean

CONFIDENTIAL

Page 15 of 24

ATTESTED


Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

447

whether similar or dissimilar to the foregoing, beyond the reasonable control of the Party bound by such obligation, provided, however, that the Party affected shall exert its reasonable efforts to eliminate or cure or overcome any of such causes and to resume performance of its obligations with all possible speed.

18. MISCELLANEOUS

18.1 Entire Agreement

This Agreement, including its attachment(s), constitutes the sole and complete agreement between the Parties and replaces all other written and oral agreements relating to the Study.

18.2 No Waiver/Enforceability

Failure to enforce any term of this Agreement shall not constitute a waiver of such term.

If any part of this Agreement is found to be unenforceable, the rest of this Agreement will remain in effect.

18.3 Assignment of the Agreement

This Agreement shall be binding upon the Parties and their successors and assigns.

The Site shall not assign or transfer any rights or obligations under this Agreement without the written consent of Quintiles and Sponsor.

Upon Sponsor's request, Quintiles may assign this Agreement to Sponsor or to a third party, and Quintiles shall not be responsible for any obligations or liabilities under this Agreement that arise after the date of the assignment, and the Site hereby consents to such an assignment. Site will be given prompt notice of such assignment by the assignee. Sponsor shall have the right to assign all of its rights under this Agreement without Site's prior written consent.

18.4 Third Party Beneficiary

The Parties agree that Sponsor shall have the right to enforce any of the provisions of this Agreement as a third party beneficiary.

Each Party to this Agreement acknowledges that except for the Sponsor, there are no third party beneficiaries with any rights to enforce any of the provisions of this Agreement.

18.5 Governing Law

This Agreement shall be interpreted under the laws of the state or province and country in which Site conducts the Study.

18.6 Survival:

The terms of this Agreement that contain obligations or rights that extend beyond the completion of the Study shall survive termination or completion of this Agreement, even if not expressly stated herein.

THIS SECTION IS INTENTIONALLY LEFT BLANK

Kowa Research Institute, Inc.
Protocol Number: K-877-302
India Specific CTA template dated 07Jul2017
KLES Dr. Prabhakar Kore Hospital & Medical Research Centre_ Dr. Veerappa Annasaheb Kothiwale_10Nov2017
_AN_clean

CONFIDENTIAL

Page 16 of 24

ATTESTED




Prof. Dr. V.A.KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

448

ACKNOWLEDGED AND AGREED BY QUINTILES RESEARCH (INDIA) PRIVATE LIMITED:

By: Suneela Thatte

Title: VP, Global Operations

Signature: 

Date: 10/NOV/2019

ACKNOWLEDGED AND AGREED BY THE INVESTIGATOR:

Name: Dr. Veerappa Annasaheb Kothiwale

Title: Principal Investigator

Signature: 

Date: 23/NOV/2017

ACKNOWLEDGED AND AGREED BY KLES DR. PRABHAKAR KORE HOSPITAL & MEDICAL RESEARCH CENTRE:

By: Dr. M. V. Jali

Title: Medical Director

Signature: 

Date: 25/11/17

Research Company agrees to abide by all obligations placed on Institution in the provisions of this Agreement concerning Confidentiality (Section 3); Intellectual Property (Section 4); Publication Rights (Section 5); Debarment (Section 10); Anti Kickback and Anti Fraud (Section 12); and Anti-Bribery (Section 13)

ACKNOWLEDGED AND AGREED BY GDD EXPERTS INDIA PVT. LTD.

By: Dr. Vinod Gyanchandani

Title: Head- Clinical Operations

Signature: 


Date: 13/NOV/2017

Kowa Research Institute, Inc.
Protocol Number: K-877-302
India Specific CTA template dated 07Jul2017
KLES Dr. Prabhakar Kore Hospital & Medical Research Centre_ Dr. Veerappa Annasaheb Kothiwale_10Nov2017
_AN_clean

CONFIDENTIAL

Page 17 of 24

ATTESTED



Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

449

**ATTACHMENT A
BUDGET & PAYMENT SCHEDULE**

A. PAYEE DETAILS

The Parties agree that the payee designated below is the proper payee for this Agreement, and that payments under this Agreement will be made only to the following payee ("Payee"):

Payee Name	GDD Experts India Pvt. Ltd.
Payee Address	GDD Experts India Pvt. Ltd, Ground Floor, Gulmohar Apartment, Opposite Hislop College, Civil Lines, Nagpur-440001, Maharashtra, India
Bank Name	Axis Bank Ltd
Bank Account Number	910020034162231
IFSC code	UTIB0000048
GST Registration Number	27AADCG0363Q1ZA
Permanent Account Number (PAN) of Payee	AADCG0363Q
PAYMENT METHOD	Electronic Fund Transfer

In case of changes in the Payee's bank details, Site is obliged to inform Quintiles in writing. The Parties agree that in case of changes in bank details which do not involve a change of Payee/Bank Account Name or change of country location of bank account, no further amendments are required.

The Parties acknowledge that the designated Payee is authorized to receive all of the payments for the services performed under this Agreement.

If the Investigator is not the Payee, then the Payee's obligation to reimburse the Investigator, if any, is determined by a separate agreement between Investigator and Payee, which may involve different payment amounts and different payment intervals than the payments made by Quintiles to the Payee.

The Investigator acknowledges that if the Investigator is not the Payee, Quintiles will not pay the Investigator even if the Payee fails to reimburse the Investigator.

B. PAYMENT TERM

Quintiles will pay the Payee Quarterly, on a completed visit per subject basis in accordance with the attached budget. Ninety percent (90%) of each payment due, including any Screening Failure monies that may be payable under the terms of this Agreement, will be made based upon prior 3 months' randomization data confirmed by subject CRFs received from the Site supporting subject visitation.


The balance of monies earned, up to ten percent (10%), will be pro-rated upon verification of actual subject visits, and will be paid by Quintiles to the Payee upon final acceptance by Sponsor of all CRFs pages, all data clarifications issued, the receipt and approval of any outstanding regulatory documents as required by Quintiles and/or Sponsor, the return of all unused supplies and Investigational Product to Quintiles or its designee, and upon satisfaction of all other applicable conditions set forth in the Agreement.

Kowa Research Institute, Inc.
Protocol Number: K-877-302
India Specific CTA template dated 07Jul2017
KLES Dr. Prabhakar Kore Hospital & Medical Research Centre_ Dr. Veerappa Annasaheb Kothiwale_10Nov2017
_AN_clean

CONFIDENTIAL

Page 18 of 24

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

450

Any expense or cost incurred by Site in performing this Agreement that is not specifically designated as reimbursable by Quintiles or Sponsor under the Agreement (including this Budget and Payment Schedule) is Site's sole responsibility.

Site shall be responsible to comply with all obligations in respect of taxes and social security contributions, if applicable, which relate to the subject matter of this Agreement including, without limitation, those that relate to the Investigator, the Institution and its employees and/or collaborators.

Site represents that the services it provides under this Agreement are taxable services under the laws governing Goods and Services Tax ("GST") in India, and that it is required to charge GST for the services rendered to Quintiles at the prevailing rate. Site represents that it is entitled to require such payment of the GST under the laws of India. Site undertakes to provide Quintiles with an invoice, to be sent to Quintiles at the address mentioned in Section K of this Attachment A., in respect of such taxable services and such invoice shall be in accordance with the applicable legislation as may be amended from time to time or any successor legislation.

All amounts specified in this Agreement are in Indian Rupees (INR) and are inclusive of all overhead fees. For the avoidance of doubt, overhead fees include any applicable overhead fees.

Major, disqualifying Protocol violations are not payable under this Agreement

C. PAYMENT DISPUTE

Site will have thirty (30) days from the receipt of final payment to dispute any payment discrepancies during the course of the Study.

D. OVERPAYMENT

In the event that Quintiles determines that (i) a mistaken or otherwise erroneous payment has been made or (ii) payment was made for services that were not provided (each an "Overpayment") Quintiles will enter a payment adjustment against future payments and Site will not receive payment until such Overpayment is earned. If, upon completion or termination of this Agreement, the payment adjustment does not cover the Overpayment, Quintiles will issue a notice letter to the Site. Upon receipt of written notice, Site shall immediately refund such remaining Overpayment to Quintiles.

E. DISCONTINUED OR EARLY TERMINATION

Reimbursement for discontinued or early termination of randomized subjects will be prorated based on the number of confirmed completed visits.

F. SCREENING FAILURE

Reimbursement of screen failure will be at the amount indicated on the pre-screening and screening visits of the attached budget, not to exceed 3 Screen Failur(s) paid per 1 subject randomized.

To be eligible for reimbursement of a screening visit, completed screening CRF pages must be submitted to Quintiles along with any additional information, which may be requested by Quintiles to appropriately document the subject screening procedures.

G. UNSCHEDULED VISITS

Payment for unscheduled visits will be reimbursed in the amount of is Nine Thousand Five Hundred Forty Five Rupees (INR 9,545) which includes overhead. To be eligible for reimbursement for unscheduled visits, completed CRF pages must be submitted to Quintiles along with any additional information which may be requested by Quintiles to appropriately document the unscheduled visit.


Kowa Research Institute, Inc.
Protocol Number: K-877-302
India Specific CTA template dated 07Jul2017
KLES Dr. Prabhakar Kore Hospital & Medical Research Centre_
_AN_clean

CONFIDENTIAL

Page 19 of 24

Dr. Veerappa Annasaheb Kothiwale_10Nov2017

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

451

H. START UP FEE

A one-time, non-refundable Study Start-Up payment of INR 80,000 will be made after site initiation and receipt by Quintiles of all original contractual and regulatory documentation and receipt of an original invoice.

I. RECORD STORAGE FEE/ARCHIVING TOTAL COST FEE

A one-time, long-term Study document storage, archiving payment of INR 133/box/month will be made to Payee following the completion of the Study at the Institution, receipt by Quintiles of all completed contractual and regulatory documentation and receipt of invoice. Trial documents will be kept in a controlled, secure facility.

J. PATIENT TRAVEL EXPENSES

Patient travel expenses will be reimbursed upon receipt of original supporting invoices up to INR 1000 per visit per patient per round trip] and are not included in the attached Budget. Invoices must contain the Patient number, amount paid, and visit number and visit date in which patient travel is being requested.

K. INVOICES

Original Invoices pertaining to this Study for the following items must be submitted to Quintiles for reimbursement at the following address:

Quintiles Research (India) Private Ltd., Bangalore
Attention: Finance PSC – Accounts Payable (Investigator Payments)
III Floor, Etamin Block,
Prestige Technology Park,
Sarjapur - Marathahalli Outer Ring Road
Bangalore – 560103, India
Phone: [Insert Phone Number]

Please note that invoices will not be processed unless they reference the Sponsor name, Protocol number, Investigator name, Site number and Payee GST registration number. Upon receipt and verification of the invoices, reimbursement for invoices will be included with the next regularly scheduled payment for subject activity

L. EC/IRB/IEC FEES

EC/IRB/IEC costs incurred will be reimbursed on a pass-through basis upon receipt of a formal invoice issued by the EC/IRB/IEC and are not included in the attached Budget. Payment will be made directly to the EC/IRB/IEC. Any subsequent re-submissions or renewals, upon approval by Quintiles and Sponsor, will be reimbursed upon receipt of appropriate documentation.

M. CONDITIONAL PROCEDURES

The following conditional procedures and related costs will be reimbursed on a pass-through basis upon receipt of an invoice at the amount indicated in the below table. Subject number and visit/dates must be included on the invoice for payment to be issued.

	Procedure Amount (INR)
Blood sample collection	300
Lab handling and/or shipping of unscheduled blood samples	130
12-lead ECG: Tracing only	500
EQ-5D-5L	500

Kowa Research Institute, Inc.

Protocol Number: K-877-302

India Specific CTA template dated 07Jul2017


KLES Dr. Prabhakar Kore Hospital & Medical Research Centre_ Dr. Veerappa Annasaheb Kothiwale_10Nov2017

_AN_clean

CONFIDENTIAL

Page 20 of 24

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

452

Problem focused physical exam	2,298
Serious adverse events (SAE)	1000
Genetic testing consent	330
Endpoint package preparation	13,389

NO OTHER ADDITIONAL FUNDING REQUESTS WILL BE CONSIDERED

These amounts exclude all applicable taxes.

All payments for this Study in accordance with the attached budget will be paid by Quintiles by wire transfer.

N. BUDGET TABLE

Visit	Total Cost Per Visit including 20% Overhead (INR)
PreScreen	13,578
Screen	19,998
Visit 2	17,331
Visit 3	4,679
Visit 4	4,679
Visit 5	13,304
Visit 6	12,535
Visit 7	12,616
Visit 8	4,679
Visit 9	13,790
Visit 10	4,679
Visit 11	12,616
Visit 12	4,679
Visit 13	12,616
Visit 14	4,679
Visit 15	13,790

Kowa Research Institute, Inc.
 Protocol Number: K-877-302
 India Specific CTA template dated 07Jul2017
 KLES Dr. Prabhakar Kore Hospital & Medical Research Centre_ Dr. Veerappa Annasaheb Kothiwale_10Nov2017
 _AN_clean

CONFIDENTIAL

Page 21 of 24

ATTESTED



 Prof. Dr. V.A.KOTHIWALE

Registrar
 KLE Academy of Higher Education
 and Research, BELAGAVI

453

Visit 16	4,679
Visit 17	12,616
Visit 18	4,679
Visit 19	12,616
Visit 20	4,679
Visit 21	13,790
Visit 22	4,679
Visit 23	12,616
Visit 24	4,679
Visit 25	12,616
Visit 26	4,679
Visit 27	13,790
Visit 28	4,679
Visit 29	12,616
Visit 30	4,679
Visit 31	12,616
Visit 32	4,679
Visit 33	13,790
Visit 34	4,679
CSED Visit	15,515
Post Study Safety Call	4,060
retest	8,169
Off *	11,931
Total Cost Per Patient (Rs)	3,53,676

* Visit can occur more than once

ATTESTED

 Prof. Dr. V.A. KOTHIWALE
 Registrar
 KLE Academy of Higher Education
 and Research, BELAGAWI

CLINICAL TRIAL AGREEMENT ORDER

This Order ("**Order**"), effective as of the Effective Date (defined below), is entered into by and among Amgen Technology Pvt. Ltd., Dynasty Business Park, A Wing, Level 4, Andheri-Kurla Road, Andheri (East), Mumbai, 400059 India ("**Company**"); KLES Dr. Prabhakar Kore Hospital and Medical Research Center, Nehru Nagar, Belgaum-590010, Karnataka, India ("**Institution**"); and Dr. Rohan Bhise, KLES Dr. Prabhakar Kore Hospital & MRC, Department of Medical Oncology, Nehru Nagar, Belagavi-590010, Karnataka, India ("**Principal Investigator**"); in accordance with, and shall be governed by, the terms of that certain Clinical Trial Agreement (contract number 181106) ("**Agreement**").

1. GOVERNING TERMS AND EFFECTIVE DATE

1.1 Governing Terms. By executing this Order, the parties agree that this Order and the parties' performance hereunder shall be governed by the terms and conditions of the Agreement, which are incorporated by this reference as if fully set forth herein. The parties hereto agree that for purposes of this Order, the term "**Site**" as used herein and in the Agreement shall be defined to include each and every non-Company party identified above, and their respective representatives. Terms used but not otherwise defined herein shall have the meanings ascribed to such terms under the Agreement.

1.2 Effective Date. For purposes of this Order, "**Effective Date**" shall mean the last date on which a party executes this Order. This Order shall remain in full force and effect until the completion by the Site of the Study or earlier termination pursuant hereto.

1.3 Records. The parties agree that for this Order the provision regarding Records in the Agreement shall be amended to state: "Site shall maintain all records required under Applicable Law and the Protocol for ten (10) years following completion of a Study or longer if required by Applicable Law. Site shall take reasonable and customary precautions to prevent the loss or alteration of any such records."

1.4 Indian Law. Without limiting the generality of Site's obligations, the Site shall carry out the Study with due observance of safety of Subjects, confidentiality and protection of Subjects' rights. The Study will be conducted by the Site in accordance with the Ethical Guidelines for Biomedical research on Human Subjects issued by the Indian Council of Medical Research Guidelines, 2000; Schedule Y of the Drug and Cosmetics Act of 1945, the Central Drugs Standard Control Organization's Good Clinical Practices Guidelines in India, and all applicable Indian regulatory requirements, whichever affords the greater protection to the Subject.

2. STUDY CONDUCT

2.1 Protocol. The Protocol for the Study is Company Protocol No. 20070782 entitled "A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy", as may be amended.


Site Representatives and/or Principal Investigator shall attend any meetings regarding the Study as reasonably requested by Company ("**Investigator Meetings**"). Such meetings may be conducted by Company to convey or exchange information with principal investigators, sub-investigators, or other research site staff to support the effective conduct or close-out of a Study. Site and Principal Investigator each agree that no additional compensation shall be due hereunder for Site Representatives or Principal Investigators respective participation in Investigator Meetings. Company may reimburse or pay Site for reasonable pre-approved expenses incurred by Site Representatives or Principal Investigator for participating in Investigator Meetings upon receipt of documentation in form and detail sufficient for Company to recognize such expenses for Company's tax reporting purposes, provided that Site complies with Company instructions and Company's applicable standards and policies related to travel and hospitality and other policies governing interactions with healthcare professionals.

The Principal Investigator will direct and supervise the Study.

Contract #: 266710
Site #: 5589
Purchase Order #: India

Page 1 of 8

ATTESTED


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

450

2.2 Data Protection. Subject to applicable law, Company may collect and process information regarding investigators or other personnel involved in Studies. Company will notify such personnel as required by applicable law.

2.3 Use of Electronic Data Capture. Electronic Data Capture ("EDC") is a technique for collecting clinical trial data where study data is delivered to Company in electronic form. For this Study, EDC will be utilized to collect Study information, specifically as the electronic case report form ("eCRF"), from Site. Site agrees that it shall (i) enter such Study data into EDC within five (5) business days of the Subject visit, and (ii) resolve all queries issued in the EDC system within five (5) business days of the query being issued. Site acknowledges and agrees that time is of the essence with respect to such Study data entry and query resolution. Any delay by Site in complying with these timelines may, in Company's sole discretion, result in delay of payment, lock of IVRS, suspension of enrollment, quality audit or any other remedy. Principal Investigator is responsible for and warrants quality data entry. Data entry shall be conducted under the supervision of the Principal Investigator.

2.4 Supervision. The Principal Investigator shall supervise and be responsible for all activities performed by members of the Study team or other external personnel to whom the investigator delegates some of his/her responsibilities under the Protocol. The Principal Investigator shall ensure compliance with the Protocol at all times.

2.5 Informed Consent. Site agrees and warrants that it will obtain a valid informed consent form from each Subject in the Study or its legal representative in accordance with Applicable Laws and this Agreement. Site shall ensure that such consent permits Company's use of the Biological Materials and Study data for at a minimum the purposes of monitoring the accuracy and completeness of the research data, performing clinical and scientific research, and medical product development.

3. REAGENTS AND STUDY DRUG

3.1 Company shall provide or reimburse the following Study Drug(s) to Site as required by Protocol: darbepoetin alfa ("Study Drug(s)"). If Site is responsible for obtaining Study Drug for use in the Study, Company will reimburse Site for purchase costs of Study Drug as detailed in a proper invoice. Such purchase or reimbursement cost shall not exceed the amount set forth in Schedule A. The Site agrees and warrants that it will not seek payment or reimbursement from any Subject or third party for the cost of the Study Drug(s) or the Study Drug that is provided without charge or reimbursed by Company under this Order.

3.2 The cost of non-Company drug(s) and/or materials and/or reagents is not paid or reimbursed by a third party; however it is required by the Protocol for Subjects participating in the Study ("Required Material(s)"). Company will reimburse the Site for the cost of the Required Material(s) as detailed in a proper invoice. Such purchase or reimbursement costs shall not exceed the amount set forth in Schedule A. The Site agrees and warrants that it will not seek payment or reimbursement from any Subject or third party for the cost of any Required Material(s) that is provided without charge or reimbursed by Company under this Order. Site also warrants that it shall not seek or accept reimbursement from any Subject or third party payor for procedures, tests, treatments, items or services that are funded or provided by Company pursuant to the Agreement.

4. PERFORMANCE PERIOD AND ENROLLMENT OF SUBJECTS

4.1 The Study will commence upon execution of this Order, approval of the IRB/IEC, and any required approvals of applicable governmental authorities, including the Drug Controller General of India (DCGI), and will continue until completion of the Study as required by the Protocol (including any amendments thereto) unless this Order is terminated earlier pursuant to the Agreement.

5. REQUIRED EQUIPMENT

5.1 The parties acknowledge that Site will require the following equipment for the performance of the Study ("Required Equipment"): Laptop. Such Required Equipment will be lent by Company or its representative to Site for use in the Study.

5.2 Delivery. As necessary, Company or its representative shall arrange for the delivery of the Required Equipment, which such equipment shall be delivered to the Site at the following address: KLES Dr. Prabhakar Kore Hospital and Medical Research Center, Nehru Nagar, Belgaum-590010, Karnataka, India.

5.3 Installation of Required Equipment. Company or its representative shall provide for installation of the following equipment: Laptop.

5.4 Technical Support of Required Equipment. Company or its representative shall provide for technical support and maintenance of the following equipment: Laptop.

6. COMPENSATION

6.1 Compensation and payment terms are as set forth in Schedule A, attached hereto and incorporated herein.

6.2 Unless otherwise specified in Schedule A, in consideration for performance under the terms of this Order, Company will make payment within a reasonable time after receipt of (i) a proper invoice and (ii) the Case Report Forms or any similar document detailing the procedures performed and/or visits completed as set forth in Schedule A, as monitored by Company or its representative. It is expected that the Case Report Forms will be completed between monitoring visits.

6.3 Payments from Company to Site due hereunder shall be made payable and sent to the following:

Payments payable to:	KLES Dr. Prabhakar Kore Hospital and Medical Research Center "Payee"
----------------------	--

From time to time, the Site may request in writing a change in Payee information. If Company agrees to the requested change, no additional amendment of the Order will be necessary.

7. MISCELLANEOUS

7.1 Principal Investigator understands and agrees that his/her personal information including name, contact details, financial information relating to, among other matters, compensation and reimbursement payments for study conduct, and other personal data in connection with Principal Investigator's conduct of the Study will be processed both by computer and manually, by Company and its affiliates and contractual partners in order to comply with Company's and its affiliates' obligations imposed by law, guidance or regulatory authorities and for other purposes including considering from time to time potential investigators for future studies or organizing safety reporting. Principal Investigator further understands and agrees that his/her personal data may, if necessary for these purposes, be made available to regulatory authorities and ethics committees. Principal Investigator understands and agrees that the Company's use and disclosure of personal data may involve use and disclosure in countries other than that where the Principal Investigator is located. Such countries may include but not be limited to: the United States, Japan, Canada, Australia, New Zealand, Switzerland, or countries in Latin America or Asia. Principal Investigator further understands that not all countries to which personal information may be transferred offer an equivalent level of protection of privacy of personal information. Principal Investigator is entitled to request access to his/her personal data held by Company or its affiliates and to have such data corrected if necessary.


7.2 Site acknowledges and agrees that Company shall have the right to disclose publicly the terms and conditions of the Agreement and this Order, including, without limitation, Site's name, description of services, and amount of payment.

7.3 Company Inspections/Monitoring/Audit. The parties agree that for this Order the provision regarding Company Inspections/Audit in the Agreement shall be amended and restated as follows: "Company Inspections/Monitoring/Audit. Company and its representatives shall have the right during reasonable business hours and after reasonable advanced notice to monitor and audit the activities of Site related to a Study. At no additional cost to Company, Site shall cooperate with any monitoring and audit conducted hereunder and make available to Company or its representatives for examination and duplication all documentation, data, and information relating to any Study. Site shall permit Company and its authorized representatives to inspect (i) the facilities where a Study is or will be performed; (ii) any equipment used or involved in the conduct of a Study; (iii) any records and source documents, including but not limited to

ATTESTED

Contract #: 266710
Site #: 5589
Purchase Order #: India

Page 3 of 8


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

medical records (whether in electronic or paper format); (iv) any related authorizations or patient informed consent forms; and (v) other relevant information necessary to determine whether a Study is being conducted in conformance with this Agreement and Applicable Laws. Further, direct access to electronic medical records for the purpose of monitoring/auditing source data is preferred, where possible, and in all cases, Site will provide the same level of access to source records to the monitor/auditor as provided to inspectors."

7.4 The parties agree that for this Order the Agreement shall be amended and supplemented by the following new provision: "Anti-Corruption. Site represents, warrants and covenants, as of the Effective Date to and through the expiration or termination of each Order or this Agreement, (i) that Site, and, to the best of its knowledge, Site Representatives, shall not, directly or indirectly, offer, pay, promise to pay, or authorize such offer, promise or payment, of anything of value, to any individual or entity for the purposes of obtaining or retaining business or any improper advantage in connection with this Agreement, or that would otherwise violate any Applicable Laws, rules and regulations concerning or relating to public or commercial bribery or corruption ("Anti-Corruption Laws"); (ii) that the books, accounts, records and invoices of Site related to this Agreement or related to any work conducted for or on behalf of Company are and will be complete and accurate; and (iii) that Company may terminate this Agreement (a) if Site or Site Representatives fails to comply with the Anti-Corruption Laws or with this provision, or (b) if Company has a good faith belief that Site or Site Representatives has violated, intends to violate, or has caused a violation of the Anti-Corruption Laws. If Company requires that Site complete a compliance certification, Company may also terminate this Agreement if Site (1) fails to complete a compliance certification, (2) fails to complete it truthfully and accurately, or (3) fails to comply with the terms of that certification. For the purposes of this Section, Site Representatives shall be deemed to further include owners, directors, officers, or other third party acting for or on behalf of Site.

IN WITNESS WHEREOF, the parties hereto have caused their duly authorized representatives to execute this Order.

AMGEN TECHNOLOGY PVT. LTD.

KLES DR. PRABHAKAR KORE HOSPITAL AND
MEDICAL RESEARCH CENTER

(signature)
By: Dr. Veena Jaguste
Title: Director, Development Operations
Date: _____

(signature)
By: _____
Title: _____
Date: _____

DR. ROHAN BHISE

(signature)
By: _____
Title: _____
Date: _____

Planned Number of Subjects	25		
Planned Number of Sites	1		
Description	Frequency/Detail	Unit Cost	Total
Patient Milestones	In accordance with Table below	11,55,900.00	2,88,97,500.00
Radiology	In accordance with Table below	4,37,520.00	1,09,38,000.00
Additional Assessments	In accordance with Table below	22,752.00	5,68,800.00
Screen Failures	In accordance with Table below	28,800.00	5,18,400.00
Re-Screens	In accordance with Table below	10,140.00	5,07,000.00
Chemotherapy Costs	In accordance with Table below	3,73,600.00	93,40,000.00
Administrative Start-Up Costs	In accordance with Table below	40,000.00	40,000.00
Miscellaneous	In accordance with Table below	1,44,000.00	1,44,000.00
Maximum Study Cost:			5,09,53,700.00
<i>Patient Milestones are inclusive of Hospital overhead fees, pharmacy costs, laboratory costs.</i>			
All Costs are denoted in:			Rupees

Per Patient Fee (Overhead 20%)

Visit Type	Visit Description	Cost
Screening	Screening	28,800.00
	Week 1	14,940.00
	Week 4	12,780.00
	Week 7	12,780.00
	Week 10	25,440.00
	Week 13	12,780.00
	Week 16	12,780.00
	Week 19	25,440.00
	Week 22	12,780.00
	Week 25	12,780.00
	Week 28	25,440.00
	Week 31	12,780.00
	Week 34	12,780.00
	Week 37	25,440.00
	Week 40	12,780.00
	Week 43	7,860.00
	Week 46	20,520.00
	Week 49	7,860.00
	Week 52	7,860.00
	Week 55	20,520.00
	Week 58	7,860.00
	Week 61	7,860.00
	Week 64	20,520.00
	Week 67	7,860.00
	Week 70	7,860.00
	Week 73	20,520.00
	Week 76	7,860.00
	Week 79	7,860.00
	Week 82	20,520.00
	Week 85	7,860.00
	Week 88	7,860.00
	Week 91	20,520.00
	Week 94	7,860.00
	Week 97	7,860.00

ATTESTED



Prof. Dr. V.A. KOTHIMALE

 KLE, Under Higher Education
 and Research, BELAGAVI

Treatment Phase*

Week 100	20,520.00
Week 103	7,860.00
Week 106	7,860.00
Week 109	20,520.00
Week 112	7,860.00
Week 115	7,860.00
Week 118	20,520.00
Week 121	7,860.00
Week 124	7,860.00
Week 127	20,520.00
Week 130	7,860.00
Week 133	7,860.00
Week 136	20,520.00
Week 139	7,860.00
Week 142	7,860.00
Week 145	20,520.00
Week 148	7,860.00
Week 151	7,860.00
Week 154	20,520.00
Week 157	7,860.00
Week 160	7,860.00
Week 163	20,520.00
Week 166	7,860.00
Week 169	7,860.00
Week 172	20,520.00
Week 175	7,860.00
Week 178	7,860.00
Week 181	20,520.00
Week 184	7,860.00
Week 187	7,860.00
Week 190	20,520.00
Week 193	7,860.00
Week 196	7,860.00
Week 199	20,520.00
Week 202	7,860.00
Week 205	7,860.00
Week 208	20,520.00
Week 211	7,860.00
Week 214	7,860.00
Week 217	20,520.00
Week 220	7,860.00
Week 223	7,860.00
Week 226	20,520.00
Week 229	7,860.00
Week 232	7,860.00
Week 235	20,520.00
Week 238	7,860.00
Week 241	7,860.00
Week 244	20,520.00
Week 247	7,860.00
Week 250	7,860.00
Last Dose of IP	22,440.00
Next Q3W visit after disease progression	20,040.00

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

Long Term Follow-Up	Month 4	480.00
	Month 7	480.00
	Month 10	480.00
	Month 13	480.00
	Month 16	480.00
	Month 19	480.00
	Month 22	480.00
	Month 25	480.00
	Month 28	480.00
	Month 31	480.00
	Month 34	480.00
	Month 37	480.00
	Month 40	480.00
	Month 43	480.00
	Month 46	480.00
	Month 49	480.00
	Month 52	480.00
	Month 55	480.00
	Month 58	480.00
	Month 61	480.00
Month 64	480.00	
Month 67	480.00	
Month 70	480.00	
Month 73	480.00	
Per Subject Totals		
Per Subject Total for Completers using CT Scans		11,55,900.00
Maximum Per Subject Total		11,55,900.00

Radiology Costs

Radiology procedures shall be paid at the rates below, if required. Amgen shall pay for either CT or MRI Scans and Scans per Patient.

Radiology Procedures (Payable on Invoice)	Cost	Frequency	Total per Patient
CT Chest & Interpretation	5,100.00	30 per Subject	N/A
CT Abdoman & Interpretation	5,400.00	30 per Subject	N/A
MRI Chest & Interpretation	6,780.00	30 per Subject	2,03,400.00
MRI Abdoman & Interpretation	7,680.00	30 per Subject	2,30,400.00
CT Brain	3,720.00	1 per Subject	3,720.00
Total Maximum Per Patient			4,37,520.00
<i>Total maximum for additional costs assumes PET/CT costs</i>			

Additional Assessments

Additional Procedures (Payable on Invoice)	Cost	Frequency	Total per Patient
Whole Body Bone Scan	10,800.00	2 per Subject	21,600.00
X-Ray Bone (max)	336.00	2 per Subject	672.00
Biopsy Sample process and handling	480.00	1 per Subject	480.00
Total Maximum Per Patient			22,752.00

Screen Failures

A max of 18 Screen Fails will be paid per Site at a rate in accordance with table below.

Visit Description	Cost
Screen Failure	28,800.00
Maximum Screen Failure Costs	28,800.00

ATTESTED



Prof. Dr. V.A. KOTHIWALE

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

Re-Screens

A max of 2 Re-Screens will be paid per Subject at a rate in accordance with table below.

Visit Description	Cost
Re-Screen Labs & Procedures	10,140.00
Maximum Re-Screen Costs	10,140.00

Chemotherapy Costs (Payable only against original invoice)

Description	Cost	Frequency	Total per Patient
Pemetrexed	60,000.00	6 per Subject	3,60,000.00
Cisplatin	1,700.00	8 per Subject	13,600.00
Total Maximum Per Patient			3,73,600.00

*Inj. Pemetrexate will be reimbursed beyond 6 cycles only for the cases where it is used as first line chemotherapy, which immediately rolls into maintenance treatment with no break or change to the treatment administered and where study IP is continued.

Inj. cisplatin will be reimbursed to the sites for maximum of 8 cycles/patient, with a reimbursement cost of no more than Rs 1,700/- per cycle and no more than Rs. 13,600/patient overall.

Administrative Start-Up Costs

Description	Cost	Frequency	Total
IRB Initial Review Fee	40,000.00	1 Total	40,000.00
Total Maximum			40,000.00

Miscellaneous

Description	Cost	Frequency	Total
Broadband charges for eCRF data entry	1,500.00	36 per Month	72,000.00
ISD phone line rent & monthly charges	1,500.00	36 per Month	72,000.00
Total Maximum			1,44,000.00

PAYMENT DISTRIBUTION

Initial Payment	50,000.00 (Estimated advance for 1 cycle for 1 subject) <i>Amgen will pay Institution this initial payment upon execution of the Agreement. In order to receive further funds towards Subject related costs, the amount earned must exceed this initial payment. In the event that the total amount earned for the Study is less than this initial payment, all unearned funds are fully refundable to Amgen.</i>
Progress Payment Frequency	Quarterly (based on calendar quarter), in accordance with Budget Worksheet attached hereto and incorporated herein by reference

The payment of the study will be made in the favor of '_____'

The EC for this study will be 'Ethics Committee of KLE University' and the payment of the EC fees will be made in the favor of 'Registrar, KLE University, Belagavi'.

Site represents and warrants that it shall not seek or accept reimbursement from any Subject or third party payors (including any "federal health care program" as defined at 42 U.S.C. section 1320a-7b(f)) for Study Drug(s), procedures, tests, treatments, drugs, reagents, materials, items or services that are funded by Company pursuant to the Agreement or provided without charge by Company for Study purposes.

In the event Site is not reimbursed for routine clinical services contemplated in the Protocol, Site may remit an invoice to Company. If Company is in agreement with the invoice, Company will reimburse Site for the invoiced amount subject to a fair market value assessment by Company.

Company shall pay for or provide those Study Drug(s), procedures, tests, treatments, drugs, reagents, materials, items, or services identified in the Protocol's Schedule of Assessments, except that the following are not paid for or provided without charge by Company:

N/A

Invoices

- 1) "Any additional activities/tests/procedures performed for the Study, which are not mentioned in this budget (schedule-A) may be reimbursed on confirmation of approval from the Amgen study team and receipt of an original invoice and rationale provided by the Site."
- 2) For all items that are payable upon invoice as indicated above, please send invoices to Company as follows:

Amgen Technology Pvt Ltd
Dynasty Business Park,
Level 4, A wing, A.K Road
Andheri (East) Mumbai 400059

Please submit invoices only for items indicated as payable upon invoice.

Version: 1

ATTESTED

Kishor
KISHOR KOTHIMALE
KLE University of Higher Education
and Research, BELAGAVI




सत्यमेव जयते

INDIA NON JUDICIAL Government of Karnataka

e-Stamp

Certificate No. : IN-KA93762720914275N
 Certificate Issued Date : 15-Jul-2015 12:05 PM
 Account Reference : NONACC (FI)/ kacrsf108/ BELGAUM6/ KA-BL
 Unique Doc. Reference : SUBIN-KAKACRSFL0836653733616091N
 Purchased by : THE PRINCIPAL K L E V K IDC BELAGAVI
 Description of Document : Article 4 Affidavit
 Description : AFFIDAVIT
 Consideration Price (Rs.) : 0
 (Zero)
 First Party : COMMISSIONERATE H F W AND A SER G O K BANGALORE
 Second Party : THE PRINCIPAL K L E V K IDC BELAGAVI
 Stamp Duty Paid By : THE PRINCIPAL K L E V K IDC BELAGAVI
 Stamp Duty Amount (Rs.) : 200
 (Two Hundred only)



NH
 Authorised Signatory
 Per Siree Basappa Nandappa
 Co-op. Credit Society Ltd.
 2nd Cross, Nehru Nagar
 North Nagar, Belgaum, 590010

Please write or type below this line

MEMORANDUM OF UNDERSTANDING

This Memorandum of Understanding made on the 14th day of August 2015 by and

BETWEEN: Commissionerate, Health, Family Welfare and AYUSH Services, Government of Karnataka, Bengaluru whose headquarters are located at 3rd Floor, IPP Building, Directorate of Health & Family Welfare Services, Anand Rao Circle, Bangalore-560009 (herein referred to as 'The First Party').

AND: KLE Vishwanath Katti Institute of Dental Sciences, Belagavi (herein referred to as 'The Second Party') whose address is J.N.M.C. Campus, Nehru Nagar, Belagavi-590010, Karnataka.

Statutory Alert:

1. The authenticity of this Stamp Certificate should be verified at www.shrestamp.com. Any discrepancy in the details on this Certificate and its available on the website renders it invalid.
2. The onus of checking the legitimacy (during use) of the certificate.
3. In case of any discrepancy please inform the Competent Authority.

Attested

Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

463

WHEREAS Commissionerate, Health, Family Welfare and AYUSH Services, Government of Karnataka (GoK), is the Competent Authority at State level to implement various Programmes and Schemes of the Health & Family Welfare Department and shall implement the Oral Health Policy to provide complete dentures to the needy senior citizens (60 years and above) who live below poverty line and this part of the policy shall be herein called as "Danta Bhagya Yojane".

WHEREAS KLE Vishwanath Katti Institute of Dental Sciences, Belagavi, located at J.N.M.C. Campus, Nehru Nagar, Belagavi-590010, Karnataka established in the year 1985 has professional, academic and technical proficiency in implementing the scheme "Danta Bhagya Yojane" and henceforth has agreed to provide the technical support and treatment for providing the complete dentures to the needy senior citizens who live below poverty line.

AND WHEREAS Commissionerate, Health, Family Welfare and AYUSH Services, Government of Karnataka, and KLE Vishwanath Katti Institute of Dental Sciences, Belagavi recognize the necessity to synergize and mutually co-operate to provide complete dentures to the needy senior citizens who live below poverty line in Karnataka and thereby to effectively implement the scheme of "Danta Bhagya Yojane" as part of the Oral Health Policy.


NOW THEREFORE, this MoU hereby bestows the covenants in terms of certain roles and responsibilities for the parties for the smooth functioning of the "Danta Bhagya Yojane" and other schemes of Oral Health Policy as and when announced by the First Party.

Responsibilities of Commissionerate, Health, Family Welfare and AYUSH Services, Government of Karnataka:

1. Health & Family Welfare Department shall implement the scheme of Danta Bhagya Yojane" in 30 Districts of Karnataka through the Government and Private Dental Colleges of Karnataka.
2. Eligibility criteria for identifying the beneficiaries, documentation process and records maintenance of beneficiary shall be made by the Health & Family Welfare Department.
3. Health & Family Welfare Department shall pay an amount of Rs. 500 (Rupees Five Hundred Only) per complete denture to the Dental College which includes the cost of treatment plan, manpower, materials, technical services, and other incidental expenses.
4. Health & Family Welfare Department shall provide the format for referral slips and monthly reports to all the concerned Institutions.
5. The Medical Officer/Dental Officer working at any State-run Government Health Centre/Government Hospital shall authorize the beneficiaries to avail the benefits of the scheme after scrutinizing the necessary documents. This does not include the Health Centres/Hospitals run by the Central Government.
6. The payments to the Colleges shall be made online directly into their bank accounts on a monthly basis.
7. Health & Family Welfare Department shall train the ANM's/ASHA's/paramedical personnel within their jurisdictional District to identify, diagnose and refer the beneficiaries to the allotted Dental College.

2

ATTESTED


Prof. Dr. V.A. KOTHIMALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

464

Responsibilities of the Dental College:


1. Dental College shall conduct some dental outreach camps and refer the beneficiaries to the Dental College or conduct on-site treatment for complete dentures.
2. Dental College shall not charge any kind of additional fees such as OPD card charges or registration fees, etc. The scheme does not include the cost of drugs, medications and other incidental expenses related to the complete dentures. However, any beneficiary having a few remaining teeth indicated for total extraction or any other minor procedures indicated as treatment plan for insertion of complete dentures shall be free of cost including tooth extractions.
3. Complete dentures shall be made using standard treatment procedures and materials.
4. The Dental College shall not deny or delay treatment for the eligible beneficiaries of this scheme. However the beneficiaries can be allotted appointment on first-cum-first serve basis and preferably on fixed days of the month to avoid undue delay of treatment.
5. The Dental College shall treat the beneficiaries of this scheme as its own patient and take all necessary measures such as informed consent.
6. The Dental College shall submit their monthly reports to the District Health & Family Welfare Officer and Deputy Director (Medical) periodically as agreed by both the parties.

The parties agree as follows:

1. Term: The Project implementation will commence on 1st of July 2015. The term of this Memorandum of Understanding is for 5 years (five years) and may be extended subject to satisfactory performance and decision of the GoK).
2. Financial provisions and management of funds: All the payments for project activities will be paid directly to the Second party on a post-audit basis, by the State level office on submission of reports by the Second Party to the Deputy Director (Medical). An amount of Rs 50,000 will be released in advance to the Second Party for provision of 100 dentures. The second party will be eligible for subsequent advance payments after completion of 100 dentures. Reports should be submitted online every month in the prescribed format including pre & post photographs of the beneficiary.
3. The Second Party shall not make any changes without prior approval from the Commissioner, Health & Family Welfare Department, Government of Karnataka. Changes in the line item shall not alter the main purpose of the project and shall be done only to ensure smooth implementation of the agreed project goal.
4. Statutory liabilities such as TDS (Tax deduction at Source), Professional Tax, etc will be the responsibility of the Member Secretary, Oral Health Policy, and the deductions will be made accordingly as applicable.
5. Visibility: The second party must take all necessary steps to publicize the fact that the Health and Family Welfare Department, Government of Karnataka, has financed the activities funded under this scheme. The Health and Family Welfare Department, Government of Karnataka, shall acknowledge the second party for its effort and technical support in implementing the project.
6. Force Majeure: Neither party shall be responsible for any breach of contract due to a Force Majeure which is irresistible, unforeseeable and exterior.

ATTESTED

3


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

465


7. Assignment: This Memorandum of Understanding and the ensuing disbursement may not be transferred or assigned to a third party in any manner whatsoever without prior written consent from the Health & Family Welfare Department, Government of Karnataka.
8. Independent second party relationship: Nothing contained herein shall be construed to imply a joint venture, partnership, or employer and employee relationship between parties. Neither party shall have any right, power, or authority to create any obligation, express or implied, on behalf of the other except as defined in this Memorandum of Understanding or as mutually agreed to under the terms of Memorandum of Understanding. The employees or agents of one party shall not be deemed or construed to be the employees or agents of the other party for any purpose whatsoever.
9. Modifications, Amendments or waivers: No modifications or amendments to this Memorandum of Understanding nor the waiver of any provision shall be valid unless presented in writing and signed by duly authorized representatives of both the parties.
10. Applicable laws- Legal disputes: This Memorandum of Understanding shall be interpreted by, and construed in accordance with the laws of the Republic of India. All disputes, differences or questions between the parties with respect to any matter arising out of or relating to, but not limited to, the existence, validity, construction, performance and termination of this agreement which the parties cannot amicably settle shall be finally settled under the Rules of Arbitration, by one or more arbitrators appointed in accordance with said Rules. The arbitration shall take place in Bangalore (India) and the arbitration proceedings shall be conducted in the English language under Indian law.

The arbitration award shall be final and binding upon the Parties and shall be enforceable in any court of competent jurisdiction, and the parties hereby waive any objections to or claims of immunity from jurisdiction and/or in respect of such enforcement.

11. Publicity: Both parties agree to consult each other in case of any requirement of publicity of the said project to the media or any other agency and act diligently in the best interest of the project.
12. Modification: Both the parties may modify this MoU based on a mutual understanding. Such understanding shall always be in writing, signed by both the parties.
13. Relationship: Nothing in this MoU shall constitute, create or give effect or recognize a joint venture, partnership or principal/agent relationship between the parties or a business entity of any kind. Neither party shall have the express or implied right or authority to assume or create any obligations on behalf of or in the name of the other party or to bind the other party to any other contract, agreement or undertaking with any third party.

ATTESTED

4


Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

466

14. Confidentiality: The second party shall treat as confidential, during as well as after, the performance of any work under this Memorandum of Understanding, any information, including any personal information defined by the Health & Family Welfare Department, Government of Karnataka, to which the Second Party becomes privy as a result of acting under this Memorandum of Understanding. The Second Party shall not disclose any such information to any other person or party which is not participating in this Memorandum of Understanding in a form that could reasonably be expected to identify the person, including individuals, to whom such information relates.

15. Termination: This Memorandum of Understanding may be terminated, in whole or in part, by either party at any time upon 90 (ninety) days prior written notice of termination to the other party.

Upon termination of work performed before the date of termination, each party shall be fully and forever released and discharged from any legal and all obligations, covenants or liabilities of whatsoever kind or nature in law or equity or otherwise arising out of or in connection with the Memorandum of Understanding by and between the Second Party and the Health & Family Welfare Department, Government of Karnataka.

16. Complete Memorandum of Understanding: This Memorandum of Understanding becomes a binding contract only upon signature by both parties and the delivery of fully signed copies to the other party.

17. Notices: All notices and demands under this Memorandum of Understanding shall be made in writing and shall be communicated by e-mail or conventional mail to the mail address of the receiving party.


18. IN WITNESS WHEREOF, the parties have executed this Memorandum of Understanding.


Read and approved:



Principal
KLE Vishwanath Katti Institute of
Dental Sciences, Belagavi
PRINCIPAL

KLE V.K. Institute of Dental Sciences
Belagavi, Karnataka - 590010


Commissioner 11/12/15
Health, Family Welfare &
AYUSH Services
Government of Karnataka
District Health & Family Welfare Officer
BELGAVI
Belagavi

ATTESTED

Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI



**KLE
VISHWANATH KATTI
INSTITUTE OF DENTAL SCIENCES**



**(Constituent College of K.L.E. Academy of Higher Education & Research, Belagavi)
J.N.M.C. Campus, Nehru Nagar, Belagavi-590 010, Karnataka, India
Department of Prosthodontics and Crown & Bridge**

☎: 0831-2470362
FAX: 0831-2470640


Web: <http://www.kledental-bgm.edu.in>
E-mail: prostho.vkids@gmail.com

DEPARTMENT OF PROSTHODONTICS

DHANTH BHAGYA YOJANE

Report from the Date of MOU – 14-08-2015 - till date

Year	NUMBER OF COMPLETE DENTURE DELEVERED PER YEAR
November 2015 to December 2015	03
January 2016 to December 2016	46
January 2017 to December 2017	71
January 2018 to December 2018	289
January 2019 to December 2019	244
January 2020 to July 2020	53
TOTAL	706


Dr. Anandkumar G Patil
Professor & Head

Dept. of Prosthodontics and Crown & Bridge
KLE VK Institute of Dental Sciences
Belagavi




Dr. Alka D Kale
Principal

KLE VK Institute of Dental Sciences
Belagavi


PRINCIPAL
KLE V.K. Institute of Dental Sciences
Nehru Nagar, BELAGAVI-590010

ATTESTED



Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

KLE V.K.Institute of Dental Sciences,Belagavi
Dantha Bhagya Yozane Collection Report
 From December -2015 to March- 2020

Date	Amount	TDS	Total	Received from
15/12/2015	50,000.00		50,000.00	NEFT No.01440615c1500041 Govt of Karnataka
26/07/2017	50,000.00		50,000.00	NEFT TT No.868890 Belgaum District Treasury
18/03/2019	66,150.00	1,350.00	67,500.00	NEFT TT No.55944 Belgaum District Treasury
25/10/2019	16,905.00	345.00	17,250.00	NEFT:RBI2991964802623: Belgaum District Treasury
31/01/2020	53,655.00		53,655.00	NEFT:RBI0322064624989: Belgaum District Treasury
Total collection Rs..	2,36,710.00			


Prof. Dr. V.A.KOTHIWALE
 Registrar
 KLE Academy of Higher Education
 and Research, BELAGAVI




 Principal
 KLE VK Institute of Dental Sciences,
 Belagavi.

Memorandum of Understanding (MOU)

Between:

Party-1:

World Alumni Network Pvt. Ltd. (WAN),
600 (FF2), Ring Road, Cross 15,
JP Nagar Phase 6,
Bangalore - 560078, India

Party-2:

KLE Vishwanath Katti Institute of Dental
Sciences,
Nehru Nagar, Belagavi-590 010
Karnataka, India

This MOU, dated 7th November 2016, establishes a mutual working relationship between the two parties (and their respective heirs, executors, administrators and assignees) as broadly outlined below:

Party-1's Role:

1. Party-1 is creating a state-of-the-art online platform as worldalumninetwork.com for all the alumni, students, staff, faculty and related individuals at global level to find, connect, communicate, collaborate and coordinate in an integrated and seamless online environment for academic, business, personal and other uses
2. Registration at this online platform by any individual is purely voluntary and it is between Party-1 and the individual members
3. Party-1 is making all the necessary investment on its own for developing the online platform with no financial obligation to Party-2
4. Party-1 will provide one Premium Membership as a respect to the head of the Party-2 at no cost to Party-2 (typically priced at tens of thousands of rupees for others)
5. Party-1 on its online platform will provide a link to Party-2's primary website

Party-2's Role:

1. To provide a clean and dependable information to members, and to ensure Party-2 can reach to the right members in its mass communication, the Party-2 will designate a person to overview the information provided by the members in the online platform
2. Since duplication of data online at multiple online places can make it difficult for finding the information, it is important for the Party-1 and Party-2 to work together closely and avoid any such duplication of data online at multiple places
3. Party-2 on its primary website will provide a link to Party-1's online platform


This MOU may be amended at any time with the mutual consent of both the parties.

Authorized signatures with seal:

Party-1


Signature

Mr. Roshan D.
Executive-University Relations
+91-9886391091



Party-2



Dr. (Mrs.) Alka D. Kale
Principal
0831- 2470362, 2444102
+91-9845240574
alkakale1@hotmail.com

PRINCIPAL

KLE V.K. Institute of Dental Sciences
Nehru Nagar, BELAGAVI-590010

ATTESTED




Prof. Dr. V.A. KOTHIWALE
Registrar
KLE Academy of Higher Education
and Research, BELAGAVI

Witnesses



Name Dr. Anurag B.
Designation Vice Principal
Phone 984422240

Signature 
Name R.A. Haver
Designation F.D.A.
Phone 0831 2470362




MOTICHAND LENGADE BHARATESH POLYTECHNIC

(Govt. Aided & A.I.C.T.E. Approved Institute, Accredited by National Board of Accreditation New Delhi.)

Run by Minority Community, F.No.1634/9875

* Knowledge * Skill * Altitude * Empowerment



2.

11 0 JAN 2015

MEMORANDUM OF UNDERSTANDING

This memorandum of understanding is signed between the KLE VK Institute of Dental Sciences, Belagavi and Motichand Lengade Bharatesh Polytechnic, Community Deveioption Through Polytechnic for a period of five(5) years with effect from 10-01-2015 for providing free dental care with the understanding that the KLE VK Institute of Dental Sciences, Belagavi shall conduct free dental checkup of students, staff & the people of adopted villages of MLBP(CDTP) college as per the confirmed programme and finalization of date, time and place.

MLBP(CDTP) shall in return look after the local logistic support which includes well lit place (room); furniture, tables, chairs and stools and electrical connection with three way plug, water for washing and drinking and tea, coffee, biscuits/snacks to the staff attending the checkup work.

If the check up camp venue is more than 30 kms from the KLE VK Institute of Dental Sciences, Belagavi, then the diesel chargeskilometer wise will be borne by MLBP(CDTP). The terms & conditions will be applicable.

Depending on the type of camp, following facility will be provided by KLE VK Institute of Dental Sciences, Belagavi

I. For checkup camp -

1. All instruments and consumable required
2. First aid material
3. Brochures, pamphlets, display posters, charts, etc.

II. Treatment camp -

1. Free checkup, extraction of mobile teeth. All patients who need treatment will be referred to KLEVK Institute of Dental Sciences, Belagavi or its satellite center situated at Bailhongal and treatment will be done at 20 % discount. Medicines needed to be given to the patients will be sponsored by MLBP(CDTP).

III. For blood grouping & Hb estimation, Rs. 10/- will be charged per person.

IV. Educational Camps: Awareness lectures regarding oral hygiene, ill-effects of tobacco will be given in Kannada / English language

Shal

KLE VK Institute
of Dental Sciences
PRINCIPAL

KLE VK Institute of Dental Sciences
Nekro Nagar, BELAGAVI-598310

[Signature]
Principal/MLBP



Excellence, Competence, Commitment, Team Work

Bharatesh Nagar, Basavan Kudachi Extn., Belgaum-590 012, Karnata

Ph: 0831-2490030. Fax: 0831-2490230 email: mlbp@mlbp.org @yahoo.co.in Website: www.mlbp.org

Scanned with CamScanner

[Signature]

Prof. Dr. V.A. KOTHIWALE
Registrar

KLE Academy of Higher Education
and Research, BELAGAVI

Created with

nitro PDF professional
download the free trial online at nitropdf.com/professional

471